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FOREWORD
This volume contains the scientific papers presented at the 51st
Annual Meeting of The Committee on Problems of Drug Dependence.
The meeting was held in Keystone, Colorado in June 1989. The
National Institute on Drug Abuse is pleased to make these
exceptional contributions to the study of drug dependence
available to the public as it has for papers presented at other
meetings of the CPDD. Once again, the topics cover a wide range
of research interests, from the anatomy of brain cells to the
prevention and treatment of drug dependency.
Of particular interest at this CPDD meeting, though not presented
in this volume, was the discussion of the formation of a new
research division within NIDA for medications development. There
is considerable excitement about the concept of developing new
medications for the treatment of addictive disorders, as well as
brain and behavior dysfunction. The programs funded by NIDA
through this new division will stimulate new research in the
neurosciences and pharmacology by members of the CPDD and other
scientists. I look forward to the volumes of proceedings of
coming CPDD meetings, in which we can expect to see the research
papers that will result from NIDA’s new medications development
program--another example of the joint concern NIDA and CPDD in
unraveling the intricacies of drug dependency.
Charles R. Schuster, Ph.D.
Director
National Institute on Drug Abuse
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Welcome and Current Status of
CPDD
William L. Dewey
Good morning ladies and gentlemen: I am Bill Dewey, Chairman of
the Board of Directors of the Committee on Problems of Drug
Dependence. It is my pleasure to welcome each and everyone of
you to the Fifty-First Scientific Meeting of CPDD.
On behalf of the Board, I thank Marty and Toby Adler; Ellen
Geller; Marie McCain and all others who worked so hard to make
sure all of the administrative aspects of the meeting go
smoothly. Lou Harris and his committee did a splendid job of
putting together this excellent program. Of course, thanks to
the participation of all of you, the science is outstanding.
The local organizing committee headed by Dick Deitrich also did
a great job. Next year's meeting will be in Richmond, VA and I
worry about us being able to match the ambience here. We will
not be able to promise you snow capped mountains outside your
bed room window, but will guarantee you the very best in southern
hospitality.
Now, I want to relate to you the current activities of CPDD and
to let you know the status of a number of the important ongoing
projects.
CPDD has one major objective and that is to rid the world of
illicit drug use. We are convinced that the only way that this
can be done is by decreasing the demand. This will never be
accomplished without a significant increase in knowledge which
only can be generated through research.
CPDD has three specific objectives. The first is to hold
excellent scientific meetings in the field of substance abuse.
We currently hold an annual meeting and at appropriate times
other meetings on a specific topic related to drug abuse. There
has been a major change in our annual meeting in recent years.
We now have multiple symposia, each dealing with important
aspects of drug abuse. The scope of these symposia includes
molecular biology, chemistry, pharmacology and clinical studies.
Each symposia is on the "cutting edge" of its discipline.
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We often hold specific topic meetings such as the one co-
sponsored by CPDD and the American Society for Pharmacology and
Experimental Therapeutics (ASPET) entitled, "Scientific
Perspectives on Cocaine Abuse". This meeting was held in
January 1987. Reprints of the document generated as a result of
that meeting, are available from the executive office of CPDD.
Last year we held a meeting on the appropriate methodologies for
the testing of medications expected to have abuse
potential or dependence liability. In 1991 we will co-sponsor a
meeting devoted to the pharmacology of kappa receptors.
The second specific objective of CPDD is to conduct a testing
program to determine the abuse potential and addiction liability
of compounds. CPDD serves as an honest broker in this regard
for compounds submitted by the pharmaceutical industry, chemists
in academia and in governmental laboratories. It is this
function of CPDD that separates it from all other scholarly
scientific societies or organizations. In recent years the
testing functions of CPDD have and are continuing to evolve and
expand.
The opioid program is long standing and well known to most of
you. In the past year we have initiated a new program for the
assessment of the abuse liability and dependence potential of
stimulants and depressant compounds. This program is running
very well. Four laboratories are participating and approximately
20 standards and seven new compounds have been tested to date.
A very exciting current function of CPDD is to expand the
testing activity to human testing. Mechanisms and protocols are
being developed for this next aspect of our attempt to provide
academia, government and industry with an independent clinical
testing facility for all new compounds.
The third specific objective of CPDD is to be ready to serve in
a consultative fashion for governmental agencies at the local,
federal and international levels. The following are a few
examples of how this is done. First and foremost the data
generated from our testing program is important information used
by FDA and WHO when scheduling decisions are made.
Secondly, CPDD has worked hard to convince congressmen and the
executive branch of government that additional and a consistent
level of high funding is needed to provide the basic, clinical,
prevention, treatment and all other types of research that is so
badly needed in the area of substance abuse. Members of CPDD
have testified before the appropriation committees of both
Houses of Congress in this regard. We feel we have been
somewhat successful in the past but recognize the need to
continue and increase this very important effort which benefits
biomedical science in government and industry as well as
academic laboratories. CPDD has responded to the new APHIS
guidelines on the humane use of laboratory animals in research
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and have taken a lead role in this important area with
politicians at all levels.
We are in the process of responding to a specific request from
the Select Committee on Narcotic Abuse of the House of
Representatives on the issue of possible legalization of illicit
drugs. They have asked us for scientific input which is needed
for the lawmakers to base their decision on this very important
question. These are a few examples of what the organization is
doing. In closing this part of my comments, I will tell you
that CPDD is constantly improving its scientific meeting, the
testing programs, and its interaction with various governmental
agencies. I hope I have convinced you that CPDD is a vital
organization, functioning well in many aspects.
At its meeting this week the Board of Directors voted for a
major change in the structure of CPDD. With a target date of
July 1, 1990, CPDD will become a membership organization.
Because of the unique functions of CPDD as described earlier, it
is not envisioned that CPDD will be like many other
organizations with open membership but might have a format
somewhat similar to that of the American College of
Neuropsychopharmacology (ACNP). We expect to differ from ACNP
by having our meetings open to the entire scientific community.
We feel this is essential to maintain progress in the multiple
research efforts to solve this important problem. The objective
is to maintain the unique and important functions of CPDD but to
provide a home organization, if you will, for the many excellent
scientists making important contributions to the multiple
aspects of this important field. The details and new by-laws
will be worked out during this year.
At this time I am very pleased to recognize six members of the
Board of Directors of CPDD who have each contributed
significantly to the function of their organization as board
members over recent years. Their terms on the beard have now
ended. As is our custom, each will be presented with a
certificate as an indication of our gratitude for their
significant contributions to CPDD. The six members who will
retire after this meeting are: Drs. Richard Deitrich; Sheppard
Kellam; Herb Kleber; Mary Jeanne Kreek; Horace Loh and Everette
May.
All of us are indebted to them for their excellent scientific
contributions to this important field and also for their hard
work and multiple contributions to the objectives of the
Committee on Problems of Drug Dependence.
Richard Deitrich: Dr. Deitrich brought his special expertise to
the Committee in the area of alcohol research. Dr. Deitrich
served as the Chairman of the Nominating Committee for the
Committee on Problems of Drug Dependence, and also was in charge
of local arrangements for this meeting at Keystone, Colorado.
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His contributions to the Committee in both of these regards were
exemplary, and we are very appreciative of his efforts.
Shep Kellam: The expertise of Dr. Kellam in the area of public
health was of immense importance to the Committee. Clearly,
drug abuse is a problem which affects many people in our
country, and the perspective from the public health point of
view was essential in the deliberations of the Committee. Dr.
Kellam's interest and expertise in interacting with various
advocacy groups, such as AARP and NAMI, were particularly
important to the functioning of the Committee on Problems of
Drug Dependence during his tenure on the Board of Directors.
Herbert Kleber: Dr. Kleber brought a great deal of clinical
expertise to the Committee. His insightful knowledge of
treatment of patients who abuse various types of drugs was
especially important to discussions of significant issues
before the Board. He was a major contributor to our Clinical
Testing Committee, which is a relatively new endeavor of the
Committee, and the expertise of Dr. Kleber and his colleagues
made this important function possible.
Mary Jeanne Kreek: Dr. Kreek served the Committee in many ways.
Her great knowledge of the effects of drug abuse, both in basic
and clinical science, were particularly valuable to the
discussions of the Board of Directors, as well as in many
symposia and scientific meetings. Dr. Kreek also served the
Committee as Chairman of the Board of Directors for two years,
and did an exceptionally good job in bringing forward the many
efforts of the Committee during that time. She also filled in
as interim Executive Officer of the Committee, simultaneously
while serving as Chairperson. Her vast energy and exceptionally
good judgement were tremendous assets to the continued progress
of the Committee on Problems of Drug Dependence. All workers in
this field, and especially all those who are struck with the
complexity of the abuse of drugs, should be appreciative of the
multiple efforts and the marked expertise of Dr. Kreek. The
organization prospered well under her outstanding leadership.
Horace Loh: Dr. loh has contributed to all the functions of
CPDD but he has been especially active on its program committee
and by organizing symposia for the scientific meetings. His
expertise as a biochemical and molecular pharmacologist has been
of great value to the Board of Directors of the Committee on
Problems of Drug Dependence. His work and the work of his
colleagues has greatly increased the quality of the scientific
meetings of the Committee.
Everette May: Dr. May, who actually retired from the Board of
Directors last year, continued his outstanding, long-lasting
commitment to CPDD by co-authoring the history of the
organization. Reprints of this document are available from the
executive office. The many contributions of Dr. May to this
field, and particularly to CPDD, are obvious to us all and are
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so extensive that they can not be described here.
We thank each of these matters of the Board for their
outstanding contributions to the Committee on Problems of Drug
Dependence.
MOTOR:
William L. Dewey, Ph.D.
Associate Provost of Research and
Graduate Affairs
Medical College of Virginia
Virginia Commonwealth University
Richmond, Virginia 23298
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Animals in Research on Addictive
and Mental Disorders: Foundation of
the Quest -for Knowledge
Frederick K. Goodwin
Let me begin with two observations: 1) Biomedical and behavioral research is
critical to the success of this Nation’s war against drugs, and 2) Basic research
on drug abuse (along with alcoholism and mental illness research) has been
targeted by the radical animal rights/stop research movement, presumably
because they feel they can play on public attitudes that these problems are not
fundamentally biomedical. In light of the implications of these observations to
the concerns of the CPDD, I plan to focus my remarks on the animal rights
issue.
I will make some general comments about the aims of the animal rights
movement, describe strategies the movement is using to accomplish its ends,
and suggest what I see as needed responses from the research and treatment
communities.
To date, various institutions including government, professional groups. patient
groups, and academia have essentially misread the agenda of the animal rights
movement. We in the research community have tended to respond to the
challenges of the animal rights activists as we have been trained, which is
intellectually. In fact, we are dealing with an anti-intellectual movement whose
fundamental philosophical premise is incompatible with the humanistic values
of the health professional. Tactically, the movement pursues its radical agenda
with political sophistication, passion, and a very effective appeal to nearly
universal sentiments about animals. We must respond on all those levels in
addition to the more purely intellectual level.
The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) is
actively responding to the threat to biomedical and behavioral research posed by
the animal rights movement. Mental and addictive disorders involve complex
human behaviors that overlap with and can be mistaken for normal, voluntary
misbehaviors. Consequently, we are vulnerable to the tacit implication that our
research substitutes biologically or psychosocially reductionistic explanations
for behavior which should be simply a matter of individual responsibility. It
certainly is much easier for groups opposed to research to mislead the public
about complex behavioral disorders than, for example, the need to develop a
new heart valve or to cure a cancer.
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It is essential that all of us educate ourselves about the animal rights movement
and understand the urgency of public education, whether or not we are directly
engaged in animal research. Since the animal tights movement is fundamentally
anti-intellectual and anti-science, each of-us is threatened by its success.
Animal Welfare vs. Animal Rights
It is important to distinguish clearly the animal welfare and animal rights
movements. Animal welfare is a traditional, well-respected part of mainstream
advocacy in this country and in most of the western world. Based on the
philosophical premise of responsible stewardship of animals, animal welfare
encompasses humane care. Traditional animal welfare advocates operate on the
premise that humans are responsible for animals, not that animals have intrinsic
rights. This latter notion conflicts not only with our cultural and religious
values concerning the sanctity of human life and our special dedication to
human rights, but also with the foundation of our entire legal system.
Traditionally, the animal welfare groups such as the Society for Prevention of
Cruelty to Animals (SPCA) have pursued their goals of preventing cruelty and
unnecessary suffering through such efforts as helping abandoned strays and
pets, building and maintaining shelters, sponsoring adoption and neutering
programs, and conducting pet care education. The SPCA and similar groups
typically have avoided the question of use of animals in research, but, when
pressed, have not opposed it.
The contemporary animal rights movement, by contrast, holds that all beings
which have a capacity for suffering have equal “interests.” This position,
developed in the mid-1970s by an Australian philosopher, Peter Singer, was
presented in the book Animal Liberation: A New Ethic for our Treatment of
Animals. As a “bible” of the animal rights movement, Singer’s work is the
basis for the movement’s assertion that the claim by humans of special rights is
“speciesism,” a moral equivalent of racism and sexism.
Currently, some 10 million Americans, allied loosely through more than 400
individual groups, are counted in the animal rights movement. Many of these
persons are genuinely concerned about human responsibilities toward the
welfare of animals. Yet they have been misled by the leaders of the animal
rights movement who have purposely obscured the-underlying philosophy and
ultimate aim of the movement--the elimination of all use of animals in research.
In choosing not to confront directly society’s widely-held sensibilities about the
primacy of human life and health, but rather to rely upon specific objections to
the use of animals in particular research areas, the movement has misled those
who would be opposed to its fundamental philosophical premises. By putting
the research community on the defensive (a position which we unfortunately
reinforced) the movement was able to present itself as reasonable and
constructive.
This image has enabled animal rights activities to infiltrate and radicalize many
traditional animal welfare organizations. Through “hostile takeovers” of animal
welfare organizations and sophisticated fund-raising, activists have come into
control of immense resources which now are being channelled into the stop
research movement. Sadly and ironically, animal welfare activities are being
curtailed by a lack of funds. Shelters must kill some 16 million animals each
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year, for example. in part because adoption and neutering programs have been
neglected while resources are diverted into the stop research movement.
Early on, the image of reasonableness encouraged the research and academic
communities, as well as government agencies, to respond reflexively--and,
often,. defensively--to secondary anti-research arguments, while ignoring the
fundamental philosophical or moral issues. When animal rights activists
claimed that cruelty to animals in biomedical research was commonplace, the
field acquiesced to demands for greater regulation of its operations, thereby
seeming tacitly to agree that the isolated and distorted examples publicized by
animal rights activists were typical of research lab procedures.. Reports issued
by the Office of Technology Assessment seemed to imply that while animal
research remained necessary now, further, progress would eventually supplant
that necessity, an implication that was further reinforced when the National
Institutes of-Health (NIH) agreed to substantially increase its funding for special
centers to develop more alternatives to the use of animals in research.
It soon became evident that attempting to appease the animal rights activists was
a profound mistake; as we accommodated and compromised--and projected a
sense of apology for our research procedures--the animal rights movement
became more strident and more successful.
The Cultural Climate and Animal Rights
As was true of other eras in which strong animal rights sentiments emerged--
during the period preceding World War I, for example, or in 1930s Germany--
specific features of the cultural climate in the U.S. and other developed
countries in recent decades fostered the rapid growth of the animal rights
movement. The late 1960s and ’70s were characterized by a subtle but
pervasive sense of demoralization or nihilism about the human condition. This
attitude set the stage for a confusion between human and other forms of life,
which is at the core of animal rights.
In the U.S., the political and social turmoil triggered by three assassinations and
by Vietnam undermined willingness to invest in the Nation’s infrastructure,
perhaps reflecting an erosion of confidence in the future and in our ability to
improve it. The legacy of that era is found today in the deteriorated condition of
infrastructure components ranging from transportation to education to
biomedical research. With, respect to research, a marker is the diminishing
percentage of GNP devoted to research and development; another is the
proportion of health care costs invested in research, which has declined nearly
50 percent over the past 25 years.
Another index of demoralization in the U.S. was the widespread mistrust of
establishments and institutions--including university research centers--in the
post-Vietnam, post-Watergate era.
A perhaps related measure of demoralization was seen in efforts during that
period to eliminate any suggestion of “moral tone” from educational processes.
As noted by Allan Bloom and others, traditional absolutes of education
frequently were abandoned in favor of “cultural relativism.” Unfortunately,
science doesn’t do well in a relativistic atmosphere--one has to master it in order
to debate it.
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It is not difficult to see linkages between the trend toward relativism, the
contemporary dismal quality of science education in U.S. primary and
secondary schools, and the growth of the animal rights movement. Today,
only four percent of the teachers in our primary schools have had a science
course beyond high school; only seven percent of our high school graduates
now meet even minimum criteria for scientific literacy.
Not surprisingly, a substantial proportion of the membership of the animal
rights movement consists of young people who tend to substitute sentiment for
reason. When pressed to discuss their position, they say, in effect, “Because I
feel strongly about not using animals in biomedical research, it’s true for me.”
Many students simply don’t understand the anti-intellectual, anti-authority, and
anti-institutional attitudes which underlie the “arguments” of the animal rights
movement.
Equally worrisome is that biomedical science means little to a generation for
whom the conquest of infectious diseases with vaccines is history. In school,
kids are taught that health is solely a matter of prevention: no smoking or drug
use, safe sex, good nutrition. The idea that killer diseases still exist is hardly
urgent to young people--disease and death are remote, something for their
grandparents to worry about.
The Secondary Anti-Research Arguments
In addition to being aware of and understanding the philosophical impetus
behind the animal rights movement, those of us who must defend research must
also be able to respond to the movement’s secondary anti-research arguments;
these essentially fall into one of the six categories discussed below.
I. “Animal research is inherently cruel.” Animal activists repeatedly use and
often distort a few isolated cases. In fact, we might be encouraged that activists
are so dependent on the publicity value of two dated instances, one involving
the Silver Spring monkeys and, another, the University of Pennsylvania Head
Injury Lab. In the Appeals Court, the principal investigator on the Silver
Spring project was acquitted on all charges of animal cruelty; indeed, during the
court proceedings, witnesses were prepared to testify that an activist member of
People for the Ethical Treatment of Animals (PETA) who had worked at the
facility had subjected an animal to severe distress in order to get a photograph
that is now being used in fund-raising by the animal rights movement. In the
other instance, activists broke into the University of Pennsylvania’s Head
Injury Research Lab in 1985, stole videotapes made over the course of many
months, and selectively edited these into a short, exploitative tape which
depicted instances of insensitivity and carelessness. Sanctions imposed by NIH
on the University for violations of the Guide for Care and Use of Laboratory
Animals have been dishonestly used by the movement to convey the message
that the research was not only inherently cruel but medically useless.
Use of anesthesia, standard in almost all invasive research, is especially
important in behavioral research, where undue pain and distress can severely
distort the validity of findings. In the few studies where pain per se is being
studied and anesthesia is not used, “thresholds” for pain are the most
informative research measure; sustained administration of genuinely painful
stimuli would be counterproductive to the overwhelming majority of research
goals.
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Research is one of the most highly regulated activities in our society, and animal
research is subject to stringent regulatory requirements. The current proposal
for revised federal regulations governing animal research runs to 132 pages of
highly detailed instructions which are subject to continuous revision by a
committee that includes non-scientists. Today, anecdotal reports from
investigators suggest that it actually is easier to receive approval to conduct
certain research with human subjects!
II. “Animal research is wasteful and duplicative.” As members of the scientific
community know all too well, competition for federal research funding is
intense. Grant applications are extensively reviewed, first, for scientific merit
and relevance by scientists with expertise in the area of proposed research and,
subsequently, by a statutory Advisory Council to ensure that the proposal is
responsive to public health demands and the mission of the funding agency.
Given limited research resources, scientists who peer review each others’
applications obviously are not going to approve frank duplication.
Grantees must certify, moreover, that they are in compliance with all federal
animal welfare policies; this requires documentation from the Institutional
Animal Care and Use Committee, which must include as members a
veterinarian, a researcher, a non-scientist, and a member of the community not
affiliated with the university site of the proposed research.
Recent legislative efforts, such as the Torricelli Bill, which has been promoted
as a “pro-science” measure to help prevent duplication, would overlap the
existing, proven system of dual review with a process that is essentially
adjudicatory in nature. The authors of “protections” such as this fail to see that
replication, a form of duplication, is essential in the task of converting
experimental findings into “truth,” and they fail to understand how new
scientific knowledge comes from multiple, overlapping findings, each building
on the other. If enacted, the Torricelli Bill would be a disaster for biomedical
science.
III. “Animal research diverts funds from treatment.” This argument,
unfortunately seductive to a few naive treatment professionals, represents an
effort by the animal rights movement to balkanize the research and treatment
communities, by pitting those who generate new knowledge against those who
apply the information in clinical settings.
The data, however, do not come close to supporting the claim. For every $100
the Federal Government spends on health care generally, less than 40 cents
supports animal research. For mental and addictive disorders exclusively, the
figure is 2 cents per $100 in treatment costs!
Uncontested, this argument is particularly threatening to the research fields
supported by ADAMHA. The Federal Government, primarily through
ADAMHA, supports approximately 85 percent of all research on mental and
addictive disorders conducted in this country. While adding all funds spent by
ADAMHA on animal research to current Federal outlays for mental health and
substance abuse care would not even create a ripple in the services budget, the
impact on research opportunities would be immense, virtually eliminating the
possibility of a scientific breakthrough based on animal research--a
breakthrough such as the discovery of lithium for treatment of manic depressive
illness.
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IV. “Animal research is unnecessary to medical progress.” Given the
widespread scientific illiteracy of the target audience, this is a persuasively
deceptive argument. Because there typically is a lag of at least 10 years between
the conduct of basic animal research and its clinical application, the relevance of
basic studies to health care often is difficult to perceive. This is particularly true
of basic studies in the fields of mental and addictive disorders.
In fact, virtually every advance in medicine either originated in basic animal
research or involved animals in a key part of its development. In the mid-1970s
(prior to the current controversy), Comroe and Dripps (1) polled clinicians in
cardiovascular-pulmonary medicine as to what they viewed as the medical
advances which were most helpful to their patients. Responses included open
heart surgery, drug treatment of hypertension, cardiac resuscitation and
defibrillation techniques, oral diuretics, chemotherapy and antibiotics, early
diagnostic methods, prevention of poliomyelitis, and others. All of the
advances were shown by the authors to have depended on animal research at
critical stages of their development.
Four of the top ten ranked advances, moreover, were shown to have originated
in unrelated fields, a finding that effectively rebuts the frequent demand of
animal rights activists that every research project must be justifiable in terms of
a predictable health application. By this yardstick, most contemporary medical
advances never would have happened.
Animal research is no less critical to advances in the treatment of mental and
addictive disorders, a fact that assumes added significance given the manner in
which the animal rights movement has targeted research on “behavioral”
disorders. Lithium, used today to treat successfully some 75 percent of patients
with manic depressive illness, was a direct and unexpected product of animal
research. Before lithium was introduced, a patient with this illness would, on
the average, spend one-fourth of his adult life in the hospital; more than one in
four with the illness died by suicide. Today, 80 percent of manic depressives
never see the hospital and the suicide rate among persons being maintained on
lithium is close to that of the general population. In the U.S. alone, lithium has
yielded direct treatment cost savings of $12 billion over the nearly two decades
since receiving FDA approval.
A timely example of a direct contribution of animal research to drug abuse
treatment is seen in the recent clinical evaluation of carbamazepine, an
anticonvulsant drug, in treating cocaine addicts. This innovative approach
stems from research conducted at the NIMH that was concerned with the
tendency of some patients with manic depressive illness to cycle rapidly
between episodes of mania and depression. At the turn of the century, Emil
Kraepelin had observed that the illness could initially be triggered by stresses;
later, Bob Post and I had hypothesized several years ago this reflected the
activation of a genetic predisposition and that, once activated, the illness
assumes its pattern of spontaneous recurrences. Post drew an analogy between
this and the process of electrical kindling in the CNS; that is, the tendency of a
highly regulated system, such as the limbic system, to respond more and more
measurably to a repetitive electrical charge and, eventually, to produce that
response spontaneously, in the form of a seizure, in the absence of the
stimulus.
Dr. Post subsequently determined that a kindled seizure could be induced
pharmacologically, through repeated but intermittent administration of cocaine
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and that the seizure--whether induced electrically or pharmacologically--could
be arrested by the anticonvulsant carbamazepine. The medication has since
been shown to be an effective treatment for a substantial number of lithium-
resistant rapidly cycling manic depressive patients.
Upon hearing reports of Post’s work, Jim Halikas, a psychiatrist at the
University of Minnesota, immediately initiated an open clinical trial of
carbamazepine in a small group of hard-core cocaine addicts (2). The
medication yielded dramatic results: cessation of use in about half of the
subjects and significant reductions in frequency of use among others.
These preliminary findings, now being evaluated in controlled studies, are
particularly noteworthy for several reasons. First, is the demonstration of
unexpected benefits that result from basic animal research; in the absence of the
theoretical basis provided by Post’s animal work, it might not have occurred to
those in the cocaine treatment community to work with an anticonvulsant.
Second, the link between the animal observation and the clinical trial was both
direct and immediate--there was no 10 or 20 year lag between the observation in
animal studies and the preliminary application to a clinical problem. And third,
the finding underscores the relevance of research on basic brain processes in
animals to human brain disorders such as addiction.
V. “Modem alternatives can replace animals in research.” This version of the
“we don’t need animals” argument holds that alternatives to the use of animals
in research exist. Regardless of how little people may know about science, most
are familiar with such buzzwords of the argument as “computer modeling” and
“tissue culture,” and most have passing familiarity with such technological
innovations such as scanning devices. With respect to computer modeling--an
“alternative” particularly appealing to young people who are caught up in the
romance of computers--the fact is deliberately obscured that computer modeling
living systems first requires actual data from living systems; that a computer
model is nothing more than a hypothesis, a way of formalizing scientific beliefs
in a way in which they can be quantitatively tested. The fact that tissue culture
cannot substitute for the complexity of an animal, particularly an organ like the
brain, is similarly obscured. And those who claim that devices such as PET
scanners offer a substitute to the use of animals conveniently overlook the many
years of animal research that were required to develop the tracer technology that
made the PET scanner useful.
VI. “Lost pets held in pounds are at risk for research use.” More than 90
percent of all animals used in research are rodents, rats and mice principally.
For every cat and dog used in brain/behavioral research, 7,000 are killed by
pounds or shelters, a number that is increasing for several reasons. One, noted
above, is the reduction in funds available for adoption and neutering programs
traditionally conducted by animal welfare groups as resources are channeled to
the animal rights agenda. Also, when State and local laws prohibit the sale of
pound animals to research facilities, these animals will be killed. At the same
time, animals must be specially bred for research purposes, at considerably
more cost.
Impact of Animal Rights on Behavioral and Biomedical Science
Even within the research community, the view often is expressed that the animal
rights movement initially was helpful in, that it increased sensitivity to animal
welfare. But the helpful phase is now long gone, replaced by the fear reflected
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in the “bunker mentality” of individual scientists and universities. We already
are seeing a sharp decrease--62 percent decrease over the past two years--in the
number of drug abuse studies using primates. Given the urgency of the drug
abuse crisis and the scientific consensus on the need for animal models, it is
difficult to ascribe such a large decrease to anything else but fear.
The animal rights movement also has had a substantial impact on the costs of
conducting research. Implementation of new animal care guidelines has been
estimated at $1 billion in the first year; this does not account for costs that will
be incurred in meeting recent requirements addressing the “psychological well-
being” of animals in research facilities. A billion dollars is roughly equivalent
to a 17 percent cut in the research budgets of the NIH and ADAMHA, the
ultimate source of most of the funds.
An ominous long-term impact of the movement is the dramatic decline in “hands
on” experience with animal research in education, including the medical
schools. A recent survey found that 42 percent of medical graduates planning
to pursue careers in clinical practice questioned the value of animal research, a
reflection of attitudes that are indirectly being nurtured in schools at all levels.
Motivated in part by attempts to appease activists, some mainline educational
organizations such as the National Association of Biology Teachers have passed
resolutions outlawing the use of animals in class, and even in some medical
schools, students are allowed to opt out of participation in laboratories where
they gain “hands on” familiarity with animals in the lab.
Without a massive effort to reinstate basic principles of science education, the
life sciences not only will be increasingly handicapped in the recruitment of
students in the future, but also will lose the current public support as today’s
students grow up. A recent National Family Opinion survey commissioned by
the Foundation for Biomedical Research found that 77 percent of the American
public support the use of animals in biomedical research; that 70 percent support
basic biomedical research, even when it will not lead directly to the cure or
treatment of a specific disease; and that 65 percent oppose organizations
attempting to stop the use of animals in research or product safety testing.
Present trends in the educational system suggest, however, that this level of
support will erode in the future.
What Must Be Done
The fundamental philosophy of the animals rights movement is becoming
increasingly well-understood, the strategies employed by the movement are
clear, and the impact, to date, is considerable. If we are to ensure the continued
vigor and productivity of the biomedical and behavioral research enterprise, the
government, universities, physicians, and patient organizations must work
proactively and collaboratively.
The pharmaceutical industry and other high-tech enterprises that depend on
basic research must also become more actively involved. The animal rights
movement currently spends more than $52 million dollars annually to stop
animal research. The biomedical research establishment in its entirety spends
about $1 million per year to conduct public education and counter the
misinformation disseminated by the movement. Although most of these funds
are provided by pharmaceutical companies, the amount is minuscule in
comparison to the many millions of dollars a company typically will spend to
market one product derived from animal research. Most companies are
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unwilling to assume high individual visibility in defense of animal research,
given the perceived risks of boycotts and demonstrations, confrontations with
stockholders, and death threats to senior corporate officers. These concerns
would be minimized if the industry acted in unison with a single action plan that
all relevant businesses would support.
Similarly, universities must be encouraged to stand fast in the face of
harassment from the animal rights movement. A strategy being employed by
movement activists is to target a specific research project at a given university
for protest demonstrations. In a well-publicized case, activists intimidated
university officials into declining a federal research grant to a senior investigator
after the application had been reviewed and approved, both for scientific merit
and animal welfare.
In the wake of this incident, ADAMHA determined the need to assess carefully
any research grant applications from a university showing any tendency to yield
to animal rights pressures. University administrators must be encouraged to
appreciate the responsibilities which the institution assumes in competing
successfully for federal research funding. The return of a grant for non-
scientific reasons--for example, to keep the campus quiet or to placate a small
vocal minority of alumni--wastes the resources devoted to the review process
and conveys the message that the process can be undermined for reasons that
have nothing to do with research. Universities that bow to “stop research”
pressures exerted by animal rights activists must understand that they are
jeopardizing their eligibility for all ADAMHA grants, not just those using
animals. Unless federal funding agencies set up a counterpressure, it is
possible that an increasing number of universities will give in to the demands of
the movement one at a time. At this writing, the National Institutes of Health
has not formulated policy in this particular area of concern; ADAMHA has taken
the initiative because research on mental and addictive disorders has been
specially targeted by the animal rights movement.
Within the research community, mechanisms are needed that will provide
incentives for scientists to devote time to nurturing and protecting the enterprise.
Currently, extensive service as a spokesperson for the use of animals in
research takes time away from the bench or clinic and may be perceived as a
handicap in competition for grants. We must explore novel means of rewarding
those academicians who are inclined and willing to do advocacy for animal
research and other areas of infrastructure concern.
And the federal life sciences agencies, principally NIH and ADAMHA, must do
a great deal more in direct public education efforts. NASA provides a good
model. The agency reaches out to primary and secondary level students to
encourage their interest in curricula necessary for careers in the space program.
There is virtually no comparable effort on the part of the federal agencies
responsible for the life sciences, and it is evident that the research community
can no longer take the interest of future generations of students for granted.
Scientists who are interested in science advocacy and public education must
develop the necessary skills. Given the tenor of the animal rights controversy,
media training--particularly in the handling of confrontational interviews-is
useful.
If the research community does not address the threat of the animal rights
movement with a single voice, the movement will continue to grow in size and
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effectiveness. If we allow this to happen, sooner or later, animal research and
all that it can provide for the health of our people with be a thing of the past.
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Implication for Research of the
1988 Anti-Drug Abuse Act
Charles R. Schuster
OPENING REMARKS
Thank you. Dr. Dewey. It's a pleasure to be with you again at
CPDD's Annual Meeting. As always, I look forward to this
opportunity for drug abuse researchers to share the progress
that is being made toward understanding and controlling the drug
problem, and to discuss the directions that drug abuse research
should be taking in the future.
Several of these directions of research are now being
established or impacted by a very significant piece of
legislation-the Anti-Drug Abuse Act of 1988, which passed in
November of last year. The Act has a total authorization level
of $2.7 billion, for covering such areas as:
*Federal, State, and local drug law enforcement;
*school-based drug prevention efforts; and
*drug abuse treatment, with special emphasis on intravenous
(IV) drug abusers at high risk for AIDS.
OVERVIEW OF THE ANTI-DRUG ABUSE ACT
Of the ten Titles of the Act, four have provisions that will
influence efforts to reduce the demand for illicit drugs. These
are:
*Title I - Coordination of National Drug Policy,
*Title II - Treatment and Prevention Programs,
*Title III - Drug Abuse Education and Prevention, and
*Title V - User Accountability. 
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I would like to cover Titles I, III, and V briefly, and then
take a closer look at Title II, which directly impacts research
programs supported by the National Institute on Drug Abuse
(NIDA) and the Alcohol, Drug Abuse, and Mental Health
Administration (ADAMHA).
* Title I of the Act creates the Office of National Drug
Control Policy, headed by William J. Bennett, which has
overall Federal responsibility for establishing the policies,
objectives, and priorities for the National Drug Control
Program. Director Bennett will have two Deputies-one each
for supply and demand reduction-as well as an Associate
Director to serve as a liaison with States and localities.
The Office is responsible for reviewing and certifying each
drug control budget request, and for establishing and
implementing a National Drug Control Strategy. This Strategy
must be completed by September 5, 1989. NIDA staff meets
weekly for providing, where possible, scientific data to
contribute to policy decisions and new strategies for demand
reduction.
* Title III of the Act expands drug abuse education and
prevention activities from the preschool level through high
school, touching children in early programs such as Head
Start, as well as runaways and homeless youth. This Title
also funds teacher-training programs for alcohol and drug
abuse prevention at the State, local, and higher education
levels.  Block grants will  be awarded  for State
community-youth-activity programs.
* Title V of the Act acknowledges that uses of illicit drugs
are accountable for their behavior. This is one of the more
controversial parts of the new law. The Title establishes new
penalties for drug possession or use; sets up the National
Commission on Drug-Free Schools;  develops tactics  for
preventing drug abuse in public housing; and extends the
Drug-Free Workplace Act to contractors and grantees of the
Federal Government.
THE ACT'S IMPACT ON TREATMENT AND PREVENTION PROGRAMS
Title II of the Anti-Drug Abuse Act authorizes new treatment and
prevention programs and reauthorizes many existing
programs-including NIDA's research activities and the Alcohol,
Drug Abuse, and Mental Health Service, or ADMS, Block Grant.
NIDA's research resources have been expanded significantly as a
result of the Act. Our research program has been reauthorized
for three years, and it received a $30 million supplemental
appropriation. With this supplement, NIDA's total budget
increases from $198 million in fiscal year 1988 to $320 million
in fiscal year 1990. Our AIDS budget jumps from just over $76
million in 1988 to nearly $140 million in 1990. And our budget
for non-AIDS related research increases from more than $122 to
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more than $180 million. Including the supplemental
appropriation and Block Grant set-asides, NIDA's current
non-AIDS budget increased 50 percent over the 1988
appropriation.
The number of grants we are funding is also changing.
NIDA-funded AIDS research will increase from 65 grants in fiscal
year 1988 to 104 in 1990. Our total non-AIDS grants will
increase from 459 in fiscal year 1988 to 488 in 1990, but will
drop from a high of 524 in 1989, including a nearly 17 percent
decrease in new grants from fiscal year 1989 to 1990.
Of the $30 million added to NIDA's research program, $10
million were added by Representative Silvio Conte (Rep., First
District of Massachusetts) to specifically fund research on the
development of new medications for the treatment of addictive
disorders. This money will expand our Medications Development
Program for drug abuse treatment-and particularly our efforts
to make LAAM and buprenorphine available as treatments for i.v.
heroin addiction. Bringing such medications into use is
absolutely necessary for reducing the spread of HIV infection
through the sharing of needles and syringes. In addition, the
Program is developing other Pharmaceuticals for treating opiate,
cocaine, and PCP abuse.
The remaining $20 million of our supplemental appropriation has
also made it possible to expand our research into the factors
that make individuals vulnerable to drug abuse, the consequences
of parental drug use on the newborn, and the development of new
prevention strategies and ways to enhance existing treatment
strategies.
Under the new law, NIDA is also responsible for conducting drug
abuse research demonstration projects of national significance.
For these, we have $7 million. These research demonstration
projects will examine:
* the feasibility and long-term efficacy of programs providing
drug abuse treatment and vocational training in exchange for
public service, and
* the effectiveness of providing maternal care in drug abuse
treatment to pregnant and postpartum women and their infants.
In addition, NIDA is providing funds to the National Institute
on Justice for a research demonstration project to conduct
outreach activities to i.v. drug abusers. Under this project,
outreach workers will provide education on ways to prevent AIDS,
and will encourage i.v. drug abusers in jails and prisons to
seek treatment for such drug abuse.
Also of interest to CPDD members, NIDA and the National
Institute on Alcohol Abuse and Alcoholism (NIAAA) will be
providing support for clinical training programs:
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* to train health professionals in the diagnosis and treatment
of alcohol and drug abuse, and
* to develop appropriate curricula and materials for such
training.
Although not specifically funded by the Act, NIDA has added some
exciting new research training programs. NIDA 's research
training has always included individual fellowships and
institutional training programs. Recently, a number of other
types of programs that will enhance research skills in minority
populations, encourage physicians to conduct drug abuse
research, and expand AIDS research training have been added to
the research training portfolio.
One of the newly announced awards is the Minority Research
Program Supplemental Award. This award provides supplemental
support for salaries, equipment, and other items to an ongoing
NIDA research grant, program project, or center grant to allow
minority applicants to improve their research capabilities and
to bring them into the mainstream of the NIDA research program.
Current funding for NIDA's research training programs total $2
million--$1.1 million for new grants and $.9 million to
continue existing grants.
A major emphasis in research training beginning in fiscal year
1990 will be in areas related to AIDS and drug abuse inter-
actions. Research areas include epidemiology and psychosocial
factors in HIV infection in drug abusers, treatment and
prevention research, and preclinical studies on the. effects of
chronic drug abuse on the immune system. An announcement on this
research training program will soon be available. A special
effort will be made during this meeting to acquaint the drug
abuse community with both the new and the older programs.
To this end, the NIDA Research Training Task Force has developed
a plan to introduce the research training program to CPDD
members, and to introduce some NIDA trainees and fellows to a
CPDD meeting. With the generous cooperation of CPDD in hosting
research reports from our training programs, 28 trainees or
fellows currently supported by NIDA (23 percent of the total)
have received travel awards to come to this meeting and make
formal presentations of their research. At least one trainee
from each institutional training program and nine holders of
individual fellowships are on the program this week. It seems to
us to be very important for new investigators to be exposed to
the breadth and depth of research areas represented at this
meeting, just as it seems very important to expose CPDD members
to the kinds and strengths of research training supported by
NIDA.
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THE ADMS BLOCK GRANT
At the administration level, the Anti-Drug Abuse Act of 1988 has
consolidated all ADAMHA treatment services funds into one block
grant, with $806 million appropriated for this in FY 1989.
Congress has mandated specific "set-asides" for these funds.
Within the total block grant appropriation, $125 million are
supplemental substance abuse funds for FY 1989. The Act
requires that each State must spend not less than 50 percent of
these funds on treatment for i.v. drug abusers, unless they
receive a waiver from the Secretary of the Department of Health
and Human Services. In addition, a certain portion of the
States' remaining funds in fiscal years 1990 and 1991 for drug
abuse must be allocated to treatment for i.v. drug abusers. The
States may use the supplemental funds to:
* develop, implement, and operate treatment programs for i.v.
drug abusers;
* train drug abuse counselors and other health care providers
to provide treatment; and
* conduct outreach activities to encourage people to seek
treatment.
Congress also mandated that the States use ten percent of their
block grant allotments for programs and services designed for
women-especially pregnant women and women with dependent
children-as well as demonstration projects to provide
residential treatment services to pregnant women.
Prior to the Act, the States were prohibited from allowing
programs to use Federal funds for construction purposes. The new
law now provides a waiver mechanism so that substance abuse
funds can be used for construction. ADAMHA will be issuing
guidelines for this provision, as well as for a requirement that
States establish a revolving fund to make loans from
appropriated funds for housing for recovering substance abusers.
One important provision of NIDA in this Act is a five percent
set-aside in fiscal year 1989 for data collection, technical
assistance, and health services research for alcohol, drug
abuse, and mental health areas. From this, NIDA and NIAAA will
receive a total of $19.5 million to be used for data collection
activities and services research. NIDA will devote $1.75 million
to services research and, in conjunction with NIAAA, $16 million
for data collection.
The Act has also reauthorized the Office of Substance Abuse
Prevention (OSAP), and has elevated this office to institute
level within ADAMHA. OSAP's responsibilities will include:
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* supporting clinical training to substance abuse counselors
and other health paraprofessionals involved in drug abuse
education, prevention, and intervention;
* assisting communities in developing comprehensive long-term
strategies for substance abuse prevention, and evaluating the
success of different community approaches toward prevention;
and
* supporting prevention, education, and treatment regarding
drug and alcohol abuse relating to pregnant and postpartum
women and their infants, as well as demonstration projects to
provide drug treatment services to these women and infants.
ADAMHA will also be administering a one-time discretionary grant
program to reduce waiting lists for drug abuse treatment; $75
million was appropriated for this program.
CLOSING REMARKS
As the focal point in the Federal government for research on
reducing demand for illicit drugs, NIDA has a critical role to
play in implementing the Anti-Drug Abuse Act of 1988. We are
working with other components of ADAMHA and the Department of
Health and Human Services, as well as with other Federal
agencies, to implement the Act's provisions.
As I have noted, passage of the Act has given NIDA a 50 percent
increase in our non-AIDS budget. This will allow us to
capitalize on opportunities and expand our efforts in the
priority areas of improving prevention and treatment strategies-
-including new medications for treatment, and more effective
training for physicians and counselors involved in the drug
abuse area-and of better understanding the 'effects of drug
abuse on mothers and infants.
In addition, the $16 million that the Act has authorized for
data collection will allow NIDA to reestablish data collection
activities on the Nation's treatment programs as well as provide
fuller and more frequent monitoring of the incidence and
prevalence of illicit drug use. The data from these studies is
essential for policy decisions in the treatment area.
We have recently established a Health Services Research Branch
in our new Division of Applied Research. The $1.75 million
provided by the Act will allow us to expand our research in the
health services area. This research will be closely coordinated
with our treatment evaluation activities, enabling us to provide
more precise data on the cost effectiveness of various treatment
interventions.
It is important to remember in any review of NIDA's research
program that AIDS is the number one priority of the Public
Health Service. Since drug abuse prevention and treatment is
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also an AIDS prevention strategy, much of our attention will be
directed toward the IV drug abusing population and their sexual
partners and children.
The Anti-Drug Abuse Act has, in effect, opened wider the windows
of opportunity in drug abuse research. NIDA will continue to
seize research opportunities as they arise, but by providing
continuity in our priority programs, we hope to encourage
greater stability in important areas that demand research
attention over several years. This Act-for the next three
years, at least-has ensured that continuity.
In conclusion, I would like to comment on the interaction
between NIDA and CPDD. I look at CPDD's annual meeting as a
progress report for NIDA. I am very glad that Dr. Goodwin, the
Director of ADAMHA, and Dr. Gordis, the Director of NIAAA, are
here to see the breadth and depth of research being sponsored by
NIDA. Ninety-one percent of the individuals presenting here are
NIDA grantees. The quality of their research gives us all great
hope that our understanding of the biological, behavioral, and
social factors leading to drug experimentation-and, in some
individuals, addiction-will lead to increasingly effective
prevention and treatment interventions. The 1988 Anti-Drug Abuse
Act has provided us with increased funds to continue our
research efforts. We all know, however, that this increased
funding must be sustained if we are to realize the gains which
our current research promises.
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Major Initiatives in Alcoholism
Research: Current Questions,
Future Answers
Enoch Gordis
INTRODUCTION
Until the early 1970s, alcohol abuse and alcoholism were not
considered areas worthy of serious investigation. This situation
changed dramatically with the creation of the National Institute
on Alcohol Abuse and Alcoholism (NIAAA) in 1971, as the focus for
the Federal government's efforts to prevent and reduce the
tremendous health, social, and economic consequences of alcohol
abuse and alcoholism in the United States.
Over the years, the NIAAA mission has changed from its initial
support for research and research training, clinical training,
and prevention and treatment services, to its present one which
focuses exclusively on research. We do not support prevention or
treatment services, but provide the research evidence necessary
to improve them. We also do not formulate or advocate for any
particular public policies but seek to develop scientific
information that can be used by the Congress and other policy
makers and advocates as a part of their deliberations on various
public policy measures.
Through an intramural scientific staff and an extensive program
of extramural research grants and contracts, NIAAA supports
epidemiologic research; research on the effects of alcohol on the
human body; research on preventing and treating alcohol abuse and
alcoholism; research training programs; health education
development programs; a research-based services demonstration and
evaluation program targeted at homeless persons with alcohol-
related problems; and research on alcohol-related public policies
that have broad implications for prevention, treatment, and re-
habilitation.
Additionally, NIAAA maintains an active science communication
program aimed at sharing with health care practitioners, policy
makers, the general public, and others involved in managing
alcohol-related programs about research findings with applic-
ability to alcohol treatment and prevention efforts. Our
scientific communications vehicles include publications such as
Alcohol Health and Research World, a professional journal
published quarterly; Alcohol Alert, a publication designed to
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quickly disseminate research findings to alcohol clinicians; the
special reports to Congress on alcohol and health, issued
triennially; and specialized monographs and reports.
Research findings are also shared with the alcohol and general
health care communities through two new on-line database services
supported by the Institute. The first of these, the "Quick Facts"
electronic bulletin board is available to anyone with a terminal
and modem. Developed under the aegis of the Institute's Alcohol,
Epidemiologic Data System (AEDS), Quick Facts provides access to
alcohol-related epidemiologic data and facilitates communication
among NIAAA staff and others interested in NIAAA programs and
data. Scientists, clinicians, and others interested in
alcohol-related research also have direct access to NIAAA's
comprehensive bibliographic data bank, the "Alcohol and Alcohol
Problems Science Database" through BRS, a commercial database
vendor. The BRS title for the database is "EtOH," named after
EtOH, one of the chemical designations for ethyl alcohol. ETCH
covers literature from the late 1960's to the present, contains
over 60,000 bibliographic records, and has grown to cover all
aspects of alcohol research: psychology, psychiatry, physiology,
biochemistry, epidemiology, sociology, neuroscience, treatment,
prevention, education, accidents and safety, criminal justice,
legislation, employment, labor and industry, and public policy.
In addition to scientific and technical journals, the database
contains entries on books, monographs, government reports,
dissertations, and conference papers.
The Institute also collaborates with other national alcohol
research institutions and is actively involved in a number of
international collaborative studies.
This extensive agenda reflects the complexity of the problem
NIAAA was created to address. Alcoholism and alcohol abuse have
many roots and many manifestations; thus, the activities of NIAAA
bring to bear the day-to-day energies of many people and a wide
spectrum of organizations, joined in investigating, clarifying,
and understanding one of the Nation's most troubling public
health problems.
MAJOR RESEARCH INITIATIVES
Remarkable progress has been made over the past 15 years in
understanding the causes and consequences of alcohol abuse and
alcoholism. However, many basic questions remain concerning
alcohol's action on the body, the mechanisms of dependence,
alcohol's impact on individuals and groups in society: and
alcohol's role in shaping the environment. For example, genetic
research has contributed substantially to our understanding of
alcoholism's etiology, however, we have not yet identified a
genetic marker for a predisposition to alcoholism or developed a
good understanding of the specific mixes of genetic/environmental
factors that predispose individuals to alcoholism. The answer to
one of the central questions in alcohol research-why people
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continue, in the face of clear evidence of harm, to consume
large quantities of alcohol. Another largely unanswered question
is what factor or combination of factors are likely to be
effective in preventing alcohol abuse and alcoholism in specific
populations. We do not yet have scientifically valid evidence of
the effectiveness of many of the commonly used treatments for
alcoholism. This lack of evidence has major implication for
continued public and private third-party support for alcoholism
treatment.
Through alcohol research, we are asking these and other questions
in our search to find way to help prevent and treat alcohol abuse
and alcoholism. Some of the major activities in alcohol research
that may provide answers to these perplexing questions are
discussed below.
PREDISPOSING FACTORS
Genetic factors, environmental factors, and the interplay of
genetics and the environment have all been implicated in the
etiology of alcoholism. However, the precise nature of the
specific genetic and environmental elements involved, and the
complex processes by which they interact, have yet to be defined.
It has been known for many years that certain families have more
than their share of alcoholic members, leading to suspicions that
alcoholism may "run in families". Studies were initiated to
define the biological and psychosocial factors that place some
families, or specific individuals within these families, at
greater risk for alcoholism. To distinguish the effect of
learning from inheritance, investigators turned to the study of
special populations such as twins, that permitted separation of
these factors. Monozygotic (identical) twins who share all
inherited traits were compared with dizygotic (fraternal) twins
who share inherited traits in the same way as non-twin siblings.
Adoptees who share an environment but not genes, and half-
siblings who share only one biological parent who may or may not
be the alcoholic, have also been studied. This research has
provided evidence of a genetic component in defining the risk for
alcoholism in a significant subset of the population. Currently,
studies involving twins and adoptees are seeking to develop more
refined knowledge about the genetic/environment interaction, as
well as the genetic determinants.
It is clear that predisposing genetic factors may remain dormant
in the absence of environmental cues and, further, that
alcoholism may develop in the absence of genetic predisposition.
It therefore has been important not only to identify the
principal environmental factors, but also the manner and extent
to which they interact with genetic factors. Consequently,
another important area of research is the study of age-related
patterns and predictors of alcohol use and abuse to identify
environmental and psychological factors that may facilitate or
constrain problem alcohol use. Under study as possible predictors
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of later problem drinking are childhood antisocial behavior,
parental drinking, cognitive functioning, attitudes,
expectations, personality, environmental stress and coping,
ethnicity, and cultural and socioeconomic factors.
Movement toward the development of an integrated causal
explanation of alcoholism that takes into account biological,
psychological, social, environmental, and developmental
influences will be an important outcome of research during the
next ten years. Formulating such an explanation will necessarily
involve not only identifying factors that promote the development
of alcoholism, but also factors that protect against it. The
opportunity to develop non-invasive techniques for screening of
high risk genotypes for alcoholism, and to employ knowledge about
causal pathways in the prevention and treatment of alcoholism,
will be important future developments. Over the next decade, the
application of modern molecular genetic techniques to the study
of alcohol-derived pathologic diseases should uncover the genetic
factors contributing to these diseases, and could provide
insights into the mechanisms by which these disorders develop.
Applying the technique of restriction fragment length,
polymorphism (RFLP) analysis in the study of a specific alcohol o
derived pathology, such as in alcoholic pancreatitis or alcohol
dementia, will provide an indication of whether a variant gene
may be involved in the expression of the disease/ and provide
information on its approximate chromosomal location and the
nature of its inheritance pattern. Further research then may lead
to the identification of the precise location of the gene on the
chromosomal map, and then to the recognition of the affected gene
and its protein product. This knowledge may be vital to
uncovering the mechanism by which injury is produced and lead to
preventive and therapeutic remediation.
To further advance this immensely important area NIAAA has
developed a collaborative research program in genetics. Involving
both NIAAA intramural scientists, and extramural scientists, this
activity will begin to examine the heritage nature of traits
associated with the risk of alcoholism and apply molecular
genetic studies to begin mapping genes important in alcoholism,
thereby providing valuable new information about the inheritance
patterns of alcoholism.
ALCOHOL AND DEPENDENCE
The majority of adult Americans who consume alcoholic beverages
do so without problems. A second group of problem drinkers or
alcohol abusers experience negative consequences of their
drinking (e.g., accidental injury and death, the loss of spouse,
children, employment, etc.) but are not dependent on alcohol. For
these individuals, health, social,. and economic consequences
develop secondary to alcohol use because of poor judgment,
failure to understand the risks, or lack of concern about the
damage to themselves or others. A third group, however, have the
disease called alcoholism and are dependent on the drug alcohol.
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These drinkers became ill when drinking is interrupted (i.e.,
they experience an abstinence or withdrawal syndrome); they are
tolerant to large amounts of alcohol; they miss alcohol intently
or "crave" alcohol at times when they are abstinent; and, in the
real world, they frequently display lack of control over their
drinking. Unlike normal drinkers who seem to have an internal
signal which says "enough", alcoholics generally cannot control
the amount of alcohol they drink on any occasion. They drink
compulsively despite the obvious damage their drinking causes.
Why is this so? Research to answer this question, particularly
research on alcohol's effect on the brain, has been progressing
at an unprecedented pace.
Though alcohol undoubtedly interacts with and affects virtually
all organs, the expression of alcohol's action on the brain is of
particular importance. Alcohol's actions include not only
intoxication, but the additional phenomena of tolerance and
dependence. Tolerance is the ability of the brain to adapt to the
presence of alcohol such that greater and greater quantities of
alcohol become necessary to produce the same effects. This
increases the likelihood that particular individuals drinking for
some desired effect or feeling will increase their alcohol con-
sumption. Dependence is the adaptation in structure and function
of the nervous system as a consequence of chronic alcohol use,
which makes it necessary for the drinker to continue consuming
alcohol in order to prevent the unpleasant withdrawal reaction.
An abundance of information derived from basic research in brain
morphology, chemistry, and electrophysiology has provided a
strong background for asking focused questions concerning the
effects of alcohol on the brain. Proceeding from current findings
and using state-of-the-art neuroscience and biobehavioral
techniques, investigators hope to illuminate the mechanisms
underlying alcohol intoxication, tolerance, dependence,
reinforcement, and craving inherent to alcohol abuse and to the
disease of alcoholism.
For instance, although it is well known that alcohol exerts
profound effects on brain function, the cellular and biochemical
bases for its actions are not yet clear. In efforts to explore
the processes of intoxication, tolerance, and dependence, current
research is characterizing the role of specific neurotransmitter
systems; the effects of alcohol on nerve cell membranes;
determinants of alcohol craving; and the structural and
functional changes seen in chronic alcohol use. Progress made in
understanding the acute and chronic effects of alcohol in the
central nervous system has been encouraging and is already
providing direction for the development of new therapeutic
agents.
Intoxication, tolerance, and dependence have been studied at a
number of functional levels within the brain, including that of
the individual brain cell, or neuron. Each neuron is surrounded
by a membrane that is composed principally of fat-like molecules
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called lipids, and of proteins embedded in the lipid structure.
It now appears that a significant degree of alcohol's actions on
the brain are exerted through the interactions of the alcohol
molecule with lipids and proteins of the cell membrane. The
disruption of the cell membrane may account substantially for the
phenomena of intoxication, and the adaptations of the cell
membrane to the presence of alcohol may account substantially for
many facets of tolerance and dependence.
Neuroscience research is helping to lay the groundwork for
understanding why alcohol consumption is so rewarding to some
people-that i they continue to drink even after they develop severe
health, social, and economic problems. Scientists hope to
identify the neuronal systems in the brain which determine the
pleasurable effects produced by alcohol and to learn if these
sites in the brain account for the pleasure produced by other
abused substances, such as cocaine and heroin.
There are many chemical messengers or neurotransmitters that
allow the neurons of the brain to communicate with each other.
One neurotransmitter that now appears to have particular
importance for explaining alcohol's action is gamma-aminobutyric
acid (GABA). A number of drugs with actions similar to alcohol
also appear to affect the GABA neurotransmitter system, including
the barbiturates and the benzodiazepine tranquilizers, such as
Valium. Some of the more interesting recent findings concern
the actions of new drugs that, while chemically similar to
Valium, have an effect opposite to that of a tranquilizer.
These new drugs have been found to block alcohol's action on the
GABA system in the brain and to reverse some of alcohol's effects
on behavior, such as loss of motor coordination.
During the next ten years it may be possible for neuroscientists
to determine the physiological processes that mediate the
relationship between alcohol craving and the appetitive behaviors
of hunger and thirst. Understanding the basic human appetitive
process could be the critical determinant for developing
successful alcoholism treatment programs. Insight into the
neurochemical actions of alcohol on neurotransmitter and membrane
receptor systems should also be forthcoming.
Most exciting in the coming years is the very real possibility
of using individual brain imaging techniques to identify neural
substrates inherent to alcohol-related phenomena, but to combine
information derived from different techniques such as magnetic
resonance imaging (MRI), positron emission tomography (PET), and
electrophysiological studies to create new conceptions of the
dynamic workings of the brain. At the very least, integrating
data from studies that have applied different technologies will
help resolve uncertainties about particular brain pathways and
behaviors that regulate responses to alcohol. Computer-aided
modeling of cell assemblies will be an additional innovation.
Because of the complex pharmacological effects of alcohol and the
sheer number of brain regions affected by alcohol, it is
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generally recognized that a global understanding of alcohol's
actions will require sophisticated technological models of
networks of brain activity- In the 1990 's, brain and behavioral
science research will also be in a position to incorporate
computer-aided modeling and imaging techniques that will allow
for a better understanding of addictive behavior and enable early
detection of alcohol -related problems.
PREVENTING ALOOHOL-RELATED PROBLEMS
Prevention is one of the most difficult area of research with
which our Institute has to deal - difficult because of the need to
study real-life situations outside of the laboratory and the
resulting number of variables beyond the researcher's control.
Yet, it is vitally important that we determine what strategies
are most effective in preventing alcohol and other drug problems
among our Nation's many subpopulation groups, particularly given
the current national concern for preventing alcohol and other
drug abuse and the massive public and private expenditures for
prevention-related activities.
In 1987, NIAAA gave added prominence to prevention research by
establishing a Prevention Research Branch within a new extramural
Division of Clinical and Prevention Research. Areas of current
research interest focus on preventing alcohol abuse by
encouraging changes in an individual or groups of high-risk
individuals; changes in the environment; and examinations of the
complex, synergistic relationships between the actions of
individuals, groups and the larger social system.
In planning prevention research in the alcohol arena, it is
important that investigators identify the outcome or the relevant
drinking behavior to be prevented (e.g. , addiction, sequelae of
alcoholism such as cirrhosis, injurious consequences of alcohol
abuse such as traffic accidents, violence and absenteeism, etc.) .
Regardless of the choice of outcome measure, alcohol prevention
research has common underlying themes: A systematic quest for
effective strategies to reduce the incidence and prevalence of
alcohol abuse and alcoholism; and/or a systematic quest for
mechanisms to ensure the diffusion and adoption of prevention
strategies proven to be effective.
The questions that remain unanswered relative to our ability to
prevent alcohol abuse and alcoholism are many. For example, with
respect to youth and young adults, what are the effects of peer
pressure, decision making skills, and personality variables on
the drinking habits of high school and college students? What are
the effects of expectancies and sociocultural variables on early
drinking habits, as well as changes in the drinking patterns of
youth over time. Because of the importance of the early years on
development throughout the life span, the efficacy of
intervention efforts for young children of alcoholics and the
impact of parenting skills training also are important areas for
research investigation.
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Another prime area for research on effective prevention
technologies is that of preventing alcohol-related problems among
special population groups. Business and professional women,
Mexican-American women, urban American Indians, and the elderly
are among the special populations currently under study. Some
researchers are investigating whether these populations have
unique qualities that may put certain members at high risk for
alcohol abuse. Others are testing the efficacy of specially
designed prevention strategies for members of these target
groups.
Scientific inquiry of the effectiveness of environmental change
in reducing alcohol-related problems is another vital component
of prevention research. An example of this type of research is to
determine whether the incidence of teenage drinking and driving
can be reduced by changing the minimum drinking age or the price
of alcoholic beverages. The involvement of alcohol in motor
vehicle accidents and in crime is also being examined. Future
research topics include the impact of changes in alcohol beverage
control (ABC) laws on problem drinking; the impact of differences
in the availability of alcoholic beverages on problem drinking;
the effects of informal drinking groups on the consumption
behavior of participants; and the influence of life stressors,
social resources, and coping responses on remission and relapse
among alcohol abusers.
Preventing alcohol-related problems through the workplace is
another area of prevention research emphasis. Employee assistance
programs (EAPS) have grown and expanded dramatically over the
past decade. Studies are being conducted to determine the extent
to which the work environment may improve or worsen problem
drinking and the comparative effectiveness of locating
intervention programs within or outside the work setting. The
structural characteristics of the worksite and the unique
characteristics of employees are being examined for their
complementary contribution to preventing relapse of alcohol
problems. Additionally, the degree to which the attitudes of key
worksite personnel influence EAPs is under study.
Over the next 10 years, efforts will be aimed at applying the
rapidly expanding knowledge on both alcohol abuse and on overall
disease prevention strategies to devise and evaluate new
prevention approaches. Contributing to the development of these
approaches will be knowledge from current research on factors
implicated in the initiation and maintenance of alcohol abuse,
including peer and parental influence and risk-taking behavior.
Advances from research on genetics in behavioral predictors will
allow for the development of more highly focused prevention
strategies. The decade also will afford the opportunity to apply
successful methods of community intervention, derived from
studies directed at reducing risks for heart disease and
hypertension, to prevention of alcohol abuse. The field of
prevention research will also benefit from the application of
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innovative statistical techniques and new behavioral research
methods permitting the rapid assessment of the impact of
intervention approaches and public policy.
TREATING ALCOHOL ABUSE AND ALCOHOLISM
Treatment outcome research and the analysis of treatment outcome
are fundamental to our ability to treat alcohol abusers and
alcoholics. It is clear that the alcohol field can no longer rely
on intuition and experience alone to justify* treatment; the
Congress, third-party payors, the public, and the alcoholic will
require that the effectiveness of alcoholism treatments be
supported by the same evidentiary base of scientific information
that is required for all the treatments for all other diseases.
Thus, research on the efficacy of currently practiced treatment
strategies and on developing new therapies, continues to be a
major NIAAA priority. As with prevention research, the Institute
has elevated treatment research within the organization to
emphasize its importance.
Primary attention paid to answering the question, what type of
treatment will be most effective in treating which type of
patient. Advances are being made in differentiating the
typologies of alcoholics and in developing strategies to match
differing patients to appropriate therapies. For example, several
studies suggest that individuals who have strong social support
system and who do not suffer major psychiatric problems may do as
well in outpatient programs as in more intensive inpatient
settings. The effectiveness of specific therapies for alcoholism
treatment also are under study, including family therapy, relaps
prevention, and behavioral approaches, such as community
reinforcement. At the end of this year, a major multi-site
cooperative study will be undertaken, this study, which involves
clinical trials of strategies for matching particular patients to
the most suitable treatment approach, will have important
implications for improving the effectiveness of alcoholism
treatment.
Another important component of alcoholism treatment research is
the development and assessment of pharmacological agents which
may eventually aid in the treatment process. Thus far, there are
few drugs available that are useful in the treatment of
alcoholism. However, recent studies from the field of
psychopharmacology have shown that certain pharmacologic agents,
such as compounds that block the re-uptake of the
neurotransmitter serotonin, and anxiolytic drugs that lack the
abuse potential of the benzodiazepines, have actions that may be
useful as adjuncts to the standard alcoholism treatment. Research
is ongoing to test whether, and for whom, such drugs may be
useful.
Effective treatment of alcoholism over the next decade will
benefit from rigorous studies evaluating therapies treatment
professionals are currently using. Studies will explore differing
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factors that may relate to the efficacy or particular treatment
approaches, such as a patient's background or personality,
characteristics of the therapist, and the treatment setting. Such
research will enhance our ability to match patients with the most
effective treatment to suit their needs.
During the next decade, investigators will be able to examine the
effectiveness of new pharmacological approaches that offer
potential benefits for alcoholism treatment research. For
example, drugs that interfere with the reward properties of
alcohol may be found to block the phenomenon of craving and
become a valuable adjunct to alcoholism treatment.
With a more precise understanding of the basis of the physiology
of alcohol withdrawal, new drugs may be developed that allow
improved medical management of the withdrawal syndrome, or reduce
the potential of delirium tremens. Research also may provide us
with a better understanding of how the withdrawal experience
affects both subsequent drinking and the potential for effective
treatment.
Due to the magnitude of health problems resulting from alcohol
abuse and alcoholism, there is growing need to improve methods of
diagnosing alcohol-related problems. The development of objective
markers of alcohol consumption would be one such means to permit
a physician to easily assess a patient's history of alcohol
intake.
Significant inroads in this direction have been made by NIAAA
intramural research staff who initiated studies on easily
accessible blood cells and examined the enzymes adenylate cyclase
and monoamine oxidase which they had previously demonstrated in
their studies with animals. Human alcoholics were found to be
significantly different from control subjects in these enzyme
activities, and more than 75 percent of the alcoholics could be
identified using the test of these enzyme activities. An
interesting feature of this study was the finding that the
differences between alcoholics and controls in enzyme activity
was evident for long periods, even if the individual remained
sober. This observation indicated that the observed difference
may be an inherent or inherited characteristics of alcoholic
subjects. Further extensive work is necessary to determine
whether the findings are indications of "state" or "trait"
differences between alcoholics and controls. The work, however,
provides some of the first indications that there may be reliable
markers not only for measuring an individual's prior history of
alcohol intake, but for measuring genetic predisposition in
certain individuals to develop alcohol-related problems during
their lifetime, even if they are not experiencing such problems.
Such diagnostic tools would provide for the physician, or other
treatment specialist, means for appropriate identification and
classification of patients for more specific treatment and
prevention efforts.
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The development of objective markers of alcohol consumption also
will have a significant impact on alcoholism treatment research.
The decade offers the potential for developing objective marker
technologies in kit form. The kits would provide alcoholism
researchers, as well as clinicians, the opportunity to monitor
treatment compliance independent of sometimes unreliable patient
self-reports. Such objective markers have the potential, thereby,
for significantly enhancing treatment efficacy. The prospect for
developing genotypic and phenotypic markers of alcohol dependence
may further contribute to the identification of patients with
particular treatment needs, and further enhance the potential for
treatment effectiveness.
CONCLUSION
Each new discovery made by alcohol researchers-however remote it
may seem to the ongoing business of helping alcohol abusers-
provides a piece of the answer to the ages-long question of what
is alcohol abuse and alcoholism and how can it be prevented and
treated. We see the future both as a challenge and as a reward: A
challenge because with more answers come more questions and we
still have far to go. A reward, because of the knowledge that the
answers we find ultimately will help diminish a public health
threat that has existed for far too long.
* Enoch Gordis, M.D., Director
Federal National Institute on Alcohol Abuse and Alcoholism,
Rockville, Maryland.
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Introduction of Nathan B. Eddy
Memorial Award
Louis S. Harris
It is a great pleasure and honor to be asked to introduce Dr. Leo E. Hollister, the
recipient of this year’s Nathan B. Eddy Award. Dr. Hollister is a distinguished
clinical pharmacologist who has made and continues to make important
contributions to drug abuse research and the Committee on Problems of Drug
Dependence.
Dr. Hollister was born and educated in Cincinnati, culminating with an M.D.
degree from the University of Cincinnati in 1943. After an internship at the
Boston City Hospital and residency at Cincinnati, he was on active duty with the
U.S. Naval Reserve from 1945-46, a task he took on again in 1950-51. He
joined the Veterans Administration System (V.A.) in San Francisco in 1947, an
association he maintained until his retirement in 1986. Along with his V.A.
appointment, Dr. Hollister always maintained an academic appointment; first at
the University of California, San Francisco and later at Stanford University where
he rose through the ranks to Professor of Medicine, Psychiatry and
Pharmacology. These multiple academic appointments provide a strong indication
of Dr. Hollister’s broad interests and expertise. On retirement from the V.A. and
Stanford, Dr. Hollister has taken on a new position as Medical Director, Harris
County Psychiatric Center in Houston, Texas and Professor of Psychiatry and
Pharmacology at the University of Texas at Houston.
As a clinical pharmacologist, Dr. Hollister has made numerous contributions to
the development of new psychotherapeutic agents and to our understanding of the
action of psychotropic drugs. His extensive publications are a wonderful
demonstration of what a clinical pharmacologist should, in the best sense, be. In
recognition of his contributions, Dr. Hollister has been awarded the Meritorious
Service Award and the William S. Middleton Award for Outstanding
Achievement in Medical Research from the V.A. He has also received the Taylor
Manor Award for Outstanding Service to the American College of
Neuropsychopharmacology (ACNP), the William Menninger Memorial Award
from the American College of Physicians and the Oscar B. Hunter Award for
Experimental Therapeutics from the American Society of Clinical Pharmacology
and Therapeutics (ASCPT).
Dr. Hollister is a dedicated member of many professional societies and advisory
boards. For instance, he has been President of ASCPT, ACNP and CINP. He
chaired the Committee on Problems of Drug Dependence from 1972-77, and
served as Executive Secretary from 1979-81, a period which saw the Committee
move from the National Academy of Sciences to its present status as a respected
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independent body. Without his dedicated leadership, I doubt this would have
been accomplished.
Thus, with the citation:
“Leo E. Hollister, brilliant clinical pharmacologist, dedicated public servant, the
Committee on Problems of Drug Dependence salutes you with the Nathan B.
Eddy Memorial Award.”
AFFILATION:
Department of Pharmacology and Toxicology, Medical College of Virginia,
Virginia Commonwealth University, Richmond, VA 23298-0613
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Peregrinations Among Drugs of
Dependence: Nathan B. Eddy
Memorial Award Lecture
Leo E. Hollister
It is a special pleasure to receive this award which
memorializes the contributions of Nathan B. Eddy to the field
of drug dependence. I was privileged to know Dr. Eddy
during the last several years of his life. It has also been my
privilege, through a long association with the Committee on
Problems of Drug Dependence, to have known personally all
previous winners of this award. There also seems to be a
good possibility that through that association I shall know
many future winners of this award.
My entry into the field of drug dependence, as with other
aspects of my career, was somewhat fortuitous. Studies in the
laboratory of Dr. Sidney Raffel, Professor of Microbiology at
Stanford, had shown the chlorpromazine had static action
against M. tuberculosis in concentrations of 5 ug/ml and cidal
action in concentrations of 10 ug/ml. As there were not too
many drugs available in the 1950s effective against this
mycobacterium, we organized a trial of chlorpromazine in
patients with pulmonary tuberculosis.
Thirty six patients entered a blind, controlled trial, 17 of
whom received chlorpromazine in daily doses of 300 mg with
the majority receiving such doses of 6 months or more.
Nineteen other patients were assigned randomly to placebo.
We found little difference between the two groups in terms of
infectiousness of sputum or x-ray changes. When the study
was terminated, the drugs were stopped abruptly. Four of
the 17 patients on chlorpromazine developed immediate
symptoms of restlessness, insomnia and gastrointestinal
disturbance which suggested a withdrawal syndrome. These
responded promptly to resuming chlorpromazine or use of
sedatives. None of the 19 patients withdrawn from placebo
showed such effects.
This experience was mentioned in a few lines in a paper
published in the American Review of Respiratory Disease,
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hardly a widely read journal in the field of drug dependence.
I was still naive enough to bel ieve that once you had
mentioned a phenomenon in the medical literature, there was no
need to repeat such mention. In retrospect, the experience
was notable. First,  i t was probably the first placebo-
controlled demonstration of a drug withdrawal syndrome.
Second, it was probably the f irst documentation of a
withdrawal syndrome in a class of drugs other than those
known to be abused. Third, it was probably the first
experience of a withdrawal syndrome occurring in the context
of therapeutic doses. Talk about missing the boat!
I had become aware of the superb work being done at the
Addiction Research Center at Lexington in explicating the
mechanism of withdrawal to alcohol and barbiturates. Having
studied the newest sedative, meprobamate, and having seen
some instances of spontaneous withdrawal from that drug, I
decided to borrow the Lexington techniques to study the
phenomenon experimentally. We accomplished three studies.
The first substituted placebo for meprobamate given chronically
in doses thought to be within the therapeutic range (median
1600 mg/day). Only 10 of 60 patients abruptly withdrawn by
placebo substitution experimented mild reactions, usually those
who had received higher than average doses. We concluded
that “symptoms from withdrawal at ordinary therapeutic doses
were infrequent and mild, resembling recrudescence of
symptoms being treated”. That statement pretty well
summarizes the story of therapeutic-dose dependence today.
Our second study looked at the results of placebo substitution
in patients (largely schizophrenics for whom the drug was
being tried to determine whether it might be helpful), who had
been treated chronically with “supra-therapeutic” doses (3.2 to
8 g/day). Sixteen of 21 patients experienced a classical
sedative withdrawal syndrome soon after placebo substitution;
14 of 19 tested showed abnormal EEGs which later reverted to
normal. However, no seizures were observed. In a third
study, 8 of 10 patients treated with similar doses of
meprobamate in combination with the phenothiazine, promazine,
also developed definite withdrawal, with a seizure in one
patient at 72 hours. Promazine, rather than protecting against
withdrawal from meprobamate, probably aggravated it. These
studies emulated those of the Lexington group - not a bad
example to follow.
During the course of these studies, we measured plasma
concentrations of meprobamate. The plasma half-life following
chronic administration was estimated to be 24 hours, with the
usual wide interindividual variations. Later, we found the
plasma half-life following single doses to be a median of 11
hours. The time-course of withdrawal reactions we observed
with meprobamate was similar to that which had been described
by the Lexington group for short-acting barbiturates.
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During 1959, I was invited to attend a pre-marketing meeting
for the new anxiolytic, chlordiazepoxide, even though I had
not studied the drug myself. At the conclusion of that
meeting, after hearing the way the drug was extolled, I
thought that if it were half as good as touted, it would very
likely be abused. This led me to initiate a study in which the
drug was used in high doses in schizophrenic patients (to
determine possible efficacy) but also to provide a basis for a
discontinuation trial. Eleven patients were treated with daily
doses of 300-600 mg for a median period of 5-6 months. Under
careful observation, they were abruptly switched to placebos.
Ten of the 11 patients demonstrated withdrawal manifestations,
although onset was delayed until the second or third day and
the peak was not attained for a couple of days more. Two
patients developed seizures, at 7 and 8 days post-withdrawal.
Measurement of plasma concentrations of the drug, and by the
methods then available probably all its metabolites, indicated a
possible half-life of 48 hours, which accounted for the
attenuated time-course of the withdrawal syndrome. This
experiment was published prior to the introduction of
chlordiazepoxide into medical practice. In a subsequent study
of the effects of diazepam in schizophrenics, one of the
participating hospitals (without my knowledge or assent)
abruptly discontinued patients from doses of 120 mg/day and
demonstrated a similar attenuated withdrawal reaction. This
study, too, was published prior to release of diazepam into
clinical practice. Somewhat to my disappointment, it took
several years before spontaneous instances of abuse of these
benzodiazepines and withdrawal reactions were reported in the
clinical literature. Nature took a long time to imitate art.
The meprobamate homolog, tybamate, provided an
opportunity to observe a different aspect of sedative drug
withdrawal. Doses of 4.9 to 14 g/day given for 4 to 16 weeks
and then abruptly withdrawn failed to elicit a withdrawal
reaction. The reason was that the plasma half-life of this
drug is so short, from 2-3 hours, that it was impossible to
sustain continued high concentrations with ordinary dosage
schedules. This experience, added to our others and to
clinical experience, led to the postulation that the rapidity of
onset and severity of a sedative drug withdrawal syndrome is
a function of the plasma half-life of the drug. Drugs having
half-lives of 6 to 24 hours are associated with the most severe
withdrawal; drugs, such as tybamate, wi th  very short
half-lives, are unlikely to produce withdrawal; drugs with long
half-lives, such as chlordiazepoxide and diazepam, produce
attenuated withdrawal reactions as we bad first noted; and
drugs with very long half-lives, such as phenobarbital,
generally produce no discernible withdrawal syndrome. This
schema has stood the test of time and is appropriate even
today,
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By the late 1950s, some generally poor work with lysergic acid
diethylamide (LSD) had been published. I felt I could do
better. Drugs of this type were easily obtained, LSD from a
friend who worked for Sandoz and mescaline by mail from
Nutritional Biochemicals Corporation. Subsequently, I became
engaged in a series of studies of these and other hallucinogens
that developed meticulous descriptions of their clinical
syndromes and time course, quantified responses to different
doses, tested a variety of psychometric and psychophysical
effects, and measured a variety of biochemical parameters.
Early on, we found that LSD and mescaline (as well as the
newly discovered hallucinogen, psilocybin) produced virtually
identical clinical syndromes despite doses differing by orders
of magnitude. The concept of the LSD group of drugs was
born, as contrasted with anticholinergic hallucinogens (the JB
series of compounds named after John Biehl, the chemist who
synthesized them) or drugs such as alpha- methyltryptamine,
which had both amphetaminelike and LSD-like effects.
To obtain information about the time-course of clinical effects,
we placed a tape recorder in the room with the subject. I
would enter and after providing a time cue would engage the
subject in describing their experiences. It was my job each
evening to review the tapes to reduce this material to data.
One of my early subjects was a creative writing student at
Stanford who said he was writing a novel and wanted to take
these drugs to see what it was like to be crazy. After
warning him that these drug effects were not especially like
those of schizophrenia, he enlisted in one of our studies.
When I entered his room to stimulate discussion, there was no
need ;  he  was  a l ready  expanding  to  the  recorder  h is
experiences. #en I later listened to these tapes, it was
obvious that this chap had enormous talent; most of what he
described was unique and probably fictional, but the
descriptions showed a masterly command of language. When
“One Flew Over the Cuckoo’s Nest” was published, I thought
it possible that hallucinogens had indeed unleashed some
creativity. Later, I came to an opposite conclusion. Ken
Kesey may have been the subject most harmed by our
experiments with these drugs.
Our studies demonstrated a remarkable similarity between
members of the LSD group, not only in clinical syndromes but
in most other aspects. The impairments they produced in
psychometric tests were mainly due to inability to sustain
attention; they enhanced aspects of color perception, including
subjective colors; they had similar effects of enhancing
primary suggestibility. Their sympathomimetic actions caused
profound elevations of plasma free fatty acids and significant
reductions in serum phosphorus levels.
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Several assertions were made that, if true, would have made
hallucinogenic drugs highly useful pharmacological tools or
treatments. First, these drugs were alleged to provide a
“model psychosis”, similar to that of schizophrenia.
Presumably by studying their mechanisms of action, we might
learn something about the pathogenesis of schizophrenia. To
test the model psychosis notion, I took tapes of subjects under
the influence of hallucinogens as well as patients with
schizophrenia and carefully edited out any allusions that might
betray their origin. Nonetheless, it was easy for a variety of
mental health professionals to identify correctly which tape
came from which source. The psychotomimetics did not really
mimic schizophrenia. This experience, as well as one with a
potential endogenous psychotogen, 3,4-dimethoxyphenylethyl-
amine, found in the urine of schizophrenics, led to a series of
postulates that such a substance would have to meet. To date,
no proposed endogenous psychotogen has met these criteria.
A second claim was that LSD, in large single doses, could
provide enough insight to cure alcoholics. We compared a dose
of 600 ug of LSD with a dose of 60 mg of dextroamphetamine,
having devised a new rating instrument, the Drinking Behavior
Inventory, to grade degrees of alcoholism. A slight advantage
was found for LSD at 3 months followup but by 6 months, both
treatments were equal. Unknown to me at the time, three
other groups were also testing this therapeutic use. Although
each group used different techniques, the conclusions were
identical. LSD was not an effective treatment for alcoholism.
A third claim was that psychedelics, as they were then being
called, would facilitate psychotherapy by breaking down
resistances. We took patients with various disorders who had
plateaued in psychotherapy and made recordings of their
psychotherapeutic interviews during 5 conditions: no drug,
placebo, LSD, mescaline and psilocybin. These were then
rated blindly by an experienced psychotherapist for the
meaningful content of each session. Mescaline was slightly
better than the other treatments in providing increased
introspection, but none of the conditions was significantly
different from the other. One might have loosened up the
patients better with two martinis.
My first meeting with Nathan Eddy occurred during the mid-
1960s. The Veterans Administration had been enlisted for a
series of cooperative trials evaluating new analgesics, under
the prodding of  Dr. Eddy and the CPDD. The chief
investigator was to be Bill Forrest, who was based at my
hospital. As I was then in charge of research there, it must
have seemed desirable to get my blessing. So I was summoned
to a meeting where every person was already known to me
except Eddy.
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Talk about presence with a capital P. I met a tall thin man
with a myasthenic face, eyes covered with bottle-bottom
lenses, with another set of lenses above them as an eye-shade.
Who could not have been impressed? He didn’t say much, but
when he did it was in crisp language that was right to the
point. The great man more than lived up to his billing.
After the meeting, I had little idea that our paths would later
join.
During a committee meeting in Washington in June, 1967, I
happened to run into Milton Joffe, then with the FDA. He
mentioned that a new drug, given the epithet, “STP”, had
appeared on the streets of San Francisco. His agency would
like to know more about it. They had already signed a
contract to study the drug with a group at Johns Hopkins
headed by a young fellow named Sol Snyder. I told Milton
that I had a protocol for LSD in my office file that could easily
be adapted to 2,5-dimethoxy-4-methylamphetamine. I would
study the drug without a contract. He went to his unlocked
desk and gave me an envelope with an ample amount. I went
from his office to catch the Friday evening plane to San
Francisco. By the following Tuesday our first STP subject
was being studied. How greatly things have changed! In a
very short time, we proved that STP belonged in the LSD
group, was more potent than mescaline, that tolerance to it
quickly developed, and that its effects could be partially
mitigated by chlorpromazine. By early September, I sent a
report to Joffe who passed it on to the members of the CPDD,
including Nathan Eddy, who had instigated the inquiry. Not
long after, I was approached about becoming a member of the
CPDD, the beginning of a long association. I have little doubt
that Eddy himself suggested my recruitment.
That same summer, new ways of studying an old drug became
available. The forerunner of NIDA, under the guidance of
Sidney Cohen, had arranged to supply various marijuana
components, including tetrahydrocannabinol ( T H C ) ,  t o
investigators. I thought it would be of some interest to
compare authentic THC with synhexyl, a synthetic homolog
which had been studied in the 1940s, to determine the extent
to which the earlier studies might be pertinent to marijuana.
Through R. K. Richards, a pharmacologist recently retired from
Abbott, I was able to obtain some 25-year old synhexyl, a
brownish-black spot of tar in a small vial. We quickly defined
the clinical syndrome from these two drugs, which was similar,
the time course, which was somewhat delayed for synhexyl,
and the fact that synhexyl was less potent. As it turned out,
the Lexington group, headed by Harris Isbell, scooped us on
THC, but our studies were complementary.
Thus, began a series of studies of THC and its homologs
which has continued to the present. From the very first, we
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were interested in structure-activity relationships and
systematical ly explored the relative potency of various
cannabinoids and THC metabolites for THC-like activity. The
two major cannabinoids in marijuana other than THC,
cannabidiol and cannabinol, had no THC-like activity. Of all
cannabinoids, THC had the greatest activity and of all THC
metabolites, only one, 11-hydroxy-THC, had as much, or
according to our estimate, slightly more activity.
Our studies of cannabinoids over the past 22 years have
touched upon virtually every aspect of their actions. They
constitute the largest series of  studies of the human
pharmacology of mari juana on record. Some have been
concerned with drug interactions, most notably with other
cannabinoids; we found none. Others have been concerned
with psychological functions, such as various aspects of
memory, time sense, goal-directed behavior, and expectancy
(contingent negative variation). Motor functions studied have
been effects on driving and the roadside sobriety test, as well
as residual impairment in simulated airplane operation.
Physiologic effects, such as those on appetite and hunger,
glucose tolerance, electrocardiogram and sleep have been
looked at. A variety of other studies have examined the
relationship between marijuana use and aggravation of
schizophrenia, the influence of setting on the marijuana
experience, and possible cytogenetic alterations from the drug.
As most of these studies have been fairly recent and may be
familiar, they will not be described in detail.
At some point in studying drugs, it becomes desirable to
measure plasma concentrations to obtain a sense of the drug’s
pharmacokinetics and to try to relate these to clinical effects.
The Swedish group, headed by Stig Agurell, was so far ahead
in techniques of measurement that I despaired of ever being
able to catch them. So following the old saying, “If you can’t
lick them, join them” we have collaborated with them during
the past 10 years, the clinical work being done in the US and
the laboratory measurements being done in Sweden. This
cooperation has elucidated the patterns of drug availability
from three routes of administration (smoking, ingestion and
intravenous administration), has found that the kinetics of the
inactive cannabinoids, CBD and CBN are similar to those of
THC, has found that heavy marijuana use as compared with
light use does not much change the kinetics, and has
correlated clinical actions with plasma concentrations. A
number of Swedish PhD candidates have based their theses on
this work.
I shall not mention my modest endeavors in the area of alcohol
use and opiate dependence. These are dwarfed by those of
many others who have made much more extensive studies.
still, the whole phenomenon of non-medical use of drugs
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commands attention. Enough needs to be done to require the
lifetimes of all of us in this room, and then some.
Please accept my thanks for this great honor, which I shall
surely cherish. Even more, I shall cherish the memory of the
many able scientists and wonderful people that my long
association with the CPDD has provided. Thank you all.
AUTHOR:
Leo E. Hollister, M.D.
University of Texas Medical School
at Houston
Houston, Texas
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Contamination of Clandestinely
Prepared Drugs With Synthetic By-
Products
William H. Soine
On the basis of the number of clandestine laboratories seized by
the Drug Enforcement Administration (DEA), the use of clandes-
tinely synthesized drugs would appear to be increasing. The num-
ber of laboratories closed by the DEA has increased from 184 lab-
oratories in fiscal year 1981 to 647 laboratories in fiscal year
1987. Although many risks are associated with the abuse of drugs,
purity is a major danger associated with these clandestinely pre-
pared drugs (Soine 1986). Compounds which can affect drug purity
can be classified as diluents, adulterants, impurities of manu-
facture and impurities of origin. The presence of diluents and
adulterants is highly variable, however, this is not true for the
impurities associated with the synthetic process. The impurities
of manufacture and origin are usually present and will vary pri-
marily in concentration. Therefore, it is not surprising that
these impurities may contribute to the pharmacological or toxico-
logical effects associated with clandestinely synthesized drugs.
This report updates information that was published in a prior
review on this subject (Soine 1986). The drugs discussed are
limited to the stimulants, amphetamines and cocaine. The syn-
thetic method for each drug is discussed, followed by the identi-
fication and occurence of synthetic impurities and their associ-
ated pharmacology/toxicology.
AMPHETAMINES
There are numerous methods reported for the synthesis of ampheta-
mine -(Frank 1983), as shown in Figure 1. The major methods uti-
lized by the clandestine chemists use starting materials that can
be easily purchased and/or synthesized. The major amphetamine
synthesized in the United States is methamphetnmine, whereas in
Europe, it appears to be amphetamine. An important precursor for
the synthesis of both amphetamine and methamphetamine is phe-
nyl-2-propanone (P2P). Four basic synthetic routes are used for
the synthesis of P2P (Frank 1983). The most frequently used
method starts with phenylacetic acid, acetic anhydride and sodium
acetate or pyridine. It is this reason that sales of large quan-
tities of phenylacetic acid (1 kg) are monitored by the DEA. The
most commonly observed by-product present in P2P prepared by this
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method is dibenzylketone (Herbst and Manske 1943). Dibenzylke-
tone will produce a synthetic impurity via the same reductive
amination reactions as P2P to give 2-(phenylmethyl)phenethylamine
(or the N-methyl homolog in the case of methamphetamine). The
methods using allylbenzene or ß-methylstyrene (Dal Cason et al.,
1984) are analogous to the methods used clandestinely for the
synthesis of 3,4-methylenedioxyphenyl-2-propanone (to be used in
the synthesis of 3,4-methylenedioxyamphetamines) from safrole or
isosafrole (Ellern 1985, Hanson 1988). Impurities present in P2P
using allylbenzene or ß-methylsytrene have not been reported.
The Leuckart method is still frequently encountered as a method
for synthesis of both amphetamine and methamphetamine. Until
1981, the main impurity present in amphetamine clandestinely pre-
pared in the Netherlands was 4-methyl-5-phenylpyrimidine (Huizer
et al., 1985). After 1981 di-(ß -phenylisopropyl)amines, DPIA,
(or the N-formyl derivative, or both) were the main impurities
observed in amphetamine in both the Netherlands and in Norway
(Lambrechts et al., 1986). It was hypothesized that the change
in impurity pattern was due to the addition of formic acid during
the P2P and formamide condensation step. It should be noted that
DPIA isomers have two chiral centers, therefore both a diaste-
reomeric pair and a meso stereoisomer are usually present in
illicit amphetamines prepared via the Leuckart method.
The most popular method for the synthesis of methamphetamine is
via reductive amination using P2P, methylamine, aluminum foil,
mercuric chloride (catalytic amount) diethyl ether and isopropa-
no1 (Frank 1983). This reaction goes in very high yields and a
very pure product can be obtained. It has been observed that
samples of illicit methamphetamine from numerous clandestine lab-
oratories have been found to contain mercury ranging from trace
levels to 1300 ppm mercury (Davidson 1983). Additional basic
contaminants have not been reported for this synthetic route.
The second most frequently encountered synthesis of methampheta-
mine is from ephedrines by conversion to the chloroephedrines
followed by reduction (Allen and Kiser 1987, Cantrell et al.,
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1988). (-)-Ephedrine or (+)-pseudoephedrine is converted to
(+)-chloropseudoephedrine or (-)-chloroephedrine, respectively,
using SOC12, PC13, PC15 or POC13. The reductive dehalogenation
to methamphetamine is accomplished using H2/catalyst, HI or HI
and red phosphorous (DEA Dec. 1986). The synthetic impurities
present in samples using this method are (+)-chloropseudoephe-
drine or (-)-chloroephedrine which also cyclize to form cis- or
trans-1,2-dimethyl-3-phenylaziridines, (Figure 2). All of these
impurities have been detected in varying levels in clandestinely
prepared (+)-methamphetamine. When synthesizing methamphetamine
using this approach or amphetamine from phenylpropanolamine,
retention of configuration at the amine carbon occurs. The enan-
tiomeric composition of illicit amphetamine or methamphetamine is
rarely reported.
Additional amphetamine analogs identified in the illicit drug
market since January 1984 are N,N-dimethylamphetamine (synthes-
ized from N-methylephedrine using HI and red phosphorous) (Tack-
ett et al. 1988, Bond 1988), N,N-dimethylphenethylamine (Clark
1986), N-ethylamphetamine (DEA Dec. 1985), 4-methyoxyamphetamine
(DEA Aug. 1985), 4-methoxymethamphetamine (DEA July 1987),
N-2-hydroxyethylamphetamine (Heagy and Allen 1987). N-2-cyano-
ethylamphetamine (DEA Aug. 1987), and 4,5-dihydro-4-methyl-5-phe-
nyl-2-oxazoline (U4Euh, prepared by the condensation of phenyl-
propanolamine with cyanogen bromide) (Inaba and Brewer 1987,
Davis and Brewster 1988). The impurities from manufacturing have
not been reported for these compounds.
The pharmacology reported for the synthetic contaminants in
amphetamines is very limited except for 2-(phenylmethyl)pheneth-
ylamine (Soine 1986). In a recent study the intraperitoneal LD50
and CD50 (convulsive dose 50) of 2-(phenylmethyl)phenethylamine
and N-methyl-2-(phenylmethyl)phenethylamine in mice was evaluated
in relation to amphetamine and methamphetamine (Noggle et al.
1985). The LD50 values for both contaminants were comparable to
that of both amphetamine and methamphetamine, however, the conta-
46
minants exhibited different non-lethal symptoms compared with
animals given the corresponding amphetamines. In doses well
below the LD50 the contaminants exhibited marked convulsive
episodes characterized by clonic and tonic seizures which suggest
greater CNS stimulation by the contaminants at the brain stem and
cord levels. These symptoms were seen for the amphetamines only
at doses at or near the amphetamine LD50 doses. The information
concerning the pharmacology of the other synthetic impurities is
minimal (Soine 1986).
COCAINE
Cocaine is obtained from the leaves of coca plants belonging to
the genus Erythroxylum (family Erythroxylacae) with the major
species used for the legal and illegal production of cocaine
being E. coca Lam. var. coca ("Bolivian" or "Huanuco coca")
(Novak et al., 1984). In general the primary method for preparing
illicit cocaine in the coca-producing area involves crushing and
soaking the leaves in a Na2CO3/kerosene mixture. Upon filtra-
tion, the kerosene filtrate is extracted with dilute H2SO4. The
acid extract is made basic and the solid precipitate obtained is
referred to as coca paste or cocaine sulfate base. Coca paste
varies in cocaine content from 30-90% cocaine. This coca paste
is further refined in cocaine "crystal" laboratories. During
this process the coca paste is dissolved in a dilute H2SO4
solution, the insolubles are filtered off and the acid solution
is made basic with ammonium hydroxide or an ammonium hydro-
xide/NaHCO3 buffer. The cocaine base, which is relatively pure
(90-95%), precipitates. The cocaine base is dissolved in ace-
tone/ether to which concentrated HCl is added from which very
pure cocaine hydrochloride precipitates. Depending on the skill
of the operator and the stage at which the sample is obtained,
numerous other alkaloids, in addition to cocaine, will be pre-
sent. The alkaloids containing a tropane nucleus include benzoyl-
ecgonine, methylecgonine, ecgonine, cis- and trans-cinnamoyl
cocaine, and ß-truxillines, and tropacaine. Due to crystall-
ization behavior similar to cocaine, the cinnamoylcocaines are
frequently detected, and are usually present in very low concen-
trations (less than 5%) (Soine 1986).
Due to the crude processing facilities that are used, residual
solvents are usually present in illicit cocaine. Because these
solvents may be indicative of solvent requirement or if samples
are being obtained from a common source the DEA has carried out
studies characterizing the volatile components present in cocaine
HCl. Prior to 1981 all cocaine samples contained trace levels of
acetone and ether. Recent studies indicate that acetone/ether is
still preferred for cocaine processing (49% of the samples).
However, a decreasing availability of diethyl ether in South
America appears to have forced the usage of other solvents such
as acetone , methylethylketone (Churchill 1985) and benzene
(Kiser 1986;. Volatile compounds that are also associated with
illicit cocaine samples are the hydrocarbons present in kerosene
(alkylbenzenes and hydrocarbons), contaminants of acetone (mesi-
tyl oxide and diacetone alcohol), and trans esterification
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products from cocaine (methyl benzoate, methyl cinnamate and
dimethyltruxillate) (Pettit 1986).
Numerous methods for the total synthesis of cocaine have been
reported in the scientific literature and many of these methods
have been attempted by the clandestine chemists (Cooper and Allen
1984).  When cocaine is obtained by total synthesis it  is
referred to as "synthetic" cocaine. To date all seizures of
operating clandestine laboratories have utilized routes through
the common intermediate, 2-carbomethoxytropinone. The most com-
monly observed route is that described in "head shop" publica-
tions which contain reprints of the work by Preobazhenski (1936).
The least commonly encountered method, although it is usually
used by the most experienced chemists, is the method described by
Findlay (1957). "Synthetic" cocaine is identified by the pres-
ence of the diastereomers of cocaine (pseudococaine, allococaine
or allopseudococaine) or by the d enantiomer of cocaine. Addi-
tional contaminants common to most of the synthetic routes are
shown in Figure 3. Contaminants that are present in both syn-
thetic and natural cocaines are benzoyl pseudotropine and benzoyl
tropine.
The biological activity associated with the naturally occurring
alkaloids of cocaine (other than cocaine and nicotine) have been
comprehensively reviewed up to 1984 (Novak et al., 1984). Based
on this review no recent reports are available concerning the
pharmacological activity of the tropane alkaloids methylecgoni-
dine, pseudotropine, and ß -truxilline, and the pyrollidine
alkaloids hygrine, hygroline and dihydrocuscohygrine. Cinnamoyl-
cocaine had previously been reported to have no pharmacological
activity (Woker 1953). Recent studies have shown that cinnamoyl-
cocaine(s) suppress the primary humoral (PFC) immune response of
mice following oral administration (Watson et al., 1983). The
presence of a potential Michael adduct in cinnamoylcocaine could
be associated with this response, however, this is unlikely since
this effect was less than that observed for cocaine at the same
dose. In in vitro studies (-)-trans-cinnamoylcocaine was one
order of magnitude less potent than cocaine in binding to the
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central high-affinity [3H]-cocaine binding site, but was compara-
ble to cocaine in binding to the peripheral (liver) high-affinity
cocaine binding site (Calligaro and Eldefrawi 1987). The and
ß-truxillines are reported to have no anesthetic action although
they were originally reported as strong heart toxins (Liebermann
1888). The activity associated with the remaining ecgonine alkal-
oids suggest that these compounds do not contribute significantly
to the CNS effects associated with cocaine (Novak et al. 1984).
It is hoped that this review will bring attention to some vari-
ables that can influence the pharmacological effects of clandes-
tinely prepared drugs. I l l icit  drugs are usually impure
and will predictably contain certain synthetic contaminants.
Unfortunately, very little is known concerning the acute and
chronic effects of these compounds.
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Structural and Conformational
Aspects of the Binding of Aryl-Alkyl
Amines to the Phencyclidine
Binding Site
Andrew Thurkauf, James Monn, Marienna V. Mattson,
Arthur E. Jacobson and Kenner C. Rice
Relatively recently, the dibenzo[a,d]cyclohepten-5,10-imines have been
introduced into the family of structures which have appreciable affinity for the
phencyclidine binding site of the mammalian CNS with the discovery that the
anticonvulsant MK-801 (Dizocilpine)1 showed high affinity for the site (Ki = 3
nM). This class is somewhat unique from other classes of PCP agonists in that
it demonstrates the highest PCP affinity of the various structure, while having
structural simplicity and the least conformational mobility.
CH3
MK-801 (Dizocilpine) des-5-methyl MK-801
Structurally, the compound is an amino bridged dibenzocycloheptane. Previous
work in our laboratories has shown that the structure may be simplified further,
by removal of the C-5 methyl group giving des-5-methyl MK-801, and still
maintain an affinity for the binding site (Ki - 120 nM) comparable to
phencyclidine.2
In an attempt to elucidate the structural requirements for binding in this series,
we undertook a study of partial structures of des-methyl MK-801. Although
structurally simple, the polycyclic nature of MK-801 permits it to be viewed as a
derivative of various partial structures. In analyzing the molecule we choose that
set of substructures which included both phenyl and the amino group.
As a bicyclic structure, MK-801 may be viewed as a tetrahydroisoquinoline or as
a dihydroisoindoline. The acyclic substructures which can be visualized are the
1,2diphenylbenzylamine or a-phenylbenzylamine.
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Substructures of MK-801
tetrahydroisoquinoline
a-phenylbenzylamine
The acyclic structures examined are shown in Table 1. While
phenylbenzylamine (1) shows little affinity for the PCP binding site, 1,2-
diphenylbenzylamine (2) retains considerable affinity for the site. The partial
structure, (3) and the homologue (4). also show little affinity for the site. The
importance of the 2-phenyl ring to the binding of 2 is demonstrated by the poor
affinity of the partially saturated analogue (5).
The bicyclic derivatives examined are shown in Table 2. While
tetrahydroisoquinoline (6) itself shows no affinity for the PCP site, the 1-phenyl
(7) and lbenzyl (2) derivatives do interact to some extent. Note that compound
(8), which can be viewed as a conformationally restricted 1,2-
diphenylethylamine, has somewhat greater receptor affinity than (7), a
conformationally restricted a-phenylbenzylamine.
dihydroisoindoline
1,2-diphenylethylamine
52
Table 1. Acyclic Analogues
Comp. # Ki (µM)
1.
2.
3 .
4 .
5 .
20
0.69
100
45
33
5 3
Table 2. Bicyclic Derivatives
Tetrahrdroisoquinoline Derivatives Dihydroisoindoline Derivatives
6.
7.
8 .
9 .
10.
11.
In the dihydroisoindole series, the parent compound (9) and the 1-phenyl
derivative (11)3 both show no affinity for the PCP binding site while the 1-
benzyl derivative (10) retains some affinity for the site. As was observed in the
tetrahydroisoquinoline series, the conformationally restricted; 1,2-
diphenylethylamine derivative (10) is more potent, in vitro, than the
conformationally restricted a-phenylbenzylamine (11).
The greater relative potency of derivatives possessing the 1,2-
diphenylethylamine substructure over those of the three alternative substructures
prompted us to further examine this system. Three conformationally restricted
analogs of 1,2-diphenylethyl amine which were examined are displayed
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Table 3. Conformationally Restricted 1,2-Diphenylethylamines
12.
13.
14 .
Ki = 50 µM
Ki = 20 µM
lC50 = 3.9 µM
in Table 3. In compounds (12) and (14)3, the rotation of 2-phenyl ring is
restricted, while in compound (13), the rotation of both phenyl rings is
restricted. While the affinities of all of these compounds are reduced, relative to
the parent compound 1,2-diphenylethylamine (2), compound (14) with a
secondary nitrogen (as in MK-801). has greater affinity than those restricted at
the carbon adjacent to the nitrogen.
With the idea that secondary amines were not inimical to the effect of the 1,2-
diphenylamine derivatives, we prepared the acyclic compound (15).
Structurally, (15) can be visualized as MK-801 with the C4a-C5 and C5-C6a
bonds removed. This compound showed very respectable affinity for the PCP
binding site.
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15. MK-801
Ki = 257 nM
In conclusion, we have synthesized a number of partial structures of the
phencyclidine agonist des-5-methyl MK-801. The structural and conformational
requirements for binding are strict within this series. Analogues in which one of
the phenyl groups is allowed free rotation showed greatly diminished receptor
affinities.
Finally, the structural studies indicate that, for the purposes of medicinal
chemistry, MK-801 is best viewed as a conformationally restricted 1,2-
diphenylethylamine derivative.
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Desipramine Treatment for Relapse
Prevention in Cocaine Dependence
Susan L. McElroy, Roger D. Weiss, Jack H. Mendelson,
Siew K. Teoh, Brenda McAfee and Nancy K. Mello
Six open (Brotman et al., 1988, Gawin and Kleber 1984, Giannini et al., 1986,
Kosten et al., 1987, Rosecan 1983, Tennant and Rawson 1983) and 5
controlled (Arndt et al., 1989, Gawin et al., 1989, Giannini and Billett 1987,
O’Brien et al., 1988, Tennant 1984) studies have assessed the efficacy of
tricyclic antidepressants for the treatment of cocaine dependence. Nine of these
trials (Brotman et al., 1988, Gawin and Kleber 1984, Gawin et al., 1989,
Giannini and Billett 1987, Giannini et al., 1986, Kosten et al., 1987, O’Brien et
al., 1988, Rosecan 1983, Tennant and Rawson 1983) have shown that tricyclics
may facilitate abstinence in cocaine-dependent patients by reducing dysphoria
(Brotman et al., 1988, Giannini and Billett 1987, Giannini et al., 1986, O’Brien
et al., 1988) and/or cocaine craving (Brotman et al., 1988. Gawin and Kleber
1984, Gawin et al., 1989. Kosten et al., 1987) associated with cocaine abuse
(Gawin and Kleber 1986). Although the dosages and time course of treatment
response reported in these studies paralleled the antidepressant properties of
these drugs, the anti-craving and mood-elevating effects were observed in
cocaine abusers independent of a concurrent diagnosis of major mood disorder
(Gawin et al., 1989, Rosecan 1983). Moreover, in 1 of the 2 negative studies
(Arndt et al., 1989, Tennant 1984) (double-blind, placebo-controlled trials with
desipramine), both the medication dose and the duration of treatment were
probably subtherapeutic (Tennant 1984).
In all of the reported studies, antidepressants were administered either during or
shortly after a period of active cocaine use. To our knowledge, there has been
only 1 report discussing the potential usefulness of antidepressants for the
prevention of relapse to cocaine abuse after abstinence had been achieved.
Weiss recently described 3 cocaine abusers who had been abstinent for 1 to 6
months and relapsed to cocaine use soon after initiating treatment with
desipramine (Weiss 1988). Development of an “early tricyclic jitteriness
syndrome” (Pohl et al., 1988. Pollack and Rosenbaum 1987) and increased
craving for cocaine were believed to be the likely precipitants of relapse in these
cases. In order to systematically investigate the efficacy of desipramine for
preventing relapse in cocaine abusers, we performed a double-blind, placebo
controlled 6-month crossover pilot study of desipramine in 15 cocaine dependent
patients who had attained 4 to 8 weeks of abstinence by completing an inpatient
substance abuse treatment program.
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METHODS
All study patients were hospitalized for cocaine dependence at the Alcohol and
Drug Abuse Treatment-Center of McLean Hospital, Belmont, Massachusetts,
where they participated in a multidisciplinary substance abuse treatment
program. The average length of stay in the program was 4 weeks, although
some patients stayed for up to 8 weeks. Abstinence during the hospitalization
was monitored by random urine drug screening. Patients who had positive
urine tests indicative of in-hospital drug use were ineligible for the study. From
September, 1986 through September, 1988, patients who met the following
criteria were recruited to participate in the study: a diagnosis of cocaine
dependence meeting DSM-III-R criteria; age between 18 and 65 years; no
significant medical or neurological problems; no history of major mood, anxiety,
eating, or psychotic disorders; consent for urine screens and blood tests; and no
past therapeutic trials of thymoleptic medication. Patients were included in the
study if they met DSM-III-R criteria for other psychoactive substance use
disorders, as long as cocaine was their preferred and most prominent drug of
abuse. Patients were also included if they had a past or current diagnosis of
attention deficit disorder with hyperactivity.
After providing informed consent, patients were randomly assigned to receive
desipramine or placebo. Medication was begun approximately 1 week prior to
discharge, after completion of the 4 to 8 week period of abstinence and inpatient
treatment. Patients were administered identical-appearing capsules of
desipramine or placebo. Desipramine was started at 50mg a day and increased
by 50mg each day to a daily dose of 200mg. Patients were randomly assigned
to receive desipramine or placebo during the first 12 weeks of the study. After
completing the first 12 weeks, patients were then crossed-over to the other
condition for the remaining 12 weeks.
Patients were assessed at baseline and weekly thereafter for 24 consecutive
weeks. During weekly interviews any potential drug use during the past week
was discussed and psychiatric symptoms and medication side effects were
assessed. To measure cocaine craving, 100 mm line analog scale ratings for.
intensity and frequency of cocaine craving were completed. Patients were
instructed to mark the intensity and frequency of their craving for the past week
on a 100 mm line, with 0 representing the absence of craving and 100
representing “more craving than ever.” The Beck Depression Inventory (BDI)
(Beck et al., 1961). the Hamilton Depression Rating Scale (Ham-D) (Hamilton
1960). a urine toxicology screen, and a side effects scale were also completed.
Relapse to cocaine use was ascertained by both clinical interviews and urine
toxicology screens. Routine blood tests (CBC, SMA-12) were obtained every 2
weeks. If patients relapsed to cocaine abuse, they were still encouraged to
remain in the study.
RESULTS
Demographic and clinical characteristics of the 15 patients are presented in table
1. Eleven patients were men and 4 were women. The mean age of the patients
was 29.5 ±: 5.7 years (range, 23 to 43 years). The average amount of cocaine
used was 23.1 ± 31.5 grams/week (range, 2-125 grams/week); the average
duration of cocaine use was 4.9 ± 3.6 years (range, 1 to 15 years). All patients
used cocaine intranasally; 5 also smoked the drug and 4 also used it
intravenously. All patients met DSM-III-R criteria for current or past abuse of
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other drugs in addition to cocaine, and most patients participated in 1 or more
modes of psychosocial treatment while enrolled in the study.
TABLE 1 Subject Characteristicsa
Variable Desipramine first (n=9) Placebo first (n=6) Differences
Age (years)
Sex (% M/F)
Amount of cocaine used
prior to hospitilization
(grams/week)
Duration of cocaine abuse
(Years)
Baseline cocaine craving-
intensityb
Baseline cocaine craving-
frequencyb
Baseline Hamilton Rating
Scale for Depression score
Baseline Beck Depression
Inventory score
Duration of time in
study (weeks)
31.9 ± 6.1 (25-43) 26 ± 2.7 (23-31) NS
78/22 67/33 NS
29.3 ± 37.8 (4-25) 13.8 ± 17.71 (2-49) NS
5.6 ± 4.3 (1.5-15) 3.7 ± 2.3 (1-6) NS
34.2 ± 34.1 31.5 ± 17.7 NS
21.9 ± 24.1 15.8 ± 11.3 NS
6.6 ± 4.8 (1-16) 7.8 ± 5.9 (2-17) NS
4.0 ± 4.8 (0.5) 9.5 ±_ 10.1 (1-24) p < .05
11.0 ± 10.7 (1-24) 6.5 ± 5.4 (1-14) NS
a Values not identified as percentages are express as mean ± SD (range).
b The range of the cocaine craving measure for both intensity and frequency
is 0 to 100, with 0 representing “no craving” and 100 “more craving than ever.”
Of the 15 patients, 9 were randomized to receive desipramine and 6 placebo
during the first 12 week phase. As shown in table 1, there were no significant
differences between those patients initially randomized to drug and those to
placebo with respect to sex, age, amount of cocaine used, duration of use, route
of use, concurrent or past alcohol or substance abuse, baseline measures of
cocaine craving, intensity and frequency. or baseline Ham-D scores. However,
the 2 groups differed significantly with respect to baseline BDI scores, with the
despiramine-first group being less depressed (p < .05) than the placebo-first
group.
Only 3 (20%) patients completed the entire 24 weeks of treatment, The
remaining 12 (80%) discontinued the study prematurely. Two of the latter
patients had crossed over from one treatment to the other. One patient dropped
out after 15 weeks of treatment, 3 weeks after being switched from desipramine
to placebo, and could not be contacted to determine his reasons for dropout. A
second patient terminated after 14 weeks, 2 weeks after being switched from
placebo to active drug, citing dry mouth, bad taste, feeling overly stimulated
and jittery, and experiencing increased craving for cocaine as the reasons for
drop out. The remaining 10 patients left the study prematurely after completing
12 weeks or less of treatment; 6 patients terminated after completing 2 weeks or
less. In total, 6 of the 12 non-completers (50%) dropped out while on placebo
and 6 (50%) dropped out while on active drug. Reasons for failure to completed
the entire 24 weeks of the study included relapse to cocaine abuse in 5 cases (3
on placebo and 2 on drug); uncomfortable or intolerable side effects without
relapse in 3 cases (all of desipramine); emergence of major depression without
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relapse in 1 case (on placebo); no longer wanting to participate in the study
because of time constraints in 2 cases (1 on placebo and 1 on drug, no relapses);
and failure to make appointments and loss of contact in 1 case (on placebo). AU
patients who relapsed to cocaine use discontinued the study.
Relapse to Cocaine Use
While they were participating in the study, 2 of 9 patients (22%) relapsed while
on desipramine and 3 of 6 (50%) relapsed while on placebo. This difference
failed to achieve statistical significance. However, this may be due in part to the
small sample size.. Relapse was not significantly correlated with age, sex,
amount or duration of cocaine abuse, baseline measures of cocaine craving and
mood, or duration of time in the study. Given the extremely high drop out rate,
however, it was difficult to accurately assess relapse over the long term. All 5
patients who, to our knowledge, relapsed to cocaine use did so while
participating in the study and within 4 weeks following hospital discharge. We
attempted to interview the other 10 patients by telephone to determine whether or
not they had relapsed to cocaine use after discontinuing the study. Of 8 patients
contacted at follow-up periods of 4 to 28 months after study termination, all
denied relapse to cocaine use.
Cocaine Craving and Mood
An analysis of variance for repeated measures was carried out to determine if
there were any significant changes in cocaine craving intensity (CCI), cocaine
craving frequency (CCF), BDI scores, and Ham-D scores over time. However,
this was not possible for the entire patient group because of insufficient data due
to the high drop out rate. The analysis was then repeated for patients who
completed the first 6 weeks of the study. There were no significant changes in
CCI, CCF, BDI scores, and Ham-D scores for the 3 patients who received
placebo for the first 6 weeks of the study. Similarly, there were no significant
changes in CCI, CCF, and BDI scores for the 5 patients who received
desipramine for the first 6 weeks of the study. However, there was a significant
decrease in Ham-D scores at weeks 3 and 4 when compared to baseline scores
(p < .05) for these patients.
Premature Study Termination by Patients Because of Adverse Effects
Premature termination due to adverse effects occurred more frequently during
treatment with desipramine than with placebo. However, this difference did not
achieve statistical significance. Termination secondary to adverse effects was
not significantly correlated with age, sex, amount or duration of cocaine abuse,
baseline measures of cocaine craving and mood, or duration of time in the study.
All 3 patients who dropped out because of adverse effects were receiving
desipramine at the time and reported either feeling overly stimulated, jittery
and/or anxious, feeling “high,” a “rush,” or a “crash” as if they were using or
had just used cocaine, and/or increased cocaine craving (all 3 patients) as the
primary reasons for ending the study. These side effects began within 1 to
several days after beginning desipramine therapy. Only 1 of the other 7 patients
ever receiving desipramine reported feeling stimulated and anxious. This was
not accompanied by feelings of cocaine intoxication and subsided after 2 weeks.
The 2 patients who relapsed to cocaine use while on desipramine did not report
adverse effects.
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DISCUSSION
Although more patients relapsed to cocaine use when treatment was begun with
placebo than with desipramine. this finding did not achieve statistical
significance. Our data suggest that treatment of cocaine-dependent patients with
desipramine - initiated well after induction of abstinence - may not be helpful in
prevention of relapse. This conclusion is inconsistent with many studies that
indicate that antidepressants may be helpful in facilitating abstinence in active
cocaine abusers (Brotman et al., 1988, Gawin and Kleber 1984, Gawin et al.,
1989, Giannini and Billett 1987, Giannini et al., 1986, Kosten et al., 1987,
O’Brien et al., 1988, Rosecan 1983, Tennant and Rawson 1983). A number of
these studies (Brotman et al., 1988, Gawin and Kleber 1984, Gawin et al.,
1989. Giannini and Billett 1987. Giannini et al., 1986, Kosten et al., 1987,
O’Brien et al., 1988) have shown that the reduction in cocaine use during
antidepressant treatment is associated with reductions in cocaine craving or post-
use dysphoria. The effectiveness of pharmacologic treatment in these studies
may thus have been due to alleviation of cocaine withdrawal symptoms.
However, in the present study, patients who completed the first 6 weeks of
treatment did not report significant changes in craving for cocaine. Hamilton
depression (Ham-D) scores but not Beck depression (BDI) scores were
significantly decreased at weeks 3 and 4 in comparison to baseline. There were
no significant changes in Ham-D and BDI scores for the 3 patients who received
placebo during the first 6 weeks of the study, even though baseline BDI scores
were significantly higher in the placebo-first group. These findings suggest that
although treatment with desipramine reduced depression, it did not promote
relapse prevention perhaps because cocaine craving was not reduced. Thus,
desipramine treatment may be more effective in facilitating rather than
maintaining abstinence from cocaine dependence because cocaine withdrawal
symptoms (particularly craving for cocaine) may diminish during protracted
abstinence (Gawin and Kleber 1986), when other factors may be more important
in precipitating relapse.
Our findings and conclusions, however, are limited by the design of the study.
First, despite random assignment, the desipramine-first and placebo-first groups
were not identical. Although the 2 groups of patients were similar with respect
to CCI, CCF, and Ham-D scores, the drug-first group had significantly lower
BDI scores. Since a recent report by Carroll (1989) has suggested that
concurrent depression may be a good prognostic sign in cocaine abusers,
patients who were given desipramine initially may have been more likely to
relapse because of a reduced degree of depression. This possibility seems
unlikely, however, since relapse was not correlated with depression scores in
our study.
Desipramine may have facilitated maintenance of abstinence for some patients
(4/9 or 44%), but it did not prevent relapse for other patients, (2/9 or 22%). The
drug also caused adverse effects (similar to the early tricyclic "jitteriness"
syndrome) in 4 of 9 (44%) patients. While these adverse effects did not
invariably lead to relapse, in contrast to the report by Weiss (1988), 3 of 4
(75%) patients discontinued the drug, fearing that persistence of these adverse
effects would cause resumption of cocaine use. Thus, desipramine may be
helpful for some cocaine abusers, but it also may be deleterious for others -
especially at the initiation of pharmacotherapy, when it may induce effects
similar to cocaine intoxication.
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Since neither relapse nor discontinuation of medication due to adverse effects
was associated with specific clinical or demographic factors (e.g., age, sex,
severity of cocaine dependence, severity or frequency of cocaine craving,
severity of depression), we are unable to identify predictors of favorable or
negative desipramine effects in cocaine abusers. Since relapse was less common
(although not significantly) when treatment was initiated with desipramine than
with placebo, desipramine treatment may be more likely to prevent relapse when
administered during the early rather than later phase of cocaine abstinence.
In summary, this study suggests that treatment of abstinent cocaine-dependent
patients with desipramine may not be effective in preventing relapse to cocaine
use or reducing craving for cocaine - even though it may reduce depression.
This finding must be considered tentative, however, in light of the study’s
design problems - unequal groups, high attrition rate, and small sample size.
Nonetheless, in some patients, treatment with desipramine appeared deleterious,
with induction of symptoms suggestive of the early tricyclic “jitteriness”
syndrome and increased craving for cocaine. When deciding whether or not to
treat cocaine dependence with desipramine, it will be important to realize that
some patients - particularly those who have achieved abstinence through
psychosocial means - may sometimes experience symptoms increasing the risk
of relapse. Currently, it is impossible to predict which patients with cocaine
dependence will respond to desipramine favorably or deleteriously. Further
research on the efficacy of tricyclic antidepressants in relapse prevention in
cocaine dependence is needed to identify those subgroups of cocaine abusers
who respond favorably to this class of medications.
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NIDA’s Medication Development
Program - 1989
Charles R. Schuster and Marvin Snyder
The development of improved treatment for drug addiction is one
of the most difficult problems confronting medical science
today. With the staggering cost of drug abuse and the burden-
some future liabilities associated with the spread of human
immunodeficiency virus (HIV) infection within the drug abusing
population, effective drug addiction treatment is necessary
now, more than ever. When NIDA alerted the Congress to the
possibility of new pharmacotherapeutic approaches to drug
addiction treatment, the Congress responded by specifying the
need for the development of new medications in the Anti-Drug
Abuse Act of 1988. NIDA has consequently made medications
development one of the top research and programmatic priorities
of the Institute, in line with the Public Health Service Plan
for Reducing the Demand for Illicit Drugs.
Drug abuse is a unique problem; individuals seek to alter, or
indeed to “experiment” with the functioning of the nervous
system in an attempt to change how they feel and how they see
the world and react to it. There is a distinction, however,
between drug abuse and drug addiction. Drug abuse is a
voluntary behavior; the casual user makes a free and conscious
decision to break the law and use mind-altering substances.
Drug addiction is a disease of the brain, resulting from
repeated self-administration of these substances.
Our brains are made up of billions of neurons. These cells
activate one another through the release of chemicals, and this
brain activity enables us to function: to see, to hear, to feel
anger, and to experience hunger for food, water, and sex.
Abused drugs disrupt brain function, short circuit, if you
will, the brain’s normal activity, so that the individual
becomes pathologically preoccupied with repeating the drug
experience, either for the pleasure it brings or the pain it
relieves. Such individuals have diminished freedom of choice.
They are not irrational but they are dysfunctional. Their
waking hours are focused on obtaining, selling, thinking about,
and experiencing drugs. One of the roles of medications in
these individuals is to restore a degree of normality to brain
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function and behavior so that they have the opportunity for
rehabilitation through counseling, psychotherapy, vocational
training, and other therapeutic services.
We pointedly use the term “medication” for that is what we
propose to develop. We have been unduly burdened by the fact
that we do not have different words to refer to chemicals used
therapeutically as opposed to those being abused. Other
languages, such as French, make a clearer distinction.
Unfortunately, semantics sometimes gets in the way of reality,
and there are those who say it is “silly” to talk about using
“drugs” to treat drug abuse. In reality, nothing could be
further from the truth. Drugs or medications are typically
used to treat the biochemical and physiological imbalances
caused by a variety of diseases. Treatment of psychiatric
conditions, like anxiety, depression, and schizophrenia is
perhaps most relevant here. Correcting the biochemical im-
balances in the brain that lead to the disordered behaviors
seen in these conditions not only improves the patient’s
emotional state, but also improves behavior and increases the
effectiveness of other forms of treatment, like psychotherapy.
As just mentioned, we will be developing therapies to restore
some normality to brain function disrupted by the abuse of
illicit drugs. We will be using the word medication to help
keep the approach and the distinction between abused drugs and
medications clear.
Drug abuse research has led to fundamental insights about
drug-receptor interactions, the structure-activity relation-
ships of drugs and the brain, and mechanisms underlying
neurotoxicity. With this information and utilizing state-of-
the-science technological advances in areas like molecular
biology, neural imaging techniques, and computer-aided drug
design and modelling, we plan to develop medications that:
1.
2.
reduce the craving for abused drugs;
block the behavioral and physiological effects of abused
drugs;
3. safely serve as replacement therapies for the treatment of
drug addiction,
4.
5.
moderate and/or climinate the process of withdrawal;
block and/or reverse the toxic effects of abused drugs;
and
6 . prevent, under certain conditions, the initiation of drug
abuse in individuals at high risk.
The development of pharmacotherapies for the treatment of drug
addiction has not received significant support from the
pharmaceutical industry. There are many reasons for this
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unfortunate circumstance. First, drug abusers are a unique
group of sick people who do not necessarily seek treatment and,
indeed, may actively avoid it. Research on this population is
difficult and is not attractive to many investigators. Second,
prior to the current cocaine epidemic, the number of drug
abusers, although large, was not of sufficient size to be
economically rewarding to pharmaceutical manufacturers and the
profit potential of new treatments was not great. Furthermore,
pharmaceutical manufacturers have noted that both the distribu-
tion and reimbursement for new medications are likely to be
carefully controlled, further reducing their attractiveness.
Third, some drugs that could be developed are either off patent
or about to come off patent, and, therefore, there is limited
protection for the product and, hence, little profit potential.
Fourth, drug companies are concerned about having their product
lines associated with drug abusers (“junkies”) in the public’s
mind. Fifth, drug companies are concerned that by introducing
a product into the drug abuse population they might decrease
the market for the product’s other potential uses or delay its
approval. The product, for example, may be placed in an
unacceptable schedule under the Controlled Substances Act or
its use restricted, like methadone. Finally, pharmaceutical
manufacturers are concerned about a large variety of liability
issues, some of which may be unique to drug abusers.
Although some of these concerns may be overrated, others are
real. The risk involved in developing treatment medications
for pregnant drug abusers, for example, has to be considered
excessive by even the most compassionate and concerned corpo-
rate officers. From a public health perspective, however, we
believe that society has been ill-served by the lack of
attention paid by the industry to the problems of drug addic-
tion. The existence of only two approved medications, metha-
done and naltrexone, available specifically for drug addiction,
is a testament to this failure.
However, the incentives of the Orphan Product Act, AIDS, and
the size and demographics of the cocaine epidemic are changing
this situation. Some discussion has taken place as to whether
the Act might be extended to all medications being developed
for the treatment of addictive disorders. Even though some of
the addictive disorders do not meet the technical criteria for
orphan conditions, the lack of private sector effort in
developing medications to treat the addictions suggests that
they are, in effect, orphan conditions. NIDA staff have been
visiting and discussing medications development with a number
of pharmaceutical firms, and we believe that there is increas-
ing interest in collaborative efforts and that these collabora-
tions will grow with time. It is nonetheless clear that
significant leadership is required, in this area - leadership
that NIDA plans to provide by committing itself, on a long-term
financial, programmatic, and scientific basis, to the develop-
ment of medications for the treatment of drug abuse.
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Starting in fiscal year 1989, NIDA expanded its efforts in the
area of medications development by establishing a research
program specifically seeking to identify new medications for
drug addiction treatment. We are quite mindful of the fact
that many of the chemicals that will be identified and/or
synthesized will, through their central nervous system (CNS)
actions, have potential value for other disease conditions
affecting the brain and behavior. We are, therefore, working
closely with our Agency leadership and sister Institutes, the
National Institute on Alcohol Abuse and Alcoholism and the
National Institute of Mental Health, so that the opportunities
to test new medications for both addictive and mental disorders
will not be lost.
Compounds for evaluation will be derived from a comprehensive
database that NIDA is developing about chemical entities with
CNS activity. The information in the database will include
pre-existing compounds, as well as compounds developed on the
basis of computer-assisted drug design and knowledge of
structure-function activity, receptor pharmacology, and the
functional mechanisms underlying drug reinforcement, euphoria,
dysphoria, tolerance and dependence.
New potential medications that meet our basic pharmacological
parameters for candidate treatment agents will then be evalu-
ated for potential efficacy and safety in animal models through
ongoing contractual relationships. The animal self-administra-
tion model for drug abuse is potentially one of the best models
of human disease available. It is highly reliable in predict-
ing the abuse liability of new compounds and it should prove an
invaluable tool for our treatment development program. The
evaluation of many proprietary compounds may be modeled after
the abuse liability testing program that is currently used to
make regulatory and scheduling decisions about new drugs.
Although NIDA now funds this abuse liability testing program,
we do not control it directly. NIDA will be more directly
involved in the new program for testing potential treatment
medications. The development of specific relationships with
individual pharmaceutical companies that will allow the Federal
Government to test and evaluate privately owned compounds and
to use the data for medications development is now being
explored.
Three issues surrounding the potential toxicity of new com-
pounds are of particular concern. Because we will be dealing
with substances that act on the CNS, and because recent
findings show that a variety of centrally acting compounds are
potentially neurotoxic, we will be paying particular attention
to both the acute and long-term effects of candidate medica-
tions on the brain. Second, the medications we are developing
are primarily being targeted to patients who are either
seropositive for HIV or at high risk of exposure to HIV. We
are particularly concerned that we do not administer anything
to these people that might accelerate the clinical course of
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the disease, increase the probability of clinical infection
after exposure, or interfere with anti-viral therapy. Given
the limited knowledge of the natural history of AIDS and the
role of co-factors in the disease, it is not clear how we will
do this. Nonetheless, it is an area of significant priority
that we are examining.
Finally, we are facing another unusual situation in developing
medications for the treatment of drug addiction. Drug addic-
tion is a disease that involves the self-administration of a
drug which, like cocaine, may produce an acute, fatal reaction.
Because a number of candidate treatment agents might potentiate
these reactions if taken with cocaine, we are working with the
Food and Drug Administration (FDA) on the issue of requiring
drug interaction studies to show safety of potential treatment
agents.
In terms of clinical trials, in fiscal year 1989 NIDA will
establish Treatment Research Units that will have a major role
in evaluating new medications and conducting the necessary
clinical trials for phases I and II of the drug development
process. We also plan to establish in fiscal year 1990
agreements with a number of pharmaceutical firms that would
agree to take promising new medications through phase III
clinical trials, New Drug Application (NDA), and approval, and
marketing of the drug in exchange for exclusive rights to the
compound for the treatment of drug addiction. In other words,
NIDA, as the lead Institute for the Agency, would, under some
conditions, perform all necessary preclinical and phase I and
phase 11 clinical studies and transfer these data to a pharma-
ceutical firm willing to complete the NDA process and market
the drug. Approaches like this have already been used success-
fully at both the National Cancer Institute and the National
Institute of Neurological Disease and Stroke, and we are
hopeful that it can work for us.
We would now like to briefly describe some of our ongoing
activities. Comprehensive discussion of the treatment of drug
addiction must begin with methadone. Methadone is certainly
not a cure for heroin addiction. It must be administered
daily. It maintains physical dependence on opiates. It is
subject to diversion and abuse. Children born to methadone-
maintained women must be withdrawn from the drug. But metha-
done is a successful treatment for heroin addiction and a
valuable tool for preventing the spread of AIDS. The evidence
indicates that children born to methadone-maintained mothers
are much healthier at birth than children born to heroin
addicts. The concept of methadone maintenance is consistent
with the medical management and treatment (not cure) of a
number of other diseases, including diabetes, heart disease,
and arthritis.
We believe that methadone maintenance has a place in the
treatment of heroin addiction. The 25-year-old heroin addict
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who comes into the clinic and is placed on methadone is no
longer an addict. That person is physically dependent on
opiates, but not addicted to them. This is an essential and not
a semantic distinction. Methadone stabilizes brain dysfunction
caused by years of heroin addiction and stops the on-off
cycling that typifies addiction. This person no longer injects
drugs, is no longer constantly involved in drug-seeking
behavior, and can be gainfully employed and involved in
rehabilitation programs. This person no longer needs to commit
crime to support his or her drug addiction. Perhaps most
importantly, the risk of contracting AIDS and/or transmitting
it to someone else is substantially reduced.
Tragically, AIDS and drug abuse are now and will continue to be
inseparable for the foreseeable future. Methadone maintenance
reduces intravenous drug abuse and thus reduces the spread of
AIDS. An unrealistic wait for a “cure” for heroin addiction and
a philosophy that refuses to accept the medically sound concept
of maintenance will needlessly sentence thousands. of people,
including innocent children, to death.
Methadone was the first medication available for the treatment
of heroin addiction. We need to continue its use until it is
replaced by something better. Such progress is attainable
through research. Medical science utilizes what it has and
improves upon it through the development of new knowledge. The
sulfa drugs were among the first true antibacterials. They
were followed by antibiotics, such as penicillin and tetra-
cycline, and then whole new classes of anti-infective agents,
each one useful in specific patients, with specific diseases,
and at specific times in their therapy. This is the goal of
NIDA’s Medications Development Program. We are attempting to
develop new, more effective medications to treat addictive
disorders, most notably heroin and cocaine addiction. We would
like to be able to provide physicians with a wide variety of
potential treatments so that these can be tailored to the needs
of a particular patient.
With newly available funds, NIDA is renewing its sponsorship of
LAAM for the treatment of heroin addiction. LAAM therapy, like
methadone, is based on the concept of maintenance. We believe
it will find greater public acceptance than methadone and that
it will be a significant improvement over methadone for many
patients. LAAM is a long-acting medication that needs to be
taken only every 2 to 3 days. Many believe that this reduction
in drug-taking behavior, by itself, will have therapeutic value
because it will break the drug-taking cycle so characteristic
of addiction. In addition, because each patient will visit the
clinic less frequently, treatment capacity should increase and
costs decrease. Most importantly, LAAM does not produce a
high; it should have little, if any, abuse liability. Con-
sequently, we do not anticipate any problems with diversion for
street use.
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We should know within a year if the available data show safety
and efficacy. If so, NIDA plans to work with the FDA to make
LAAM available as rapidly as possible and will explore the
mechanisms of a treatment Investigational New Drug (IND) to
accomplish this goal. This mechanism has been effectively used
in the AIDS arena, and we believe it is appropriate to follow
this approach with drug addiction. Under this program,
patients would be treated with LAAM while it is still awaiting
final approval by the FDA.
For those patients who wish to detoxify from heroin or be
medically withdrawn from methadone, NlDA-sponsored research has
been examining techniques and medications to facilitate this
process. One such medication is an anti-hypertensive agent
called clonidine which interestingly has shown value in the
treatment of heroin addiction. Clonidine by itself and in
combination with naltrexone appears to be quite helpful and is
currently being used to assist patients to rapidly become free
of physical dependence on heroin (Kleber et al., 1985; Charney
et al., 1986).
For those patients who are opiate-free but require “protection”
against re-addiction to heroin, NIDA developed, in a partner-
ship with DuPont, the narcotic antagonist naltrexone. Patients
whose heroin-free state is “maintained” by naltrexone Cannot
get high from any street narcotic. Naltrexone seems, in many
ways, to be an ideal medication. In effect, it “immunizes”
against narcotic addiction. However, there have been signi-
ficant problems with patient compliance. People don’t want to,
or forget to, take it. The patient has to be highly motivated
to take a medication when its only action is to block the
effects of heroin, a drug he’s not supposed to be using. We
believe however, that naltrexone offers substantial, unrealized
benefits in our battle against both drug abuse and AIDS. We
are, consequently, developing a “depot” form of this medica-
tion, which is slowly released over time. In this way, a
single injection will provide protection against heroin for
periods of 30 days or longer. The problems of patient com-
30-day window of drug-free opportunity, there should be
pliance will be greatly reduced. If we can give patients a
substantial improvements in treatment outcome. Clinical studies
of this new formulation will begin late next year. Again, as
with all of the medications under development, every effort
will be made to make the naltrexone depot available as soon as
possible in the development process.
We are also conducting clinical trials of buprenorphine, a new
type of medication that combines some of the effects of opiate
agonists with many of the effects of antagonists. This
medication may be especially useful in helping addicts detoxify
from heroin and may also serve as a useful maintenance agent.
If ongoing studies at our Addiction Research Center prove
successful, large-scale trials of buprenorphine should begin
next year.
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Buprenorphine may also be a useful treatment for combined
heroin and cocaine addiction. In one study, patients who were
being treated with buprenorphine for heroin addiction, and who
were also cocaine addicts, were observed to reduce the abuse of
cocaine (Kosten et al., 1989). In another study, recently
published in the journal Science (Mello et al., 1989), monkeys
that had been self-administering cocaine greatly reduced their
use of it once they had been treated with buprenorphine. This
is  a  very  exc i t ing ,  though s t i l l  pre l iminary ,  f ind ing .
Needless to say, we will be following up on these discoveries
as quickly as possible.
We would be remiss if we did not mention naloxone, a short-
acting narcotic antagonist. This medication is used to treat
the respiratory depression that follows a heroin overdose, and
over the years has saved the lives of thousands of people. It
is a success story that is frequently overlooked when we fail
to see the addict as a person; someone with a life-threatening
disease, who needs our help and our compassion.
What we have presented thus far is an abbreviated summary of
our Medications Development Program’s efforts to improve the
treatment of heroin addiction. A signif icant amount of
research is also ongoing to more precisely identify the
mechanisms underlying drug addiction, and we are hopeful that
this research will lead to innovative conceptual approaches to
treatment.
An additional area of particular interest and concern involves
the treatment of the pregnant addict. We are attempting to
develop medications that will allow us to treat the mother
without affecting the fetus. The scientific and technical
problems are considerable but we think addressable. This is a
new, high priority area that will involve a considerable amount
of basic research.
Heroin addiction is very different from cocaine addiction.
Although both substances are legally classed as narcotics, they
represent two distinctly different kinds of abused substances.
Heroin is a depressant drug. It acts directly on opiate
receptors and thereby affects brain activity. Self-admimstra-
tion of heroin satisfies the need for heroin for periods of 4
to 6 hours. Cocaine is a stimulant drug. Its effects last for
minutes rather than hours. In contrast to heroin, the self-
administration of cocaine does not satisfy the need for
cocaine. Rather, it stimulates craving for more cocaine. It
acts indirectly on brain and behavior by modifying the release
of other chemicals in the brain.
In light of what we understand about cocaine, the concept of
maintenance therapy, vis-a-vis methadone, is not applicable to
the treatment of cocaine addiction and is not consistent with
our stated goal of normalizing brain function and behavior. We
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are developing medications, however, that are designed to
assist in treatment by a) blocking the euphoria and “rush”
experienced by cocaine addicts, b)reducing the “crash” seen
after stopping cocaine use, c) reducing the ensuing. depression
and loss of the ability to experience pleasurable emotions, d)
reducing the intense “craving” for cocaine, and e) acting as
“antidotes” to toxic reactions and/or neurotoxicity.
There is new hope in regard to the treatment of cocaine
addiction. We are beginning controlled clinical trials of two
new medications that appear to hold considerable promise in
treating intravenous cocaine and crack addiction. One medica-
tion, carbamazepine, has been studied at the National Institute
of Mental Health for a number of years. Carbamazepine is
approved as an anti-epileptic treatment, and it blocks the
occurrence of seizures. Cocaine can produce these brain
abnormalities and it has been suggested that a medication that
controls these localized brain seizures might reduce craving
for cocaine. One preliminary test of this idea proved success-
ful in about one-third of the patients (Kuhn et al., 1989), and
the studies are being enlarged as quickly as possible. One
study will be run at NIDA’s Addiction Research Center and
another in one of our Treatment Research Units.
Another new medication, flupenthixol, showed even greater
initial success in an open study of crack abusers (Gawin et
al., 1989). This medication is proposed to normalize the
disruptive effects of cocaine on dopaminergic systems. If
flupenthixol proves to be safe and effective in our upcoming
clinical trials, we will do whatever is necessary to ensure its
rapid development and approval.
Let me emphasize that we do not envisage that our Medications
Development Program will discover a magic bullet to cure drug
addiction. We will develop medications that will help to
normalize the brain and behavior of people made sick by drugs.
As mentioned earlier, these medications will give us the
opportunity to engage addicts in a variety of essential
rehabilitative services. These services are crucial; they give
the addict the skills needed to change destructive behaviors
into adaptive behaviors. We will fail those addicts who seek
help if we do not ensure that psychosocial counseling and
rehabilitation services are available to all those patients we
put on medications. Just as insulin will not save a diabetic
who cannot change his diet and lifestyle, medications to to treat
drug addiction. will not work by themselves. They must be part
of a comprehensive treatment program that gives addicts the
capabilities to achieve a life without drugs.
Medications play an essential role in our fight against
disease. They are also vital part of the search for solutions
to drug addiction. I hope that the scientists and physicians
present at this meeting will join us in this initiative to
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improve the treatment of drug addiction and prevent the spread
of AIDS through effective pharmacotherapcutic interventions.
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A Schema for Evaluating
Methadone Maintenance Programs
John C. Ball
 The Status of Drug Abuse Treatment Evaluation
There is a particular need to evaluate the effectiveness of
methadone maintenance programs in the United States in the AIDS
era. This is because programs which reduce or eliminate IV drug
use by patients can influence the spread of HIV in high risk
metropolitan areas. Beyond the AIDS issue, there is a
fundamental need to unravel the dynamics of treatment and
rehabilitation in order to improve the effectiveness of drug
abuse treatment generally.
A considerable body of scientific and medical knowledge has been
published during the past twenty-five years about methadone
maintenance treatment. Most of this research falls within two
broad classifications: (1) pharmacological or clinical studies
of the efficacy of specific drugs, dosages or related treatment
regimens, (2) patient outcome studies which measure the overall
effectiveness of methadone maintenance treatment. Investigators
in both of these research areas have advanced our knowledge
considerably and these contributions have been reviewed in a
series of research monographs sponsored by the National
Institute on Drug Abuse.
Nonetheless, in the past decade, researchers have noted that
there is a pervasive lack of knowledge about how treatment is
actually carried out in methadone maintenance programs. Indeed,
this somewhat perplexing void in our knowledge of drug abuse
treatment has been dubbed the "black box" of treatment.
A Four Domain Schema for Treatment Evaluation
In order to conceptualize drug abuse treatment broadly and,
thereby, to open the "black box" of treatment, an evaluation
schema which includes four domains of data collection has been
established. These four domains are: the patients, the
treatment domain, services provided, and program outcome. Each
of these domains will be delineated with respect to data
obtained from a three-year comprehensive evaluation of six
methadone maintenance programs in three cities. (Figure 1).
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The first domain consists of patient data. In the three cities
evaluation, patient data was obtained through face-to-face
interviews at the programs as well as by record reviews. Repeat
interviews with the ASI were obtained in 1986 and a follow-up
study of patients who left treatment completed. In general,
patient data has not been neglected in contemporary program
evaluation.
The second domain in the schema is the treatment domain. This
domain includes the setting or environment in which treatment
occurs, the treatment policy followed, the leadership and staff
who provide services, as well as the physical facility and other
resources. In the three cities evaluation, treatment domain
data was obtained with respect to 51 variables. This domain of
treatment - which includes a major portion of the black box -
has been conspicuously neglected in drug abuse treatment
evaluation.
The third domain in the evaluation schema encompasses the actual
provision of treatment and rehabilitative services. In
methadone maintenance programs, this domain includes: number of
methadone doses dispensed on site and as take-homes; dosages
prescribed; hours of clinic operation; patient attendance;
number, type and duration of counseling sessions (e.g.,
individual or group); educational or vocational services; type
and frequency of medical services provided on site; referral
services provided; psychiatric coverage provided; frequency of
obtaining urine specimens and urinalysis procedure; as well as
any other services provided. In the three cities evaluation,
data were obtained with respect to 35 service provision
variables. This services provided domain has also been neglected
in evaluation, but somewhat less so than the treatment domain.
The fourth domain of the schema is patient and program outcome
following treatment. The area of patient outcome has not been
neglected. Thus, there has been a realization that it is
necessary to collect information about patient characteristics
following treatment in order to determine whether or not
positive change has occurred. In drug abuse treatment
evaluation, common outcome criteria are: reduction of drug abuse
(by type of drug), reduction of criminality, retention in
treatment, improvement in employment and reduction in welfare
status. In the three city evaluation, patient outcome was
measured by means of ASI scales as well as additional variables.
Conversely, the study of proaram output has been strangely
neglected. Although Dr. Dole advocated performance based
ratings of programs in 1982, these studies were not undertaken.
Therefore, program output remains a largely unexplored area. In
the three cities evaluation, program outcome was measured in two
ways: (1) the adequacy of the treatment domain and the adequacy
of services provided, and (2) differential effectiveness in
patient outcome rates.
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The present evaluation schema has made it possible to
conceptualize, measure and analyze dozens or scores of
treatment related variables in each of the four domains. As a
consequence, detailed information about patients in methadone
maintenance treatment has been obtained; comprehensive
knowledge about how methadone clinics are staffed and
function has been compiled; the actual provision of medical,
counseling and other services enumerated and analyzed; and
the effectiveness of individual program according to
objective outcome criteria determined.
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Figure 1: Treatment Evaluation Schema - Four Domains of Data
METHADONE MAINTENANCE PROGRAMS
TREATMENT SERVICES
I. PATIENTS II. DOMAIN III. PROVIDED IV. OUTCOME
Sample, Scope Entire Census; 51 Variables 35 Variables 11 Variables
Sample of 633
Source of Data Interviews Interviews, Records Interviews, Records From I, II & III
& Records & Observation & Observation
First Measurement 1985 1985 1985 1985
Second Measurement 1986 1986 1986 1986
Place of Measurement* At Programs At Programs At Programs (Analysis)
Data Collected By: ISR; MES ME Staff-4 ME Staff-4 Follow up of 107
by ISR
* Data Collection was at six methadone maintenance programs;
two each in New York City, Philadelphia and Baltimore.
Evaluation of Treatment for
Cocaine Dependence
Charles P. O’Brien, Arthur Alterman, Dan Walter, Anna Rose
Childress and A. T. McLellan
INTRODUCTION
The enormous increase in cocaine availability in the 1980’s has presented a
completely new problem to the substance abuse treatment community. The
clinical picture presented by patients exposed to cheap widely available cocaine
is new to all of us. The added complication of a new form, crack. which makes
free base cocaine accessible to the most vulnerable of our citizens is a further
unpredictable development.
As with any new disease or syndrome, there is a period of time in which
clinicians must orient themselves, set up treatment programs based on
extrapolation from similar illnesses and on their intuition and then observed the
results. Changes and improvements in treatment techniques should be based on
feedback from organized studies and preferably from controlled studies with
random assignment. Such a deliberate and rational process is unusually difficult
when faced with the clinical problems presented by cocaine dependent patients
in the late 1980’s. Patients apply for treatment while they are in a crisis and
often as an acute emergency. Frequently violence or threats of violence are
involved. These threats may be either suicidal or homicidal and not infrequently
directed toward members of the staff if patients’ demands are not immediately
met. This air of crisis inhibits a systematic research approach and also interferes
with an effective treatment program. It is not surprising, therefore, that there are
few studies currently available which describe the results of treatment for
cocaine dependence. Rather than review the existing studies, we will briefly
present a description of the patient populations, the treatment retention rates and
the current status of four treatment studies being conducted at our research
center.
POPULATIONS AND TREATMENT PROGRAMS
Table 1 shows the five different populations of cocaine dependent patients. All
are veterans who voluntarily applied at the Philadelphia Veterans Medical Center
for treatment of cocaine dependence. Over 90% are black in contrast to about
60% black among opiate dependent applicants. A large majority were legally
employed just prior to applying for treatment and crime-related activities were
relatively small, significantly less than we find among opiate dependent
applicants (Table II). The average cocaine dependent applicant had been using
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cocaine less than three years and only 11% of the non-methadone population
had had prior treatment for substance abuse.
1. General Program. This is our basic cocaine treatment program. We
currently receive 6-13 new applications for treatment each day and patients are
accepted as vacancies occur. The only exclusionary criterion is immediate need
for hospitalization, usually because of psychosis. The program consists of five
days per week in a multimodality day hospital program which includes group
therapy, activities therapy, individual counseling and psychoactive medication
as indicated. As as be seen from Table 1, only 37% of patients completed the
four week intensive outpatient program. The clearest indicator of early
termination from outpatient care is homelessness. One hundred per-cent of
homeless applicants have failed to complete the program.
2. Behavioral Treatment Study. This outpatient program randomly assigns
patients to either psychotherapy or drug counseling with or without a behavioral
treatment paradigm which involves extinction of conditioned responses to
cocaine related stimuli (Childress et al. 1989). The 51 patients who volunteered
for this study were almost all black and 89% were employed prior to beginning
treatment. They spent more on cocaine than the other groups and the retention at
four weeks for this group was 75%.
TABLE I
FIVE COCAINE DEPENDENT POPULATIONS
N
% Black
Mean Age
%Employ
Yrs Ed
Drug cost
Yrs Coc
4 wk retnt.
*10 weeks retention in methadone/desipramine treatment
3. Desipramine for Cocaine Abusing Methadone Patients. Cocaine is a major
drug of abuse among dependent patients receiving methadone treatment. Those
with persistent positive urines for cocaine were given the opportunity to
participate in a double-blind trial of desipramine or placebo added to methadone
treatment. Seventy-eight percent of the 59 patients who volunteered completed
10 weeks of treatment. The results of the trial are reported elsewhere (Arndt,
1988).
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TABLE II
Cocaine Dependent vs. Opiate Dependent Outpatients
Legal Problems
* p< .001
RANDOMIZED TRIAL OF OUTPATIENT VS. INPATIENT
TREATMENT
Populations 4 and 5 of this report participated in randomized trial in which
cocaine dependent volunteers were randomly assigned to either a 28 day
intensive outpatient program or an inpatient therapeutic community, also of 28
days duration. This study is still in progress, but we will present a preliminary
report because of the current need for systematic data on the efficacy of
treatment for cocaine dependence.
The research subjects were 60 male cocaine dependent patients. Thirty-five
were treated in the four week Day Hospital program of the Philadelphia VA
Medical Center and 25 in the 28 day inpatient rehabilitation program of the
Coatesville VA Medical Center. These two facilities are in the Philadelphia
metropolitan area about 40 miles from each other by car. Of the 35 Day Hospital
patients, 26 has been randomly assigned to Day Hospital treatment, while the
remaining nine were “non-random” subjects who agreed to participation
provided they were treated in the Day Hospital. Of the 25 patients. 16 had
agreed to random assignment and by chance received inpatient treatment, while
nine participated as non-random subjects who agreed to participation contingent
on inpatient treatment. All patients had been screened for participation at the
Philadelphia VA Medical Center’s Central Intake Unit.
Procedures. All patients underwent both medical and physical examinations,
including laboratory evaluations. On this basis, all were determined to be
cocaine dependent. This diagnosis was subsequently confirmed by the NIMH
Diagnostic Interview Schedule (Robins, et al., 1981). None of the subjects
were demented, mentally retarded, currently psychotic, or suffering from an
unstable medical condition requiring immediate attention. Informed consent was
obtained following full disclosure. The subjects agreed to participation in a
study evaluating the relative efficacy and costs of inpatient versus Day Hospital
treatment for cocaine dependence. The Day Hospital program consisted of 27
hours of treatment over the five weekdays. Treatment consisted primarily of
group therapy supplemented by individual counseling, medical care, family
therapy, vocational counseling and recreational therapy. Group therapy
concentrated on overcoming denial, helping the patient to structure his life
around non-substance related activities and becoming involved in a self-help
group. The inpatient treatment was quite similar except for meals and housing
and more. structured recreational events.
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During the intake process the Addiction Severity Index (ASI - McLellan, et al.,
1980, 1985) was administered to all subjects. This instrument obtains
historical/sociodemographic information and also assesses level of
functioning/problems in seven areas of life functioning: medical, employment,
alcohol -related, drug-related, legal, family/social and psychological. The ASI
consists of a semi-structured interview which takes a trained research technician
about 40 minutes to administer. An abbreviated follow-up version is employed
to assess post-treatment functioning. Follow-up evaluations were obtained four
months after entry into treatment, i.e. three months after projected completion of
the course of treatment.
PRELIMINARY RESULTS OF THE INPATIENT VS
OUTPATIENT STUDY
Baseline Findings. Baseline data were analyzed using t-test for continuous data
and chi square (Yates correction) for nominal data. In all cases, the data were
evaluated both for all subjects (N’s =35 and 25) and for randomized subjects
only (N’s =26 and 17). The Day Hospital and inpatient groups of subjects did
not differ in basic sociodemographic characteristics such as age, race, years of
education, marital status and socioeconomic class. As was the case with the
other three populations we have studied, almost all of the patients were black.
ASI Findings. The data revealed relatively low problem levels for all groups in
the medical and legal areas. Moderate problems levels were reported with
respect to alcohol and drug problem levels. Thus, the cocaine dependent
patients had been using cocaine less than 2.5 years and drinking to intoxication
for about 6 years. Negligible heroin use was reported. While the problem levels
are certainly serious, the overall drug problem level was lower than that
reported for heroin dependent patients at the same facility and the alcohol
problem level was lower than that for the alcohol dependent patients we treat.
Psychological problem level was also at a moderate level, while reported
employment and family social problems were relatively high for these patients.
Treatment Completion. The rates of completion for the month of rehabilitation
were 43% for the Day Hospital and 86% for inpatients when all subjects were
considered. The difference between the two groups were significant X2 = 8.72,
d.f. = 1,n = 54, p = .003. Considering the randomized subjects only, the Day
Hospital completion rate was 42% while 88% of the randomized inpatients
completed treatment. Again, the difference between the two groups was
significant: X2 = 7.02, d.f. = 1, n = 40,p = .008.
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Table III
ASI DATA FOUR MONTHS AFTER BEGINNING TREATMENT
OUTPATIENT, N=18 INPATIENT, N=15
Treatment Outcome. A follow-up ASI interview at four months following
treatment entry has been obtained on 83% of eligible patients. Seventy-six
percent of all patient reported no cocaine use in the prior 30 days and those who
were using cocaine were averaging only 1.2 days per month. Urine tests tended
to support the patients’ statement, but we do not have sufficient urine data yet to
report. It should be noted that there were no consequences to reporting drug use
to the follow-up interviewer. ASI data were obtained on 18 patients (14
randomized) and 15 patients (nine randomized). The data were evaluated
utilizing one way analyses of variance with repeated measures. There was a
significant effect for time for all groups. inpatient, outpatient, randomized and
non-randomized. Differences between baseline and follow-up were significantly
improved at p<.04 or better for all ASI factors except Medical and
Psychological variables. There were no differences between those patients who
had received inpatient treatment and those who had received outpatient treatment
despite the much higher treatment completion rate for the inpatients.
SUMMARY
1. At the Philadelphia VA Medical Center, veterans applying for treatment of
cocaine dependence were significantly different from applicants dependent on
opiates or alcohol without cocaine. The cocaine dependent patients were almost
all black and they were mostly employed. Few were involved in crime and, for
most, this was the first course of substance abuse treatment. Their use of
cocaine began within the past three years and they had relatively few
psychiatric, medical, employment or family problems when compared with
other applicants for substance abuse treatment.
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2. Completion rate for a course of outpatient treatment for cocaine
dependence varies from a low of 37% in the general Day Treatment Program to
76% in a special Behavioral Treatment Program and 78% among methadone
patients receiving an additional medication for cocaine dependence. Completion
of a 28 day course of inpatient treatment was 86% whether the patient selected
inpatient care or was assigned to it on a random basis.
3. Those outpatients who remained in treatment generally did well and
refrained from cocaine use even during the course of outpatient, either day
hospital treatment or behavioral treatment. When both inpatients and outpatients
were re-examined four months after beginning treatment, there was significant
improvement on almost all ASI categories. Both drop-outs and completers were
re-examined. Despite the significantly greater completion rate for the patients
assigned to inpatient treatment, both groups showed equal levels of
improvements at the 4-month follow up point.
4. These preliminary results from five different treatment populations
suggest that cocaine dependent patients can be engaged in treatment and that
significant improvement is possible.
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Current Status of Alcoholism
Treatment Outcome Research
Richard Fuller
This review is selective rather than comprehensive. I have chosen those areas
which I consider the most important, and in those areas have selected either the
papers which I consider the most important or illustrative of the area. The
views expressed are mine and not those of the National Institute on Alcohol
Abuse and Alcoholism.
Alcoholism treatment has developed mostly from three sources: 1) the
experience of recovering people and clinicians who had worked for years with
recovering alcoholics 2) pharmacotherapeutic research, and 3) behavioral
therapy research. The class example of the first source is the prototype self-
help movement, Alcoholics Anonymous (AA). Alcoholics Anonymous
developed before alcoholism treatment was an active area of research, and, thus
to a large degree, its efficacy not been evaluated by randomized controlled
clinical trials (RCTs). This situation is similar to accepted pharmacotherapies
such as the antiarrhythmic medications, quinidine and procainamide, which
became accepted into medical practice before clinical trial methodology was
developed. Once a treatment becomes accepted, it is difficult to do a RCT to
test its efficacy because of the ethical dilemma of depriving half of the patients
of a treatment perceived as effective.
Much of what is done in alcoholism treatment appears effective, and health
utilization data discussed below supports this. Yet, for the specific components
of standard treatment we often lack compelling data that the changes in behavior
seen are, in fact, the result of the treatment. In contrast, pharmacotherapies and
behavioral therapies were usually developed in academic settings and their
efficacy has been tested by RCTs. (This is not entirely true for disulfiram
which was initially evaluated by uncontrolled studies, and only more recently
evaluated by RCTs). Our knowledge of the effectiveness of two of the
pharmacotherapies, disulfiram and lithium, is enhanced because not only large
scale multi-site studies with sufficient sample size to assure acceptable statistical
power. While some behavioral therapies have been found to be effective, their
generalizibility is limited because the sample sizes were modest and the benefit
may occur only in a special subtype of alcohol dependent person recruited into
those studies.
From a broad perspective, alcoholism treatment is effective. Holder and Blose
(1986) studied the effect of alcoholism treatment on health care utilization and
costs of federal employees in a health insurance program provided by the Aetna
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Insurance Company. In the years before treatment, alcoholics incurred
gradually increasing health care costs. These costs increased markedly (two
and one-half times) in the six months before treatment. The costs declined
during the year after treatment and remained stable for the next two years (the
period of data collection). For individuals under 45, costs declined to a point
comparable to the lowest pretreatment levels. This is an important study and
strongly indicates that what is done under the rubric of alcohol treatment is
effective. A skeptic can argue that without a concurrent control group one
cannot be sure that is was spontaneous remission rather than treatment which
was responsible for this happy outcome. However, the temporal linkage is so
strong that this possibility seems unlikely. This study does not, however, settle
the issue of what components in the treatment package are critical and which are
unnecessary.
The most common approach to the inpatient treatment of alcohol dependence is
the “Minnesota Model” or some variation of it. It is called The Minnesota
Model because it evolved from three treatment centers in Minnesota: Pioneer
House, Hazelden and Willmar State Hospital, which were founded in the late
1940s and early 1950s. In its simplest form, treatment consists of assessment
and admission to a residential treatment facility for 3-6 weeks followed by
intensive attendance at AA (Cook, 1988a). The inpatient phase is intensive,
offering counseling, lectures, and group therapy. The content is based on the
principles of AA and the goal is abstinence. The staff includes both recovering
persons and professionals.
Post-treatment surveys have been done on patients treated at Hazelden
(Gilmore, 1985). It is difficult to accept the results of these surveys at face
value because of several serious methodological problems. In the only survey
to cover a full one year period almost half of the questionnaires were either not
sent or not returned. Cook (1988b) recalculated the outcome results by
including patients unaccounted for. His calculations indicated a “good
outcome” for 63%. However, as Cook points out, this figure is probably an
exaggeration because of lack of clearly defined outcome criteria. Furthermore,
the surveys relied on self-report and the use of self-report alone to evaluate
alcohol treatment outcome research results in inflated outcome results (Fuller et
al., 1988). Additional methodological problems of these studies include lack of
control or comparison groups and need for longer follow-up (Cook 1988b).
Lectures are one component of the Minnesota Model. Do they add benefit to the
other components of the model? This question has not been answered.
However, whether patients retain the material they have been taught has been
studied. Two different teams of investigators (Sanchez-Craig and Walker,
1982 and Becker and Jaffee 1984) found that alcoholics tested 3 weeks after
beginning abstinence were unable to recall treatment-related information
presented in a film and, thus, unlikely to influence post-treatment behavior.
While this questions the therapeutic value of one part of the Minnesota Model, a
more important question is how effective is AA, the central core of the
Minnesota Model. Most studies of AA are correlational in nature and support a
relationship between attendance at AA and abstinence. Only a few controlled
evaluations of AA persons have been done and these were in court-mandated
programs (Brandesma, et al., 1980, Ditman et al., 1967) or with patients in a
methadone maintenance programs (Stimmel et al., 1983). Whether the results
of these studies are generalizable to other alcoholics is unknown. Because of
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AA’s central role in so much of alcoholism treatment, it is unfortunate that more
controlled studies of it have not been done. It reflects the problem of trying to
study a treatment after it has become firmly established in practice. The Holder
and Blose (1986) data indicate the alcoholism treatment does work. What is
missing is more specific information about the benefit of the various activities
done under the table alcoholism treatment.
An effective pharmacological treatment for alcoholism would be of great
benefit. Vincent Dole (personal communication) was told by Bill W., one of
the co-founders of AA, that what alcoholism treatment needed was a methadone
equivalent, i.e. a medication that would abolish craving. Unfortunately, alcohol
does not act on a specific receptor as the opioids do and a magic bullet for
alcoholism treatment is not currently available. Nevertheless, research is being
done on development of “anti-craving” drugs.
Disulfiram is the most widely used medication, specifically used to treat
alcoholism. It causes an adverse reaction if a person drinks alcohol, and thus,
is a deterrent to drinking. The initial studies reported excellent results, but these
studies had serious methodological flaws. Only 10% of the studies were
controlled. The studies were not “blinded”, relied on self-report only, and the
therapists were the ones assessing the response to treatment. The recently
published multi-site VA cooperative disulfiiam study was a randomized
controlled, blinded clinical trial of 605 men (Fuller, et al., 1986). There were
two control groups: a 1 mg disulfiram dose and a no-disulfiram group. One
mg is not sufficient to cause disulfiram-ethanol reaction (DER) and this group
was a control for the threat of a DER. The no-disulfiram group was a control
for the counseling all the patients received. There were no significant
differences in the proportion of men achieving continuous abstinence for one
year among the disulfiram group (18.8%) and two control groups (22.5% and
16.1%. respectively) nor in time to first drink among the three groups.
There was a highly significant relationship between compliance to regimen and
continuous abstinence. Forty-three percent (50/1165) of the men judged to be
compliant were abstinent compared to only 8% (26/315) of the non compliant
men. This significant relationship was true for all three treatment groups,
suggesting that something occurred in these men’s lives to promote both
compliance and abstinence or vice versa.
Among the men who relapses and who provided all seven treatment response
assessment interviews (about half of the men who relapsed), there were
significantly fewer drinking days during the year (49.0 + 8.4) reported by the
250 mg dose disulfiram patients compared to the two control groups (75.4 +
11.9) and 86.5 + 13.6. respectively). This significant increase in abstinent
days in the conventional disulfiram dose patients was corroborated by a
cohabiting relative or friends. The men who provided all assessments
interviews were slightly but significantly older and had lived significantly
longer at their current address than those who provided less than 11 follow-up
interviews. Abstinence is difficult to achieve for any addiction and these
findings suggest that disulfiram may be partially beneficial, i.e. reduce the
frequency of drinking in men who can not remain abstinent.
Faithful compliance with the medication regimen was the Achilles’s heel for
many men in the VA study, only 20% were compliant. One study (Azrin et al,
1982) of 43 men attending a rural outpatient clinic found significantly more
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abstinent days in men whose spouses supervised the administration of
disulfiram than those who were given it to administer themselves. Another
recent study (Sereny et al. 1986) has indicated that if supervised disulfiram (in
the report administered by the staff) can be mandated as part of the treatment,
this will result in greater rates of abstinence among clinic attenders who
previously had failed the treatment. These methods of giving disulfiram
deserve more study because they are likely to increase compliance. Disulfiram
tablets  have been implanted subcutaneously to  assure compliance.
Unfortunately, the DER is weak or non-existent and a recent controlled study
showed no benefit from implanted disulfiram (Johnson et al., 1987). Work is
in progress to develop an injectable form of disulfiram,
Calcium carbamide is another deterrent drug with a short duration of action (12
hours). It is available in Canada, but not in the United States and there have
been no controlled trails assessing its efficacy.
Lithium carbonate is another medication which held promise of being an
effective treatment. Both human data (Judd and Huey. 1984) and animal data
(Ho and Tsai, 1976) indicated reduced craving for alcohol and/or reduced
consumption. Fawcett et al. (1987) did a randomized controlled blinded study
of lithium carbonate in 104 alcoholics. Overall, there was no difference in
resumption of drinking between patients receiving lithium and those receiving
placebo except for the compliant patients. The compliant lithium carbonate
patients were significantly less likely to resume drinking than were the placebo
patients. However, compliance was not determined by the same method in both
groups. Compliance in the lithium carbonate group was measured by blood
levels and in the placebo group by pill counts.
The results of VA cooperative study of lithium carbonate (Dorus et al) have
been presented at meetings and the results arc soon to be published. This study
of alcoholics with and without depression found no benefit from lithium
carbonate in either type of alcoholic; and no differences were found between
patients complaint with the lithium carbonate or the placebo regimen. Because
of the sample size (286 non-depressed alcoholics and 171 compliance in both
active drug and placebo groups. this study appears to provide the definitive
answer about the efficacy of lithium carbonate.
Disulfiram and lithium carbonate have been the most extensively studied of the
pharmacological treatments. The serotonin uptake inhibitors are currently the
most actively investigated medications. These agents block the presynaptic
uptake of serotonin, and, thus, increase the concentration of serotonin at the
synapse. Interest in these blockers derives from animal studies showing a
negative correlation between brain serotonin levels and spontaneous alcohol
consumption and more than a dozen animal studies showing that specific
serotonin uptake blockers decrease alcohol preference and intake in rodents
(Gorelick, 1989). furthermore, several studies have found significantly lower
levels of cerebrospinal fluid 5-hydroxyindol acetic acid (5-HIAAA), the major
metabolite of serotonin in alcoholics both during acute withdrawal and abstinent
for at least 5 days and a negative correlation between length of abstinence and
the cerebrospinal 5-HIAAA levels (Gorelick, 1989).
Four double-blind, placebo-controlled human studies, using different serotonin
uptake blockers have been reported. While all found a reduction in alcohol
intake, only one study was done with alcohol dependent subjects (Gorelick,
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1986). The others recruited “social drinkers” and “early stage problem
drinkers”. Gorelick studied 10 subjects received either fluoxetine (up to 80 mg
orally daily) or placebo and could request alcohol according to a fixed interval
schedule, i.e. 60 ml f 97.5 proof alcohol once an hour 13 times daily. During
the first week fluoxetine caused a significant reduction of daily alcohol intake
from 317 ml to 273 ml (a 14% reduction) and a significant decrease in alcohol
craving as rated by nurses. However, this effect lasted only one week. There
were no significant changes during the remainder of the study.
While these medications have been shown to decrease alcohol consumption, the
decrease is usually modest (about 10%) and the effect was quite transient in
Gorelick’s study. These factors limit the potential benefit of these medications
unless one of the other members of this class of agents (e.g. fluovaxamine) are
shown to be more potent and long lasting or the chemical structure of one of
these medications can be altered to enhance its effect
Other pharmacological agents e.g. naltrexone and bromocriptine are being
studied, but the data either are too preliminary and are not available to reach any
conclusions, Agents like emetine have been used to create an aversive
conditioning response to alcohol. This literature is characterized by a lack of
controlled clinical trials (Wilson, 1987). Short-term conditioned aversion
reactions to alcohol can be produced, but the efficacy of chemical aversion
conditioning independents from standard treatment has not been demonstrated
(Wilson, 1987).
The other major category of therapies studied are the behavioral therapies which
are derived from three theoretical psychological models: classical conditioning,
operant conditioning, and social learning theory. Most of the controlled studies
of alcoholism treatments have been of behavioral approaches. However, many
of the studies have recruited subjects who are not alcohol dependent and the
sample sizes of the studies are often small (less than 60). Behavioral therapies
applied to alcoholism treatment include aversion therapy, cue exposure,
community reinforcement, self-control training, stress management, social
skills training, marital behavioral therapy and relapse prevention. Aversion
therapy is an example of a classical conditioning response that attempts to
produce a conditioned aversion response to alcohol by pairing an aversive
stimulus with the sight, smell or taste of alcohol. Chemical aversion therapy
using emetine has been discussed above.
Another example of classical conditioning is based on extinction training. Cue
exposure involves presenting the patient with stimuli associated with alcohol
consumption but preventing him from drinking. Eventually the patient reports
less craving for alcohol and during trials manifests attenuated autonomic
reactions to alcohol cues. The ultimate value of such diminished responses has
yet to be demonstrated.
Community reinforcement is based primarily on principles of operant
conditioning. Community reinforcement involves enhances access to
reinforcing activities, e.g. family, non-drinking social club, and work, and
makes access to these reinforcers contingent on abstinence. Azrin et al. (1982)
have combined community reinforcement and disulfiram. They have reported
that this combination resulted in almost complete abstinence during a six month
study contracted with patients assigned to “traditional;” therapy drinking 50% of
the time by the sixth month. These are remarkable results but the sample
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consisted of 43 men seen at a rural Illinois outpatient clinic. Currently
controlled studies are being done in the United States and Poland to corroborate
or refute these results.
Marital therapy is relevant because post-treatment research has (Moos and
Moos, 1984) shown a strong relationship between favorable family adjustment
and sustained abstinence. McCrady and associated (1986) compared three out-
patient treatment conditions: 1) minimal spouse involvement; 2) alcohol-
focused spouse involvement; and 3) alcohol focused spouse involvement plus
behavioral marital therapy. At six months there were no significant differences
among the three groups in either total abstinence of number or abstinent days,
although all subjects had markedly decreased their drinking. However, the
marital therapy subjects decreased their drinking more quickly, relapses more
slowly, and maintained their marital satisfaction better after treatment. O’Farrell
et al (1985) also found better marital functioning in those receiving behavioral
marital therapy and significantly more alcohol-free days in the marital behavior
group members.
Relapse prevention strategies rely on cognitive therapy techniques to avert post-
treatment relapses. Marlat (1989) has presented data of a controlled trial in
“problem drinkers,” showing fewer relapses and drinking days n the drinkers
receiving relapse prevention training. Whether this method is effective in
alcohol-dependent individuals, remains to be demonstrated.
Conclusion: Alcohol treatment works as measured by a reduction in health care
utilization. However, what specifically under the rubric of alcoholism treatment
works is, for the most part, not known because adequate controlled studies
have not been done. Disulfiram appears to increase abstinent days in men with
families and residential stability. Some behavioral therapies appear promising,
but have been studied in small samples and often in non-dependent alcohol
abusers so that generalizability is unknown. We need new innovative treatment
methods, a better understanding of current methods, and learn how to enhance
treatment by matching treatments to specific patient subtypes.
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Pain Modulation: Opiates and
Chronic Pain
Howard L. Fields
INTRODUCTION
Persistent and/or frequently recurrent pain is a problem that
afflicts millions of people. For example, in a recent survey,
8% of a random sample of the population of the United States
reported back pain severe enough to limit their activities for
at least 30 days (Taylor and Curran 1985). This translates
into about 20 million people losing 500 million work days from
back pain alone. Thus, the cost, both in terms of human
suffering and economic loss is staggering. Patients with
arthritis, cancer pain, severe headache and low back pain
provide us with a serious challenge to elucidate the neural
mechanisms that mediate the pain and to devise better ways to
treat it. Over the past two decades the related fields of pain
research and clinical treatment have begun to address these
objectives. In this paper, I will briefly review some of the
significant advances that have contributed to our understanding
of chronic pain. I will also discuss recent work on the
mechanisms of opiate analgesia that may help us to understand
some chronic pain patients.
TRANSMISSION
The transmission of activity evoked by noxious stimuli begins
with the transduction process in the peripheral terminals of
the primary afferent nociceptor (PANS). The message is
conducted to pain transmission neurons in the spinal cord
dorsal horn and from there to thalamus and cortex. In human
subjects, PAN discharge and subjective pain intensity covary
across the same range of stimulus intensities (Gybels et al.,
1979). Across this same range of stimulus intensities primate
spinothalamic tract neurons and human subjective pain ratings
also covary (LaMotte and Campbell 1978; Price et al., 1978). A
similar stimulus intensity/discharge frequency relationship has
been demonstrated for neurons at thalamic and cortical levels
(Kenshalo et al., 1980; Kenshalo and Isensee 1983). These
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studies indicate that stimulus intensity is encoded in a direct
manner by neuronal discharge frequency at each level of the
pain transmission system. With this simple code, the
mechanisms for persistent pain can be understood by a single
unifying principle: any process which leads to prolonged
increases in activity in PANS or central pain transmission
neurons can contribute to persistent pain.
There are several distinct neural processes that have the
potential to produce pain or to increase its duration and/or
intensity. The most straightforward cause of persistent pain
is a persistent, active tissue-damaging process (e.g. cancer,
arthritis or a herniated intervertebral disc). In these cases
the pain will persist unless the underlying disease is cured.
This possibile cause for chronic pain is the one most often
recognized and correctly managed by physicians.
Sensitization. In some cases of persistent pain no active
tissue damaging process can be identified. The patient may
point to an area that they say is painful but nothing can be
found that would be expected to activate a primary afferent
nociceptor. A theoretical possibility in such cases is that
primary afferent nociceptors have been sensitized so that
intense stimuli are no longer required to activate them. Thus,
normally innocuous stimuli such as brushing the skin or weight
bearing on joints can provoke pain. In fact, sensitization of
primary afferent nociceptors (PANS) does occur under
'physiological' conditions (LaMotte et al., 1983). Peripheral
inflammatory mediators such as histamine, prostaglandins and
leukotrienes can sensitize PANS (Lembeck 1983; Levine et al.,
1984). Furthermore, there is now good evidence that peptide
neuromodulators (e.g. substance P), are released from the
peripheral terminals of PANS and contribute to their own
sensitization (Juan and Lembeck 1974).
Sympathetic Efferents. Activation or sensitization of PANS may
be produced by activity of sympathetic efferents. Certain
patients have a burning pain that can be completely relieved by
blockade of sympathetic efferents. Such patients are said to
have sympathetically maintained pain (reflex sympathetic
dystrophy (De Takats 1937), or causalgia, if there is
accompanying nerve damage (Mitchell 1965). Whether sympathetic
efferents can activate or sensitize PANS is still an open
question (Roberts 1986). however, there is evidence for
sympathetic efferent induced peripheral release of
prostaglandins which can sensitize some PANS (Gonzales et al.,
1989). It should be pointed out that experimental studies of
sympathetically maintained pain have focussed on cutaneous
PANS. However, the innervation of the skin is quite unique and
chronic cutaneous pain is rare. Studies of other PANS may be
required to elucidate the mechanism of sympathetically
maintained pains.
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Muscle Spasm. The investigation of sensitization of deep
receptors, particularly musculoskeletal PANS, is needed to
understand muscle pain which seems to be extremely common in
patients referred to chronic pain management centers (Fishbain
et al., 1986). Such patients have muscles with focal areas of
contraction and tenderness (myofascial pain syndrome (Travell
and Simons 1983)). The pathology and cause of this 'syndrome'
is unknown (some even question the validity of the concept).
However, many of these patients obtain dramatic pain relief
with stretching or with injections of small amounts of local
anesthetic into tender-points of the involved muscles. This
observation implicates muscle PANS.
Neuropathic Pain. Persistent pain is occasionally produced by
injury of either the peripheral or central nervous system.
Damage to the axons of PANS can result in the generation of
spontaneous action potentials from sites along the damaged axon
(Devor 1984; Howe et al., 1977). Such ectopic impulses would
be interpreted as pain by the patient. Spontaneous discharge
can also be reliably observed in central pain transmission
neurons following damage to their afferent input (Lombard and
Larabi 1983)
Prolonged Effects of Afferent Input. In addition to the
sensitization of PANS by noxious stimulation or sympathetic
nervous system activity, there is good evidence that noxious
stimulation in the periphery can induce very long lasting
changes in spinal cord neurons. For example, a brief burst of
impulses from muscle PANS can enhance spinally mediated
withdrawal reflexes for hours (Woolf and Wall 1986). Whether
such long lasting changes in the spinal cord contribute to any
clinical chronic pain syndrome is unknown, however, some recent
clinical studies are consistent with this possibility. In thes
studies, patients who were premedicated with opiate analgesics
or local anesthetic block to reduce preoperative or
intraoperative pain had less post-operative pain (McQuay et
al., 1988; Bach et al., 1988).
PAIN MODULATION
In the discussion to this point I have considered only
processes that are subsumed under the general category of pain
transmission. However, it is clear that central pain
transmission neurons are under the control of powerful
modulating networks, some of which have endogenous opioid
peptide component neurons.
The discovery of these networks, and of the endogenous opioid
peptides that contribute to its action, are among the most
dramatic breakthroughs in the understanding of pain.
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Although it had been appreciated for many years that complex
brain pathways modulate sensory transmission, the presence of a
selective pathway for controlling pain was first clearly
demonstrated by the discovery of stimulation-produced analgesia
(SPA). Reynolds, in 1969, showed that electrical stimulation
in the midbrain area of the rat produces an analgesic effect.
During stimulation, the rats gave no evidence of being
disturbed by noxious stimuli. However, they were able to move
and to orient to visual and auditory stimuli. When the brain
stimulation was stopped, noxious stimulation produced a variety
of pain-associated behaviors: attempts to escape,
vocalization, biting, and signs of anxiety. In an attempt to
apply this observation clinically, several groups of
neurosurgeons placed electrodes in that same regions of the
human brain, the midbrain periaqueductal gray matter (Hosobuchi
et al., 1977; Richardson and Akil 1977). These surgeons
demonstrated an analgesic phenomenon apparently similar to that
reported in the rat: over a period of approximately 10 to 15
minutes, patients experienced a fading of pain. The
demonstration of SPA in humans firmly established the existence
of a selective pain suppression system.
Subsequent animal studies have shown that SPA can also be
obtained from discrete sites in the medulla. Anatomical
studies have demonstrated that there is a discrete pathway from
the midbrain to the medullary SPA sites and from the medulla to
the dorsal horn of the spinal cord and trigeminal nucleus
caudalis (Basbaum and Fields 1984).
Opioid Peptides. The endogenous opioid peptides are found in
the periaqueductal gray and medullary analgesia region, and in
the spinal cord. Thus, there is a striking parallel between
the distribution of endogenous opioid peptides and the sites
that, when electrically stimulated, produce analgesia. In
addition, microinjection of opiates at these same sites
produces analgesia, indicating that morphine produces analgesia
by mimicking the effect of opioid peptides.
As mentioned above, the modulation network projects to the
spinal cord, where it inhibits pain-transmission neurons. The
brainstem cells that project to the spinal cord and inhibit
pain transmission are concentrated in two regions, the rostral
ventromedial medulla, which is rich in serotonin, and the
dorsolateral pons, which is rich in norepinephrine. Electrical
stimulation in either region inhibits nociceptive spinal
neurons and produces behavioral analgesia.
Activation of the Analgesia System. Research to date indicates
that stress and pain are both major activating factors (Basbaum
and Fields 1984). In man, stress may be produced by anxiety or
by any extreme emotional state. Assuming endogenous opioid
involvement, the activity of the analgesia system can be
demonstrated by giving naloxone, a narcotic antagonist, to
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subjects who have not received exogenous opiates. In normal,
pain-free individuals, naloxone itself has no effect. However,
naloxone increases the reported intensity of postoperative
dental pain, indicating that the stress and pain of the surgery
is sufficient to activate the analgesia system (Levine et al,
1978; Gracely et al., 1983).
Another approach to determining the physiological function of
pain modulation networks to monitor the activity of its
constituent neurons. To this end we have recorded from neurons
in the rostral ventromedial medulla (RVM) (Fields et al.,
1988). This area, which includes the nucleus raphe magnus, is
a convenient area to study using neurophysiological methods. A
high percentage of its neurons have activity that is influenced
by noxious stimulation and project to the spinal cord dorsal
horn.
The study of RVM neurons has provided us with unexpected
insights into the functional circuitry underlying pain
modulation. Most of our studies have been carried out in rats
under light barbiturate anesthesia. Radiant thermal stimuli
are delivered to the skin under feedback control and single
unit activity is monitored using extracellular recording
techniques. The time of onset of escape reflexes is also
monitored using a force transducer. With these techniques we
have defined three classes of neuron in the RVM: on-cells whose
discharge increases abruptly just prior to withdrawal from
noxious heat; off-cells, whose activity decreases just prior to
withdrawal; and neutral cells, whose activity is not correlated
with noxious stimulation or withdrawal. These neurons are
intermixed in RVM and a similar percentage of each class can be
shown to project to the spinal cord (Vanegas et al., 1984).
Although it is presently unclear what, if anything, neutral
cells contribute, there is compelling evidence that both on and
off cells modulate nociceptive transmission.
Simultaneous recording from both on and off cells in RVM under
light barbiturate anesthesia reveals that they are active
during alternating periods. Thus the RVM alternates between
periods when on-cells are active and periods when off-cells are
active (Barbaro et al., 1989). Withdrawal reflex latency is
shorter when on-cells are active, longer when off-cells are
active (Heinricher et al., 1989). When morphine is given, off-
cells fire continuously, while on-cells become silent, both
effects being reversed by naloxone. Neutral cell activity is
unaffected by morphine. Since off-cells are the only cell
class whose discharge is increased by morphine and since
lesions of RVM or its projection route to the spinal cord block
opiate analgesia, it is clear that off-cells are RVM inhibitory
output neurons.
Nociceptive Facilitation. The more intriguing question that
arises from these studies is that of the function of the on-
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cell. Its discharge pattern and the fact that, with most
manipulations, its discharge changes in a reciprocal way to
that of off cells suggest that the on-cell facilitates
nociceptive transmission. Direct support for this concept
comes from pharmacological studies. First, alpha-l adrenergic
agonists excite on-cells when iontophoresed nearby and alpha-2
adrenergic agonists have an inhibitory action (Heinricher et
al., 1988). Significantly, adrenergic agonists have no direct
effect on off-cells. The functional importance of these
studies is indicated by microinjection of drugs into RVM;
alpha-l agonists facilitate and alpha-2 agonists inhibit
spinally mediated nocifensor reflexes (Sagen et al., 1985).
Further experimental evidence that on-cells facilitate
nociception comes from studies of acute physical dependence in
rats. In lightly anesthetized rats when naloxone is given
after a single dose of morphine, an abstinence syndrome is
produced. One of the most reliable features of this abstinence
syndrome is a shortening of nocifensor reflex latency. During
this period of hyperresponsiveness on-cells fire at rates that
are much higher than they were in the pre-morphine baseline
period (Bederson et al, 1987). In fact, the magnitude of the
hyperresponsiveness is directly correlated with the increase in
on-cell discharge. Since off-cells are not firing during this
period, this data is consistent with the idea that the on-cell
has a direct facilitating effect on nociceptive transmission.
The notion that a central modulatory network can both suppress
and facilitate pain transmission is an important conceptual
advance. If, as is generally accepted at present, pain
modulation were a unidirectional inhibitory process, activity
of the network could only be manifested at the behavioral level
in the presence of noxious input. By having a facilitatory
component it becomes possible, with the nervous system intact,
to generate a pain signal in the absence of a noxious stimulus
in the periphery. Thus activity in on-cells could drive dorsal
horn nociceptive transmission neurons. It is not clear whether
an-cell driving of dorsal horn neurons could produce a
specific, well-localized somatic pain. However, because pain
intensity is encoded by discharge frequency, it is easy to see
how on-cell activity, through a generalized excitatory effect
on nociceptive transmission neurons, could increase the
perceived pain intensity produced by any stimulus.
These studies also suggest a potential link between chronic
pain and opiate dependence. If there were individuals with
relatively greater on-cell firing in any given situation, they
might experience a given noxious input as more intense.
Similarly, intense but not frankly noxious stimuli might be
experienced as painful. Such individuals might also have a
relatively greater on-cell discharge with falling plasma opiate
levels and thus experience abstinence as more unpleasant.
Along these lines, it is interesting that low back pain has
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recently been shown to be a reliable measure of naloxone
induced opiate abstinence in ex-addicts (Heishman et al.,
1989). Thus, the distinction between patients requesting drugs
for pain and those who need drugs to avoid abstinence may be
somewhat artificial. It also raises the possibility that some
groups of patients with chronic pain may be at relatively
higher risk for opiate dependence. At the very least, opiates,
by inducing dependence, could play a role in perpetuating pain.
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Clinical Effectiveness of Analgesics
in Chronic Pain States
Harlan F. Hill and C. Richard Chapman
INTRODUCTION
In recent years the problem of chronic pain has been recognized and
its impact on society and the health care system has captured the
attention of both health care providers and administrators, We now
know that conventional medical methods for managing acute pain are
inappropriate therapies for many chronic pain patients. Surgical
and pharmacologic solutions to pain problems have largely given way
to behavioral and rehabilitation approaches. This paper briefly
reviews the present and potential contributions of pharmacology to
the comprehensive, multidisciplinary treatment of chronic pain. We
argue that pharmacologic therapy is an underused resource. Careful
consideration of the varieties of chronic pain and review of a
largely overlooked literature on opioid management of certain
chronic pains suggests that selective application of analgesic drugs
can be of substantial value in the management of certain chronic
pain states.
Although we recognize the profound influence of behavioral factors
in the chronic pain problems seen in major referral clinics, we
argue here that many of the chronic pains seen in conventional
medical practice do, in fact, exist because of persisting
nociception; still others originate in abnormal neurologic function.
It is the responsibility of the physician to pursue the possibility
of nociception or neuropathology assiduously and not simply to "rule
it out." When the cause of pain can be defined, pharmacologic
therapies are major elements in the physician's therapeutic
armamentarium.
Types of Chronic pain. states can be divided
conveniently and usefully into three broad categories. First,
certain chronic pains are based on ongoing nociception. In these
pains, the nervous system is intact and tissue damage is the
persistent stimulus. Examples of chronic nociceptive pain are
arthritis, cancer pain, arachnoiditis and myofascial pain. Then,
there are pains that arise from damage to the central or peripheral
nervous system; chronic neuropathic pain such as reflex sympathetic
dystrophy, postherpetic and trigeminal neuralgias, diabetic
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neuropathy, post-stroke pain, phantom limb pain, and many others.
Finally, many cases of chronic pain exist for which an underlying
cause or pathophysiology cannot be found; or, the pain behavior
greatly exceeds that expected for the evident pathophysiology.
These so-called idiopathic pains defy medical treatment and
sometimes arise from it.
Most chronic pain patients present with one of the three categories
mentioned above. It is important to distinguish patients with
neuropathic pain from other pain patients because the drugs that
relieve neuropathic pain are not the conventional analgesics that
modulate pain of nociceptive origin. Appropriate treatment must
address the specific type(s) of pain involved in the oatient's
complaint. Furthermore, many patients have more than one type of
chronic pain. This is especially true of cancer patients who
frequently have chronic nociceptive pain, chronic neuropathic pain
and idiopathic pain simultaneously (Foley 1985). Successful
treatment of the neuropathy only or nociceptive pain alone will
still leave behind a chronic pain patient.
NEUROPATHIC PAIN
Certain drugs that do not modulate nociception can relieve or reduce
non-nociceptive, neuropathic pain; such drugs have been referred to
as atypical analgesics. Their pain relieving actions are pain
mechanism specific. A prime example of this is seen with reflex
sympathetic dystrophy syndrome (RSDS). RSDS is an excruciatingly
painful condition resulting from injury to peripheral nerve and
involving sensitization of nociceptive nerve endings to
norepinephrine released from sympathetic postganglionic terminals.
Knowing the pathophysiology allows selection of adequate therapy and
pain relief even though the drugs employed (guanethidine or local
anesthetics) are not usually viewed as analgesics.
neuralgia,
In trigeminal
nociceptive axons in one or more trigeminal branches
undergo focal demyelination and discharge spontaneously (Burchiel
1980); drugs most commonly used as anticonvulsants (carbamazepine,
phenytoin, clonazepam) are very useful as "analgesics" under these
well-defined conditions. They act by limiting the generation of
impulses at ectopic sites on primary afferents (Fields 1987).
Use of tricyclic antidepressants in chronic pain states continues to
be an area of active research. The ability of drugs such as
amitriptyline and doxepin to relieve pain of postherpetic neuralgia
(Max et al., 1988) and diabetic neuropathy (Max et al., 1987) has
been further documented in several well-controlled studies.
Tricyclic antidepressants are effective in these chronic pain states
at lower doses and in shorter times than required for their
antidepressant effects. Their effectiveness in other disorders such
as post-stroke pain (Leijon and Boivie 1989) opens the possibility
that tricyclics may ameliorate a variety of deafferentation pains in
addition to their widely known benefits. The mechanisms responsible
for the analgesic effects of tricyclic antidepressants remains
unclear, although they do not seem to depend on either the relief of
depression or the actions of serotonin directly (Kishore-Kumar et
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al., 1989). Tricyclic antidepressants may relieve pain by blocking
reuptake of both norepinephrine and serotonin in the central nervous
system; blockade of serotonin reuptake alone is not sufficient.
Locally applied steroids and local anesthetics are also useful for
certain chronic pains. Epidural steroids effectively relieve the
persistent inflammation and pain of arachnoiditis. Local
anesthetics can produce highly localized sympathetic blockade which
alleviates pain in reflex sympathetic dystrophy, and they are
effective in many neuralgias (especially lidocaine) for suppressing
ectopic neuronal firing (Lindstrom and Lindblom 1987). Lidocaine
infusion can relieve pain of diabetic neuropathy for as long as 21
days after a single 30-minute infusion (Kastrup et al., 1987). The
most resistant neuropathic pains are those produced by
deafferentation. In such cases, pain arises centrally due to
altered neuronal dynamics in the spinal cord and/or brain (Lombard
and Larabi 1983; Fields 1987). The central mechanisms underlying
deafferentation pain remain mysterious and there is no generally
accepted, adequate treatment although carbamazepine, tricyclic
antidepressants and even opioids have been reported to be beneficial
(Urban et al., 1986).
NOCICEPTIVE PAIN
Conventional analgesics act by modulating generation or central
transmission of nociceptive information. Nonsteroidal
antiinflammatory drugs (NSAIDs) can modulate nociceptive impulse
generation by inhibiting production of prostaglandins and related
products in peripheral tissue. Opioids act at many levels of the
central nervous system (CNS) to decrease nociceptive
neurotransmission. Conventional analgesics are most useful in
chronic pain states maintained by nociceptive processes. Chronic
pain from rheumatoid arthritis and cancer (inflammatory components)
respond to NSAIDs. Opioids alleviate such pains as well; however in
practice they are usually reserved for the chronic pain of cancer.
Cancer pain usually has a distinct nociceptive component,
stimulation of normal nociceptors by ongoing tissue damage, which is
the sine qua non for opioid treatment. Second, cancer patients are
expected to have a shortened life expectancy, so the complicating
issue of physical dependence on opioids is of less concern. We
address this issue below.
In rheumatoid arthritis, opioids may decrease pain effectively, but
they do not affect joint destruction and inflammation and may
obscure the need for antiinflammatory drugs (Carruthers 1980). Gout
is another example of a painful condition maintained by ongoing
nociception; its treatment with colchicine and uricosuric drugs is
quite specific for the underlying pathology. Finally, the pain of
migraine and tension headache are effectively treated with
ergotamine and tricyclic antidepressants, respectively (Couch and
Hassanein 1979). So even the nociceptive chronic pains cannot be
approached singularly with respect to adequate pharmacological
treatment for pain reduction; optimal treatment depends on an
understanding of the underlying pathophysiology.
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IDIOPATHIC PAIN
We often suspect that patients who suffer persistent pain without
evident cause are expressing some underlying psychopathology or
using their sick roles for secondary gain. The usual "pain clinic"
approach to such patients is to withdraw all analgesics, protect the
patient from further invasive diagnostic and therapeutic
interventions, establish rapport and trust, and retrain the patients
to live with themselves and others in a more functional way. Most
physicians regard analgesic drugs as ineffectual for such problems
and possibly counterproductive; typically, referral clinics assume
that the patient has already tried and failed all conventional
therapies.
There is strong evidence that opioids are effective in relieving
many chronic idiopathic pain even when all other treatments have
failed. According to Taub (1982) patients with chronic intractable
pain can be effectively treated with relatively low daily doses of
opioids for prolonged periods up to 6 years with few management
problems, in most cases without need to increase dose. He reported
an incidence of inappropriate opioid usage of only 4.2% of 313
patients. Similar results with patients having a wide variety of
chronic pain states not relieved by other methods, have been
reported by Tennant and Uelman (1983) and France et al., (1984)
reported similar results with patients having a wide variety of
chronic pain states. In the most completely documented of these
studies, Portenoy and Foley (1986) found that opioids provided
partial or complete pain relief of chronic intractable pains in
about 60% of the patients studied for up to 4 years. Half of their
patients used the opioids for pain control for between 4 and 7 years
on a daily basis and the daily dose used remained stable over time
in nearly all cases.
There are other reports that chronic pain patients gain clear relief
from short term opioid administration (Price et al., 1986; Gourlay
et al., 1986a). It is thought-provoking to see that the effective
plasma opioid concentration for relief of postoperative pain is
exactly the same as for patients with chronic pain of nociceptive
origin (Gourlay et al., 1986a). So far, there is only one voice of
dissent in the research literature. In striking contrast to these
and other reports, Arner and Meyerson (1989) claim that opioids are
ineffective in similar patients with chronic idiopathic pains .
Nonetheless, the weight of the evidence favors the efficacy of
opioids in chronic pain. To understand the issue properly, we will
need to determine those types of chronic pain for which opioids are
ineffectual. They do not alleviate neuropathic pain states, for
example. However, they modulate pain at the level of the CNS and
therefore should work whenever there is a nociceptive component in
the painful condition.
Unfortunately, we note a strong, decisive rejection of opioid
therapy for chronic pain patients among many pain specialists. This
is difficult to understand in light of the evidence that exists:
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these drugs can be beneficial for the right patients under the right
circumstances. Perhaps physicians involved with chronic pain
patients have inadequate understanding of opioids and therefore fear
them inappropriately. The issues of most concern are tolerance,
physical and psychological dependence and addiction.
Tolerance. Tolerance to opioids refers to a change in patient
responsiveness to a drug such that more of the drug is required to
produce a particular magnitude of effect. One of the most widely
held misconceptions about opioids is that tolerance must develop.
Even such experts as Nyswander and Dole (1986) state that "In
summary, tolerance and physical dependence are inevitable
consequences of repeated administration of narcotic drugs." Yet,
reports of lack of tolerance development over years of daily opioid
use in chronic pain patients continue to accumulate (Kanner and
Foley 1981; Nyswander and Dole 1986). According to Twycross (1974),
opioid tolerance is minimal in most cancer patients treated with
oral doses of diamorphine for prolonged periods; dose increases,
when required, usually follow increased pain due to tumor
progression. Even when infused intrathecally for months for
treatment of pain in cancer patients, morphine did not consistently
induce tolerance (Yaksh and Onofrio 1987). Gourlay et al., (l986b)
found that many cancer pain patients treated with daily doses of
methadone or morphine in carefully tailored dosage regimens did not
require dose escalation over time. Furthermore, the minimum
effective plasma concentration of meperidine remained stable over
prolonged periods (e.g., 12 months) of drug administration in
chronic pain patients (Glynn and Mather 1982). Finally, in all of
the studies of opioid treatment of chronic non-neoplastic pain
described above pain relief was maintained with opioids without need
for dosage escalation for years in the large majority of nearly 400
patients.
Physical Dependence. The clinical importance of "inevitable"
physical dependence is often exaggerated. When tolerance does
develop, physical dependence usually accompanies it. However, there
are many reports of apparent lack of physical dependence in patients
using opioids for pain control for years (Nyswander and Dole 1986;
Twycross 1974; Glynn and Mather 1982). Physical dependence is not
inevitable and it presents an easily controlled clinical situation
when it does occur. As long as opioids are administered in
appropriate doses and times, physical dependence is essentially
transparent. Physical dependence becomes a clinical issue at the
end of a treatment period and is readily managed in the large
majority of patients by appropriate tapering of opioid intake.
Addiction. Investigators who have studied opioid treatment of
chronic idiopathic and cancer pain agree that de novo addiction is
very rare (Foley 1986). However, inappropriate use of opioids does
occur. Drug abuse including alcoholism is a significant problem
among patients with chronic pain. Maruta et al., (1979)
reported that 41% of a chronic pain clinic population misused
medication to a degree sufficient to warrant diagnosis as drug
abusers. This is not surprising since depression occurs frequently
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in this population and there is a correlation between rates of
depression and drug abuse.
The abuse of medications is a serious problem among chronic pain
patients seen at major referral clinics largely because well
intentioned physicians feel that they must do something for the
patient and can envision no other alternatives than a trial on
medication. For some patients, medication prescription validates an
otherwise questionable claim to invalid status to family or
employer. When the drugs are ineffectual, patients self administer
increasingly greater doses. This, in turn, causes side effects
including affect disturbance; these symptoms of toxicity are then
addressed with further prescriptions by physicians unaware of the
patient's circumstances. Thus, to a large extent, the problems of
drug abuse among chronic pain patients can be attributed to
misprescription of psychoactive medications on the part of
physicians. In their zeal to limit this problem, pain specialists
have tended to obscure appropriate indications for opioids.
CANCER PAIN
Many recommend that cancer pain be treated with an "analgesic
ladder" approach (WHO 1986). The notion that cancer pain is
unidimensional is implicit in this strategy; the main goal is to
decrease pain intensity and that can be achieved by using
increasingly "stronger" analgesics. This approach is effective in
about 70% of cancer pain patients. What about the remainder? Many
cancer patients suffer with neuropathic pain along with their
nociceptive pain. A recent report by Tanelian and Cousins (1989)
illustrates the situation clearly for a patient with nociceptive and
neuropathic pain associated with Pancoast tumor. In this case the
patient's pain could only be made bearable by a combination
carbamazepine and hydromorphone; either drug alone is clearly
inadequate in patients having such a combination of chronic pains.
Optimal treatment of cancer pain requires appreciation of the fact
that many patients have a complex mixture of different types of
chronic pain that may respond differentially to conventional and
atypical analgesic drugs.
CONCLUSIONS AND RECOMENDATIONS
Chronic pain is not one thing; the term encompasses three classes of
persisting pain problems. Moreover, patients sometimes suffer with
more than one cause of pain, each of which may require different
medication. Pharmacologic interventions can be of great value for
chronic pain patients when the underlying problems are accurately
diagnosed and the choice of medications is based on the type(s) of
chronic pain. Sweeping policy statements that conventional
analgesic medications are ineffectual or contraindicated when pain
is chronic represent gross oversimplification and are
counterproductive for all but perhaps the highly selected patient
populations of certain major referral clinics.
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The potential value of opioids for some chronic pain problems merits
further exploration even though it is controversial because of the
general apprehension that accompanies these drugs in our society.
We propose on the basis of compelling literature that academic pain
clinics undertake controlled trials of opioids with selected chronic
pain patients. Comparisons between opioid management and
behavioral/rehabilitative therapies in patients with chronic
idiopathic pain could be of great value.
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Arthritic Inflammation in Rats as a
Model of Chronic Pain: Role of
Opioid Systems
Albert Herz, Mark J. Millan and Christoph Stein
Chronic pain represents a state of great significance both for
the individual and for society as a whole. The pathology of
chronic pain is multifarious and the cause often unknown. The
detection of opioid receptors and endogenous ligands of these
receptors initiated a new era in pain research. Most research
has focused on the modulation of acute pain. In contrast, the
role of opioids in the response to chronic pain has been the
subject of only a limited number of studies, largely due to the
experimental and ethical problems involved in such investiga-
tions. Only recently has the role of opioids in chronic pain
attracted high interest and some aspects of this work shall be
discussed in the present paper which concentrates on two models
of chronic pain, polyarthritis and monoarthritis induced by
Freund's adjuvant in the rat.
Opioid Research over the last 15 years has revealed a highly
complex picture of endogenous opioid systems: a considerable
number of opioid peptides deriving from three opioid peptide
precursors are presently known; there is also a multiplicity of
opioid receptors, the targets of these peptides; mu, delta and
kappa receptors are the most important types. In view of the
differential affinity and selectivity of various endogenous
opioid peptides for these receptor types it has been suggested
that dynorphin and related peptides represent the endogenous
ligands of the kappa receptors; most probably the enkephalins
are related to the delta receptors; so fax, however, no endo-
genous ligand of the mu receptors has been detected - although
ß-endoqhin exhibits a certain preference for this receptor
type. The mu receptor type seems to play a particularly impor-
tant role in the modulation of pain; thus, it is not surprising
that most of the conventional opioids used in pain therapy have
a high affinity for this receptor type (Höllt 1986; Millan
1986).
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POLYARTHRITIS AS A MODEL OF CHRONIC PAIN
Inoculation of rats at the tail-base with Mycobacterium butyri-
cum leads to a generalized disease state; swelling and inflamma-
tion of the limbs and tail is a prominent feature which is
acccompanied by an increased sensitivity to noxious pressure
applied thereto; this observation, together with decreased
appetite, weight loss, disruption of circadian rhythms, hyper-
ventilation and, possibly, scratching suggests the animals may
be experiencing chronic pain (Colpaert et al., 1980; Colpaert
1987; Millan et al., 1988; Calvino et al., 1987).
CHANGES IN OPIOID PEPTIDES
The most impressive changes seen in rats suffering from chronic
arthritic pain is the rise in dynorphin levels in the lumbal
dorsal horn. This increase (of up to 250%) reaches its maximum
about 3 weeks after inoculation and parallels the time course of
inflammation and hyperalgesia. Within 10 weeks these parameters
become largely normalized. In the brain significant increases in
dynorphin content are found only in the thalamus; ß-endorphin
increases in the anterior pituitary and in plasma pointing to
accompanying stress; minor but not always significant increases
in methionine-enkephalin content are found in the spinal dorsal
horn (Millan et al., 1986, 1987).
These data pointing to a particular role of dynorphin (and other
peptides such as -neo-endorphin deriving from prodynorphin) in
the chronic pain state are supplemented by the finding that the
expression of the prodynorphin gene under these conditions is
considerably enhanced in the spinal cord (Höllt et al., 1987;
Iadarola et al., 1988) indicating an increased functional state
of the dynorphin system. This view is supported by the observa-
tion that in chronic arthritic rats, naloxone induces a stronger
increase in firing of dorsal horn neurones than in control rats.
This is roost easily explained by an increased inhibitory tone
mediated by dynorphin (Ménétry et al., 1988). In this context it
should be mentioned, however, that the in vitro and in vivo
release of met-enkepahlin from the spinal cord of chronic pain
rats was found to be decreased (Bourgoin et al., 1988; Cesselin
et al., 1988; Przewlocki et al., 1986). (Dynorphin release has
not been measured so far.) Possibly the enkephalins react diffe-
rently than dynorphin.
OPIOID RECEPTORS
Some minor changes in opioid receptors have been found in the
chronic arthritic state in rats: While the density of mu and
delta opioid receptors did not change in brain and spinal cord,
a small decrease in kappa opioid receptors was detected in the
spinal cord (Millan et al., 1986). This finding of a sliqht
down-regulation of this receptor type is in line with an in-
creased dynorphinergic tone in the spinal cord in chronic
arthritic rats (see above).
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NOCICEPTIVE THRESHOLD
Nociceptive thresholds in chronic arthritic rats are affected
differently: a pronounced hyperalgesia is observed when pressure
is applied to the tailor the paw; in contrast, the nociceptive
threshold is increased when radiant heat is used as a noxious
stimulus. The supersensitivity to pressure is further enhanced
by MR 2266, an opioid antagonist with benzomorphane structure
exhibiting some selectivity for kappa opioid receptors (but not
by application of naloxone which lacks selectivity for particu-
lar opioid receptor types). The effect of MR 2266 is stereospe-
cific and not observed in the radiant heat test. These data
suggest that an enhanced activity of dynorphin neurones in the
spinal cord may, via kappa receptors, act to moderate the hyper-
sensitivity of inflamed tissue to imposed noxious pressure: that
is, dynorphin in this sense may combat polyarthritic pain
(Millan et al., 1987). Further information, however, is required
to confirm this hypothesis and its generality is not clear.
Of particular interest are the changes in the response of
chronic arthritic rats to opioid agonists. Several papers show
an increased antinociceptive response to mu and delta opioid
receptor ligands (Millan et al., 1987; Neil et al., 1986;
Kayser, 1988). Some discrepancies exist concerning kappa opioid
receptor agonists. While Neil et al. (1986) report an increased
duration of effect of U-50,488H, Millan et al. (1987) found a
reduced effect of this kappa agonist in the paw pressure test.
The mechanism of supersensitivity to morphine- like opioids
which is not accompanied by an upregulation of mu receptors
awaits clarification.
MONOARTHRITIS - UNILATERAL INFLAMMATION
A second model of prolonged pain has gained increasing impor-
tance in recent years: monoarthritis or, rather, unilateral
inflammation induced by inoculation of Freund's adjuvant into
the plantar surface of a single hind-paw in rats. From an
ethical point of view, this model is advantageous as the
intensity and generality of pain is much reduced in comparison
to the polyarthritic model - as can also be deduced from
measurments of stress hormones. In addition it has the advan-
tage that the reaction of the inflamed paw and the non affected
paw can be compared in the same animal. As will be shown below,
this immediate comparison of both paws is an ideal model for
studying peripheral antinociceptive effects of opioids manifest
in inflamed tissue (Millan et al., 1988a; 1988b).
There are some important differences between the mono- and the
polyarthritic model - although there are also close similarities
between these. While in the case of polyarthritis there is a lag
time of several days or even a week before the swelling deve-
lops, the swelling and inflammatory process in monoarthritis
commences a few hours after inoculation and is quite strong
after one day; however, also in this model the pathological pro-
cesses persist for several weeks arid in sane cases the
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inflammation spreads to the contralateral paw; the changes in
opioid peptide levels resemble those seen in polyarthritis: an
increase in dynorphin is the predominant finding; it is
restricted to the dorsal horn of the affected side as long as
the inflammation is restricted to one paw. No changes in opioid
receptor density were found in the ipsi- as compared to the
contralateral dorsal horn. Concerning nociceptive thresholds,
similar changes were found as in the polyarthritic model: a
decrease in threshold in the paw pressure test on the inflamed
side which was further decreased by naloxone and MR 2266, indi-
cating that endogenous opioids (in particular dynorphin) tend to
counteract the inflamnation-induced hyperalgesia (Millan et al.,
1988a; 1988b).
PERIPHERAL SITES OF OPIOID ANTINOCICEPTIVE ACTION
Several papers published in the last couple of years have
claimed peripheral sites for the antinociceptive actions of
opioids, although these reports are controversial and in some
cases it is not even clear whether they are dealing with effects
mediated by opioid receptors. The model of unilateral inflamma-
tion offers the opportunity to study possible peripheral anti-
nociceptive/opioid effects (Stein et al., 1988a; 1988b; 1988c;
1989; Joris et al., 1987).
The key-finding indicating a peripheral site of opioid action in
inflamed tissue was the observation that a low dose of morphine
(2 mg/kg) greatly increased paw pressure thresholds in the in-
flamed paw, but did not change this threshold on the noninflaned
contralateral side. Similar results were obtained with the
selective kappa agonist U-50,488 (10 mg/kg) and further experi-
ments showed that intraplantar injection of naloxone - but not
its inactive (+)isomer - antagonized the effect of the systemi-
cally applied agonists (Stein et al., 1988b). In subsequent
experiments, receptor selective opiods were applied intraplant-
arly. Low doses of DAGO (a mu receptor specific agonist), DPDPE
(a delta receptor selective agonist) and U-50,488H (a kappa
receptor selective agonist) exhibited antinociceptive effects in
the paw- pressure test when injected into the inflamed paw, but
not when injected into the non-inflamed paw. These effects were
antagonized by the respective receptor-specific antagonists
CTAP, ICI 174,864 and binaltorphimine (Stein et al., 1989).
These findings suggest that opioids can produce antinociceptive
effects by a local opioid receptor-specific mechanism in
inflamed tissue. Several questions, however, remain to be clari-
fied: which are the endogenous ligands for these receptors, what
stimuli call them into play and what is the anatomical source of
these endcgenous opioids. Studies addressing these issues are
going on in our laboratory.
In summary, this chapter has reviewed some studies examining
animal models of chronic pain. So far, the most widely used
model is the polyarthritic rat. More recently, unilateral
hindlimb inflammation has begun to replace the former, mainly
for ethical and practical reasons. Significant findings
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concerning alterations in endogenous opioid systems - in both
models - are: Increased levels of dynorphin in the spinal cord
and evidence for its role to counteract inflamnation-induced
hyperalgesia. Exogenous opioids exhibit enhanced antinociceptive
activity in the inflamed tissue which is apparently due to a
recruitment of local opioid receptors therein. Future studies
will focus upon the mechanisms of activation of these peripheral
receptors and their endogenous ligands in prolonged inflammatory
pain.
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Use of the Formalin Test in
Evaluating Analgesics
A. Cowan, F. Porreca and H. Wheeler
INTRODUCTION
The choice of dilute formalin as a noxious stimulus in analgesic
research is a relatively new development, the rat paw formalin
test having evolved in only the past decade (Oubuisson and Dennis
1977; Abbott 1988; Bustamante et al., 1989). Formalin provides a
continuous (tonic) background of pain that may be neurochemically
and neurophysiologically different from the transient (phasic)
pain associated with conventional hot plate and tail flick tests
(Dennis et al., 1980; Abbott et al., 1982; Dennis and Melzack 1983).
The corresponding test with mice has been developed by Hunskaar
and his colleagues (Hunskaar et al., 1985; Hunskaar and Hole 1987)
and others (e.g. Murray et al., 1988) while Alreja et al. (1984)
have described a version of the test with rhesus monkeys. By
studying tonic pain, the hope is that results from the animal lab-
oratory will have a more direct bearing on drug therapy used in
the persistent types of pain encountered clinically.
In our experience, the rat paw formalin test is proving to be an
acceptable model (both ethically and pharmacologically) of steady
prolonged pain. There is still a need to compare (in a comprehen-
sive manner) key experimental opioids and clinically used analges-
ics against formalin. In the present work, morphine has been run
in the model and compared with (a) PO 117302, a selective kappa
agonist (Leighton et al., 1987; Clark et al., 1988) and (b) four
narcotic antagonist analgesics that are used clinically - bupren-
orphine, butorphanol, nalbuphine and pentazocine.
MATERIALS AND METHODS
Animals. Male Sprague Dawley albino rats (70-90 g; Zivic-Miller)
were used. They were acclimated to individual Plexiglas obser-
vation chambers (L, 21 cm; W, 25 cm; H, 30 cm) for at least 1 hr
before testing.
Behavioral testing. After the acclimation period, each rat was
injected S.C. into the dorsal surface of the right hind paw with
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50 µl of 5% formalin or 50 µl of saline. Preliminary experiments
have revealed two spontaneous behaviors indicative of pain: (a)
flinching/shaking of the paw and/or hindquarters, sometimes obser-
ved as a rippling motion across the back, and (b) licking/biting
of the injected paw. These behaviors were monitored between O-10
min (early/acute phase) and 20-35 min (late/tonic phase) following
the injection of formalin or saline.
Assessment of antinociceptive activity. The potencies of morphine
sulfate (Mallinckrodt) and PD 117302.HCl, that is, (±,I-trans-N-
methyl-N[2-(l-pyrrolidinyl)-cyclohexyl]benzo[b]-thiophene-4-acet-
amide (Parke-Davis) were assessed in both early and late phases of
the formalin model. Buprenorphine HCl (NIDA), butorphanol tartrate
(Bristol Labs), nalbuphine HCl (Endo Labs) and pentazocine HCl
(Sigma) were only evaluated against the late phase. Doses are
expressed in terms of the free base.
Test compounds were injected S.C. Pretreatment times were chosen
so that peak antinociceptive activity coincided with the obser-
vation period. For early phase behaviors, morphine and PD 117302
were given 20 min and 30 min, respectively, before the formalin.
For late phase behaviors, PD 117302 was injected 10 min before the
formalin; the other compounds were injected immediately before the
formalin.
Separate groups of rats (n = 5-10 per dose) were used to generate
dose-response curves in each phase of the response and for each
agent. Results are expressed as mean % antagonism of formalin-
induced flinching (or licking) ± S.E. and are calculated for
individual drug-treated, formalin-injected rats as follows:
(Mean F response-mean saline response)-Individual response x 100
(Mean F response-mean saline response)
where "mean F (formalin) response” is the mean behavioral score
obtained in concurrently run vehicle-treated, formalin-injected
rats, and "mean saline response” is the pooled behavioral score
for rats injected with 50 µl saline into the hind paw.
Antinociceptive potency is expressed as the A50 and 95% confidence
limits and was obtained by linear regression from the % antagonism
of formalin-induced responses.
RESULTS AND DISCUSSION
The recording of flinching and licking, at 5 min intervals for 90
min post-formalin, clearly demonstrated a biphasic response for
both behaviors (figure 1). An immediate (acute/phasic) effect
(O-7 min) was followed by a prolonged (tonic) response which, for
flinching, was maximal between 20 and 50 min and persisted for up
to 80 min. Late phase licking was of shorter duration (18-38 min).
We have found licking to be much more variable than flinching.
In our opinion, flinching is the more reliable measure in the rat
for evaluating different types of analgesic.
117
Time (min)
FIGURE I. Time course of flinching and paw licking in rats
(n = 17) after s. c. injection of formalin into the right
hind paw at T= 0. Each point is the mean behavioral sCOre
per 5 min ± S.E. Closed symbols represent values which are
significantly different from controls (injected with saline
into the hind paw); P<O.05 (Student's t test).
Despite the preceding cautionary remark, morphine was exception-
ally consistent as an antinociceptive agent in the rat paw formalin
model. Thus, A50 values for morphine against early (1.1 mg/kg,
0.9-1.4) and late (0.6 mg/kg, 0.5-0.7) flinching and early (1.8
mg/kg, 1.1-3.7) and late (0.7 mg/kg, 0.5-0.8) licking were compar-
able.
The situation was very different with PD 117302. This kappa agon-
ist was 27 times more potent against late flinching (0.2 mg/kg,
0.09-0.3) than against early flinching (5.2 mg/kg, 3.5-8.9) (fig-
ure 2). In contrast, PD 117302 was 5.3 times more potent against
early phase licking (0.06 mg/kg, 0.02-0.11) than against late
phase licking (0.4 mg/kg, 0.3-0.6). However, as with morphine,
there was a relatively poor correlation between the dose of PD
117302 and antagonism of formalin-induced licking during the
early phase. We therefore believe that, based on the flinching
results, the tonic pain state has a greater influence on kappa,
as opposed to mu, systems.
Reproducible dose-response lines were obtained with the narcotic
antagonist analgesics assayed in the formalin model. The rank
order of potency for attenuating flinching after S.C. administrat-
ion was buprenorphine>nalbuphine>butorphanol>morphine>pentazocine
(table 1). Four out of the five agents were (like PD 117302)
fully efficacious against flinching, the exception being nalbuph-
ine (figure 3). Efficacy was also lower for this compound after
i.c.v. and intrathecal administration (unpublished results).
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Dose of PD 117302 (mg base/kg, s. c.)
FIGURE 2. Dose-response lines for PD 117302 for antagonism
of early phase (0-10 min) and late phase (20-35 min) flinch-
ing induced by Formalin in rats. Each point is the mean %
antagonism of formalin control ± S.E. Significant difference
from formalin + water was determined with ANOVA followed by
Dunnett's test (*P<0.05; **P<O.01).
TABLE 1. Effect of Test Agents on Late Phase flinching in
the Rat Paw Formalin Test.
A50 (mg/kg, s.c.)
Buprenorphine 0.03 (0.02-0.04)
Nalbuphine 0.08 (0.04-0.35)
Butorphanol 0.1 (0.02-0.4)
Morphine 0.6 (0.5-0.7)
Pentazocine 0.9 (0.7-1.2)
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Buprenorphine
Nalbuphine
Dose (mg base/kg, s.c.)
FIGURE 3. Dose-response lines for morphine buprenorphine
and nalbuphine for antagonism of late phase flinching induced
by formalin in rats.
In conclusion, formalin evokes a robust, spontaneous response
(flinching) in rats - ideal for testing analgesics. Formalin may
be a noxious stimulus of choice in assessing the efficacy and
antinociceptive potency of kappa agonists/mixed agonist-antagonists.
The rat paw formalin test as described may be utilized in a mean-
ingful way to investigate both phasic and tonic aspects of pain.
Finally, receptor-selective agents (as exemplified by morphine
and PD 117302) show differential activities in the model depending
upon the phase of pain examined and the nature of the endpoint under
study.
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Nicotine Abstinence Effects
John R. Hughes
The valid effects of tobacco abstinence include
slowing of the EEG. increased REM density with
subsequent sleep awakening, decreased heart rate,
thyroid functioning, and performance and increased
caloric intake, sweet taste, weight, anger, anxiety,
difficulty concentrating, restlessness, and
impatience.
Tobacco withdrawal effects possess within-and
between-subject reliability, are prevalent (50 -
80%) and can be of clinical magnitude. Tobacco
withdrawal peaks in 1 - 2 weeks and declines to pre-
cessation levels by 4 weeks with no evidence of
protracted withdrawal except for hunger and craving.
Several lines of evidence indicate tobacco
withdrawal is due in large part to nicotine
deprivation.
Tobacco withdrawal is similar to classical drug
withdrawal syndromes in that animal models are
available, it is associated with tolerance, has some
evidence of symptom stages, 'and is reduced by
gradual reduction. Tobacco withdrawal is dissimilar
to classical drug withdrawal syndromes in that
antagonist precipitated, protracted and conditioned
withdrawal have not been demonstrated. The role of
tobacco withdrawal in smoking relapse is unclear.
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Disruption of Schedule-Controlled
Behavior During Abstinence from
Phencyclidine and
Tetrahydrocannabinol
Robert L. Balster
The repeated administration of many drugs of abuse results in
the production of dependence as evidenced by an abstinence
syndrome upon discontinued exposure. Animal models that have
been developed for studying drug dependence have traditionally
relied on weight loss and/or directly observable signs of drug
withdrawal. Using this approach it has been difficult to
establish animal models for dependence on drugs such as cocaine
and amphetamine, phencyclidine (PCP), tetrahydrocannabinol
(THC), caffeine and nicotine. This presentation reviews some
studies which have used the disruption of schedule-controlled
responding during drug withdrawal in rats and monkeys as a more
quantitative and subtle measure of drug abstinence effects,
with a particular focus on our research with PCP and THC. The
pioneering research with morphine by Thompson and Schuster
(1964) and Holtzman and Villarreal (1973) in rhesus monkeys
provides the background for this approach.
Based upon evidence we obtained for an observable PCP with-
drawal syndrome in rhesus monkeys self-administering very large
doses of intravenous PCP (Balster and Woolverton, 1980),
subsequent research found that disruption of food-maintained
fixed-ratio performance in monkeys and rats occurred 12-16
hours after discontinuation of intravenous infusion of doses of
PCP which had little, if any, effects on behavior during
treatment (Slifer et al., 1984; Beardsley and Balster, 1987).
These behavioral effects occurred without clear observable
signs of withdrawal, were immediately reversed by re-admini-
stration of PCP, and showed recovery after a few days. Cross-
dependence between PCP and ketamine was also demonstrated using
this model. We were also able to characterize a dependence
upon THC in rhesus monkeys using this approach; however, in
this case, the onset of behavioral disruption was delayed by a
day or more, consistent with the slower elimination of THC than
PCP (Beardsley et al., 1986). THC abstinence produced disrup-
tion of behavior could also be reversed by re-administration of
THC.
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In a recent study by Woolverton and Kleven (1988) using this
same general approach, continuous infusion of cocaine was able
to produce disruption of operant behavior during withdrawal;
however, the relative dose and duration of treatment required
was quite extensive. A recent study by Carroll et al. (1988)
illustrates behavioral studies of caffeine dependence. This
study also illustrates the disruption of behavior during
abstinence from a drug which has been self-administered, thus
combining studies of drug reinforcement and dependence.
The use of alterations of learned behavior in animals during
drug withdrawal provides a very useful tool to study depen-
dence. With the increased ability to detect subtle drug
abstinence effects, it may became necessary to re-evaluate
traditional definitions of physical dependence. It has been
proposed to use the term behavioral dependence on drugs to
describe the condition where subtle behavioral effects during
abstinence are the primary indices of withdrawal (Balster,
1985). It may be that for- some drugs and/or under some
conditions it may be useful to make distinctions between
physical and behavioral dependence.
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Anxiogenic Effects of Drug
Withdrawal
M. W. Emmett-Oglesby
Drug withdrawal syndromes consist of signs (objectively observable)
and symptoms (subjectively experienced). Traditionally, classes of drug
withdrawal giving rise to signs are said to cause physical dependence,
whereas classes of drug withdrawal giving rise to symptoms are said to
cause psychological dependence. However, both phenomena are ex-
pressions of physiological reactions to drug withdrawal, and rather than
assigning drug withdrawal to one of these two classes, it is probably
more appropriate to conceptualize all drugs of dependence as produc-
ing withdrawal syndromes that involve mixtures of both signs and symp-
toms. Subjective events cannot be studied in animals, so it is not
surprising that our knowledge of symptoms of drug withdrawal is less
complete than our knowledge of signs of drug withdrawal. Nonetheless,
withdrawal from dependence on drugs such as benzodiazepines and
cocaine produce symptoms that appear to be critical in maintaining drug
dependence, and animal models may be useful in helping to understand
these problems. One symptom of withdrawal shared across many
drugs of dependence is anxiety, and it should be possible to use animal
models of anxiety to investigate this aspect of drug withdrawal. This
paper reviews the results with one such model, discrimination of the an-
xiogenic drug, pentylenetetrazole (PTZ), by rats. In this technique, rats
are trained to discriminate PTZ using a food-reinforced choice-task.
Prior to chronic treatment with a benzodiazepine, the benzodiazepine
antagonist, flumazenil, does not substitute for PTZ. However, following
a week of diazepam administration, 60 mg/kg/day, flumazenil substi-
tutes for PTZ in a dose-related manner (e.g., Emmett-Oglesby et al.
1987, 1988). In experiments with ethanol, immediately following four
days of ethanol, rats selected the saline lever; by 12 to 18 hours after
the last dose of ethanol, they selected the PTZ lever, and by 48 to 72
hours after terminating ethanol, they again selected the saline lever.
The amount of PTZ-lever selection was proportional to the duration of
ethanol administration and was a direct function of the daily dose of eth-
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anol administered (Lal et al. 1988). In experiments with chronic cocaine
-administration, after terminating a two week course of 60 mg/kg/day of
cocaine administration, rats initially selected the saline lever, but by 48
hour selected primarily the PTZ lever, and at two-weeks after stopping
cocaine, they again selected the saline lever (Wood at al. 1989).
These data are consistent with the hypothesis that a PTZ-like stimulus
arises during withdrawal from a variety of drugs. Because drugs such
as beta-carbolines, that substitute for PTZ are anxiogenic in humans,
these data further suggest that the PTZ discrimination has utility for in-
vestigating an aspect of drug withdrawal that may be related to the
human problem of anxiety. Such a model should be useful for exploring
treatments that alleviate this problem, as well as for understanding the
neurobiologic bases of this aspect of withdrawal.
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Caffeine Abstinence Effects in
Humans
Roland R. Griffiths
Although caffeine is the most widely used behaviorally
active drug in the world, caffeine physical dependence has
been only moderately well characterized in humans and is
not widely recognized by the lay population or by health-
care professionals. For example, the most recent version
of the influential diagnostic manual of the American
Psychiatric Association (DSM-III-R) does not acknowledge
the existence of clinically significant caffeine physical
dependence. In fact, physical dependence is among the
most clearly demonstrated adverse effects of habitual
caffeine use. Such dependence is manifested by
biochemical, physiological, behavioral, and subjective
disturbances which occur upon termination of chronic drug
administration. Thirty-three published reports--including
clinical observations, case studies, survey studies and
experimental manipulations, which provide information
about the signs, symptoms and time course of the caffeine
withdrawal syndrome--have been reviewed recently
(Griffiths and Woodson, 1988). Headache and fatigue are
the most prominent caffeine withdrawal symptoms, with
a wide variety of other signs and symptoms having been
reported at lower frequency (e.g., anxiety, rhinorrhea,
irritability, impaired psychomotor performance,
nausea/vomiting, yawning, insomnia, confusion,
diaphoresis, muscle pains/stiffness, coffee craving).
When signs and/or symptoms of caffeine withdrawal
occur, the severity can vary from mild to extreme. At its
worst, caffeine withdrawal has been repeatedly
documented to be incompatible with normal functioning
and sometimes totally incapacitating. The withdrawal
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syndrome follows an orderly time-course, with onset
occurring at 12 to 24 hours, peak occurring at 20 to 48
hours, and duration most often being described as being
about 1 week. The pharmacological specificity of caffeine
withdrawal has been established by the observations that:
1) severity is an increasing function of maintenance dose;
2) withdrawal occurs after administration of caffeine in
capsules as well as in beverages; 3) caffeine withdrawal
symptoms are suppressed by administration of caffeine in
capsules, tablets, or beverages; 4) magnitude of
suppression is an increasing function of dose; and 5)
caffeine is more effective at suppressing withdrawal than
a variety of other drugs. The proportion of heavy caffeine
users 500 mg/day) who will experience symptoms after
caffeine abstinence is unclear; however, the proportion
has been reported to be greater than 80% in a study using
a relatively unselected subject population. There has been
wide variability, perhaps reflecting stable individual
differences, in incidence, severity and duration of
withdrawal symptoms. Although the minimum conditions
necessary to induce physical dependence are also unclear,
there is evidence for withdrawal symptoms occurring
after termination of caffeine after short-term exposure
to high doses 600 mg/day for 6 to 15 days) or after
long-term exposure to relatively low doses (100 mg/day).
Several studies suggest that physical dependence may
substantially potentiate the reinforcing effects of
caffeine.
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Behavioral Assessment of Subtle
Drug Abstinence Effects: Overview
and Discussion
Joseph V. Brady
The practices associated with the assessment of drug-
related abstinence effects have traditionally relied
upon physiochemical characterization and physiological
activity in relationship to known standards of
pharmacological equivalence. Such abstinence effects,
popularly referred to as withdrawal, have long been the
defining characteristics of drug abuse disorders,
constituting evidence of so-called physical dependence.
This concept has conventionally been applied rather
narrowly to describe only conditions involving
continuously repeated drug administration leading to a
syndrome of biochemical and physiological effects with
a characteristic time course corresponding to active
drug elimination following cessation of drug intake and
reversible by drug re-administration. The increasingly
prominent role of more refined behavioral methodologies
however, has extended the range of such evaluations and
provided a more comprehensive basis for analysis of a
drug's abstinence effects. The resulting advances in
knowledge about drug actions, and particularly in
research technology, as the presentations in this
symposium clearly document, have made possible a more
operational approach to pharmacological assessment of
abused drugs and have called attention to the need for
reappraisal of traditional concepts and definitions in
the field.
The fact, for example, that a range of the most
commonly used and abused drugs including nicotine,
caffeine, and even marijuana and cocaine, under an
equally broad range of self-administration conditions
were not thought to be associated with the more obvious
biochemical and physiological abstinence effects has
long diverted attention from their dependence potential
and delayed full appreciation of their abuse liability.
It is now abundantly clear however, largely as a result
of the research in which the participants in this
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symposium have been pioneers, that behavioral
assessment methodologies can provide a framework for
the analysis of subtle drug abstinence effects without
constraining such evaluations by limiting definitions
to conditions that produce the more traditional
physical dependence withdrawal syndrome. Indeed, it is
now well documented that the development of more
sensitive behavioral assessment procedures can reveal
abstinence effects under conditions where the typical
biochemical and physiological syndromes are either not
observed or do not covary with the measured behavioral
changes.
The most obvious contribution to be recognized in this
current series of presentations is of course
methodological. John Hughes has called attention to
some important distinctions to be made both from
topographic and functional perspectives in confronting
the vast array of effects that follow drug withdrawal.
Moreover, the presentation by Roland Griffiths
impressively documents the generalizeability of these
categorical changes to a caffeine withdrawal data base
that extends the range of John Hughes' nicotine
abstinence effects.
A second major strength revealed by the methodological
advances detailed in these presentations resides not
only in their increased sensitivity to abstinence
induced behavioral changes, but as well in the greater
degree of quantitative objectivity that they provide
when compared to more traditional procedures that rely
solely on observational techniques. Bob Balster's
analysis of THC and PCP abstinence effects based upon
schedule-controlled response rate and pattern changes
for example, documents the quantitative nature of such
abstinence effects. Moreover, this approach is
advantaged by a methodology that reveals the graded
expression of such effects by providing measurement of
a continuous variable unlike the nominal variables
conventionally used in such abstinence assessments
(e.g. vocalization, piloerection, convulsions, etc.).
But these presentations represent more than a
refinement of existing behavioral methodologies and
their rigorous application to the assessment of subtle
drug abstinence effects. They call attention as well
to the novel initiatives that drug abuse research has
spawned in extending what used to be called state
dependent learning and is now familiarly known as drug
discrimination. It has become increasingly clear, for
example, that the assessment of so called subjective
effects or symptoms (as contrasted with objectively
measured signs) need not be the exclusive domain of our
human subject research colleagues. The application of
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this methodology to the laboratory animal evaluation of
pharmacological agents has added a new dimension to the
assessment of subtle drug abstinence effects.
Michael Emmett-Oglesby's work for example, has
demonstrated convincingly that animals can be trained
in much the same way that speaking humans are trained,
to emit a discriminated operant in reporting the
symptomatic effects of precipitated withdrawal.
Moreover, while this approach requires no gratuitous
assumptions about what aspect of the abstinence
syndrome is being discriminated, it does hold promise
of providing somewhat more specific information about
the nature of the interoceptive changes involved. In
this regard of course, some caution must be exercised
in adapting models suggested by such clinical
vernacular as "anxiety". While the realities to which
such referents call attention can not be denied, their
specification in "pop psychology,, terms obviously
leaves much to be desired. It is indeed a sad
commentary on our beloved "psych" desciplines that they
remain unique among the fields aspiring to scientific
status in embracing terminology taken from common usage
as though it were a technical language. Mathematicians
have their symbols and equations, chemists their
structures and formulas, and even physicists have their
quarks. Only the disciplines indentified by the
"psych" prefix persist in their recourse to street
corner terminology with all its excess meaning, as a
basis for technical reference.
Polemics aside, perhaps the most significant
implication of the subtle abstinence effects revealed
by the assessment procedures described in these
presentations relates to still unsettled issues
regarding the extent to which such residuals of drug
use contribute to the maintenance of abuse performances
and to relapse in those numerous cases where our most
effective treatment interventions prove evanescent.
The broad environmental perspective we have all come to
appreciate in confronting substance use and abuse
problems emphasizes not only the complexity of the
etiologic, maintaining, and relapse factors that
characterize such disorders but as well the web of
social myths that surround this domain. These myths
and expectations function in curious ways to exacerbate
the problem by perpetuating notions and explanations
that endow terms like "addiction" "loss of control" and
particularly "abstinence avoidance', with undeserved
explanatory powers. One important advantage of the
research approaches described is their generally
operational orientation, which, though certainly not
culture-free in any literal sense, does strive for
definitional precision in clarifying the variables that
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characterize the abstinence syndrome as well as the
range of associated biomedical and behavioral
antecedents and consequences.
Of particular significance in this regard of course is
the convincing demonstration that these subtle
abstinence effects can now be detected, recorded, and
quantitatively measured, and that their conditions of
occurrence can be specified with accuracy and
precision. Under such circumstances, it should now be
possible to provide more definitive answers to the
abiding questions of how and to what extent these
subtle behavioral changes following withdrawal from
self-administrated drugs of abuse contribute to the
persistence and reoccurrence of such disorders, as well
as their interactive effects upon treatment and
prevention. The operational form in which such
questions must of course be put would seem to focus
upon changes in the reinforcing function of a drug in
relation to the nature and degree of such abstinence
effects. The experimental designs required to answer
such question may not be as straightforward as we would
like, but they are certainly not beyond the technical
advances in the field.
There are of course several other important
implications of the subtle abstinence effects findings
reported in these presentations that require at least
brief mention. The generally accepted pharmacological
lore about relationships between tolerance and
dependence (i.e. abstinence) has not been the focus of
this symposium, of course, but the data upon which
these extensive analyses and discussions have been
based would seem to hightlight the need for a closer
look at the essential features of these presumably
interacting processes. It is certainly clear from
these presentations that the more obvious indicators of
drug tolerance effects do not seem to be a necessary
precursor condition for demonstrating the subtle
abstinence effects described. And from a more
systematic perspective, these remarkably detailed and
sensitive evaluative analyses would seem to require
that those of us who have found it so easy to
distinguish between the abuse and dependence processes
on the basis of operationally defined but somewhat
over-simplified all-or-none criteria take another look
at our self-evident solutions to the conceptual
problems that continue to plague the field.
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Assessing the Reinforcing
Properties of Drugs
Chris-Ellyn Johanson
Drug self-administration studies using humans as experimental subjects are few in
number compared to those using animal subjects. Nevertheless, human drug self-
administration research has made important and unique contributions to our
understanding of the reinforcing properties of drugs relevant to drug abuse. Further,
despite their low frequency, the goals pursued in these studies have been broad.
This paper will review these various goals by describing selected examples of
individual studies. The use of specific examples to describe research goals will also
enable those unfamiliar with this type of human research to appreciate the range of
conditions under which such studies can be conducted. For those interested in more
extensive reviews, I recommend Griffiths et al (1980) and Henningfield et al
(1986).
ESTABLISHING DRUGS AS REINFORCERS
For each new type of drug studied in humans, it is initially essential to determine
whether the drug functions as a positive reinforcer before additional research
questions can be pursued. In addition to determining whether responding is
maintained by contingent drug delivery, such studies often evaluate the effects of a
variety of environmental variables. The rationale of this approach is that if the drug
is serving as a reinforcer, the responding it maintains should change when
manipulations are made that have been shown to alter responding maintained by
other events. In addition, if the reinforcing properties are related to the
pharmacological actions of the drug, appropriate pharmacological manipulations
should also be expected to modify responding. An additional test of whether a drug
is functioning as a reinforcer is to compare results in human studies with those
obtained with animals. In animal studies, it is more feasible to fully characterize the
reinforcing properties of drugs. Thus, if under the more limited conditions used
with human subjects results are comparable, the likelihood that these results are valid
is increased. But likewise, by demonstrating comparability with the results obtained
with humans, the validity of animal models is better established
Methods
In general, the types of procedures that have been used in animal studies have been
modified for human self-administration studies. Modifications have been necessary
to decrease any risk of toxicity and have included carefully selecting participants,
using relatively low doses, limiting drug exposure within experimental sessions, and
minimizing the length of the experiment.
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Two types of dependent measures have been used to measure the reinforcing
properties in most human drug self-administration studies. Henningfield and
Goldberg (1983) used a free-operant procedure to evaluate i.v. nicotine in human
cigarette smokers. Nicotine (1.5 mg) was available to subjects by responding on a
lever under a fixed-ratio 10 schedule of drug delivery. The rate of injections self-
administered during each 3-hr session was used as the measure of reinforcing
properties. Subjects who had no history of drug abuse (except for nicotine
cigarettes) initially self-administered few injections. Over time, however, rate of
injections increased. As further evidence that nicotine was functioning as a
reinforcer, these investigators showed that responding declined dramatically when
saline was substituted for nicotine.
Choice measures have also been used in human drug self-administration studies.
Johanson and Uhlenhuth (1980a) evaluated the reinforcing properties of 5 mg d-
amphetamine administered orally in normal human volunteers without a history of
drug abuse. In their procedure, there were 9 experimental sessions and subjects
were not required to remain in the laboratory after ingesting the drug capsule.
During the initial four sessions, subjects received drug and placebo twice on separate
sessions. During the last 5 sessions, subjects were given a choice of which capsule
they preferred and the measure of reinforcing properties was the number of times
drug was selected. They found that amphetamine was chosen over placebo on 4 out
of 5 sessions and considered this evidence that amphetamine was functioning as a
reinforcer.
Effects of Behavioral Manipulations
In behavioral studies using other types of reinforcers, increasing the behavioral
requirements can result in a decrease in the number of reinforcers obtained. Similar
findings have also been obtained with drug reinforcers. Bigelow et al (1976)
evaluated the reinforcing properties of sedatives in male subjects with a history of
sedative abuse who resided on a research ward. A maximum of 20 doses was
available during daily 7-hr sessions; the drug available on different days was either
30 mg pentobarbital or 10 mg diazepam. Subjects were required to ride an exercycle
for 2 minutes to obtain a single token which could be exchanged for drug or money.
When the cost per ingestion was 1 token, subjects took almost all available (20)
doses of both drugs. However, as the requirement increased to 3, 5 or 10, the
number of doses self-administered decreased. For instance, when the cost/dose was
3 tokens, approximately 5 doses of pentobarbital were self-administered whereas all
20 doses of diazepam were self-administered. When the cost increased to 10 tokens,
self-administration of pentobarbital was totally suppressed whereas about half of the
diazepam doses were still self-administered. The relative sensitivity of responding
maintained by pentobarbital to response requirements has also been shown in animal
studies (Goldberg et al. 1971).
In a similar study using the same experimental paradigm and doses of pentobarbital
and diazepam, Griffiths et al 1976) showed that drug self-administration was also
affected by the minimum interingestion interval between doses. When the interval
was 0, the exercycle riding requirement was completed for approximately 75% of the
available doses. However, as the interval increased, responding declined and this
decline was more pronounced for pentobarbital than for diazepam
In summary, early drug self-administration studies clearly demonstrated that the
paradigms used for humans were sensitive to behavioral manipulations that have
been shown in other studies to modify maintained responding. Such sensitivity was
136
further evidence that the drugs were functioning as positive reinforcers and that
responding maintained by drugs in an experimental setting with humans as subjects
was predictable.
Effects of Pharmacological Manipulations
As a method of verifying that the response-maintaining characteristics of drugs are
related to their other pharmacological properties, drug self-administration studies
have evaluated the effects of manipulating dose, or magnitude of reinforcement.
Relative to animal studies, it is somewhat difficult to generate a complete dose-
response function with humans because of potential toxicity at the higher doses.
Nevertheless, many studies have succeeded in evaluating a wide enough dose range
to demonstrate that responding in humans can be influenced by the magnitude of
drug reinforcement. Henningfield and Griffiths (1980), for instance, showed that if
the dose of nicotine per puff was increased, rate of puffing (drug self-administration)
decreased. This result is similar to the results obtained using animal subjects with a
variety of drugs including i.v. nicotine under conditions (e.g., ratio schedules)
where rate of responding influences drug intake (Johanson and Schuster 1975).
That is, as dose is increased, rate of responding decreases. In contrast, with
reinforcers such as food, rate of responding tends to increase with magnitude. The
drug self-administration results have been interpreted as demonstrating that other
properties of the drugs influence rate of responding non-specifically (Johanson
1978). Therefore, in animal studies, non-rate procedures such as drug choice
paradigms have been used and it has been shown that relative choice increases with
dose (Johanson and Schuster 1975). Using a similar choice paradigm with humans,
Fischman and Rachlinski (1989) also showed that choice of cocaine increased as the
dose available increased.
Comparison of Animal and Human Studies
The results described above not only indicate that the procedures that have been
developed for human self-administration studies are sensitive to a variety of
independent variables, but also underscore the similarity between the results obtained
in human and animal studies. Another extremely convincing example of the
comparability between human and animal studies can be seen in Figure 1. Several
investigators have shown that local anesthetics, such as procaine, can maintain
responding in rhesus monkeys (Johanson 1980). Because procaine is not abused by
humans, the procaine results appeared to be an exception to the general finding that
animals self-administer the same drugs that humans abuse (Johanson and Balster
1978). However, Fischman has shown that procaine is also a reinforcer in humans
(Fischman 1989). In a choice paradigm, procaine was clearly selected over saline
but when given a choice between 8 mg cocaine (i.v.) and different doses of procaine
up to 96 mg, cocaine was overwhelmingly preferred. Likewise, in a study using
rhesus monkeys, Johanson and Aigner (1981) also showed that procaine was
preferred over saline but that when given a choice between cocaine and procaine,
cocaine was preferred even when there was a 16-fold difference in dose.
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268-365 0 - 90 - 6 : QL 3
COCAINE VS PROCAINE CHOICE
Figure 1: The number of choice
trials during which cocaine (at the
dose indicated above each bar) was
selected over the dose of procaine
shown below the bar. See text for
details.
PROCAINE DOSE
A second example of the similarity between the results obtained with animals and
those obtained with humans can be seen in Figure 2 which shows the pattern of
responding maintained by ethanol in both humans and rhesus monkeys.
Figure 2:
Pattern of
ethanol self-
administration
in monkeys and
humans. See
text for details.
ASSESSING DEPENDENCE POTENTIAL
One important goal of drug self-administration studies is to evaluate the dependence
potential of drugs. If human studies are to be useful in this regard, it is necessary to
demonstrate that the results generated under laboratory conditions correctly predict
which drugs would be abused. Thus, some studies have compared the reinforcing
properties of drugs that are known to be abused by humans with other CNS drugs
which are not drugs of abuse. For instance, Griffiths et al (1979) showed that
responding was maintained by pentobarbital but in the same drug-experienced
subjects, chlorpromazine was not a reinforcer. Likewise, Johanson and her
colleagues using a choice paradigm showed that under the same conditions where
responding was reliably maintained by &amphetamine. other psychomotor
stimulants that are also abused, such as phenmetrazine, were also selected over
placebo, whereas drugs such as fenfluramine and mazindol which are not abused by
humans were not self-administered (Chait, et al. 1987. Johanson and Uhlenhuth
1980a, Johanson and Uhlenhuth 1982). Given these differential findings, it appears
that results from human studies designed to assess dependence potential of new
drugs are likely to yield valid predictions.
Drug self-administration studies can be difficult and time-consuming to conduct in
humans. Traditionally, measures of subjective effects have been used to assess
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dependence potential. One goal of human drug self-administration studies has been
to evaluate the relationship between subjective effects and drug self-administration.
For instance, de Wit et al (1986) compared the subjective effects of amphetamine in
those subjects who preferred this drug over placebo in a choice paradigm with the
subjective effects produced in subjects who did not prefer amphetamine, and found
predictable differences between the subjective response of these two groups. Chait
et al (1987) using a similar choice paradigm with normal volunteers evaluated the
reinforcing effects of several pharmacologically related psychomotor stimulants and
found that the profile of subjective effects was similar for those drugs that were self-
administered compared to those that were not. However, Roache and Griffiths (in
press) did not find a reliable relationship between measures of self-administration
and drug liking with benzodiazepines in subjects who were previous sedative
abusers residing on a research ward. Differences between subjective effects and
level of drug self-administration have also been found in other studies (Johanson and
de Wit 1989). Thus, while subjective effects may be useful predictors of
dependence potential, the independent assessment of reinforcing properties in drug
self-administration studies may add important information for reliably predicting the
probability that humans will abuse a particular drug.
The assessment of the discriminative stimulus effects of drugs has been used in
animal studies to indicate dependence potential. In a series of studies that evaluated
both the reinforcing and discriminative stimulus effects of psychomotor stimulants in
humans without a history of drug abuse, differences were noted across the two
paradigms. For instance, although mazindol was not preferred over placebo in an
experiment using a choice paradigm, in subjects that were trained to discriminate d-
amphetamine from placebo, mazindol substituted as a discriminative stimulus (Chait,
et al 1986, 1987). Since few drug discrimination studies have been conducted in
humans, further research is necessary to determine the usefulness of drug
discrimination methods to measure dependence potential (see paper by Bigelow).
DISCOVERING VULNERABILITY OR RISK FACTORS
Another goal of human drug self-administration studies has been to determine
whether certain types of individuals are more likely to find certain drugs reinforcing.
Such differences might indicate that individuals with these characteristics are
vulnerable to drug abuse. The types of possible risk factors that have been studied
in human drug self-administration studies have included demographic characteristics,
psychological status, and drug use history.
In one series of studies, diazepam preference was assessed in several groups of
subjects differing in levels of anxiety using the out-patient choice procedure
previously described for amphetamine. The rationale of this experiment was that
subjects who experienced a positive change in mood might be more likely to self-
administer a substance that produced such a change (i.e., self-medication). Thus
anxious subjects because of their high and presumably aversive levels of anxiety and
who experience a decrease in their levels of anxiety when administered diazepam
might be more likely than others to self-administer this drug. Subjects initially
sampled the effects of 10 mg diazepam and placebo under double-blind conditions
and then were given 5 independent opportunities to choose whether to self-
administer diazepam or placebo. In normal volunteers, diazepam was not preferred
to placebo (Johanson and Uhlenhuth 1980b). In subjects with moderate to severe
levels of anxiety, diazepam preference was the same as in the control group, i.e., all
subjects preferred placebo to a greater extent than drug despite the fact that diazepam
decreased anxiety as measured by the Profile of Mood States (de Wit et al 1986).
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However, in the group of subjects with the highest levels of anxiety and who wished
to receive treatment, preference for diazepam was slightly increased However,
placebo was still preferred on more than 50% of the choice opportunities even in this
group (McCracken et al. in press). Thus it appears that a decrease in anxiety in
subjects suffering from anxiety disorders is not sufficient for establishing diazepam
as a reinforcer.
Previous drug history may also influence reinforcing properties. In an experiment
by Johanson and her colleagues, the influence of previous alcohol consumption on
diazepam preference was evaluated using a modified choice procedure (de Wit, et al.
1989). Experimental sessions were conducted within the laboratory and 4 mg doses
of diazepam were available for a maximum of seven occasions during 4-hr evening
sessions (total possible dose of 28 mg). Under these conditions, subjects with a
history of greater but non-problematic alcohol consumption (approximately 11
drinks/week) preferred diazepam on more sessions than subjects with a history of
light consumption (approximately 4 drinks/week). Furthermore, within sessions,
the subjects who were moderate alcohol drinkers self-administered a greater
proportion of the available doses.
Griffiths and his colleagues have also demonstrated that drug history can influence
reinforcing properties. In their studies, subjects were recruited who had a history of
sedative abuse and tested on a closed research ward. As previously shown with
pentobarbital, diazepam was reliably self-administered across a range of
experimental conditions (Griffiths, et al. 1979, Griffiths et al. 1980, Roache and
Griffiths in press). This is in contrast to the results obtained by Johanson and her
colleagues that indicated that diazepam was not a reinforcer in subjects who did not
have a history of sedative abuse (Johanson and Uhlenhuth 1980b).
There are clearly many factors that could account for the influence of previous drug
history on diazepam preference. Although additional research is required to
determine the mechanisms accounting for the influence of drug history, these studies
illustrate the possibility of evaluating risk factors within an experimental context in
human subjects. Furthermore, the existence of populations of subjects that are more
likely to self-administer a particular class of drug allows questions concerning
relative dependence potential within this class to be addressed (Griffiths et al. 1984).
Animal research has clearly demonstrated that the reinforcing effects of drugs are not
solely determined by their pharmacological properties but are the result of an
interaction between the effects of the drug and the environmental conditions under
which it is available. Therefore, environmental factors that increase drug self-
administration may also be viewed as risk factors. However, few human drug self-
administration studies have evaluated the ability of behavioral factors to modify the
reinforcing properties of drugs (but also see Behavioral Treatments below). Early
self-administration studies that were reviewed above (Bigelow, et al. 1976,
Griffiths. et al. 1976) demonstrated that response requirements and minimum
interingestion interval could influence the probability that sedatives would be self-
administered. A mom recent example is the study described above by de Wit et al.
(1989). As previously reviewed, under a choice paradigm where normal volunteers
were allowed to choose between diazepam and placebo, placebo was preferred
(Johanson and Uhlenhuth 1980b). However, when the experimental conditions
under which diazepam was available were altered, it was found that diazepam
preference drastically increased to over 50%. Unfortunately, the modifications that
yielded an increase in reinforcing properties were numerous (laboratory setting,
multiple doses available per session, subjects tested in a group context) so additional
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research is necessary to determine what aspect of the environment accounts for the
increase in reinforcing properties. Nevertheless, this study does indicate that the
elucidation of environmental circumstances that enhance a drug’s reinforcing
properties and which therefore might constitute a risk factor is possible using human
subjects.
EVALUATING POTENTIAL TREATMENTS
Pharmacological Treatments
Human drug self-administration paradigms are ideal for determining whether
medications are capable of decreasing drug taking behavior. An excellent example of
this approach is Mello et al. (1981). In their study, male heroin addicts resided on a
research ward for a month. After an initial drug-free period, they were allowed to
respond under a second-order schedule on a portable manipulandum to obtain either
money or a dose of heroin. For 10 days, a total of 4 doses of 10 mg heroin was
available every day with each injection separated by 6 hr. In order to obtain each
dose, it took about 90 min of responding to complete the behavioral requirement
under the second-order schedule. In three subjects that were treated with a narcotic
antagonist, 50 mg/day naltrexone, few injections of heroin were self-administered.
In contrast, subjects administered a placebo antagonist worked for a large proportion
of the available heroin. A similar study was conducted by Mello et al. (1982) to
evaluate the effectiveness of a mixed opioid agonist-antagonist, buptenorphine, to
decrease heroin self-administration and similar results were found. That is, subjects
maintained on gradually increasing doses from 0.5 to 8 mg/day buprenorphine over
a 14 day period self-administered less of the available heroin than subjects who were
medicated with a buprenorphine placebo. As the authors stated, the results from
both of these studies not only demonstrate that naltrexone and buprenorphine may be
useful medications for suppressing heroin abuse but they also indicate that human
self-administration paradigms are useful for evaluating potential treatments. Given
the difficulty of conducting long-term clinical trials of new pharmacological agents
for the treatment of drug abuse, the approach of initially conducting laboratory
studies using self-administration procedures is extremely appealing.
Laboratory studies may also be helpful in understanding the mechanisms underlying
the usefulness of particular medications. With this in mind, Fischman and Foltin
(1988) assessed the ability of desipramine which has been shown in clinical trials to
be effective in the treatment of cocaine abuse to decrease cocaine self-administration.
The ability of cocaine to maintain self-administration was evaluated both before and
during a period of chronic desipramine treatment. The number of injections self-
administered under these two conditions did not differ as might have been predicted
from the clinical data However, the number of injections that the investigators were
able to administer decreased when desipramine was being given because of
cardiovascular toxicity. Furthermore, while subjects worked to obtain and requested
nearly maximum levels of cocaine to self-administer, their verbal response to
questions concerning their desire to self-administer cocaine indicated a decrease in
craving. In addition, the subjective effects of cocaine were altered during the chronic
desipramine period showing decreases in positive mood effects and increases in
negative mood effects such as anxiety. Thus these results indicate that desipramine
does produce alternations in the profile of cocaine’s subjective effects which may be
useful in treatment settings.
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Behavioral Treatments
Behavioral approaches are also used to treat drug abuse and it is possible to evaluate
their effectiveness in experimental settings. Stitzer and her colleagues evaluated the
ability of alternative reinforcers to decrease methadone self-administration using
outpatients being treated in a methadone maintenance clinic (Stitzer, et al. 1983). On
two days of each week, subjects were offered the opportunity to choose between
extra methadone doses and money. When the choice was between a $1 and drug,
drug choice increased as dose of methadone increased. That is, when the dose was
1 mg, money was selected on about 80% of the opportunities whereas when the
dose was 50 mg, drug was chosen exclusively. However, when the amount of the
money option was increased to $5, the dose-response function for methadone was
shifted downward and even when the extra dose available was 50 mg, only about
60% of the choices were for drug. This study illustrates that behavioral factors such
as financial alternatives can alter drug self-administration. The results also show,
however, that this ability to decrease drug intake is related to its dose. Both findings
have important implications for designing behavioral treatment interventions.
In another study by Stitzer and her colleagues, these investigators evaluated the
effects of two kinds of behavioral interventions on the self-administration of illicit
drugs within a treatment context (Iguchi et al. 1988). Methadone maintenance
patients who had tested positive for illicit drug use 70% of the time over the last 12
weeks were selected. Half of these subjects were given methadone take-home
privileges contingent upon the submission of negative urines. The other half were
also given contingent positive reinforcement (take-home medication) but were also
punished if their urines were positive by a reduction in methadone dose. Both
groups showed similar levels of success as defined by negative urines and remaining
in the treatment program. However, the group that received punishment had higher
drop-out rates from the program. The authors concluded that aversive consequences
can influence treatment outcome by increasing the probability that patients who do
not respond to treatment will remove themselves from the situation, thus limiting the
ability of therapists to intervene any further.
DESCRIBING CONSEQUENCES OF DRUG SELF-ADMINISTRATION
Toxic effects which are seen in drug abusers are often difficult to attribute to the drug
itself as many other factors contribute to manifest toxicity in the environment outside
the laboratory. Thus, measuring the effects of drugs that are self-administered in a
laboratory setting offers an opportunity to evaluate the contribution of the drug itself
to changes in health and behavior of drug abusers. Unfortunately, few experimental
studies have been conducted even in animal subjects and even fewer with humans.
For humans, this is largely due to the unwillingness to expose subjects to the doses
that are likely to produce toxic consequences. Thus, while the effects of drugs on
physiological functioning are routinely measured in human drug self-administration
studies, the doses are kept necessarily low. Nevertheless, while these studies may
not reveal actual toxicity, they may show that drugs alter the functioning of certain
physiological systems; it can then be assumed that toxicity is likely at higher doses
(Fischman and Foltin 1989).
In addition to physiological alterations, some studies have also evaluated the effects
of drugs at self-administered doses on mood. Griffiths et al. (1980), for instance,
showed that hostile behavior and feelings of dysphoria were more likely on days
when subjects self-administered diazepam than when pentobarbital was taken. These
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findings clearly have implications for the use of these drugs in a treatment context.
However, they are also relevant in situations where these drugs are being abused
because they indicate that benzodiazepines may disrupt social interactions.
Another example of how drug self-administration studies can be useful for
evaluating the consequences of drug use is from a study by Mendelson et al (1976).
Heavy and casual marijuana smokers resided on a research ward for one month and
for 2 1 days during this period were allowed to respond on a portable manipulandum
under a fixed interval schedule to earn marijuana cigarettes or money.
Approximately 30 minutes of work was required to earn 1 cigarette or $0.50.
Relative to days when drug was not available, marijuana even at relatively high
levels did not disrupt performance. Further, patterns of responding within days
indicated that rate of responding correlated with rate of smoking. These data
suggested, therefore, that marijuana did not produce an “amotivational syndrome.”
However, in a further analysis of the data, Mendelson et al (1976), showed that
there was an inverse relationship between amount of marijuana consumed and the
rate of responding on the following day. While there are clearly many possible
interpretations of these data, this study does indicate that self-administration studies
may be useful for evaluating changes in performance that occur at doses that are self-
administered
CONCLUSION
This report has reviewed the types of research questions that can be answered in
human self-administration studies. The goals illustrated are not exhaustive but
include a wide enough sample to demonstrate the utility of these procedures.
Furthermore, by using specific examples, it is hopefully possible for those
unfamiliar with the research area to appreciate the range of conditions under which
evaluations of the reinforcing properties of drugs can be made with human subjects.
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Behavioral and EEG Studies of
Acute Cocaine Administration:
Comparisons with Morphine,
Amphetamine, Pentobarbital,
Nicotine, Ethanol and Marijuana
Scott E. Lukas, Jack H. Mendelson, Leslie Amass and
Richard Benedikt
Over the past five years we have been engaged in studies designed to determine
the electrophysiological correlates of drug-induced behavioral states. Since the
basic mechanism of drug-seeking behavior is not completely understood, the
identification of such correlations between mood states and electrophysiological
activity can be very important in relating these changes to the reinforcing
properties of various drugs of abuse.
Measures of brain electrical activity have been useful in characterizing various
naturally-occurring behavioral states such as sleep and wakefulness, but
electrophysiological correlates of drug-induced states such as euphoria have been
difficult to obtain. A major problem with detecting such a relationship between
brain electrical activity and drug-induced mood changes is the difficulty
associated with accurately measuring changes in subjective mood states without
introducing EEG artifacts. Questionnaires and visual analog scales alter a
subject’s levels of alertness which, in turn, affects the EEG (Otto, 1967;
Matousek and Petersen, 1983). Therefore, we have developed a nonverbal
instrumental device for recording continuous changes in drug-induced mood
states which requires a minimum of effort and, as such, does not alter the
subjects’ level of alertness (Lukas et al., 1986a,c.)
M E T H O D S
Adult male and female volunteers provided informed consent to be prepared with
scalp EEG electrodes and intravenous catheters for blood withdrawal. Subjects
who received drugs intravenously did not have blood withdrawn. Subjects
served as their own controls and received placebo as well as all doses of a drug.
The following drugs and doses were tested: morphine (5, 10 or 20 mg, i.v. ),
amphetamine (5, 10 or 20 mg. i.v.), pentobarbital (50, 100 or 200 mg. i.v.),
nicotine (0.75, 1.5 or 3.0 mg, i.v.), cocaine (32, 64 or 96 mg, i.n.), ethanol
(0.35 or 0.7 g/kg, p.o.) or marihuana (1.26 or 2.53% -THC, i.h.)
Continuous measures of drug-induced behavioral states were obtained by having
the subjects operate an instrumental joystick device (Lukas et al., 1986c.) In
addition to providing data indicating the onset, duration and offset of drug
effects, the subjects could push two different buttons to indicate euphoric or
pleasurable and dysphoric or unpleasant experiences. All joystick responses
were recorded on the polygraph paper directly below the EEG recordings.
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Morphine, amphetamine, pentobarbital and nicotine were administered as slow
injections over 120 seconds. Marihuana cigarettes were smoked using a
modified water pipe device and using a specific series of inhale/hold/exhale
instructions. Ethanol solutions were pumped through a tube that rested in the
subjects’ mouth at a rate of 23 ml per minute. Cocaine was administered
intranasally as an aerosol. Two computer-controlled, one-second bursts (one in
each nostril) were provided with a five second inter-burst interval. A customized
air brush device was used to deliver the cocaine(Figure 1.) These techniques
were used so that subjects could remain seated with their eyes closed and their
left hand on the joystick device during drug administration. Thus, subject
movements were kept to a minimum in order to eliminate EEG artifacts.
EEG activity was recorded on a polygraph and on FM magnetic tape for
subsequent off-line computerized power spectral analysis. Data were recorded
continuously from thirty minutes before to two hours after drug administration.
A digital time code (which was copied onto the polygraph tracing) was also
recorded on tape to aid in the identification of specific EEG epochs that were
associated with abrupt behavioral changes as indicated by joystick responding
(Lukas et al., 1986b.)
Discrete samples of EEG activity that occurred while subjects reported feeling
good or euphoric were digitized and subjected to Fast Fourier Transformations in
order to generate the corresponding power spectra. In addition, the data from
some subjects who received ethanol or cocaine were further analyzed using EEG
topographic mapping techniques. These mapping techniques assembled
information from multiple EEG leads by simultaneously creating power spectral
arrays from all electrode sites. The values between electrode sites were computed
with a three-point linear interpolation algorithm using the activity from the nearest
three electrodes. The data were then combined into a composite color-coded
(Duffy et al., 1979; Lukas et al., 1989) map which provided an overall view of
brain electrical activity.
R E S U L T S
Subjects reported drug-induced behavioral changes by operating an instrumental
joystick device. Multiple paroxysmal bursts of euphoria occurred within a few
minutes of drug administration and each one typically lasted 1-10 minutes while
subjects continued to detect the drugs’ unique pharmacological effects (Figure 2.)
The total duration of euphoria was dose-related. Dysphoric responses after
nicotine and ethanol were frequently reported immediately after the highest doses,
but were usually replaced by euphoria within a few minutes. When questioned
after the studies were over, subjects were very accurate in correctly identifying
the intermediate and higher drug doses.
A microanalysis of the EEG after low and intermediate doses of all drugs tested
revealed that EEG alpha activity was significantly increased during these episodes
of drug-induced euphoria. Further analysis of some records using topographic
mapping techniques revealed that the increase in EEG alpha activity after ethanol
and cocaine was most prominent over the occipital area. In addition, ethanol-
induced euphoria was associated with a significant increase in EEG alpha over
more frontal and parietal areas while cocaine-induced increases remained over
occipital and parietal areas.
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Air Brush
Figure 1
Intranasal drug delivery device for providing a computer-controlled metered
dose of cocaine as a fine spray. The air brush is supported by a flexible metal
arm which permits the subjects to receive the cocaine without moving. The air
compressor and valve system are located outside the experimental chamber so
that the subject is not disturbed during their operation.
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Time After Drug Administration (min.)
Figure 2
Behavioral profiles after acute drug administration. Changes in behavior were
continuously recorded via an instrumental joystick device. Data are from
individual, representative subjects. Shaded blocks below each profile indicate the
actual drug delivery times.
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D I S C U S S I O N
One of the more interesting findings in the present report is that a number of
drugs from various distinct pharmacological classes produced a similar EEG and
behavioral response. It should be noted that the highest drug doses typically
produced immediate and profound stimulation or depression, which may have
concealed the EEG alpha response observed after the lower doses. This was
most evident after the higher doses of cocaine in which behavioral stimulation
was associated with EEG dyschronization (beta activity) and pentobarbital which
resulted in behavioral depression and EEG slow wave activity. However, the
low and intermediate doses all resulted in paroxysmal bursts of euphoria, which
were associated with increases in EEG alpha activity. EEG alpha activity was not
increased during controlled joystick responding, so it is unlikely that this
neurophysiologic response is movement-related.
The relatively brief nature of these drug-induced euphoric episodes is difficult to
explain. While plasma drug levels were not obtained for all drugs, it does appear
that both a threshold level and a relatively rapid rate of increase in plasma drug
levels is necessary for euphoria to occur. However, these data only reflect the
concentration of drug in blood and not in the central nervous system.
The neurobiological significance of increased EEG alpha activity during drug-
induced euphoria is not completely understood. Increases in EEG alpha activity
are frequently associated with pleasurable, free-floating and extremely relaxed
states (Lindsley, 1952; Brown, 1970; Wallace, 1970; Matejcek, 1982) that are
not unlike those associated with transcendental meditation (Wallace, 1970.) The
covariance between increased EEG alpha activity over the entire scalp and
subjective reports of euphoria suggests that this neurophysiologic response may
be associated with drug-induced reinforcement. These data further suggest that
drugs of abuse may share a common mediator that is associated with
reinforcement. This interpretation supports the contention of Mello (1983) that
drug abuse is a form of stimulus administration and that the direction of change
is relatively unimportant while the speed and magnitude of change dictate the
response.
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Plasma Delta-9-THC Levels as a
Predictive Measure of Marijuana
Use by Women
Jack H. Mendelson, Nancy K. Mello, Siew Koon Teoh,
Barbara W. Lex, Scott E. Lukas and James Ellingboe
A number of studies carried out at our Center examined marijuana-induced
alterations in hormonal homeostasis in women (Mendelson et al., 1984,
Mendelson et al., 1985 a,b). However, plasma delta-9-THC levels were not
measured in these studies, and we have been unable to locate any reports which
describe relationships between plasma delta-9-THC levels and marijuana
smoking by women. The purpose of this study was to determine plasma delta-
9-THC levels in women prior to, during and following a period of marijuana
self-administration on a clinical research ward.
METHODS
Subjects
Sixteen adult female volunteers (average age 26, range 21 to 34 years) with a
history of regular marijuana use, gave informed consent for participation in
studies to evaluate the effects of marijuana smoking on reproductive function in
an inpatient clinical research study. Volunteer subjects with a mean of 13.5
years of education were recruited through advertisements in local newspapers.
Subjects were fully informed about the nature and duration of each phase of the
study and were told that they could withdraw at any time. Each woman was in
good health as determined by clinical and laboratory examinations. Urine
screens for drug use other than marijuana and pregnancy tests were performed
before admission to the research ward and all were negative.
Sequence of Drug Conditions
After admission to the research ward, subjects were drug-free for 7 days.
Marijuana cigarettes were available for 21 days. After the period of marijuana
availability, subjects remained on the ward for an additional 7 days, under drug-
free conditions, to evaluate the time course and severity of any marijuana-related
abstinence syndromes (cf. Mendelson et al., 1984).
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Marijuana Cigarettes
All marijuana cigarettes were obtained from NIDA in lot standard dosage form.
Maximal standardization and the equivalent dosage and “draw” characteristics of
these cigarettes were ensured by machine rolling. Each cigarette weighed
approximately 1 g and contained 1.83% of 9-tetrahydrocannabinol as assayed
by NIDA. Details of the Soxhlet and modified Lerner extraction procedures and
the gas chromatogmphic assay procedure are available from NIDA.
Marijuana and Money Acquisition Procedures
Operant techniques were used to provide an objective and quantitative measure
of performance for 2 alternative reinforcers, marijuana and money. Subjects
could work for money at a simple operant task throughout the study. The
opportunity to work for money was intended to encourage subjects to remain in
the study during the 14 days when marijuana was not available. Points earned at
the operant task could be accumulated for money, payable at the end of the
study, or could be exchanged for marijuana cigarettes during the period of
marijuana availability. Patterns of operant acquisition of marijuana by women
have been reported previously (Mello and Mendelson 1985).
Blood Sampling Procedures
Blood samples for THC analyses were obtained on admission to the ward; again
after 7 drug-free days; on alternate days during the 21 day period of marijuana
cigarette availability; and 1 and 7 days following cessation of marijuana use.
Blood samples were taken between 8 and 9 a.m. Most recent marijuana
smoking for each subject prior to blood sampling occurred between 11 p.m. and
1 a.m.
RADIOIMMUNOASSAY OF DELTA-9-TETRAHYDROCANNABINOL
(DELTA-9-THC) IN PLASMA
Delta-9-THC was analyzed by radioimmunoassay using kits obtained from the
Research Triangle Institute, where they were prepared with support from
Contract No. 271-81-3828 from the National Institute on Drug Abuse. The kits
provided I-125-labeled delta-8-THC, rabbit anti-delta-9-THC serum, an
immunobead second antibody reagent, blank human plasma, delta-9-THC
standards in human plasma, blank human plasma and delta-9-THC controls.
Plasma samples were analyzed in duplicate, following the protocol supplied with
the kits. In our laboratory the sensitivity was 1.0 ng/ml. Intraassay CVs,
calculated from duplicates of all samples, including those with very low delta-9-
THC concentrations, averaged 21.4%. Interassay CVs, determined using
controls supplied by the Research Triangle Institute, were 12.6% for the high
control (31.2 ng/ml mean value) and 12.4% for the low control (8.0 ng/ml mean
value). According to information from the Research Triangle Institute, cross
reactivities for other cannabinoids in this assay were as follows: delta-9-THC
100%. 11-nor-9-carboxy-delta-9-TCH 0.6%, 11-hydroxy-delta-9-THC 21%.
delta-8-THC > 70%. cannabinol 30%. cannabidiol 0.23%. 8-alpha-hydroxy-
delta-9-THC 10% and 8 beta-hydroxy-delta-9-THC 7%. In order to ascertain
the accuracy of our radioimmunoassay procedures we forwarded selected
plasma samples to Dr. Roger Foltz (Utah Toxicology Laboratory) for
confirmatory gas chromatographic analysis. Plasma delta-9-THC values
obtained with the RIA procedure were higher than those determined by gas
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chromatography (Wilcoxon Matched Pairs Test t [n=21] = 47.0, z = 3.482, p =
0.0164). but the linear correlation between the 2 methods was highly significant
(r2 - 0.992).
RESULTS
The 16 women who participated in this study were classified into 3 groups
based upon the actual number of marijuana cigarettes smoked on the research
ward. Table 1 presents smoking behavior, plasma delta-9-THC levels and
demographic data for the 3 groups of subjects. Four subjects in group 1
smoked an average of 4.7 marijuana cigarettes per day on the research ward.
Subjects in group 2 smoked an average of 2.7 marijuana cigarettes per day on
the research ward, and subjects in group 3 smoked an average of 0.4 marijuana
cigarettes per day during the study. There were no significant differences
between the ages of the subjects or their level of education. Subjects in group 1
reported an average past history of marijuana use of 15.5 years which was
approximately twice as long as the duration of marijuana use reported by
subjects in groups 2 and 3 (7.7 and 7.6 years, respectively). Subjects in group
1 reported an average use of marijuana 35 times per month and subjects in
groups 2 and 3 reported average use of 13 and 7.6 cigarettes per month,
respectively. No detectable levels of plasma delta-9-THC were found for the 5
subjects in group 3. In contrast, peak delta-9-THC levels for the group 1
subjects were 75.8 ng/ml and 32.9 ng/ml for subjects in group 2.
TABLE 1
Group Use Per
Study Day
1
(N=4)
4.7
2
(N=7)
2.7
3
(N=5)
0.4
Peak Years Times Used
9 THC (ng/ml) of Use Per Month
75.8 15.5 35
32.9 7.7 13
N.D. 7 . 6 7 . 6
Individual values for peak delta-9-THC levels for group 1 and 2 subjects as well
as mean levels are shown in figure 1. Peak delta-9-THC levels were
significantly greater for group 1 as compared to group 2 subjects (P < .05).
Figure 2 shows individual and mean delta-9-THC levels for group 1 and 2
subjects on study days 2 and 7. Mean plasma delta-9-THC levels were greater
for group 1 subjects on day 2, however, these differences did not achieve
statistically significant values. On day 7, when subjects had been abstinent from
all marijuana use since their admission to the research ward, plasma delta-9-
THC levels were similar for both groups of subjects. Figure 3 shows plasma
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FIGURE 1
delta-9-THC levels on day 30 (the first day following cessation of marijuana use
on the research ward) and on day 35. No statistically significant differences
were observed for plasma delta-9-THC levels for the 2 groups of subjects.
DISCUSSION
Relationships between marijuana smoking and plasma THC levels observed in
this study are consistent with the pharmacokinetic profile of marijuana effects
described by Hunt and Jones (1980). A good correlation was found between
the number of marijuana cigarettes smoked and peak plasma delta-9-THC levels.
Women who reported the highest level of marijuana smoking prior to
participation in the study smoked the greatest amount of marijuana during the
research ward study. Those women who reported smoking the least amount of
marijuana prior to the study smoked the smallest number of cigarettes during the
study in comparison to other subjects. Thus verbal reports by women of past
history of marijuana use, at least when obtained in the context of a research
program, appear to be highly reliable when confirmed by observations of
marijuana smoking under controlled investigator-observed conditions.
Women who reported the longest duration and greatest use of marijuana prior to
the study, smoked the largest number of cigarettes on the research ward and had
the highest peak plasma delta-9-THC levels. Moreover, these women also had
higher plasma delta-9-THC levels when they entered the study in contrast to
other subjects. These data suggest that plasma delta-9-THC levels may be a
reliable marker for not only past history of marijuana use but also for predicting
future smoking behavior when marijuana cigarettes are freely available.
However, lack of significant differences between plasma delta-9-THC levels
following 5-7 days of abstinence in women who smoked various amounts of
marijuana suggest that plasma delta-9THC levels would be a poor marker for
previous marijuana use approximately 1 week after cessation of smoking. If
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THC and THC metabolite levels in urine specimens are related to plasma delta-
9-THC levels, similar problems would be encountered in interpreting the
significance of urine testing for either determining past history of marijuana use
or predicting future marijuana smoking behavior.
Plasma delta-9-THC levels were undetectable in those women who smoked less
than 1 marijuana cigarette (average 0.4 marijuana cigarettes) per day during the
study. These women reported they smoked an average of 7.6 marijuana
cigarettes per month and none had detectable plasma delta-9-THC levels on
admission to the study. Thus the women who used marijuana least frequently
had the least probability of detection of plasma delta-9-THC levels prior to or
following the study. If plasma delta-9-THC levels are correlated with long term
presence. or absence of delta-9-THC in urine, similar false negative findings
might be anticipated from urine test results. We have been unable to locate any
study which has attempted to correlate plasma delta-9-THC levels following
observed marijuana use with the magnitude and duration of positive results in
urine screening tests. Since it has been argued that false positives in marijuana
urine screening may be more likely to occur than false negatives, such studies
may be of assistance in determining the effectiveness of urine tests in pre-
employment screening and work place settings.
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Opioid Receptors and Ligands
Hans W. Kosterlitz, Alistair D. Corbett and Stewart J.
Paterson
INTRODUCTION
One of the main problems of our understanding of the mode of
action of the endogenous opioid peptides is the multiplicity of
the fragments of pro-opiocortin, pro-enkephalin and prodynorphin.
Furthermore, none of the fragments interact with only one of the
µ- , and sites of the receptors (Kosterlitz and Paterson,
1985). The complexity of the system has recently been aggravated
by the finding that the non-peptide morphine is present in low
concentrations in animal tissue where it can be biosynthesized
from its non-morphinan precursor reticuline (Donner et al, 1986,
1987; Weitz et al., 1986, 1987). Its possible physiological
significance in animal tissue is still uncertain (Kosterlitz,
1987).
It is important to note that the binding interaction of a
molecule may or may not lead to a biological response of either
excitatory or inhibitory activity. Pharmacologically, such
activity would indicate that the response is that of an agonist.
An antagonist compound would also bind to the receptor but block
its excitatory or inhibitory response.
A difficulty of the interpretation of the physiological effects
of the endogenous opioid peptides is due to the fact that almost
all are degraded by peptidases. It is therefore necessary
either to use antipeptidases or synthetic peptidase-resistant
analogues, the action of which may be different from the
endogenous peptides.
BIOASSAYS OF OPIOID µ-, AND RECEPTORS IN ISOLATED TISSUE
PREPARATIONS
While a final understanding of the mode of action of opioid
peptides or non-peptide opioids has to await investigations in
vivo, the pharmacological effects of opioid compounds and their
physiological properties are often more readily analysed in
excised tissues. By such an approach, it is possible to decide
whether a synthetic opioid has agonist or antagonist properties
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or a combination of both. Such a differentiation is not
possible in binding assays on homogenized brain membranes.
In the bioassays used in this section, the opioid peptides or
non-peptides have high selectivity for one of the µ-, o r
K-receptors. The assay tissues are from five different species
which have opioid receptors of one, two or three subtypes
(TABLE 1). The opioid receptors of the rabbit vas deferens
interact with K-ligands, e.g. dynorphin A and U-69,593, those
of the hamster vas deferens with ligands, e.g. [D-Pen2,D-Pen5]
enkephalin, those of the rat vas deferens mainly but not
solely, with µ-ligands, e.g. morphine and [D-Ala2,MePhe4,Gly-ol5]
enkephalin and ß-endorphin those of the guinea-pig ileum with µ-
and K-ligands, e.g. [D-Ala2,MePhe4,Gly-ol5] enkephalin, dynorphin A
and U-69,593, and, finally, those of the mouse vas deferens
interact with all three µ-, and K-ligands (Kosterlitz and
Paterson, 1985) .
TABLE 1
Opioid Receptor Activity (37°C) in Rat Vas Deferens (RVD),
Hamster Vas Deferens (HVD), Rabbit Vas Deferens (LVD), Guinea Pig
Ileum Myenteric Plexus (GPI) and Mouse Vas Deferens (MVD)
LVD HVD RVD GPI MVD
Morphine
[D-Ala2,MePhe4,Gly-o15]enkephalin
ß-Endorphin
[Met]- and [Leu] enkephalin
[D-Pen2,D-Pen5]enkephalin
Dynorphin A
U-69,593
Naloxone
(-)-Bremazocine
(-)-Ethylketazocine
a 0 = no effect, A = agonist, ANT = antagonist. Antipeptidases
were present for assay of [Met]- and [Leu]enkephalin and
dynorphin A. (Kosterlitz 1985; Kosterlitz and Paterson 1985;
McKnight et al., 1985; Paterson et al., 1984)
b Lahti et al., 1985. (5 ,7 ,8ß)-(+)-N-methyl-N(7-(l-
pyrrolidinyl)-l-oxaspiro-[4,5]dec-B-yl)-benzeneacetamide
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There are unsolved problems concerning the physiology and
pharmacology of opioid compounds. Firstly, almost all
endogenous opioid peptides are liable to degradation by
peptidases and, secondly, potent selective agonists have only
recently become available.
TABLE 2
Binding Affinities of µ-, and K-Opioid Antagonists and
Their Relative Binding Affinities in Homogenates of
Guinea Pig Brain. Antagonist Activity (Ke)
Affinity Relative Affinity Antagonist
CTOP 0.52(µ) >0.998 - - 16.1
Naltrindole 8.3 0.01 0.98 0.01 0.11
Norbinaltor-
phimine 2.9 (K) 0.02 0.03 0.95 0.14
a Hawkins et al., 1989. b Portoghese et al., 1988
c Portoghese et al., 1987
d Selective agonist for the u-site, [D-Ala2,MePhe4,Gly-ol5]-
enkephalin (GPI), for the site, DPDPE (MVD), and for the
K-site, U-69,593 (GPI)
The new antagonist for the K-site, norbinaltorphimine
(Portoghese et al., 1987), has considerable selectivity for the
K-receptor but appears to be degraded in brain tissue (Birch et
al, 1987). Its properties will be discussed in a later section.
One of the selective antagonists, ICI 174,864, is highly
selective but is of low potency (Cotton et al., 1984). It  is
now superseded by the potent and selective antagonist
naltrindole (Portoghese et al., 1988). Recently, a selective
u-antagonist, CTOP, has become available (Hawkins et al., 1989)
but its antagonist potency (Ke = 16 nM) is lower than that of
the antagonist of naltrindofe (Ke = 0.11 nM) or that of the
K-antagonist norbinaltorphimine (Ke = 0.14 nM). (TABLE 2).
It is important to be aware of the fact that ligands may be
agonists at opioid receptors in some tissues but antagonists in
others. Ethylketazocine and bremazocine are examples of this
behaviour, as they are K-agonists in the guinea-pig ileum and
the vasa deferentia of the mouse and rabbit but u-antagonists in
the vas deferens of the rat and antagonists in the vas
deferens of the hamster. (TABLE ]).
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BINDING ASSAYS OF µ-, AND K-LIGANDS IN MEMBRANES OF
GUINEA PIG BRAIN
The affinity of a ligand is given as its binding affinity
constant, (K i , nM)
-1, which is the reciprocal of its inhibition
constant. (TABLES 3-5). In addition, it is useful to determine
the relative binding affinities by the ratio Ki
-1 for µ, 6 or
f o r for for K), the maximum being 1.00.
The temperature of the binding assays was 25°C when peptidase
resistant compounds were used and 0°C when peptides that are
sensitive to enzyme activity were used.
TABLE 3
Binding Affinities of u-Selective Opioids and Their Relative
Binding Affinities for the µ-,
of Guinea Pig Brain
and K-sites in Homogenates
µ-Affinity Relative Affinity
[Met]enkephalyl-Arg-Arg-
Val-NH2 16.7 0.77 0.03 0.20
[Met]enkephalyl-Arg-Arg-
Val-Gly-Arg-Pro-Glu-Trp-
Trp-Met-Asp-Tyr-Gln (BAM 18) 3.4 0.68 0.06 0.26
[Met]enkephalyl-Arg-Phe 0.29 0.60 0.36 0.04
ß-Endorphin 0.49 0.52 0.45 0.03
Morphine 0.56 0.97 0.02 0.01
Tyr-D-Arg-Phe-Lys-NH2 0.28 0.998 0 0.002
Relative binding affinities at the µ-, and K-sites are:
for or f o r for for K )
a Hurlbut et al., 1987; Kosterlitz 1985; Kosterlitz and
Paterson 1985; Paterson et al., 1984; Schiller et al., 1989.
In TABLE 3 four peptides are shown that, at the u-site, have
relative affinities varying between 0.52 and 0.77. Two of
these are [Met]enkephalins extended at the C-terminus with
-Arg-Arg in positions 6 and 7. [Met]enkephalyl-Arg-Arg-Val-NH2
is of particular interest since it has the very high affinity
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of 16.7 nM-1. The relative affinities of this peptide and its
possible precursor, BAM 18 (Hurlbut et al., 1987) are 0.77 and
0.68 at the u-site, 0.20 and 0.26 at the K-site and very low at
the site. In contrast, [Metlenkephalyl-Arg-Phe and
ß-endorphin have much lower binding affinities of 0.29 nM-1 and
0.49 nM-1. Their relative affinities are 0.60 and 0.52 at the
u-site, 0.36 and 0.45 at the site and very low at the K-site.
The binding pattern of morphine is very different. As discussed
in the Introduction, morphine is an endogenous compound, but is
present only in low concentrations. Its binding affinity is of
an average order but it is of particular interest that this
plant opioid has the very high relative u-affinity of 0.97 which
is much higher than the relative affinities of any of the known
endogenous µ-opioids in animal tissue.
Since none of the endogenous peptides is sufficiently
selective for the u-site, it was important to obtain synthetic
compounds. Tyr-D-Arg-Phe-Lys-NH2 (TABLE 3) and [D-Ala
2,MePhe4,
Gly-ol5]enkephalin (TABLE 1) fulfil this purpose.
TABLE 4
Binding Affinities of Selective Opioids and Their Relative
Binding Affinities for the µ-,
of Guinea Pig Brain
and K-Sites in Homogenates
Affinity Relative Affinity
[Leu]enkephalin 0.85 0.06 0.94 0
[Met]enkephalin 1.10 0.09 0.91 0
[D-Ala2,D-Leu5]enkephalin 0.74 0.10 0.90 0
[D-Pen2,D-Pen5]enkephalin 0.37 0.004 0.996 0
a Kosterlitz and Paterson 1985; Paterson et al., 1984
selective ligand, [D-Pen2,D-Pen5]enkephalin has become
important, as is the already mentioned antagonist natrindole
(TABLE 2).
The endogenous ligands, [Met]enkephalin and [Leu]enkephalin
have relative affinities of 0.91 and 0.94 but the low values of
0.09 and 0.06 at the µ-site (TABLE 4). These high values at
the site should be compared with the corresponding maximum
values for the peptide µ-ligands of 0.77 (TABLE 3) and for the
K-ligand of 0.83 (TABLE 5) The availability of an even more
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TABLE 5
Binding Affinities of K-Selective Opioids and Their Relative
Binding Affinities for the µ-,
of Guinea Pig Brain
and K-Sites in Homogenates
K-Affinity Relative Affinity
Dynorphin A
Dynorphin B
-Neo-endorphin
Dynorphin A (1-8)
[D-Pro10]dynor-
phin A (1-11)
8.7 0.13 0.04 0.83
8.5 0.14 0.03 0.83
5.1 0.10 0.23 0.67
0.75 0.22 0.16 0.62
34.7 0.05 0.01 0.94
U-69,593 0.74 0.001 0 0.999
PD 117302 1.72 0.003 0 0.997
a Kosterlitz 1985; Kosterlitz and Paterson 1985;
Paterson et al., 1984
b Birchmore et al., 1987. (+)-trans-N-methyl-N-
[2-(l-pyrrolidinyl)-cyclohexyl]benzo[b]thiophene-
4-acetamide
With regard to K-ligands, there are no endogenous peptidase-
resistant compounds of high potency, with the possible
exception of dynorphin A (1-17). Dynorphin A (1-17) and
dynorphin B (1-13) and a-neo-endorphin have high affinities at
the K-sites (5.1-8.7 nM-1). In contrast, the fragment
dynorphin A (1-8), present in many areas of the nervous system
in higher concentrations than dynorphin A (1-17), has a much
lower affinity at the K-site (0.75 nM-1) and is also much less
selective. The physiological significance of this difference
between the two peptides is still not understood (TABLE 5).
Non-peptide ligands with a very high degree of selectivity for
the K-binding,site are U-69,593 and PD 117,302 with relative
affinities at the K-site of more than 0.99. Another interesting
compound is [D-Pro10]dynorphin A (1-11) which has the highest
affinity to the K-site so far observed but its relative
affinity at the K-site is somewhat lower than the values
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obtained with the two compounds,
CONCLUSIONS
An investigation of the present state of our knowledge of the
opioid receptors and their ligands confirms that analyses of
their mode of action is now increasingly complex. The synthesis
by Portoghese and his group of compounds which are selective
antagonist and almost selective K-antagonists is of high
significance. We may expect that our understanding of the
mode of action of endogenous opioid fragments will be much
faci l i tated.
The discovery by the groups of Goldstein and of Spector that
morphine is an endogenous opioid, although present only in low
concentrations, may not only be of pharmacological but also of
physiological significance. Whatever the results of future
experiments may indicate, it is interesting that morphine is
the only known member of the morphinan group having such a
highly selective µ-opioid ligand. The known endogenous opioid
peptides are much less selective in this respect.
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The Role of Opioids in Analgesia
and Gastrointestinal Function
Thomas F. Burks
Two of the most striking pharmacological effects of
opioids in animals and humans are those affecting
sensory perception of pain and those affecting
gastrointestinal function. The antinociceptive or
analgesic effects of opioids occur primarily from
their actions in the brain and spinal cord. The
antidiarrheal effects of opioids result both from
central nervous system and enteric nervous system
sites of action (Parolaro et al., 1977; Stewart et
al., 1978; Shook et al., 1987). Other
gastrointestinal effects of opioids, as described
below, may also be mediated by either central or
peripheral chemosensitive sites.
Recognition of multiple types of opioid receptors in
the central nervous system and in the periphery
(Martin et al., 1976; Lord et al., 1977) has provided
new insight into opioid regulatory functions.
Availability in recent years of agonist and antagonist
ligands with selectivity for the individual types of
opioid receptors has provided an opportunity to
determine which supraspinal, spinal and peripheral
receptors are responsible for opioid analgesic effects
and for opioid gastrointestinal effects. Selective
agonists have been given by intracerebroventricular
(i.c.v.) and intrathecal (i.t.) injection techniques
to ensure that agonists reach critical sites or to
limit their actions to specific sites. The major
selective agonists employed were DAMGO ([D-Ala2, N-
methyl-Phe4, Gly5-ol]enkephalin) and PL017 ([MePhe3, D-
Pro4]morphiceptin) for mu receptors (Handa et al.,
1981; Chang et al., 1983), DPDPE (cyclic [D-Pen2, D-
Pen5]enkephalin) for delta receptors (Mosberg et al.,
1983), and U-50,488 (trans-3,4-dichloro-N-methyl-N-[2-
(1-pyrolidinyl)-cyclohexyl]-benzeneacetamide
methanesulfonate) for kappa opioid receptors (Von
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Voigtlander et al., 1983). In most experiments,
morphine has been employed as a standard, mu-
preferring opioid agonists.
Analgesia
The antinociceptive (analgesic) effects of DAMGO,
DPDPE, U-50,488 and morphine have been evaluated in
unanesthetized rats and mice. In rats, all four
agonists produced dose-related analgesia after i.c.v.
administration in the hot plate test (Galligan et al.,
1984). The order of potency was DAMGO > morphine >
DPDPE > U-50,488. This study established that a
highly selective delta opioid agonists, DPDPE, can
produce analgesia after i.c.v. administration.
More extensive studies of analgesic actions of
receptor-selective opioid agonists have been carried
out in mice. DAMGO, morphine, DPDPE and U-50,488
produced anaglesia in the mouse writhing test (Porreca
et al., 1987). The rank order of potency after i.c.v.
administration was DAMGO > morphine > DPDPE > U-
50,488. Similar results were found after i.t.
administration, except that all agonists were much
more active in the writhing test after i.t. than after
i.c.v. administration. In the mouse hot plate test,
DPDPE was more potent when give i.t. than i.c.v.,
morphine was approximately equipotent by the two
routes, and DAMGO and U-50,488 were more potent when
given i.c.v than i.t.
Evidence to date indicates that mu, delta and kappa
opioid receptors in the central nervous system can
independently mediate analgesia. For example, the
analgesic actions of DAMGO, but not DPDPE, are blocked
by the mu-selective antagonist, ß-funaltrexamine,
where as anaglesic responses to DPDPE, but not those
to DAMGO, were blocked by the delta-selective
antagonist, ICI-174,864, (Hey-mans et al., 1988).
Morphine, PL017 and U-50,488, but not DPDPE, produced
significant analgesia when administered subcutaneously
(s.c.) in mice (Shook et al., 1987).
Dynorphin-(1-13) given i.c.v. to mice failed to
produce analgesia and attenuated analgesia induced by
morphine (Friedman et al., 1981). However, dynorphin
was found subsequantly to produce analgesia after i.t.
administration to mice or rats (Piercy et al., 1982;
Han and Xie, 1982). We found that dynorphin-(l-9)
given i.t. in mice produced dose-related analgesia in
the warm water tail flick test (Porreca et al., 1983).
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Gastrointestinal Transit
Opioids of the morphine type have long been known to
inhibit flow of contents through the gastrointestinal
tract. Morphine was shown to produce dose-related
inhibition of small intestinal transit in rats after
i.c.v., s.c. or intragastric administration, with the
i.c.v. route approximately 100-fold more potent than
the S.C. route (Galligan and Burks, 1983). It was
subsequently discovered that morphine can also inhibit
gastrointestinal transit by means of actions in the
spinal cord of the mouse or rat (Porreca and Burks,
1983; Koslo et al., 1985). The important site(s) of
morphine anti-transit actions after systemic
administration have been the subject of debate, with
advocates for purely peripheral sites of action
(Tavani et al., 1979; Manara et al., 1986) and those
proposing both central and peripheral sites of
antitransit actions (Parolaro et al., 1977; Stewart et
al., 1978; Burleigh et al., 1981). In studies using
the highly selective mu opioid antagonist, CTP (D-Phe-
Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2), it was found that
i.c.v. administered CTP blocked the analgesia induced
by S.C. administered morphine, but not morphine's
antitransit effect (Shook et al., 1987). When the
peptide antagonist, which does not effectively cross
the blood-brain barrier, was given s.c., it blocked
the antitransit effects of low (0.3 mg/kg) doses of
S.C. morphine, but only partially inhibited the
antitransit effects of high (3 mg/kg) doses of S.C.
morphine. Thus, with systemic doses that produce
analgesia, morphine appears to exert small intestinal
antitransit effects by actions both in the periphery
and in the central nervous system.
The roles of brain and spinal opioid receptors in
mediation of antitransit effects where explored in
mice and rats with receptor selective agonists. In
mice, DAMGO and morphine given i.c.v. and i.t.
produced dose-related inhibition of small intestinal
transit (Porreca et al., 1984). DPDPE and U-50,488
were essentially inactive when given i.c.v. However,
DPDPE produced dose-related inhibition of transit when
administered i.t. U-50,488 produced only modest
antitransit effects when given i.t. Similar results
were obtained in rats (Galligan et al., 1984).
Morphine and PL017 given peripherally (s.c.) produced
dose-related inhibition of small intestinal transit in
mice (Shook et al., 1987). DPDPE and U-50,488 did not
exhibit antitransit effects when administered
peripherally.
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Antidiarrheal Effects
Pathological diarrhea results usually from excessive
secretion of fluid and electrolytes into the lumen of
the intestine. The rate of fluid secretion exceeds
the rate of absorption, there is net accumulation of
fluid in the lumen, and diarrhea results (Cooke,
1989). Mucosal transport in the small intestine is
regulated primarily by neural mechanisms (Cooke, 1989;
Sheldon et al., 1989). Brown and Miller (1983)
discovered that mucosal transport in the intestine can
be regulated by the central nervous system. We
examined in mice the antidiarrheal properties of
receptor selective opioid agonists. When give i.c.v.,
morphine, PL017 and DPDPE inhibited experimental
diarrhea in a dose-related fashion (Shook et al.
1989). Interestingly, the mu agonists, morphine and
PL017 given i.c.v., inhibited diarrhea at doses much
lower than those needed to produce analgesia or to
inhibit gastrointestinal transit. DPDPE was
equipotent in inhibiting diarrhea and in producing
analgesia, but did not affect the rate of transit. U-
50,488, given i.c.v., inhibited diarrhea only at
extremely high doses and had no effect on transit.
When given peripherally (s.c.), morphine, PL017, DPDPE
and U-50,488 all inhibited diarrhea in a dose-related
manner. The antidiarrheal effects of the mu, delta
and kappa opioids were probably attributable to
effects on mucosal transport of fluid and electrolytes
because the antidiarrheal effects occurred at doses
lower than those necessary to inhibit gastrointestinal
transit.
Gastric Secretion
The effects of receptor-selective opioid agonists on
gastric acid secretion were assessed in pylorus-
ligated rats (Fox and Burks, 1988). The mu opioids,
morphine, PL017, and DAMGO, all produced dose-related
inhibition of gastric secretion after i.c.v.
injection. When given i.v., larger doses of morphine
and PL017 inhibited gastric secretion, but DAMGO had
no effect. DPDPE did not alter gastric secretion when
given either i.v. or i.c.v. However, i.v.
administration of U-50,488 produced a dramatic
increase in volume of gastric secretion and acid
output, whereas i.c.v. administration of U-50,488 had
no effect. These data indicate that mu opioids act in
the central nervous system to decrease acid secretion,
U-50,488 acts peripherally to increase secretion, and
DPDPE has no effect either centrally or peripherally.
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Conclusions
Supraspinal and spinal opioid receptors clearly
mediate antinociceptive responses in rats and mice.
Mu and delta opioid receptors and, to a lesser extent,
kappa opioid receptors, are associated with
antinociception. Supraspinal, spinal and peripheral
mu opioid receptors also mediate gastrointestinal
antitransit effects in rats and mice. Spinally
administered DPDPE and U-50,488 produced modest
antitransit effects, but essentially no effects after
i.c.v. or s.c. administration. In contrast, mu, delta
and kappa agonists can act at both brain and
peripheral opioid receptors to produce antidiarrheal
effects. Qualitatively different effects associated
with different opioid receptors were observed with
gastric acid secretion.. Mu opioids appear to act in
the brain to inhibit gastric secretion, U-50,488 acts
peripherally to increase secretion, and DPDPE had no
effect.
It is evident that opioids can act at multiple types
of receptors in the brain, spinal cord and periphery
to produce functional changes. The specific changes
observed depend on the site of opioid action, the
types of receptor involved, and the specific endpoint
measured.
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Opioid Delta Receptor Involvement
in Behavioral and Neural Plasticity
Joe L. Martinez, Jr., Gery Schulteis, Brian E. Derrick, Susan
B. Weinberger, Teresa A. Patterson, Edward L. Bennett and
Mark R. Rosenzweig
Opioid peptides affect complex cognitive furctionirq, as
assessed in a variety of conditioniq paradigm, in both
rodents and monkeys. learning and memory of both avoidance
and appetitive conditioning tasks are influenced by opioids
(see Schulteis et. al., 1989, for review). In many instances
the behavioral actions of opioid peptides depend on opioid
receptor activation, since many of their effects are blocked
by opioid antagonists (see Martinez et al., 1988, Schulteis
et. al., 1989, for review). Because all of the naturally
occurring opioid peptides have at least some affinity for all
types of opioid receptors (Kosterlitz and Paterson 1985), it
is not yet known which opioid receptor type(s) contributes to
the behavioral effects observed following treatment with
opioid peptides. The recent development of selective opioid
receptor agonists and antagonists (see Schulteis et al.,
1988, Schulteis and Martinez 1989, for references) has
allowed the commencement of the analysis of the contribution
of specific opioid receptor types to particular behavioral
actions. This paper focuses on the role played by opioid
receptors in three different situations: l) avoidance
conditioning in rats and mice, 2) taste avoidance
conditioning in chicks, and 3) long-term potentiation in the
rat hippocampus.
AVOIDANCE CONDITIONING IN RODENTS AND CHICKS
Our studies investigate the modulatory role of the opioid
pentapeptide [leu]enkephalin (LE) on learning and memory (see
Martinez et. al., 1988, Schulteis et. al., 1989, for review).
LE has higher selectivity for the opioid receptor than any
other naturally occurring opioid peptide; it has only
moderate affinity for the n receptor and negligible affinity
for K receptors (Kosterlitz and Paterson 1985).
[Met]enkephalin (ME), which shares many of LE's effects on
conditioning, has a slightly greater affinity for µ receptors
than LE, but it also possesses responsible selectivity for
receptors. Thus, we hypothesized that the effects of
enkephalins on the acquisition and retention of learned 
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behaviors are mediated by opioid receptors, and that this
type of opioid receptor plays an important role in modulating
the strength of a learned response.
An initial experiment testing this hypothesis used the
selective receptor agonist [D-pen2,D-pen
5]enkephalin
(DPDPE) (Schulteis et al., 1988). In this study, male
Swiss-Webster mice were given intraperitoneal (i.p.)
injections of LE or DPDPE, 2 min prior to training in a
one-way active avoidance paradigm. Both IE (30 and 100
µg/kg) and DPDPE (11.6 µg/kg) impaired acquisition of
the avoidance response. The dose-response functions for
both peptides were U-shaped, an effect commonly seen in
studies of drug effects on learning and memory (see Schulteis
et al., 1989, for further discussion). If animals are
retested 24 hrs after training, then those animals that were
impaired during acquisition were still impaired upon retest
(Schulteis et. al., 1988). Thus injections of LE or DPDPE
prior to training resulted in learning impairments; the
peptides did not simply impair the ability of the animals to
perform the response during training.
Since stimulation of receptors by exogenously administered
ligands impairs learning, we hypothesized that the effects of
these ligands would be reversed by concurrent administration
of a selective antagonist, and that blockade of receptors
with an antagonist which prevents endogenous opioids with
affinity and selectivity for receptors from binding to
these sites, would enhance learning. The results of several
experiments support these hypotheses. Concurrent i.p.
injection of LE (100 µg/kg) and ICI 174,864 (1.0 mg/kg), a
selective receptor antagonist, results in complete reversal
of the impairment in learning produced by LE (Schulteis and
Martinez 1989). In addition, both ICI 174,864 (3.0 mg/kg)
and the less potent, but equally selective analog ICI 154,129
(30 and 100 mg/kg), by themselves significantly enhance
acquisition of the active avoidance response (Schulteis and
Martinez 1989, Schulteis et. al., 1988). Thus endogenous
opioid peptide systems may modulate learning by acting
through the opioid receptor. We suggest that LE and perhaps
the closely related peptide ME are the endogenous ligands
involved in this effect.
Studies in rats using an automated shelf-jump avoidance
paradigm confirmed our results in mice. Both LE (1.0 and 3.0
µg/kg) and DPDPE (1.16 but not 11.6 µg/kg) were found to
impair acquisition of the shelf-jump response in rats
(Weinberger et al. 1988). A similar level of impairment was
produced by equimolar doses of the two peptides, and the
dose-response function for the impairment produced by DPDPE
in the automated shelf-jump task was U-shaped. These
results, together with our findings that DPDPE and LE both
impair acquisition of a one-way active avoidance response in
mice, and that LE impairs acquisition of the same response in
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rats, further support our suggestion that opioid receptors
are implicated in the effects of LE on conditioning. In
addition, these results indicate that the involvement of
receptors in acquisition impairment extends to at least two
rodent species and to two different avoidance conditioning
tasks.
Recently we investigated the generality of the involvement
of opioid receptors by studying their role in taste
avoidance conditioning in the two-day old chick (Patterson
et. al., 1989). Chicks naturally peck at a bright shiny bead,
and readily learn to avoid pecking if the bead is coated in
a bitter-tasting substance. This single-trial learned
response is quite robust, since 80-90% of saline-treated
control animals will avoid the bead when it is represented
24 hrs after the original training.
LE (0.01 - 10.0 nmoles/hemisphere) and [D-pen2,L-pen
5]-
enkephalin (DPLPE; 0.003 - 0.10 nmoles/ hemisphere) were
administered to chicks intracranially (i.e.) into the medial
hyperstriatum ventrale (MHV) 5 min before training. Both
drugs produced U-shaped dose-response functions, with a 1.0
nmole dose of LE and a 0.03 nmole dose of DPLPE impairing
acquisition of the response. We also found that ICI 174,864
(10.0 nmoles/hemisphere) , when given in combination with the
impairing dose of LE or DPLPE, reversed the effect of both
peptides. These latter studies provide further evidence that
the effects of LE and DPLPE on learning in the chick are
mediated by opioid receptors.
The effects of selective agonists and antagonists on
acquisition of the taste avoidance response following i.e.
injection in chicks are remarkably similar to those described
above for rodents. Selective opioid receptor agonists
impair conditioning, produce U-shaped dose-response
functions, and are antagonized by selective antagonists in
both rodents and chicks.
LONG-TERM POTENTIATION IN THE CA3 REGION OF THE RAT
HIPPOCAMPUS.
In addition to the modulatory effects on avoidance
conditioning produced by receptor agonists and antagonists,
we are investigating a long-lasting form of synaptic
plasticity (long-term potentiation: LTP) in the rat hippo-
campus that may be initiated by activation of receptors.
UTP is an enduring change in synaptic efficacy observed
following high frequency activation of afferent projections
to and within the hippocampal formation (see Bliss and Lynch
1988 , for review). LIP is a promising model for the synaptic
plasticity that may underlie some types of memory. LTP
induction in many hippocampal pathways requires activation of
the N-methyl-D-aspartate (NMDA) receptor, a glutamate 
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receptor subtype requiring both glutamate and sustained
postsynaptic depolarization for its activation. The mossy
fiber projection to area CA3, a putative enkephalinergic
pathway, is unique in that NMDA receptor antagonists do not
block LTP at messy fiber-CA3 synapses (Harris and Cotman
1986). By contrast, naloxone, an opioid receptor antagonist,
does block LTP induction at these synapses (Derrick et. al.,
submitted, Martin 1983). This blockade is not observed with
(+)-naloxone, an inactive stereoisomer, indicating that the
effects of naloxone on LTP are due to antagonism of opioid
receptors. Induction of LTP in responses evoked in
commissural afferents to the same population of CA3 pyramidal
cells is unaffected by naloxone (Derrick et. al., submitted).
Exogenous application of agonists selective for µ or
receptors produces marked excitation of hippocampal pyramidal
cells (see Corrigal 1983, for review). Although it was
suggested that GABAergic inhibition may be indirectly
involved in this effect (see Bliss and Lynch 1988, for
review) and that the blockade of LTP induction by naloxone
may result from a blockade of these disinhibitory effects of
endogenous opioid peptides (Bramham et. al.. 1988, Martin
1983), we found that coadministration of bicuculline, a GABA
antagonist, and naloxone did not overcome the naloxone
blockade of LTP. Together these findings suggest that LTP
induction at the mossy fiber-CA3 synapse uses a unique
mechanism that directly involves opioid receptor activation
(Derrick et. al., submitted). 
Figure 1. The effect
of DPDPE (1.0 and 10
pmoles) on field evoked
by stimulation of mossy
fiber or commissural
afferents. Maximal in-
creases were observed
at 0-30 min and at 90
min after DPDPE appli-
cation. Data are
reported as the maximal
percent increase from
baseline. Mann-Whitney
U-test, two-tailed:
* p<0.05,
** p<0.01.
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The high frequency stimulation needed to induce LTP may
release opioid peptides (Bramham et. al., 1988). This
hypothesis suggests that exogenous application of opioid
agonists should mimic the effects of high frequency
stimulation of enkephalinergic pathways. We found that DPDPE
produced increases in mossy fiber-CA3 evoked responses that
were significantly greater than those observed in the non-
opioid commissural pathway to CA3 (Derrick and Martinez
1989), and that DPDPE produced a long lasting enhancement in
mossy fiber-CA3 responses qualitatively similar to LTP. The
increase in mossy fiber responses was greater 90 min
following than immediately following peptide application (see
Figure 1). By contrast, DPDPE effects on commissural
responses had nearly returned to baseline by 90 min. Similar
effects were not observed following application of agonists
selective for µ or K receptors. Together, these results
suggest that induction of LTP at mossy fiber-CA3 synapses is
dependent on opioid receptor activation, and that opioid
receptors may be the implicated receptor type.
CONCLUSIONS
All of the studies reviewed above suggest that opioid
receptors play an important role in behavioral and neural
plasticity. The modulatory actions of enkephalins in several
tasks and species (mice, rats, chicks) appear to be mediated
by stimulation of the receptor. Further S receptors may
play a direct role in the induction of LTP at mossy fiber-CA3
synapses. Thus, it is evident that receptors appear to be
critically involved in mechanisms of neural plasticity at
several levels of analysis.
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Thermoregulation and the Opioid
System
Martin W. Adler and Ellen B. Geller
One of the most commonly utilized measures of the actions of a variety of drugs
from numerous pharmacological classes is body temperahure (Tb). Despite that,
little thought is given to the relationship between Tb, and thermoregulation. Tb, is
merely a reflection of heat-gain and heat-loss mechanisms:
Body Temperature = Heat Gain + Heat Loss
Just because a drug alters Tb does not mean that it interferes with or affects
thermoregulation. It does not mean that it alters the ability of the body to maintain
a temperature around a given point, the set point. In mammals, including the
human, Tb is regulated in an exquisitely narrow range. This tight regulation
allows an organism to maintain a thermodynamically stable internal environment in
which the rates of a myriad of biochemical reactions can be altered without having
to compensate for changes in ambient temperature. We become aware of
thermoregulation only when something like infection occurs with resulting fever.
If the temperature keeps going up as the result of release of substances such as
endogenous pyrogen or IL- 1 or as a result of malignant hyperthermia, we begin to
look for ways to return the Tb to normal On the other hand, we look to raise the
Tb in circumstances where hypothermia occurs, as with stranded winter mountain
climbers, inadequate ambient temperature in the homes of the aged, or a child
falling through the ice and suffering from the so-called “near-drowning”
syndrome. Furthermore, physicians are always looking for better ways to alter Tb
and exert thermoregulatory control when they cool patients during cardiac surgery
or heat patients in treating some forms of cancer. Our crude ability to modify and
modulate the thermoregulatory system is impeded by our poor understanding of
the system itself. If we knew more about it, perhaps we could more effectively
use it in conditions such as cardiac surgery, preservation of organs for transplant,
treatment of stroke, treatment of trauma to the spinal cord, and treatment of
malignancies.
There appear to be three components in temperature regulation: a set of sensors to
monitor ambient and core temperatures, portions of the CNS (especially the
hypothalamus) to receive and coordinate this information, and the effector system
of nerves and organs utilized by the regulator to make appropriate responses.
Although the sensory and effector systems are fairly well understood, we know
very little about the regulator (coordinator) part of the system. The recent data that
has been forthcoming about the opioid system indicates that this system is
intimately involved in thermoregulation and, perhaps, is the coordinating or
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regulatory part of the system. Before giving some indication of what we believe
that involvement to be, it may be worthwhile summarizing the very confusing
literature about the possible role of several neurotransmitters in thermoregulation.
Among the most frequently implicated transmitters in thermoregulation are
norepinephrine, dopamine, serotonin, acetylcholine, and histamine (Cox and
Lomax, 1977; Myers, 1980; Lomax and Schönbaum, 1979). Although it is
generally accepted that all of these substances play some role, the degree of their
involvement is still very much unresolved. The only neurotransmitter that
virtually all investigators agree is involved in therrnoregulation is norepinephrine
(NE). When microinjected into the preoptic anterior hypothalamus (POAH), NE
causes a dose-dependent hypothermia in most species studied. This effect can be
blocked by prior injection of an alpha adrenergic antagonist into the hypothalamus
(Rudy and Wolf, 1971). Dopamine (DA) has also been shown to induce
hypothermia when injected into the POAH in most species, and this decrease can
be antagonized by DA receptor blockers. Based on this and other evidence, it has
been proposed that catecholamines mediate heat loss or block heat production
(Myers, 1980). Other investigators have reported opposite results in rats, however
(Cox et al., 1980; Lin et al., 1982). Likewise, there is contradictory evidence for
the role of serotonin (5-HT). In most species, 5-HT elicits a dose-dependent
hyperthermia when microinjected into the POAH and is thought to be involved in
heat-gain mechanisms (Myers, 1974; Borsook et al., 1977). However, elevating
levels of 5-HT in hypothalamus by stimulation of the midbrain raphe, or by
administration of the precursor 5-HTP, or by inhibiting 5-HT uptake has been
shown by others to cause a decrease in metabolism, cutaneous vasodilation, and
hypothermia in rats (Lin, 1984). The story on acetylcholine (ACh) is even more
confusing. Whether it results in a hyperthemtic or hypothermic effect is very
much dependent on the species and route or brain site of administration. It has
been implicated in both heat-production and heat-loss pathways (Lin, 1984;
Myers, 1980). Results with histamine have been more consistent: it causes
hypothermia at normal ambients whether administered systemically or centrally
(Lomax and Green, 1979). Of course, there are a host of possible reasons as to
why after so many years of research we still have no clear picture of the role these
and other transmitters play in regulating Tb, but it appears that this system relies on
redundant pathways and balancing complex interrelationships among
neurotransmitters, neuropeptides. hormones, and cations in order to maintain its
remarkable stability. The opioid peptides, at a minimum, may just represent one
more group of substances that can affect Tb. On the other hand they may turn out
to have a command function in the overall system.
We can begin the opioid story with a brief review of the effects of these drugs on
Tb. Until the last few years, we knew little about the actions of opioids other than
morphine. What was known was that the effect of morphine given by a parenteral
route varied with the species.
TABLE 1 Morphine on Body Temperature in Various Species
HYPOTHERMIA HYPERTHERMIA DUAL EFFECT
dog cat rat
rabbit horse mouse
bird cow primate
goat
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A further confounding factor is that the effect is often determined by the route of
administration. For example, in the rat, morphine has a well-known hyperthermic
effect when admininistered by a parenteral route in low doses and a hypothermic
response in high doses. On the other hand, intracerebroventricular (icv)
administration results in only a dose-related hyperthermia (Geller et al., 1986)
Studies in our laboratory have been primarily in the young adult male
Sprague-Dawley rat. Tb is measured in most instances by means of a temperature
probe inserted 7 cm into the rectum. Animals are essentially unrestrained and Tb is
measured several times over a 3- to 4- hour period with each animal acting as his
own control (Geller et al., 1986). Unless stated otherwise, the effects of all the
opioids and opioid peptides on Tb are blocked by naloxone. After testing a large
number of opioids administered by the subcutaneous (SC) and the icv route, we
found that the drugs separated into 5 classes based on the nature of the effects they
produced, as described below.
TABLE 2 Effects of Opioids on Body Temperature in Rats
GROUP 1: dual response; antagonized by naloxone; stereospecificity
GROUP 2: hyperthermia; antagonized by naloxone; stereospecificity
GROUP 3: hypothermia; partially antagonized by naloxone; stereospecificity
GROUP 4: little effect; naloxone causes hypothermia
GROUP 5: little or no effect
Our first attempt to put some order into the chaos was a 2-receptor model (Geller et
al., 1983.) This dual receptor hypothesis might explain the dual effect of
morphine on Tb,. Briefly, the low-dose hyperthermia is due to the presence of a
high number of receptors with high affinity but low intrinsic activity. The high-
dose hypothermia is due to a smaller number of hypothetic receptors with lower
affinity but high intrinsic activity. As we continued our work, we began to define
the components of that system and came up with our current hypothesis that the
thermal actions of the opioid system are based on a 2-receptor model. There is a
p-receptor-mediated hyperthermia and a K-receptor-mediated hypothermia.
Further, the µ actions are, at least in part, due to actions in the brain, while K
actions are primarily outside the brain (Geller et al., 1986). We were able to
predict that a drug such as U-50,488H, the highly selective K agonist, would
cause a drop in Tb and it did (Adler et al., 1986). Since the guinea pig has a
preponderance of K receptors, we predicted that it would be even more sensitive
than the rat to the hypothermic effects of U50,488. As expected, it was (Adler et
al., 1988).
Using gradient-layer calorimeters, we have begun to look at whether heat-gain or
heat-loss factors are responsible for the changes in Tb with µ and K agonists in
unrestrained animals. The precipitating event for the drop in Tb, with U50,488
appears to be a decrease in oxygen consumption. Decreased heat loss probably
results from a homeostatic attempt to conserve heat and a decrease in available heat
with the decline in VO2. If a drop in Tb is always associated with K activity, then
we would expect similar patterns regardless of the opioid inducing the effect.
Methadone, when given in doses high enough to produce hypothermia, causes
similar changes in VO2 and Q. The only difference lies in the recovery from the
hypothermia, which may be attributed to methadone’s actions on µ receptors
(Lynch et al., 1987).
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To further explore the hypothermic effect of K receptor activation, we looked at
the combination of U50,488 with another drug known to drop Tb. We chose
chlorpromazine (CPZ). In this case, the hypothermia results primarily from an
increased heat loss, rather than an effect on O2 consumption. If we combine
U50,488 and CPZ, we get a composite of the effects seen with the individual
drugs, as illustrated in figure 1.
HOURS
FIGURE 1 Potentiation of U50,488 and CPZ. At time 0, rat received SC
injections of 5 mg/kg CPZ and 80 mg/kg U50,488H, dissolved in saline.
The increased heat loss caused by CPZ added to the decrease in O2 consumption
caused by U50 results in a potentiation of the hypothermia. At the doses used,
each drug alone lowered Tb by about 2°C. Combined, however, the temperature
dropped by over 8°C. Individual animals have shown drops of over 11°C (Adler
and Geller, 1987). There are no deaths at normal ambient temperature. The
reason for the huge drop in Tb is a large spike in heat loss plus a decrease in VO2.
There is certainly no question that calorimetry can provide important insights into
the mechanisms by which opioids affect thermoregulation. A number of other
approaches are also needed. For example, changing the ambient temperature can
tell us something about set point. Another approach is behavioral
thermoregulation. If an animal’s physical ability to choose an ambient temperature
is not impaired, we can learn much about set point by determining if an animal
chooses a warmer or cooler environment. Such a technique has been used to study
the effects of µ. K, and 6 agonists in rats (Spencer et al., in press.)
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More recently, we have begun to use selective opioid peptides and opioid
antagonists to pick apart the effects of opioids on Tb and thermoregulation.
Although these studies are still in their initial phase, there are a few findings of
special interest. ID-Ala2, N-MePhe4, Gly5-ol]-enkephalin (DAGO), a µ-selective
opioid peptide, elicits a dose-related hyperthermia preceded by a small, transient.
hypothermia. We felt that this hypothermic effect might be the result of some
activity at K receptors and, indeed, the K-selective antagonist nor-BNI
(Portoghese et al., 1987) antagonized this initial decrease in Tb. Interestingly, the
purportedly k-selective antagonist, ß-FNA, only partially prevented the
DAGO-induced increase in temperature when given 18-24 h before DAGO. It also
only partially blocked the hyperthermia caused by icv morphine.
Surprisingly, both the low-dose hyperthermia and the high-dose hypothermia
produced by SC morphine could be blocked by naloxone or either of the more
selective antagonists. We had not expected these results based on our model. (In
fact, the less selective K antagonist WIN 44441 had blocked the high but not the
low dose effect of morphine.) Just as surprising was the finding that neither
antagonist blocked the hypothermia caused by the purported K agonist dynorphin.
Naloxone, even at 10 mg/kg, did not completely block it, either. On the other
hand, as would be predicted from our model, the hypothermia produced by the
K-selective U-50488H was antagonized by nor-BNI and naloxone but not by
ß-FNA. Although additional doses and routes of administration need to be done,
these preliminary results may indicate that the model needs to be modified to
accommodate subtypes of µ and K receptors or an as yet unknown interaction
between the receptors. In our hands, DPDPE, the highly selective 6 agonist, and
naltrindole. the selective 6 antagonist, appear to have no significant effect on Tb
either individually or in combination.
We have focused on µ and K because the evidence is strong, not only from our
data but from studies in several other laboratories, that µ is a receptor mediating
primarily hyperthermic responses while K is predominantly involved in mediating
hypothermic effects. Although the activation of 6 receptors may produce some
small effects on Tb, them is no compelling evidence that it has a significant role in
thermoregulation. The same is true for receptors in the rat. Perhaps the use of
calorimetry, along with behavioral thermoregulatory methods and studies at
various ambient temperatures, will shed more light on the question of the role of
opioids in thermoregulation. It is hoped that such studies will provide us with the
information needed for important contributions to therapeutics as well as increase
our knowledge about the functions of the endogenous opioid system.
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Interactions of the Opioid and
Immune Systems
Robert M. Donahoe
The discipline of psychoimmunology is concerned with the
inter-dependencies between neural and immune processes. The
conceptual premise of this discipline is that immunological
function can be influenced by neuroendocrine and behavioral
processes and vice versa. Since addicting drugs of abuse
modulate both neural and immune functions, these substances
make interesting probes for study of the neuroimmune network.
Indeed, the foundations of psychoimmunology can be traced to
observations made over seventy years ago that morphine
modulates phagocytic capacity of human leukocytes (Archard et
al., 1909).
Discoveries in the early 1970s (Pert and Snyder, 1973; Simon
et al.. 1973; Terenius, 1973) that opiates exert their
effects through specific binding sites (receptors) on the
cell surface and that such receptors are the basis for
intersystemic responses to both exogenous and endogenous
opioids (Hughes et al., 1975) set the stage to appropriately
conceptualize the neuroimmune effects of opiates. There was a
growing awareness at the time that opiate addicts frequently
experience elevated levels of opportunistic infections and
cancer (Sapria, 1968; Harris and Garret, 1972; Louria, 1974).
Evidence was also accumulating that addicts experience
clinically detectable signs of immune depression (Brown et
al., 1974). These circumstances led to consideration of the
hypothesis that opiates may directly influence immune
function. It was not recognized then, and is still evident
today that this is not an easily testable hypothesis. The
role of opiates themselves in induction of immunodeficiency
cannot be tested prospectively in humans and retrospective
studies suffer from the uncertainty that immune depression
evident in addicts may be the result of immune paralysis
induced by frequent exposure to multiple foreign antigenic
insults and repeated infections rather than a direct effect
of opiates. Notably, the findings of Falek et al., (1972)
were of particular relevance to the uncertainties inherent to
this situation. 
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In cytogenetic analyses using phytohemmaglutinin-stimilated
whole blood cultures, Falek et al. (1972) showed that heroin
addicts had elevated - levels of chromosomal damage. Since
their analyses were dependent on errant mitotic events during
DNA replication, they demonstrated a deficit in lymphocytes
that was not easily attributable to immune paralysis. In a
separate study (Madden et al., 1979), they showed that this
damage was not likely to be related to direct chelation of
DNA by opiates but rather to inhibition of DNA repair
mechanisms which further suggested some direct metabolic
effect of opiate binding to T-cells. Thus, their studies
encouraged further consideration of the notion that opiates
might influence T-cells directly.
Their cytogenetic observations led the Falek group to examine
the immune status of heroin addicts using the total T-cell E-
rosette assay as an immunological measure of T-cell
functional integrity. This procedure is a receptor-mediated
assay which exploits the ability of T-cells to combine
specifically with sheep erythrocytes (E) in a microscopically
visible rosette formation. Using this assay, McDonough, et
al. (1980) showed that heroin-addict lymphocytes exhibited a
naloxone-reversible depression of E-rosette formation which
suggested that opiate receptors on the lymphocytes were
responsible for the effect observed. Contemporaneous with
these findings, Wybran et al. (1979) showed that morphine
used in vitro also caused depression of E-rosette formation
through interaction with naloxone-reversible stereospecific
opioid receptor sites on the T-cell. Taken together, these
studies confirmed the suspicion that the immunological
effects of opiates could be mediated directly on T-cells
within the immune system.
Several pharmacological studies have since identified opiate-
binding sites on lymphocytes, including sites for naloxone on
purified T-cells (Madden et al., 1987). Others have shown
that morphine compromises the immune status of mice relative
to their ability to reject bacterial infections (Tubaro et
al., 1983). Also, there is considerable literature
documenting the fact that many different branches of the
immune armamentarium are affected by alkaloid and peptide
opioids (reviewed by Donahoe and Falek, 1988). These findings
and the other evidence linking opiate use with
immunomodulatory phenomena as discussed previously provide
strong support for the hypothesis that opiate and other drug
abuse are direct causal factors in opportunistic diseases
like AIDS. However, as with all suspicions of the potential
for opiates to be immunocompromising, this hypothesis, as
applied to AIDS, is a difficult one to prove.
The main questions are how to distinguish immunological
effects of opiates from those attributable to other milieu
factors common in addiction and how to assess
immunocompetency prospectively? The nature of the former 
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issue has been discussed above. The latter question is basic
to all clinical in vitro evidence that immunoresponsiveness
of an individual is depressed cannot be taken as a priori
proof that that individual is immunocompromised. Such proof
can only be obtained de facto, i.e., when it is apparent that
the individual in question is incapable of warding off
opportunistic infections and cancers. therefore, with
addicts, there is an inextricable linkage of one research
problem with the other which makes study of the issues
involved very complex, that is, evidence of immunocompromised
conditions cannot be attributed to the opiate per se and
evidence that opiates can depress immune parameters that are
measurable in in vitro assays cannot be taken as unequivocal
proof of immunocompromised immune status.
Because of these circumstances, research strategies to assess
the immunological impact of opiates and other drugs of abuse
must be based on development of strong circumstantial
evidence. In several previous reviews (Donahoe, 1988;
Donahoe and Falek, 1988), we have presented the
conceptualization that the immunocompromising potential of
opiates and other addicting drugs of abuse is best estimated
by thoroughly analyzing the interconnections between the
neuroendocrine and immunological systems while using the
drugs of interest as pharmacological probes. In essence, this
implies that understanding the way drugs affects immunity
requires knowledge of the direct effects of such drugs on the
cells of the immune system, their indirect effects which
occur through induction of neuroendocrine products with
immunoregulatory properties and, perhaps also, modulation of
peripheral synapses between neurons and immune cells, as well
as the combination of all of these potential types of
interactions.
Our current in vitro investigations stem from this
conceptualization and have focused on the ability of opiates
and other drugs of abuse to modulate expression of T-cell
surface receptors that are pertinent to the regulation of
immunoresponsiveness. This direction was chosen as the result
of previous studies (Donahoe et al., 1985; Donahoe et al..
1988) that identified receptor modulation as a major, and
probably key means by which drugs of abuse influence immune
function. In this context, modulation of immunity by drugs of
abuse is the consequence of altered expression of surface
receptors on cells of the immune system regardless of whether
the effect is mediated directly by the drug of interest or
indirectly through alteration in neuroendocrine secretions.
For this reason, we are trying to understand how drugs of
abuse and the neuroendocrine changes they induce affect
expression of several different regulatory molecules on T-
cells which we know from other studies (Donahoe et al., 1985;
Donahoe et al., 1986; Donahoe and Falek, 1988) to be affected
by drug exposure in vivo and in vitro. 
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Principally, we have been analyzing drug effects on CD2, CD4
and CDS antigenic markers on T-lymphocytes. We also plan to
include the T-cell receptor/CD3 complex and class I and II
histocompatibility markers as well as the other molecules
pertinent to T-cell function. By understanding how opiates
and other drugs of abuse influence both independent and
interdependent expressions of these T-cell antigenic markers,
we should be in a position to better delineate the
immunoresponsive effects of these drugs and thereby estimate
their ability to compromise immune function as well as assess
the means by which such compromise immune comes about. Since
the CD4 marker is the viroreceptor for the AIDS virus, HIV1,
this approach also bears special relevance to determining how
drugs of abuse that modulate this molecule can influence
infections with this virus. 
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Site-Directed Affinity Ligands as
Tools to Study the Phenomenology
and Mechanisms of Morphine-
Induced Upregulation of Opioid
Receptors
Richard B. Rothman, Joseph B. Long, Victor Bykov, Kenner
C. Rice and John W. Holaday
Selective site-directed irreversible ligands have proven useful for the
in viva and in vitro study of opioid receptor subtypes (Portoghese et
al. 1979; Goldstein, and James, 1984; Simonds et al. 1985; Rothman et
al. 1988; Holaday et al. 1986) several examples of which are described
by the other participants of this symposium. In our laboratories, we
have attempted to determine the specific targets of various site-
directed irreversible ligands. This approach has led to the further
delineation of opioid receptor subtypes, which in turn has permitted the
selective assay of these various subtypes of opioid receptors. Although
Table 1
Effect of Site-Directed Irreversible Ligands on
Opioid Receptor Subtypes
Agent
BIT1 D D N N N
FNA2 N A N PD N
UPHIT3 N N N N D
FIT1 N A D N N
(+)-TSF4 N A D N N
Tabulated are the effects of the irreversible ligands on opioid receptor
subtypes. “D” means the membranes can be depleted of a binding site,
“A” means the binding site is altered, “N” means no effect, and “PD”
means partially depleted. (+)-TSF refers to (+)-trans-3-methylfentanyl
isothiocyanate 1(Rothman et al. 1984).2(Rothman et al. 1988).3(De
Costa et al. 1989). 4(Kim et al. 1988).
a thorough review of the model of the opioid receptors presented in
Table 1 is beyond the scope of this paper, in vitro (Rothman et
al. 1985b; Rothman et al. 1985a; Demoliou-Mason, and Barnard, 1986),
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and in vivo evidence (Vaught et al. 1982; Holaday et al. 1986; Heyman
et al. 1989; Sheehan et al. 1986), collectively indicates the existence of
an opioid receptor complex composed of interacting µcx, and
binding sites (the term “cx”means “in the complex”), as well as µcx,
and sites not associated with the receptor complex (the term ncx
means “not in the complex).
As illustrated in Table 1, the judicious use of site-directed irreversible
ligands, together with appropriate [3H]ligands, permits selective assay
conditions. For example, since [3H][D-ala2,D-leu5]enkephalin labels
both the and binding sites, pretreatment of membranes with
FIT permits selective assay of the site, while pretreatment of
membranes with BIT permits selective assay of the  site using this
radioligand (Rothman et al. 1984). Using this approach, we
demonstrated that chronic morphine upregulated the binding site
(Rothman et al. 1986a). In this paper we review and summarize our
studies of the phenomenology and mechanisms of morphine-induced
upregulation of opioid receptors.
METHODS
Drug treatments and i.c.v. injections of ß-funaltrexamine are described
in detail elsewhere (Danks et al. 1988; Rothman et al. 1988). Frozen
membranes pretreated with BIT or FIT were prepared from whole rat
brain (minus cerebellum) as previously described (Danks et al. 1988).
Briefly, lysed-P2 membranes were divided into two aliquots. The first
(“+Na-membranes”) were resuspended with 50 mM TRIS-HCL, 0.4 M
NaCI, pH 7.4, incubated for 60 min at 25° C, and subsequently
washed three times by centrifugation. During this procedure, the
second pellet was kept on ice (“-Na-membranes”). The two pellets
were then pretreated with either 1 µM BIT or 1 µM FIT as previously
described (Rothman et al. 1984) and kept frozen at -70° C until
assayed. [3H][D-ala2,D-leu5]enkephalin assays proceeded for 4 to 6 hr
at 25° C in 10 mM TRIS-HCL, containing 100 mM choline chloride, 3
mM MnCl2, 1 mM 2-mercaptoethanol, and a protease inhibitor cocktail.
Nonspecific binding was determined using 20 uM levallorphan.
[3H][D-ala2,D-leu5]enkephalin binding surfaces were generated by
displacing two concentrations of [3H]ligand by concentrations of [D-
ala2,D-leu5]enkephalin. The binding surfaces were fit to a one site
binding model using MLAB (Knott, and Reece, 1972) for the best-fit
estimates of the Kd and Bmax. The method of binding surface analysis
is described in greater detail elsewhere (Rothman, 1986b; Rothman et
al. 1988). In the figures, an asterisk (*) indicates significantly different
from control (t-test, p<0.01).
RESULTS
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using -Na-membranes. The binding sites upregulated by chronic
morphine were apparently labile to preincubation in 0.4 M NaCI.
Chronic naltrexone increased the Kd of the binding site (Figure
3), using both -Na and +Na membranes. In contrast, chronic morphine
significantly increased the Kd of both binding sites using both -Na-
and +Na-membranes.
Figure 3
D(cx)-Na D(cx)+Na D(ncx)-Na
MEMBRANE TYPE
D(ncx)+Na
Effect of Chronic Drugs on the
Kd of Binding Sites (±SD, n=3)
To determine if the morphine-induced upregulation of the binding
site is linked to the development of tolerance and dependence, rats
were administered (i.c.v.) 20 nmol of the irreversible u-antagonist ß-
FNA 60 min prior to pelleting. As reported in Figure 4, although ß-FNA
did not effect the Bmax of the binding site, it did prevent the
upregulation.
DISCUSSION
Although current dogma holds that chronic morphine does not alter
opioid receptors (Robson et al. 1983), the data reviewed in this paper
demonstrate that both chronic morphine and chronic naltrexone
upregulate opioid receptors. Since chronic morphine increases the
Bmax of the site, and not the binding site, it would be difficult
to detect the approximately 20% increase in the total number of
binding sites. However, our use of site-directed irreversible ligands
permitted us to detect the change occurring in one site using a ligand
which labeled two binding sites.
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In the first series of experiments, the effects of the Na-preincubation on
and binding sites were determined. As shown in Figure 1,
Na-preincubation decreased the Kd of the binding site, and
increased the Kd of the binding site. Na-preincubation had no
significant effect on the Bmax values-data not shown . In subsequent
Figure 1
D(cx)-Na D(cx)+Na D(ncx)-Na
MEMBRANE TYPE
D(ncx)+Na
Effect of Na-prelncubation on Kd values (mean±SE (n=6)}..
Figure 2
D(cx)-Na D(cx)+Na D(ncx)-Na
MEMBRANE TYPE
D(ncx)+Na
Effect of Chronic Drugs on the Bmax
of Binding Sites (±SD, n=3)
experiments, the effect of chronic morphine and chronic naltrexone on
the and binding sites were determined using -Na- and +Na-
membranes, and compared as a percentage of the control values.
As reported in Figure 2, chronic naltrexone increased the Bmax of the
and the binding sites, using both -Na and +Na-membranes.
Chronic morphine increased only the Bmax of the binding site
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Figure 4
PBO/SAL PBO/FNA MOR/SAL
GROUP
MOR/FNA
Effect of ß-FNA on morphine induced
upregulation of Binding Sites (±SD, n=4)
chronic naltrexone did not. Similarly, chronic naltrexone increased the
Bmax of the binding site whereas chronic morphine did not.
Moreover, although the mechanism(s) by which the preincubation in
Table 2
Effects of Chronic Morphine and Chronic
Naltrexone on Opioid Receptor Subtypes
K d B m a x
Chronic
Morphine
Chronic
Naltrexone
Summary of the effect of chronic morphine and chronic naltrexone on
the binding parameters of opioid receptor subtypes. increase in
value; decrease in value; no change in value).
If both drugs upregulated opioid receptors via the same mechanisms,
then we should have observed identical changes in the binding
parameters of the binding sites. Instead, the pattern of alterations in
binding parameters differed (Table 2). For example, chronic morphine
increased the Kd of the binding site whereas 0.4 M NaCl alters
196
binding parameters is not known, the fact that the sites
upregulated by chronic morphine are labile to this procedure, and
those upregulated by chronic naltrexone are not, supports the
hypothesis that chronic morphine and chronic naltrexone upregulate
opioid binding sites by different mechanism(s).
Although the studies described above established that chronic
administration of morphine upregulates the opiate receptor complex,
they do not directly address the hypothesis that the observed
upregulation is a relevant in vitro marker of the development of
tolerance and dependence. Although the acute administration of
morphine has no effect on the binding site (Danks et al. 1988), it
remained a possibility that chronic morphine would upregulate the
opiate receptor complex even if tolerance and dependence were not
to develop. Such a finding would suggest that the observed
upregulation is not related to the phenomena of tolerance and
dependence.
To test this hypothesis, rats were administered ß-FNA, prior to and
during morphine administration, a drug we observed to attenuate the
development of tolerance and dependence. If the observed
upregulation is linked to the development of tolerance and
dependence, the predicted result would be an attenuation of the
upregulation. The observation (Figure 4) that ß-FNA administration
blocked the upregulation supports the hypothesis that morphine-
induced upregulation of the opioid receptor complex is a relevant
biochemical marker of tolerance and dependence.
Although it is tempting to discard these observations on the basis of
now classic studies conducted in the adrenergic systems (Creese, and
Sibley, 1981) a more fruitful approach is to hypothesize that the
mechanism(s) responsible for the development of tolerance and
dependence to morphine in the CNS are more complex than
previously thought on the basis of investigations carried out in simpler
model systems (Sharma et al. 1975; Chavkin, and Goldstein, 1984).
Models of tolerance and dependence must explain three phenomena
which are generally accepted to be inseparable consequences of
chronic morphine: 1) agonist subsensitivity (tolerance), 2)
dependence, and 3) antagonist supersensitivity (as the degree of
tolerance increases, less naloxone is required to produce withdrawal
(Way et al. 1969; Wei et al. 1973)).
Based in part on our results, we postulated an anti-opiate model of
tolerance and dependence (Rothman et al. 1986a; Danks el al. 1988;
Simonds, 1988), which hypothesizes morphine causes release of
endogenous anti-opiate peptides, which are largely responsible for the
development of tolerance and dependence. Recent data that the
chronic administration of morphine downregulates the MIF receptor
(an anti-opiate receptor) (Zadina et al. 1989) suggests that this anti-
opiate might play a major role in morphine tolerance and dependence.
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Because of the space limitations of this paper, we refer the reader to
(Rothman et al. 1989) for more complete description of this model.
Although speculative, this model provides for many testable
hypotheses. It is hoped that morphine-induced upregulation of the
opiate receptor complex will prove to be a useful in vitro marker with
which to examine the anti-opiate hypothesis of morphine tolerance
and dependence.
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Mu Antagonist and Kappa Agonist
Properties of b-Funaltrexamine
(b-FNA): Long Lasting Spinal
Antinociception
Qi Jiang, Julius S. Heyman and Frank Porreca
The multiplicity of opioid receptors has led to the development of novel and
irreversible probes to facilitate the study of the effects mediated by individual
receptor subtypes. One such compound ß-funaltrexamine (ß-FNA)(Portoghese et
al,. 1980). Using the electrically stimulated guinea pig ileum longitudinal muscle
preparation and-the mouse vas deferens as bioassays in vitro, ß-FNA has been
characterized as a reversible K agonist and an irreversible µ antagonist (Takemori et
al., 1981; Ward et al., 1982b,c). Antinociceptive studies in the mouse in vivo (acetic
acid-induced writhing test and tail flick test) and studies of gastrointestinal
propulsion as pharmacologic endpoints are consistent with the conclusion that ß-
FNA acts as a reversible K agonist and as an irreversible µ antagonist if the data are
interpreted in light of findings in vitro (Ward and Takemori 1983a,b).
A growing body of evidence suggests, however, that some opioids classified as K
preferring may act as µ antagonists in systems where they exert no agonist actions
when given alone. For example, K agonists such as ethylketocyclazocine and MR2034
have been found to be potent antagonists of [D-Ala2, NMePhe4, Gly-ol]enkephalin
(DAMGO) and [D-Ala2, D-Leu5]enkephalin (DADLE) in the field-stimulated rat vas
deferens (Gillan et al., 1981). Additionally, the K agonists U50,488H, tifluadom.
ethylketocyclazocine and MR2034 were found to consistently antagonize the increase
in striatal dopamine metabolism and respiratory depression produced by morphine
(Wood 1984). In recent studies using µ opioid inhibition of rat urinary bladder
motility, Sheldon et al. (1987,1989) found that K agonists such as U50,488H.
ethylketocyclazocine and tifluadom, as well as dynorphin A-(1-17) antagonized the
effects of some µ agonists. such as morphine. Additionally, the antagonism of
morphine by dynorphin A-(1-17), but not the direct agonist effect of morphine, was
blocked by the K antagonist, nor-binaltorphimine (nor-BNI)(Takemori et al., 1988).
suggesting that dynorphin A-(1-17) modulated morphine effects through a K receptor
(Sheldon et al., 1989).
In the pharmacological characterization of ß-FNA in vivo Ward and colleagues allude
to the fact that the agonist actions of ß-FNA in the mouse writhing test are present
up to 48 hr after subcutaneous (s.c.) administration of the compound (Ward et al.,
1982a; Ward and Takemori 1983a,b); this time course parallels closely, that of ß-
FNA to antagonize the antinociceptive effects of morphine, a µ agonist. in the tail
flick test (Ward et al., 1982a). Additionally. it is often difficult to detect actions of
K agonists following direct administration into the brain or spinal cord, particularly
in tests utilizing heat as the nociceptive stimulus (Porreca et al., 1984). Thus, it
seemed possible that the µ antagonist properties of ß-FNA might be the result of its
long-lasting agonist actions at the K receptor, rather than by direct interaction at the
µ site. The present study was designed to test this possibility using the mouse acetic
acid-induced writhing test, a reliable indicator of central K agonist actions (Porreca
et al., 1987).
199
METHODS
Male, ICR mice (20-30 g. Harlan) were used for all experiments. Animals were kept
in groups of 5 in temperature controlled room with a 12 hr light-dark cycle (lights
on 7:00 A.M. to 7:00 P.M.). Food and water were available ad libitum until the time
of the experiment. I.th. injections were made according to the modified method of
Hylden and Wilcox (1980). Injections into the subarachnoid space between L5 and
L6 were made to unanesthetized mice using a Hamilton microliter syringe fitted with
a 30-gauge needle. All i.th. injections were made in a volume of 5 µl.
Acetic acid writhing test
The method used was as previously described (Porreca et al., 1987). Each mouse
received i.th. administration of agonist, antagonist, or saline at various times prior to
the intraperitoneal administration (i.p. ) of acetic acid (0.6%. 10 ml/kg), and was then
placed into an individual observation chamber. After 5 min, the mouse was observed
for a further 5 min, and the number of writhes displayed by each mouse was counted.
Percent antinociception was determined according to the following formula:
% antinociception = 100 x (mean number of writhes in control group - number of
writhes for each test mouse)/(mean number of writhes in control group), where the
control group was defined as all animals treated with i.th. saline.
Tail flick test
The thermal nociceptive stimulus was 55°C warm water with the latency to tail flick
or withdrawal taken as the endpoint. After the determination of control latencies.
the mice received graded doses of id. agonist, or antagonist at various times. ß-
FNA was given i.th. as a single injection and testing took place 10 min and 1, 2, 4,
24, 48 and 72 hr later. In some antagonist studies, ß -FNA was given as a single
pretreatment dose at various times up to 48 hr prior to testing. Nor-BNI was always
given 10 min prior to the agonist, or in the case of pretreatment with ß -FNA. at 10
min prior to testing. A cutoff time of 15 sec was employed; if the mouse failed to
demonstrate a tail-flick, the tail was removed from the water and that animal was
assigned a maximum score. Mice not responding within 5 sec in the initial control
trial were eliminated from the experiment. Antinociception at each time point was
calculated according to the following formula % antinociception = 100 x (test latency
- control latency)/(15 - control latency).
RESULTS
Both ß-FNA and U50,488H produced dose-related antinociception when tested 10
min after i.th. administration in the writhing test (Figure 1a). While ß -FNA
produced a long-lasting antinociception in this test (Figure 1b,c,d), U50,488H failed
to produce significant antinociception after 1, 2. and 4 hr (Fig. 1b,c,d). The
antinociceptive effect of ß-FNA was dose- and time-related up to 48 hr after a
single i.th. administration. Nor-BNI (0.37 nmol, i.th.) produced no agonist actions in
either analgesic test, but administration 10 min prior to testing in mice pretreated
with ß-FNA (at -10 min or -4 hr prior to testing) resulted in a rightward
displacement of the i.th. ß-FNA dose-response curves in the writhing test; the ß-
FNA lines were shifted 62 and 34 fold when the agonist was given 10 min or 4 hr
prior to testing (Table I).
I.th. ß-FNA failed to produce agonist effects in the tail-flick test, while morphine
was active in both analgesic tests. For this reason, the antagonist profile of ß -FNA
could only be evaluated in the tail-flick test. In addition to its long-lasting agonist
effects in the writhing test, i.th. pretreatment with ß-FNA (18 nmol at -12 hr) also
produced a long-lasting antagonism of the analgesic effects of i.th. morphine in the
tail flick test the ß-FNA pretreatment resulted in a 3-fold rightward displacement
of the morphine dose-response line. Pretreatment with nor-BNI (-10 min. 0.37
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nmol) did not antagonize the antinociceptive effects of morphine in the tail-flick test
and additionally, did not block the antagonism of morphine by ß-FNA in this test.
Further, i.th. nor-BNI (0.37 nmol at -10 min) did not antagonize the antinociceptive
effects of i.th. morphine in the writhing test. When tested as an antagonist against
i.th. morphine antinociception. the time course of id. ß-FNA antagonist actions in
the tail-flick test showed an inverse relationship to that for i.th. ß-FNA agonist
effects in the writhing test.
TABLE 1
Effects of i.th. ß-FNA in the mouse acetic acid writhing test. ß-FNA was given 10
min or 4 hr prior to testing in the absence and presence of i.th. nor-BNI (0.37 nmol);
the K antagonist was always given 10 min prior to testing. Ten mice were used in
each test group.
Dose ß-FNA control
(nmol) (± S.E.)
nor-BNI
(± S.E.)
control
(± S.E.)
nor-BNI
(± S.E.)
0.0019 25.8 ± 6.8
0.019 42.5 ± 6.8 9.8 ± 7.3 21.2 ± 4.6
0.19 77.2 ± 12.2 39.5 ± 8.1 51.6 ± 9.4 20.0 ± 12.7
1.88 94.3 ± 3.9 54.6 ± 9.7 71.7 ± 10.7 50.0 ± 14.9
18.8 94.4 ± 5.6 63.2 ± 11.8
FIGURE 1
Antinociceptive effects of i.th. ß-FNA or U50,488H in the mouse acetic acid
writhing test when given 10 min (a) or 1, 2 or 4 hr (b, c, d, respectively) before
testing.
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DISCUSSION
Following the characterization in vitro of ß-FNA as a reversible K agonist and an
irreversible µ antagonist (Ward et al., 1982b,c). many studies have used this
compound as a tool with which to characterize the receptor involvement of opioids
in the production of effects in vivo such as antinociception (e.g., Hayes et al., 1986;
Zimmerman et al., 1987). respiratory function (Ward and Takemori 1983c; Hayes et
al., 1985a) and other actions such gastrointestinal propulsion (Ward and Takemori
1983b; Hayes et al., 1985a; Heyman et al., 1987) and development of physical
dependence (Gmerek and Woods 1985; Aceto et al., 1986). Additionally, this
compound has also been extremely useful in studies in vitro, in classifying actions of
selective agonists in bioassays such as the mouse vas deferens and guinea-pig ileum
(e.g., Ward et al., 1982b,c; Gintzler and Hyde 1984; Smith 1986; Hayes et al., 1985b).
From these diverse studies, it is clear that ß-FNA has played a significant role in the
development of current understanding of opioid actions in vitro and in vivo.
Analysis of the mechanism of ß-FNA actions, however, has been somewhat
controversial. Radioligand binding studies in mouse brain, have suggested that ß-
MA may bind in a reversible (preferring K sites over µ or and an irreversible
(preferring µ sites over sites)(Ward et al., 1985) fashion. The irreversible nature of
ß -FNA binding at the µ site was confirmed using rat brain (Tam and Liu-Chen 1986;
Liu-Chen and Phillips 1987). and has been suggested to include both the µ1, and the
µ2 binding sites (Recht and Pasternak 1987). In the course of studies designed to
employ ß-FNA as a long-lasting µ antagonist at the spinal level, we observed that
this compound produced long-lasting antinociception in the writhing test after i.th.
administration to mice. Additionally, the time-course of the agonist activity of i.th.
ß-FNA in the mouse writhing test paralleled closely its ability to antagonize morphine
in the tail flick test. Coupled with other observations that K agonists could, under
some circumstances, act as µ antagonists (e.g., Wood 1984; Holaday et al., 1985;
Tortella and Holaday 1987; Sheldon et al., 1987) and with the fact that the analgesic
effects of centrally-given K agonists can be difficult to detect in many tests
(especially those emphasizing heat)(Porreca et al., 1987). it seemed possible that the
long-lasting p-antagonist properties of this compound were related to its K agonist
actions. This concept was particularly intriguing as the receptor binding
characteristics of ß-FNA had been determined using brain, rather than spinal cord,
tissues. The present study has thus systematically examined and extended the
pharmacology of this important opioid tool in vivo using two analgesic tests and
administration of selective K agonists and antagonists at spinal sites in the mouse.
We have focused on the actions of ß-FNA as an agonist or antagonist at the spinal
level. Unlike administration of U50,488H, a highly selective K opioid agonist (Von
Voigtlander et al., 1983), ß-FNA produced long lasting antinociceptive effects after
i.th. administration in the writhing test. The antinociceptive actions of i.th. ß-FNA
were shown to be K mediated in that they were blocked by the K antagonist, nor-
BNI (Takemori et al., 1988) whether ß-FNA was given either either 10 min or 4 hr
prior to testing. ß-FNA was not effective in-the tail-flick test following i.th.
administration, the nature of its antagonist actions could also be investigated.
Pretreatment with ß-FNA but not nor-BNI, produced a rightward shift of the i.th.
morphine dose-response line. I.th. nor-BNI did not, however, prevent the
antagonism of morphine produced by I.th. ß-FNA indicating that the antagonist
actions of this compound were not related to its K agonist properties, and thus were
probably mediated through actions at the µ receptor. On the basis of the present
experiment, we conclude that i.th. ß-FNA produces its long-lasting agonist actions
through K receptors, and that its antagonist properties are most likely the result of
activity at µ receptors. The nature of its long lasting interaction at these receptors
appears to be similar, however, in that the agonist and antagonist time-course are
similar.
202
In conclusion, this study has demonstrated long-lasting agonist actions of i.th. ß-
FNA in an analgesic test emphasizing chemical stimulation. Additionally, at the
spinal level, the antagonist profile of this compound appears to be mediated through
different receptors than its agonist actions. These experiments suggest a complex
mechanism of action for this compound and indicate that the possibility that ß-FNA
antagonizes µ agonists by its own agonist action at K receptors cannot be supported.
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Urine Screening: What Does it
Mean?
D. E. McMillan
Surveys conducted by the National Institute on Drug Abuse suggest that
men and women of working age frequently use psychoactive drugs (NIDA,
1986) and it seems likely that a considerable portion of this drug usage
occurs on the job. One recent survey found that one in ten of all job
applicants and employees tested positive for drugs (U.S. Department of
Labor, 1989). Estimates of the dollar cost of workplace drug abuse suggest
that the cost of drug abuse in the workplace may be as much as $700 billion
(Walsh and Gust, 1986). Although data on both prevalence and costs are
imprecise,
there is general agreement that drug usage at the workplace is a serious
problem, not only in terms of dollar costs, but also in work-related
accidents, job dismissal, illness and mortality.
In response to the problem, the Reagan administration initiated a broad
based program with an ultimate goal of a "drug-free workplace" with the
federal workforce serving as a model for American business. The
President's Executive Order directed federal agency heads to develop
policies on drug abuse, including employee assistance programs (EAPs),
training programs and a drug testing program. Since that time a large
number of private companies in the United States have initiated programs
designed to eliminate drug use in the workplace, the centerpiece of which
is frequently a drug testing program. These programs have been widely
publicized and exceedingly controversial for legal, moral and scientific
reasons. To set the stage for later papers, I would like to review briefly
some of these issues about which you will be hearing in greater detail later
in the symposium.
A.  ANALYTICAL AND PHARMACOLOGICAL CONSIDERATIONS
The consequences of screening the urine of a worker or job applicant for
illegal drugs include refusal to hire, dismissal from the workforce and other
forms of discipline, loss of the worker's reputation and other punishments,
as well as more positive outcomes, such as referral to treatment. Because
the consequences of a positive screen are so important, the chemical
analysis of the urine must be absolutely accurate. 
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An adequate drug test usually consists of two parts: an initial screening test
and a confirmation test when the initial screen is positive. A number of
initial screens are available, including the EMIT, ADX and TDX. These
screens have the advantages that they are highly automated, reasonably
specific and relatively inexpensive. Thus, they permit the rapid and
inexpensive screening of large numbers of urine specimens. Unfortunately,
reasonably specific is not adequate when the consequences of a positive
drug test are so important. Therefore, these initial screening tests are used
only to enable the testing laboratory to eliminate drug negative specimens
from further consideration, while positive specimens must be validated by a
confirmation test.
The "gold standard" of confirmation tests is gas chromatography-mass
spectrometry (GC/MS), a procedure with a high degree of analytical
accuracy. Although the GC/MS test is more difficult and expensive than
initial screens, confirmation of a positive screen with this test is an
extremely reliable index of drug exposure. It is most unfortunate that with
the widespread proliferation of drug testing programs many companies do
not perform any confirmation testing (U.S. General Accounting Office,
1988; Thomas-Holladay et al., 1989). Failure on the part of a company to
perform a confirmation test probably results from ignorance on the part of
management as to the importance of a confirmation test and a desire to do
drug testing at the lowest possible cost. Obviously, this can be a false
economy, since a positive drug test consisting only of an initial screen is
subject to legal challenge.
Although an initial screen, followed by a GC/MS confirmation, under
conditions of a carefully documented chain of custody appears to be quite
straightforward, in practice this is not necessarily so. Under the Mandatory
Guidelines for Federal Workplace Drug Testing Programs cutoff points
have been established for both the initial screen and the GC/MS
confirmation (Federal Register, 1988). The need for cutoff points arises
because our increasing analytical capacity has resulted in our ability to
measure ever smaller amounts of drug or drug metabolites in urine.
Theoretically, the ultimate level of analytical precision might be reached
when a single molecule of drug or drug metabolite can be detected in body
fluids. Obviously, at this extreme the accidental inhalation of a few
molecules of marijuana smoke would be detected. Although we have not
yet reached this level of precision and sensitivity, our ability to measure
drug exposure has probably outstripped our ability to interpret the results.
Cutoff points have been recommended in the Mandatory Guidelines
(Federal Register, 1988) which are designed to eliminate problems such as
passive inhalation of marijuana smoke. Unfortunately, private companies
are not required to follow these federal guidelines and many do not. For
example, in a six state survey of union workplaces in the midsouth, only
24% reported that their company used the guidelines (Thomas-Holladay et
al., 1989). In our experience in the Occupational Substance Abuse
Prevention Program at the University of Arkansas for Medical Sciences we
have found that companies often have rational reasons for adopting cutoff
points other than those recommended by the federal guidelines. For
example, a company may institute a policy that no contract worker can go
on a worksite without a drug-free" urine. When a worker's urine is positive
in the initial screen and negative on confirmation, the company may have 
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to pay the contractor's workforce during the period between the screen and
the availability of the confirmation test Thus, the company might have
economic reasons for wanting to have most positive screens confirmed in
the GC/MS test. Toward this end the company might set a high cutoff
point in the initial screen and a low cutoff point in the GC/MS
confirmation.
Some companies can have difficulty in understanding the results reported
to them. According to the Mandatory Guidelines, results can be reported
as negative or positive, but the Medical Officer may request a quantitation
of the test results (Federal Register, 1988). In our program we nave found
that most Medical Officers do want a quantitative report; however, with
small companies, the Medical Officer is frequently a part-time general
practitioner, or perhaps an occupational nurse, with little or no experience
in interpreting drug testing data. For example, the Mandatory Guidelines
recommend 100 ng/ml as a cutoff point for the initial screen and 15 ng/ml
for the GC/MS confirmation for marijuana. The initial screen shows
various degrees of cross reactivity to a variety of 9-tetrahydrocannabinol
(THC) metabolites. The method has a sensitivity down to 10 ng/ml for
combined cannabinoids to which cross reactivity occurs. The GC/MS is for
a specific 9-THC metabolite, 9-THC-9-carboxylic acid, which can be
measured reliably at levels of 2 ng/ml. Thus, both initial and confirmatory
assays are sensitive well below the recommended cutoff points. How a
company interprets and uses this quantitative information is frequently
beyond the control of the testing laboratory.
Perhaps the greatest source of confusion in drug testing programs is the
meaning of a positive report. The detection of a drug in the urine of a
worker does not imply that the worker was impaired at the time of testing,
or even that the worker ever was impaired. A positive result is indicative
only of exposure, not pharmacological effect This should not be surprising
since the recommended cutoff points for initial screens for marijuana,
cocaine and opiates are based on metabolites rather than the parent drug
and the GC/MS analysis for marijuana and cocaine are also based on
metabolites.  Many of these metabolites are not psychoactive.
Furthermore, these metabolites are frequently detectable long after the
psychoactive effects of the drug have terminated.
Closely related to the issue of screening for detection of exposure to a drug
versus impairment of performance is the question of whether or not a
confirmed positive drug screen means that the worker has a drug
"problem". Some companies feel that one confirmed positive drug screen is
adequate evidence for action, while others may require repeated positive
tests, or evidence of impaired performance.
A final issue that should be mentioned is that drug testing programs are
biased toward the detection of drugs or metabolites that remain in the body
for long time periods. For example, cocaine metabolites are detectable in
the body for only a few days, while metabolites of marijuana can be
detected for a month or more in the urine of chronic users. Thus, a drug
testing program is more likely to detect the weekend marijuana smoker
than the weekend cocaine user. Which of these workers represents the
greatest problems in the workplace is not clear. 
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B. COST EFFECTIVENESS
The basic assumption underlying the screening of the workforce for
exposure to illegal drugs is that the screening program is an effective
deterrant to drug use. According to recent surveys, drug usage (during the
past month) declined in the military by over 80% during the 8-year period
after drug screening was initiated (NIDA, 1988). Whether or not similar
decreases in exposure can be demonstrated in private industry seems less
clear and the degree to which the drop in drug usage by the military has
improved military performance is also unclear.
At this time there is a strong movement toward development of drug
screening programs in American companies. These programs are not
without financial costs. Depending on the particular test and the number
of workers to be tested, drug screens cost in the range of $15 - $30 per
specimen and GC/MS confirmation generally costs from $35 - $100. Thus,
the screening of 100 million workers might cost about $2 billion based on a
10% rate of positive initial screens and average price levels. This figure
represents a very small fraction of some estimates of losses due to
substance abuse; however, estimates of losses due to substance abuse are
based on soft data and there have been very few studies that have
attempted to measure the cost effectiveness of drug testing programs. Do
drug testing programs really reduce employee drug use and does the
reduction of employee drug use lead to decreases in accidents,
absenteeism, utilization of treatment resources and increases in
productivity? It is a fundamental assumption in drug testing programs that
a drug-free workplace will increase productivity and decrease costs, but
there are few data available that compare the savings produced by a testing
program with the costs of the program.
C. LEGAL AND MORAL CONSIDERATIONS
Some individuals have held that mandatory drug testing is a violation of an
individual's civil rights. In general, courts have upheld the employer's right
to screen job applicants for drug use and to screen workers involved in
accidents or other work incidents for evidence of drug usage. The random
screening of selected employees or all employees is less well established.
Certainly everyone agrees that the worker has certain rights and that the
worker's dignity should be protected.
Although the Mandatory Guidelines (Federal Register, 1988) specify that
an employee with a confirmed positive drug test must be referred to an
employee assistance program (EAP), in private industry many companies
make little attempt to meet the federal guidelines (Thomas-Holladay et al.,
1989). Many smaller companies do not even have an EAP to which to refer
workers and frequently punitive actions result from positive drug tests up to
and including job dismissal. In our program we nave been reluctant to
work with companies that do not refer current employees with positive
drug tests to the EAP; however, the policing of private industry is not a
burden appropriate for testing laboratories to assume and for those testing
laboratories that feel squeamish about the use to which their testing results
might be put, it is likely that other testing laboratories with less concerns
about what happens to the worker will be only too ready to perform the
testing.
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These issues are very complex. Certainly the public has a right to expect
that those workers with jobs critical to public safety are not using
performance-impairing drugs that compromise public safety. Similarly, the
company hiring a worker would like to know that that worker does not
have a serious drug problem and the company owes it to its stockholders to
reduce any factor that increases costs and lessens productivity, including
illegal drug use. However, the company also has a responsibility to the
impaired employee to refer him to a treatment facility. Finally, the worker
also has a right to his or her dignity and to freedom from unnecessary
harassment and discipline by management.
For better or for worse, the industrial base of this nation, with the
encouragement of the federal government has embarked on a massive
experiment in drug testing. They are doing so with little education of
either management or the workforce as to the meaning of the data being
provided, inadequate determination of the cost effectiveness of the
approach and with important legal and moral questions as yet unanswered.
It is important that scientists, physicians, lawyers, ethitists, economists and
others concerned with these complex problems work together to find
answers to some of these questions.
The next series of papers will assess the state of knowledge in some of
these areas. Dr. Royer Cook will provide further details about the
prevalence of drug abuse in the workplace. Dr. Dennis Crouch will review
research on drug testing program effects on absenteeism, accidents and
costs. Captain Leo Cangianelli will report on the experience of the military
with their drug testing program. Professor Eleanor Schroeder will update
the current legal status of drug testing. Finally, concluding remarks and a
summary will be made by Dr. John Grabowski.
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The Effects of a Drug Testing
Program in the Navy
Leo A Cangianelli
HISTORICAL OVERVIEW
Two significant incidents early in this decade had a great impact
on the U.S. Navy's resolve in fighting its "War on Drugs":
In November 1980, the Department of Defense (DOD) conducted the
first of four surveys to investigate the prevalence of drugs in
the military and the consequences on work performance and health.
The second incident took place in the spring of 1981, when results
of autopsies on fourteen sailors killed in a crash of an EA-6B
Prowler on the deck of the USS NIMITZ revealed that six of the
flight deck crew had traces of marijuana in their blood system.
Each incident effected a measured response on the part of the
Navy: the first started the development of a well thought out
long range program; the Nimitz crash greatly accelerated this
program.
The First DOD Survey
The results of the survey, titled "The Burt Study,"1 revealed a
shockingly high incidence of drug use 2 in all the services with
marijuana use of epidemic proportions. The highest prevalence was
in the Navy and Marine Corps: 47 percent of E-l to E-5 Navy
personnel (essentially those junior members under 25 years of age)
had used marijuana in the thirty days prior to completing the
survey questionnaire.
The survey also revealed that drug use was not an off-duty
problem -- 26 percent of the junior enlisted reported being under
the influence of drugs while at work, and nearly one-half of these
respondents reported using drugs on 40 or more occasions in the
previous year. To Navy leadership, this latter result was
particularly devastating because of the obvious impact on combat
readiness and national security.
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To verify the survey statistics, the Navy conducted random
urinalysis testing on a similar group of sailors in Norfolk,
Virginia, and San Diego, California, and confirmed the findings of
the DOD report.
"Zero Tolerance" Edict
In response to the survey results, Chief of Naval Operations,
Admiral Thomas B. Hayward, tasked his drug prevention staff with
developing a strong program aimed at "Zero Tolerance" of drug use
and stressed that the Navy's renewed emphasis on pride, profes-
sionalism and readiness, was incompatible with drug use. He
promulgated the "get tough" policy in July 1981 in a message,
NAVOP 097-81, in which he admonished commanding officers and
supervisors that the illegal use of drugs, regardless of the
degree of acceptance in the civilian sector, would not be
condoned.
This policy contrasted with the Navy's previous policy of
depending heavily upon treatment and education programs to deal
with the problem.
The USS NIMITZ Incident
Media treatment surrounding autopsy results of the six flight deck
crew members, the second incident impacting the "War on Drugs",
caused public outrage. Congress demanded that the Navy take a
tougher stance on drug use.
Ironically, at the time of the NIMITZ crash and the adverse
publicity, the Navy was involved in long-range planning to combat
drug use. This plan was not altered but was accelerated: the
planned three-year implementation of the program was speeded up
and was in place in one year.
In December 1981, Admiral Hayward launched his three-pronged
offense against drug use and announced the goal of "Zero
Tolerance": (1) any unauthorized use of illegal drugs, including
marijuana, would be considered a serious breach of discipline;
(2) violators would receive stiff penalties including courts
martial and administrative "bad paper" discharges; and
(3) urinalysis testing aimed at detecting, identifying, and
deterring drug abusers, would be implemented on a wide scale.
The detection and deterrence program and Admiral Hayward's hard-
nosed, get tough policy to stamp out drug use was announced in a
special videotaped message sent fleetwide. The famous expression,
"Not on my watch! Not on my ship! Not in my Navy!" was first
decreed in his video message and became the "battle cry" for the
program.
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NAVY POLICY
The new Navy policy was promulgated in two messages issued on
December 23, and 29, 1981 (NAVOPS 172-81 and 178-81). The program
commenced one month later on February 1, 1981, and remains the
same today with only minor changes. Essentially, the policy
contained in the two directives states:
"The illegal possession, use, and distribution of drugs
and drug paraphernalia are not tolerated in the U.S. Navy
at any time: ashore, afloat, on or off duty, on or off
base ...It is Navy policy to make full use of urinalysis
testing to assist in controlling drug abuse...." Policy
requires that senior personnel be separated after a single
incident of drug use. Junior personnel may be allowed a
second chance if they demonstrate exceptional potential
for continued service.
URINALYSIS TESTING
Implementation of the policy places emphasis on urinalysis testing
of new recruits at the point of entry within 48 hours of their
arrival at "boot camp" and again immediately upon arrival at the
first training school. Processing for separation is mandated for
individuals who produce an initial "positive" for any drug other
than marijuana. Those testing positive for marijuana may be
retained and randomly tested once each month for six months. A
second positive for any drug results in processing of an
individual for separation.
A confirmed positive urinalysis test at entry is considered a
first drug use incident. A second drug use incident is cause for
mandatory processing for separation.
This intensive testing program early in the member's career is
designed to demonstrate a strong commitment by the Navy to
identify and eradicate drug abuse.
Once a sailor reports to his or her first duty station, the member
is subject to the command urinalysis screening program wherein 20
percent of each unit is tested every month. Most of these are
random tests but testing can be conducted incident to a search and
seizure, for probable cause, during medical examinations or to
determine fitness for duty.
In addition to urinalysis testing, commanders use every means
available to identify individuals involved in any way with illegal
drugs. This includes special investigative agencies, on and off
base, to identify traffickers supplying illegal drugs to Navy
personnel; drug detection dog searches to locate and identify drug
"stashes"; health and welfare inspections; and randomly searching
vehicles for contraband. Traffickers are court-martialed and
placed in pretrial confinement.
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Leaders set the example. Any use or possession of illegal drugs
by leaders is considered reprehensible and totally inconsistent
with the exemplary role they play in the Navy. Consequently,
officers and senior petty officers who use or possess drugs are
processed for separation at the first drug incident. Junior
enlisted personnel may be afforded a second chance provided they
totally reject the drug use and show potential for continued
drug-free naval service. Following a first drug use incident,
junior enlisted personnel are disciplined, educated or counselled,
and generally returned to duty following successful
rehabilitation.
Collection and Laboratory Testing
Random samplings and unit "sweeps" are two ways of conducting
urinalysis inspections in the Navy and serve as strong deterrents
to drug use. In the random sampling program, individuals selected
for testing are chosen at random through combinations of social
security numbers, computer number selections, etc. A unit sweep
is the testing of an entire unit or a subunit -- an identifiable
segment or class of a unit -- e.g., a division, barracks, all E-4
and below, all officers, all personnel who have reported for duty
in the last month, etc. The urinalysis program is designed so
that a member's chance of selection, and therefore detection,
remains constant throughout the individual's enlistment.
A sample of at least 60 milliliters of urine is provided under the
direct observation of a designated individual. The observer signs
a ledger certifying that the specimen bottle contains the sample
provided by the member and that it has not been tampered with in
any way. The submitting member signs the ledger and initials the
label on the specimen bottle. The coordinator initials the label
and records the information on a Urine Sample Custody Document
(OPNAV 5350/2). The coordinator prepares the sample for shipment
to the cognizant drug screen laboratory.
The Navy Drug Testing Laboratory system tests over two million
specimens annually. Each sample is tested for seven drug classes
at five locations: Great Lakes, Il., Jacksonville, Fl., Norfolk,
Va., Oakland, Ca., and San Diego, Ca. The drug classes and cutoff
levels are as follows:
DRUG
THC (MARIJUANA)
COCAINE
OPIATES:
MORPHINE
CODEINE
HEROIN (6 MAM)
AMPHETAMINES
PCP
LSD
SCREENING
LEVEL
100 NG/ML
300 NG/ML
300 NGIML
300 NG/ML
300 NG/ML
1000 NG/ML
25 NG/ML
.5 NG/ML
CONFIRMATION
LEVEL
15 NG/ML
150 NG/ML
4000 NG/ML
2000 NG/ML
10 NG/ML
500 NG/ML
25 NG/ML
.4 NG/ML
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When the sample reaches the drug testing laboratory, the specimen
packages are inspected, the specimen bottle is numbered, and a
sample is poured into the testing vials. Samples are screened
using the radioimmunoassay (RIA) method which tests for a class of
drugs; negative samples are eliminated from further testing.
From samples that test positive, two additional aliquots are
poured and forwarded for simultaneous RIA screening and
confirmation testing by the gas chromatography/mass spectrometry
(GC/MS) equipment. The testing data for each positive sample are
summarized, evaluated, reviewed within the lab, and only when all
three tests (two RIA and one GC/MS) prove the sample to be
positive above the cutoff levels are the results reported back to
the submitting command.
To assure consistency across the entire system, the labs function
under a centrally-managed, standardized operating procedure
controlled by the Naval Medical Command. Quarterly inspections
are conducted to enforce this policy and each lab conducts an
intensive internal quality control program which requires that at
least 20 percent of the samples tested in the lab are for quality
assurance.
In addition, a centrally-monitored external quality control
program is administered by the Armed Forces Institute of Pathology
(AFIP) and closely monitored by both line and medical leadership.
External quality control is conducted in two separate and distinct
procedures. The "blind" sample program imposes 48 samples per
week on each laboratory--36 of which are negative and 12 of which
are positives. These samples are provided by the AFIP directly to
certain designated field commands who place their own label with
an AFIP SSN on the bottle and include these samples with their own
collected specimens. The entire package is submitted to the
designated laboratory for testing. Results are monitored by AFIP
and Navy line leadership. In the "open" sample program 24 spiked
samples are provided to each lab for testing. In this case the
lab must correctly identify the drugs and levels for each sample.
Since 1982, when this program was implemented, none of the labs
have reported a "false positive" of 6,000 negative blind samples
submitted annually.
Each year, Navy line leadership conducts a full inspection of each
laboratory with assistance from at least two leading civilian
forensic toxicologists. This inspection has opened Navy labs for
external technical scrutiny by the scientific world and has paved
the way for Navy to become the model program for drug forensic
testing.
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EDUCATION AND TREATMENT PROGRAMS
In addition to a wide variety of command education and prevention
programs, treatment and counselling programs are available
worldwide and are designed to deal with all types of drug use
problems from experimental use to full drug dependency. Four
free-standing and twenty hospital-based residential alcoholism
rehabilitation facilities are among the best in the world annually
treating over 6,000 Navy and Marine Corps personnel. The
intensive, six-week multi-disciplinary therapeutic program
includes counseling, education, and participation in self-help
groups. Over 85 Counseling and Assistance Centers provide
screening, referral, outpatient counseling, and aftercare to Navy
members whose problems do not require the inpatient treatment.
CONCLUSION
A program of this magnitude is not problem free. While there is
close management and oversight of the laboratory process, urine
sample collection procedures are the weakest link.
Over 2,000 Navy commands are responsible for collecting samples
under chain of custody procedures which must be followed
precisely. These procedures are explicitly outlined in Navy
policy directives; a handbook provides guidance for urine
collection teams.
Experience has shown that drug users will go to great lengths to
defeat urinalysis testing including substituting clean urine,
adulteration of the sample with foreign substances, and dilution
with water. Direct observation and close supervision of the
collection process, and attention to detail during the chain of
custody process, have proven the best countermeasures.
The Navy's program is a resounding success. Follow-on DOD surveys
in 1982, 1985, and 1989, have shown that drug prevalence has been
reduced from 33 percent in 1980 to 5.4 percent today.
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The "Zero Tolerance" policy remains the cornerstone of the
program. Sixty four percent of respondents in follow-on surveys
agreed that urinalysis testing has reduced drug use in the
military and 81 percent believed that the program has not hurt
morale. 3
The Navy's urinalysis program remains a national standard for a
sound, valid, and legally-supportable testing plan. Analysis
indicates that the multi-faceted approach of urine testing for
identification and deterrence, appropriate application of
discipline, and referral for treatment and counseling when
relevant, are the essential features of a successful drug
prevention and control program.
FOOTNOTES
1Subsequent DOD studies, titled "The Worldwide Survey of
Alcohol and Nonmedical Drug Use Among Military Personnel," were
conducted in 1982, 1985 and 1988. To compile the statistics for
the 1988 DOD survey, about 19,000 questionnaires were mailed to
selected installations worldwide requesting anonymous responses.
To provide correlations and consider significant predictors of
drug use, a model of any drug use during the previous 12 months
was incorporated into the survey questionnaire. Conclusions are
reached after extensive computer analysis and review by survey
teams.
2"Drug use" is defined as use of marijuana, cocaine, PCP, LSD,
or other hallucinogens, heroin or other opiates, inhalants,
"designer drugs" or other non-medical drugs.
31985 Worldwide Survey of Alcohol and Nonmedical Drug Use
Among Military Personnel, Research Triangle Institute, June 1986,
Page 154.
AUTHOR
Captain Leo A. Cangianelli, U. S. Navy, is the director of the
Navy's Drug and Alcohol Abuse Prevention and Control Division,
Washington, DC.
217
Legal Aspects of Urine Screening
Elinor P. Schroeder
Federal initiatives such as President Reagan's 1986 Executive
Order 12,564, requiring the head of each Executive agency to
establish a drug testing program, and Public Law 100-71, 101 Stat.
468 (1987), governing the scope of Federal Government drug
testing, have been the driving force for employment drug testing
in this country. That fact, plus the availability of constitutional
challenges to government's actions, make it not surprising that
most of the judicial analysis of drug testing programs has involved
the public sector. The outcome of this litigation will, however,
strongly influence developments in the private sector as well.
FEDERAL LAW
Fourth Amendment
On March 21, 1989, the United States Supreme Court upheld the
constitutionality of two different federally mandated employment
drug testing programs. While the Court did not give a blanket
approval to drug testing under any and all circumstances, the
sweeping language of these opinions, allowing testing of workers
without individualized suspicion of drug use, will undoubtedly be
used to justify many programs. In Skinner v. Railway Labor
Executives' Association. 109 S. Ct. 1402 (1989), by a vote of
seven to two, the Court upheld regulations promulgated by the
Federal Railroad Administration requiring railroads to conduct
blood and urine tests of employees involved in serious train
accidents and authorizing railroads to conduct breath and urine
tests after certain rule violations. In National Treasury
Employees Union v. von Raab, 109 S. Ct. 1384 (1989) , by a vote of
five to four, the Court held that the Customs Service did not
violate the Fourth Amendment by requiring a urine test of
applicants for positions directly involving drug interdiction or
enforcement of drug laws and for positions requiring the carrying
of a gun. The Court found the record inadequate to evaluate a
testing requirement for a third category of positions, those
involving the handling of "classified" material, and it remanded
that portion of the case for further findings. 
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In both cases, the Court first cane to the fairly unremarkable
conclusion that urine tests are "searches" within the meaning of
the Fourth Amendment, because they infringe upon long-established,
widely-recognized, and serious expectations of privacy.
Traditional Fourth Amendment analysis requires that the government
have probable cause and obtain a warrant before proceeding with a
search. There are, however, some exceptions to the warrant
requirement, when "special needs, beyond the need for law
enforcement," make obtaining a warrant impracticable, New Jersey
V. T.L.O., 469 U.S. 325, 351 (1985). The court determined that
there was no need for the protection a warrant provides from
arbitrary government action in either Skinner or von Raab because
the tests were standardized and those in charge of the program
had little discretion in selecting individuals to be tested.
Moreover, in Skinner, the fleeting nature of the metabolic evidence
required that tests be performed immediately, without the delay
entailed in seeking a warrant. Noting the possibility that the
results of a post-accident drug test might be turned over to law
enforcement authorities, the Court left "for another day" the
question whether routine use of test results in criminal
proceedings would present a problem. 109 S. Ct. at 1415 n.5.
As to the Fourth Amendment's requirement of probable cause,
although the Court has remarked that probable cause is not an
"irreducible requirement" of a valid search, New Jersey v. T.L.O.,
supra at 340, until Skinner and von Raab. the search of an
individual other than a prison inmate had never been upheld without
some level of individualized suspicion. See New Jersey v. T.L.O.,
supra (search of student's purse by public school principal after
the student was caught smoking in the school bathroom); O'Connor
v. Ortega, 480 U.S. 709 (1987) (search of public employee's office,
desk, and files as part of investigation of specific financial
improprieties); Bell v. Wolfish. 441 U.S. 520 (1979)
(suspicionless body cavity searches of prison inmates).
Actually, Skinner could have been shaped to fit this requirement
of individualized suspicion. The FRA regulations required
mandatory testing of all crew members on a train involved in a
serious accident, even if some were not suspected of having
played a part in the accident. The government presented evidence
of significant problems of alcohol and drug abuse among railroad
workers, including 34 fatalities, 66 injuries, and over $28 million
in property damage during an eight-year period from the errors of
alcohol and drug-impaired employees. That information, combined
with the difficulty of determining individual responsibility in
the chaotic aftermath of a major train accident, could have led
the Court to allow a presumption of reasonable cause to test all
crew members. Instead, the majority in Skinner abandoned entirely
any requirement of individualized suspicion and in its place
imposed a balancing test that measures the employees' privacy
interests against the government's interest in drug testing.
Performing this balancing, the Court termed the privacy interests, 
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those very interests that were significant enough to trigger the
Fourth Amendment in the first place, "minimal," while the
government's interest in "regulating the conduct of railroad
employees to ensure safety", 109 S. ct. at 1414, was "compelling."
The Court also rejected arguments that post-accident testing is
unreasonable because the results of blood and urine tests for
drugs other than alcohol do not reveal current intoxication or
degree of impairment. The Court reasoned that the tests do provide
relevant information that may aid investigation, and, in any event,
another of the government's purposes is to deter drug use in the
first place, and that purpose is furthered by tests that reveal
only past use. Consistent with this rationale, a few days after
Skinner and von Raab, the Court vacated a decision that the
District of Columbia school system could conduct drug tests of
certain employees as part of a regular medical exam only if the
tests were capable of detecting current impairment. Jones v.
McKenzie. 833 F.2d 335 (D.C. Cir. 1987), vacated sub nom. Jenkins
v. Jones. 109 S. Ct. 1633 (1989).
The key to the distorted reasoning in Skinner is its companion
case, von Raab, which could not have been decided as it was under
pre-Skinner Fourth Amendment analysis. There was no evidence of
a drug problem in the Customs Service. In his announcement of
the program to employees, the Commissioner of the Service
described the testing program as setting "an important example in
our country's struggle with this most serious threat to our
national health and security," 109 S. Ct. at 1401; as the dissent
pointed out, this is pure symbolism. Of the first 3,600 employees
tested, there were only 5 positive results. Clearly, there was
no basis for suspicion of any individual or for the kind of group
suspicion that might have been found in Skinner. Having adopted
a new balancing test in Skinner, however, the majority found
several compelling governmental interests in drug testing:
"ensuring that front-line interdiction personnel are physically
fit, and have unimpeachable integrity and judgment," 109 S. Ct.
at 1393, eliminating "the risk that employees who may suffer from
impaired perception and judgment will be promoted to positions
where they may need to employ deadly force," id., "deterring drug
users from seeking such promotions," id. at 1395, and "protecting
truly sensitive information from those who, under compulsion of
circumstances or for other reasons, . . . might compromise [it],"
id. at 1396. It was on this last point, protecting important
information, that the remand occurred. The Customs Service had
included in its testing program positions such as "Accountant,"
"Animal Caretaker," Baggage Clerk," "Attorney," and "Messenger."
It was not clear from the record that all occupants of these
positions would actually have access to classified information.
Attorney General Thornburgh has declared that Skinner and von
Raab give a "green light" to drug testing, in both the public and
private sectors, and in large part, he may be right. Among the
questions that remain to be answered in the wake of these
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decisions is what other groups of workers may be subjected to
suspicionless drug testing. Although there have been arguments
that safety is the only justification for testing, the Court relied
on both public safety and integrity concerns. The safety rationale
certainly would include all law enforcement and most other public
safety officers, as well as the operators and maintainers of means
of mass transportation. In addition, both majority opinions and
Justice Scalia's dissent in von Raab mentioned favorably a Court
of Appeals decision, Rushton v. Nebraska Public Power District.
844 F.2d 562 (8th Cir. 1988), which upheld testing of workers at
a nuclear power plant. As Justice Scalia pointed out in his
dissent in von Raab, the safety rationale would also include the
operators of dangerous equipment, construction workers, and school
crossing guards, as well as automobile drivers. Cf. National
Gypsum Co. v. Kansas Employment Security Board of Review. 244
Kan. 678, 685, 772 P.2d 786 (1989) ("The threat posed by employee
drug use ... is particularly dangerous when employees are engaged
in the operation of heavy equipment, work on wallboard production
lines, and use extremely hazardous materials. . . .")
The Court's second rationale for drug testing was the need to
insure that employees could not be bribed or blackmailed into
revealing sensitive information or compromising the mission of
their agency because of a drug habit. This integrity/honesty
factor certainly justifies testing members of the military and
employees of law enforcement and intelligence agencies. The
Court's remand on the question of access to classified information
does indicate that there must be some people working in this
country who may not be subjected to suspicionless drug testing,
but a powerful argument can be advanced that the Court's reasoning
might include others with access to important, although perhaps not
"classified," information. For instance, employees with knowledge
unconstitutional); NTEU v. Lyng, 706 F. Supp. 934 (D.D.C. 1988)
(computer specialists and motor vehicle operators in Department
See, e.g., Bangert v. Hodel, 705 F. Supp. 643 (D.D.C. 1989) (random
testing of Department of Interior workers in "sensitive" positions
Another major unanswered question from Skinner and von Raab is the
constitutionality of random testing. A few lower courts have
allowed random testing in what they termed "pervasively regulated"
industries, on the ground that workers in those fields have a
reduced expectation of privacy. See, e.g.. Shoemaker v. Handel.
795 F.2d 1136 (3d Cir.), cert. denied. 479 U.S. 986 (1986)
(jockeys) ; Rushton v. Nebraska Public Power District supra
(nuclear power plant workers); Policeman's Benevolent Association
v. Township of Washington. 850 F.2d 133 (3d Cir. 1988), cert.
denied. 109 S. Ct. 1637 (1989) (police officers); McDonell v.
Hunter. 809 F.2d 1302 (8th Cir. 1987) (prison employees). On the
other hand, district courts have been routinely striking down the
random testing components of Executive agency testing programs.
of trade secrets, or employees of law firms, accounting firms, and
publicly-traded corporations with access to "insider" information,
might be equally subject to blackmail or bribery.
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of Agriculture); Harmon v. Meese, 690 F. Supp. 65 (D.D.C. 1988)
(Department of Justice employees). If "random" means only
"suspicionless", random testing entails a great potential for
supervisory abuse and harassment. A truly random system, however,
such as one in which individuals to be tested are selected by
lottery, would eliminate the supervisor's discretion and thus
the possibility of discriminatory selection. One of the reasons
no warrant was required in Skinner was the unlikelihood of abuse
of discretion by railroad supervisors; similarly, in von Raab
the occasions for testing were set forth in the regulations and
were not controlled on an individual basis by Customs Service
officials. Further, one of the compelling governmental interests
found in both cases was deterring drug use. If one is interested
in deterring workers from ever using drugs, a truly random testing
program would be a very effective mechanism.
Handicap Discrimination
A "predictable. and inevitable consequence" of employment actions
based on the results of drug tests will be challenges under federal
and state laws prohibiting discrimination on the basis of handicap,
although those challenges may require employees to make some fairly
unsavory arguments about themselves. The Rehabilitation Act of
1973 prohibits Federal contractors and recipients of Federal
financial aid from discriminating against "otherwise qualified
individuals with handicaps." 29 U.S.C. §§ 793(a), 794. For
employment purposes, an "individual with handicaps" is defined as
a person who has or is perceived as having "a physical or mental
impairment which substantially limits one or more of such person's
major life activities." 29 U.S.C. § 706(8) (B). Almost all of
the states have laws prohibiting discrimination against the
handicapped; their coverage varies, but most follow the federal
definition. While alcoholism and drug addiction have been found
to be impairments, a 1978 amendment to the Rehabilitation Act
excludes from its coverage for employment purposes "any individual
who is an alcoholic or drug abuser whose current use of alcohol
or drugs prevents such individual from performing the duties of
the job in question or whose employment, by reason of such current
alcohol or drug abuse, would constitute a direct threat to property
or the safety of others." 29 U.S.C. § 706(8) (B). The Supreme
Court has commented that by this amendment Congress did not intend
to exclude from the protection of the Act all alcoholics and drug
addicts. School Board of Nassau County v. Arline, 107 S. Ct.
1123, 1130 n.14 (1987). Therefore, the issue will be the
significance of a positive test. Would a positive test for
marijuana, for instance, allow an employee to argue that he or
she is a "drug abuser" and therefore protected from discharge
unless his or her drug abuse constitutes a direct threat to
property or safety? Casual use of drugs, particularly alcohol,
might be found to be either not an impairment at all, or at the
most a "voluntary" impairment, which is probably not covered by
the Act. On the other hand, any consumption of illegal drugs
might be considered "abuse," or an employee who tested positive 
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might contend that he or she is in fact an abuser. To date, there
have been only two reported cases on this point, although more
litigation can be anticipated as the threshold questions of
constitutionality are answered. In Burka v. New York City Transit
Authority. 680 F. Supp. 590 (S.D.N.Y. 1988), the Rehabilitation
Act was held to apply only to those otherwise qualified drug
abusers who have been or are being rehabilitated, and not to
individuals who tested positive but had not sought rehabilitation.
In McCleod v. City of Detroit. 39 Fair Emp. Prac. (BNA) 225
(E.D.Mich. 1985), the court assumed that use of marijuana is a
"physical impairment," but held that being denied a job as a fire
fighter (the position at issue) did not "substantially limit. .
.[the] major life activity" of working; there were still plenty
of jobs in the labor market for which plaintiffs were qualified.
If drug testing of applicants becomes commonplace, this rationale
may no longer suffice, for continuing positive tests may make an
individual unemployable.
STATE LAW
State Constitutional and Statutory Rights
In a few States, constitutional protections against unreasonable
searches and seizures or invasions of privacy have been interpreted
more broadly than their federal counterparts. See Horsemen's
Benevolent and Protective Association. Inc. v. State Racing
Commission. 403 Mass. 692, 532 N.E.2d 644 (1989) (random and
reasonable suspicion drug testing of licensees in state racing
industry violates the Massachusetts Declaration of Rights);
Hennessey v. Coastal Eagle Point Oil Co., No. W-003611-86 (N.J.
Super. Ct. 4/28/89) (random drug testing of private sector
employees violates New Jersey constitution). Over half the States
have considered legislation authorizing or regulating drug testing;
as of this writing, twelve, Iowa, Kansas, Louisiana, Minnesota,
Nebraska, North Carolina, Rhode Island, Tennessee, Utah, Vermont,
Virginia, and Wisconsin, have enacted laws on the subject. While
most of these laws restrict an employer's freedom to test and
limit disciplinary action after a positive test, the Utah statute
gives great freedom to private sector employers and limits employee
rights. Skinner held that when a private search is the result
of the Government's "encouragement, endorsement, and
participation," 109 S. Ct. at 1412, the Fourth Amendment is
implicated. Federal regulations requiring private sector
employers to conduct drug tests will probably be held to preempt
conflicting State laws. See French v. Pan Am Express. Inc., 869
F.2d 1 (1st Cir. 1989) (Rhode Island drug testing statute is
preempted by Federal Aviation Act, as applied to a pilot for an
interstate air carrier); Alverado v. Washington Public Power Supply
System. 111 Wash.2d 424, 759 P.2d 427 (1988), cert. denied. 109
S. Ct. 1637 (1989) (Federal preemption of the field of nuclear
safety prevents application of Washington Constitution to drug
testing at nuclear power plant). 
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Common Law Torts
State tort law offers a variety of possible challenges to drug
testing, such as wrongful discharge, invasion of privacy, outrage,
defamation, and negligence. There has been very little litigation
under State common law to date, but it can be anticipated that
State courts will be heavily influenced by developments under the
Fourth Amendment, and employers with well-designed programs
containing sufficient procedural safeguards will not face a great
risk of tort liability. Even though most States have recognized
exceptions to the employment-at-will rule, workers fired for
failing a drug test must find some public policy embodied in State
law that his or her firing allegedly violated. In States with
drug testing statutes, a firing in compliance with the law will
not be found to violate public policy. Even in States without
statutes, it may be hard for at least some workers to make a
compelling public policy argument, see Luedtke v. Nabors Alaska
Drilling Inc., 768 P.2d 1123,4 Indiv. Emp. Rights Cases (BNA) 129
(Alaska 1989) (public policy supporting health and safety outweighs
public policy supporting employee privacy rights; discharge of
two workers on North Slope oil drilling rigs who tested positive
for marijuana upheld). Moreover, since there is no cause of action
for "wrongful refusal to hire," applicants who fail pre-employment
drug tests are cut of luck.
torts of outrage, such as invasion of privacy and intentional
infliction of emotional distress, require egregious behavior, "an
unjustified intrusion ... of such magnitude as to cause an
ordinary individual to feel severely offended, humiliated, or
outraged." K-Mart Corp. Store No. 7441 v. Trotti, 677 S.W.2d
632, 636 (Tex. App. 1984) . Once again, well-designed drug testing
programs that conform to public sector constitutional requirements,
where employees are given advance notice of the testing program,
and where reliable tests are used, will probably stand up to most
tort challenges. See, e.g., Trotti (invasion of privacy to search
employee's locker, where employees were allowed to bring their
own locks); Kelley v. Schlumberqer Technology Corp., 849 F.2d 41
(1st Cir. 1988) (affirming verdict against employer for invasion
of privacy and negligent infliction of emotional distress under
Louisiana law, where employee was fired for failing a drug test
that involved direct observation of urination); Bodewig v. K-Mart,
Inc., 54 Or.App. 480, 635 P.2d 657 (1981), pet. denied. 292 Or.
450, 644 P.2d 1128 (1982) (tort of outrageous conduct found where
employer required strip search of employee suspected of theft, in
presence of complaining customer).
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Drug Screening in the Workplace:
Use, Abuse and Implications
John Grabowski and Peter B. Silverman
INTRODUCTION
Drug abuse constitutes a complex and substantial problem for
which numerous solutions have been proposed. Typically, the
goal has been to produce rapid and dramatic change. This has
not been achieved at any of the possible points of
intervention. Walsh (1989) has noted that efforts to reduce
supply at the source, or by capture of supplies in transit have
been of limited effectiveness. Reports of the effectiveness of
prevention efforts to reduce demand are equivocal. The "zero
tolerance" approach with users has limitations. Finally, the
development of efficacious treatments has been a slow and
difficult process.
The perceived magnitude of the problem and frustration with the
results of each of the single interventions (optimally
implemented or not) have led to proposal of exceptional
solutions. They are exceptional in so far as they stray
substantially from standard practice, require substantial
effort for the possible benefit, or are contrary to the current
wisdom or indications of available data. Thus, for example, at
one extreme, Buckley (New York Times), proposed that all drugs
should be legalized. At the other extreme, the concept of
"zero tolerance" emerged with the view that any contact with
drugs should bring rapid and harsh penalties. Concurrently
there has emerged the call for panpopulation urine screening.
This has been variously proposed as an adjunct, a deterrent, or
a cure.
The desirability of the goal of reducing drug abuse in the
workplace is clear. The means for doing so are less clear.
Fundamental concerns reside in: whether drug screening serves
any of the proposed functions; the determinants of its
efficacy; and the possible short and long term consequences.
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PROCEDURES AND CIRCUMSTANCES FOR DRUG SCREENING
A. Drug Testing Technologies, Procedures, and Costs
The technologies for screening, their limitations and
advantages have been discussed extensively in the literature
and summarized by Hawks and Chiang (1987). Strict adherence to
chain of custody rules for specimens can reduce the probability
of errors from this source, although they can never be
eliminated. Appropriate combinations of immunoassays,
chromatographic and spectrographic techniques can provide
reliable screening and confirmation procedures. Precise
laboratory procedures potentially assure a specified level of
certainty concerning results. Yet problems of poor quality
control will be difficult to resolve in the public sector. As
Finkle has noted, "In the climate where there is money to be
made, inevitably there will be incompetent and inadequately
staffed laboratories... the tests are very easy to do badly and
difficult to do well" (NYT, 1986). Elaborate and costly
efforts to increase quality control being implemented by
various professional societies and the NIDA can be expected to
reduce, but not eliminate, this source of error. In brief,
under the best of conditions, the tests can produce reliable
results but problems of unreliability can emerge under
conditions that are presumed to be acceptable (Lundberg, 1986;
Hansen et al, 1985).
While costs for testing with high specificity and sensitivity
are substantial, it is likely that these costs can be reduced
by improvements in technology and increased volume of testing.
However, the current costs of drug testing by proficient
laboratories using appropriate techniques have been estimated
by Miike (personal communication, 1988) and are considerable.
High volume and the special circumstances for the military
testing program minimized costs, yet 3.6 million drug tests
with 92,653 positives, cost the military over $52 million in
1986 (Miike, personal connnunication, 1988).
B. Types of Screening
The Urban Mass Transportation Administration (UMTA) has
described the range of possible employment testing strategies
in nonclinical settings related to transportation workers as
imposed on December 21, 1988 (53 FR 47156; 1988). These
requirements have had the most pervasive reach outside of the
military screening program. The basic types of testing
specified include; preemployment screening, random screening
during employment, reasonable cause screening, return to duty
screening, and post accident screening. (An additional
category in part intended to preclude performance enhancement
has been incorporated in athletics). The goal of the several
categories is said to be "a drug free workplace". While
several of these approaches are preventive, others are intended
to place blame.
Preemployment screening assures that only those who have
abstained from drug use for a sufficient period will be
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employed. Random screening will identify those using
behaviorally active drugs and is intended to detect and have
deterrent value. However, it appears that most random testing
is insufficiently frequent to have demonstrable benefit in
terms of prevention. For example, following the 50% rule,
employees are tested only once every two years. Patterns of
drug use can alter dramatically during such extended periods.
Further, some companies refrain from random screening because
of the potential for legal action. This view was voiced at DOT
hearings by those in the transportation industry. Procedural
problems also exist such as keeping testing dates confidential
and the need for elaborate bookkeeping and supervision.
Reasonable cause screening can be viewed as quasi-diagnostic.
If an employee has been observed to engage in inappropriate
behavior, testing may be requested by supervisors. (Two
potential problems are that a minimally trained supervisor is
making judgements about drug effects and performance in a
situation rife with conflicts, and the behavioral problem
itself may warrant referral to an Employee Assistance Program
whether or not its origins reside in drug abuse). Return to
duty screening with long term repeated follow-ups is typically
related to prior positive screens but may also be used as a
means of implementing screening on existing employees not
covered by preemployment screening. Finally, post-accident
testing is explicity intended to identify or rule out factors
contributing to accidents. In general, screening other than
post-accident is an effort to preclude impaired performance.
Testing in athletics on the other hand addresses drug related
enhancement of performance, may deter drug use that might
permit continued participation despite injury, and presumably
is intended to have some larger social benefit.
Reasonable cause testing and particularly the subset of
post-accident testing may be the most widely accepted types.
Currently, preemployment screening is the most commonly used.
C. Screening Sites and Poulations
The general acceptability of screening appears to be related to
perceived consequences of drug effects on performance.
However, it is also determined by factors such as company size,
union strength, and cost. Large companies are more likely to
screen than small companies. Cost of testing programs,
insurance, presence of EAPS, and treatment are pertinent in
these decisions. Schools may be thought of as special
workplace sites and whether or not testing can or will be
implemented depends on the community view. Ironically, one
school district that imposed testing did so for all drugs other
than alcohol and tobacco (NYT, 1986) thereby following the
approach of most industrial testing programs.
There is no agreement on who should be tested. "Fairness" might
dictate that all, if any, employees should be tested and some
companies have taken that approach. Others acknowlege
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privately that differential rules apply. Data on drug abuse
(e.g. Cook, 1988) suggest that some subgroups of the work force
have higher prevalence rates and therefore a data based
approach would adhere to differential, or targeted populations
for testing. Others have suggested that testing should focus
on professions based on risk in lives, money, or power. Data
strongly support screening during treatment for drug abuse, and
the high correlations between drug/alcohol use and accidents
dictate that post accident testing is indicated. (Peculiarly,
some treatment programs refuse to test due to concerns that
patients will feel they "are not trusted.") However, the issue
of who to test has not otherwise been satisfactorily addressed.
D. Policies
It has been stated that the "model policy" is intended to "get
the substance abusing employee into treatment, afford the
opportunity for help, and get the individual back on the job"
(Walsh, 1989). There are no data about the extent of adherence
to the model policy. It can be expected that small companies
have difficulty implementing this costly approach. Policies
can be dramatically changed by events. Thus for example, Exxon
did not use available data in terms of fitness for duty for a
tanker captain and has now announced a policy that assures
dismissal of those found to have used drugs. AMTRAK, like
Exxon, had not used previously available data concerning those
involved in a serious accident. Punitive rather than
rehabilitative policies are likely to be the mode given the
costs of the latter.
CONSEQUENCES OF TESTING
A. Reduction in Illicit Drug Use
Proponents of drug screening in the work place predict the
consequence will be reduction in drug use in this environment.
They further believe that other drug use will be reduced.
There are some data such as those from the military that
suggest reductions may occur. However, screening in that
highly regulated environment is not an adequate test of the
effect. Evaluation of changes in rate of positives due to the
screening program in civilian environments will necessarily be
contaminated. Substantial public interest, concern, and the
changing perceptions about drug use have apparently produced
the reductions that Musto (1987) predicts in his description of
cycles of cocaine use (e.g. see NIDA, 1989, High School Senior
Survey). Reduced rates of drug use by current high school
seniors are predictive of reduced rates of use by the next
generation of employees. Therefore, future reductions of drug
use attributed to screening programs may be in fact the result
of other processes. In the face of substantial cost and
problems, determination of the contribution of effects of drug
screening on drug use should precede widespread implemention.
Further, it should be noted that the drug use rates in some
environments are sufficiently low (Cook, 1988) to assure that
there will be little evidence of effect. It is more likely
that screening programs in low use environments will create
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problems for nonusers, given false positives rates.
.
B. Reduction in Therapeutic Drug Use
Grabowski and Lasagna (1987) proposed that a major concern that
emerges with the current furor about drug use is exacerbation
of lay public fears about being "addicted". Added to this is
the new concern that they will be "caught" using their
therapeutic agents. Some individuals may stop using
therapeutic agents prior to a known drug screen to preclude the
need for responding to questions about use or about their
health status. While stated policies indicate that providing a
list of prescription (or nonprescription drugs) prior to
testing will obviate the need for concern, it presents obvious
problems. This is an undesirable consequence since compliance
is a major problem that can be complicated by drug screening .
C. Public Health Issues
Decreases in substance abuse will enhance the public health.
It is unclear that drug screening will have benefit
proportional to the cost. The data suggest that drug abuse in
industry is relatively low, although high enough to be of
concern in certain subgroups. Further, it can be argued that
in some groups such as pilots any use is problematic although
the FAA acknowledges there are no data to support current
concerns (53 FR 47156; 1988). (In fact, the gravest public
health problems appear to be in unemployed drug abusing
populations.) To the extent that testing patterns in companies
do not reflect the "model policy", individuals who are fired
due to drug use may resort to more, rather than less, drug
use. While the company is no longer responsible, the public
sector must deal with a more severe problem with few
constraints on the individuals behavior. Despite the need to
resolve the potentially severe problems in the workplace,
resolution through dismissal has difficulties parallel to those
of expulsion of young people from school.
D. Legal Issues
The First legal concerns are constitutional. When the employer
is "the state", or one acting for the state (e.g. via contract
or grant), the employee has a constitutional right of privacy
that cannot be encroached on in the absence of compelling
interest. The private employer with no link to the state has
substantial freedom to determine conditions of employment.
Commenting on a specific case involving random unannounced
testing of firefighters, Judge H. Lee Sarokin, noted that "the
harassment, coercion, and tactics utilized here, even if
motivated by the best of intentions should cause us all to
recognize the realities of government excesses and the need for
constant vigilance against intrusions in constitutional rights
by its agents"(NYT, 1986). Judge Sarokins point reflects
dissatisfaction with the necessarily intrusive character of
testing if it is to achieve the goal of reducing or deterring
drug use; i.e. properly implemented it will be intrusive. A
critical concern is whether decisions on panpopulation drug
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screening will provide the precedent of screening for other
disease or behavioral problems including those with genetic
origins whether or not relevant to performance.
Secondary legal issues include tort liability of the employer
for the acts of its employees. Is the company that does not
test or intervene liable if its employees under the influence of
drugs cause an accident, cost fortunes in the stock market, or
otherwise harm the public. Certainly, dram shop laws place
responsibility on bars for serving liquor to intoxicated
individuals subsequently involved in accidents. Corporations may
be held liable for accidents whether or not drugs were
contributory and thus have a vested interest in decreasing all
determinants over which they have control. Many corporations,
including the transit authorities now subject to the UMTA
regulations, are concerned they might be held liable for
untoward consequences of random testing. For example, an
employee fired due to a false positive could sue with costly
consequences.
RELATIONSHIPS TO OTHER TESTS OR CONTINGENCIES
There is no question that employers, educators, and directors of
organizations must have contingencies and consequences to govern
behavior. Absences as well as inappropriate behavior on the
work premises are of interest to the employer. The questioned
relationships are those between positive urines, behavior and
consequences. Similarly one should question denial of
employment based on HIV positivity rather than inability to
complete work. Abberant behaviors about which employers are
concerned are observable without drug screening and have
numerous possible causes other than drug use.
Wide spread screening for drugs may be the precursor for
pervasive HIV or other screening. Genetic screening is already
in place in some employment settings although it has been
observed to be unjustified given available data (Murray, 1986).
Future genetic testing will face similar issues with progress of
the Genome Project mapping the human genetic makeup. Expert
concerns have already led to contesting acceptance of certain
procedures as evidence in courts (Lewin, 1989). To the extent
that drug screening sets precedents for employee-employer or
population - government relationships, great caution should be
used in implementation.
CONCLUSIONS
Several questions were posed at the outset. The answer to the
question of whether screening can serve as preventive, cure, or
adjunct is circumstance dependent. Screening in treatment
settings with proper behavioral contingencies is an essential
tool, but must be properly implemented (e.g. Havassy and Hall,
1982). There is little evidence that random testing procedures
as proposed will have the desired effect. The main preventive
consequence of testing will be that those who can not abstain
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for even brief periods will fail preemployment screening.
Current systems for testing will not substantially alter the
general problems of drug abuse for several reasons. First, drug
abuse is most prevalent in unemployed populations. Second, it
occurs at low rates in most industries. Third, the consequences
of improperly implemented tests may be more severe than benefit
attained. The cost of testing properly is more substantial than
most companies can afford and thus model policies will not be
implemented. There has not been suitable determination of the
long term consequences in relation to broader social and
technological issues or on the prevalence of drug use itself.
Systematic studies of, screening and outcomes in industry will be
the only means for evaluating the real consequences of testing
programs. These studies must meet all criteria for clinical
studies or they will be intolerably confounded by the changing
social circumstances. The American Society for Clinical
Pharmacology and Therapeutics has called for research in diverse
areas related to screening. This must be paralleled by
thoughtful study of the related social issues with heavy
reliance on the data. Most important, a critical evaluation of
the range of issues and consequences should be addressed in a
scientific forum.
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Neurobehavioral Teratogenicity of
Gestational Cocaine Exposure
Linda Patia Spear, Cheryl L. Kirstein, Nancy A. Frambes
and Carole A. Moody
An escalating number of human offspring are born to mothers who have
used cocaine during pregnancy; as neonates these offspring appear to
exhibit a number of behavioral and physiological alterations (e.g.,
Chasnoff et al., 1987). In view of the increasing need for the
establishment of animal models to assess the effects of early cocaine
exposure, a number of research groups including our laboratory have
begun to investigate the neurobehavioral consequences of gestational
exposure to the dopamine (DA) uptake inhibitor cocaine. In our work, we
have focused initially on assessment during the early postnatal period.
Given the available clinical population of exposed offspring, correlations
between human and animal data might be expected to be closer when
examining laboratory animal populations early in life. We have observed
that prenatal cocaine exposure results in a number of behavioral,
biochemical and physiological alterations in the offspring when examined
early in life, as summarized below.
GENERAL DOSING AND TREATMENT PROCEDURES
In these experiments, Sprague-Dawley rat dams were subcutaneously
(s.c.) injected during the mid-light cycle with cocaine hydrochloride daily
from gestational days 8-20. (E8-20) at doses of 0 (saline control) 10, 20 or
40 mg/kg/3cc. In-some of our work, we have focused only on the 40
mg/kg dose, a dose well above threshold for producing neurobehavioral
alterations. Control dams included in these experiments consisted of
dams allowed ad lib access to lab chow (LC), and in some studies dams
pair-fed to animals in the 40 mg/kg dose group (PF). In all but our initial
study (Spearu et al., 1989b), all offspring were fostered to surrogate dams
on postnatal day 1 (P1).
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COCAINE/BENZOYLECGONINE (BE) DATA
To determine whether S.C. administration is an appropriate method for
administering cocaine to the dams, we examined the distribution of
cocaine-and the cocaine metabolite benzoylecgonine (BE) in brain and
plasma of dams and their near-term fetuses 0.5 and 2 hrs. post-injection
on E20 following chronic daily S.C. injections of 10, 20 or 40 mg/kg/3cc
cocaine beginning on E8 (Spear et al., 1989a). Dose-dependent
increases in brain and plasma levels of cocaine were observed in both
the dams and fetuses. Maternal plasma levels were found to be in the
range of, or exceeding, those reported in human cocaine users.
Significant amounts of both cocaine and BE were observed in fetal brain.
Taken together, these results suggest that the S.C. route is appropriate in
rats for administering cocaine in investigations of potential
neurobehavioral ramifications of gestational cocaine exposure.
MATERNAL/LITTER DATA
In general, these doses of cocaine produced few notable effects on the
progress of gestation or fetal physical development. In a number of our
studies maternal weight gain was observed to be slightly reduced during
pregnancy (by 6-9 percent) in dams treated with 40 mg/kg cocaine.
However, no significant difference in offspring body weights at either P1
or P21 were found in cocaine exposed offspring in any of our studies. No
differences in gestational length or in resorption rates were observed,
athough non-significant trends for an increase in resorption rate was
sometimes noted with the 40 mg/kg dose. Moreover, no differences were
observed in litter size or the ratio of male/female pups in the litters.
Cocaine-exposed offspring also exhibited normal reflex maturation and
development of physical landmarks (see Spear et al., 1989b).
COGNITIVE TESTS
In spite of normal rates of physical development, offspring exposed
gestationally to cocaine exhibit pronounced cognitive deficits when tested
during the neonatal to weanling age periods. Cocaine-exposed offspring
often fail to exhibit evidence of conditioning even in simple classical
conditioning tasks that are readily learned by control age-mates,
particularly in circumstances when the training parameters used
produced only modest levels of conditioning in control offspring (see
Spear et al., 1989c, for further discussion). In more challenging
cognitive tasks, these cognitive deficits may be particularly pronounced.
In future work, we plan to investigate in more detail the circumstances
under which-cocaine-exposed offspring exhibit these learning deficits,
and to examine whether the deficits in cognitive performance observed
during the neonatal to weanling age period are also observed later in life.
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BEHAVIORAL AND PSYCHOPHARMACOLOGICAL APPROACHES TO
EXAMINE DA ACTIVITY
Behaviorally, cocaine-exposed offspring exhibited a reduction in
footshock-precipitated wall climbing at P12 in the absence of alterations
in footshock sensitivity thresholds (Spear et al., 1989c). Given that wall
climbing has been previously shown to be strongly related to levels of
catecholamine activity at this age, these data suggest that there may be
some net attenuation in catecholaminergic function in pups exposed
gestationally to cocaine. Cocaine-exposed offspring also exhibit an
attenuated response to the DA agonists apomorphine (P12 test) and
cocaine (P11 test), along with an accentuated response to the DA
antagonist haloperidol (P8 test) (see Spear et al., 1989c). This pattern of
psychopharmacological alterations is consistent with the suggestion that
there may be a functional attenuation in DA activity in these offspring, a
hypothesis that needs to be tested using a multitude of approaches as
discussed further below.
(DDPAC + HVA)/DA ratios
Dose of Haloper idol
Figure 1 Ratios of (DOPAC + HVA)/DA following saline, 0.1, 0.5 or 1.0
mg/kg haloperidol in P11 offspring of dams exposed gestationally to 40
mg/kg cocaine (C40) and control dams (LC). Data are collapsed over
striatal and nucleus accumbens brain samples.
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BIOCHEMICAL STUDIES OF DA FUNCTION
Because of these behavioral and psychopharmacological signs of
potential alterations in the DA system in cocaine-exposed offspring, we
have begun to examine DA system function using neurochemical and
hormonal response measures. One approach that we have used is to
examine haloperidol-induced increases in the ratio of the DA metabolites
(DOPAC + HVA)/DA in cocaine-exposed offspring. In this study, DOPAC,
HVA and DA were analyzed via HPLC-EC in caudate and nucleus
accumbens of P11 rat pups sacrificed 60 min. following injection with
saline, 0.1, 0.5 or 1.0 mg/kg haloperidol. The results of this study are
shown in Figure 1 which presents data collapsed across nucleus
accumbens and striatum as there were no significant interactions
involving brain region in our analyses of these data. In these P11 pups,
as is typically the case in adults, haloperidol increased (DOPAC +
HVA)/DA ratios. However, offspring exposed gestationally to cocaine
showed significantly less of an increase in this ratio in response to the low
(0.1 mg/kg) dose of haloperidol than LC control pups.
P11 PLASMA PROLACTIN LEVELS
HALOPERIDOL DOSE (MG/KG)
Figure 2 Plasma levels of prolactin in P11 offspring of dams given 40
mg/kg cocaine (C40) or injected with saline and given free access to food
(LC), with the pups being sacrificed either immediately upon removal from
the nest (C) or 60 min. following 0.1, 0.5 or 1.0 mg/kg haloperidol.
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In collaboration with Dr. Cynthia Kuhn (Duke University) we have also
examined DA in the tuberoinfundibular system where DA exerts a chronic
inhibitory effect on prolactin secretion. Treatment with the DA antagonist
halopetidol increases prolactin release by blocking this inhibition. As can
be seen in figure 2, cocaine-exposed offspring exhibited a reduction in
the magnitude of the haloperidol-induced increase in prolactin at the two
lower doses of haloperidol. These data suggest that the
tuberoinfundibular DA system, like striatal and mesolimbic DA systems,
may be sensitive to the effects of gestational cocaine exposure.
These attenuated neurochemical and hormonal respones to low doses of
halopendol in offspring exposed gestationally to cocaine are in contrast to
the psychopharmacological data discussed above where cocaine-
exposed offspring were observed to be more sensitive to
halopetidol-induced behavioral alterations. Although a number of
hypotheses can be generated as to how these findings can be reconciled,
without additional data it may be premature to do so. Gestational
exposure to cocaine may induce a multitude of alterations within the DA
system that may ultimately affect DA function. Some of these alterations
may be directly induced by the drug exposure per se, whereas others may
be compensatory to initial drug-induced alterations in the development of
portions of this system. Consequently, it may not be appropriate to infer
from data limited to but a few indices of a neurotransmitter system as to
how the functioning of that neurotransmitter system as a whole is altered
by gestational drug exposure. Thus, although these data suggest that
exposure to cocaine early in life alters subsequent functioning within the
DA system, other aspects of the DA system need to be examined (D1 and
D2 receptor binding, density of presynaptic DA terminal endings, number
of DA uptake sites, etc.) to derive a profile of alterations in the DA system
necessary for determining the ultimate impact of gestational cocaine
treatment on DA function.
OTHER NEUROCHEMICAL AND PHYSIOLOGICAL ALTERATIONS
Neurochemical alterations in cocaine-exposed offspring are not restricted
to the DA system. In work conducted in collaboration with Dr. Ken
Leskawa (University of Louisville), we observed that offspring exposed
gestationally to 40 mg/kg cocaine exhibited a transient elevation in whole
brain levels of gangliosides and glywlipids evident at P1 but not P11.
These substances play a number of critical roles in development,
including cell-cell recognition, cell surface structural changes and
regulation of protein receptor function and cell growth. Given that levels
of particular gangliosides and glywlipids show developmental increases,
whereas others decline, the significance of these transient elevations in
gangliosides and glywlipids in cocaine-exposed offspring remain to be
determined.
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Cocaine-induced alterations in offspring may not be restricted to the
nervous system. We have preliminary data on thymus weights of pups
exposed to 40 mg/kg cocaine during gestation and control pups. As can
be see in figure 3, cocaine-exposed pups exhibited a transient decrease
in thymus weights at P1 which was no longer evident by P11; conversely,
a significant increase in thymus weights (compensatory hypertrophy?)
was seen in cocaine-exposed offspring at P21. These preliminary data
suggest a potential alteration in immune system function in offspring
exposed gestationally to cocaine, a possibility that needs to be examined
further.
THYMUS WEIGHTS
AGE
Figure 3 Thymus weights of P1, P11 and P21 offspring of dams given 40
mg/kg cocaine (C40) or injected with saline and given free access to food
(LC).
SUMMARY
Gestational cocaine exposure has an impact on a number of behavioral
and physiological measures examined during the neonatal to
weaning age period. Notable effects of early cocaine exposure include a
disruption in cognitive function, along with a profile of DA alterations.
Observed physiological differences do not appear to be restricted,
however, to the DA system, or even the nervous system. Such data may
have important implications regarding the prognosis for future
development of human offspring exposed gestationally to cocaine.
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Cocaine Binding Sites Related to
Drug Self-Administration
Mary C. Ritz, John W. Boja, Frank R. George and
Michael J. Kuhar
Cocaine is a powerfully reinforcing drug that leads to several
physiological, psychological, and sociological problems in users.
It produces this and a variety of other pharmacological effects
through its interactions with several central nervous system
binding sites. It is well established that cocaine inhibits
monoamine uptake, and that these transporters appear to be labelled
by 3H-cocaine (Reith et al., 1980; Kennedy and Hanbauer 1983;
Schoemaker et al., 1985; Calligaro and Eldefrawi 1987). In
addition. studies from our laboratory have shown that (-)cocaine
interacts with both sigma and muscarinic cholinergic receptors in
brain (Sharkey et al., 1988a, 1988b). The affinity of cocaine for
these latter binding sites is much lower than for monoamine
transporters, and we have shown that cocaine binding to these sites
is not associated with the reinforcing properties of cocaine.
However, cocaine interactions with these sites may become relevant
at higher, toxic doses of the drug.
Dopamlne Transporters Mediate Reinforcing Properties of Cocaine
The goal of initial studies was to determine the relative
importance of various brain receptors in medlating the reinforcing
properties of cocaine. We reasoned that the identification of
pharmacologically relevant receptors required that an association
exist between the potency of cocaine-related drugs in animal models
of substance abuse and their potency at binding sites in the brain.
It appeared likely that cocaine would exhibit stereospecificity for
relevant receptors such that (-)cocaine would exhibit a higher
potency for the receptor of interest than (+)cocaine, just as it
does in cocaine self-administration studies. Cocaine should also
exhibit a micromolar affinity for the receptor of interest since
micromolar blood, and therefore brain, concentrations of cocaine
are associated with its euphoric effects in humans (Fischman et al.,
1976).
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Our results illustrated that the potencies of cocaine-like drugs in
self-administration studies correlate with their potencies in
lnhibiting 3H-mazindol bindlng to the dopamine transporters in rat
striatum, but not with the potency in binding to a large number of
other presynaptlc and postsynaptic binding sites (Ritz et al.,
1987). These results are consist with many previous studies
indicating that brain dopaminergic neuronal systems, particularly
meso-limblc pathways, have been implicated in the mechanism of
action of cocaine (Goeders and Smith 1983; Martin-Iverson et al.,
1986; Wise 1984).
Does Amphetamine Binding to Dopamine Transporters Medlate-its
Reinforcing Properties?
Amphetamine and cocaine have often been viewed as belonging to the
same pharmacological class of drugs, the psychostimulants, and have
been shown to produce similar physiologic, behavioral and subjective
effects in humans. However, increasing evidence indicates that
amphetamine and cocaine have important differences in
pharmacological effects and in underlying molecular mechanisms
(McMillen 1983; Langer and Arbilla 1984). In addition, our previous
data had shown that amphetamine, relative to cocaine, is more potent
in self-administration studies than would have been expected based
Log Inhibition of 3H-Mazindol Binding
Figure 1: The Bindlng of Cocaine- and Amphetamine-Related
Compounds at Dopamine Transporters. Slope and p values were
determined by multiple regression analysis: Compounds showns
are as follows: A) Mazindol, B) WIN 35,065-2, C) WIN 35,981, D)
Methylphenidate. E) 1-Cocaine, F) d,1-Norcocaine, G) Dimethocaine.
H) Procaine, I) Chloroprocaine, J) d-Pseudococaine, 2) d-Amphetamine,
3) d,1-Cathinone, 4) 1-Amphetamine, 5) Phentermine, 6) d-Ephedrine,
7) Bentphetamine, 8) Phenmetrazine, 9) Diethylproprion.
10) Phendimetrazine, 11) 1-Ephedrine, 12) Clortemine,
13) d,1-Methylenedioxyamphetamine, 14) Chlorphentermine.
Source: Ritz and Kuhar. J Pharm Exp Ther 248, 1010-1017, 1989.
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on its inhibition of mazindol binding at the dopamine transporter.
The goal of a subsequent investigation, then, was to determine
whether the mechanism of action associated with amphetamine-
reinforced behavior might also be associated with dopaminerglc
neuronal systems. Thus, we assessed in vitro binding potency and
stereospecificity of amphetamine at both pre- and post-synaptic
monoamine receptor sites in order to determine which of these sites,
if any, might be related pharmacologically to amphetamine
self-administration.
The results of this study suggested that amphetamine binding to the
mazindol site on the dopamine transporter is not associated with the
reinforcing properties of amphetamine, as it was shown to be for the
reinforcing properties of cocaine (Figure 1). We found no
significant relationship between the reinforcing potencies of
phenylethylamines and their inhibition of 3H-mazindol binding into
dopamine transporters, and that the potencies of these drugs at this
site were not generally predictive of their reinforcing properties.
Indeed, our analyses indicates that the reinforcing effects of
phenylethylamines were not positively correlated with inhibition of
ligand binding to any of the pre- or post-synaptic monoamine sltes
tested. However, the self-administration of amphetamine and related
compounds appeared to be inversely related to the inhibition of
3H-paroxetine binding to the serotonln transporter, suggestlng that
serotonin uptake inhibition opposes the reinforcing effects of
amphetamine (Figure 2). This effect does not appear to be related
to direct effects of drug binding at 5-HT2 receptor sites (Ritz and
Kuhar 1989).
Log Inhibition of 3H-Paroxetine Binding
Figure 2: Binding of Amphetamine-Related Compounds at Serotonin
Transporters. The compounds shown are named in the legend for
Figure 1.
analysis.
Slope and p values were aetermined by multiple regression
Source: Ritz and Kuhar. J Pharm Exp Ther 248, 1010-1017, 1989.
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Our biochemical studies have shown that cocaine, but not
amphetamine, binding to mazindol sites on the dopamine transporter
is significantly related to the reinforcing properties of these
drugs. Furthermore, there appears to be a significant inverse
relationship between drug binding to the serotonin transporter and
the reinforcing value of amphetamine, but not cocaine. Binding to
the norepinephrine transporter sites does not appear to be
significantly related to the reinforcing potency of either cocaine
or amphetamine.
Serotonerglc Neurons Influence Amphetamine Reinforcement
Behavioral studies of the effects of the potent serotonin reuptake
lnhibitor. fluoxetine, on cocaine- and amphetamine-reinforced
responding in rats were consistent with the biochemical data
described here. Figure 3 indicates that pretreatment with 2.5, 5.0
and 10.0 mg/kg fluoxetine significantly (p < 0.05) decreased rates
of responding maintained by amphetamine (0.125 mg/kg/inf), but had
no effect on responding maintained by cocaine (1.0 mg/kg/inf).
Thus, we have obtained evidence from both biochemical and behavioral
studies suggesting that the binding of amphetamine and related drugs
to the serotonin transporters opposes the reinforcing properties of
these drugs. It appears that serotonin uptake inhibition may be
important for modulation and attenuation of the rewarding effects of
amphetamlne and related compounds (Porrino et al 1989).
DOSE FLUOXETINE (mg/kg)
Figure 3: Effect of Serotonin Uptake Inhibition on Cocaine and
Amphetamine Self-Administration.
Source: Porrino et al., Life Sci, 1989 (in press).
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Does Cocaine Binding to Dopamine Transporters Mediate Genetic
Differences in Cocaine-Reinforced Behavior?
Several studies have shown the influence of inherited traits on the
reinforcing properties of drugs (George and Goldberg, 1989). Since
we have previously shown that the interaction of cocaine with the
dopamine transporter was a primary influence on the reinforcing
properties of cocaine, we assessed whether the dopamine transporter
could account for genetic differences in cocaine reinforcement.
Studies have shown genetic differences in the predisposition of
several rat strains to ingest cocaine, via the oral route of
administration (George and Goldberg, 1989). Cocaine, self-admin-
istered orally, served as a strong reinforcer in Lewis rats only.
Cocaine served as a marginal reinforcer in NBR rats, and did not
serve as a reinforcer in ACI or F344 rats. Receptor binding studies
using these same rat strains indicated that there were rio dif-
ferences in either affinity or number of 3H-GBR 12935 binding sites
between any of these four strains. Likewise, there were no differ-
ences in either affinity or number of 3H-SCH 23390 and 3H-spiperone
binding to D1 and D2 receptor sites, respectively. In addition,
there were no differences between strains in the affinity of
(-)cocaine at 3H-GBR 12935 binding sites on the dopamine transporter.
These results suggest that although the dopamine transporter plays a
primary role in determining the reinforcing potency of cocaine in
animals for which it serves as a reinforcer, differences in cocaine
binding to this site do not account for individual or strain dif-
ferences in whether or not cocaine serves as a powerful reinforcer.
It is possible that further analysis of cocaine binding to dopamine
transporters or postsynaptic receptor sites using additional brain
regions or autoradiographic techniques would detect significant
differences between strains which differ in their propensity to
self-administer cocaine. In other studies, autoradiography
illustrated significant differences between mouse strains in
receptor number (Bmax) which were undetected or masked using initial
receptor binding techniques using relatively crude brain membrane
preparations (Belknap 1990, Moskowitz and Goodman 1985).
3H-WIN 35,065-2 Binding to Dopamine Transporters
In a final series of experiments we assessed the binding character-
istics of 3H-WIN 35,065-2 to cocaine binding sites on dopamine
transporters. In this cocaine analog, the tropane and phenyl rings
of cocaine are directly attached to each other, eliminating the
ester linkage. This derivative has been shown to serve as a more
important reinforcer than cocaine under a fixed interval schedule of
i.v. injection (Spealman and Kelleher 1981). It has also been shown
that WIN 35,065-2 inhibits 3H-cocaine binding to brain membranes
(Sershen et al., 1982). It was hypothesized that this analog of
cocaine might prove to have some advantages over cocaine in binding
assays because it is more potent in both behavioral and biochemical
studies. It is also likely to be more resistant to metabolic
degradation in in vivo studies do to the elimination of the ester
linkage between the benzene and tropane rings.
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The results of our study have shown that the binding of 3H-WIN
35,065-2 to striatal membranes is saturable and reveals two binding
sites (Ritz et al., submitted). Saturation experiments indicate a
low affinity binding site that is apparent KD of approximately 105
nM and a Bmax of 115 fm/mg tissue. A high affinity site has also
been identified with an apparent KD of 6.2 nM and a Bmax of 8.8
fm/mg tissue. The results show that 3H-WIN 35,065-2 binding to both
high and low affinity sites in striatum is sodium dependent, and
that 6-hydroxydopamine lesions result in a loss of both high and low
affinity sites. These results, in addition to pharmacological
characterizations, suggest that the ligand binds to sites closely
associated with the dopamine transporter. Thus, our results suggest
that 3H-WIN 35,065-2. because of the structural similarities to
cocaine, its higher binding affinity compared to cocaine and its
relatively greater resistance to metabolic breakdown, may be a
useful ligand for examining cocaine binding sites on the dopamine
transporter.
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Mechanisms of Phencyclidine
(PCP)-n-Methyl-d-Aspartate
(NMDA) Receptor lnteractionr
Implications for Drug Abuse
Research
Stephen Ft. Zukin and Daniel C. Javitt
INTRODUCTION
Phencyclidine (1,1-phenylcyclohexylpiperidine; PCP; “angel dust”), originally
developed as a general anesthetic in the late 1950’s, was found to produce loss of
consciousness and-analgesia sufficient for the performance of surgical procedures
while not causing significant respiratory or cardiovascular depression (Greifenstein et
al. 1958; Meyer et al., 1959; Johnstone et al., 1958). However, a significant
proportion of patients subjected to PCP anesthesia developed psychotic episodes
typically lasting 12 to 72 hours but occasionally as long as 7 to 10 days. These
episodes were characterized by excitation, unmanagability, paranoia, concreteness of
thought (Greifenstein et al., 1958; Meyer et al., 1959) and “maniacal episodes”
(Johnstone et al., 1958). Subanesthetic doses (0.1 mg/kg i.v.) doses were
subsequently found to induce psychotic episodes in normal volunteers and to rekindle
presenting symptomatology in recompensated schizophrenic subjects (Davies and
Beech 1960, Luby et al., 1959, 1962). In addition, subanesthetic doses of PCP, but
not LSD, amobarbital or amphetamine, could induce abnormalities in tests of abstract
reasoning, cognitive processing, attention, motor function and proprioception in
normal volunteers which closely resembled those seen in patients with chronic
schizophrenia (Rosenbaum et al., 1959; Cohen et al., 1962). Despite evoking
behavioral effects apparently so dysphoric, PCP emerged as a major drug of abuse
during the 1970s (Petersen and Stillman 1978) and the rate of PCP abuse increased
again during the 1980s (Crider, 1985). PCP possesses powerful reinforcing and
abuse-promoting effects (Balster, 1986). The key to developing interventions
targeting the clinical and public-health problems posed by PCP-like drugs will be.
found in elucidating the mechanisms underlying their psychotomimetic and abuse-
promoting properties.
PCP binds with high affinity to a specific brain PCP receptor (Zukin and Zukin 1979;
Vincent et al., 19779; Reynolds et al. 1987). Several lines of evidence indicate that the
PCP receptor is a site within the ion channel gated by the NMDA-type excitatory
amino acid receptor. First, PCP and NMDA receptors are co-localized in the central
nervous system (Maragos et al., 1988). Second, PCP receptor ligands have been
shown to inhibit NMDA receptor-mediated conductances noncompetitively (Anis et
al., 1983) in a voltage- and use-dependent fashion (Honey et al., 1985; Huettner and
Bean 1988). Finally, binding of PCP receptor ligands is enhanced by NMDA
receptor agonists, such as L-glutamate or NMDA, and is diminished by competitive
NMDA receptor antagonists such as D(-)-2-amino-5-phosphonovaleric acid
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(D(-)AP5) (Javitt et al., 1987; Fagg, 1987, Loo et al., 1987). Such data suggest a
model in which NMDA and PCP receptors-represent distinct sites associated with a
supramolecular NMDA receptor complex. The identification of noncompetitive
inhibition of NMDA receptor function as the mechanism underlying the
psychotomimetic effects of PCP suggests that elucidation of the functioning of the
NMDA receptor complex may reveal mechanisms relevant to the pathogenesis and
treatment of schizophrenia.
MECHANISMS OF PCP - NMDA RECEPTOR INTERACTlON
In order to elucidate mechanisms underlying NMDA receptor activation, binding of
the selective PCP receptor ligand [3H]MK-801 was determined in the presence and
absence of L-glutamate and either glycine or D-serine, agents which had previously
been shown to stimulate binding to PCP receptors (Reynolds et al., 1987; Javitt and
Zukin 1989a). L-glutamate has been shown to mediate its actions as an agonist at the
NMDA recognition site while both glycine and D-serine mediate their actions at a
non-strychnine sensitive glycine recognition site associated with the NMDA receptor
complex For these studies, rat forebrain homogenates were subjected to extensive.
washing, freezing and thawing in order to reduce the high endogenous concentrations
of L-glutamate and glycine present in crude brain homogenate. Specific binding of
[3H]MK-801 was determined at 12 - 16 time points between 5 min and 24 hr using a
filtration radioreceptor assay in the presence of a 5 mM Tris buffer system adjusted to
pH 7.4 and a low (30 µM) concentration of Mg2+ (Javitt and Zukin 1989b).
These studies resulted in three novel findings. First, analysis of association curves
using a computer-assisted, non-linear curve fitting technique revealed the presence of
two distinct components of [3H]MK-801 binding: a fast component with a t½ of
approximately 5 min and a slow component with a t½ of approximately 3 hrs (figure
1). This suggests that PCP-like agents do not gain access to their receptor only via
open channels, since channel-blocking drugs which interact exclusively with open
channels should manifest single exponential association and dissociatiqn (Starmer
and Grant 1985). A model of PCP-NMDA receptor interaction consistent with bi-
exponential association of [3H]MK-801 would be one in which PCP-like agents can
gain access to their recognition site via two distinct paths, each corresponding to one
of the observed kinetic components of binding. It has been suggested that channel
blocking drugs having pKa values near physiological pH may associate with their
biding sites via both fast, hydrophilic and slow, hydrophobic paths (Ibid.). At pH 7.4
MK-801 (pKa=8.2 (Huettner and Bean 1988)) would exist in both deprotonated and
protonated forms. The former would be capable of association via both hydrophilic
and hydrophobic paths while the latter would be capable of association only via a’
hydrophilic path. When channels were maximally activated in the presence of
combined L-glutamate and glycine, we found that >90% of [3H]MK-801 binding
displayed fast kinetics of association, suggesting that the fast path represents binding
of [3H]MK-801 to its receptor following diffusion to the binding site via a path
corresponding to the open NMDA receptor channel. In the absence of added L-
glutamate or in the presence of D(-)AP5, >99% of [3H]MK-801 binding displayed
slow kinetics of association, suggesting that the slow path represents binding of
[3H]MK-801 following diffusion to the binding site via a path associated with closed
NMDA receptors channels. The latter path could involve diffusion of deprotonated
[3H]MK-801 through the lipid bilayer, through hydrophobic domains of the receptor
complex or through the (closed) NMDA receptor gating mechanism. Bi-exponential
kinetics of association of [3H]MK-801 in the presence of L-glutamate alone indicate
that association via fast and slow paths can occur simultaneously, supporting the
concept that different underlying processes must be involved. The ability of PCP-like
agents to reach their binding site within closed NMDA channels over the course of
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FIGURE 1: Association curves of 1 nM [3H]MK-801 under control conditions
(filled circles) or in the presence of 10 µM concentrations of D(-)AP5 (open circles),
glycine (open triangles), L-glutamate (filled triangles), or L-glutamate plus glycine (open
squares). Under control conditions or in the presence of D(-)AP5, binding was fit best
by single exponentials with apparent t½ values of 3.2 and 5.8 hours, respectively. In the
presence of combined L-glutamate and glycine, binding was best fit by a single
exponential with an apparent t½ of 12 minutes. In the presence of L-glutamate alone,
binding was best fit by dual exponentials with apparent t, values of 5.5 minutes and 1.6
hours for the fast (dashed line) and slow (dotted line) components, respectively
(Reprinted from Javitt and Zukin 1989b; Copyright 1989, American Society for
Pharmacology and Experimental Therapeutics).
hours may be relevant to course of PCP intoxication since it suggests that PCP can
reach its site of action even in the absence of NMDA receptor activation.
A second finding of these studies (Javitt and Zukin 1989b) was that L-glutamate
significantly increased total steady-state [3H]MK-801 binding’ while D(-)AP5
significantly decreased total steady-state [3H]MK-801 binding (figure 2), presumably
by displacing endogenous agonists from the NMDA receptor. This finding differs
from those of previous studies which had reported no change in equilibrium binding
following the addition of glutamate and glycine (Kloog et al., 1988; Bonhaus and
McNamara 1988). A third finding of our studies (Javitt and Zukin 1989b) was that
the Hill coefficient for stimulation of [3H]MK-801 binding by L-glutamate was
significantly greater than unity (figure 3). While glycine shifted the dose-response
curve to the left, it did not alter the Hill coefficient significantly. This finding suggests
that more than one molecule of agonist is required to induce NMDA channel
activation.
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FIGURE 2: Specific binding (mean ± s.e.m) of 1 nM [3H]MK-801 to fast (open
bar) and slow (filled bar) components under control conditions or in the presence of 10
µM concentrations of D(-)AP5 (AP5), glycine (GLY), L-glutamate (L-GLU) or L-
glutamate plus glycine. Total bar height represents total steady-state binding of
[3H]MK-801 under conditions specified. Significant between-groups variation was
found for fast (p<.001), slow (p<.01) and total (p<.001) steady-state binding. Values
represent mean ± s.e.m of 4 - 6 expeiments. *p<.05 vs. control **p<.01 vs. control
(Reprinted from Javitt and Zukin 1989b; copyright 1989, American Society for
Pharmacology and Experimental Therapeutics).
A model of NMDA receptor functioning which was could account for these findings
is one involving the existence of two independent sets of agonist recognition sites
within each functional NMDA receptor complex Occupation of both sets by agonist
would be required for channel activation and fast [3H]MK-801 binding. Partial
activation would not permit channel opening but would permit slow diffusion of
[3H]MK-801 to its binding site via a hydrophobic path. In the total absence of
agonist, however, the channel would remain closed and in a conformation to which
PCP receptor ligands could not bind. This model is similar to models which have
been proposed to account for the functioning of nicotinic acetylcholine (Hess et al.,
1983) and GABA, (Aoshima et al., 1987) receptors. If future studies confirm a
functional similarity between NMDA and nicotinic receptors, it may indicate that
NMDA receptors are structurally homologous to receptors of the Class I superfamily
of ligand-gated channels, which includes nicotinic, GABAA, and strychnine-sensitive
glycine receptors as well (Barnard et al., 1987).
ROLE OF NMDA RECEPTORS IN PSYCHOTOMIMETIC EFFECTS OF PCP
The ability of PCP-like agents to bind with high potency to a site within the NMDA
channel suggests that PCP-induced NMDA channel blockade may be relevant to the
clinical effects of PCP. The degree. to which PCP receptors mediate the
psychotomimetic effects of PCP has been a subject of controversy in the literature.
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FIGURE 3: Stimulation of specific 1 nM [3H]MK-801 binding by L-glutamate in the
absence (filled circles) or presence (filled triangles) of 10 µM glycine following 24 hour
incubations. D(-)AP5 (50 µM) was added under all conditions to decrease basal
binding. Inset, Hill plots of specific 1 nM[3H]MK-801 binding Correlation coeficients
(r) were >.95 for both plots. In both the absence (filled circles) and presence (filled
triangles) of 10 µM glycine Hill coefficients were significantly greater than unity.
(Reprinted from Javitt and Zukin 1989b; copyright 1989, American Society for
Pharmacology and Experimental Therapeutics).
Both haloperidol-sensitive (Su et al., 1988) and monoamine reuptake (Smith et al.,
1977; Garey and Heath 1976) sites have been proposed as potential alternative sites
for mediation of the psychotomimetic effects of PCP. Several lines of evidence,
however, support a unique role of the PCP receptor in this regard. First, PCP
receptors have been shown to mediate the discriminative stimulus effects of PCP in
rodents (Browne, 1986). The rank order of potency with which a large number of
drugs from distinct chemical classes can induce the PCP response in animals trained
to discriminate PCP from saline corresponds to their rank order of binding to PCP
receptors and inducing NMDA receptor blockade (Ibid.). By contrast, agents which
selectively bind to the and/or dopamine reuptake sites neither induce PCP-like
discriminative stimulus effects nor antagonize the discriminative stimulus effects
induced by PCP receptor ligands (Ibid.). These findings suggest that PCP receptors
mediate the interoceptive cues induced by PCP and PCP-like agents. Second,
psychotomimetic effects similar to those induced by PCP can be induced by ketamine,
a related arylcyclohexylamine derivative (Siegel, 1978). The psychotomimetic effects
of ketamine are induced by doses approximately 10-fold greater than PCP (Ibid.),
which is consistent with its ten-fold lower potency of binding to PCP receptors
(Zukin and Zukin 1979, Vincent et al., 1979). By contrast, ketamine is essentially
inactive at both DA reuptake (Vignon et al., 1988) and sites. Finally, PCP-induced
psychosis has been found to be associated with serum concentrations of PCP as low as
20 nM, while serum concentrations greater than 400 nM are associated with gross
impairments in consciousness (Walberg et al., 1986). PCP receptors have been shown
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to bind PCP with an affinity of approximately 30 - 50 nM (Reynolds et al., 1987;
Sircar et al., 1987; Wong et al., 1988), suggesting a highly significant degree of
receptor occupancy by levels of PCP present during low-dose PCP psychosis. By
contrast, binding sites and DA reuptake sites have been shown to bind PCP with
affinities of approximately 600 (Wong et al., 1988) and 700 (Vignon et al., 1988) nM,
respectively. The affinity of PCP for these sites is thus significantly lower than its
affinity for PCP receptors. Furthermore, the affinity of PCP for these sites suggests
that they would be affected only to a limited extent by concentrations of PCP that
have been demonstrated to cause robust psychotomimetic effects.
In summary, the unique behavioral effects of PCP and related drugs, which are
accompanied by a high degree of abuse potential, appear to be mediated at the PCP
receptor which is located within the NMDA-receptor gated ion channel. Our
experimental data from experiments measuring the effects of NMDA receptor
activation on binding of [3H]MK-801 to PCP receptors support a model of NMDA
receptor functioning in which two molecules of agonist are required for NMDA
receptor activation. This model is similar to models which have been proposed for
the nicotinic acetylcholine receptor, suggesting the possibility of functional and
structural homology between NMDA receptors and members of the Class I
superfamily of ligand-gated channels. The psychotomimetic effects of PCP are
observed at serum concentrations similar to the concentration at which PCP binds to
the NMDA-associated PCP receptor. It is hoped that future studies may clarify
mechanisms whereby agents influencing NMDA receptor functioning may influence
behaviors or lead to therapeutic approaches related to drug abuse.
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Characterization of the Actions of
Phencyclidine on Midbrain
Dopamine Neurons
Edward D. French, Stefanie Levenson and Angelo Ceci
INTRODUCTION
The dopaminergic A10-mesolimbic-mesocortical systems originating
within the ventral tegmental area (VTA) are increasingly implicated
as playing a seminal role in reward mechanisms associated with
drugs of abuse (Wise and Bozarth, 1987). Thus, the stimulation of
these neurons by PCP and the a-benzomorphan compounds seemed a
likely mechanism by which these drugs exert their reinforcing as
well as psychotomimetic effects. Since there is compelling
evidence for the existence of two distinct receptor populations for
PCP and a-ligands, with both PCP and drugs having affinity for
both sites, it is important to determine which receptor population
is linked to the activation of these neurons, and whether these
effects might share a common mechanism of action, such as blockade
of central NMOA receptors. In this report we will provide data
that compares and contrasts the potency of various PCP- and
ligands for effecting changes in A10 firing, and whether these
effects, which might reside with PCP's noncompetitive blockade of
NMDA receptors, are shared by those compounds which competitively
antagonize central NMOA receptor activation. We will also present
evidence that PCP's unique bimodal effect (excitation/inhibition)
on A10 activity is mediated via independent transmitter systems.
METHODS
Electrophysiology
All experiments were carried out on male Sprague-Dawley derived
rats according to procedures reviewed and approved by the Univ.
Arizona IACUC Committee according to established federal
regulations for the treatment of animals. The preparation, single-
unit extracellular recordings and identification of presumptive
dopamine neurons in chloral hydrate anesthetized rats has been
described in detail elsewhere (French, 1986, 1988). Challenge drug
injections were administered i.v. according to a cumulative dosing
regimen while continuously monitoring changes in A,, cell firing
rate.
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Behavior
The locomotor effects of PCP (5 mg/kg), d-amphetamine (AMP, 1.5
mg/kg), scopolamine (1.25 mg/kg) and the competitive NMDA
antagonist, NPC 12626 (50 mg/kg) in rats with 6-hydroxydopamine
lesions (8µg/2µl/side) of the nucleus accumbens were measured in
photocell cages as previously described (French and, Vantini, 1984).
Lesions
Animals were prepared with unilateral excitotoxic lesions of the
nucleus accumbens (kainic acid, 2µg/O.75µl), medial prefrontal
cortex (N-methyl-D-aspartic acid, 25µg/0.6µl) or radiofrequency
lesions of the dorsal raphe nucleus. Also, the neurotoxin
parachloroamphetamine (PCA, 5 mg/kg/day for 2 days) was used to
deplete central serotonin (5-HT) levels. Subsequent
electrophysiological assessments were begun after a recovery period
of 7-10 days in the lesioned animals and 24 h after the last
injection of PCA.
RESULTS
A series of drugs covering the spectrum from high-affinity PCP-
receptor ligands (MK-801) to high-affinity u-receptor ligands
(ditolylguanidine (DTG)) were tested for their ability to alter
the firing rate of A,, DA neurons. As can be seen in figure 1,
MK-801 which has been shown to have the highest affinity and
selectivity for the PCP receptor (Wong et al, 1986) was the most
potent of all the compounds in activating dopamine cell firing,
followed by PCP, (+)SKF 10047 ((+)SKF) and ketamine (KET). The
maximal activation elicited by MK-801, PCP,(+)SKF and KET was
approximately 40%. Moreover, only PCP showed an inflection in the
dose-response profile with a slowing component emerging at doses
>1 mg/kg.
Of the highly u-preferring compounds (+)pentazocine ((+)PTZ)
produced a maximum increase of only 15%, while DTG failed to
produce any activation of firing. Calculations of relative potency
(Tallarida and Murray, 1987) found MK-801 to be 2, 4, 10 and 80
times more potent than PCP, (+)SKF, KET and (+)PTZ, respectively
in evoking increased firing. Thus, it would appear that activation
of the DA neurons comprising the mesolimbic-mesocortical system is
mediated via PCP, not u-receptors. The fact that (+)PTZ and DTG,
high-affinity ligands for the haloperidol-sensitive u-site (Weber
et al., 1986), with little to no affinity for the PCP receptor,
were virtually devoid of effects on these neurons supports this
conclusion. Furthermore, the activation of A,, neurons by PCP,
(+)SKF and MK-801 was not attenuated by haloperidol (Freeman &.
Bunney, 1984; French, 1986, 1989) which has the highest known
affinity for the -site.
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FIGURE 1. Cumulative dose-response effects of PCP and u-drugs on
firing rate of A,, neurons following i.v. administration.
The potency of PCP-like drugs to alter A,, activity was found to
correlate positively (r=0.97) with their affinity for the PCP
receptor and consequently with their potency as NMDA antagonists
(Aram et al., 1986). Whether blockade of central NMDA receptors
on mesolimbic-mesocortical DA neurons is the primary mechanism by
which PCP and PCP-like drugs produce their psychopharmacological
effects remains an intriguing issue. Although directly acting NMDA
antagonists have been shown to elicit PCP-like behaviors (Koek et
al, 1986), there is some debate as to how PCP-specific these NMDA
actions are (Willette and Balster, 1988). Since PCP and related
drugs appear to have a common electrophysiological effect on A
neurons, the response of these cells to directly acting NMDA
antagonists might indicate their potential for having
psychotomimetic properties. In these experiments we measured
changes in A,, firing during cumulative dosing with i.v. injections
of NPC 12626 (60 mg/kg) and (±)CPP (40 mg/kg), both high affinity
selective NMDA blockers (Davies et al., 1986; Ferkany, personal
communication). Both compounds failed to significantly change
firing rate up to 45 min. from the last injection. The maximum
effect elicited by NPC was +2.2% and that of (±)CPP +8.2%.
Moreover, following CPP infusions subsequent challenge with
incremental doses of PCP failed to increase activity more than
10%; a marked attenuation of PCP's normal 40% plus degree of
activation. In the behavioral assessment we did find that NPC
12626 (50 mg/kg, i.p.) produced a significant degree of locomotor
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hyperactivity accompanied by some ataxia. However, these effects,
like that of scopolamine were not sensitive to 6-OHDA lesions of
the accumbens; in marked contrast to the significant reductions in
PCP and d-AMP-induced activity in these lesioned animals (Table 1).
Thus it would appear that mesolimbic presynaptic DA mechanisms do
not mediate the PCP-like behaviors produced by competitive NMDA
antagonist.
TABLE 1
Photocell counts
Challenqe drug Sham 6-OHDA P-value
Saline 244 ± 34 382 ± 70 NS
PCP (5 mg/kg 855 ± 77 502 ± 88 0.01
NPC 12626 (50 mg/kg) 677 ± 84 627 ± 107 NS
d-AMP (1.5 mg/kg) 1562 ± 127 718 ± 92 0.01
SCOP (1.25 mg/kg) 550 ± 56 723 ± 87 NS
Unlike the other drugs we have tested PCP is unique in that it
produces a bimodal (excitation/ inhibition) effect on A,, cell
firing. Since the mesolimbic nucleus accumbens and mesocortical
prefrontal cortex contain relatively high concentrations of PCP
binding sites as well as provide inhibitory and excitatory inputs
to the VTA, respectively (Wolf et al., 1979; Christie et al.,
1985), we examined the effects of excitotoxic lesions of these two
areas on the response of A10 cells to PCP. As can be seen in fig.
2, the downward component normally produced by PCP at doses >1
mg/kg is eradicated in accumbens lesioned animals and replaced with
a significantly elevated and sustained level of activity (88% in
kainate and 55% in electrolytic lesioned animals). However, at
doses <1 mg/kg neither basal firing rates nor the magnitude of
excitation differed from controls. In contrast, destruction of the
medial prefrontal area failed to alter the dose-response
characteristics to PCP. These results, while strongly implicating
accumbal feedback systems in the inhibitory component of PCP action
also indicate that medial prefrontal excitatory amino acid
afferents to VTA are apparently not involved in the PCP-induced
excitation of A10 firing. Thus, it seemed reasonable to conclude
that the low-dose stimulating effects of PCP were operationally
determined by (an)other system(s).
Since the dorsal raphe nucleus provides substantial input to the
VTA and serotonin (5-HT) has been implicated in some PCP-induced
behaviors (Nabeshima et al., 1984) we next focussed on the possible
involvement of this transmitter system in the PCP-induced
activation of A10 neurons. In these experiments we found that
disruption of central 5-HT function by radiofrequency lesions of
the dorsal raphe (5-HT: 54% of control) or depletion of 5-HT by
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FIGURE 2.
kainate (
accumbens,
prefrontal
different
Response of AlO dopamine neurons to PCP in animals with
), or radiofrequency ( ) lesions of the nucleus
or N-methyl-D-aspartic acid ( ) lesions of the medial
cortex. The response of the control groups were not
and were therefore combined ( ). N=6-9 animals/group.
cumulativte dose-PCP (ma/kg, i.v.)
FIGURE 3. Attenuation of the response of A10 neurons to PCP
following disruption of central 5-HT function.
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parachloroamphetamine pretreatment (5 mg/kg once every 24 hr for
2 days) (11% of control) completely prevented PCP's low-dose
excitatory effects (fig. 3). The fact that pretreatment with the
5-HT2 selective antagonist ritanserin (5 mg/kg, i.p. 1-4 hr before)
also blocked PCP-induced activation of A10 neurons strongly
suggests a role for this 5-HT receptor subtype in this response.
More recently, we have also observed that 8-OH-DPAT, a 5-HT10
agonist which is a potent inhibitor of 5-HT cell firing, also
antagonized the activating effects of PCP (fig. 4). Thus, it seems
reasonable to conclude that PCP's primary low-dose stimulatory
effects on A10 DA neurons are mediated via an interaction with 5-
HT afferents to the VTA. The precise mechanism by which this
occurs and the potential involvement of the median raphe 5-HT
system is being investigated further.
PCP-CUMULATIVE DOSE (MG/KG, I.V.)
FIGURE 4. Response of VTA and substantia nigra pars compacta DA
neurons to PCP following saline or 8-OH-DPAT (30 ug/kg)
pretreatment, respectively.
DISCUSSION
The data presented here clearly establish a positive correlation
between the ability of PCP and PCP-like drugs to activate A10 DA
neurons and their affinity for central PCP receptors. The
ineffectiveness of high affinity u-specific ligands to alter DA
cell firing further argues against the participation of u-receptors
in the stimulation of these A10 neurons by PCP or
psychotomimetics. Since the potency of these drugs to stimulate DA
activity also correlated with their potency as non-competitive NMDA
receptor antagonists (MK-801>PCP>(+)SKF 10047>KET)(Kemp et al.,
1987), we sought to determine if competitive blockers of glutamate
action at NMDA sites would also mimic PCP's effects. Our data show
that this is not necessarily the case since rather large i.v. doses
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of direct NMDA antagonists (NPC 12626 and (±)CPP) did not stimulate
A10 activity. Although it could be argued that these phosphonic
acid compounds do not readily enter into brain, this seems unlikely
since a comparable dose of NPC 12626 administered i.p. elicited
both locomotor hyperactivity and ataxia. Furthermore, (±)CPP
pretreatment markedly diminished PCP-induced activation of A10
neurons, much in accord with radioligand binding studies showing
that a competitive antagonist can lower binding to the PCP receptor
(Javitt, et al., 1987; Kemp et al., 1987; Reynolds et al, 1987).
Also, systemic doses less than those used here have been shown to
be anticonvulsant, anti-ischemic and to produce some PCP-like
behaviors in drug discrimination paradigms. However, antagonism of
microiontophoretic NMDA-induced neuronal excitations by
systemically administered antagonists will be needed to
definitively settle this issue. In addition, our data showing
that NPC 12626-induced hyperactivity is not sensitive to 6-OHDA
lesions of the nucleus accumbens is also another indication that
while competitive blockade of the NMDA receptor complex produces
some PCP-like behaviors, these effects are not mediated through a
common site of action: the mesolimbic dopaminergic pathway.
Our studies into the sites and mechanisms by which PCP produces its
rather unique dose-dependent bimodal effect also produced some
interesting findings which strongly suggest that these two
phenomena are independently subserved through different CNS
transmitters. The low dose excitations are sensitive to disruption
of serotonergic transmission possibly originating in the dorsal
raphe nucleus, while the higher dose slowing component may involve
a negative feedback pathway to the VTA from the nucleus accumbens.
In conclusion, we have shown that the activation of mesolimbic-
mesocortical dopamine containing systems by PCP, and the
benzomorphans is mediated by the PCP receptor. If the midbrain DA
neurons are crucially involved in the reinforcing as well as
psychotomimetic properties associated with both classes of drugs,
then it would seem a logical conclusion that PCP receptors play the
pivotal role in these actions.
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Cerebral Pathways Activated by
PCP-Like Compounds: Relevance
to Neurotransmitters and Their
Receptors
M.F. Piercey and W. E. Hoffmann
Phencyclidine (PCP, "angel dust") is a hallucinogenic drug of
abuse which, when taken in large doses, produces a schizophreni-
form syndrome that is easily mistaken for positive symptom
schizophrenia (Luisada, 1978). Consistent with the widely held
theory that schizophrenia is a hyperdopaminergic state, PCP
evokes release of the neurotransmitter dopamine and induces
certain dopaminergic behavioral effects such as stereotypy in
animals (Domino and Kamenka, 1988). Moreover, PCP intoxication
can be partially treated with antipsychotic dopamine antagonists
such as haloperidol (Luisada, 1978). Evidence has accumulated
that PCP and related arylcyclohexylamines are channel-blocking
agents at the NMDA excitatory amino acid receptor. Thus, PCP
blocks the effects of NMDA and related excitatory amino acids
(Anis et al., 1983) and high affinity PCP binding sites are co-
distributed with those for NMDA receptors (Maragos et al., 1986).
A low affinity PCP binding site has been identified as the
"opioid" sigma receptor site thought to be associated with
"delirious" states (Sircar et al., 1986).
We have utilized Sokoloff's (1977) 2-deoxyglucose (2-DG) auto-
radiographic-methods to identify which brain pathways are altered
by PCP. The techniques have been previously detailed (Piercey et
al., 1988a). Briefly, 25 µCi 2-DG is injected in the saphenous
brain 45 minutes prior to sacrifice. Animals are restrained over
this time either in a plaster cast or, more recently, an animal
restrainer, to allow periodic sampling of arterial blood for
inclusion of plasma radioactivity and glucose into the Sokoloff
equations for estimating brain glucose metabolism from autoradio-
grams. While drug effects are unaltered, the increased activity
allowable in the restrainer tubes has resulted in increased
control metabolic rates (compare table 1 with tables 2 and 3).
Following sacrifice, the brains are removed, rapidly frozen,
sectioned on a cryostat, autoradiograms developed, and analyzed
by area analysis on a Loats image analyzer.
Utilizing this method, PCP was found (Piercey and Ray, 1988a,b)
to induce dramatic stimulation of brain forebrain pathways,
particularly dopaminergic structures, Papez' (1937) limbic
circuit, and some parts of the cerebral cortex (Table 1).
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TABLE 1. Effects of PCP (5 mg/kg) and Haloperidol (0.1 mg/kg) on
Regional Glucose Metabolism in the Rat Brain.
Structure
Cerebral Cortex
Olfactory Cortex
Dorsal Prefrontal
Frontal Cortex
Motor Cortex
Dense column
Light column
Sensory Cortex
Dense column
Light column
Piriform Cortex
Parietal Cortex
Auditory Cortex
Striate Cortex 17
Striate Cortex 18
Papez Circuit
Mamillary Body
AV Thalamus
Anterior Cingulate
Entorhinal Cortex
Hippocampus
Dentate
Dendritic Zone
Pyramidal Layer
Fornix
Dopaminergic Zones
M Prefrontal Cortex
Caudate
N Accumbens
Olfactory Tubercle
Globus Pallidus
Substantia Nigra
VTA
(µmole glucose/1OO g/min)
Control PCP PCP+Hal
85±5
72±3
73±4
75±3
75±3
87±5
87±5
83±3
81±5
111±4
81±4
76±4
85±5 222±10*
90±8 214± 5*
78±3 111± 3*
50±2 61± 2*
47±3
66±3
41±1
32±4
79± 5*
132± 7*
42± 4
43± 3*
107±5
77±2
53±3
69±3
46±2
46±2
53±3
126± 6*
85± 6*
77± 7
94± 7*
49± 3*
63± 2*
51± 5*
103± 6*
93± 3
103± 5
81± 3
115± 5*
159± 2*
127± 5*
95±10*
85± 7*
80± 2*
137±12*
52± 5
108±11*
69± 5+
59± 4*,+
70± 5
45± 3*
56± 4*
45± 4*
96± 4
80± 5
93± 5*
71± 3
102± 8*
212± 6*
220± 5*
105± 7*
57± 3
76± 5*
129± 5*
41± 1
43± 1*
138± 3*,+
117± 2*
73± 6*,+
75± 6 +
65± 4*,+
76± 4*,+
51± 2
Plaster cast restrainers, n=4 except for controls where n=8.
* significantly different from controls, (p<0.05)
+ significantly different from PCP (p<0.05)
Depressed areas include the sensory cortex, lateral habenula, and
the inferior colliculus. A rather remarkable effect is the
induction of vertical light/dark metabolic columns in the motor
cortex, possibly due to repeated use of specific motor pathways
associated with stereotypic behaviors (Piercey and Ray, 1988a,b).
The stimulant effects of PCP in the dopaminergic zones are
partially antagonized by haloperidol (table 1), reminiscent of
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the weak effects this agent has in treating overdoses in man.
Non-dopaminergic areas are unaffected by haloperidol (Piercey and
Ray, 1988b). Amphetamine, a schizophreniform agent which acts
primarily through stimulation of dopamine release, mimics PCP in
stimulation of dopaminergic areas but does not at all stimulate
Papez circuit (table 2). Amphetamine does not stimulate the
cerebral cortex. The inability of haloperidol to dramatically
inhibit PCP's affects or amphetamine to mimic most of them
indicates that much of PCP's effects do not involve dopamine.
However, stimulation of dopaminergic regions could be responsible
for some of the psychotomimetic as well as reinforcing properties
of PCP.
TABLE 2. Effects of Amphetamine
Metabolism in the Rat Brain.
Structure
Cerebral Cortex
Olfactory Cortex
Dorsal Prefrontal
Motor Cortex
Sensory Cortex
Piriform Cortex
Parietal Cortex
Auditory Cortex
Striate Cortex 17
Striate Cortex 18
Retrosplenial Cortex
Papez Circuit
Mammillary Body
AV Thalamus
Anterior Cingulate
Entorhinal Cortex
Hippocampus
Dentate
Dendritic Zone
Pyramidal Layer
Fornix
Dopaminergic Zones
M Prefrontal Cortex
Caudate
N Accumbens
Olfactory Tubercle
Globus Pallidus
Substantia Nigra
VTA
(10 mg/kg) on Regional Glucose
(µmole glucose/lOO g/min)
Control Amphetamine
154±14
148±10
158± 5
166± 6
165± 8
158± 4
181± 9
182± 6
174± 7
141± 6
158±11
151± 4
156± 5
102± 5
84± 5
136± 9
100± 7
69± 3
141± 8
164± 5
82± 8
139± 6
92± 5
74± 7
101± 7
154±12
158±12
176±17
211±20
150± 8
167± 9
190±11
147±11*
147±12
114±10
154±14
145±14
146±13
100± 9
64± 4*
119± 8
91± 4
85± 5*
146±14
226±17*
116± 7*
172± 9*
122± 8*
147±15*
135± 9*
Animal tube restrainers, n=4
* significantly different from controls, (p<0.05)
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TABLE 3. Effects of CPP (100 mg/kg) and MK-801 (1 mg/kg) on
Regional Glucose Metabolism in the Rat Brain.
Structure
Cerebral Cortex
Olfactory Cortex
Dorsal Prefrontal
Motor Cortex
Sensory Cortex
Piriform Cortex
Parietal Cortex
Auditory Cortex
Striate Cortex 17
Striate Cortex 18
Retrosplenial Cortex
Papez Circuit
Mammillary Body
AV Thalamus
Anterior Cingulate
Entorhinal Cortex
Hippocampus
Dentate
Dendritic Zone
Pyramidal Layer
Fornix
Dopaminergic Zones
M Prefrontal Cortex
Caudate
N Accumbens
Olfactory Tubercle
Globus Pallidus
Substantia Nigra
VTA
(µmole glucose/100 g/min)
Control CPP MK-801
139±11
143± 7
143±14
162±11
158± 6
162± 9
161±15
151±14
147±11
131±12
152± 6
145± 3
157±13
93± 5
83± 3
125± 2
91± 3
40± 4
133± 9
150± 8
95± 7
139± 6
78± 6
70± 7
91± 6
164±10
124± 5
129± 8
142± 7
174± 7
131± 8*
153±12
138± 5
139± 6
96± 3*
151± 8
131± 9
115± 6*
95± 4
76± 5
121± 6
79± 6
59± 4*
119± 9
156±10
84± 5
176± 9
84± 5
77± 5
97± 8
237± 7*
153± 8
164±13
138±11
224±12*
181±11
160±11
176± 5
212± 5*
292±13*
321± 9*
292±15*
228±14*
182± 1*
158±10*
212±13*
86± 5
85±10*
200± 6*
231± 9*
138± 7*
217± 7*
140± 6*
105± 8*
125± 9*
Animal tube restrainers, n=4-7
l significantly different from controls, (p<0.05)
The severe "rage" response, which includes delusions of "super-
human" strength, are a component of PCP's behavioral syndrome
(Luisada, 1978) but not that for amphetamine. It is tempting to
associate this intense PCP effect with this circuit that Papez
suggested integrated emotional sensations and expressions.
There is a strong suggestion that PCP's effects are associated
with NMDA receptors. Regions excited by PCP are endowed with
high concentrations of high affinity PCP receptors. Areas
containing high concentrations of sigma receptors are, in
contrast, not excited by PCP (Piercey and Ray, 1988a,b). Since
the high affinity PCP receptors are intimately related to NMDA
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receptors (Maragos et al., 1986), PCP's effects, including those
of dopaminergic areas, may be expressed through those receptors.
This suggestion is further supported by the fact that PCP's
effects are imitated by MK-801 (table 3), another NMDA receptor
channel-blocking agent which is weaker than PCP in stimulating
dopamine release (Domino and Kamenka, 1988).
It is not clear how PCP's dramatic stimulant effects could be
evoked by antagonism of a strong excitatory amino acid. This
question is heightened by the fact that CPP, an NMDA receptor
antagonist, does not mimic the effects of PCP and MK-801 in
effects on brain energy metabolism (table 3); indeed, CPP
depressed metabolism in the cingulate gyrus. If PCP's stimulant
effects are associated with NMDA receptors but not their
blockade, then one is led to suggest that PCP somehow stimulates
these receptors, perhaps by inducing them to open for short
periods of time. However, electrophysiological experiments do
not support this speculation (Anis et al., 1983).
Positron-emission-tomography (PET), a non-invasive technique,
allows 2-DG analysis in living, human patients. PET scans of
schizophrenic patients consistently reveal a metabolic gradient
("hypofrontanality") increasing from frontal to occipital cortex
(Buchsbaum, 1985). Some hypofrontanality is observed also in
PCP-intoxicated patients (Dr. Joseph Wu, personal communication).
PCP-treated animals also show some hypofrontanality (compare
frontal to sensorimotor to parietal and then striate cortex,
table 1). However, unlike PCP-treated animals, predominant
metabolic effects in schizophrenic and PCP-intoxicated patients
are depressions; only the occipital cortex region is stimulated.
The reasons for these differences between animal and human
studies is not clear, but could be due to the need to maintain
patients in a relatively quiet state in order to obtain PET-
scans.
The pathways and neurotransmitters associated with behavioral
effects of PCP are beginning to be revealed. Resolution of the
perplexing contradictions could lead to new insights into
psychiatric states, including drug abuse.
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Behavioral Pharmacology of PCP,
NMDA and Sigma Receptors
Robert L. Balster
The effects of PCP in animals has been proposed as a model of
schizophrenia. There are a number of rationales for this
proposal, including: a) the similarities between the PCP
psychosis which occurs in some PCP abusers and schizophrenic
disease; b) the ability of PCP to exacerbate schizophrenia;
and c) certain commonalities in the altered perceptions and
thought processes of persons under the influence of PCP and
schizophrenic patients. The neuropharmacological rationale for
the model includes the observation that PCP has a number of
dqpaminergic actions, and alterations in dopamine function have
been hypothesized to occur in schizophrenia. Therefore,
studies of the neural basis for PCP intoxication in animals may
provide clues to the underlying pathology present in psychosis.
PCP is now thought to produce many of its behavioral and
pharmacological effects through actions at a specific receptor
in the central nervous system. This PCP receptor has been the
subject of intensive research. One of the early findings was
that this receptor may also mediate the effects of certain
opioids which also produced psychotomimetic effects. These
opioids were hypothesized by W. R. Martin and his colleagues to
act upon an opiate receptor subtype referred to as the sigma
receptor, so-named because the prototypic agonist was SKF-
10, 047, or N-allylnormetazocine (NANM). Indeed, early research
suggested that the sigma receptor was not an opioid receptor at
all, but rather was identical to the PCP receptor. This was
supported by biochemical data showing common binding sites for
PGP-like drugs and sigma agonists and by behavioral data
showing considerable similarities in their effects.
Results of recent research have complicated this situation
considerably. Binding studies with the radiolabeled sigma-
agonist (+)-N-allylnormetazocine, and with other ligands,
demonstrated the existence of a high-affinity binding site
which differed in many ways from the PCP receptor. Although
PCP also had some affinity for this site, the pattern of
displacement by other drugs, as well as other data, provide
clear evidence that this site is distinct from the PCP site. 
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Interestingly, haloperidol and some other antipsychatic drugs
have a high affinity for this site but not for the PCP recep-
tor. The fact that PCP and some psychotomimetic opioids and
antipsychotic drugs bind to this site has led to speculation
that this site may also play a role in PCP intoxication and/or
schizophrenic disease. Although this may prove to be the case,
considerable confusion presently exists in the research
literature because this non-PCP site is now often referred to
as the sigma receptor (Quirion et al., 1981), even though it
seems increasingly clear that this is not the sigma receptor
hypothesized by Martin, and is certainly not the PCP/sigma
receptor which had been well characterized. Nor is it clear
that the site mediates pharmacological effects of drugs which
bind there, including those of sigma-agonist opioids.
Drug discrimination procedures in animals are often used as a
model for subjective effects of drugs. This presentation
reviewed data from my laboratory which addresses the question
of which of these sites is likely to be involved in the
production of the discriminative stimulus effects of PCP and
(+)-N-allylnormetazocine in animals. Drugs were studied which
have selective affinities for either the PCP receptor (e. g.
ketamine and MK-801) or for the high-affinity, haloperidol-
sensitive (+)-NANM binding site (e. g. DIG, (+)-3-PPP, (+)-
ketocyclazocine and (-)-butaclamol). In rats trained to
discriminate PCP from non-drug, the ability of drugs to
substitute for the PCP stimulus was perfectly predicted by
their ability to bind to the PCP receptor. MK-801, for
example, was found to substitute completely for PCP with a
potency predicted by its high affinity for the receptor
(Willetts and Balster, 1988a). Although (+)-NANM also has PCP-
like discriminative stimulus effects (Brady et al., 1982), it
is less potent than PCP, consistent with its relative potency
to PCP at the PCP receptor. Since (+)-NANM has a greater
affinity than PCP for the high-affinity site, this is further
evidence that this site is not responsible for the discrimina-
tive stimulus effects of PCP or (+)-NANM in this procedure.
Ihis, and other evidence, provides strong support for the
conclusion that the PCP receptor, and not the high-affinity
(+)-NANM binding site, is responsible for discriminative
stimulus effects of PCP (Balster and Willetts, 1988). The
answer to the question of whether or not the "sigma receptor"
plays a role in the effects of PCP and (+)-NANM depends upon
which sigma receptor is being referred to. The confusing
nomenclature is unfortunate.
Rats were also trained to discriminate (+)-NANM from non-drug.
Haloperidol, DTG, (+)-3-PPP, (+)-ketocyclazocine and (-)-
butaclamol all failed to produce (+)-NANM-like effects; nor
were they able to function as antagonists of (+)-NANM (Balster,
1989). On the other hand, PCP, MK-801, ketamine, (-)-2-MDP,
etoxadrol and dextrorphan all substituted fully for the (+)-
NANM stimulus with a potency predicted by their relative 
affinity for the PCP receptor and unrelated to their actions at
the high-affinity site (most are inactive at this site).
It seems clear from the results of our studies that the high-
affinity, haloperidol-sensitive (+)-NANM binding site, referred
to by some as the sigma receptor, is responsible for the
discriminative stimulus effects of neither FCP nor the sigma-
agonist (+)-NANM. If one assumes that these effects are
related to the ability of these drugs to produce a schizo-
phrenia-like intoxication in humans, then the PCP receptor
remains the cellular target of interest as possibly playing a
role in psychosis and as a possible site of action for novel
antipsychotic drugs. On the other hand, the high affinity of
some antipsychotic drugs for the high-affinity (+)-NANM site
continues to serve as a rationale for continued investigations
of its possible role in psychosis.
These results bear upon recent interest in potential therapeu-
tic uses of PCP-like drugs such as MK-801 as neuroprotectants.
Certain types of neural injury, such as that caused by the
ischaemia resulting from stroke, may have a basis in excito-
toxicity. Glutamate is an excitatory amino acid neurotrans-
mitter hypothesized to act upon at least three subtypes of
receptors. Excessive activation of the N-methyl-D-aspartate
(NMDA) receptor subtype as a result of brain insult is hypothe-
sized to produce a calcium-dependent neural degeneration.
Under many circumstances, these effects can be blocked by PCP-
like drugs. Indeed, PCP has been found to be a noncompetitive
antagonist of NMDA-receptor activation in many biochemical and
electrophysiological models (lodge et al., 1987). Unfortun-
ately, NMDA antagonism by PCP-receptor acting drugs is also
likely to result in PCP intoxication, a side-effect which would
limit their clinical utility.
NMDA antagonism can also result from drugs which act directly
at the glutamate binding site to produce competitive inhibition
of agonist binding. It is unknown whether NMDA antagonists
acting in this way will also produce PCP-like intoxication. We
have obtained data in animals showing potentially important
differences in the discriminative stimulus effects of PCP-like
drugs and competitive NMDA antagonists such as CPP and NPC
12626. In rats trained in a PCP discrimination, CPP (Willetts
and Balster, 1988b) and NPC 12626 (Ferkany et al., 1989) fail
to substitute fully for the PCP stimulus. In addition, PCP
fails to substitute fully in rats trained to discriminate NPC
12626 from non-drug (Willetts et al., 1989). Finally, the
competitive NMDA antagonists CPP and NPC 12626 are considerably
more effective than PCP-like drugs in antagonizing NMDA
discrimination (Willetts and Balster, 1989). Thus, there is a
good possibility that drugs can be developed with a separation
between NMDA antagonist effects and PCP-like side effects. On
the other hand, these results leave unresolved the role that
NMDA antagonism by PCP may play in the production of PCP
intoxication, and whether interactions between PCP and NMDA 
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receptors would be a fruitful target for research on the neural
basis of schizophrenia.
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Clinical Implications of PCP, NMDA
and Opiate Receptors
Jefferey Wilkins
INTRODUCTION
Phencyclidine (PCP) is best known as a substance of abuse with the potential to
cause psychosis and violence. Less wellknown is the recent discovery that PCP
may provide the molecular basis for compounds that will treat various
psychiatric and neurologic disorders. PCP binds to select central nervous system
(CNS) receptors with high affinity and specificity (Zukin and Zukin 1979,
Vincent et al., 1979). PCP receptors are co-distributed throughout the CNS with
N-methyl-d-aspartate (NMDA) receptors (one of three excitatory ammo acid
receptors [Honore 1989]) and is displaced competitively by endogenous peptides
(see Zukin, this monograph). This suggests the existence of endogenous PCP
ligand(s). Lodge and colleagues (1982) found that PCP noncompetitively
inhibits the NMDA receptor (the NMDA receptor system is postulated to
mediate cellular ‘damage from stroke and epilepsy), while animal studies have
shown PCP to protect against CNS damage from experimentally-induced
ischemia and hypoglycemia, and block experimentally-induced seizures (see
review by Honore 1989). PCP is also a psychotomimetic agent, and along with
PCP agonists, causes neuronal cell death (Olney et al., 1989). PCP, PCP
agonists, and presumably the endogenous PCP ligand, have the potential to both
cause and prerent CNS damage. Despite these varied and complex CNS actions
of PCP. evidence suggests that PCP agonists and antaeonists may be useful in
the diagnosis and treatment of psychiatric disorders including schizophrenia, and
as tools for defining the biochemistry of complex behaviors, including violence.
This manuscript attends to the psychiatric implications of PCP’s receptor actions,
discussed in terms of testable hypotheses and the degree to which each
hypothesis has been evaluated.
We focus on five hypotheses derived from findings and postulates of other
investigators and incorporated with results from our studies. These include:
1) Administration of PCP agonists, PCP antagonists, and amphetamine,
combined with biological measures, will separate schizophrenics into two
groups. This classification scheme will provide clinicians with a method for
selecting optimal pharmacologic treatment approaches to schizophrenia,
including choosing between traditional neuroleptics versus atypical
antipsychotic medications.
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2) primate behavioral responses to PCP predict PCP-induced behavior in
humans. That PCP induces aggression in primates but does so by first
blocking social affiliative behaviors has implications for understanding
violence in humans, including its biological basis. Behaviors altered by PCP
in the human will be found to be a function of PCP dose, predisposition to
psychosis, and social status.
3) PCP-induced protracted psychosis and post-hallucinogen perceptual disorder
(DSMIIIR) are sequelae of recirculating PCP in individuals prone to
psychotic responses to PCP. Treatment would include acidification of body
fluids to wash out PCP from the body, thereby preventing CNS uptake of PCP
through the blood-brain-barrier.
4) PCP agonists will help manage evolving stroke and early hypoglycemic
shock. PCP agonists will be used as supplements in treating epilepsy that is
unresponsive to conventional treatment. PCP agonists or antagonists will
prove useful in treating dementia depending on the endogenous PCP ligand
level.
5) neuropsychological deficits observed in PCP users are the result of PCP-
mediated neurotoxic effects (Olney et al., 1989). Independent studies of PCP
abusers and patients receiving ketamine will provide information on the risks
of administering PCP agonists to humans.
PCP and Schizophrenia
We hypothesize that schizophrenics are divisible into two groups analagous to
Crow’s hypothesis of schizophrenia (Crow 1980): those with a supersensitive
response to normal amounts of endogenous PCP ligand, and those with
dysfunction of the feedback loop regulating PCP ligand activity, resulting in
excess PCP ligand levels (see figure). The first group’s supersensitive response
to the PCP ligand results from excessive A10 dopaminergic activity that
sensitizes the PCP receptor. The second group’s elevated PCP ligand levels
result in CNS toxicity as described by Olney et al. (1989) The dysfunctional
feedback mechanism is analogous to hypothalamic-pituitary-adrenal (HPA) axis
dysfunction in endogenous depression. A small dose of PCP agonist worsens
positive symptoms of schizophrenics analagous to Crow’s Type I, while the
same dose does not affect Type II schizophrenics. A large dose of PCP agonist
further worsens Type I positive symptoms, whereas Type II negative symptoms
moderately improve, reflecting amphetamine-like activity from PCP (Balster
1986). Responses to an amphetamine (see discussion below) and PCP
antagonist challenge test also differ between the groups: Type I patient’s
positive symptoms improve, while Type II patients do not respond. We
postulate that individuals who manifest psychotic responses to PCP or PCP
agonists have a biologic diathesis for sensitivity to PCP similar to that found in
Type I schizophrenics, but with a diminished genotypic expression.
Three historical clinical observations have implicated PCP in the etiology of
psychosis: the untoward psychiatric effects seen in approximately 10% of
patients recovering from PCP-anesthesia (Greifenstein et al., 1958; Bums and
Lemer 1981). the PCP-induced exacerbation of psychosis in schizophrenics
(Luby et al. 1959). and PCP-induced psychosis in recreational drug users
without history of psychosis (Fauman and Fauman 1980). We postulate that
Type  I  s ch i zoph ren i c s  wou ld  f i nd  PCP  use  ave r s ive  wh i l e  Type  I I
schizophrenics would abuse the drug for its amphetamine-like alleviation of
negative symptoms. Based upon an early 1980’s study of urine PCP levels in
1,454 psychiatric admittees to the West Los Angeles V.A. Medical Center,
Brentwood Division (Gorelick and Wilkins 1986), we believe there is a bias of
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dopamine disorder alters the tonal response of PCP receptors to the PCP ligand
in predisposed individuals, resulting in psychosis.
PCP, Violence, and Stereotypy
Despite reports of violence associated with PCP use by humans (Fauman and
Fauman 1980). a causal relationship between PCP and aggressive behavior
remains unclear. We investigated the effects of varying doses of PCP on
aggressive, affiliative, and individual behaviors in vervet monkeys (Wilkins et
al. 1988; Dillon et al. 1987). Small doses of PCP attenuated affiliative
behaviors, increased their liklihood of receiving aggression, but had no impact
on locomotion. Low PCP doses caused dramatic grooming decreases, while
aggressing and engaging in stereotypies were unaffected. At higher PCP doses,
aggression and stereotypy obtained maximums substantially. above baseline
values. When grooming was at its lowest level, aggression and stereotypies
were at their maximum levels. Increased aggression was also noted in untreated
cagemates. Loss of grooming and related affiliative behaviors appears to
precede rapid development of aggression. The stepwise relationship between
PCP-induced blockade of complex affiliative i.e. grooming) behaviors and
development of extreme agonistic i.e. aggression) and stereotypic behaviors,
indicates that social behavior protects against aggression. We propose that these
PCP doses combined with amphetamines would produce stereotypy and
aggressive behavior. If a small dose of PCP were given with amphetamine and
neuroleptic, the affiiiative, aggressive, and stereotypic behaviors would be
blocked in monkeys, and the analogous behaviors blocked in schizophrenics.
Experimentally, we found that a larger PCP dose produced stereotypy and
aggression in monkeys, without the need of supplementary amphetamine. Based
upon known actions of dopamine blockers, we assume that neuroleptics would
block the above behaviors.
Animal models exploring neurotransmitter functions in PCP-mediated behaviors
may lead to development of new antipsychotic, antiviolence, and other types of
psychotropic medication (See Balster, this monograph). Drugs that alter
dopamine, serotonin, and sigma receptor activity appear to interact with
behavioral actions of PCP. Dopaminergic system enhancement precedes PCP-
induced stereotypy in rats (Hiramatsu et al., 1987; French and Vantini 1984).
PCP is also thought to exert direct agonistic action on 5-HT2 receptors at
medium to high doses and indirect agonistic action on 5-HT1 receptors at low
and medium doses, as well as release met-enkephalin indirectly or directly by
binding of PCP to sigma opioid receptors (Nabeshima, 1988). PCP also appears
to activate central sigma systems with attendant locomotor activation in the rat
(Iwamoto 1989). These models suggest that an ideal antipsychotic and
antiviolence agent may be one that is a dopamine and/or serotonin antagonist
and also blocks central sigma activity. In schizophrenics (see figure and earlier
discussion)  or  subjects  receiving PCP agonists ,  blood measures of
neurotransmitter metabolites (e.g. homovanillic acid reflecting CNS dopamine,
5-hydroxy-indole acetic acid reflecting serotonin) and sigma activity in
leucocytes (Wolfe 1988) may parallel the findings in animal studies.
PCP Induced Protracted Psychosis and Post Hallucinogen Perceptual
Disorder
We propose that PCP-induced protracted psychosis and post-hallucinogen
perceptual disorder are sequelae of recirculating PCP in individuals predisposed
to psychosis. Non-ionized PCP is lipophilic and hence accumulates in fatty
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some schizophrenic patients, compared to age/sex matched affective disordered
patients, to abuse PCP, reflecting self-medication of negative symptoms (we did
not dichotomize the subjects into Type I or Type II). Of 221 PCP positive
subjects, 50 were schizophrenic (22.6%), while 13 were diagnosed with affective
disorders (5.9%). Furthermore, 14.3% (50 of 350) of all schizophrenics were
PCP positive, whereas only 8.0% (13 of 162) of all affective disordered
individuals were positive. Though PCP positive patients in both groups tended
to be young (54% of each group were between 25 and 34). schizophrenics were
more likely to have high urine PCP concentrations (20% >100 ng/ml) than
affective disordered patients (7.7% >100 ng/ml). The only diagnostic groups
with greater rates of PCP use than schizophrenics were drug abusers and
alcoholics. Our data is consistent with 4 previous studies (reviewed by
Schneider and Siris 1987).
Select CNS actions of PCP. taken together with the dopamine hypothesis of
schizophrenia (Haracz 1982) may explain a number of unresolved clinical
phenomenon including: the wide spectrum of clinical presentation, the
developmental nature of schizophrenic signs and symptoms, stress-related
exacerbations of psychosis in stabilized schizophrenics, specific patterns of
substance abuse, and the significant percentage of patients who are unresponsive
to dopamine blocking neuroleptics. Haracz (1984) has postulated that long term
potentiation (LTP) processes within the CNS control the timing of psychotic
development in schizophrenics. PCP ligand activity may mediate LTP actions
since 2-APV and 2-APH, drugs with PCP-like actions, are effective in altering
LTP using the brief tetanic stimulation model (reviewed by Honore 1989). PCP
ligand activity may also be involved in stress-induced psychotic exacerbations in
schizophrenics. Pechnick et al. (1989) found that PCP doses as low as 0.5
mg/kg result in increased ACTH and corticosterone levels for up to 5 hours in
rats. We postulate that stress results in increased endogenous PCP ligand levels
in schizophrenic patients, leading to exacerbation of psychosis (esp. in Type 1
schizophrenics) and subsequent release of hypothalamic-pituitary-adrenal axis
(HPA) stress hormones. This hypothesis is supported by recent in vitro findings
(Su 1989) that endogenous steroid hormones, perhaps functioning in a feedback
loop regulating PCP ligand levels, bind as a ligand to CNS sigma receptors.
Crow (1980) has proposed a division of schizophrenia into Type I (acute state)
and Type II (defect or chronic state). Type I schizophrenia is believed to result
from excessive dopamine activity, and is characterized by positive symptoms
including delusions, hallucinations, thought disorder, normal computerized axial
tomography (CAT) scans, and in general, a positive therapeutic response to
neuroleptics. Type II schizophrenia is believed to result from structural CNS.
deficit(s), and is characterized by negative symptoms including affective
flattening and poverty of speech. abnormal CAT scans, and a generally negative
therapeutic response to neuroleptics. Amphetamines worsen Type I symptoms
but improve Type II symptoms. Cesarec and Nyman (1985) and Van Kammen
and Boronow (1988) observed decreased negative symptoms in schizophrenics
given amphetamines; these reductions were lost when amphetamine therapy was
discontinued. Van Kammen et al. (1982). Angrist et al. (1985), and Lieberman
et al. (1985.1987) report that schizophrenics exacerbating psychosis when given
amphetamines are those patients who relapse sooner upon discontinuation of
neuroleptic medication (e.g. Type I patients). Amphetamine administration
upsets  the mesolimbic (A10).  and dopaminergic systems of  Type I
schizophrenics. These observations are consistent with French et al. (1988),
who found that exogenously administered PCP alters A10 dopaminergic
function (See French and Piercey, this monograph). We postulate that a
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tissue (Misra et al., 1979). Lysis of fat may liberate PCP into the circulatory
system, from where it is readily absorbed by brain. Washout of PCP from brain
and other tissues is accomplished by acidifying tissues (e.g. patients are given
cranberry juice, which contains the acidifying agent hippuric acid). We have
also shown that acidification of body fluids results in significant decreases in
blood-brain-barrier (BBB) uptake of PCP into the CNS (Wilkins 1986). Using
the intracarotid single bolus injection technique (Oldendorf 1971), we found
that as the injection mixture pH increases from 7.5 to 8.4, there was a modest
5% increase in the Brain Uptake Index (BUI) of PCP (65.8 + 5 to 70.8 + 5.6).
Lowering the injection mixture pH from 7.5 to 6.8 resulted in a 36% decrease in
BUI of PCP (65.8 + 5 to 42.4 + 1.5) (Student t test, p <.01). As the pH of the
BBB capillary network is lowered, ionization of PCP increases and PCP uptake
by brain decreases.
PCP Agonists and Neurologic Disorders
An optimal PCP agonist would help manage evolving stroke and early
hypoglycemic shock, without attendant psychotomimetic effects. In both cases,
patients manifest a dangerous and quickly changing clinical picture where a PCP
agonist would block or attenuate ischaemic or hypoglycemic CNS damage while
other stabilizing medical procedures are performed. Based on evidence that the
NMDA receptor is central to epilepsy pathophysiology (Schwarz et al., 1987).
we postulate that PCP agonists may also treat epilepsy or at least refractory
epilepsy. We also speculate that PCP agonists may treat progressive CNS
disease states, including AIDS-related dementia and dementia of the Alzheimer’s
type.
CNS Toxicity from PCP
We propose that PCP-induced neuropsychological deficits are secondary to CNS
toxic effects of PCP agonists (Olney 1989). PCP induces neurotoxic effects on
medium-to-large sized neurones in layers III and IV of the posterior cingulate
and retrosplenial cortices, causing significant neuropsychological deficits in PCP
abusers. In a study of PCP abusers, Lewis and Hordon found that 30%
manipulated brain damage according to Trails B Test (a subtest of the Halstead-
Reitan battery). Seventy percent were in the mild, moderate, or severe
impairment range as determined by the Category Test, and a Mean Full Scale IQ
of 92.5. These results may be complicated by polydrug abuse and aldulterated
PCP. Neuropsychological deficits observed in PCP users are the result of PCP-
mediated neurotoxic effects (Olney et al., 1989). We propose that studies of
PCP abusers and patients receiving ketamine anesthesia will provide information
on the risks of administering PCP agonists to humans.
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Integration of PCP Actions with Crow’s
Type I and Type II Schizophrenia
Anticipated Results
Response to PCP
agonist (small dose)
Response to PCP
agonist (larger dose)
Type I
worsens pos.
symptoms
worsens pos.
symptoms
Type II
No effect
moderate improvement in
negative sx (as amphetamine)
Response to PCP
antagonist
Ratio CSF & Blood
HVA: CSF PCP ligand
improvement in
pos. symptoms
High
no response
Low
Positron Emission Tomography: High
ratio of dopamine to
PCP/sigma receptor activity
Low
Drug abuse
pattern
Tendency to Abuse of PCP (as
avoid PCP CNS stimulant)
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Cannabinoid Modulation of Cyclic
AMP. Accumulation in
Synaptosomes
Patrick J. Little and Billy R. Martin
9-Tetrahydrocannabinol ( 9-THC) and other cannabinoids
disrupt many membrane-bound enzyme systems. The
precise role that this disruption may play in the
pharmacology of the cannabinoids is unknown. Moreover,
it is unclear whether these membrane effects represent
a specific interaction with the enzyme molecule, or a
non-specific change in activity of the enzyme due to
perturbation of the lipid environment. One enzyme that
has received much of the focus is adenylate cyclase, an
integral membrane protein responsible for the formation
of cyclic adenosine 3',5'- monophosphate (CAMP). The
role of CAMP as a second messenger in most tissues
including the CNS has been well documented. The
ability of cannabinoids to alter adenylate cyclase
activity has been best characterized in tissue culture,
while these effects have not been as well characterized
in brain preparations. The purpose of this
investigation was to use structurally novel
cannabinoids, which display potent cannabimimetic
effects in mice, as probes to aid in further
elucidation of the effects of cannabinoids on CAMP
accumulation in the brain.
Male ICR mice were decapitated and their brains minus
cerebellum were homogenized in 0.32M sucrose. A crude
P2 homogenate was layered on a discontinuous ficoll
gradient to obtain synaptosomes. Synaptosomes were
then maintained in a Krebs-Henseleit buffer and effects
of cannabinoids on forskolin-stimulated increases in
CAMP accumulation were determined. Levels of cAMP were
determined using a competitive binding assay, with
dextran-charcoal adsorption and centrifugation used to
separate bound and free CAMP. All cannabinoids tested
had little or no effect on basal CAMP levels, therefore
the effects on forskolin-stimulated (either 0.1 or 1
µM increases in CAMP were determined. 9-THC (1-100
nM) decreased CAMP levels by approximately 10%
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following stimulation by 0.1 µM of forskolin, while
concentrations of 9-THC above 1 µM had little or no
effect. CP-55,940 and CP-55,244 are structurally novel
cannabinoids which possess very potent activity in
mice. CP-55,940 significantly (p < 0.05) decreased
CAMP levels in a concentration-dependent manner
following 1 µM forskolin, with 1 µM decreasing levels
by 15%. CP-56,667, the (+)-enantiomer of CP-55,940,
inhibited forskolin-stimulated (1 µM) increases in CAMP
by approximately the same level, however a
concentration of 30 µM was required to observe similar
degrees of inhibition. CP-55,244 significantly (p <
0.05) decreased the level of forskolin-stimulated (0.1
µM) CAMP accumulation between 0.03-10 µM with a maximal
inhibition of approximately 20%. CP-55,243, the
(+)-enantiomer had no effect on CAMP levels at
concentrations as high as 30 µM. Unlike the other
structurally novel cannabinoids, levonantradol enhanced
forskolin-induced increases in CAMP by approximately
15% between 0.01-0.3 µM. Dextronantradol, the
(+)-enantiomer also augmented the increase in CAMP
caused by forskolin. Both levonantradol and
dextronantradol decreased CAMP levels at concentrations
above 1 µM.
Thus, there are some differences between the effects of
the structurally novel cannabinoids and 9-THC on CAMP
accumulation in mouse synaptosomes, although they
produce the same qualitative effects in vivo. Thus,
the precise nature of the role that adenylate cyclase
may play in the pharmacology of 9-THC is unclear and
needs to be more thoroughly investigated.
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Withdrawal From Benzodiazepine
Dependence as a Discriminative
Stimulus
M. W. Emmett-Oglesby and D. A. Mathis
Rats were maintained on a baseline of chlordiazepoxide (CDP), given in
a nutrionally-balanced liquid diet, in two doses daily (100 mg/kg/day).
Six-hours after the morning administration of CDP, subjects were
trained to discriminate the benzodiazepine antagonist, flumazenil, 20
mg/kg, from saline using food reinforcement in a two-lever choice pro-
cedure. The discrimination was acquired rapidly, and lower doses of
flumazenil substituted for the training stimulus with an ED50 of approxi-
mately 0.64 mg/kg. Cocaine, a drug with stimulus properties distinct
both from CDP and withdrawal from CDP, was also tested. Rats se-
lected the saline lever, indicating that the discrimination was based on
an effect of flumazenil. In additional tests, the anxiogenic drug, pen-
tylenetetrazole (PTZ), substituted for flumazenil. In contrast, rats
trained to detect PTZ and tested with flumazenil alone did not substitute
flumazenil for PTZ. However, if rats trained to detect PTZ were given
this CDP diet for two weeks, flumazenil also substituted for PTZ. These
data are consistent with the suggestion that subjects learned to discrimi-
nate withdrawal from CDP, and the data from tests with PTZ suggest
that a predominant component of this discriminative stimulus is PTZ-like
in character.
ACKNOWLEDGEMENTS: Supported by NIDA Grant DA RO1-3521.
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Medicine, Fort Worth, TX 76107-2690
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[3H]AHN 086 Acylates Peripheral
Benzodiazepine Receptors in the
Rat Pineal Gland
A. H. Newman, R. T. McCabe, J. A. Schoenheimer,
P. Skolnick, K. C. Rice, J-A Reig and D. C. Klein
The peripheral-type benzodiazepine receptors (PBR), located
in a variety of peripheral tissues and in the brain, have been
characterized by two selective ligands, Ro 5-4864 and PK
11195. We have reported that PBR in rat kidney and heart are
s e l e c t i v e l y a c y l a t e d  b y A H N 086, an
isothiocyanato-derivative of Ro 5-4864, and AHN 070, an
isothiocyanato-derivative of PK 11195. These ligands have
proven to be useful tools in the characterization of the PBR
in these tissues. The synthesis of [3H]AHN 086 (NEN, S.A. 45
Ci/mmol) has recent ly provided a high aff in i ty,  select ive
radioligand with which to characterize PBR. Rat pineal gland
was chosen for this initial study since it has been shown to
have a high density of PBR.
[3H]AHN 086 was incorporated into rat pineal protein, bovine
pineal protein and ovalbumin, however significant specific
incorporat ion was only detected in the rat  pineal. Gel
f i l t r a t i o n  h i g h  p e r f o r m a n c e  l i q u i d  c h r o m a t o g r a p h y  o f
digitonin-solubilized membranes from this tissue revealed a
major peak of radioactivity with a retention time of 18.2 min
corresponding to approximately 27 kDa. A major  band
corresponding to 30 kDa protein was labeled by t3H]AHN 086
using sodium dodecyl sulfate-acrylamide gel electrophoresis
(SDS-PAGE). The incorporation of [3H]AHN 086 into this
protein was inhibited by preincubation with the cols ligand.
In addition, significant specific binding of [3H]AHN 086 was
not observed in bovine pineal gland and ovalbumin (tissues
that do not have high affinity binding sites for Ro 5-4864).
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[3H]AHN 086 [3H]AHN 070
The a parent molecular mass of PBR in rat pineal obtained
with [3H]AHN 086 is in good agreement with the target size
o f  P B R  e s t i m a t e d  b y  r a d i a t i o n inactivation using
[3H]diazepam and by photoaffinity labeling with
[3H]f luni t razepam (both 1,4-benzodiazepines that bind to
c e n t r a l  a n d  p e r i p h e r a l  b e n z o d i a z e p i n e  r e c e p t o r s ) .  I n
contrast, several studies using the isoquinolmecarboxamide
[3H]PK 14105 to photoaffinity label PBR in several different
tissues obtained a molecular mass of approximately 18 kDa.
These findings may indicate a multimeric arrangement of 18
and 30  kDa pro te ins  in  rodent  t i ssue . W e  h a v e  n o w
synthesized [3H]AHN 070, and are presently characterizing
i t s  b i n d i n g  t o  P B R . F u t u r e  s t u d i e s  w i t h  t h e s e  t w o
irreversible radiol igands s h o u l d  p r o v e valuable in
de te rm in ing  the  mo lecu la r  a r rangement ,  s t ruc tu re  and
function of PBR.
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Identification of Metabolites of
CP-55,940 Formed In-Vitro by
Mouse Livers
Brain F. Thomas and Billy R. Martin
A number of analogs of the basic cannabinoid molecule have been synthesized
attempting to define structural requirements for analgesic activity. This research
has produced potent analgesic agents such as (-)-cis-3-[2-hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP-55,940).
The structural differences between the naturally occurring cannabinoid delta-9-
tetrahydrocannabinol 9-THC), and this synthetic agent are quite dramatic, yet
this compound has been shown to retain potent cannabimimetic activity in a
number of behavioral tests. Due to the relatively recent development of this
synthetic agent, its metabolism has yet to be thoroughly investigated. This study
was undertaken to elucidate the primary metabolites of CP-55,940 formed in
mouse liver preparations enriched with the appropriate cofactors for oxidative
metabolism.
An S-9 supernatant prepared from the homogenate of 6 livers was enriched with
0.48 mg/ml NADPH, 0.16 mg/ml NADH, 0.4 mg/ml glucose-6-phosphate,
and 1.0 µl/ml glucose-6-phosphate dehydrogenase prior to incubation with 2.0
mg of (X-55,940 and 3.0 µCi of 3H-CP-55,940 at 37°C for 1 hr. The isolation
of metabolites extracted with diethyl ether was performed using an HPLC
equipped with a 25 cm C-8 reverse-phase column and a methanol/water
gradient. The isolated metabolites were heated with BSTFA to form the
ttimethylsilyl derivatives and, analyzed using a Hewlett-Packard 5988 Gas
Chromatograph/Mass Spectrometer (GC/MS). Non-metabolized CP-55,940
was identified in the HPLC fraction collected at 33 min. The HPLC fractions
collected between 16 and 18 min were pooled prior to derivatization and
analysis by GC/MS. This sample was found to contain 5 monohydroxylated
metabolites of CP-55,940 that could be separated on the gas chromatograph
using an oven temperature ramp programmed at 10°C/min. The mass-spectral
data obtained indicated that the 5 metabolites differed only with respect to the
position of the hydroxylation on the dimethylheptyl side chain of CP-55,940.
The HPLC fractions collected from 10 to 12 min were also pooled prior to
GC/MS analysis. A number of compounds were detected in this sample that
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have been tentatively identified as metabolites that are dihydroxylated on the
side chain.
METABOLIC PROFILE OF CP-55,940
The determination that the side chain is extensively hydroxylated by the P450
mixed function oxidase system is interesting because it has been reported that
metabolites of 8-THC that are hydroxylated on the side chain retain some
cannabinoid activity (Ohlsson et al. 1980). In addition the formation of the
side chain hydroxyl group produces an-additional chiral center in the molecule.
In support of these findings, the side chain hydroxylation reported to occur in
this in-vitro preparation is consistent with the metabolic profiles of other
cannabinoids (Harvey and Brown 1987).
Supported by NIDA grant #DA-03672 and NIDA training grant #DA-07027.
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A New Analysis of Whole-Body
Calorimetry Data
T. J. Lynch, R. P. Martinez, M. B. Furman
E. B. Geller and M. W. Adler
We have used gradient layer, whole-body calorimetry to
study the mechanism by which mu and kappa opioid
agonists induce hypothermia in rats. Continuous plots
of drug-induced changes in body temperature (TB),
whole-body heat loss (Q) and oxygen consumption (VO2)
and the Q/VO2 ratio were generated. Though simple
enough, Q/VO2, as related to ongoing changes in Tm, has
not appeared in the literature. We have referred to it
as relative heat conservation since
depicts
it graphically
how morphine, methadone and U50,488H induce
hypothermia despite sharp decreases in both VO2 and
heat loss (Lynch et al., NIDA Res. Mono. 76, 1986).
Regresslon analyses between log TB and selected
measures such as Q, VO2 and Q/VO2 yield correlation
coefficients in the range 0.65 to 0.80. These are
disappointingly low for such physical measures.
Correlation of log TB vs Q/VO2 is poor because with the
onset of drug-induced hypothermia, log TB decreases
continually, while Q/VO2 first increases but then
decreases below basellne. However, correlation between
log TB and the cumulative integral of the increase In
Q/V02 Q/VO2) yields a Pearson's I of 0.99 for the
onset of hypothermia. During recovery from hypothermia,
the same r value is obtained for the relation between
log TB and the cumulative integral of the decrease in
Q/VO2. The analysls reduces the four chart traces, TB,
Q, VO2 and Q/VO2 from an entire experiment to two
straight lines, one for onset of, and another for
recovery from opioid-induced hypothermia. The analysis
proves that change in TB is proportlonal to the
integral of relative heat conservation, and that this
can be quantltated without calculations based on the
specific heat of rat tissue. We are hoping that the
peak changes In Q/VO2 caused by various opiolds,
together with characteristic slopes of the regression
equations (see figure) will tell us more about how
agonists and antagonists affect different receptor
populations. (Supported by NIDA Grants 5F32DA05300 and
DA00376)
Affiliation: Temple University School of Medicine, Dept. of
Pharmacology, Philadelphia, Pennsylvania 19140
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METHADONE-INDUCED HYPOTHERMIA IN THE RAT
Tb = BRAIN CORTICAL TEMP Q/VO2 = REL. HEAT CONSERVATION, CAL/ML O2
Cumulative Integral of Q/VO2 Increase Cumulative Integral of Q/VO2 Decrease
TB =ANTILOG [-.01225 ( Q/VO2)+1.5756] TB=ANTILOG [.00445 ( Q/VO2)+1.5104]
r = -.995 r = .993
Novel [D-Pen2, D-Pen5]Enkephalin
Derivatives With Increased Sigma
Receptor Potency and Selectivity:
Potential Tools for Opioid
Pharmacology
Thomas F. Burks, Thomas H. Kramer, Peg Davis
Gaza Toth and Victor J. Hruby
Improved definition of the central and peripheral
functions of delta opioid receptors requires highly
selective ligands. Presently, cyclic [D-Pen2, D-
Pen5]enkephalin (DPDPE) is considered the most
selective delta opioid agonist available for
experimental use. It was our aim to develop new
analogs of DPDPE with increased selectivity for delta
vs. mu opioid receptors. Halogen (F,Cl,Br,I)
substitutions were introduced in the para position of
the Phe4 residue of DPDPE. These compounds were
evaluated in the mouse vas deferens (MVD) and guinea
pig ileum longitudinal muscle/myenteric plexus (GPI)
bioassay preparations for delta and mu potency
(assessed by IC50 values) and for delta selectivity
(assessed by the ratio of the IC50 in GPI to the IC50
obtained in MVD). Naloxone and selective antagonists,
CTAP for mu receptors and ICI 174,864 for delta
receptors, were employed to confirm specificity in
each preparation. The compounds were evaluated in
vivo for analgesic activity in the mouse hotplate test
after intracerebroventricular (i.c.v.) and intrathecal
(i.t.) administration.
All of the [p-halogenated-Phe4]DPDPE analogs
demonstrated improved potency and specificity for
delta opioid receptors
the MVD assay,
in comparison with DPDPE. In
[p-F-Phe4]DPDPE was the most potent
(IC50 = 0.84 nM) and [p-I-Phe
4]DPDPE was least potent
(IC50 = 2.65 nM). In the GPI, [p-Cl-Phe
4]DPDPE was the
most potent (4.8 µM) and [P-I-Phe4]DPDPE was least
potent (IC50 = 46.1 µM). The order of selectivity
assessed by ratio of IC50 values for GPI/MVD was [P-I-
Phe4]DPDPE (17,374-fold selective) >[p-Br-Phe4]DPDPE
(8959-fold) > [p-F-Phe4]DPDPE (5993-fold) > [p-Cl-
Phe4] DPDPE (5399-fold) > DPDPE (1336-fold). In MVD,
all analogs and DPDPE were competitively antagonized
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by ICI 174,864 but were unaffected by CTAP.
Conversely, in GPI all were antagonized by CTAP
indicating that effects in the GPI reflect actions at
mu receptors. All of the analogs produced analgesia
after either .i.c.v. or i.t. administration in mice.
The A50 values were similar to those obtained with
DPDPE, ranging from 0.3 to 6.0 nmoles/mouse i.c.v. and
3.3 to 18.2 nmoles/mouse i.t.
We conclude that additional conformational restriction
induced by p-halogenation of the Phe4 residue of DPDPE
produced enhanced selectivity for delta opioid
receptors. Further, analgesic potency of these
peptides is associated with agonist actions at delta
opioid receptors. These agents hold great potential
as new tools for the study of the delta opioid
receptor and its functions.
(Supported by USPHS grants NS19972, DA04248, DA02163,
and DK36289.)
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The Immune System and
Dependence
N. Dafny, P. M. Dougherty and N. R. Pellis
Morphine
Morphine dependence and the expression of withdrawal are
dependent upon several discrete CNS regions. Ablation of these
sites attenuates both the acute response to morphine as well as
the expression of withdrawal (1). In addition, repeated
administration of morphine directly to these areas induces a
state of dependence identical to that observed following
systemic injection of opiate (2). This syndrome has also been
suggested to have an important immune component. An interaction
between CNS opioid activity and lymphoid system has recently
been suggested (3). Indeed ,there is significant overlap
between many brain regions involved in the manifestation of
opiate effects and those associated with immune system (IS)
modulation (4). Yet, the participation of the IS in modulation
central opioid actions has been underscored by the finding that
various immunomodulating agents such as interferon (5),
cyclosporin (6) and immune suppressive doses of gamma
irradiation (7) attenuate the severity of naloxone-precipitated
opiate abstinence in morphine-dependent rats. This has led to
the hypothesis that an intact IS is essential for the expression
of opiate withdrawal. This study tests this hypothesis by
examining whether rats by adoptive transfer of splenic
mononuclear cells will restore the withdrawal signs precipitated
with naloxone in morphine-dependent rats.
Eighty-four male Fischer rats were used as donors of spleen
cells. Cells from two donors were transferred (i.v.) to a
single recipient (8). In some experiments splenic lymphoid cell
populations were fractionated into plastic adherent and
non-adherent subpopulations. Physical dependence upon morphine
was induced by subcutaneous implantation of a pellet containing
75 mg of drug base for 72 hours. Five signs of naloxone
precipitate withdrawal were scored. Wet dog shakes, teeth
chatters, fecal boli, hyperactivity, scream to touch and
diarrhea (3,5,6).
Adoptive transfer of 2-6 X 108 splenocytes to irradiated rats
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(500 rads) prior to chronic morphine treatment restores the
severity of all withdrawal signs precipitated by naloxone. In
contrast, adoptive transfer of fractionated splenocyte
subpopulations only partially restores withdrawal severity; and
adoptive transfer of irradiated-splenocytes, red blood cells, or
diluted number of normal splenocytes did not have any observed
restorative effects (Fig. 1).
Figure 1. Summary of
min after 1.0 mg/kg naloxone (ip) injection.
the signs of withdrawal observed for 1 0
The responses of animals to ionizing irradiation is rather
conveniently stratified in a dose-dependent manner among the 3
major radio-sensitive organ system, the IS, the GI tract and the
CNS. Exposure of animals to ionizing irradiation can at the
appropriate dosages render them incapable of responding to
antigenic stimulus without measurable changes in other body
systems (9). Thus, irradiation was used to produce an animal
model to test the effects of lymphoid organ ablation upon brain
opioid activity. It was shown that irradiation reduce the
severity of naloxone precipitated withdrawal (group 2) and
transfer of splenic immune cell population from intact donors to
irradiated recipients prior to chronic morphine treatment
restored the severity of the withdrawal signs precipitated by
naloxone (group 3). The control groups established that the
adoptive transfer procedure itself does not explain the effects
of immune reconstitution in counter-acting irradiation-induced
withdrawal suppression. Moreover, the finding of a minimum cell
numbers necessary for restoration of withdrawal, and the
necessity of both splenocyte cell fractions for the full
restoration supports the conclusion of a complex active
participation of lymphoid cells in the manifestation of
withdrawal. Whether the role played by the IS in opiate
withdrawal is active or supportive remain to be resolved.
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Irreversible-Affinity Ligands for Mu
Opioid Receptors
J. M. Bidlack, D. K. Frey, A. Seyed-Mozaffari and S. Archer
The morphine derivatives, 14 ß-(bromoacetamido)morphine (BAM), 14ß-
(bromoacetamido)morphinone (BAMO), 14ß-(bromoacetamido)-7,8-
dihydromorphine (H2BAM), and 14ß-(bromoacetamido)-7,8-dihydro-
morphinone (H2BAMO) were tested for their abiity to bind irreversibly
to opioid binding sites in rat brain membranes. In the absence of a
disulf ide bond reducing.  agent ,  these aff ini ty I igands bound only
reversibly to opioid binding sites, The four ligands had receptor
affinity and selectivity profiles similar to morphine. When membranes
were incubated with dithiothreitol (DTT), followed by the affinity
l i g a n d s ,  a n d  t h e n  e x t e n s i v e  w a s h i n g ,  t h e  a f f i n i t y  l i g a n d s
inhibited the binding of the µ-selective peptide [3H][D-Ala2,
(Me)Phe4,Gly(ol)5]enkephalin (DAGO) to membranes Under conditions
when 90% of the [3H]DAGO binding was inhibited, binding to and K
opioid binding sites was not altered by membrane alkylation with the
affinity ligands, The irreversible inhibition of µ opioid binding was
dependent on the concentrations of DTT and the affinity ligands.
Opioids that bind to the µ opioid binding sites partially protected the
µ binding site from alkylation, In addition to [3H]DAGO binding, the
binding of other radiolabeled opioids to µ binding si tes was also
inhibited by alkylation with the affinity ligands. The specificity of the
alkylation is the result of DTT breaking a disulfide bond at or near µ
opioid binding sites, This disulfide bond does not appear to be shared
by or K opioid binding sites. These studies demonstrate that upon
reduction of a specific disulfide bond at or near the µ opioid binding
site, 148 -bromoacetamido derivatives of morphine will akylate this
site, resulting in the specific affinity labeling of µ opioid binding sites
ACKNOWLEDGEMENTS: Supported by grants DA03742 and DA01674
from the National Institute on Drug Abuse.
AFFILIATIONS: Department of  Pharmacology,  The Universi ty of
Rochester, School of Medicine and Dentistry, Rochester, NY 14642 and
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Differential Release of Substance P
and Somatostatin in the Rat Spinal
Cord in Response to Noxious Cold
and Heat: Effect of Dynorphin
A(1-17)
Paul J. Tiseo, Martin W. Adler and Lee-Yuan Liu-Chen
Dynorphin A, 1-17 (DYN), the proposed endogenous ligand for the kappa
opioid receptor, has been reported to demonstrate no antinociceptive activity
when tested in analgesic assays involving noxious heat (eg.. tail-flick and hot
plate assays). Using a rat tail-flick analgesic assay that utilizes extreme cold as its
noxious stimulus (an ethylene glycol/water mixture maintained at -10° C), we
have reported a dose-related and naloxone-reversible antinociceptive effect for
i.c.v. administered DYN. To investigate the mechanism of this antinociception,
we designed a  push-pull perfusion system which allowed us to measure changes
in neuropeptide release in the spinal cord during exposure to noxious heat or
cold. Male S-D rats were surgically implanted with two lengths of PE- 10 tubing
inserted into the spinal subarachnoid space via the cisterna magna. At the time of
testing, samples of CSF were collected both in the presence and absence of a
noxious stimulus and substance P (SP) and somatostatin (SST) levels were then
measured by RIA. Exposing the animal’s tail to the noxious cold (30 sec/min
for 20 min) resulted in a significant elevation in SP release (75% above baseline
levels) but no change in the level of SST release. Conversely, exposure to
noxious heat (50°C, 20 sec/min for 20 min) produced a significant increase in
SST release (56% above baseline), but no change in the level of SP release.
When DYN was administered i.c.v. just prior to noxious cold stimulation, there
was a significant and dose-related (10-30 µg) inhibition of SP released in
response to the stimulus. Naloxone (10 mg/kg, s.c.) was able to markedly reduce
this inhibition. These results suggest that nociceptors specific for different types
of thermal stimuli release different neurotransmitters in the dorsal horn, and that
DYN produces antinociception to noxious cold, at least partly, by reducing the
levels of SP released in response to the stimulus.
Temple University School of Medicine, Department of Pharmacology
Philadelphia, PA.
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Naltrexone Discrimination in
Morphine-Treated Monkeys
C. P. France and J. H. Woods
Opioid antagonist discrimination in morphine-treated subjects has
been shown to be a useful method for studying opioid dependence
and withdrawal in animals (e.g., France and Woods, 1987). In the
present study, discriminative stimulus effects of opioid and
nonopioid compounds were studied in three morphine-treated (1.78
or 3.2 mg/kg/day 3 hrs prior to experimental sessions) rhesus
monkeys discriminating between subcutaneous injections of saline
and 0.01 mg/kg of naltrexone (France and Woods, in press).
METHODS
Experimental sessions consisted of two or more discrete, 15-
minute cycles. Monkeys responded under a fixed ratio 5 schedule
of stimulus-shock termination; under this schedule brief electric
shock was scheduled to be delivered every 15 sec in the presence
of a distinctive stimulus (green lights). Monkeys could
postpone schedule shocks and terminate the shock-associated
stimulus for 30 sec by responding five times consecutively on the
lever appropriate to the substance injected (subcutaneous) prior
to that cycle (left lever, saline; right lever, 0.01 mg/kg
naltrexone). Five-minute response periods alternated with 10-
minute time out periods during which responses had no consequence
and the shock schedule was not in effect. During test sessions
five consecutive responses on either lever postponed scheduled
shocks and increasing doses of drug were administered over
consecutive cycles.
RESULTS AND DISCUSSION
Increasing doses of naltrexone produced a dose-related switch
from the saline to the naltrexone lever with complete generaliza-
tion occurring to doses of naltrexone larger than 0.0032 mg/kg.
Other drugs with opioid antagonist actions (e.g., naloxone)
substituted completely for naltrexone (i.e., produced an average
of at least 80% responding on the naltrexone lever) and their
potency as discriminative stimuli was similar to their reported
potency for precipitating directly observable signs of
withdrawal in morphine-dependent monkeys (Gmerek et al., 1987).
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Doses of opioid antagonists that produced responding on the
naltrexone lever did not markedly alter rates of lever pressing.
A wide variety of opioid agonists as well as several nonopioids
failed to substitute for the naltrexone discriminative stimulus
up to doses that decreased markedly or eliminated lever pressing.
Monkeys also responded on the naltrexone lever when they received
saline, rather than morphine, 3 hrs prior to testing. Responding
on the naltrexone lever, whether produced by administration of an
antagonist or termination of morphine injections, was accom-
panied by signs that are characteristic of opioid withdrawal
(irritability, miosis. salivation). Among the opioids and
nonopioids studied, only compounds with morphine-like agonist
actions under other conditions attenuated naltrexone-appropriate
responding in morphine-abstinent monkeys (i.e., monkeys that had
received saline rather than morphine 3 hrs prior to experimental
sessions).
These data demonstrate the use of drug discrimination in
morphine-treated monkeys and suggest dependence develops to
single, daily injections of modest doses of morphine. The
effects of opioid agonists, antagonists, and partial agonists
under the conditions reported here are qualitatively similar to
results obtained from observational studies in morphine-dependent
monkeys (e.g., Gmerek et al., 1987). Drug discrimination,
therefore, might provide an efficient, highly-quantitative
alternative for studying opioid dependence in nonhuman primates.
In the coming year, it has been proposed by us to the Drug
Evaluation Committee of the CPDD that compounds submitted to the
CPDD for narcotic drug evaluation should be evaluated in both
this procedure and in the observational procedures in morphine-
dependent monkeys. Supported by USPHS Grants DA05018 and DA00254.
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Delta Opioid Receptor Selective
Alkaloid Agonists and Antagonists
J. H. Woods, B. DeCosta, A. E. Jacobson, K. C. Rice,
F. Medzihradsky, C. B. Smith, S. Comer, C. P. France and
G. Winger
Assessment of the functional role(s) of the delta opioid
receptor have been restricted by a lack of systemically active
agonists and antagonists. Portoghese and colleagues (Portoghese
et al., 1988) have recently synthesized a series of indole
derivatives of naltrexone and oxymorphone that showed
considerable delta selectivity in the guinea pig ileum and mouse
vas deferens preparations. For example, naltrindole (Compd. 1,
ibid. was 152 times more potent as a competitive antagonist of
D-Ala2,D-Leu5-enkephalin (DALA) in the mouse vas deferens than of
morphine in the guinea pig ileum. Methyl-naltrindole (Compd. 4,
ibid.) was 8 times less potent as an antagonist of DALA than
naltrindole in the mouse vas deferens, but showed no antagonist
activity (at 200 nM) against morphine or ethylketazocine in the
guinea pig ileum. Oxymorphindole (Compd. 8, ibid.), the N-methyl
analogue of naltrindole inhibited the electrically-induced twitch
in the vas deferens but not in the guinea pig ileum.
Our results confirm and extend those of Portoghese et al.
(1988). We (Woods et al., this volume) found naltrindole to
displace tritiated D-Pen2,D-Pen5-enkephalin (DPDPE) in rhesus
monkey brain membranes with an EC50 of 0.21 nM compared to 9.53
nM against Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO) and 20.5 nM
against U-69,593. Methyl-naltrindole had a very similar binding
profile but had a slightly higher relative affinity for the mu
receptor. Oxymorphindole displaced DPDPE with an EC50 of 3.37 nM
compared to 1080 nM against DAGO and 688 nM against U-69,593.
In the mouse vas deferens, naltrindole appeared to be a delta-
receptor selective, competitive antagonist. Up to 3 x 1O-6 M
naltrindole did not inhibit the twitch; the pA2 for naltrindole
was 9.44 against a delta agonist and 7.71 against a mu agonist.
Although naltrindole (10-7 M) shifted the U-50,488 (kappa
agonist) dose-effect curve slightly to the right, a pA2 could not
be determined because it also decreased the maximum response.
Methyl-naltrindole had a similar profile of antagonist activity
except a pA2 could be calculated for methyl-naltrindole in
combination with U50,488; it was 7.82. Oxymorphindole inhibited
the twitch of the mouse vas deferens by 61%. Its inhibitory
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actions were prevented by ICI 174864, a delta-receptor specific
antagonist with a peptide structure. Since the effects of
oxymorphindole were also antagonized by naltrexone, its partial
inhibition might also have a mu-receptor component.
Oxymorphindole failed to exert thermal analgesic actions in rats
up to 100 mg/kg (Comer et al., 1989) and exerted only a small
analgesic effect in rhesus monkeys at a dose of 56 mg/kg. As
other delta agonists have been shown to do, oxymorphindole
antagonized the analgesic effects of morphine in rats; this
effect was prevented by intracerebroventricular administration of
ICI 174864. Oxymorphindole and naltrindole failed to substitute
for the training stimulus in monkeys discriminating 1.0 mg/kg of
codeine from saline. Up to a dose of 3.2 mg/kg naltrindole
failed to antagonize the discriminative stimulus effects of the
mu agonist alfentanil or the kappa agonist ethylketocyclazocine.
Oxymorphindole also failed to maintain drug-injection responding
in rhesus monkeys trained to self-inject alfentanil or cocaine.
Taken together the results obtained with these compounds to date
suggest the delta receptor mediates a different set of
behavioral actions from those associated with either the mu or
kappa receptor. (Research supported
05018.)
by USPHS DA 00254 and DA
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Biologically Active Conformer for
Fentanyl and its Derivatives
Mark Froimowitz
In order to determine the three-dimensional structure responsible for its
biological activity, MM2 calculations have been performed for fentanyl
and its derivatives with a methyl group in the 3- and 4-position of the
piperidine ring. lnitial calculations were performed on the (piperidine)
N-methyl analogs of the compounds and the results for these are shown
in the table. As with flexible 4-phenylpiperidines such as meperidine,
ketobemidone, 3-demethylprodine, and atabicyclane opioids, fentanyl
has equal populations of two mirror image conformers when the phenyl-
containing 4-substituent is in the preferred equatorial conformation.
Uslng a previously defined ligand model consistent with the general
structure-activity relationships of phenyl-axial and phenyl-equatorial
opioids, one conformer appears to be associated with typical morphine-
l ike act iv i ty and the other with atypical  act iv i ty including opioid
antagonism. As in the more active enantiomer of ß-prodine, the cis-3-
methyl In the more active enantiomer causes the molecule to favor the
conformer associated with atypical activity. This is consistent with the
atypical structure-activity relationships in the two compounds with regard
to the effect of phenyl hydroxylation. In ß-prodine, the introduction of a
phenyl meta hydroxyl appears to convert the compound from an agonist
into an antagonist while hydroxylation of any position of either ring In
fentanyl generally decreases the potency of the compound.
While it appears that fentanyl and its trans-3-methyl derivative act in
phenyl equatorial conformers, phenyl axial conformers appear to be
favorable for the cis-3-methyl derivative and those with an additional 4-
substltuent. This may account for the 16 to 34-fold increase in potency
in compounds with these substitutions.
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As with previous calculations on phenazocine, the N-phenethyl group in
fentanyl  is qui te f lexible with smal l  energy di f ferences between
conformers. However, based on constrained fentanyl analogs that
retain activity, it appears that a trans dihedral angle is required for the
ethyl group. This leaves two possible conformations of the N-phenethyl
group due to the symmetry of the piperidine ring.
Table. Computed steric energies (kcal/mole) of (piperidine) N-methyl
derivatives of fentanyl and analogs. Rotation is about the
amide nitrogen-piperidine bond.
phenyl-equatorial phenyl-axial
6 0 °  1 8 0 °  3 0 0 ° 6 0 °  1 8 0 °  3 0 0 °
fentanyl 2.8 1.6 1.6 8.7 4.6 4.6
cis-3-methyl 6.1 5.5 6.8 8.8 5.7 8.4
trans-3-methyl 2.7 2.3 - 10.9 7.0 7.3
4-methyl 8.2 7.1 7.1 13.5 6.9 6.9
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A New Hypothesis on the
Mechanism of Morphine’s Effect on
the Pupil
Thomas J. Lynch, Paul J. Tiseo and Martin W. Adler
We have formed a new view of how morphine (MS) induces pupillary
fluctuations in the rat, based on studies using infrared video pupillometry,
EEGs, respirometry, brain pO2 measurement, kindling electrical stimuli and i.p.
vs i.c.v. injection. In place of a presumed selective effect of MS (i.p.) on the
Edinger-Westphal nuc. (EWN), we believe the primary effect of i.p. MS and
the cause of miotic fluctuations is global intermittent electrographic bursting
(IEB), propagating to and enslaving the EWN. Several types of data support
this. First, after i.p. injection of MS, the first effect is most often an EEG burst
of 5-20 min. duration. Second, IEB is global rather than limited to oculomotor
structures. Therefore, it is highly unlikely that IEB starts in the EWN. Third.
the onset of each miotic transient is time-locked with the beginning of each EEG
burst, and the onset of each mydriatic transient is time-locked with the cessation
of each burst. Fourth, respiratory slowing (10%. 5-10 sec. duration) occurs 3-
5 seconds before all burst cessations and related mydriatic transients. This
means that part of morphine’s cyclic effect on the pupil occurs first in a
respiratory center. Fifth, administration of an alerting stimulus (handclap)
during MS-induced miosis causes immediate respiratory slowing followed by
burst cessation and a mydriatic transient. The sequence of events during such
arousal-induced conversion from burst-ON miosis to burst-OFF mydriasis is an
exact replica of the normal transition which occurs during MS-induced pupillary
fluctuations. This emphasizes the role therein of respiratory centers and,
particularly, the reticular activating system, in which the former and the EWN
are embedded. Sixth, EEG bursts induced by non-opioid means during MS-
induced mydriasis also cause miotic fluctuation; miotic transients were time-
locked to the onset of the kindling EEG after discharges in the cortex when
elicited by stimulation of the amygdala. Similar effects were seen when IEB
was elicited by a bicyclic organophosphate. These results indicate that burst
propagation, even from distal structures, can be a key influence on
parasympathetic outflow from the EWN. They also indicate that MS-induced
miotic transients are not simply correlated with MS-induced EEG bursts but are
caused by them. However, part of the old hypothesis remains intact, since we
see a different response after i.c.v. injection. Instead of an initial EEG burst
and miosis, mydriasis occurs slowly, without bursting. As drug effect
continues, bursting and miotic fluctuations develop. Given i.c.v., it seems a
direct effect of MS on EWN appears briefly, before bursting can be elicited in
surrounding brainstem. As for the effect of i.p. MS on the pupil, we believe
the original question of whey MS causes pupillary fluctuation should be
rephrased as - “Why does MS cause IEB?”
3 0 4
AFFILIATION
Department of Pharmacology, Temple University School of Medicine,
Philadelphia, PA 19140
(Supported by NIDA Grant 5F32DA05300).
305
Intracerebroventricular (ICV)
Clonidine Produces an
Antianalgesic Effect Through
Spinal Dynorphin A(1-17)
Mediation
James M. Fujimoto and Kathleen Schaus Arts
Clonidine is thought to attenuate opiate withdrawal symptoms by
acting on the locus coeruleus in a manner similar to morphine. On
the other hand, Ossipov et al (1984) administered clonidine to the
locus coeruleus and antagonized the analgesia produced by
etorphine microinjected into the periaquaductal gray area. A
number of reports indicate that clonidine administered into the brain
produces an antianalgesic effect. We studied this antianalgesic
effect in order to see whether it was similar to antianalgesia
produced by physostigmine where spinal dynorphin A(1-17) may
be an endogenous opioid mediating antianalgesia (Fujimoto and
Rady, 1989).
ANTAGONISM OF MORPHINE BY CLONIDINE.
In male ICR mice, clonidine, 0.6 µg administered ICV at 10 min.,
antagonized the antinociceptive response (tail flick test, expressed
as % MPE) to morphine administered intrathecally, IT, at 5 min.
ED50 of morphine (log dose vs. probit %MPE) was increased from
0.21 µg (0.11-0.40, 95% Cl) to 0.83 (0.41-1.67). Next, dose (1.2
µg) and time (5 min.) of IT morphine was kept fixed while the dose
of clonidine, ICV 10 min., was changed. Maximal antagonism
occurred at 0.4 µg clonidine and as dose was raised up to 8 µg,
effect became less: a biphasic effect occurred. Administration IT of
naloxone (3 fg, 5 min) or nor-BNI (10 ng, 5 min) antagonized this
antianalgesic action of clonidine on morphine analgesia.
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NALOXONE, NOR-BNI UNCOVER ANAGESIA TO CLONIDINE.
By itself i.c.v. clonidine (dose up to 50 µg) did not produce
analgesia. However, naloxone (5 fg) or nor-BNI (10 ng) given IT at
5 min. uncovered an analgesic action of clonidine, ICV 3 pg. This
result along with those above indicated that clonidine had two
effects: an overt antianalgesic and latent analgesic action. Because
of the “paradoxical” actions of naloxone and nor-BNI, we proposed
that the antianalgesic action of ICV clonidine was mediated spinally
by an endogenous opioid which had antianalgesic actions.
DYNORPHIN A (1-17), ENDOGENOUS ANTIANALGESIC OPIOID?
Dynorphin A (1-17) appears to be this endogenous opioid.
Dynorphin A (10 pg, 5 fmole) administered IT antagonized dose-
dependently the analgesic action of morphine, IT 1 pg. In turn,
this action of dynorphin A was antagonized by IT naloxone (5 fg) or
nor-BNI (10 ng). Thus, antagonism of the action of dynorphin A
and “paradoxical ” effects of naloxone and nor-BNI occurred at the
same respective small doses. In addition, response to dynorphin
A may involve receptors unique to dynorphin A because neither
mu receptors (tested by DAMPGO) nor kappa receptors (tested by
U50,488H) were blocked at the doses of naloxone (5 fg) and nor-
BNI (10 ng) used.
Present results are consistent with a hypothesis that dynorphin A (1-
17) may mediate a spinal antianalgesic system, a newly
discovered function for dynorphin A(1-17), which can be activated
supraspinally by clonidine or physostigmine. (Supported by the VA
and NIDA 00451).
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Characterization of Dynorphin
A (1-17)-Induced Place Preference
in Rats
Edgar T. lwamoto
Certain drugs which are self-administered intravenously or which
induce place-preferences in rats may do so by activating endogenous
kappa-opioid systems. Young and Khazan (1983), Tang and Collins
(1985), Steinfels et al. (1982) and Collins et al. (1984) showed
that kappa opioids such as ethylketocyclazocine, ketocyclazocine,
pentazocine, butorphanol, nalbuphine and nalorphine are self-
administered intravenously by rats. The fact that these drugs are
kappa agonists with partial-agonistic or full antagonist activity
at the mu-opioid receptor suggests that central kappa receptor
stimulation may be a determinant of drug dependence. This premise
is further substantiated by the work of Khazan and collaborators who
reported that dynorphin1-13 at doses of 125 and 250 ug/kg/injection
was self-administered intravenously by rats (Khazan et al., 1983).
Recently we reported that one intracerebroventricular injection of
2.3 or 3.5 nmol of dynorphin1-17 induced a significant preference
response in rats in the place-conditioning paradigm (Iwamoto, 1988).
Place preferences were not induced by two probable metabolites of
dynorphin1-17, [leu
5]-enkephalin and des-tyrosine dynorphin A2-17; the
latter peptide does not bind to opioid receptors (Walker et al.,
1982; Young et al., 1987). A 10-fold excess of naloxone was
necessary to antagonize dynorphin preferences; these data
indicated that kappa receptors may be important determinants of
dynorphin-induced place conditioning. Stevens et al. (1988)
reported that rats self-administered dynorphin1-17 into the the CA3
region of the dorsal hippocampus. The purpose of the present
experiments was to examine the dorsal hippocampus as a site of
action of dynorphin-induced place conditioning, and to characterize
dynorphin1-17- induced conditioned place preferences using dynorphin
congeners and nor-binaltorphimine, a selective kappa receptor
antagonist (Portoghes et al., 1987).
Sprague-Dawley male rats were implanted unilaterally with a guide
cannula aimed at the dorsal hippocampus. After one week, animals
received either 'treatment' (peptide in 500 nl of phosphate buffer
or 500 nl of buffer alone) or 'no treatment' (no injections) before
being placed in the black or white chamber of a three-chambered
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place-conditioning apparatus (Iwamoto, 1986) for 20 min; the next
day the rats received the opposite treatment and were placed in the
opposite chamber. On Day 3, the animal was started in the middle
gray chamber and given free-access to the entire place-conditioning
apparatus for 15 min. The number of sec spent in the treatment-
paired (T) and the non-treatment-paired (NT) chambers was recorded.
A preference ratio, PR, was calculated as [T-NT]/[T+NT] for each
rat. As an example, if T = 450 sec and NT = 200 (with the remaining
250 sec being spent in the middle gray chamber), then PR = +0.38.
One dorsal hippocampal injection of 1 nmol of dynorphin,.,, (DYNA)
conditioned a significant (Tukey's test) place preference response:
DYNA PR = 0.38 ± .07 versus buffer treatment, PR = 0.02 ± .07. Two
nmol of nor-binaltorphimine coadministered with the 1 nmol of DYNA
completely blocked the DYNA preference response, PR = 0.09 ± .05.
Nor-binaltorphimine alone was inactive in the place conditioning
paradigm, PR = 0.04 ± .05 (N = 12 for all groups). In other
experiments, significant place preferences were also conditioned by
single, dorsal hippocampal injections of 1 nmol of dynorphin1-17 amide
(PR = 0.37 ± .lO), 1 nmol of dynorphin B (PR = 0.33 ± .11 and 1
nmol of alpha-neo-endorphin (PR = 0.34 ± .lO); the control PR = -
0.02 ± .06. The following peptides were inactive in the dorsal
hippocampus (control PR = 0.01 ± 0.04): 1 nmol of dynorphin,.,, (PR
= 0.10 ± 0.03), 1 nmol of dynorphin (Experiment 1, PR = - 0.11 ±
.07; experiment 2, PR = 0.08 ± .07), 2 nmol of dynorphin1-8 (PR =
0.06 ± .14) and 1 nmol of rat beta-endorphin (PR = 0.06 ± .08). The
caudate nucleus was a negative site; 2 nmol of DYNA was inactive.
In a separate experiment, subcutaneously administered nalorphine was
used as the conditioning drug. On Days 1,2,4,6,7 and 9, buffer or
1.25, 2.5 and 5 mg/kg of nalorphine hydrochloride was administered
SC immediately before place conditioning for 20 min. On Days 3,5
and 8, all animals were injected with buffer before being placed in
the opposite chamber for the 20 min conditioning session. Testing
was performed on Day 10. Nalorphine induced place preference
responses in a dose-related manner (control PR = - 0.13 ± .16; 1.25
mg/kg PR = 0.07 ± .08; 2.5 mg/kg PR = 0.12 ± .07; and 5 mg/kg PR =
0.26 ± 0.07, N = 5 per group. Significant slope of the regression,
P = .002). The PR for the 5 mg/kg group was significantly different
from control, P < .05, Tukey's studentized range test.
The present data suggest that DYNA-induced place preference in rats
is mediated at kappa receptors in the dorsal hippocampus, that
activity resides in the full-length, 17 amino acid peptide, and that
the effect is mimicked only by certain prodynorphin products. Since
there is little evidence that nalorphine is a partial mu-opioid
agonist, the results of the SC-administered nalorphine conditioning
experiment support the hypothesis that some opioid alkaloids can
condition place preferences by stimulating kappa receptors.
A complete list of references may be obtained from the author.
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Evidence for Rapid Development
and Loss of Opioid Tolerance to
Fentanyl in the Rat
Thomas H. Kramer, Elizabeth A Ayres, and
Thomas F. Burks
We are seeking to improve our understanding of the in vivo potency of opioid drugs
and the phenomenon of tolerance by studying relationships between drug
concentration and effect in intact animals. By correlating effect with concentration,
rather than dose, we hope to control for the influence of drug disposition on apparent
pharmacologic effect. These studies represent our initial experience with simultaneous
assessment of pharmacokinetics and pharmacologic effect.
METHODS
We measured the antinociceptive actions of the synthetic µ opioid fentanyl in male
Sprague-Dawley rats. Jugular venous cannulae were implanted under anesthesia three
days prior to study. On the day of testing, fentanyl citrate (30 or 100 µg/kg) was
injected subcutaneously, intraperitoneally, or intravenously in a single dose. Blood
samples were obtained frequently after the dose, and the plasma separated and frozen.
Antinociception was measured using a standard 55° C hotplate. Latency (in seconds)
to jumping or hindpaw licking was recorded before and frequently throughout the
experimental sessions. Maximum allowable latency was 45 sec. Fentanyl
concentrations were measured by radioimmunoassay (FEN-RIA 200, Janssen Life
Sciences). Controls included rats which underwent identical preparation and testing
but received saline injections rather than fentanyl (Control 1, n=4), and rats treated
with fentanyl and tested for antinociception, but not subjected to surgery or blood
sampling (Control 2, n=5). Hematocrit was determined periodically in the first control
group. Fentanyl concentration vs. time data were fit to standard pharmacokinetic
equations by weighted nonlinear least squares regression1. Hotplate latencies were
plotted against time and concentration and evaluated for each individual-rat.
RESULTS
Mean control latency (± SD) was 11.3 ± 2.7 sec. The onset of antinociceptive effect
was extremely rapid after fentanyl administration. Intravenous fentanyl produced
maximal latency (45 sec) within 30 sec of dosing; subcutaneous or intraperitoneal
dosing demonstrated a delay of several minutes before onset of apparent effect.
Maximal latency was achieved in 18 of the 20 rats which received fentanyl. Non-
treated control rats demonstrated no trend to increasing or decreasing latency over the
study period. Though hematocrit was decreased as much as approximately 40% at
the end of the studies, this was not associated with a change in nociceptive responses.
Fentanyl-treated animals showed distinctly biphasic antinociceptive responses, with
increases in hotplate latencies occurring subsequent to loss of the original
antinociceptive effect. The temporal pattern of the peaks and valleys in the effect vs.
time profile was different for each animal, such that taking the mean latency of the
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group at each time point obscured the pattern present in the individuals. The increases
and decreases in latency progressed in a systematic fashion and could not be
accounted for by random variation in response or imprecision in measurement. Mean
peak latency (first peak, ±SD) was 43.3 ± 4.0 sec; mean “valley” latency was 12.6 ± 8.4
sec; mean second peak latency was 28.4 ± 11.5 sec. Control and “valley” latencies
were not significantly different; mean latencies at peak 1 and peak 2 were both
different from control and valley latencies, and from each other (all p<0.01, ANOVA
followed by Neuman-Keuls test).
Fentanyl pharmacokinetics were unremarkable in these rats. All concentration data
sets were best fit to biexponential pharmacokinetic equations with bolus, zero-order,
or first-order drug input for the intravenous, subcutaneous, or intraperitoneal routes
of administration, respectively. Fentanyl elimination appeared linear and independent
of dose. Mean (±SD) distribution and eljmination rate constants ( and ß) were 0.058
± 0.025 min-1 and 0.0074 ± 0.0041 min-1, respectively. Importantly, no late increases
in concentration, associated with increased antinociception or otherwise, were noted.
DISCUSSION
Several potential explanations for recurrent antinociceptive responses should be
considered. An effect of blood loss or learning over the course of the experiment is
ruled out by the stable responses in control group I. Late increases in total fentanyl
concentration, caused by enterohepatic recirculation of drug, for example, are not
present as demonstrated by the linear and non-complex pharmacokinetics observed.
Late increases in free, but not total, fentanyl concentration might be caused by the
progressive loss of plasma proteins which bind fentanyl, due to blood sampling.
However, animals in control group 2, which did not undergo sampling, still
demonstrated biphasic antinociceptive responses to fentanyl.
Formation of an active metabolite of fentanyl might also explain these results,
however, little or no evidence is available to support the existence of a fentanyl
metabolite with opioid agonist activity. Fentanyl metabolism has been characterized
in the rat; the principle fentanyl metabolite is a des-phenethyl derivative2,3 which
should not have appreciable opioid receptor affinity. Other metabolites (present in
much smaller quantities2,3) would need to possess extraordinary potencies to produce
the effects noted here after a single dose.
A final possible cause of these results is rapid desensitization to the effects of high
fentanyl concentrations. The early concentrations measured in these studies are far
in excess of those needed to produce antinociception in our paradigm. It is possible
that these high concentrations rapidly induce a tolerant state. As redistribution of
fentanyl out of the brain is extremely rapid4, reduction in brain fentanyl to more
modest levels could occur faster than resensitixation to the effect of fentanyl. This
would result in loss of antinociceptive effect, followed by return of effect as
resensitization occurred in the post-distributive phase of fentanyl elimination.
REFERENCES
1. Statistical Consultants Inc. Amer Statist 1986; 40:52.
2. van Wijngaarden I, Soudijn W. Life Sci 1968; 7:1239-1244.
3. Goromaru T, et al. Drug Metab Disp 1982; 10:542-546.
4. Hug Jr CC, Murphy MR. Anesthesiol 1981; 55:369-375.
AFFILIATION
Department of Pharmacology, College of Medicine, The University of Arizona,
Tucson, AZ 85724.
Supported by USPHS Grant DA02163.
311
Inpatient vs. Outpatient Cocaine
Abuse Treatments
Thomas R. Kosten, Bruce J. Rounsaville and
Susan H. Foley
Two widely used treatments for cocaine abuse are
brief (21-28 day) inpatient hospitalizations and
outpatient psychotherapy. While some studies have
suggested that one year outcome for these two forms
of treatment may be equivalent for alcoholics, these
two treatments have not been compared for cocaine
abusers. Furthermore, comparisons of comorbid
psychopathology in these patients at intake to the
two types of programs have been incomplete. We have
therefore compared these two treatments in cocaine
abusers who were carefully diagnosed using DSM-III-
R. Preliminary results in 303 treatment seeking
cocaine abusers (153 outpatients - OP and 150
inpatients - IP) indicate that they are
predominantly male (66% OP vs 73% IP), white (58% OP
vs 69% IP), unmarried (72% OP vs 70% IP), young
adults (29 ± 0.6 years OP vs 27 ± 0.5 years IP). In
comparing the IP to the OP cocaine abusers on rates
of comorbid psychopathology and severity of cocaine
abuse several differences emerged. The IP cocaine
abusers reported more days of cocaine use over the
month before admission to treatment (17 ± 2 days vs
10 ± 1 days) and more years of abuse (4.5 ± 1 years
vs 2.5 ± 0.5 years). Rates of psychopathology
showed more antisocial personality in OP (37% vs
29%) and more attention deficit disorder in IP (25%
vs 40%). Depression and anxiety disorders showed
significant gender effects with females having
higher rates of depression in IP than OP (35% vs
18%). In contrast, rates of depression were higher
in OP males than in IP males (22% vs 35%), and there
were no differences in anxiety. The onset of the
anxiety, which were mostly phobias, and attention
deficit disorders generally preceded the cocaine
abuse (90% and 99%, respectively), but the
depressive disorders and alcoholism both had their
onset most frequently after cocaine abuse (65% vs
312
80%), respectively). Overall, the IP cocaine
abusers had more severe cocaine abuse, past
suicidality and current depression, particularly in
females and more attention deficit disorder in the
younger males (< 30 years old). This increased
psychopathology and severity of cocaine abuse may
lead to the need for hospitalization.
Department of Psychiatry
Yale University School of Medicine
New Haven, Connecticut
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Outcomes
Treatment
Forest Tennant
of Cocaine-Dependence
Little is known about treatment outcomes of cocaine dependence or its natural
epidemiologic course. The author has been able to track 67 cocaine-dependent
athletes from four different sports. They were identified between 1983 and 1988.
and they have been followed for periods ranging from 4 to 60 months (mean
19.3). At the time of identification, 25 (37.3%) were treated by standard, in-
patient hospitalization and 42 (62.7%) were treated as outpatients. During follow-
up. these patients submitted a total of 2,484 observed urine specimens which
were analyzed for alcohol and metabolites of cocaine, and marijuana. A total of
41 (60.3%) suffered relapses which required some form of retreatment. Neither
inpatient nor outpatient treatment appeared to influence outcome since 16 (64.0%)
of hospitalized versus 25 (59.5%) of non-hospitalized cases required retreatment
(PNS).
During the 1980’s cocaine addicts have increasingly sought medical detoxifi-
cation. We have attempted to develop a low cost, outpatient procedure which can
be utilized in our system of clinics throughout Southern California. The medical
regimen is a step-wise procedure which utilizes amantadine, levo-dopa, bromo-
criptine, desipramine, and prazosin as well as ammo acid supplements. Patients
attend the clinics daily until their urine is negative as determined by immunoassay.
Between 1985 and 1988, three separate pilot studies were done in West Covina,
California to determine the feasibility of this approach. Outcomes indicate that
over 50% can be detoxified by this method (See Table).
The major conclusion to date is that low cost. outpatient treatment of cocaine
dependence with dopamine agonis ts ,  amino acid supplements .  and
antidepressants is an effective detoxification procedure in about one-half of the
cases. We do not have long-term follow-up data on relapse rates in this group.
Despite some success in treating cocaine addiction, there is an obvious need for a
more effective medical treatment.
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COCAINE ADDICTS TREATMENT OUTCOMES
Study Urine
No. Dates No. End-Point*
No. Succesful
Treatment
1 Oct. ‘85 -Aug. ‘86 77 EMIT
300 ng/ml
37 (57.8%)
2 Sept. ‘86 - April ‘87 29 EMIT 16 (66.7%)
300 ng/ml
3 Jan. ‘88 -Dec. ‘88 71 PFI
30 ng/ml
37 (52.1%)
l EMIT is Enzyme Immunoassay with a urine testing sensitivity of 300 ng/ml and PFI is Polarized
Fluorescent Immunoassay with a sensitivity of 30 ng/ml.
AFFILIATIONS:
Community Health Projects Medical Group, 336½ South Glendora Avenue.
West Covina, California 91790
and
UCLA School of Public Health, LoS Angeles, California 90024
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Carbamazepine Treatment of
Cocaine Dependence in
Methadone Maintenance Patients
with Dual Opiate-Cocaine
Addiction
Kenneth L. Kuhn, James A. Halikas and Kenneth D. Kemp
ABSTRACT
The cocaine epidemic of the past decade is undermining the
efficacy of methadone maintenance (MM) treatment. In an open
clinical trial, 12 MM patients addicted to cocaine were offered
carbamazepine (CBZ) as a pharmacological adjunct in the treat-
ment of cocaine dependence. Patients reported mild opiate with-
drawal symptoms after initiation of CBZ treatment. Methadone
serum trough (MST) levels taken before CBZ were compared with
levels taken 7-10 days later, with an average decrease in MST
levels of 60%. Patients (6) who continued on CBZ (average 144
days) reported a reduction in cocaine use, documented by random
urine drug screens. Non-completers (6) who did not continue on
CBZ (average 17 days) had no change in cocaine use.
METHODOLOGY
The 12 MM patients were intravenous cocaine users, who averaged
86 cocaine using days per 100 days prior to referral to the
cocaine clinic. The average amount of cocaine use was 3.5 grams
weekly; average cocaine use history was ten years; history of
illicit drug use was 22 years. Of the 12, three were female,
and of the nine males, four were black. Their average age was
41. They averaged 11 lifetime drug related arrests and four
prior treatments. All punitive sanctions for drug use were
suspended during participating in this program.
CLINICAL OBSERVATIONS
Four patients began CBZ treatment as inpatients on the chemical
dependency unit at the University of Minnesota. MM dose range
was 65-80 mg, given as a morning dose. Because of intense crav-
ing in the first two patients, CBZ dose was increased to 800-
1200 mg/day, given in two equal doses. Within 36-48 hours both
patients complained of restlessness and insomnia which was pro-
gressive during the night, and was relieved by the next morning
MM dose. An opiate withdrawal rating scale documented objective
criteria for mild methadone withdrawal, with symptoms reappear-
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ing 12-16 hours after the MM dose. This suggested the possi-
bility that CBZ had lowered the steady-state equilibrium of the
methadone. Urine drug screens were negative for other hepatic
enzyme inducing drugs. MST levels were below 80ng/ml, with a
range of 61-79ng/ml.
Eight patients began CBZ as outpatients, with weekly prescrip-
tions given to six and daily monitored dosing in two. Pre-CBZ
MST levels were above 120ng/ml with a range of 121-179 ng/ml.
Outpatients were started on lower CBZ doses, with 100mg taken
three times daily as the most frequently used schedule.
Compliance was determined by CBZ serum levels and random urine
screens. Post-CBZ MST levels taken 7-10 days after starting CBZ
decreased by an average of 60%. MM dose increases of 10mg were
recommended when MST levels were below 80ng/ml. Patients who
were given weekly prescriptions had more difficulty stabilizing
on the medication compared with the two monitored patients.
In addition to the pharmacologic therapy, a two hour weekly
support group was offered. The group provided HIV-l prevention
and chemical health education, relapse prevention, peer support
and a review of traditional recovery issues. Patients openly
shared their concern regarding the possible effect of CBZ on
methadone metabolism, which reduced compliance in the study.
RESULTS
The six MM patients who took CBZ (average 144 medication days)
reduced their frequency of cocaine use from 65/100 days pre-
treatment to 23/100 day post-CBZ therapy, an overall change of
65%. Non-completers (6) reduced their overall cocaine use by
less than 20%. While improved outcome of the CBZ completer
group may be a measure of program compliance rather than
pharmacologic effect of CBZ, it merits further investigation.
DISCUSSION
CBZ is known to stimulate the P450 microsomal hepatic enzymes,
resulting in decreased steady-state levels of phenytoin, primi-
done, doxycycline, clonazepam and other medication metabolized
by this common pathway in the liver. However, its specific
effect on methadone has never been studied pharmacokinetically.
This finding is being investigated in a controlled setting.
Although the use of CBZ in MM patients requires a dosage adjust-
ment in the methadone, it may prove to be a useful adjunct in
the treatment of cocaine dependence in this population.
AUTHORS
Kenneth L. Kuhn, M.D., Fellow in Chemical Dependency
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Quantitative Urine Screening
the Diagnosis and Treatment
Cocaine Abuse
for
of
Forest Tennant
Recently, radioimmunoassay (RIA) and polarized fluorescent immunoassay (PFI)
screening techniques have been developed which have sensitivity levels below the
usual qualitative screening techniques, and the ability to quantitate drugs of abuse
within specific ranges. Quantitative results are very compatible to those obtained
by gas chromatography/mass spectrometry. Additionally, these techniques can
rapidly determine urine concentrations and have a low enough cost to be
routinely utilized in a clinical setting. Since introduction of the PFI technology to
the commercial market in 1987, we have utilized it with several hundred patients
to assist with the diagnosis and treatment of drug abuse. Reported here is a series
of 138 cocaine users. One group of 67 patients were referred for counseling and
urine testing, and who reported occasional use of cocaine ranging from 1 to 3
times per week. The other group of 71 atients claimed to be addicted and
voluntarily entered an outpatient detoxification program. Urine specimens
collected from patients. on the day of admission, revealed that urine
concentrations of cocaine metabolites were significantly different in the two
groups.
Admission urines contained cocaine metabolite in 54 (76.1%) of the 7 1 addicted
patients and in 24 (35.8%) of the occasional users. The 17 addicted patients who
showed no cocaine metabolite in urine on the day of admission reported that they
had ceased cocaine administration 4 to 16 days prior to this time, but they were
experiencing so many withdrawal symptoms that they desired medical treatment.
Only 3 of the 67 (4.5%) occasional users compared to 40 (56.3%) of the addicted
patients showed cocaine metabolite in their urine on admission at a level of 1000
ng/ml or above (x2 = 24.24; df = 1; P<.005). Two of the three occasional users
who demonstrated over 1000 ng/ml on admission were teenagers who
immediately, after the test, informed their parents that they were using cocaine
daily. They were consequently transferred to detoxification treatment. The third
patient submitted two urine specimens within the following two weeks which did
not contain cocaine metabolite. Twenty-nine (40.8%) of the addicted, compared
to 2 (3.0%) of the occasional users, demonstrated 5000 or greater ng/ml
concentration on admission (x2 = 77.19; df = 1; P<.005). Sixteen (16) of 24
(66.7%) occasional, compared to 10 of 54 (18.5%) addicted patients who had
cocaine metabolite in urine on admission had concentrations less than 300 ng/ml
(x2 = 17.06; df = 1; P<.005). The mean urine concentration of addicted and
compared to occasional users was 2435.2 ± 2298.1 S.D. (Range 40-5000) and
192.7 ± 673.8 S.D. ng/ml (Range 30-5000) respectively
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(t = 45.43; df = 136; P<.005). The mean urine concentrations among the 54
addicted patients and 24 occasional users who submitted a positive urine on
admission were 3201.9 ± 2115.3 S.D. (Range 40 - 5000) and 537.9±1053.1
S.D. ng/ml (Range 30-5000) (t = 25.12; df= 76; P<.005).
Although there was overlap in urine concentrations between the occasional and
addicted users, data from these subjects indicate that it is frequently possible to
determine if a drug user is likely addicted, or an occasional user. Even in
questionable cases, repetitive quantitative testing over a few days time will likely
clarify the question, since occasional users usually clear their urine withing 2 to 3
days. In addition to a significant difference between the admission urine
concentrations of addicted and occasional users, high drug concentrations in the
addicted users was often associated with a poorer treatment outcome. Twenty
(20) of 31 (64.5%) addicted users, with an admission urine concentration under
1000 ng/ml comared to 17 of 40 (42.5%) with urine concentration over 1000
ng/ml, were able to detoxify and leave treatment with a negative urine
(P<.005). Some addicted patients did not appear to be able to totally clear their
urine of cocaine metabolite for as long as two to three weeks after they reported
cessation of cocaine use. Other recent studies also document that cocaine addicts
may not clear their urine for several days after last use.
Clearly, an
great part, be based on the treatments’ ability to eliminate all cocaine metabohtes
attempt to evaluate treatment efficacy of cocaine addiction should, in
from urine as determined by sensitive, quantitative testing. The receptivity of
Practitioners are encouraged to utilize quantitative urine testing to enhance the
quantitative urine testing with patients and third parties has been gratifying.
diagnosis and treatment of cocaine abuse.
AFFILIATIONS:
Community Health Projects Medical Group, 336½ South Glendora Avenue,
West Covina, California 91790
and
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Urine Testing During Treatment of
Cocaine Dependence
William M. Burke, Narispur V. Ravi, Vasant Dhopesh,
Barry Vandegrift, lradj Maany and A. Thomas McLellan
During the past decade the use of cocaine has reached epidemic proportions in the
United States. As a result of increased availability and relative decrease in price
cocaine has become a major health problem in all segments of society. A number
of treatment programs that have been designed to address this problem include
urine monitoring as part of the therapeutic approach. There are, however,
indications that the current literature may underestimate the length of time that
metabolites can be detected in the urine after the use of large amounts of cocaine.
When using urine monitoring, misinterpretation of results may lead to
inappropriate interventions that could weaken the therapeutic alliance as well
as decrease the value of testing in the eyes of both the patient and the therapist.
This may be particularly true with the treatment of cocaine dependence where
lapses and relapses are frequent occurrences in the natural history of the
disease and it becomes important to distinguish single use from repeated use.
Until recently the literature suggested that benzoylecgonine could be detected in
the urine for only 72 hours after last use of cocaine . This is the current
standard of practice for interpreting results. However, there is an anecdotal
report in the toxicology literature of one patient excreting low levels of
benzoylecgonine for 15 days and Weiss and Gawin have recently reported three
cases of protracted elimination of cocaine metabolites in high-dose cocaine
abusers. Their study found that benzoylecgonine could be detected at levels of
300ng/ml or above for 10 - 22 days after cessation of cocaine intake and at that
level, without subsequent cocaine use, after an earlier sample with lower levels.
We examined the question of the persistence of benzoylecgonine in the urine by
studying the pattern of excretion, as measured by the EMIT test, in 35 male
veterans who had recently used large amounts of cocaine and were being treated
in a drug free environment. Our report confirmed the observations of Wiess and
Gawin with a larger sample. There were 11(31.4%) patients who excreted
benzoylecgonine for 120 hours or longer following admission. In addition 8
patients had their last positive test on the day following a negative test. The
results of these studies suggest it is necessary to reassess our current
understanding of the length of time that cocaine metabolites remain detectable in
the urine.
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The prolonged persistence of benzoylecgonine and its reappearance a! levels
above 300ng/ml after a sample below this level, which was observed in this
study raises a caution flag. The appearance of benzoylecgonine in the urine more
than 72 hours after reported last use may no! necessarily represent repeated
use and clinical judgment should be used in interpreting the meaning of such a
result in order to avoid a therapeutically damaging error. Since our findings
corroborate those of Weiss and Gawin, it may be important for treatment
programs to reassess their current understanding of the length of time
benzoylecgonine remains detectable in urine and the significance of a urine that
is positive for it.
Models of recovery have been proposed both generally and for cocaine
dependence specifically. For purposes of planning treatment these models can be
combined to a simple time frame of early, middle, and late treatment
components. Professional care is usually necessary in early and middle
treatment components and may be necessary in the late component; self help
groups offer considerable benefit at all stages. We believe that just as a
therapeutic program needs to be tailored to match the individual’s level of
severity to provide an appropriate intensity of services so the urine monitoring
needs to be modified to have a balance between severity and the intensity of
monitoring. We suggest that an initial urine be examined to confirm the patient’s
history of various substances used. After the initial urine is obtained, we
suggest a 5-7 day disuse period be established following which urine testing is
initiated and urines are monitored daily until three consecutive negative
specimens are obtained. Following this any positive urine can be considered
prima facie evidence of reuse of cocaine.
In the early phase with its high relapse rate, emphasis is placed on attaining and
maintaining abstinence; it is the time when closes! monitoring is necessary.
Urine testing a! this time is focused on establishing when the urine no longer
reflects prior use and frequent testing to detect lapses and relapses. When a drug
free baseline is established random specimens can be obtained 2 or 3 days a
week to monitor for reuse. Urine testing in the middle phase serves as a monitor
for relapse and as a support for the patients to use as a tool as they build their
own personal relapse prevention program. After sustained clean urines for 4 to
6 weeks it should be possible to decrease frequency of monitoring to 1 day week.
We suggest continuing weekly random monitoring 3 to 6 months after last use
then moving to twice monthly random urines for an additional 4 to 6 months.
The late component is life long. Urine testing in this phase serves both the
monitoring function and as a means of building an objective record of
achievement. An individualized plan according to clinical picture and needs of the
patient to establish an objective record of sobriety should be designed. Any
further monitoring would be based on the clinical situation and a schedule
mutually agreed upon by patient and therapist. In conclusion we recommend that
programs monitor urine based on the severity of the clinical problem and stage
of recovery starting with frequent random samples and systematically progress
to less frequent samples as the clinical situation improves with concomitant
increase in frequency of urine monitoring if lapses occur.
Penn-VA Center for Studies on Addiction
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Desipramine Treatment of Cocaine
Abuse in Methadone Maintenance
Patients
I. Arndt, L. Dorozynsky, G. Woody, A. T. McLellan and
C. P. O’Brien
This is the final report of a double-blind, placebo controlled trial of
desipramine in the treatment of cocaine abuse in methadone maintained
outpatients. After gving informed consent, 79 male veterans on
methadone maintenance who met criteria for DSM-III cocaine abuse were
assigned to either DMI or placebo in a 2:1 ratio. Fifty-nine patients
completed the 12-week medication phase during which dosages of DMI
were adjusted to give a blood level of 150-300ng/ml, if possible. An
Addiction Severity Index, Beck Depression Inventory, cocaine craving
scale and urine toxicology screens were done at baseline, at 4-, 8- and
12-week medication points and at the 1-, 3-and 6-month follow-up.
When the groups were compared at baseline and at the end of the
twelve-week medication phase, both the placebo and DMI group
improved. The improvements reached significance for the DMI group in
money earned, drug use, days of reported cocaine use, days of crime
illegal income, psychiatric status and cocaine craving. The placebo group
also showed improvement, with lower drug use, fewer days of opiate use
and fewer days of cocaine use. On ANCOVA, however, the groups differed
significantly from each other in only two items, the employment pattern
difference and in the days of psychiatric problems. The latter decreased in
the active medication group and increased in the placebo group. The
groups also showed a trend toward a difference in the days of alcohol
consumption and in days working. There were no significant differences
between the groups in the medical factor, days of medical problems,
money earned, welfare income, drug use factor, days of opiate use, days of
cocaine use, days of depressant use, alcohol factor, days intoxicated, legal
factor, crime days, illegal income, psychiatric factor, Beck score, or in
report of cocaine craving.
Urine toxicology results showed a high rate of cocaine and other drug use
with no significant differences between DMI and placebo groups during the
medication phase. Urine toxicologies are shown graphically in Figure 1.
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There was no change within the groups over time or in the time vs. group
interaction. The DMI group was divided into therapeutic and
non-therapeutic in terms of blood level of DMI in weeks 4-12 and
compared to the placebo group. There were no significant differences
between the groups in drug use scores, cocaine craving or urine
toxicology results.
At the 1 -month follow-up point, the placebo group had less opiate-positive
urines than the DMI group, and at the 3-, and 6-month points, the DMI
group had significantly more positive cocaine urines than the placebo
group. See Figure 2. The DMI group also reported significantly more
alcohol use than the placebo group at all follow-up points indicating a
possible adverse effect.
Figure 1.
% COCAINE POSlTIVE URINES IN 12 WEEK
MEDlCATlON PHASE - DMI VS. PLACEBO
Figure 2. % Urines Positive for Cocaine
at Follow-Up: DMI vs. Placebo
AFFILIATIONS: Philadelphia VA Medical Center and Univ. of
Pennsylvania Medical School
This work was supported by NIDA Grant DA-03997.
323
A Laboratory Procedure for
Evaluation of Pharmacotherapy for
Cocaine Dependence
Henry Kranzler and Lance Bauer
INTRODUCTION
Childress and colleagues (1988) have found that abstinent, co-
caine-dependent subjects report increased subjective desire for
cocaine and exhibit increased autonomic nervous system arousal in
response to cocaine-associated stimuli. These laboratory find-
ings are consistent with those obtained in more naturalistic
studies and suggest that cocaine-associated stimuli evoke re-
sponses that can precipitate relapse. The goal of our research
program is to identify treatments that will reduce the magnitude
of these stimulus-evoked responses and thereby reduce the prob-
ability of relapse.
METHODS
We are currently employing a laboratory procedure similar to that
used by Childress and colleagues to evaluate the potential utility
of bromocriptine in relapse prevention. In our procedure, pa-
tients are exposed to cocaine-associated and neutral stimuli (i.e.,
videotapes) in two laboratory sessions, scheduled one week apart.
Subjective desire for cocaine and measures of autonomic nervous
system arousal (heart rate, skin conductance level, peripheral
skin temperature, respiratory sinus arrhythmia, pulse transit
time) are recorded during baseline periods and during the pres-
entation of both films. During the one-week interval between
sessions, subjects receive either bromocriptine (1.25 mg b.i.d.)
or placebo in double-blind fashion.
RESULTS
To date, 10 male, cocaine-dependent patients (Avg. age = 27.4
yrs., Avg. number of grams used during preceding month = 18.6)
have completed the protocol. The results have thus far confirmed
our hypotheses. The cocaine film evoked a greater increase in
self-reported desire for cocaine than did the neutral film (F(1,
8)=19.4,p<O.O1). This effect was larger during Laboratory Ses-
sion 1 than it was during Laboratory Session 2 (Session: F(1,8)=
6.85,p<O.O4, Film X Session: F(1,8)=11.2,p<O.O1). The cocaine
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film also evoked a greater decrease in respiratory sinus arrhyth-
mia, an index of cardiac vagal tone, than did the neutral film,
but only during Laboratory Session 1 (Film X Session: F(1,8)=6.67,
p<O.O4). Changes in peripheral skin temperature were not as
tightly coupled to the desire for cocaine as was RSA. Skin tem-
perature was lower during the cocaine film than it was during the
neutral film (F(l,8)=5.07,p=0.05). However, the magnitude of this
difference did not vary over laboratory sessions.
In order to relate these changes in psychophysiology to current
theories of cocaine craving, we also had patients rate the inten-
sity of symptoms of cocaine withdrawal and cocaine intoxication
before and after each film. Interestingly, symptoms of acute
cocaine intoxication (e.g., restlessness, heart palpitations,
feeling a "rush") were rated as more intense following the co-
caine film than after the neutral film. These symptoms declined
in intensity over laboratory sessions and paralleled the changes
in self-reported desire for cocaine and in RSA. Symptoms of co-
caine withdrawal (e.g., sadness, fatigue, weakness) were not re-
ported after the cocaine film and were not affected by any of the
experimental variables.
CONCLUSIONS
These preliminary findings suggest that cocaine-associated stim-
uli, when presented in a controlled laboratory environment, evoke
significant changes in the subjective desire for cocaine, in
symptoms that are associated with acute cocaine intoxication, and
in respiratory sinus arrhythmia amplitude. Subsequent analyses,
conducted at the conclusion of the study, will enable us to eval-
uate the effects of bromocriptine on these interrelated phenomena.
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Social Impact of Crack Dealing in
the Inner-City
Bruce D. Johnson, Terry Williams, Harry Sanabria and
Kojo Dei
INTRODUCTION
This paper reviews the existing literature and
advances a central theme: the expansion of hard drug
use/abuse, and particularly the sales/ distribution
of crack, is both a symptom and an important factor
in the continued relative decline of inner-city
communities.
METHODS
The scientific literature in several related areas
were reviewed. Ethnographic research in low income
communities was reviewed with particular care.
Overall impression: the scientific literature can
document the relative decline of inner-city
communities and institutions, but generally ignores
the process of decline and, especially, the impact of
hard drug use and sales.
MAIN FINDINGS
The social and economic situation facing inner-city
youths and young adults has deteriorated
substantially since the mid-1960s in: employment
opportunities, educational performance, family
cohesion, and housing. In most American metropolitan
areas, low income "ghettos," primarily composed of
ethnic minorities, have expanded in size and become
more isolated economically and socially from
middle-class America.
The drug revolution has brought American society
epidemics of drugs: marijuana and LSD (1960-75),
heroin (1955-73), cocaine powder (1975-84), and crack
(1985-present). In comparison with heroin and
cocaine powder sales which are usually conducted by
"free lance" sellers, crack sales are more frequently
controlled by organized crack distribution groups
("crews," "posses," etc.).
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Crack selling organizations can now be found in
inner-cities of most metropolitan areas--These have
become more cohesive. Freelance selling has been
undermined by police trying to prevent "drug
supermarkets." Declining wholesale prices of cocaine
has increased profits for suppliers. Upper level
dealers now control the work performance and gross
sales by crack user-dealers and those engaged in a
variety of support roles. Drug selling and the
illicit drug business has expanded dramatically in
economic importance: the crack economy has become a
major factor in the inner-city; sales have become a
major "job" for otherwise unemployable youths.
The economic wealth gained by crack distribution
groups permits the self and social selection of
violent persons as employees (guards), permits
purchases of lethal weapons (knives,
semi-automatic weapons),
guns,
and the systematic use of
intimidation (threats of and actual violence) to
control "staff," competitors, and local inner-city
As drugmarkets. sales have
prominent in the inner-city,
become particularly
criminality by users and
dealers appear to have increased, becoming more
frequent and severe.
Drug use and selling has had substantial impact on
the economic wealth and subcultural lifestyles of the
criminal underclass.
over half) of arrestees and criminals and from
A large percentage (usually
inner-city backgrounds are now regular users of
heroin, cocaine, and crack. Arrests for felony drug
sales, especially of crack, have increased
substantially since 1985. Governmental efforts to
control the drug trade has led to a vast expansion
(nearly doubling) of the jail, prison, probation, and
parole systems since 1978.
While several persons may sell crack who are not
crack users, most such sellers probably begin its use
and rapidly become dependent. Most crack and hard
drug abusers experience important declines in their
(already low) economic well-being, and typically live
well below poverty levels. Sharing needles is a
primary cause of AIDS among heroin abusers: crack
abusers and dealers are at high risk for AIDS via
exchange of sex for crack.
DISCUSSION
Unless important changes are made in how American
society responds to inner-city problems,
bad conditions, which are being
the already
aggravated by drug
sales and abuse among substantial numbers of
inner-city youths, may become even worse by the year
2000.
Affiliation: Narcotic and Drug Research, Inc.
11 Beach Street, New York, NY 10013
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Cocaine and Heroin Use by
Methadone Maintenance Patients
John C. Ball, Alan Ross and Jerome H. Jaffe
The SiX Programs
(Use in past 30 days for long-term patients)
Although methadone maintenance treatment is effective in stopping IV drug use by
most addict patients, a minority continue to use cocaine and heroin while in treatment.
Factors associated with this continued drug abuse is the topic addressed in this
research. The percentage of long-term patients at six methadone maintenance
programs who used cocaine or heroin is shown above. Overall, 24.4 percent of the
386 male patients used heroin and 16.3 percent used cocaine in the past 30 days.
But the differences in drug use by patients at the six programs were notable. Thus,
heroin use was 11 times higher in one program than in another and cocaine use was
6 times higher. Analysis of these findings revealed that the factors associated with
continued drug use among these patients were: inadequate programs, low methadone
dosage (with respect to heroin use) and length of current treatment. For both drugs,
program was the most significant factor. These findings demonstrated that some
programs are markedly more effective than others.
ADDICTION RESEARCH CENTER, P.O. BOX 5180, BALTIMORE. MD 21224.
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The Prevalence and Self-Reported
Consequences of Cocaine Use
Alison M. Trlnkoff, Christian J. Ritter and James C. Anthony
This paper extends the initial work on U.S. cocaine prevalence
which was reported on at the 1985 CPDD meeting. In the new
work, prevalence estimates are based on an estimation procedure
that makes the age-race-sex distribution balanced to that of the
nation as a whole. Prevalence rates of cocaine use (on more
than 5 occasions) were generated for certain social role and
lifestyle characteristics, including educational level, marital
status, living arrangements, and full-time employment status.
Data were gathered fran a sample of adults interviewed in
1980-1984 fran four sites of the NIMH Epidemiologic Catchment
Area Program, including Los Angeles, (n=14,333). In addition,
rates of self-reported consequences of cocaine use were calcu-
lated separately for cocaine users obtained from all five sites.
Striking differences in prevalence were found by education and
marital status with lifetime rates highest among those who were
cohabiting (34.5%) and lowest among those who were married
(2.1%). These differences remained after controlling for age of
respondent. Respondents who were employed full-time had a
higher prevalence of cocaine use than those who were not.
Individuals residing in households at the time of interview had
a 6.4% lifetime prevalence of cocaine use, vs. hospitalized
respondents (22%), and incarcerated respondents (40.3%). Cocaine
use consequence rates varied greatly across sites, with self-
reported tolerance (27.6%-51%) and withdrawal sickness
(7.8%-33%) figuring prominently among sustained daily users.
AFFILIATIONS: Center for Nursing and Health Services Research,
University of Maryland School of Nursing, 655 West Lombard
street, Baltimore, MD 21201; Department of Sociology and
Anthropology, Kent State University, Kent, OH 44242; Department
of Mental Hygiene, Johns Hopkins School of Hygiene, 615 N. Wolfe
Street, Baltimore, MD 21205.
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Characteristics of Non-Referred
Cocaine Abusing Mothers
Iris E. Smith, Suzette Moss-Wells, Refilwe Moeti and
Claire D. Coles
The purpose of this study was to determine whether women who
had recently delivered an infant prenatally exposed to cocaine
and who did- not seek treatment for their addiction could be
differentiated from women who enrolled in alcohol and drug
treatment programs. The experimental subjects for this study
were selected from the population of women who delivered
full-term infants at a major inner city hospital, who admitted
to use of cocaine during pregnancy and were not seeking alcohol
and/or drug treatment (n=29). The comparison group was
randomly selected from the population of women who were
admitted to two local drug treatment facilities during the same
time period (n=50). Experimental subjects were interviewed 14
days post delivery, using the Addiction Severity Index (ASI)
and the Psychiatric Symptom Checklist 90-R (SCL-90R). The same
interview battery was given to the comparison group on the
first day following admission to the treatment facility. All
participants were required to sign an Informed Consent Form
prior to participation.
Demographic characteristics, mean subscale scores on the ASI
and SCL-90R, and individual item responses on the ASI were
compared for the two groups of women using Analyses of Variance
and Chi Square procedures. The results indicated that the
non-treatment sample were less impaired in their social and
psychological functioning than women who were receiving drug
treatment. Significant differences were found on the
Somatization (F1,79=4.72; p<.03) and Anxiety (F1,79=3.73;
p<.05) subscales of the SCl-90R. Analyses of the ASI subscales
indicated that non treatment mothers showed less impairment
with regard to medical status (F1,82=12.8; p<.001); alcohol
use (F1,82=1,73; p<.000l); drug use (F1,72=10.8; p<.001);
psychiatric status (F1,79=8.5; p<.004); family and social
relationships (F1,83=10.2;p<.002). The women who were
admitted to treatment were older (F1,83=5.4; p<.02); better
educated (F1,83=10.7; p<.002) 'and more likely to be
Caucasian. In addition, women who sought treatment were more
likely to report suicidal ideation in the past 30 days and were
more often rated withdrawn, hostile, anxious or distractible by
the research interviewers.
Department of Psychiatry, Emory University School of Medicine
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Amplitude ModuIated Frequency
Response During Acute Cocaine
Intoxication in Rabbits
S. O’Connor, S. Kuwada, N. DePalma, T. Stanford and
A. Tasman
The overall purpose of our investigation is to develop an animal model of
cocaine withdrawal using EEG and evoked potential techniques. The ultimate
goal is to detect electrophysiological correlates of withdrawal effects that may be
transportable to studies of pharmacologic intervention in humans. An animal
model is indicated because the dose and schedule of the addiction and
withdrawal can be controlled. Rabbits offer several appealing characteristics as
the animal of choice. Foremost is their capacity to remain motionless for long
periods. This docility, even under the influence of acute cocaine intoxication,
minimizes muscle movement artifact in the EEG. Lagomorph brain and blood
volume are also relatively large compared to the rat. Both characteristics afford
experimental flexibility when recording multi-lead EEG or correlation with
repeated measure assays of serum cocaine concentration.
In humans, only scalp electrodes are practical for clinical measurements and
these electrodes detect EP activity, primarily from the thalamus and cortex.
Dural electrodes are preferred in the animal because their fixed location and low
impedence reduces experimental variance in multi-session designs, but these
electrodes readily detect neural activity from peripheral auditory nuclei. Thus, it
was important to inquire whether or not cocaine has any effect below the
thalamus in rabbits. The technique chosen for exploring this issue is the
amplitude modulated frequency response (AMFR).
Sinusoidal modulation of a sinusoidal carrier tone excites cells specifically
sensitive to the modulating frequency (MF) in all auditory nuclei. These cells
emit sinusoidal responses at the MF that can be detected by Fourier
Transformation of the-EEG. Incremental increases in the MF result in linear
phase shifts in the transformed data from any one nucleus. The slope of the
phase shift vs frequency change is a measure of conduction delay, and the
amplitude at a given frequency is a measure of the intensity of neuronal activity.
In addition, more peripheral nuclei have cells that are sensitive to progressively
higher MFs. Thus, examination of the AMFR can identify the functional loci of
the neural generators by both temporal and spectral correlations with the
stimulus parameters.
Three female Dutch-belted rabbits were fitted with calvarial screws resting on the
dura close to the saggital sinus at the vertex and over the frontal sinus. At the
time of surgery, a teflon catheter was placed in the right external jugular and a
0.5 cm square by 10 cm long brass bar was cemented to the skull. After a week
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of recovery, experiments were conducted with an ear clip serving as amplifier
ground. Each rabbit was restrained by a body stocking and her head was
immobilized by clamping the bar in a vice. AMFR stimuli were generated by a
PDP-11/73 computer and transduced by headphones through plastic tubes firmly
imbedded in customized binaural earplugs. Carrier tones were 5000. Hz at 90
dB above detected threshold. MF ranged between 10 Hz and 800 Hz with a 30
percent depth of modulation. The recorded EEG was Fourier transformed and
the amplitude and phase of the peak centered at the MF was computed.
Well defined linear regions in the plot of response phase as a function of MF
above 70 Hz demonstrated that the AMFR was sensitive to neural activity
peripheral to the medial geniculate body. In addition, responses were evident
for two structures responding to MF below 65 Hz; most probably in thalamus
and cortex. Injections of saline did not change any of the results. A retrograde
extension of the linear phase vs MF region below 70 Hz in response to an
injection of pentobarbital supported the presumption of a thalamo-cortical origin.
Four percent cocaine HCl was diluted in saline and injections of 1 m4/Kg and 2
mg/Kg were used to test the effect of acute cocaine intoxication on the AMFR.
Previous experiments had determined the seizure threshold to be at or above 6
mg/Kg. When cocaine was injected, no effect on AMFR phase or amplitude was
observed for MF greater than 70 Hz, whereas dramatic changes in both the
phase and amplitude properties of the AMFR were seen for MF below 65 Hz. A
fourfold increase in the amplitude at MF=45 HZ was seen in response to the
lower dose. The amplification occurred within 2 minutes of the cocaine
injection, lasted for five minutes, and completed a monotonic decay towards
baseline levels within twenty minutes.
Responses to the 2 mg/Kg dose yielded very similar results, but the amplitude in
the 45 Hz range of MF was both larger and less sinusoidal since consistent
harmonics in the Fourier transform were observed In response to two doses of
1 mg/Kg separated by 30 minutes, two similar transient increases were
observed, but instead of returning to baseline, the AMFR amplitude continued to
decay until only very small responses were observed an hour after the second
dose. It is postulated that this phenomenon may be a correlate of the post
intoxication “crash” experienced by humans.
This work was performed in collaboration with Yale University and was funded
by NIDA, grant # D004060-02S1
AFFILIATION
Department of Psychiatry and Anatomy, University of Connecticut School of
Medicine, Farmington, CT
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Buprenorphine Suppresses
Cocaine Self-Administration in
Rhesus Monkeys
Nancy K. Mello, Jack H. Mendelson, Mark P. Bree and
Scott E. Lukas
Cocaine abuse has increased among heroin dependent persons, including those
on methadone maintenance treatment programs (Kosten et al., 1986, 1987; Kaul
and Davidow, 1981) and has reached epidemic proportions in the general
population (Kozel and Adams, 1986). At present, there is no uniformly
effective pharmacotherapy for cocaine abuse (Kleber and Gawin, 1984; Gawin
and Ellinwood, 1988) and the dual abuse of cocaine plus heroin is a difficult
treatment challenge. The opioid mixed agonist-antagonist buprenorphine is an
effective pharmacotherapy for heroin abuse (Mello and Mendelson, 1980; Mello
et al., 1982) and this is the first report that buprenorphine suppresses cocaine
self-administration in the rhesus monkey (Mello et al., 1989).
Five adult rhesus monkeys with a 262 ± 79 day history of cocaine self-
administration were surgically implanted with a double-lumen silicon@ rubber
i.v. catheter under aseptic conditions to permit treatment with buprenorphine or
saline during cocaine self-administration. The i.v. catheter was protected by a
custom-designed tether system that permits monkeys to move freely. An
average of 64 responses was required for food (1 g banana pellet) and for i.v.
cocaine (0.05 or 0.10 mg/kg/inj) on an FR4 (VR 16:S) operant schedule of
reinforcement. Food sessions began at 11 a.m., 3 p.m., 7 p.m. and 7 a.m.;
cocaine sessions began at 12 noon, 4 p.m., 8 p.m. and 8 a.m. Each session
lasted for 1 hour or until 20 drug injections or 65 food pellets were delivered.
Fresh fruit, vegetables, biscuits and multiple vitamin supplements were provided
daily.
Buprenorphine was administered at two doses (0.40 and 0.70 mg/kg/day) that
effectively suppressed opiate self-administration in our previous studies in the
primate model (Mello et al., 1983). Daily buprenorphine treatment (or an equal
volume saline control solution) was administered each day beginning at 9:30
a.m. Each dose of buprenorphine and saline was studied for 15 consecutive
days (60 sessions), then buprenorphine was abruptly discontinued and daily
saline treatment was resumed.
All monkeys reduced cocaine self-administration during buprenorphine treatment
(P < 0.0001). On the first day of buprenorphine treatment (0.40 mg/kg/day),
cocaine self-administration decreased by 50% or more in 4 of the 5 subjects
(range 50 to 67%). Average cocaine self-administration decreased by 49% to an
average dose of 1.60 ± 0.25 mg/kg/day during the first 5 days of buprenorphine
treatment (P < 0.01). Average cocaine self-administration fell to 77% and 83%
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below baseline during Days 6 to 10 and 11 to 15 of buprenorphine treatment.
During the second 15 days of buprenorphine treatment at 0.70 mg/kg/day,
cocaine self-administration decreased to between 91% and 97% below baseline
levels. Analysis of data from individual subjects showed that both the time
course and degree of buprenorphine’s suppression of cocaine-maintained
responding was equivalent in animals that self-administered relatively high (4
mg/kg/day) and low (2.1 mg/kg/day) doses of cocaine during the saline baseline
treatment period. Individual monkeys returned to base line levels of cocaine
self-administration at different rates ranging from 15 to 58 days ( 30.5 ± 10
days).
Food-maintained responding was also suppressed by 31% during the first 15
days of buprenorphine treatment (0.40 mg/kg/day). During the second 15 days
of treatment with a higher dose of buprenorphine (0.70 mg/kg/day). food self-
administration gradually recovered to average 20% below baseline. Although
these changes in food-maintained responding were statistically significant (P <
0.05 to 0.01) it is unlikely that they were biologically significant. There were no
correlated changes in body weight and animals continued to eat daily fruit and
vegetable supplements. Analysis of the pattern of food self-administration
across the four daily sessions by individual monkeys indicated that
buprenorphine treatment did not change the overall distribution in comparison to
saline treatment. Animals were not sedated and activity levels appeared normal.
These data indicate that buprenorphine treatment suppressed cocaine-maintained
responding but did not produce a generalized suppression of behavior.
These preclinical data suggest that buprenorphine may be an effective
pharmacotherapy for the treatment of cocaine abuse. However, clinical
evaluation of buprenorphine treatment will require double-blind (buprenorphine
versus placebo) trials with randomized patient assignment and independent
indices of compliance with the treatment regimen (buprenorphine blood levels)
and objective measures of drug use (frequent drug urine screens). These data
also suggest that buprenorphine may be potentially valuable for the treatment of
dual addiction to cocaine and heroin because it suppresses heroin use by heroin
addicts. Data from one open clinical trial of buprenorphine treatment are
consistent with the hypothesis that buprenorphine may be efficacious for
reduction of cocaine abuse, as well as heroin abuse. Opioiddependent patients
treated with daily sublingual doses of buprenorphine for one month (average 3.2
mg/day; range 2 to 8 mg) had significantly fewer cocaine positive urines than
patients treated with methadone (Kosten et al., 1989). If buprenorphine reduces
cocaine abuse as well as dual cocaine and heroin abuse, the benefits to society in
terms of reduction of drug abuse problems and the associated risks for HIV
infection are incalculable. These data are in press in Science (1989). This
research was supported by DA-02519, DA-04059, DA-00101, DA-00064 and
DA-00115 from NIDA and RR-05484 from NIH.
Alcohol and Drug Abuse Research Center
Harvard Medical School -McLean Hospital
115 Mill Street
Belmont, MA 02178
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Effect of Intravenous Infusion and
Oral Self-Administration of
Cocaine on Plasma and Adrenal
Catecholamine Levels and
Cardiovascular Parameters in the
Conscious Rat
Walter R. Dixon, Andi Piang-Ling Chang, Juan Machado,
Brenda Lau, Adrien Thompson, Shannon Gallagher and
William Sanders
Cocaine stimulates the cardiovcascular system. The major dose-
related effects are significant increases in both heart rate and blood
pressure. A number of clinical studies document cardiovascular toxic-
ity related to cocaine abuse. These symptoms include hypertensive
crisis, disturbance of heart rhythm and fatal heart attacks. In this
study, we have examined the effects of cocaine on cardiovascular para-
meters and endogenous adrenal catecholamine levels after oral and
intravenous administration.
METHODS
Male Sprague-dawley rats weighing 350 grams were used in this
study. Two groups of rats were used. (1) The rats were given water ad
libitum and at 8:00 A.M. each morning, water was removed and the
animals given their allotment of food for 1 hour followed by water or
cocaine for 1 hour. The cocaine was introduced in gradual increments:
0.01%, 0.02%, 0.04%, 0.06% and 0.08% w/v on days 8, 12, 16, 31 and 39
respectively. (2) Rats were infused with cocaine (1.1 mg/kg) intrave-
nously every 2 hours (total infusion time of 3 minutes for each infu-
sion) for 7 days. One day before the termination of infusion and oral
self-administration, the femoral artery and vein was catheterized with
PE-50 tubing so that blood could be withdrawn. The blood pressure
and heart rate measured at the end of 6 weeks oral administration of
cocaine and after termination of cocaine infusion using a Model 7
Grass polygraph. Adrenal glands were removed after termination of
cocaine infusion or-oral self-administration and homogenized in 0.4 N
perchloric acid, centrifused and the supernatant filtered (nalgene syr-
inge filter). Plasma NE, Epi and DA and endogenous NE, Epi and DA
were determined by high pressure liquid chromatography with electro-
chemical detection (HPLC-EC). All the results were expressed as the
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mean ± SE. Statistical analysis of the data was performed using
Student-Neuman-Keuls test.
RESULTS
After chronic infusion of cocaine, the B.P. (99± 4mmHg) was un-
changed from control (101 ± 2mmHg). However, the H.R. (308 ± 4
beats/min) decreased compared to the levels prior to cocaine infusion
(328 ± 7 beats/min). After 6 weeks of oral cocaine treatment, B.P. (104
± 3 mmHg) was unchanged from control rats (106 ± 5mmHg) not
treated with cocaine. However, the H.R. decreased (270 ± 10 beats/
min for oral cocaine-treated rats versus 347 ± 8 beats/min for control
rats). After cocaine infusion, plasma NE levels (0.462 ± 0.032 ng/ml)
were significantly higher than the NE levels (0.144 ± 0.009 ng/ml) after
oral cocaine administration. Plasma Epi levels (0.959 ± 0.127 ng/ml)
after cocaine infusion were also higher than the Epi levels (0.419 ±
0.155 ng/ml) after oral self-administration. The NE levels in adrenal
glands (10.2 ± 1.7 ug/gland pair) after cocaine infusion is similar to the
NE levels (13.6 ± 1.0 ug/gland pair) after cocaine oral self-administra-
tion. The Epi levels in adrenal glands (38 ± 1.8 ug/gland pair) after
cocaine infusion is similar to the Epi (41.9 ± 4.1 ug/gland pair) levels
after cocaine oral self-administration but significantly higher than the
Epi levels (24.6 ± 0.8 ug/gland pair) found in adrenals from untreated
control rats. Control rats infused with 0.9% saline every two hours for
one week (a procedure similar to the cocaine-infusion experiment) had
adrenal NE (6.4 ± 0.5 ug/gland pair) and Epi (27.0 ± 0.7 ug/gland pair)
levels comparable to levels in control untreated rats. However, adre-
nal Epi levels (37.7 ± 1.5 ug/gland pair) of rats supplied with food on a
limited basis was similar to rats on the oral cocaine regimen for 6
weeks but significantly higher than levels in control untreated rats or
saline-infused control rats. These results indicate that cocaine appears
to have a direct action at the adrenal medulla which may account, in
part, for the increase in adrenal and plasma levels of NE and Epi.
Moreover, food deprivation seems to be as effective as cocaine in in-
creasing adrenal Epi levels suggesting that a stressful stimuli may be
the initial event.
ACKNOWLEDGEMENTS
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Cocaine Stimulates LH and
Decreases PRL in Female Rhesus
Monkeys
Nancy K. Mello, Jack H. Mendelson, Mark P. Bree,
Maureen L. Kelly and John M. Drieze
The recent increase in cocaine abuse has been accompanied by clinical evidence
that chronic cocaine use has adverse effects on reproductive function in both
men and women. Hyperprolactinemia is often associated with chronic cocaine
abuse and persists during cocaine abstinence (Dakis and Gold, 1985; Cocores et
al., 1986; Mendelson et al., 1988, 1989). In pregnant women, cocaine use
increases the risk for spontaneous abortion and may be associated with fetal
malformation in the offspring (see Cregler and Mark, 1986; Smith et al., 1984;
Chasnoff et al., 1989 for review). Yet, there have been surprisingly few
systematic studies of cocaine’s effects on reproductive hormones in humans or
in animal models.
The effects of acute cocaine administration on anterior pituitary hormones were
studied in female rhesus monkeys during the follicular phase of the menstrual
cycle (Days 4-7). Synthetic luteinizing hormone-releasing hormone (LHRH)
was used to mimic endogenous hypothalamic LHRH and stimulate release of
anterior pituitary gonadotropins, LH and FSH. These studies are still in
progress and this report describes data obtained under three conditions: (1)
cocaine only (0.4 mg/kg. i.v.) with placebo LHRH; (2) LHRH only (100 mcg
i.v.) and placebo cocaine, and (3) cocaine (0.4 mg/kg, i.v.) + LHRH (100 mcg
i.v.). Ten min integrated plasma samples were collected for 40 min before
intravenous administration of cocaine or equal volume vehicle control solution.
After a collection of one 10 min post-cocaine plasma sample, LHRH or placebo
LHRH was administered and plasma samples were collected for an additional
100 min. Samples were analyzed for LH, FSH and prolactin.
The effects of cocaine only, LHRH only, and cocaine + LHRH on LH in 3
female monkeys are shown in Figure 1. Cocaine administration was followed
by a significant increase in LH (P < .01) of 45.8 percent. The cocaine
stimulated increase in LH-was greater than that measured after administration of
LHRH only (37.7 percent). Cocaine significantly enhanced LHRH stimulation
of LH in comparison to LHRH and placebo cocaine conditions (P < .01).
FSH increased significantly within 20 to 30 min after LHRH and placebo
cocaine administration. LHRH-stimulated FSH levels also were significantly
higher after 0.4 mg/kg cocaine than after placebo cocaine (P < .01). Cocaine
alone did not change FSH from baseline levels of 10.9 ± 0.4 ng/ml.
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Figure 1: Cocaine and LHRH Effects on LH (N = 3)
Figure 2: Cocaine and LHRH Effects on Prolactin (N=3)
Figure 2 shows the acute effects of cocaine only, LHRH only, and cocaine +
LHRH on prolactin in 3 female monkeys. Prolactin decreased significantly after
administration of cocaine alone (P <.01) and after cocaine + LHRH (P <.01).
LHRH had no effect on prolactin under placebo cocaine conditions. An acute
cocaine-induced suppression of prolactin was also reported in male and
ovariectomized rats (Ravits and Moore, 1977; Steger et al., 1981). These data
are also consistent with reports that acute cocaine administration increases
dopamine release in rodent (Peris and Zahniser, 1987). Inhibitory control of
prolactin release is mediated by dopaminergic systems and cocaine appears to act
like a dopamine agonist. An acute cocaine-related decrease in PRL may presage
hyperprolactinemia often seen during chronic cocaine abuse and in abstinent
cocaine abusers. This research was supported by DA-00101, DA-00064 and
DA-04059 from the National Institute on Drug Abuse, ADAMHA and RR-
05484 from NIH.
Alcohol and Drug Abuse Research Center
Harvard Medical School-McLean Hospital
115 Mill Street
Belmont, MA 02178
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Rate Altering Effects of Magnesium
on Cocaine Self-Administration
Kathleen M. Kantak, Scott I. Lawley and
Stephanie J. Wasserman
Magnesium (Mg2+) has been shown to have effects similar to those of
stimulants such as cocaine and amphetamine. An inverted U-shape response is
observed on mouse resident-intruder aggression with Mg2+ excesses and
deficiencies. Tolerance develops to the aggression enhancing doses of MgC12,
but not to the aggression inhibiting doses of MgC12. In addition, Mg2+
potentiates the dose dependent effects of cocaine, and attenuates the dose
dependent effects of haloperidol on mouse aggression. There is also evidence
that the stereotyped sniffing and locomotor stimulating properties of
apomorphine and l-amphetamine are attenuated by Mg2+ deficiencies; and
these behaviors are potentiated by Mg2+ excesses. In a conditioned place
preference (CPP) paradigm in mice, post-conditioning injections of MgC12
were shown to potentiate cocaine induced CPP in a manner similar to
amphetamine. Taken together, these data indicate that Mg2+, having behavioral
effects similar to other stimulants, might interact with cocaine in a rat self
administration paradigm. Recent studies have shown that rats will substitute 6
mg/kg/infusion MgC12 for 0.75 mg/kg/infusion cocaine over a 10 day period.
In contrast, in drug naive rats, MgC12 is not self administered. Therefore,
Mg2+ may be a potent substitute for cocaine, but have low abuse potential. If
so, then it would be expected that Mg2+ treatments might have rate altering
effects on self administered cocaine.
Male Wistar rats were surgically implanted with a jugular catheter. All rats were
infused daily with 0.5 ml of 8.5 units/ml heparinized saline followed by 0.1 ml
of 1000 units/ml heparinized saline. All animals received 5 days of access to
the 0.75 mg/kg/infusion training dose of cocaine before experiments began.
Three experiments were performed. In the first experiment, the dose response
of S.C. MgC12 on a cocaine dose response was examined in 5 groups of rats.
Following 1 hr access to 2, 1, 0.5, 0.25 and 0.1 mg/kg/infusion cocaine,
different doses of MgC12 (0, 15, 30, 125 or 250 mg/kg) were injected. In a
second experiment, the effects of a 15% required-Mg2+ diet and a 100%
required-control diet, fed for 3 weeks, were examined on cocaine dose
responses. A third experiment examined the effects of 0, 30, and 125 mg/kg
MgC12 on cocaine dose responses under both cocaine reinforcement and
cocaine extinction conditions in a single group of rats.
MgC12 caused a dose dependent shift to the left in the dose response function
for self administered cocaine. The reductions in responding for cocaine by
MgC12 were most pronounced at the 0.1 and 0.25 doses of cocaine. In
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contrast, a 15% required-Mg2+ diet caused a shift to the right in the cocaine
dose response function. This increase in the rate of responding for cocaine was
most evident at the 0.1 cocaine dose. The results of the first experiment were
replicated by the third experiment where MgC12 reduced the rate of cocaine self
administration. Furthermore, under extinction conditions, MgCl2 attenuated
the normal increased rate of responding observed in the 0 mg/kg control group.
These data indicate that MgC12 reduces responding for cocaine and are
therefore consistent with other data showing that MgC12 substitutes for
cocaine, enhances the potency of cocaine, and has stimulant-like properties.
Since MgC12 apparently has a low abuse potential, a therapeutic potential for
MgC12 in cocaine abuse can be hypothesized. The reduction in extinction
responding for cocaine by MgC12 may indicate that MgC12 is also capable of
reducing withdrawal craving for cocaine. It is unlikely that the reductions in
cocaine responding in these studies are related to motor disturbance. The
response rate reductions only occurred at selective doses of cocaine; and the
reductions were seen with doses of MgC12 which have previously been shown
to enhance the motor activating effects of apomorphine and I-amphetamine.
Department of Psychology, Boston University, Boston, MA 02215.
Supported by NIDA grant DA04325.
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Binding of [3H]GBR 12935 in the
Striatum, Medial Prefrontal Cortex,
Nucleus Accumbens and Olfactory
Tubercle of Rat
S. Izenwasser, L. L. Werling and B. M. Cox
Inhibition of dopamine uptake has been suggested as the mechanism by which
cocaine produces its reinforcing effects. The striatum, while rich in dopamine
terminals, is not implicated in drug reinforcement whereas the mesolimbic
dopamine pathway appears to play a primary role. It is therefore possible
that the binding properties and drug sensitivities of these areas might differ.
Inhibition of dopamine uptake and competition against [3H] GBR 12935 (1
nM) binding by GBR 12909, cocaine, amfonelic acid, nisoxetine, fluoxetine.
and carbamazepine were examined in the striatum, medial prefrontal cortex,
nucleus accumbens, and olfactory tubercle of rat. Additionally, competition
against [3H] GBR 12935 binding by methylphenidate was examined. In each of
these brain regions, dopamine uptake was found to be sodium-dependent and
was inhibited by GBR 12909 (IC50 = 5 nM), cocaine (IC50 = 400 nM), and
amfonelic acid (IC50 = 1 nM). Furthermore, each of these compounds
inhibited binding of [3H] GBR 12935 with the following order of potency:
amfonelic acid > GBR 12909 > cocaine > methylphenidate, except in the medial
prefrontal cortex where amfonelic acid was much less potent. Cocaine and
methylphenidate each inhibited approximately 70% of the specific binding at
high concentrations, suggesting that about 30% of the [3H] GBR 12935
binding was to sites insensitive to these inhibitors of dopamine uptake.
Amfonelic acid recognized two sites, a high affinity site (Kl = 1 nM) and a
lower affinity site (Kl = 150 nM). Competition curves for nisoxetine and
fluoxetine (inhibitors of norepinephrine and serotonin uptake, respectively)
showed no inhibition of [3H] GBR 12935 binding at 1 µM or less and at 10 µM
these drugs produced only about 40% inhibition. Furthermore, at a 100 nM
concentration (well above the IC50’s of 1 nM observed for inhibition of
norepinephrine or serotonin uptake, respectively) nisoxetine and fluoxetine
had no effects on the maximal inhibition produced by cocaine, GBR 12909 or
methylphenidate, suggesting that [3H] GBR 12935 was not binding to
norepinephrine or serotonin uptake sites. For all of these compounds, the
order of potency was the same for inhibiting dopamine uptake and competing
against [3H] GBR 12935 binding. Carbamazepine, however, potently
inhibited dopamine uptake (IC50 = 1 nM) yet did not inhibit binding of [
3H]
GBR 12935 at concentrations up to 100 µM. Thus, carbamazepine appears to
inhibit dopamine uptake by a mechanism which is unrelated to the [3H] GBR
12935 binding site. In conclusion, these findings suggest that the dopamine
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uptake systems and their drug sensitivities are not significantly different
among brain regions involved in drug reinforcement and other brain regions.
Furthermore, there may be more than one mechanism by which dopamine
uptake can be regulated.
Supported by a grant from the National Institute on Drug Abuse.
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of the authors and are not to be construed as reflecting the
views of the Department of Defense or the Uniformed Services
University of the Health Sciences. Animals used for this study
were acquired and cared for in accordance with the guidelines
published in the NIH Guide for the Care and Use of laboratory
Animals (National Institutes of Health Publication No. 85-23.)
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Microdialysis Studies of
Psychostimulants
Bartley G. Hoebel and Luis Hemandez
In a drug discrimination paradigm, rats trained on systemic d-amphetamine (AMPH, 1 mg/kg)
generalized to high doses of dl-phenylpropanolamine (PPA, 10, 20 and 40 mg/kg) in tests at 80%
body weight*. Because rats will also generalize to amphetamine injected locally in the nucleus
accumbens2 and will self-inject amphetamine into the accumbens3, we chose the accumbens for
microdialysis. At normal body weight AMPH (2 mg/kg) caused significant dopamine (DA)
release coupled with a decrease in DOPAC and HVA. AMPH also increased extracellular
serotonin (5HT) significantly, suggesting that 5HT may be responsible for some of
amphetamine’s stimulus properties and behavioral effects5. PPA (20 mg/kg) increased
extracellular DA like AMPH, which may partially explain stimulus generalization, but compared
to AMPH, PPA had less effect on DA and the opposite effect on DOPAC. In rats at 80% body
weight these drugs lacked their presynaptic effects on the accumbens DA system (see figure).
Reducing body weight to 80% of normal weight significantly decreased basal extracellular DA in
the NAC4, while at the same time increasing basal serotonin. This suggests that changes in
drug self-administration in food deprived or underweight animals may relate to changes in the
mesolimbic system. Drug discrimination may also be affected by deprivation or body weight.
AMPH5 or cocaine (COC)6 given by way of the microdialysis probe (reverse microdialysis)
increased DA and 5HT significantly and decreased DOPAC. Cocaine, procaine and lidocaine in
equimolar concentrations (7.3 mM) infused by reverse microdialysis had large, small and zero
effect, respectively, showing that procaine is mildly dopaminergic and that local anesthesia is not
responsible for cocaine’s or procaine’s effect7. Local PCP8 and local nicotine8 also released DA.
The effect of nicotine was blocked by i.p. mecamylamine, a nicotine antagonist. To summarize,
AMPH. COC and PCP increase extracellular DA and 5HT when applied directly to the
mesolimbic terminal region where amphetamine can generate stimulus properties and behavior
reinforcement. Body weight is a factor in basal DA release and in the acute, presynaptic response
to amphetamine.
DA released by drugs of abuse is clearly involved in positive reinforcement. particularly in the
NAC where it is necessary and perhaps sufficient to reward approach and operant behavior10.
The discovery that DA release is subject to classical conditioning11 suggests that DA in the
NAC might play a role in learning drug reward and in relapse caused by conditioned stimuli.
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Semtonin release by drugs of abuse may contribute to addiction through antidepressant properties.
Extracellular 5HT increased in the hypothalamus with local fluoxetinel2, an antidepressant, and
amphetamine-induced release of hypothalamic 5HT increased with chronic systemic LiCl13, both
antidepressants. Inhibiting the serotonin systems with 8-OHDA eliminated conditioned
suppression of saccharin intake14. This suggests that one function of some 5HT system is some
aspect of conditioned negative reinforcement (learned avoidance). Microdialysis suggests that
AMPH, COC, fluoxetine and LiCl may have 5HT effects in common, so it is possible that these
drugs enable systems for escape or avoidance of aversive consequences. It is not inconceivable
that serotonergic properties of some drugs of abuse could help explain addiction in terms of
facilitating the escape from aversive aftereffects. In conclusion, the results support the working
hypothesis that DA plays a role in drug positive reinforcement (learned approach) and suggests
that serotonin plays a role in drug negative reinforcement (learned escape or avoidance).
(Supported by USPHS grant DA-03597).
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Psychostimulant Properties of
MDMA
Lisa H. Gold, Mark A. Geyer and George F. Koob
The debate over the therapeutic usefulness of methylenedioxymethamphetamine
(MDMA) versus its neurotoxic and abuse potentials has resulted in a renewed
interest in the basic pharmacological effects of this amphetamine analog. Based
on human reports of mild sympathomimetic side effects and biochemical studies
indicating that MDMA activates both the serotonin and dopamine systems, the
neuropharmacological basis for the psychostimulant effects of MDMA were
investigated.
BEHAVIORAL PROFILE OF MDMA-INDUCED LOCOMOTION
MDMA (2.5-10.0 mg/kg, SC) dose dependently increased locomotor activity
measured in photocell activity cages for at least 2 hours [1]. Characterization of
the qualitative aspects of the behavioral effects produced by MDMA was
conducted using the Behavior Pattern Monitor (BPM) System. Each BPM
chamber consists of a black Plexiglas holeboard with three floor holes and seven
wall holes, a 4 x 8 array of infrared photobeams and a rearing touch plate. A
similar range of doses (1.25-10.0 mg/kg, SC) were also found to increase
horizontal locomotion for at least 2 hours measured in this apparatus [2]. In
addition this hyperactivity was accompanied by an initial decrease in investigatory
holepokes and rearings followed by subsequent increase at the highest doses
tested. Rats injected with 5.0 and 10.0 mg/kg exhibited thigmotaxis and a
tendency to avoid the center of the experimental chamber, a behavioral profile
similar to hallucinogen-like drugs.
Various psychostimulant drugs can produce a conditioned locomotion when
tested in the presence of environmental cues that were repeatedly associated with
the drug experience. MDMA (5mg/kg, SC) paired for 5 days to a distinct
environment paired with the presence of an olfactory stimulus. produced
enhanced locomotion during a test probe with the odor alone [3]. The
observation that the stimulus properties of MDMA can also become associated
with environmental cues indicates a behavioral effect which MDMA has in
common with other classical psychostimulants such as amphetamine and cocaine.
NEUROCHEMICAL PROFILE OF MDMA-INDUCED LOCOMOTION
The neurochemical substrates for the psychostimulant properties of MDMA have
also been investigated. The role of the mesolimbic dopamine system in the
locomotor stimulation produced by MDMA was examined following 6-OHDA
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lesions of the nucleus accumbens. As with amphetamine and cocaine, destruction
of dopamine terminals in the region of the nucleus accumbens attenuated the
MDMA-induced hyperactivity. Interestingly, rats treated with amphetamine (0.5
mg/kg, SC) after a previous injection of MDMA (5 mg/kg, SC) seem to exhibit
an enhanced locomotor response or sensitization. This may reflect the behavioral
effects caused by serotonin neurotoxicity associated with exposure to MDMA, as
has been reported by others [4]. Thus, a loss of serotonergic inhibition of a
dopamine-mediated component of locomotor hyperactivity results in an increased
locomotor response. The importance of this serotonergic modulation of
dopamine neurotransmission was demonstrated further by showing that a
serotonin antagonist, methysergide (2.5-10.0 mg/kg, SC), markedly potentiated
the increase in locomotion produced by MDMA (10.0 mg/kg, SC) [5].
CONCLUSIONS
In summary, the stimulation of locomotor activity by MDMA and the importance
of mesolimbic dopamine in this response reflects similarities with the prototype
stimulant, amphetamine. It is important to note that these parameters are
frequently associated with rewarding aspects of drugs and drug abuse.
Additionally, the behavioral profile of MDMA shares certain characteristics with
hallucinogen-like agents. This mixture of stimulus properties and neurochemical
actions suggests a unique pharmacology for MDMA which may be associated
with potential behavioral toxicity in addition to the previously revealed
neurotoxicity.
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Comparison of the Behavioral and
Neurochemical Effects of 5,7-DHT,
MDMA and D, L-Fenfluramine
Stanley A. Lorens, Norio Hata, Theresa Cabrera and
Margaret E. Hamilton
Three experiments were performed. In the first, separate groups (n=9-10) of male Sprague-
Dawley rats (250 9) were injected with different doses of 5,7-dihydroxytryptamine (5,7-
DHT; 0, 50, 100 and 150 ug/kg, i.c.v.; 30-45 min followinq nomifensine and desipramine, 15
mg/kg, i.p.) or 3,4-aethylenedioxymethamphetamine (MDMA; 0, 10, 20, and 40 mg/kg, s.c.,
b.i.d x 4 d) then subjected to a series of behavioral tests beginning 2-3 weeks post-
injection. The rats were sacrificed 10 weeks post-injection and regional CNS monoamines
and metabolites determined by HPIC. 5,7-DHT produced selective and dose-dependent but non-
uniform reductions (46-95%) in regional 5-HT and 5-HIAA concentrations. The hippocampus
and hypothalamus were the most and least sensitive, respectively. In contrast, MDMA
produced uniform falls in CNS 5-HT and 5-HIAA levels which did not exceed 39%. The lowest
dose (50 ug) of 5,7-DHT reduced open field exploration. All 5,7-DHT doses impaired
swimming ability. 5,7-DHT failed to affect the acquisition of one- and two-way conditioned
avoidance responses. MDMA did not affect any of the behaviors studied.
In the second experiment, rats (n=6-12/goup) were treated with 5,7-DHT (0, 50 or 200 ug,
i.c.v.), MDMA (0, 10 or 40 ug/kg, s.c., b.i.d. x 4 d), or d,l-fenfluramine (FEN; 0, 5 or
20 mg/kq, s.c., b.i.d x 4 d). Open field behavior (12 min), morphine analgesia (5.0 mg/kg,
s.c.), and swimming ability (14 min) were examined on the 3 days immediately preceding
sacrifice either 2 or 8 weeks later. The effects of 5,7-DHT on CNS 5-HT and 5-HIAA levels
were substantially greater than those produced by the substituted amphetamines. The
neurochemical effects of the treatments, furthermore, were greater 2 weeks than 8 weeks
post-injection. The 5,7-DHT 200 ug dose potentiated morphine analgesia 8 but not 2 weeks
post-injection. No other behavioral effects were observed.
In the third, rats (n=8-12/group) were treated with either saline (1.0 ml/kg, s.c., b.i.d.
x 4 d), MDMA (40 mg/kg, s.c., b.i.d. x 4 d) or FEN (12 mg/kg, s.c., b.i.d. x 4 d). The
animals were food deprived and trained for 5 weeks in a 8-arm radial maze for food
reinforcement. The performance of the MDMA, FEN and saline treated animals did not differ.
Repeated high doses of MDMA and FEN do not lead to dysfunctions in exploratory behavior,
motor coordination or stamina, thermal pain sensitivity, morphine analgesia, avoidance
conditioning, or short-term spatial memory. 5-HT neurons, furthermore, recover from the
depleting effects of MDMA and FEN. The behavioral effects of 5,7-DHT appear to be test,
dose and time dependent. The functional consequences of substantial reductions in CNS 5-
HT levels, however, are subtle and difficult to discern.
Department of Pharmacology (Building 135), Loyola University Medical Center, Haywood, IL
60153. (Supported by NIDA Contract 271-87-8117)
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Comparison of Responses by
Neuropeptide Systems in Rat to the
Psychotropic Drugs,
Methamphetamine, Cocaine and
PCP
G. R. Hanson, L. P. Midgley, L. G. Bush, M. Johnson and
J. W. Gibb
Similar schizophrenia-like psychotic episodes occur following
intense use of methamphetamine (METH), cocaine and pheney-
clidine (PCP) and are thought to relate to the impact of these agents
on CNS dopaminergic (DA) activity. Interestingly, these 3 drugs
of abuse have different mechanisms of action; thus, METH induces
monoamine release, cocaine blocks the reuptake of monoamines
and PCP has diverse effects including blockade of the NMDA-
related calcium channel as well as activation of the sigma receptor.
Examination of the striatal dopaminergic system, following multiple
doses  (5  admin i s t r a t ions  wi th  6 -h r  in te rva l s )  o f  METH (15
mg/kg/dose), cocaine (30 mg/kg/dose) or PCP (15 mg/kg/dose),
demonstrated that only METH significantly lowered the content of
dopamine (DA) and i ts  metaboli te,  DOPAC, while al l  3 drugs
caused  s ign i f ican t  decreases  in  s t r i a ta l  ty ros ine  hydroxylase
activity. These DA neurochemical parameters do not seem to reflect
a common mechanism for the psychotic actions of these agents.
Changes  in  ex t rapyramida l  and  l imbic  t i s sue  con ten t  o f  the
n e u r o p e p t i d e s ,  n e u r o t e n s i n  ( N T ) ,  d y n o r p h i n  A  ( D Y N )  a n d
substance P (SP), have been shown to be indicators of fluctuations
in DA postsynaptic activity. Because METH, cocaine and PCP are
thought to exert their schizophrenia-like effects by altering DA
activity, these peptide systems were evaluated in order to identify a
common neurochemical basis for the psychotropic actions of these
drugs. We observed that intense treatment (see above) with any one
of the 3 drugs caused NT increases (approximately 150-250% of
control) in the striatum and nucleus accumbens as well as increases
in striatal DYN levels. Such common changes suggest that these
peptide systems might contribute to the comparable psychotropic
effects of these drugs of abuse. In contrast, the effects of these
agents were distinct on the 3 peptides (i.e., NT, DYN and SP) in
the nigra as well as on striatal SP and accumbens DYN systems.
Perhaps these peptidergic pathways contribute to the unique
pharmacological features of these agents. (Supported by USPHS
grants DA 00869 and DA 04222).
Affiliation: Department of Pharmacology and Toxicology, Univer-
sity of Utah, Salt Lake City, UT 84112.
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Evidence of Pharmacological
Tolerance to Nicotine
Heidi F. Villanueva, John R. James and John A. Rosecrans
Previous studies have demonstrated that tolerance develops
to the disruptive effects of nicotine in both rats and mice in
an operant response paradigm. Continuing research
investigating the mechanisms of tolerance to nicotine have
utilized pre- and post-session administration of nicotine to
determine whether tolerance develops only to pre-session
administration (behavioral tolerance) or if tolerance develops
to both pre- and post-session administration (pharmacological
tolerance). Preliminary investigations have demonstrated that
the dose response curve is shifted to the right (indicating
tolerance) following both pre-and post-session administration
of nicotine. These results suggest that tolerance develops
primarily due to pharmacological changes in the organism
(Hendry & Rosecrans, Psychopharmacology, 77: 339-343, 1982;
Meltzer, unpublished doctoral dissertation, 1980) produced by
either a change in pharmacokinetic properties or by a change
in receptors. However, operant studies in this laboratory and
activity studies by Stolerman et al. (Psychopharmacolgia, 30:
329-342, 1973) have suggested that there may be a one dose
tolerance effect when nicotine Is administered prior to the
test session. The present studies have attempted to further
separate and identify the behavioral and pharmacological
factors involved in the development of tolerance to nicotine.
In the f irst study, 24 mice were trained to respond for
sweetened milk on a fixed ratio (FR) 20 schedule of
reinforcement. nice were matched according baseline
responding and randomly assigned to one of three groups:
saline, nicotine-l, or nicotine-14. The saline mice received 5
ml/kg immediately after each of 14 daily operant sessions. The
nicotine-l mice received 1.2 mg/kg nicotine following the first
operant session and 5 ml/kg saline following the next 14
operant sessions. The nicotine-14 mice received 1.2 q g/kg
nicotine after each of the 14 daily operant sessions. On day
15, all mice received 1.2 q g/kg nicotine prior to the operant
session. Response rates of al l  groups were signif icantly
d isrupted  by  pre-sess ion  n ico t ine  and t h e r e  w a s  n o
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difference between the three groups. Post-session injections
were then continued for another 14 days with the saline and
nicotine-l groups receiving saline after each session and the
nicotine-14 groups receiving nicotine after each session. All
mice were challenged a second time with 1.2 q g/kg pre-session
nico t ine .  The  response  ra tes  o f  the  three  groups  were
s i g n i f i c a n t l y  g r e a t e r t h a n  d u r i n g  t h e  f i r s t  c h a l l e n g e ,
suggesting that all groups had developed tolerance to the
disruptive effects of nicotine despite their different post-
s e s s i o n  d r u g  h i s t o r i e s .  T h i s  s u g g e s t s  t h a t  t h e r e  i s  a
behavioral mechanism i n v o l v e d  i n t h e  d e v e l o p m e n t  o f
tolerance to nicotine.
Because previous studies in this laboratory had involved
rats and mice trained on a variable interval (VI) schedule of
reinforcement, a second study was undertaken to investigate
the influence of schedule differences in the development of
pharmacological and behavioral tolerance. The second study
was identical to the first. with the exception that the mice
were trained on a VI-15. second schedule of reinforcement. The
results from the first challenge indicated that the nicotine-
14 group was tolerant to the disruptive effects of nicotine,
while the saline and nicotine-1 groups were not. This suggests
that a pharmacological mechanism is responsible for the
development- of tolerance on a VI schedule. When the mice
received their second pre-session injection’ of nicotine, all
three groups displayed some tolerance, with the saline groups
continuing to respond significantly less than the two nicotine
g r o u p s .  I t  i s  n o t  p o s s i b l e  t o  d e t e r m i n e  w h e t h e r  t h e
development of tolerance on the second challenge is due to
pharmacological or behavioral mechanisms. However, the
display of tolerance in the saline group 14 days after the
initial pre-session administration of nicotine does suggest
that there is a one-dose ef fect and that this ef fect lasts
for at least two weeks.
AFFILIATION: Department of Pharmacology & Toxicology, Medical
C o l l e g e  o f Virginia- Virginia Commonwealth
University, Richmond, Virginia.
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Intravenous Cocaine Infusions in
Humans: Dose Responsivity and
Correlations of Cardiovascular vs.
Subjective Effects
C. Muntaner, K. M. Kumor, C. Magoshi and J. H. Jaffe
Eight experienced IV cocaine users were intravenously.
administered 0, 10, 20, and 40 mg of cocaine hydrochloride
on separate days in a pseudo-randomized ascending dose
series, such that the 20 mg dose always preceded the 40 mg
dose. They were subsequently administered 0, 20, and 40 mg
of cocaine in a fully randomized presentation order.
Cardiovascular effects of cocaine were significantly
different from placebo for the 20 mg but not the 10 mg
dose, in contrast to subjective responses which differed
from placebo for the 10 mg dose. Subjective effects of
cocaine did not differ between the 20 mg and 40 mg dose
conditions for the pseudo-randomized trials, but did differ
in the fully randomized trials. This lack of difference in
responsivity between the 20 and 40 mg dose in the earlier
trials may possibly have been due to contrast effects.
Cardiovascular responses were not consistently correlated
with subjective responses, either within a cocaine dose
condition or across doses.
AFFILIATION: NIDA, Addiction Research Center, Baltimore, MD
21224
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In Utero Exposure to Cocaine and
the Risk of SIDS
Barbara Lounsbury, Marta Lifshitz and Geraldine S. Wilson
The incidence of death from sudden infant death syndrome (SIDS) in
infants exposed to cocaine in-utero has been reported to range
from 0.55% (no increased risk) to 15% (75-150 fold increased
risk). These studies raise important public health issues about
the appropriate management of infants exposed to intrauterine
cocaine . The wide variability in the reported incidence of SIDS
in this population indicates further studies are needed.
This is a report on the incidence of SIDS in 124 infants exposed
in-utero to cocaine alone or in combination with other drugs com-
pared to 50 infants exposed only to other illicit drugs. Subjects
were born in a metropolitan public maternity hospital over a one
year period from 9/l/86 to 8/31/87. Mother-infant pairs were
identified at the time of delivery by obstetrical and by social
worker interviews. Occurrence of SIDS was ascertained by review
of City of Houston death records of subjects whose cause of death
was listed as SIDS, ill-defined conditions or respiratory
conditions. At the time of the record review all 174 infants were
at least 9 months of age. No significant differences in maternal
characteristics were ‘seen except that 58% of cocaine users and 36%
of other drug users were black (p=.03). There were no
differentiating infant factors except significantly more frequent
and severe symptoms of withdrawal in infants not exposed to
cocaine (p=.OO8). No infant exposed to cocaine alone had a major
congenital abnormality. Two infants exposed to cocaine in
combination with narcotics had ventricular septal defect. Upon
review of death records only one infant exposed to cocaine and
ethanol was reported to have died from SIDS and this was confirmed
by review of autopsy records. No infants in the non-cocaine group
died of SIDS. This represents a risk of SIDS in infants exposed
to cocaine in-utero of 0.8%. Although the-risk of this exposed
group is 1.5 times the reported risk in the general population
(0.54 per 1000) the 95% confidence- interval ranges from no risk to
a maximum risk of 3.3%. This supports recent reports that the
risk of SIDS is minimally if at all increased in ‘the in-utero
cocaine exposed infants.
Baylor College of Medicine, Dept. of Pediatrics, Houston, Texas
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Evaluation of Cognitive Skills in
Ethanol- and Cocaine- Dependent
Patients During Detoxification
Using P300 Evoked Response
Potentials (ERPs)
Leslie Amass, Scott E. Lukas, Roger D. Weiss and
Jack Mendelson
The P300 ERP is an extremely sensitive electrophysiological measure
of information processing ability believed to reflect memory updating
processes, and is therefore a very useful probe for the study of
cognitive functioning during protracted withdrawal. In both acute
studies with ethanol (Church et al., 1982; Campbell et al., 1980; Lewis
et a/., 1970) and during acute and chronic alcoholism (Chu et al., 1978;
Gross et al., 1988) studies have demonstrated decreased amplitude
and increased latency on both auditory and visual evoked responses.
Visual ERP paradigms have been highly successful in documenting
depressed P300 ERP amplitudes and Increased latencies In both
abstinent alcoholics (Porjesz et al., 1982, 1985) and individuals at risk
for alcoholism (Begleiter et al., 1984, 1987; O’Connor et al., 1987;
Patterson et al., 1987). However, several investigators have questioned
the above studies (Neville et al., 1985; Polich et al., 1987, 1988;
Steinhauer et al., 1987) because of variability in both the cognitive
demands of the tasks and of the subject populations, as well as the
failure to replicate the findings when auditory ERP paradigms are used.
At present, Information regarding the effects of chronic cocaine use on
cognitive function is limited.
The recent debate as to whether P300 ERPs represent a possible
biological  marker for  a lcohol ism or s imply ref lect  the residual
neurotoxic effects of ethanol exposure is currently unresolved. The
present study was conducted to determine if parametric manipulations
in the cogni t ive demands of  the task are useful  for  d iscerning
fundamental  populat ion d i f ferences between substance-abusing
populations. Changes In information processing skills in chronic
ethanol and cocaine users during detoxification were determined using
P300 ERPs and reaction times generated by the performance tasks.
Sixteen non-medicated, male and female patients (22-41 yrs) admitted
to a 28-day t reatment  program for  ethanol  or  cocaine/ethanol
dependence, and eight age-and sex-matched, non-drug using controls
(21-53 yrs) provided Informed consent and were monitored once a
week for four weeks. Subjects were prepared with scalp electrodes
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over Cz, T3, and T4 sites and placed in a sound- and Iight-attenuated
chamber for recording of EEG activity and P300 ERPs. P300 ERPs
were recorded with eyes open using an oddball paradigm consisting of
pure tone 1 kHz auditory stimuli of 100 msec duration. Subjects
participated in both easy (30 dB difference) and hard (10 dB difference)
auditory discrimination tasks alone and in combination with a visual
reaction time task in order to measure individual responsiveness to
manipulations in task difficulty and processing-load requirements.
Increased P300 latencies were evident under all hard task conditions in
each group, independent of processing requirements. Reaction times,
whi le fastest  In the cocaine/ethanol  group,  were unaf fected by
manipulations in task difficulty suggesting that latency and reaction time
are independent processes. Ethanol-dependent patients displayed the
longest latencies and slowest reaction times overall, with P300 latency
at its longest durlng hard test conditions. increased processing loads
resulted in an attenuation of P300 amplitude across all groups;
however, ethanol-dependent patients had the lowest amplitudes
overall. P300 amplitudes showed some recovery across the four
weeks in both ethanol- and cocaine/ethanol-dependent patients,
although this trend was non-significant. Moreover, ethanol-dependent
patients displayed markedly attenuated P300 amplitudes during easy
task conditions which were strikingly similar to those seen during the
hard task conditions In non-drug using controls.
These results suggest that ethanol-dependent patients’ stimulus-
e v a l u a t i o n  a n d  p r o c e s s i n g  s k i l l s  a r e  m o r e  i m p a i r e d  t h a n
cocaine/ethanol-dependent patients during protracted withdrawal,
particularly during hard task conditions. Furthermore, P300 ERPs
obtained during relatively easier task conditions were particularly
useful measures for delineating fundamental population differences in
cognitive capacity. Further refinement of this task may yield a useful
neurophysiological correlate of sensory awareness in drug-dependent
populations. This research was supported by NIDA grants DA03994,
DA00115 and DA00064.
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Induction and Loss of Acute
Tolerance to the Cardiac
Chronotropic Effect of Cocaine in
Humans
John J. Ambre, Timothy J. Conndly, Tsuen-lh Ruo and
Thomas K. Henthom
Acute tolerance develops to the cardiac chronotropic and subjective effects of
cocaine in humans. We have shown that tolerance to the chronotropic effect is
incomplete (heart rate decline in the presence of stable plasma cocaine
concentrations approaches a plateau that exceeds the baseline heart rate (Ambre et
al., (Clin Pharmacol Ther 44:1-8, 1988). We also showed that tolerance
development can be described as an exponential process with a half-time
averaging 26 minutes. Studies described hem are aimed at full specification of a
pharmacokinetic and dynamic model. Steady state cocaine infusions were used
to induce a full or maximal state of tolerance. Cocaine challenge infusions were
then given at intervals after full tolerance induction to determine the rate of
tolerance loss.
Subjects were regular intravenous cocaine users who abstained from cocaine use
for at least 24 hours prior to the study. Subjects were continuously monitored
with real time display of a high resolution electrocardiographic tracing and six
beat average heart rate recording. Subjects were sitting or semireclining in bed
throughout. Blood samples were obtained from a forearm vein. Plasma cocaine
concentrations were measured by gas chromatography/mass spectrometry.
Through an intravenous line established in the opposite arm, subjects received an
intravenous dose of 100 mg cocaine by constant rate injection over 10 minutes
followed by an infusion designed to maintain stable plasma concentrations in the
range of 1000 ng/mL. Cocaine infusions were continued for 3 hours to allow
full tolerance development. A 100 mg challenge dose was administered over 10
minutes in each subject at an interval of 4 and/or 20 hours from the end of the
induction infusion. Placebo studies consisted of saline infusion.
Heart rate reached a peak at the end of the 10 minute injection and then declined
toward a plateau and/or declined with concentrations when the infusion is
stopped The data were evaluated as plots of effect vs. concentration in temporal
sequence (phase plot). Acute tolerance development was associated with
clockwise opening (hysteresis) of the phase loop. Data from early (4 hr)
challenge doses indicated that tolerance was still maximal. The slope of initial
response was decreased and the limbs of the phase plot were superimposed (no
hysteresis). Response was shown to be linearly related to concentration in the
presence of tolerance (up to 1500 ng/mL). Data from challenge doses at 20
hours indicated that tolerance had been lost (or sensitivity restored). Phase plots
indicated initial slopes identical to the original response and clockwise opening
of the loop was evident again.
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Therefore, we have shown that maximal tolerance persists at 4 hours after the
induction infusion and tolerance has disappeared at 20 hours. Obviously,
further studies at intervals between 4 and 20 hours will be required to fully
define the rate of tolerance loss. These results, however, allow some definite
conclusions about the design of a pharmacodynamic model. In our earlier
studies we used .a model that allowed data description and calculation of
tolerance development rate without mechanistic assumptions. Our goal is to
acquired data to support a mechanistic model. Others have proposed tolerance
models for other drugs. A model used for nicotine, but proposed to be generally
applicable, is the “antagonist-force” model of Porchet (J Pharmacol Exp Ther
244, 231-236, 1988). A major limitation of the model is the requirement that
rates of development and disappearance of tolerance be identical. With a half-
time for cocaine acute tolerance development of about 30 minutes, the Porchet
model predicts return of full sensitivity within 3 hours (five or six half-lives).
Our results show that this is clearly not the case for cocaine (under conditions of
our study, simulating typical exposure).
We propose a model of acute tolerance based on receptor pharmacology
including both rapidly reversible processes that may be predominant in situations
involving short term cocaine exposure and more slowly reversible processes
(e.g. receptor catabolism) that are significant when drug exposure is prolonged.
SUPPORT: NIDA Grant DA04073
AFFILIATION
Departments of Medicine and Anesthesia, Northwestern University Medical
School, Chicago, IL
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Human Psychopharmacology of
Intranasal Cocaine
Stephen T. Higgins, John R. Hughes and Warren K. Bickel
Despite the widespread use and abuse of cocaine,
much remains to be learned about the human
psychopharmacology of this compound. In the present
study, the acute effects of intranasally
administered cocaine hydrochloride (placebo, 48, &
96 mg/70 kg) on human learning and performance were
investigated in 8 (5 M & 3 F) recreational cocaine
users under double-blind conditions. Subjects
performed the Digit Symbol Substitution Test (DSST),
the Repeated Acquisition and Performance task, and
visual-analog ratings of drug effect immediately
before and every 15-30 min for 2 hrs after drug
administration. Heart rate and blood pressure were
measured every 5 min, and ECG and skin temperature
were measured continuously for 1 hr predrug and at
least 2 hrs postdrug administration. The 48 and 96
mg doses significantly increased overall rates of
responding and the number of trials completed
correctly in the DSST procedure throughout the 2 hr
postdrug observation period (i.e., DSST performance
was enhanced); the 2 active doses were both
significantly different from placebo but not from
each other. Neither overall rates of responding nor
accuracy were significantly affected by cocaine in
the Repeated Acquisition and Performance procedure.
Visual-analog ratings of drug effect, heart rate,
systolic pressure, diastolic pressure, mean arterial
pressure, pressure-rate product, and skin
temperature were significantly increased as an
orderly function of drug dose. These effects were
also generally discernible throughout the 2 hr
postdrug observation period. There were no effects
of cocaine on ECG. These results suggest that acute
intranasal doses of cocaine do not impair learning
and can significantly enhance some aspects of human
performance. However, doses that enhance
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performance also significantly increase cardiac
output underscoring the dangers associated with
cocaine use. To our knowledge, this study is the
first to document that acutely administered cocaine
can enhance performance in rested subjects under
controlled laboratory conditions. The current
widespread use of cocaine both in and outside the
workplace demands that additional studies be
conducted to more fully characterize that behavioral
effects of this compound.
AFFILIATION
Human Behavioral Pharmacology Laboratory,
Departments of Psychiatry and Psychology, University
of Vermont, Burlington, VT 05401
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Effects of the Combination of
Cocaine and Marijuana on the
Task-Elicited Physiological
Response
Richard W. Foltin and Marian W. Fischman
In 1986, we reported at this meeting that combining intranasal cocaine
or smoked marijuana administration with task performance increased
heart rate and mean arterial pressure above levels observed following
either drug or task performance alone. In this paper, we report the
effects of combinations of cocaine, smoked marijuana, and task
performance on heart rate and blood pressure.
METHOD
Eight adult male research volunteers, 25 to 36 years of age, with
histories of cocaine and marijuana use, participated in nine
experimental sessions. The study consisted of testing the effects of a
single dose of intranasal cocaine hydrochloride (4, 48, 96 mg) in
combination with a single smoked marijuana cigarette (1-gm, 0-
2.9% 9THC) administered per session. Heart rate (HR) and blood
pressure (systolic, SP; diastolic,DP) were recorded every two minutes.
A marijuana cigarette was smoked over a five-min period using a
uniform puffing procedure. Five-min after completion of the puffing
procedure, subjects were given 100 mg of white powder consisting of
cocaine and lactose for inhalation. Ten-minutes of serial acquisition
performance was repeated 25 and 70-min following the start of
marijuana smoking. All of the subjects received low dose
combinations prior to high dose combinations.
RESULTS
Cocaine alone produced dose-dependent increases in HR up to 15
bpm, and marijuana alone produced concentration-dependent
increases in HR up to 27 bpm. Task performance alone increased HR
by about 5 bpm. The combination of all three events resulted in peak
HRs of about 37 bpm. Cocaine alone produced dose-dependent
increases in SP up to 12 mmHg, while marijuana had no significant
effect on SP. Task performance alone increased SP by about 7
mmHg, and the combination of task performance, cocaine and
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marijuana administration increased SP to those levels seen following
combinations of task performance and cocaine administration alone. A
similar pattern of results was evident for DP. There was no significant
effect of either cocaine or marijuana on any dimensions of
performance on the serial acquisition task.
DISCUSSION
The current study pointed to the importance of measuring drug effects
under conditions in which some behavioral demands are being made
on the drug-taker. HR and blood pressure changes were related both
to the drug administered and the concurrent behavioral requirements
in the test session. Although combinations of cocaine and marijuana
increased HR, these increases were no larger than those observed
following the highest concentration of THC alone. In sharp contrast to
the limited effect of cocaine on marijuana-induced changes in HR, is
the large supplemental increase in heart rate during performance of a
learning task. Combined administration of cocaine and marijuana
increased blood pressure to the same degree as cocaine
administration alone. As was observed with heart rate, task
performance significantly incremented both SP and DP above levels
seen following cocaine and marijuana administration alone. Maximal
blood pressure increases observed with combinations of all three
events were similar to those observed following cocaine and task
performance alone.
The results suggest that HR and blood pressure elevations following
illicit drug use can combine with ongoing behavior to further increase
these physiological responses. Such combinations may be one factor
contributing to the adverse cardiovascular consequences of drug use.
AFFILIATION
Division of Behavioral Biology, Department of Psychiatry and
Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD
Funded by DA-03476 and DA-03818 from the National Institute on
Drug Abuse.
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Cocaine Attenuates Opiate
Withdrawal in Human and Rat
Theresa A. Kosten
Greater opiate dependence, based on the DSM-III R
criteria, is associated with more severe naloxone
precipitated opiate withdrawal, while greater cocaine
dependence is associated with less severe opiate
withdrawal (Kosten, et al, in press). This suggests
that chronic or acute cocaine may reduce opiate
withdrawal symptoms. To test this idea, we conducted
two experiments: 1) we investigated the effects of
chronic cocaine use on opiate-withdrawal in human by
comparing cocaine dependent opiate addicts to non-
cocaine dependent opiate addicts on measures of opiate
use and withdrawal: 2) we investigated the effects of
acute cocaine administration on severity of
precipitated opiate withdrawal symptoms in rat.
METHOD
Chronic cocaine effects on opiate withdrawal in human.
We studied 52 opiate addicts (63% male, 69% male, 33
years old) who-applied for methadone -treatment. A
naloxone injection (0.8 mg/kg, s.c.) was given and
ratings of opiate withdrawal symptoms were made every
5 min for 20 min. Symptoms included tearing, tremor,
vomiting, yawning, restlessness, pupillary dilation,
gooseflesh, and sweating. Drug dependence (DSM IIIR)
was assessed with the SCID and drug use history was
gathered at intake. Those subjects who met DSM IIIR
criteria for cocaine dependence formed the cocaine-
dependent group (n=19); those who did not formed the
non-cocaine dependent group (n=33).
Acute cocaine effects on opiate withdrawal in rat.
Five male, Sprague-Dawley rats (250g) were implanted
with 5 morphine pellets (75 mg ea, S.C.). After 1
week, a naloxone injection (1 mg/kg, s.c.) was given
and opiate withdrawal symptoms were observed every 15
min for 1 hr. Symptoms included tearing, tremor,
chewing, stretch, diarrhea, ptosis, jumping,
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irritability, tail wag, piloerection, salivation, and
wet dog shakes. Morhpine implants were repeated 1
week later and cocaine injections (20 mg/kg, i.p.)
were given 15 min prior to the naloxone test.
RESULTS
Opiate use. Opiate use did not differ between the
cocaine and non-cocaine dependent groups. Opiate
dependence (total rating on SCID opiate use section)
was 32.4 ± 0.2 for the former and 31.7 ±0.4 for the
latter group. There were no differences in years of
opiate use (12.8 ± 1.0 vs. 15.5 ± 1.9 yr) or in self
rating of use frequency on a 6 point scale where 6 was
multiple daily use (3.6 ± 0.2 vs. 2.2 ± 0.3).
Opiate withdrawal. Total ratings of precipitated
opiate withdrawal were less with chronic cocaine use
in human (15.4 ± 2.1 vs. 20.7 ± 1.8 ) and after acute
cocaine administration in rat (16.2 ± 2.7 vs. 29.2 ±
2.1). Specifically, chronic cocaine in humans reduced
tremor, pupillary dilation, and sweating; but, yawning
was heightened (p's<0.05). Acute cocaine
administration in rat reduced diarrhea, ptosis,
salivation, and wet dog shakes (p's <0.05). There
were trends for less restlessness in human and less
chewing in rat with cocaine (p's<.1)
DISCUSSION
These results show that both chronic and acute cocaine
reduce the severity of naloxone-precipitated opiate
withdrawal. The data from the human study cannot be
explained by differences in opiate use. Moreover, the
results are consistent with the rat study, where we
controlled for opiate and cocaine dose, length, of
opiate exposure, and timing of cocaine administration.
Across species, the common cocaine effect on specific
opiate withdrawal symptoms is the reduction in the
hyperthermic response; sweating is decreased in human
cocaine users and salivation is decreased after acute
cocaine in rat. The mechanisms by which these cocaine
effects on opiate withdrawal work are unknown.
Nonetheless, the use of cocaine by opiate addicts may
be explained, in part, by their discovery that cocaine
reduces opiate withdrawal severity. These results
should help direct treatment strategies for this dual
addiction as well as suggest new pharmacotherapies.
From the Depts. of Psychology and Psychiatry, Yale
University. Supported by NIDA grant P50-DA04060.
Morphine pellets supplied by NIDA.
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Teen Addiction Severity Index
(T-ASI): Clinical and Research
Implications: A Preliminary Report
Yifrah Kaminer, Oscar Bukstein and Ralph Tarter
The Teen Addiction Severity Index (T-ASI), is
a clinical interview utilizing the dimensional
approach for the assessment of severity of
adolescent substance abusers. The T-ASI,
modeled after the ASI, is composed of seven (7)
domains: substance use; school performance:
family relationships; peer/social
relationships; employment status; legal status
and psychiatric status. The T-ASI aims to fill
the need for a reliable and valid clinical
instrument for youths known or suspected to use
drugs. Initial psychometric studies on 50
cases indicate that this scale is both
clinically useful and reliable. The clinical
and research implications, particularly for
improving patient-treatment matching and
treatment prognosis, will be discussed.
University of Pittsburgh
School of Medicine
3811 O'Hara Street
Pittsburgh, PA 15213
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Relative Abuse Liability of
Benzodiazepines in Methadone
Maintained Populations in Three
Cities
Martin Y. lguchi, Roland R. Griffiths, Warren K. Bickel,
Len Handelsman, Anna Rose Childress and
A. Thomas McLellan
The purpose of this study was to examine general patterns of licit and illicit
benzodiazepine use among individuals enrolled in methadone maintenance (MM)
in order to determine whether a clinical pattern of differential dependence or abuse
liability might be detected. The focus of this study was on MM clients who
reported experience with a variety of sedatives/tranquilizers in their lifetime.
METHODS
Subjects were selected in two phases from three (MM) clinics in three cities.
In Phase I, all clients reporting to the clinics at least 3 days/week and enrolled in
MM were asked to participate in a brief survey of their lifetime use of ten different
benzodiazepines and barbiturates. The list of examined drugs included diazepam,
lorazepam, alprazolam, clorazepate, oxazepam, chlordiazepoxide, nembutal.
secobarbital, tuinal, and phenobarbital. In all, 547 clients were recruited from
three clinics located in Baltimore, MD (n=50), Philadelphia, PA (n=218), and the
Bronx, NY (n=279). Fewer than 4% of all subjects identified as eligible for the
Phase I survey were missed or refused to be interviewed. The Baltimore clinic
was 74% male, 70% white, and 30% black. The Philadelphia clinic was 100%
male, 40% white, and 60% black. The Bronx clinic was 69% male, 28% white,
17% black, and 55% hispanic. Mean ages were 36, 37, and 35, respectively.
Subjects qualified for Phase II if they indicated that they had used more than
seven of the ten different sedatives/tranquilizers in their lifetime. In all, 13
subjects (26%) met the Phase II eligibility criterion in Baltimore, 27 subjects
(12.4%) met the criterion in Philadelphia, and 32 subjects (11.5%) met the
criterion in the Bronx. In Baltimore, all 13 eligible clients were. selected for Phase
II and 11 were interviewed. In Philadelphia, 15 subjects were randomly selected
and interviewed. In the Bronx, 15 subjects were randomly selected and 14 were
interviewed. In all, 36 white subjects, 3 black subjects, and 1 hispanic subject
were recruited for the the Phase II interviews. The proportion of non-white to
white participants in Phase Il was generally representative of all subjects eligible
to be interviewed in Phase II.
A research assistant with no relationship to clinical services was assigned at
each location to conduct the initial survey. All clients meeting the inclusionary
criteria were identified and the research assistant was provided with a master list
of clients to be surveyed. Clients were approached at the dispensing window and
provided with the brand names and full color pictures of the ten benzodiazepines
and barbiturates. Clients were asked to identify the various drugs and doses they
had tried in their lifetime (licit or illicit) by circling a xeroxed representation of the
various drugs. Clients were also asked to indicate if any sedative or tranquilizer
use had occurred within the previous six months.
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All subjects who indicated experience with from seven to ten of the drugs in
Phase I were eligible for the Phase II interviews. Subjects were randomly
selected and interviewed by a single investigator. The 90-minute, semi-structured
interview examined each subject’s lifetime prescription and non-prescription use
of each drug. Chlorpromazine was also included in the interview as a negative
control. Subjects were asked to provide ratings of relative preference and ratings
of “high” associated with each drug. Additional questions probed reasons for
use, means of acquisition, and lifetime patterns and frequencies of use/abuse.
Subjects received compensation in the amount of $15.
SELECTED RESULTS AND DISCUSSION
Subjects were asked to rank order each sedative/tranquilizer with respect to
relative preference. Some between clinic variation was noted, but in general the
data indicated a strong and consistent preference for diazepam, lorazepam. and
alprazolam over all other compounds. Subjects were also asked to rate the
intensity of the “high” associated with each of the drugs on a 100mm analog scale
from “not at all” to “extremely.” Ratings of relative high for diazepam,
lorazepam, and alprazolam. were comparable to pentobarbital and significantly
greater than for oxazepam, chlordiazepoxide, and phenobarbital.
Substantial differences were also noted between the benzodiazepines with
respect to proportions of subjects who reported obtaining the drug only by
prescription, never by prescription, or from both licit and illicit sources in their
lifetime. Fewer than 10% of all subjects reporting lifetime experience with
diazepam or alprazolam stated that they used the drug only by prescription.
Fewer than 18% of all subjects reporting experience with lorazepam or clorazepate
reported use only by prescription. This was in sharp contrast to their reported use
of chlordiazepoxide (44% by prescription only) or oxazepam (66% by
prescription only).
Subjects were asked about the reasons provided to the MD regarding their
need for the medication and to also provide the actual reasons for obtaining the
prescription. Over two-thirds of those who obtained prescriptions for lorazepam
or diazepam reported that their actual motive for obtaining the drug was, “to get
high,” or “to sell.” Similar reports were obtained for clorazepate (50%) and
alprazolam (43%). Fewer than 20% of those using chlordiazepoxide and fewer
than 9% of those using oxazepam by prescription reported obtaining the
prescription for reasons other than those which might be considered “therapeutic.”
In summary, the data suggest that for this population of drug abusers, there exists
a clear differential abuse liability for the examined benzodiazepines. The data
were consistent with respect to multiple indices of inappropriate versus
appropriate patterns of use, as well as with respect to ratings of relative preference
and associated “high.” These findings are also consistent with previous reports
from a variety of clinical and research settings which suggest that diazepam,
lorazepam, and alprazolam are much more likely to be abused than oxazepam or
chlordiazepoxide (Griffiths & Sannerud, 1987; Weddington & Carney, 1987;
Stitzer, et al., 1981; Woody, et al., 1975). Great caution would appear to be
indicated when prescribing benzodiazepines for addiction-prone clients.
Research supported in part by NIDA grants DA 03889 and T32 DA07209.
(References available upon request).
Affiliations: University of Medicine & Dentistry of New Jersey, School of
Osteopathic Medicine; Department of Psychiatry & Behavioral Sciences, Johns
Hopkins/FSK Medical Center. University of Vermont College of Medicine;
Bronx, VAMC; & Philadelphia VAMC/University of Pennsylvania.
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Are Smokers Trying to Stop and
Smokers Not Trying to Stop the
Same Experimental Model?
David P. L. Sachs and Neal Benowitz
Paid, volunteer smokers, who are not necessarily trying to stop,
have been reported to replace about 25% of their trough, venous se-
rum nicotine (nic) level when using 2mg nicotine polacrilex (nic
pol) and about 50% with the 4mg dose. In the present study we
wanted to both refine techniques for helping subjects stay on a
fixed schedule, qlh while awake, for nic pol administration and‘also
to determine whether smokers trying to stop behaved in the same way
as the paid volunteers used in earlier studies, who were not trying
to stop smoking.
Ten subjects, highly motivated to stop smoking, were randomly as-
signed to receive either 2 or 4mg nic pol, double-blind, according
to an every hour while awake schedule, independent of subject desire
for cigarette (cig). Subjects were assessed at a cig smoking base-
line session 1 week before their Target Quit Date (Visit -1), 1 day
before their Target Quit Date (Visit 0), and at the end of the first
week (Visit 1) and the 2nd week (Visit 2) of treatment. Subjects
were referred back to their primary physician after Visit 2 for 3-6
more months of nic pol treatment. They received 30 minutes of in-
struction in how to correctly use nix pol at Visit 0. Venous blood
was drawn in the afternoon, 1 hr after the last cig (Visits -1 and
0) or last piece of nic pol (Visits 1 and 2). At each visit vital
signs and exhaled air carbon monoxide were determined; venous blood
was drawn for nic and cotinine; the POMS, tobacco withdrawal symp-
toms, and medication (med) side effects were determined. Number of
pieces of med used/day was assessed by counting the returned used
and unused med as well as by concomitantly kept daily diary cards.
Residual nic in used med was also assessed. Also at each visit sub-
jects were issued daily tobacco withdrawal symptom and med side ef-
fect forms to complete each evening, using a O-4 Likert Scale.
There were no differences between subjects in the 2 groups on demo-
graphic or smoking variables. Non-smoking status at Visits 1 and 2
was confirmed by exhaled air carbon monoxide < 8 ppm.
During Baseline smoking: Se Nic (ng/ml): 18.2±10.8; 23.5±16.9(2 v
4mg p=NS); Se Cotinine (Cot)/ml): 244.2±31.4; 290.0±168.8(p=NS).
At the end of the 2nd treatment week (Visit 2), results were: #
Pieces/Day: 12.2±2.8; 13.2±2.0(2 v 4mg p=NS); Se Nic: 17.7±4.7;
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37.8±17.8(p=NS); Trough, Venous Nic Replacement: 110±39%; 434±399%
(p=NS); Se Cot: 252.6±109.6; 515.9±111.7(p<O.O2); %Nic Extracted
from Used Nic Pol (measured residual nic): 75.3±7.0%; 73.0±10.5%
(p=NS). Subjects using the 2mg dose obtained 1.51±0.14mg nic/piece;
those receiving the 4mg dose extracted 2.92±0.42mg/piece (p<0.01).
When the 30, daily tobacco withdrawal symptom scores were averaged
across the baseline smoking interval in the 2nd week of treatment,
the sum of all of these symptoms showed a significant decrease for
the 4mg treatment condition but not the 2mg: 0.96±O.13 (+1 SEM) to
0.77±O.21 (4mg, p=O.O3); 1.31±O.19 to 1.26±0.13 (2mg, p=NS). This
total symptom score included symptoms from 3 major areas, tobacco
withdrawal symptoms, med side effects, and medical symptoms, such as
shortness of breath. Nearly all of the significant decrease in
total symptom score in the 4mg group was secondary to decreased
withdrawal symptoms, particularly self-reported craving for cigs.
Each evening subjects separately assessed "craving for cigs," "de-
sire/urge for cigs," and "physical need for cigs." Craving decreased
significantly in the 4mg group from baseline smoking to the end of
the 2nd treatment week: 2.63±O.43 (±SD) to 1.05±O.99, p=O.O4.
During this same time period there was no change in the 2mg condi-
tion: 2.91±O.75 to 2.8O±1.08. Similarly the Total Mood Disorders
Score from the Profile of Moods State (POMS) Questionnaire fell sig-
nificantly in the 4mg group, 32.2 at Visit -1 to 8.0 at Visit 2
(p<O.05). Not only was there not even a decreasing trend in the
total Mood Disorder Score for those in the 2mg treatment condition;
rather, there was an increasing trend from 28.0 to 43.2. All 6 of
the POMS subscale scores showed an improving trend for the 4mg
treatment while they all worsened in the 2mg condition.
In conclusion, the 4mg dose significantly lowered total tobacco
withdrawal symptom score, particularly craving for cigs; the 2mg
dose did not. The 4mg dose also significantly improved the Total
Mood Disorder Score on the POMS; the 2mg did not. Subjects in both
the 2mg and 4mg nic pol groups maintained steady state serum nic
levels during treatment that were identical to the trough, venous
nic levels produced when they smoked cigs. In other words percent
trough nic replacement was 100% or better in both groups. There-
fore, subjects trying to stop smoking, and who were highly motivated
to do so, used nic pol differently than subjects who were paid vol-
unteers who were not trying to stop smoking. Motivated subjects
extracted more nic per piece even though mean number of pieces of
med used per day was similar in both groups. Consequently, paid
volunteers who are not also trying to stop smoking are not necessar-
ily the same experimental model as smokers who are trying to stop.
DAVID P.L. SACHS, M.D., Director, Palo Alto Center for Pulmonary
Disease Prevention, Palo Alto, CA; NEAL L. BENOWITZ, M.D., Chief,
Division of Clinical Pharmacology and Experimental Therapeutics, San
Francisco General Hospital, San Francisco, CA.
This research and presentation were supported by NIDA Grants DA04986
(DPLS) and DA02277 (NLB).
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Attention Problems in First Grade
and Shy and Aggressive Behaviors
as Antecedents to Later Heavy or
Inhibited Substance Use
S. Kellam, N. Ialongo, H. Brown, J. Laudolff, A. Mirsky,
B. Anthony, M. Ahearn, J. Anthony, G. Edelsohn and
L. Dolan
Aggressive behavior at least as early as age six has been
shown to predict heavy substance use in adolescence and
probably into adulthood, particularly for males. Replicated
many tims, this predictor should now be a focus of etiologic
research. Less attention has been paid to shy behavior as an
inhibitor of later substance use, and to attention deficits
and their role int he developmental paths leading to heavy
use.
We have reported earlier analyses on aggressive and shy
behaviors and on the role of attention problems in predicting
substance use (Kellam et al, 1983). This prior work made use
of prospective epidemiological data gathered on children from
first grade to age 16 to 17 from Woodlawn, a poor black urban
Chicago neighborhood. We focus in this report on the baseline
and evolving patterns of co-occurrence of attention problem
with shy and aggressive behaviors, and with achievement scores
and depression in the period of fall to spring of first grade.
We use epidemiological data from children in Baltimore
gathered as part of two randomized field preventive trials
carried out by the NIMH Hopkins Prevention Research Center,
supplemented by NIDA.
The data are teacher ratings of shy and aggressive behaviors
and concentration problem gathered with the TOCA-R, a
structured interview developed by Lisa Werthamer-Larsson, PhD.
based on the earlier Woodlawn version: self-reports by the
children of depressive symptom using a modified Kovacs Child
Depression Inventory revised by Gail Edelsohn, M.D.:
California Achievement Test scores, and continuous Performance
Tests and other- of attentional parameters developed
by A. Mirsky, PhD., B. Anthony PhD., M. Ahearn in
collaboration with the NIMH Laboratory of Psychology and
psychopathology.
In Baltimore in the fall of first grade, at baseline, shy
children were as much at risk for attention problem as were
aggressive children. Children who were both shy and
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aggressive behaving (loners who fought and broke rules) were
at almost twice the risk for attention problems. Attention
problems were also highly related to poor achievement, and
with poor achievement to depressive symptoms in children.
Attention and achievement were at the center of this baseline
model, with shy and aggressive behaviors on the left and
depressive symptom on the right. These patterns of
relationships in the fall of first grade were based on 1000
children epidemiologically sampled in the eastern half of the
city in 1986. Hierarchical log linear analyses provided the
basis for these inferences.
Since the data were cross-sectional, the direction of effects
could not be determined, but using fall and spring data
together, we could test a set of cross-lag longitudinal models
to reveal evolving relationships, or directions. using only
the control children, who were representative of the original
total population, hierarchical regression analyses were done.
The prospective longitudinal results from fall to spring of
first grade reveal attention problems leading to aggressive
behavior particularly among boys. In contrast, attention
problem led to shy behavior among girls. Attention problems
themselves in the Woodlawn data were not nearly as strong in
predicting later heavy substance use as was aggressive
behavior. Also in Woodlawn shy behavior predicted inhibition
of later use.
The new Baltimore data suggest that aggressive behavior and
shy behavior may unfold developmentally from attention
problems, with important gender differences. In boys attention
problems lead to the aggressive predictor, leading to
increased risk of heavy substance use; in girls attention
problems lead to the shy predictor, leading to reduced risk of
substance use. This gender difference in the developmental
paths may be related to the gender differences commonly found
in the prevalence of heavy substance use in man compared to
women. Attention problem appear to be an underlying condition
that may lead to developmentally important behavioral,
achievement, and psychopathological outcomes. Instead of a
specific diagnostic entity, it may be a more general form of
pathology associated developmentally with various more
specific pathological expressions. The biological and
enviromnental origins, as well as the developmental paths
leading from attention problems should be fruitful research
directions in the pursuit of etiology of substance abuse and
other problem outcoms.
References furnished upon reqest.
AFFILIATION: John Hopkins School of Hygiene and Public Health
Department of Mental Hygiene, Baltimore, MD
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The Association Between Non-
Recreational Benzodiazepine Use
and Other Substance Abuse
Linda B. Cottler
Dependence on benzodiazepines, or minor
tranquilzers, has been referred to as the
iatrogenic disorders of the '80's. Therefore, who
uses them and in what patterns they are used
becomes important especially if legitimate use
leads to abuse. The focus of this paper is to
determine whether the propensity to use other drugs
and medications predicts licit use of
tranquilizers. In addition, it evaluates
epidemiological data for evidence of the closeness
of sites of action of benzodiazepines, barbiturates
and alcohol.
Data from the St. Louis NIMH Epidemiological
Catchment Area survey, a study of the mental
disorders in the general population, were used.
Lifetime alcohol use, illicit use of
benzodiazepines, sedatives, opiates, and other
drugs and recent prescribed tranquilizer use were
obtained on this sample of over 3000 persons.
Twice as many women as men reported licit (non-
recreational) use of tranquilizers in the 6 months
prior to interview (13% vs. 6%) and use increased
with age. In contrast, illicit use decreased with
age and use rates among men were over those 3 times
those of women. Prescribed tranquilizers tended to
be used in combination with other psychoactive
drugs. Women with a past history of a DSM-III
alcohol disorder had higher rates of tranquilizer
use (21%) than women with a recent history (11%)
and no history (13%). These findings suggest that
benzodiazepines may be successfully used to treat
alcoholism or are used to substitute for alcohol.
In addition, rates of prescribed tranquilizer use
among persons abusing other substances were
variable, but rates of illicit tranquilizer use
among other substances abusers were high. When
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multivariable models were used to predict
tranquilizer use, use was predicted by illicit
opiate use among women and illicit sedative use
among men.
AFFILIATION: Department of Psychiatry, Washington
University School of Medicine, St. Louis, MO 63110
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Degree of Familial Alcoholism:
Effects on Substance Use by
College Males
M. E. McCaul, D. S. Svikis, J. ST Turkkan,
G. E. Bigelow and C. C. Cromwell
There is convincing evidence from family, adoption and twin studies for the
importance of genetic factors in the development of alcoholism in males. The
present studv examined the relation of familv historv of alcoholism to the risk of
other varities of drug use/abuse in male off spring. Survey data were collected
from 744 male college students (age range: 18 - 25 years). who described the
extent of their own drug and alcohol experience and the extent of alcohol-related
problems in their first- and second-degree relatives (permitting DSM-IIIR
diagnostic classification). Students’ drug use data were analyzed with respect to
whether they had no alcohol-dependent relatives (FHN; N=504), only second-
degree (FHP-2; N=94), only first-degree (FHP-1; N=99), or both first- and
second-degree alcohol-dependent relatives (FHP-1 & 2; N=43). There were no
significant differences across groups for age (Mean ±S.D.= 20.6 ±1.9 years) or
years of school (Mean ±S.D.= 14.2 ±1.6). The study cohort was 82% white,
14% black and 4% other.
There was a significant effect of family history status on age at first alcohol
intoxication (p<0.001) and first use of marijuana (p<0.001), self-reported
drinks/month (p<0.05), and lifetime use of marijuana (p<0.05). FHP- 1 & 2
students reported first intoxication at 14.1 years old, approximately one and a half
years earlier than FHN or FHP-2 students. Age of FHP-1 students (14.9) also
was significantly lower than FHN students. An identical pattern was found for
age at first use of marijuana, which started in all groups about one year later than
alcohol use. Mean drinks/month was 56.0 for FHP- 1 & 2 students as compared
with 37.9 for FHN students. More than twice as many FHP- 1 & 2 students
(19%) reported consumption of 100 or more drinks per month in comparison
with FHN (8%) or FHP-2 (6%) students. FHP-1 & 2 students reported an
average of 255 occasions of marijuana use as compared with an average of 88
occasions for FHN students.
There also was a significant effect of family history on the proportion of users (all
p<0.01) and the number of lifetime occasions of use (all p<0.05) for cocaine,
hallucinogens and sedatives. Generally, more FHP-1 and FIP-1 & 2 students
reported any lifetime use than FHN or FHP-2 students. As shown in Fig. 1 for
cocaine and sedatives, FHP-1 & 2 students reported significantly more lifetime
occasions of use than students in any other group. For hallucinogens, FHP-1
students reported more use than FHN students. Finally, FHP-1 and FHP-1 & 2
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students were more likely to report personal problems with both alcohol
(p<0.001) and drugs (p<0.001) than FHN or FHP-2 students.
Differences in self-reported alcohol and drug use patterns and associated
problems were found as a function of family history of alcoholism. The greatest
level of use was found for FHP-1 & 2 students, an intermediate level for FHP-1
students, and the least in students with no affected relatives. While similar
findings have been reported in offspring of alcoholic probands. this is the first
report of the significant role of family history in determining the onset, amount,
and broad extent of substance use in a diverse population of college males. These
data highlight the need to focus future prevention efforts on these high-risk youth.
Lifetime Occasions
FAMILY STATUS
Fig.1 Mean number of lifetime occasions of use for cocaine, sedatives, and
hallucinogens as a function of family history status.
AFFILIATIONS. The Johns Hopkins University School of Medicine and The
Francis Scott Key Medical Center, Baltimore, MD
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Preference for Ethanol in Males
With or Without an Alcoholic First
Degree Relative
H. de Wit and S. G. McCracken
Epidemiological evidence suggests that genetic factors play a role in
the development of alcoholism. However, the mechanism by which
such a biologically-based risk factor increases alcohol consumption
is not known. Laboratory studies have been undertaken to determine
whether individuals with a family history of alcoholism (family
history positive; FI-IP) differ from those without alcoholic relatives;
FHN) in terms of their physiological, subjective and behavioral
responses to an acute dose of ethanol (ETH). Although differences
have been reported between FHP and FHN individuals,  the
relationship between the observed differences and excessive alcohol
consumption is not understood.
In the present study, ETH self-administration was measured directly
in a laboratory study with FHP and FHN individuals, to explore the
relationship between subjective responses to ETH and drinking
behavior. The reinforcing and subjective effects of a low dose of
ETH (0.5 g/kg) were studied in 11 male, light social drinkers with an
alcoholic first-degree relative (FHP) and in 11 males with no
alcoholic relatives (FHN). Candidates with a history of major
psychiatric disorder, alcohol-related problems or total alcohol
abstinence were not accepted. The groups were matched for age,
race and drinking history. Reinforcing effects were measured using
a  7 -sess ion ,  double -b l ind ,  double -dummy cumula t ive  dos ing
preference procedure comparing ETH to a placebo. The procedure
consisted of a sampling phase followed by a choice phase, during
which subjects could choose their  preferred dose of ETH (or
placebo). Subjective effects were assessed before and after ingestion
of beverages, using the Profile of Mood States and a visual analog
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scale.
The FHP and FHN groups both chose ETH on about 60% of choice
sessions, and they ingested average doses of 0.9 g/kg. The groups
did not differ in ratings of drug liking, identification of the ETH and
placebo  beverages ,  psychomotor  impa i rment  a f t e r  ETH or
breathalyzer ETH levels. On the POMS, the groups did not differ in
their responses to ETH, but the FHP group scored marginally higher
than the FHN group on several scales indicative of dysphoric mood
(e.g., higher on Fatigue, lower on Friendliness) independently of
drug administration. The only difference between the groups in
response to ETH was on the visual analog scale, where the FHP
group reported a slightly faster onset of ETH effects (“feel drug” and
“high” scales).
These findings suggest that a family history of alcoholism does not
necessarily confer on other family members a differential subjective
response to ETH, or an increased tendency to consume the drug.
However,  these conclusions may be limited by the sample of
individuals accepted into the study: The participants were a highly
functioning, university-based sample, who were carefully screened
f o r  a n y  h i s t o r y  o f  p s y c h i a t r i c  a n d  d r u g - r e l a t e d  p r o b l e m s .
Differences in responses to ETH between FHP and FHN individuals
may only emerge in a less highly selected sample.
This research was supported by USPHS grants  DA02812 and
M01RR00055.
Affiliation: Department of Psychiatry, Pritzker School of Medicine,
The University of Chicago, Chicago IL 60637
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Sedative/Tranquilizer Use and
Abuse in Alcoholics Currently in
Outpatient Treatment: Incidence,
Pattern and Preference
Barbara Wolf, Martin Y. lguchi and Roland R. Griffiths
Sedative use plays a significant, although often underestimated role in
alcoholics; there are reports that 30-50% of the patients admitted for alcohol
treatment are currently using sedatives (Busto et al: Br J Addict 78 : 429-435,
1983; Sokolow et al: Br J Addict 76 : 147-158, 1982). Moreover, there is an
ongoing controversy with respect to the therapeutic use of benzodiazepines in
patients with alcohol abuse or dependence. While some clinicians argue that
benzodiazepines are strictly contraindicated in alcoholics because of their increased
risk to abuse these compounds, other clinicians claim that they may be used safely
in the majority of alcoholics, when taken under close medical supervision and for
relatively short periods of time.
AIMS: The purpose of this study was to examine the life-tune exposure, incidence
of extended intake, pattern, dosage. and duration of sedative use in alcoholics who
were in outpatient treatment. Additional questions addressed the sources of the
drugs, reasons for their use, their therapeutic, recreational, and adverse effects.
Another focus was on drug preference and differences between various
compounds with respect to the reported euphoriant effect.
METHOD: The data are derived from an interview study which was conducted
during a 10 week period and was aimed to include all patients currently enrolled in
an outpatient treatment center for alcoholics. The study consisted of two parts, a
screening interview and a detailed interview. During the initial interview all
patients were asked, if they ever had used sedatives, and, if so, which drugs and
for how long. Those patients who reported a life-time experience with sedatives
exceeding 30 days were asked to participate in a paid structured detailed interview.
RESULTS: The total target population for the initial interview consisted of 139
patients; 118 or 85% of the patients completed the initial interview. Of these 118
patients. 29% reported having no experience with sedatives, 25% having a limited
experience of less than 30 days, and 46% having a life-time exposure exceeding
30 days. An evaluable detailed interview was obtained in 46 clients who represent
the designated “experienced” patients; there was a statistically significant
preponderance of females in this group. The majority of the “experienced”
sedative users were in fact polydrug abusers, a high proportion of them having
experience with other drugs such as marijuana, stimulants, and cocaine. Sixteen
patients or 35% reported continued sedative use during the current outpatient
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treatment; only four of them received them by prescription, the rest from illicit
sources. The patients reported having used of a variety of sedatives recently,
predominately benzodiazepines (BZD). Diazepam (Valium ) was by far the most
frequently mentioned sedative (89%), followed by methaqualone (Quaalude ) and
lorazepam (Ativan ). The overall duration of use of any kind of sedative was
longer than one year in 81% and exceeded 5 years in 46%. Sixty-seven percent of
the patients reported having used one or more sedatives daily for some period of
time. The BZD were considerably more frequently used on a daily basis than the
non-BZD; this, however, may reflect more the difference in availability than in
drug preference. Seventy percent reported using doses higher than therapeutic
BZD doses (30mg diazepam or an equivalent dose of another BZD derivative). in
33% even exceeding 80mg diazepam. In 61%. the sedative use could be classified
as abuse; this included higher than therapeutic doses, not for therapeutic purposes,
but to get “high” and/or counteract the effects of other drugs, combination with
alcohol, and illicit sources. Fifteen percent reported an appropriate use of BZD as
medically prescribed; none of these seven patients had a history of polydrug
abuse. Twenty-four percent reported both use and abuse of different compounds
or using the some compound in different ways at different times. Initially, the
primary reason for sedative use was to get get “high” in the majority of patients.
However, the motive for using sedatives changed over time in many of them. The
proportion of patients taking sedatives to treat alcohol withdrawal symptoms, to
counteract the adverse effects of other drugs, primarily cocaine, and to relief
symptoms such as anxiety, sleeping difficulties, and tension considerably
increased over time. The non-BZD were obtained almost exclusively from illicit
sources. Within the BZD class, diazepam showed the highest proportion of
“street” use, while clorazepate (Tranxene ) and flurazepam (Dalmane ) were
obtained mainly by prescription. The patients were asked to rate the preference
and the intensity of the “high” (100mm analog scale) of each sedative with which
they had experience. These two measures covaried. Ratings of drug preference
and intensity of the “high” showed that diazepam was not different from
methaqualone, ethchlorvynol (Placidyl ), seco/amobarbital (Tuinal ), lorazepam
or alprazolam (Xanax ), but was significantly greater than chlordiazepoxide
(Librium ) and clorazepate (paired t-test comparing pairs of drugs in subjects with
experience with diazepam and the comparison drug).
CONCLUSION: About one half of the surveyed alcoholic patients had a history of
past or current sedative use. Only a relatively small proportion of the patients. in
p a r t i c u l a r  t h o s e  w i t h o u t  c o n c o m i t a n t  p o l y d r u g  a b u s e .  u s e d  t h e
sedatives/tranquilizers appropriately, while the majority abused some or all
compounds. With respect to the intensity of the “high” and drug preference,
diazepam was rated similarly to lorazepam and alprazolam, as it also was to
methaqualone. ethchlorvynol. and Tuinal . A difference within the BZD class
with respect to the abuse liability was suggested by preference and intensity of the
“high” which were rated greater for diazepam. lorazepam, and alprazolam than
other compounds such as chlordiazepoxide and clorazepate. These differences
may have an impact on the prescribing practices of BZD to alcoholics.
Supported by NIDA grant DA-03889
AFFILIATIONS: 1The Johns Hopkins University, Francis Scott Key Medical
Center, Baltimore, MD; 2University of Medicine & Dentistry of New Jersey,
Camden, NJ
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A Tale of Three Cities: Risk Taking
Among Intravenous Drug Users
Robert Booth, J. T. Brewster, Stephen Koester,
W. Wayne Wiebel and Rick Fritz
In the United States, 20% of the 98,000 diagnosed AIDS cases
as of June, 1989 were ibtravenous drug users (IVDU), and
another 7% gay or bisexual IVDUs. Among intravenous drug
users AIDS appears to be transmitted by small amounts of
blood contained in shared needles, syringes, or "cookers".
Studies have found a direct relationship between the
frequency of injection, the number of partners shared with,
the amount of needle sharing,
Research has also shown a relationship between the number of
and HIV seropoeitivity.
sexual partners of IVDUs and seropositivity.
The present investigation was initiated to add further
understanding about risk-taking behaviors among intravenous
drug users. A total of 345 IVDUs were interviewed from
Baltimore, El Paso and Denver. Subjects were screened for
sighs of recent intravenous drug use prior to inclusion in
the study. Their average age was 35 years, with 58% between
30 and 40. Males constituted 69% of the sample. Ethnically,
50% were black, 31% Hispanic, and 15% white. Self-report data
revealed 86% had injected cocaine in the six months preceding
their interview, 83% heroin and 68% speedballs (combined
heroin and cocaine). The average age of first injection was
20.3 (range 10-56) and weekly injection 22.9 (range 12-77).
Assessed risk behaviors included frequency of injection,
sharing needles and "cookers", number of needle partners, and
number of sexual partners. Protective measures associated
with these activities consisted of cleaning needles with
bleach or other disinfectants, as well as use on condoms.
Over 50% reported injecting drugs daily and 70% shared
needles with others, averaging 6.3 partners in the past six
months. In addition, 86% had shared a "cooker" and nearly 50%
injected in a "shooting gallery". More than half of the males
sampled had two or more sex partners, including 18% with five
or more. Females averaged 19 sex partners in the preceding
six months with 22% reporting sex with five or more. Two-
thirds of the total sample never used a condom, while only 6%
always used this form of protection.
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On the other end of this risk continuum are those IVDUs who
took precautions to avoid AIDS. These included 29% who did
not share needles, 24% who always cleaned their needles with
an effective agent, 8% who had no sexual relations and 6% who
always used a condom. Subjects following such practices could
be considered low risk if they adopted safe behaviors in
other associated areas of their lives. However, in an
analysis of total risk, it was found that only 14 subjects
(4%) practiced safe needle use (including sharing a "cooker")
and safe sex.
Despite these findings, forecasting a g-rim future for
intravenous dnlg users, some encouraging results were seen.
Of the 14 low risk subjects, 9 were from Baltimore, nearly
two-times their sample representation. Even more telling was
an analysis of risk according to location: Baltimore subjects
were significantly less at risk according to number of needle
sharing partners, borrowing needles, sharing a "cooker",
injection in a shooting gallery, cleaning needles, use of
disinfectants, number of sexual partners and use of condoms
than either their cohorts in El Paso or Denver.
Street outreach to modify risk behaviors among IVDUs began in
Baltimore approximately two years prior to funding in El Paso
and Denver. These results appear to suggest that there may be
a potential to moderate risk through intervention.
AFFILIATION:
UNIVERSITY OF COLORADO HEALTH SCIENCES CENTER
DEPARTMENT OF PSYCHIATRY
ADDICTION, RESEARCH AND TREATMENT SERVICES
DENVER, CO
UNIVERSITY OF ILLINOIS SCHOOL OF PUBLIC HEALTH
URBANA, IL
Supported by the National Institute of Drug Abuse
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Diagnostic Agreement Between
DSM-III and DSM-III-R
Dependence Disorders
Linda B. Cottler and John E. Helzer
The DSM-III-R criteria have recently been published
and include major revisions in the concept of
psychoactive substance dependence. For example, in
DSM-III-R, tolerance and withdrawal are among 9
symptoms which have equal weight, so neither is
necessary for a diagnosis. Three out of 9 symptoms
are required for a dependence disorder: abuse is a
residual category. A duration criterion is
necessary, yet is vague and subject to
interpretation. Many factors might affect the
diagnostic agreement between 2 systems.
Reliability of the items used, clarity of questions
number of questions for each criterion, and the
extent to which questions accurately reflect
criteria will have an impact.
A reliability study of the CIDI Substance Abuse
Module, an interview assessing both DSM-III and
III-R criteria, offered us the opportunity to
evaluate diagnostic agreement between DSM-III and
III-R dependence criteria. Our sample included 39
persons in treatment for substance abuse or
dependence. The rate of system overlap, percent
agreement and percent positive in both systems, and
Kappa values are reported to evaluate whether one
system is more stringent than the other. Alcohol
and marijuana dependence were more likely in the
DSM-III-R system. Only half of the persons
diagnosed with DSM-III-R cannabis dependence were
also diagnosed as dependent in the DSM-III system.
Tobacco dependence was more likely to be diagnosed
in the DSM-III system. Diagnostic agreements were
highest for amphetamine, opiate and sedative
dependence.
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Reasons for differences and overlaps are discussed,
as well as the clinical and epidemilogical
implications of this preliminary work. Further
studies are underway using a more heterogeneous
population.
AFFILIATIONS: Department of Psychiatry, Washington
University School of Medicine, St. Louis, MO
63110.
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In Their Own Words: Drugs and
Dependency on New York City’s
Streets
Alisse Waterston
This paper examines problems of drug dependence from
the perspective of users themselves whose involvements
and experiences in the work force, the shelter system,
the criminal justice system, and personal networks are
presented. My approach to understanding street addicts.
differs from the most widely accepted conceptualization
by social scientists, policy makers, and perhaps, the
general American public. In this "traditional"
conceptualization, s t r e e t addicts a n d a d d i c t
"subculture(s)" are peripheral, marginal and deviant.
A brief look at the intellectual history of the drug
use field provides some context for my conceptual
alternatives. Social science interest in drug users
emerged from the topical and methodological specialties
of the Chicago school of urban studies. Social science
attention on urbanism highlighted the seamy side of
life, urban decay and disorganization, with a
particular focus on minorities, gangs, opium addicts,
hoboes and juvenile delinquents. Each study seemed to
contain a world unto its own, while also representing
inevitable, undesirable features of city life. Studies
of social problems led to the development of social
deviance as a sub-specialty, in which drug use was a
substantive area of study. This approach directs
attention to the deviant subculture, and remedies are
directed at deviant actors. The fit between studies in
social deviance and culture-bound field studies rests
on a common outcome of their approaches: distancing
and exoticizing the subject.
In my view, a more accurate perspective addresses the
systematic interrelationship between street addicts and
the larger political, economic, social and cultural
systems within which they live. Based on two
ethnographic studies of street addicts in New York
City, I have attempted to wed micro-phenomena -- data
on daily of street addicts -- to macro constructs and
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explanations. The experiences of street addicts
suggest t h a t t h e i r lives are c o n s t a n t l y a n d
continuously shaped by relations within a range of
"public" and "private" arenas. The focus here has been
on understanding their experiences in terms of larger
constraints, inequality, conflict, institutionalized
social control, dependency, accommodation, and the role
of dominant cultural values. Today's "drug scene" is
best understood as a feature of late capitalism in
which addicts serve particular economic, political and
ideological functions. Briefly, the economic functions
of street addicts center on their position as low-wage,
vulnerable and disorganized workers, as bearers of
costs in their daily reproduction, and as consumers of
goods produced by the international drug trade. The
most important ideological function of street addicts
and the symbolic images of deviance and decadence they
provoke, is in providing a convenient scapegoat for
society's ills. Frequently drawn from the city's
poorer neighborhoods which are largely inhabited by
racial and ethnic minorities, drug users are easily
blamed for their individual bad habits and the destruc-
tive outcomes of drug use. As a social group, street
addicts also serve a political function. In their
present form, street addicts are a captive entity,
separated form their class by mandates and practices in
the state management of "deviants." Fashioned into a
separate group and ideologically separated, street
addicts function as a divisive tool within their class,
ensuring that conflict not spill outside the boundaries
of poor and working class communities.
The findings presented here unmask some long-held as
sumptions about drug users, and suggest a rethinking of
social program goals and approaches. The consequences
of our current social responses to the "drug problem"
must be examined since many of the difficulties faced
by street addicts stem from the policies and practices
we have helped shape. It is our responsibility,
therefore, to step back and honestly reflect upon our
contributions to the problems of drug dependence.
Narcotic and Drug Research, Inc.
11 Beach Street
New York, N.Y. 10013
and
Department of Anthropology
City University of New York
Graduate Center 33 West 42nd St.
New York, N.Y. 10036
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Outpatient
Maintenance/Detoxification
Comparison of Methadone and
Buprenorphine
Rolley E. Johnson, Paul J. Fudala, Charles C. Collins,
Jerome H. Jaffe
A 180-day, phase II clinical study is being conducted in 150
outpatient volunteer subjects to compare the effectiveness of
buprenorphine or methadone in treating opiate dependence.
Subjects are males and females between the ages of 21 and 50
years. Criteria for admission include 2 opiate-positive urine
samples (with no more than 1 methadone-positive sample) and a
history consistent with opiate addiction. Subjects are required
not to have participated in a structured methadone or
buprenorphine maintenance or detoxification program for more
than 7 total days within 12 months of beginning the present
study. Other exclusionary criteria include pregnancy, a
psychiatric severity score of 7 or greater on the Addiction
Severity Index, and active cardiovascular or hepatic disease.
While potential subjects may be polydrug users, those who are
found to have a dual dependency as assessed by clinical
interview are excluded from the study.
Subjects are stratified into drug and dosage groups according to
sex, age, and response to a naloxone challenge injection (0.4 mq
IM) using the Clinical Institute Narcotic Assessment score.
Medication doses are given double-blind, double dummy (i.e.,
methadone orally, buprenorphine sublingually). Subjects are
monitored by medical staff for adverse drug effects. Those who
cannot tolerate or be maintained on their prescribed dosages are
provided a 21-day methadone detoxification. Subjects are
required to participate in individual counseling sessions (30 to
60 min per week) using a relapse-prevention model. Voluntary
group sessions are also offered.
The primary outcome measure to assess treatment effectiveness
will be the number of urine specimens positive for illicit drugs
using a weighted analysis based on time in treatment. Secondary
outcome measures will include retention time in study, number of
missed clinic visits, subject-reported side effects and
depression, subject-reported opiate-like and withdrawal effects,
and results from blood chemistries and urinalyses.
AFFILIATION: NIDA, Addiction Research Center, Baltimore, MD.
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Time Course of Repeated
Naloxone Challenge After Single
Morphine Doses in Humans
Stephen J. Heishman and Maxine L. Stitzer
Acute physical dependence refers to the abstinence syndrome precipitated by an
opioid antagonist following a single dose of an opioid agonist (Martin & Eades,
1964). Previous studies in our laboratory have demonstrated the occurrence of
naloxone-precipitated abstinence from 45 minutes (Heishman & Stitzer, 1988) to 6
hours (Bickel et al., 1988; Heishman et al., 1989) after acute morphine
administration in nondependent humans. The purpose of this study was to
determine whether naloxone-precipitated abstinence could be observed as long as
24 hours after a single morphine dose and whether the abstinence syndrome could
be repeatedly elicited by two successive naloxone challenges.
METHOD
Participants were six males 24-37 years old, reporting a history of prior opioid use
of 2-18 years and average current opioid use of 8 times per month. Subjects lived
on an inpatient research ward during the 5-week study. No abstinence symptoms
or signs were observed in any subject after a 10 mg/70 kg naloxone challenge
before the start of the study. Subjects participated in eight experimental sessions in
which they received i.m. injections of morphine (18 mg/70 kg) followed 6 and 24
hours later by i.m. naloxone (10 mg/70 kg) or placebo challenge. Subjects were
exposed twice to each of four experimental conditions: placebo (6 hr)-placebo (24
hr), placebo (6 hr)-naloxone (24 hr), naloxone (6 hr)-placebo (24 hr), and naloxone
(6 hr)-naloxone (24 hr). Experimental sessions involved baseline measurements
before the naloxone or placebo challenge, followed by a 60-min post-challenge
assessment period- Physiological measures were recorded continuously throughout
sessions and a battery of pupil photographs and subjective and observer ratings of
abstinence was completed at baseline and 5, 15, 30, 45, and 60 min post-challenge.
RESULTS
Naloxone challenge at 6 hr postmorphine reversed morphine-induced miosis.
respiratory depression, and subjective reports of opiate symptoms, drug high, good
drug effects, and drug liking. At 24 hr postmorphine, naloxone had no effect on
these agonist measures, which had returned to premorphine levels and were no
longer measureable. However, at 6 or 24 hr postmorphine. naloxone precipitated
subjective reports of withdrawal symptoms, bad drug effects, and withdrawal
sickness. Additionally, at both times, naloxone significantly increased observer
ratings of Himmelsbach abstinence signs, primarily yawning and perspiration
Subjective ratings of bad drug effects and withdrawal sickness were significantly
less at 24 hr than that at 6 hr postmorphine. However, composite withdrawal
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symptoms and observer-rated abstinence signs did not differ in intensity at 6 and 24
hr postmorphine.
When naloxone challenge at 24 hr was preceded by naloxone at 6 hr postmorphine,
the magnitude of abstinence symptoms and signs was clearly attenuated- Subjective
ratings of withdrawal symptoms, bad drug effects, withdrawal sickness and
observer-rated abstinence signs were slightly elevated, but not significantly greater
than respective placebo levels.
DISCUSSION
This study demonstrated that a naloxone-precipitated abstinence syndrome can
occur at least as long as 24 hr after a single dose of morphine in nondependent
humans, when agonist effects are no longer observable. This suggests that
morphine induces some biological change persisting beyond its measureable
effects, which may represent the beginnings of opioid physical dependence. These
results also indicated that when naloxone challenge at 24 hr was preceded by
naloxone at 6 hr postmorphine, the precipitated abstinence syndrome at 24 hr was
attenuated, at least with these drugs. doses, and temporal interval. This is
consistent with the hypothesis that initial naloxone administration reset receptor
mechanisms for the development of opioid physical dependence (cf., Krystal et al.,
1989). However, it is possible that with a longer acting agonist, larger doses of
agonist or antagonist, or a shorter interval between the first and second antagonist
challenge, one might observe repeated antagonist-precipitated abstinence following
acute agonist treatment.
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Evaluation of the Abuse Potential
of Picenadol
Donald R. Jasinski and Kenzie L. Preston
The agonist/antagonist analgesic picenadol is a racemic mixture of an opioid
agonist (d-isomer) and an opioid antagonist a-isomer). Picenadol also has
anticholinergic activity. Two studies were done to assess its abuse potential In
the first, picenadol 18.75, 37.5, and 75 mg, morphine 15 and 30 mg, and placebo
were given IM every other day under double blind conditions to 6 adult male
opioid abusers according to a latin square design. Structured questionnaires
administered at fixed time intervals before and after dosing measured drug
identification, degree of subjective change, euphoria, dysphoria, sedation and
symptoms.
Picenadol 75 mg was distinguished from morphine by sedation, dysphoria, and
hallucinatory activity, probably from anticholinergic activity. Picenadol 18.75 mg
was morphine-like. Picenadol 37.5 mg was morphine-like with some dysphoric
effects. The second study was similar except for dosages. Picenadol 12.5, 25,
and 50 mg were compared with placebo and morphine 10 and 20 mg. At these
doses, picenadol produced morphine-like effects and had some dysphoric effects
but was not hallucinogenic.
Picenadol had less euphorigenic potential than morphine and, in our opinion, has
a lesser abuse potential.
AFFILIATION
Francis Scott Key Medical Center, Johns Hopkins University School of
Medicine, Baltimore, MD.
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A Pilot Study of a Neuro-Stimulator
Device vs. Methadone-in Alleviating
Opiate Withdrawal Symptoms
Elsayed Elmoghazy, Bruce D. Johnson and
Frederick A. Alling
INTRODUCTION
Methadone with gradual withdrawal is the only FDA-approved technique for
detoxifying from heroin or opiate dependency. Cerebral electro stimulation
appears to be a promising nonchemical alternative for detoxification from opiates.
but the results of prior research is mixed, and the biochemical mechanism of
action is not documented.
RESEARCH QUESTION
Can a Neuro Stimulator Device (NSD) be as or more effective than methadone in
overaIl results and in alleviating a variety of opiate withdrawal symptoms?
METHODS
The Neuro Stimulator Device (NSD) is an experimental proprietary device,
similar to a walkman, which weighs about a half pound, generates a weak
current with frequency range of 50-300 HZ and pulse duration of 30 MSEC.
Two wires lead to surface electrodes taped over the mastoid bone behind each
earlobe. A pilot studv of the NSD involved 125 patients at St. Luke’s-Roosevelt
Hospital (Manhattan) for 7-day opiate detoxificaton between 11/87-4/88. All
addicts applying for admission were invited to participate. Patients who gave
informed consent wore the NSD, but were randomly assigned and blinded to two
experimental groups. Patients in the “NSD” group received the active NSD and
placebo methadone; those in the “methadone” group received regular declining
doses of methadone but a placebo wave in the NSD device.
The pilot study encountered usual problems of research with addicts. Less than
half of the eligible agreed to participate; the dropout rate was over half among
those in both groups. Efforts were made to double blind the monitors, but these
were not always successful. Electrodes frequently came off, batteries on the
NSD failed. Clear records of whether and how long subjects wore the NSD were
not systematically maintained. Data collection procedures changed during the
study. Thus, the results reported below are very preliminary and based upon less
than adequate methods.
FINDINGS
The Medical Director rated all patients on presence of objective withdrawal
symptoms from none, to low-moderate and high during their stay in the locked
detoxification ward. The results show that patients in the NSD group did, at
least, as well as those in the Methadone group.
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Table 1. Patterns of Objective Withdrawal Symptoms During
Dextoxification Among Experimental Subjects
Experimental Groups
NSD Methadone
Active NSD Placebo NSD Wave
Patterns of Withdrawal Placebo Declining Doses
Symptoms Over Time Methadone Real Methadone
N % N % T-Test
No Withdrawal Symptoms 7 18 7 24
Objective Symptoms Reduced 5 13 3 10 NS
Mixed Objective Symptoms 27 69
Total 39 69
19 66 NS
29 100 NS
In 3-4/88. 17 subjects responded to a 38 question computer-driven interview
about the severity of subjective withdrawal and craving symptoms. For 9 of the
38 subjective symptoms, subjects in the NSD group had significantly (P<.05)
lower severity of symptoms than those in the Methadone group, and for 22 other
symptoms the NSD subjects had lower severity of 4 or more points. Statistical
significance for those 22 symptoms was not attained because of sample sire and
the variability of responses.
Table 2. *Mean severity of selected withdrawal and craving symptoms
among those using the Neuro Stimulator Device versus methadone.
Symptom Mean C Mean B Sign/ Points
N=10 N=7 difference
Overall Withdrawal
Symptom 13 21 .05 8
Perspiration 11 22 .03 11
Gooseflesh 6 16 .01 10
Breathing Difficulty 7 15 8
Craving for Heroin 13 21
.05
NS 8
Craving for Cocaine 4 8 .05 4
*Severity of Withdrawal and Craving symptoms is measured on a 33 points scale
(From 1 to 33). low scores are favorable.
DISCUSSION
The evidence from this pilot study suggest, in a preliminary way, that the NSD
maybe as effective or more effective than methadone during detoxification from
opiates and in alleviating a wide variety of objective and subjective symptoms.
The small sample sires and various data collection flaws limit the confidence in
such preliminary results. A larger study designed to address these methodological
difficulties and collect data from a larger sample is being undertaken in 1989.
AFFILIATION:
Hospital Center2
Narcotic and Drug Research, Inc.1 St. Luke’s-Roosevelt
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Pavlovian Conditioning to
Morphine in Opiate Abusers
David B. Newlin, Mary Beth Pretorius and Jerome H. Jaffe
Previous demonstrations of conditioned responses to opiate cues
in humans have not involved opiate conditionig trials in the
laboratory. This experiment was a direct application of
Siegel's (1975, 1983) Pavlovian conditioning model of morphine
tolerance to human opiate abusers.
We were particularly interested in the placebo response for
several reasons. First, the conditioned response is pivotal to
the Pavlovian model because it is the proposed mechanism of
situational specificity of tolerance and other conditioning
phenomena. If there were no measurable placebo response, as has
often been the case in animal research, then other models are
needed to account for the results (Baker & Tiffany, 1985).
Demonstration of the drug-opposite response to morphine cues
has been a focus for controversy in the animal literature, and
human subjects allow more comprhensive measurement of the
placebo response. In addition, it is possible to measure mood
in humans to assess affective components of the conditioned
respnse. Third, the conditioned response to opiate cues is
important clinically because it may mediate relapse behavior.
Finally, ethical concerns dictate that subjects in a morphine
conditioning study have opiate experience. Therefore, it may
prove difficult to measure the development of conditioned
morphine tolerance in the laboratory because they are already
tolerant to opiates. However, this previous conditioning
history would not interfere with expression of the placebo
response.
DESIGN
The experimental design was entirely within-subjects, with
Session (1 through 7) and Trial (1 through 20) as repeated
factors. Sessions were: 1) no injection, 2) morphine, 3)
morphine, 4) morphine, 5) morphine, 6) placebo, and 7)
nmphine. Morphine was always 20 mg i.m., and the nurse who
performed the injectionwas blind. The first six sessions were
all in the same distinctive laboratory environment, and the
seventh session was in a different distinct &amber. The two
chambers were counter-balanced between subjects, and the time
of testing (a.m. vs. p.m.) was also counter-balanced.
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SUBJECTS
Subjects were 12 male opiate abusers on the inpatient unit of
the NIDA Addiction Research Center. Their mean age was 34.8
years, and the mean number of years of previous opiate use was
9.6 years. The subjects were generally light opiate users, and
none of them were observed to experience withdrawal symptoms
upon entry to the inpatient unit.
RESULTS
The heart rate response to morphine was biphasic. Morphine
significantly (p<.0001) increased heart rate immediately after
the injection, but decreased (p<.001) heart rate from 80 to 100
minutes later compared to a no-drug control condition. Placebo
significantly (p<.Ol) decreased heart rate throughout the
post-drug interval compared to the no-drug control. The effect
of morphine on finger temperature was also biphasic; it
initially decreased
(p<.05). Morphine significantly (p<.0001) increased cheek
(p<.05) temperature, then increased it
temperature, and placebo increased cheek temperature (p<.05)
during the rising morphine blood curve. Cheek temperature
showed significant (p<.001) differentiation between the
conditioned and novel environments. The results for motor
activity were generally nonsignificant.
Oral temperature, MBG Euphoria, and pupil diameter showed only
morphine effects. The drug and placebo effects were both sign-
ificant and in the same direction for the analgesia measure
(p<.0001) and POMS Negative Affect (p<.001). For static ataxia,
morphine increased (p<.01) body sway and placebo decreased
(p<.05) sway.
DISCUSSION
The results provided relatively strong evidence for autonomic
and subjective responses to morphine placebo. The placebo
response consisted primrily of decreases in heart rate and
static ataxia, and increased analgesia. Placebo was dysphoric,
as indicated by increased POMS Negative Affect after placebo
injection.
Evidence for development of tolerance to morphine in the
laboratory and differentiation of the conditioned and novel
enviroments was relatively spotty, probably because of the
subjets' previous opiate histories. The results indicate that
morphine effects can be conditioned in the laboratory, and they
correspond to some extent with Siegel's (1975, 1983) Pavlovian
model. Some placebo responses were in the same direction as the
drug effect, and some were opposite in direction. Further
research is needed to assess the motivational significance of
these conditioned responses.
AFFILIATION: NIDA Addiction Research Center, 4940 Eastern
Avenue, Baltimore, MD 21224.
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Effects of Tramadol in Humans:
Assessment of its Abuse Potential.
Kenzie L. Preston and Donald R. Jasinski
Tramadol is an analgesic one tenth as potent as morphine. To assess its abuse
potential, tramadol 75, 150 and 300 mg, morphine 15 and 30 mg, and placebo were
given IM to 12 volunteer non-dependent opiate abusers. Treatments were tested
under double blind conditions on consecutive days according to two 6 x 6 latin
squares. Subjective, observer-rated and miotic changes were assessed prior to
dosing and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, and 12 hours after dosing.
Subjective effects were measured with ARCI subscales and a series of visual analog
scale measures including drug effect, liking, drug identification, and symptoms.
Observers rated subjects for drug effect, liking, and signs on a series of visual
analog scales.
The onset, time to peak and duration of psychoactivity for morphine and tramadol
were similar. Morphine produced typical effects including miosis and increases in
ratings of drug effect, drug liking, MBG (euphoria) scale scores, and identifications
as an opiate. Tramadol 300 mg was also identified as an opiate, but did not
produce morphine-like subjective or behavioral effects. Tramadol also did not
produce miosis. The magnitudes of the effects produced by tramadol were less
than that predicted by its analgesic potency relative to morphine. The effects of
tramadol 75 and 150 mg were not different from placebo. There was no evidence
that tramadol produced dysphoric effects as have been shown for agonist/
antagonist opioids such as pentazocine.
We conclude that the parenteral analgesic preparations of tramadol have
significantly lesser abuse potential than equianalgesic preparations of morphine.
AFFILIATION
Francis Scott Key Medical Center, Johns Hopkins University School of Medicine,
Baltimore, Maryland 21224
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Acute Opioid Physical Dependence
in Humans: Maximum Morphine-
Naloxone Interval
Kimberly C. Kirby, Maxine L. Stitzer and Stephen J. Heishman
Acute opioid physical dependence has been demonstrated in a variety of species,
but the effect of varying the temporal interval between agonist and antagonist
administration has not been systematically investigated until recently. Heishman
et al. (in press) showed that the minimum interval between injections necessary to
observe antagonist precipitated withdrawal in humans is between 15 and 45 min.
The purpose of this study was to find the maximum interval between agonist and
antagonist exposure that would still allow observation of precipitated withdrawal.
METHOD
Subjects
Participants were 6 male volunteers, 33-43 yrs old, with a 7 1/2 to 31 yr history
of opiate use. Their average current opiate use was approximately 4 times per
week. They were not currently opiate-dependent. Participants lived on an 8-bed
inpatient research unit during the study and 1-2 volunteers participated at a tune.
Procedures
Half of the subjects received morphine doses of 18mg/70kg and half received
doses of 30mg/70kg. Doses were determined by conducting a naloxone challenge
6 hrs after administering the 18mg dose of morphine and looking for abstinence
signs or symptoms. If abstinence signs and symptoms were not observed, the
subject was assigned to the higher dose. Analysis indicated there were no
significant differences between morphine dose groups. The naloxone dose of
10mg/70kg was chosen on the basis of previous work using a 6-hr agonist-to-
challenge interval.
The intervals between agonist and antagonist injections were 6, 12, 24, 36, 48,
60, and 72 hrs. Each subject was exposed once to each interval in a random
order. All injections were given intramuscularly under double-blind conditions.
Once during each condition a placebo morphine injection occurred at one of the
scheduled injection times. All morphine and placebo morphine injections
occurred on the inpatient ward. Prior to naloxone injections, the volunteer was
seated in an experimental room and physiological measures were given 30 min.to
stabilize. Respiration rate, heart rate, blood pressure, and skin temperature were
recorded continuously. Pupil photos were taken and observer and subject ratings
recorded 15 min prior to the scheduled injection time and at 5, 15, 30, 45, and 60
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min post-injection. Observer measures consisted of traditional Himmelsbach
signs, such as yawning, lacrimation, perspiration, and restlessness. Subject
report measures included opioid and withdrawal symptom questionnaires, each
containing 15 adjectives describing opioid and withdrawal symptoms. A drug
effects questionnaire was also completed by the subject; this assessed global drug
effects such as good and bad drug effects and general feelings of withdrawal
sickness.
RESULTS
Naloxone effectively reversed residual morphine effects (e.g., pupillary
constriction and reports of good drug effects) that were present at 6 and 12 hrs
post morphine. By 24 hrs, morphine effects were no longer evident, and
naloxone had no effect on measures designed to detect reversal of residual
morphine effects.
Naloxone elevated observer ratings of abstinence at 6, 12, and 24 hrs. Ratings of
abstinence were somewhat higher at the 12 hr challenge as compared to the
challenge at 6 hrs, but this difference was not significant By 36 hrs,
postnaloxone ratings did not differ from the prenaloxone baseline, indicating that
naloxone did not precipitate an abstinence syndrome when the morphine and
naloxone administrations were separated by 36 hrs or longer.
Composite subject ratings from the 15-item withdrawal symptom questionnaire
agreed with observer ratings in that at 6, 12, and 24 hrs naloxone elevated ratings
of abstinence . Unlike the observer ratings, the subject reported withdrawal
symptoms at 6 and 12 hrs were similar, while the symptoms were significantly
reduced by 24 hrs. Subjects’ rating of withdrawal sickness and bad drug effect
were elevated at 6 and 12 hrs, but were not significantly elevated from pre-
challenge scores at 24 hrs post-morphine. Examining the individual items in the
composite withdrawal symptom rating showed that at the 24 hr condition,
subjects continued to give elevated ratings on items such as yawning and watery
eyes, while items such as upset stomach and abdominal cramps were similar to
the prenaloxone rating. This might suggest that feelings of nausea are more likely
to lead subjects to identify symptoms as withdrawal sickness and/or bad drug
effect than are symptoms such as yawning and watery eyes.
CONCLUSION
When these results are integrated with previous work of Heishman, we conclude
that acute physical dependence effects can be observed at agonist-to-challenge
intervals from 45 min to 24 hrs post-morphine. This time course suggests
temporal spacing of exposures may be important in the development of physical
dependence. We have begun to systematically investigate the possibility of a
temporal window for acute physical dependence in our laboratory.
REFERENCES
Heishman, S.J., Stitzer, M.L., Bigelow. G.E.. Liebson, I.A. (in press). Acute
opioid physical dependence in humans:
interval.
Effect of varying the morphine-naloxone
Journal of Pharmacology and Experimental Therapeutics.
Dept. of Psychia. & Beh. Science, Johns Hopkins University School of Medicine
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Acute Physical Dependence in
Man: Repeated Naloxone-
Precipitated Withdrawal After a
Single Dose of Methadone
Curtis Wright, George E. Bigelow and Maxine L. Stitzer
Opioid abstinence syndromes have been precipitated in man by naloxone
administration in both clinical and experimental settings following pre-treatment
with opioid agonists. Naloxone is normally without subjective or objective effect
in opiate-free individuals in doses below 2 mg/kg. In contrast, naloxone has been
reported to precipitate withdrawal in doses of 0.2 mg/kg after a single dose of 18-
30 mg of morphine in nondependent post-addicts and in doses of 0.002 mg/kg in
opioid-dependent subjects. The degree of induced naloxone sensitivity in man
thus provides an estimate of acute physical dependence following the administra-
tion of opioid drugs.
In an attempt to extend-the use of this technique to single-dose studies of other
opioid agonists, six non-dependent naloxone-insensitive human volunteers with a
history of prior opioid abuse were pre-treated with a single dose of 30 mg
methadone i.m., and their subsequent sensitivity to naloxone was determined in a
double-blind experimental protocol. Each subject participated in a four-week
inpatient study in which they were challenged with naloxone at 54, 30 and 6
hours after receiving methadone in a three-condition randomized-block design .
Condition
1
Condition
2
Condition
3
Pre-treatment 6 hours 30 hours 54 hours
30 mg
methadone Placebo Placebo Naloxone
30 mg
methadone Placebo
Naloxone Naloxone
30 mg
methadone Naloxone Naloxone Naloxone
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Opioid agonist and antagonist effects were measured by a combination of self-re-
port using subjective-effect visual analog and adjective rating scales, physiologic
measures and observer ratings. Naloxone challenge was performed using a cu-
mulative dosing technique consisting of a placebo injection followed by a series of
naloxone injections (0.5 mg, 1 mg, 2 mg & 6 mg ) to reduce the risk of an un-
pleasantly strong abstinence reaction. The subjects stopped nearly all sessions at
the 0.5 mg-1.0 mg dose levels, and ratings from these levels were used in the
analysis.
RESULTS
All subjects developed a mild to moderate opioid agonist effect lasting 12-24
hours after the administration of the methadone, and no subject developed an ad-
verse drug effect. All demonstrated unequivocal naloxone sensitivity at 6, 30, and
54 hours after a single dose of methadone, with skin temperature decrease, pupil-
lary dilation, and subjective withdrawal ratings being the most sensitive indices of
naloxone sensitivity. The intensity of the reaction did not vary significantly across
the three challenge times. such that the reaction was fully established at 6 hours
and persisted through 54 hours with undiminished intensity.
All subjects had repeated naloxone challenges after a single dose of methadone in
condition -3, and precipitated withdrawal of nearly equal intensity was observed
at the 6-, 30, and 54-hour challenges under that condition.
All subjects had a 54 hour challenge in all conditions, but that challenge was the
first challenge in condition 1. the second challenge in condition 2, and the third
challenge in condition 3. The number of prior naloxone challenges did not affect
the intensity of the reaction at the 54 hour challenge, which was nearly uniform
across all these conditions.
This study establishes that a single 30 mg dose of methadone in an individual with
a previous history of drug abuse induces a sensitivity to naloxone at the 0.01-0.02
mg/kg level lasting at least 54 hours, and that the intensity of this sensitivity is lit-
tle affected by repeated naloxone challenge under the conditions of this study.
Supported by NIDA Grants R01 DA-03889, T32 DA-07209 & K05 DA-00050
AFFILIATION
Behavioral Pharmacology Research Unit, Department of Psychiatry and Be-
havioral Sciences, The Johns Hopkins University School of Medicine, Baltimore,
Maryland 21224
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Neurolectic Correlates of
Nonsteroidal Analgesia
Sean O’Connor, Allan Tasman, Nancy DePalma and
Scott Zaccheo
Evoked potentials provide objective measures of the brain’s response to specific
stimuli. By choosing the sensory modality and controlling the intensity, timing
and context of the stimulus, the EP can be analyzed for correlates of specific
neural systems’ responses attributable to both pathology and pharmacologic
intervention. When noxious stimuli are used, the recorded waveforms are called
nociceptive evoked potentials (NEPs), and are useful for studying objective
concomitants of the experience of pain.
Our laboratory has developed techniques and apparatus that facilitates the
collection of NEP data when the investigator is interested in responses spanning
several stimulus intensities and in repeating the test at frequent intervals in order
to track kinetic properties of analgesic drugs. The approach uses brief bursts of
electrical current applied to the center of an upper incisor tooth surface in a way
that directs the current into the tooth pulp.
Two devices are key in enabling many tests to be repeated on one subject in a
way that assures the resulting NEPs can be used to detect drug effects . The first
is a silastic mold custom fitted for each subject, then modified to permit stimuli
to be delivered to precisely the same location on the subject’s tooth in each test
even if weeks apart. An 18 gauge needle is mounted on a retractable guide so
that the mold can be removed and replaced with ease. The tip of the needle is
modified so that a 3 mm diameter plastic cup rests squarely on the surface at the
base of the tooth pulp. The needle and cup are filled with conducting electrode
gel so that very little variation in contact impedance or locus is encountered. A
plastic tube is also mounted on the mold to direct a stream of dry air over the
tooth’s surface. Thus, surface moisture which could conduct the applied current
away from desired pathway is minimized.
The second device is an electronic circuit that is under the control of the
computer which manages NEP data collection. The circuit generates current
pulses that are precisely timed, biphasis to minimize stimulus artifact, and
carefully controlled in amplitude. The pulses are also electrically isolated from
all other apparatus and limited to 500 microamps in amplitude in order to assure
subject safety and to preclude tissue damage. Six digitally controlled channels
are available, and each channel can be preset to any one of a thousand different
pulse intensi t ies  in  order  to col lect  data  that  span an individual’s
intensity/response range in any one test.
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NEPs are standardized against each individual’s subjective profile as a function
of stimulus intensity. Using the method of ascending and descending limits, the
pulse intensity marking sensory threshold is determined. Another amplitude,
determined by the subject as the most painful intensity tolerable without
blinking, is defined as the reference pulse. The subject is then given a series of
paired pulses of which the first is always the reference pulse. The second is
chosen by the operator unknown to the subject. The subject rates the subjective
intensity of the second pulse as a fraction between sensory threshold and
reference on a continuous dial marked “0”. “1/4”, “1/2”, “3/4”, and “1/1”. A
long-linear regression model of the subjective data is computed and used to
determine the current intensities corresponding to 0.10,20,40 and 80 percent of
the subjective response between threshold and an asymptotic response limit
which is usually slightly above the reference level. These intensities are encoded
into the pulse generating apparatus.
The computer then delivers a train of 50 msec long pulses at intervals uniformly
distributed between 1.6 and 2.0 seconds to eliminate timed expectations by the
subject. The current intensities are randomly distributed between the five active
channels, and the EEG recordings are sorted by current intensity. The peak
amplitude of the NEPs are checked to see that they fit the mathematical model of
the subject response determined over the full stimulus range.
Pilot studies demonstrated a very good ability to provide highly repeatable
results in baseline measures, both subjective and objective, taken a week apart in
all subjects. The advantage of the NEP approach is that a complete block of data
can be collected in seven minutes, permitting serial testing as an experimental
analgesic is metabolized.
The oral presentation reviews data from double blind, placebo controlled, 3 way
crossover design testing the analgesic effect of two forms of ibuprofen; the
standard pill preparation and a liquid form that is more rapidly absorbed by the
gut. The results demonstrate that analgesic effect is clearly differentiated from
placebo effect in the first hour of testing by significant decreases in NEP
amplitude. Moreover, a kinetic model of the data detects the more rapid onset of
analgesia afforded by the liquid ibuprofen.
The cost of developing the apparatus and techniques and of conducting
ibuprofen studies was funded by the Upjohn Corporation.
AFFILIATION:
University of Connecticut School of Medicine, Farmington, CT 06032
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Oral Naloxone Treatment of
Narcotic Induced Constipation:
Dose Response
Joan A. Culpepper-Morgan, Charles Inturissi,
Russel Portnoy and Mary Jeanne Kreek
Opioid agonists are known to cause constipation in individuals
who require chronic administration of these drugs for pain or
methadone maintainence. This symptom is often resistant to
treatment with conventional laxatives. Naloxone, a specific
opioid antagonist, reverses all opioid effects and induces
narcotic withdrawal when given intravenously. However, Kreek
et.al. observed that methadone maintained patients who were
given oral naloxone underwent profound withdrawal that was
mostly limited to the gastrointestinal tract (GI) (1). This was
felt to be due to the limited systemic bioavailability of
naloxone which is inactivated by glucuronidation in the 3-OH
position on first pass through the liver (2).
We have examined the ability of orally administered opioid
agonists to delay GI transit in the guinea pig and found mu and
kappa agonists to be equipotent by this route (3). We have
recently reported on the effects of orally administered narcotic
antagonists in the same guinea pig model. We have determined
that, despite limited systemic bioavailability, orally
administered naloxone can reverse opioid agonist induced slowing
of GI transit (4). Although, a primary gut wall site of action
is implied the low levels of plasma naloxone that can be
measured by radioimmunoassay should parallel the local gut wall
concentration.
Therefore the aim of the present study was to determine if
orally administered naloxone can reverse. narcotic induced
constipation without causing systemic withdrawal or the
recrudescence of pain. A related aim was to determine if
efficacy or adverse reaction could be related to plasma naloxone
levels.
Three patients who required chronic treatment with opiates for
the relief of pain and who were unable to have a spontaneous
bowel movement without the use of laxatives were studied.
Patients were given a single daily oral dose of naloxone in a
titration study design. Doses ranged from 0.5 mg to 16 mg.
Plasma levels of naloxone were measured by radioimmunoassay on
extracted (active naloxone only) and unextracted (active
naloxone + inactive glucoronide) plasma (5).
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Extracted plasma naloxone levels were < 10% of unextracted
levels. The peak naloxone plasma levels for each dose
administered are shown below. Patient A had a dose related
improvement in spontaneous laxation and stool consistency and
MAXIMUM EXTRACTED PLASMA NALOXONE LEVELS
vs DOSE IN 3 PATIENTS
DOSE OF ORAL NALOXONE
(mgs)
no adverse reactions. Patient B had symptoms of withdrawal at
doses greater than 12 mg and crampy abdominal pain. At doses of
8-10 mg patient C had symptoms of pending laxation but did not
have a spontaneous bowel movement or symtoms of withdrawal.
We conclude, that first pass biotransformation of orally
administered naloxone significantly reduces the amount of active
compound that is delivered to the systemic circulation. Some
patients may have transit that is to slow to obtain steady gut
wall levels of drug, such as patient C. Steady state naloxone
levels betwen 3 and 6 ng/ml seem to be associated with
spontaneous laxation without narcotic withdrawal. Lastly,
Albeck et. al. have demonstrated that the pharmacokinetic
profile of naloxone may indicate that it has a prolonged
terminal half life of up to 120 minutes (6). Therefore, future
evaluation of oral naloxone for the treatment of narcotic
induced constipation should titrate the patients dose using
single doses less than 12 mg going on to multiple doses of 12 mg
or less at intervals of 6-12 hours. These studies are currently
in progress
1) Kreek, MJ, Ann of the NY Acad Sciences. 281: 350-370, 1976
2) Fujimoto, JM , Proc. Soc. Exp. Biol. Med. 133: 317-319, 1969
3) Culpepper-Morgan JA; et.al. Life Sciences. 42: 2073-2077,
1988
4) Culpepper-Morgan JA, et.al. Clinical Research. 37:366, 1989
5) Hahn, EF et.al. J. Pharm. Pharmacol. 35: 833-836, 1983
6) Albeck, H et. al. J. Chromatography. 488: 435-445, 1989
AFFILIATIONS: Rockefeller University, Cornell University Medical
College, Memorial Sloan Kettering Cancer Center, and Norwalk
Hospital.
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HIV Risk Behavior: Antisocial
Personality Disorder, Drug Use
Patterns, and Sexual Behavior
Among Methadone Maintenance
Admissions
Dušan Nolimal and Thomas J. Crowley
The literature suggests an association between Antisocial Personality Disorder
(ASPD) and drug use. The risk of Human lmmunodeficiency Virus (HIV)
infection has been associated with intravenous drug use, equipment-sharing
and high-risk sexual activities. Intravenous drug users (IVDUs) may not be a
homogenous population. They might vary considerably in their risk for HIV
contraction and transmission. These findings led the authors to hypothesize
that IVDUs with ASPD are more likely to be involved in HIV-risk behaviors,
and have more problems with alcohol and non-opioid drugs than non-ASPD
IVDUs.
Shortened NIMH Diagnostic Interview Schedule (DIS-III) and HIV-Risk
Behavior Interviews were given to 52 consecutive methadone maintenance
admissions (MMAs). One interviewer completed each evaluation the first day
of admission. The validity of the self-report data was assessed through
consistency controls of comparing the sample data with other relevant sources.
Data were scored for lifetime and/or last year ASPD, number of ASPD signs
and symptoms, alcohol abuse/dependence, non-opioid drug abuse/dependence,
injection-equipment sharing and cleaning, and sexual behavior. T-test, Chi-
square, correlation and regression statistics were used to compare ASPD with
the non-ASPD group.
There were-no significant differences in sex, age, race, marital status,
education, employment, monthly income and number of previous treatments
between the groups. Fifty MMAs (96%) were diagnosed as lifetime opioid
IVDUs. Forty-four (85%) used drugs intravenously and 29 (56%) shared
equipment 12 months prior to the admission. All studied subjects but two
were sexually active in the previous year. No one was HIV seropositive at the
time of admission.
DIS-III diagnosis indicated that 40% of the MMAs met the criteria for a
definite diagnosis of lifetime ASPD. Antisocial MMAs were more likely to have
an earlier criminal record, sexual relations, drug use and intravenous drug
use. They reported significantly more lifetime and last year non-opioid drug
problems. related to alcohol (p=.01) and cocaine (p=.03) than non-antisocial.
The ASPD patients had more injection-sharing partners (mean=2.6 vs. 1.0,
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p=.0009). and shared equipment more often (p=.01), than non-ASPD
patients. Also, the ASPD group had more sex partners (mean=6.1 vs. 1.6.
p=.01). The relationship between ASPD and HIV-risk behavior was strongest
for lifetime diagnosis of promiscuity (p=.0002) and prostitution (p=.0004).
There were no significant differences in frequency of daily intravenous drug
use per year, equipment cleaning when shared, frequency of daily sexual
activities per year and condom use patterns between the groups. Number of
ASPD signs and symptoms across the entire sample significantly correlated
with a frequency of HIV-risk behavior (r=.378 for no. of sharing partners;
r=.369 for no. of sex partners). The 15% of MMAs with the highest number
of antisocial signs accounted for 49% of all last year sex partners and for
22% of all last year equipment-sharing partners. The number of sharing
partners correlated significantly (r=.45) with the number of sex partners.
The study indicates that ASPD among MMAs is associated with more HIV-risk
behaviors and conditions, including a high prevalence of equipment-sharing,
sex partners, and alcohol and cocaine problems. The number of antisocial
signs and symptoms correlates with the frequency of HIV-risk behaviors.
Promiscuity and prostitution are highly associated with ASPD and
significantly increase the risk for HIV’s spread. Individuals with multiple
equipment-sharing partners are also likely to have multiple sex partners.
Overall, there is a wide variation in levels of HIV risk behavior among MMAs,
but individuals with a high number of ASPD lifetime features are at high risk
to contract and transmit HIV.
AUTHORS:
Dušan Nolimal, M. D.
Thomas J. Crowley, M. D.
Department of Psychiatry
University of Colorado School of Medicine
4200 East 9th Avenue, C268
Denver, Colorado 80262
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Primary Medical Care for IVDU’s:
Model for Future Care
Richard S. Schottenfeld and Patrick G. O’Connor
BACKGROUND: IVDU’s have traditionally faced problems
gaining access to medical care and drug abuse treatment,
obtaining comprehensive medical and drug abuse treatment,
and receiving coordinated care from multiple providers. In
New Haven, fewer than 1/4 are in drug abuse treatment
programs, and only 1/6 IVDU’s with AIDS had ever been in
treatment. This is in contrast to the Netherlands where low
threshold treatment programs serve virtually all addicts.
What has been the impact of HIV infection and AIDS in this
population? What new services or approaches to treatment
need to be developed to address these problems? What are
the advantages and disadvantages of providing comprehensive,
integrated primary medical care and drug abuse treatment in
one program?
RESULTS Because methadone regulations mandate admission
and annual physical examinations, we had previously
developed a small, primary medical care facility (Central
Medical Unit, CMU) to provide physical examinations and
limited primary medical care as part of our multi-modality
treatment program. In July, 1988, additional funds were
made available, allowing us to add a--full-time internist,
nurse practitioner and medical.. technician to the previous
staffing (part-time internist, nurse practitioner,
physician’s associate, AIDS educator, and secretary).
RESULTS CMU now provides 1) primary medical care to IVDU’s
enrolled in substance abuse treatment programs, 2) opiate
detoxification and introduction to drug abuse treatment, 3)
consultation and teaching about drug abuse to the Primary
Care Clinics (PCC) and medical service of Yale-New Haven
Hospital, and 4) medical support to a medical van used in a
NIDA-sponsored comprehensive AIDS outreach and prevention
project.
During the first four months of full staffing, there were
1392 pat i ent  v i s i t s . A sample of  146 consecutive
unduplicated, patients revealed that 72% were Caucasian and
A
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63% male, with an age range of 21 to 71 years. 83 patients
were referred from methadone maintenance and 63 from drug-
free treatment programs for  opiate,  cocaine or  alcohol
disorders. Screening and preventive health care services
were the primary reason for visits in 42% (62/146) of these
patients. The remaining 84 patients were referred for
evaluation and management of active medical problems: 21%
(18/84) had HIV related illness and 26% (22/841 suffered
from other direct complications of intravenous drug use
( e . g . ,  hepat i t i s ,  c e l lu l i t i s ) .  A  w ide  range  o f  genera l
medical problems, including hypertension, diabetes, and
common infections were cared for as well.
DISCUSSION: Benefits of the expansion of CMU include: 1)
better coordination of care when patients are hospitalized,
faci l i tat ing hospital  treatment,  discharge planning and
f o l l o w - u p ;  2 ) better compliance with treatment--CMU
clinicians encourage patients to  r e turn  t o  drug  abuse
treatment programs, and clinicians in drug abuse treatment
reenforce the need for  continued medical  treatment;  3)
improved ability of medical providers to care for IVDU’s.
Additional advantages to providing coordinated and
integrated primary medical care and drug abuse treatment in
o n e  f a c i l i t y  a r e  l i k e l y : 4) CMU can function as a low
threshold, entry level program for IVDU’s who typically drop
o u t  o f  o r  n e v e r  u t i l i z e  d r u g  a b u s e treatment programs
because of  str ingent program rules and insistence on
abstinence--CMU would not, however, prescribe opiates,
sedatives, or  needles  and syringes that would enable
continued drug use; 5) CMU will identify cohorts of IVDU’s
with HIV that can be used in clinical trials of therapeutic
agents, thus improving the medical care of IVDU’s and
contributing to scienti f ic  advance; 6) CMU can develop
service modules for women IVDU’s (Women’s Health Services to
address prenatal, post-partum care, battering, prostitution,
sexually-transmitted diseases, and parenting issues) and for
ch i ld ren  o f  IVDU’s  (Ped ia t r i c  C l in i c  t o  address  ch i ld
development and adequacy of medical care).
A potential disadvantage of combining medical and drug abuse
treatment services in one setting is the possibility that
neither treatment will be provided well, thus forestalling
adequate care. To avoid this pitfall, programs need to
define clearly which services they can provide and when they
need to refer to specialty clinics.
Because primary medical care facilities are available in
most communities in the U.S. , developing drug abuse
t rea tment  se rv i ces  in  these  f a c i l i t i e s  may  be  a  c o s t
effective alternative to developing new drug abuse treatment
services. (Yale University School of Medicine)
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HIV-Infected lV Drug Users in
Methadone Treatment: Outcome
and Psychological Correlates-A
Preliminary Report
Steven L. Batki, James L. Sorensen, David R. Gibson and
Peg Maude-Griffin
The effectiveness of methadone maintenance treatment (MMT) for intravenous
drug users (IVDUs) with HIV infection is crucial in limiting the spread of AIDS (1).
This study examined MMT effectiveness and the role of psychiatric symptoms in
treatment outcome among HIV-infected IVDUs. Psychological distress was studied
because it is common in HIV-infected IVDUs and because of evidence that depression
and other psychiatric symptoms predict poor drug abuse treatment outcome (2). The
role of cocaine was examined because of the importance of cocaine use in IVDUs with
AIDS (3).
METHOD: Subjects were the first 42 consecutive HIV-infected IVDUs admitted to
MMT at the Program for AIDS Counseling and Education (PACE) at San Francisco
General Hospital Substance Abuse Services. Measures were prospectively taken at
entry, and after three months and 12 months of MMT. IV drug use measures included
the Addiction Severity Index (ASI), urine tests, and skin examination for needle marks.
Psychological measures included the Beck Depression Inventory (BDI), the Beck
Hopelessness Inventory (BHI), and the depression and suicidality items from the ASI.
Two thirds of the subjects were male; the majority were black or hispanic. Mean age
was 37.5 years with a mean of 12 years of heroin use. About half of the subjects had
previous MMT. 62% were heterosexual. Most subjects had some symptoms of HIV
infection.
RESULTS: Subjects demonstrated significant decreases in IV drug use and heroin use
in the first three months of MMT. Cocaine use decreased, but not significantly. Urine
testing and skin puncture examination confirmed the direction of these changes.
Clinical improvement was maintained at the 12-month follow-up (4) (Fig. 1).
NEEDLE, HEROIN, AND COCAINE USE
AT 12 MONTHS
Figure 1
(N = 21)
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Subjects had high levels of psychological distress at entry. 60% had moderate to
high levels of depression on the BDI. BDI scores did not decline significantly during
MMT; mean scores consistently exceeded moderate levels. The Beck Hopelessness
Inventory measures pessimism and is a useful predictor of suicidality. 57% of subjects
had moderate or higher levels of hopelessness on the BHI. As with the BDI, there was
no significant decrease in hopelessness scores during treatment. Items from the ASI
were also used to assess psychological distress. More than 72% of subjects reported
depression in the month prior to entry. Half of the depressed patients, or nearly 37%
of the entire group, reported thoughts of suicide, and a strikingly high 13% of patients
reported making a suicide attempt in the month prior to entry.
Patients who reported initial depression on the ASI had almost six times the
number of days of IV drug use at 12 months (p<.03) than patients who denied
depression at entry into MMT. Depression at intake also predicted later cocaine use.
Subjects with intake BDI scores over 30 had 10 times the number of days of cocaine use
at 12 months than subjects with low BDIs at entry. Among the measures of distress,
suicidality at intake appeared to be the most consistent predictor of future drug use
outcome. Patients with suicidality at intake reported almost three time as many days of
heroin use, 16 times as many days of cocaine use, and nearly three times as many days
of total IV drug use at 12 months of treatment than patients with no suicidality
(Fig. 2). Cocaine abuse at admission to MMT was an even more robust predictor of
MMT outcome than were measures of psychological distress. Patients who reported
cocaine use at intake had significantly more days of heroin, cocaine, and total IVDU at
12 months than those patients who denied pre-admission cocaine use.
ASI SUICIDALITV AT INTAKE AS A PREDICTOR OF
F igure  2
12 MONTH DRUG ABUSE OUTCOME
(Intake N=42)
DISCUSSION: MMT is associated with significant decrease in IV drug use in HIV-
infected patients despite the prevalence of psychological distress at entry and
throughout the first year of MMT. Higher levels of depression, hopelessness, suicidality,
and cocaine use at intake appear to be predictive of poor treatment outcome at 12
months of MMT. This is the first study known to us to prospectively examine MMT
outcome in HIV-infected IVDUs. These early results show that MMT is effective even
in this severely distressed group of patients. Further studies should determine whether
early assessment and treatment of depression and cocaine use among HIV-infected
IVDUs will improve treatment outcome.
REFERENCES:
1. Batki SL, Sorensen, JL, Faltz, B, Madover, S. AIDS among intravenous drug users:
Psychiatric aspects of treatment. Hosp Comm Psychietry 39:449-441, 1988
2. Rounsaville BJ, Kosten, TR, Weissman, MM, KIeber, HD. Prognostic significance of
psychopathology in treated opiate addicts: A 2.5-year follow-up study. Arch Gen
Psychiatry 43:739-745, 1986
3. Chaisson RE, Becchetti P, Osmond D, Brodie B, Sande HA, Moss AR. Cocaine use and HIV
infection in intravenous drug users in San Francisco. JAMA 261:561-565, 1989
4. Sorensen JL, Batki SL, Gibson DR. Dunontet R, Purnell S, Maude-Griffin P. Methadone
maintenance and behavior change in seropositive drug abusers: The San Francisco General
Hospital Program for AIDS Counselling and Education (PACE). Paper presented at the V
International Conference on AIDS, Montreal, June 1909
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Mode of HIV Transmission Among
Seroconverted Intravenous Drug
Users (IVDUs): 1987 and 1988
Cohort Study
Tooru Nemoto, Lawrence S. Brown, Jr., Beny J. Primm,
Kenneth Foster and Alvin Chu
OBJECTIVE
To investigate the mode of HIV transmission among IVDUs who were
enrolled into the methadone maintenance programs in New York
City, especially focusing on drug and sexual behaviors among
seroconverted IVDUs.
METHODS
A total 440 subjects (218 in 1987 and 222 in 1988) were
recruited from the methadone maintenance programs in Manhattan
and Brooklyn, New York City. The characteristics of subjects
were: 62% males and 38% females; 51% Blacks, 42% Hispanics, 7%
Whites and others; Mean age = 33 years. Thirty-seven percent
and 77% of the subjects were recruited from the newly admitted
patients in 1987 and 1988, respectively. There was no signifi-
cant difference between the subjects and patient population of
the methadone programs in age, sex, and ethnicity. After
informed consent, a standardized questionnaire was administered
by trained interviewers. Also, blood was collected and tested
for HIV antibody by ELISA and Western Blot techniques.
RESULTS
The overall HIV infection rate was 60% in 1987 and 52% in 1988.
No significant association was found between HIV serostatus and
ethnicity, sex, type of admission, and levels of education both
in the 1987 and 1988 cohort groups. However, there vere signi-
ficant associations between HIV serostatus and age groups in
1987 (p <.10) and in 1988 (p <.01), that is, the older groups
were more likely to be found seropositlve. Among the 1987
cohort group, 25 subjects reported that they had previously
tested for HIV serostatus. Two reported HIV positive and 23 had
HIV negative. Nineteen out of 23 (83%) who reported previous
HIV seronegatlve status, were found to test HIV seropositive.
Among the 1988 cohort group, 40 subjects reported that they had
previously tested for HIV serostatus and were HIV negative.
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Twenty-three out of 40 (57%) who reported previous HIV seroneg-
ative status, were found to test HIV seropositive.
In the 1987 cohort group, no significant difference was found
between the seroconverted and remaining HIV seronegative sub-
jects in age, sex, ethnicity, levels of education, locations of
clinics, and drug and sexual behaviors. However, in the 1988
cohort group, significant differences were found between the
seroconverted and remaining HIV seronegative subjects on the
frequency of sharing needles during the past 5 years (p=.003),
the frequency of sharing cookers during the past 5 years
(p=.006), the number of needle sharing partners during the past
5 years (p=.008), the frequency of using shooting galleries
during the part 5 years (p=.003), and the frequency of cleaning
needles during the past 5 years (p=.013). No significant
difference was found in these drug behaviors during the past 12
months. The type of drugs (heroin, cocaine, and marijuana) and
the way of drug taking behaviors (intravenous, skin-pop, smok-
ing, snorting) were examined. In the 1988 cohort group, the
seroconverted subjects reported significantly higher frequencies
of using speedball than those who remaining seronegatlve
(p=.02). In the 1987 cohort group, all subjects who remained
seronegative reported they stopped needle sharing and reduced
number of sex partners.
DISCUSSION
The study was different from the cross-sectional studies in HIV
seroprevalence among IVDUs which reported the association
between HIV serostatus and demographic variables, and drug and
sexual behaviors. This study mainly focused on the drug and
sexual behaviors, and demographic variables which differentiated
the seroconverted IVDUs from the remaining seronegatlve IVDUs in
the 1987 and 1988 cohort groups. The limitations of self-report
by subjects on HIV serostatus, and drug and sexual behaviors
should be considered. However, this study clearly demonstrated,
especially among the 1988 cohort group, that needle sharing
behaviors and needle sharing at shooting galleries during the
past 5 years significantly differentiated the seroconverted
IVDUs from the remaining seronegative IVDUs. Also, the serocon-
verters reported significantly higher frequencies of using speed-
ball during the past 12 months. This study supported the past
research findings that HIV infection among IVDUs was strongly
associated with needle sharing behavior, needle sharing at
shooting galleries, and IV cocaine use. Furthermore, this study
demonstrated that these high risk behaviors for HIV infection
discriminated the seroconverted IVDUs from the remaining sero-
negative IVDUs. In order to prevent HIV Infection among IVDUs,
more effective interventions to educate IVDUs to stop needle
sharing and engaging in high risk drug behaviors are needed.
AFFILIATIONS: Addiction Research and Treatment Corporation,
Brooklyn, NY and Harlem Hospital, College of Physicians and
Surgeons, New York, NY.
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Developmental Decline in Infants
Born to HIV-Infected Intravenous
Drug-Using Mothers
R. Kletter, R. J. Jeremy, C. Rumsey, P. Weintrub and
M. Cowan
OBJECTIVE
To chart prospectively the course of development of infants
exposed in utero to the human immunodeficiency virus (HIV),
and compare infants who have become infected with those who
have not.
METHODOLOGY
Participants
Three groups of infants born to intravenous (IV) drug-using
women:
Group I: Uninfected infants of uninfected mothers
(Control; N = 13)
Group II: Infected infants of HIV-infected mothers
(Infected; N = 9)
Group III: Uninfected infants of HIV-infected mothers
(Uninfected; N = 12)
The infants are still being followed and new ones enrolled
into the ongoing study.
Instruments and Procedures
Infants are assessed every 3 months on the Bayley Scales of
Infant Development. The examiners are "blinded" about the
mothers' and the infants' HIV infection status.
Analyses
The Bayley exam yields standardized scores of infants' mental
and motor performance, the Mental and the Psychomotor
Development Indices (MDI and PDI, respectively), with a mean
of 100 and a standard deviation (SD) of 16 for each of monthly
ages between 3 and 30 months.
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We compared the scores of the three groups of infants at each
of the ages of 3, 6, 9 and 12 months (there are still too few
data at the older ages).
RESULTS
1. Mental Development. The Infected infants showed declining
MDI scores with age between 3 and 12 months, in contrast to
both non-infected groups which did not change significantly.
However, while the Control group continued to perform near
normal MDI level, the Uninfected group continued to score about
one standard deviation lower.
2. Motor Development. The Infected infants declined in their
PDI scores. In contrast, both non-infected groups continued
to perform near normal.
DISCUSSION
We found that during the first year of life, the mental and
motor development of HIV-infected infants is slowing down, as
indicated by decreasing MDI and PDI scores.
However, the two non-infected groups differed significantly in
their typical level of mental functioning during the first year
of life. While the MDI scores of the Control infants stayed
at around 100, which is average for normal infants, the scores
of the Uninfected ones stayed about one standard deviation
below the average for normal infants. Thus, the Control infants
behaved during the first year of life as expected of average
normal infants. In contrast, both groups of infants of HIV-
positive mothers diverged from normal, but in different ways.
Those who became infected with HIV (Infected) declined with
age from average to poor, while those who somehow avoided
becoming infected in utero (Uninfected) did not decline
significantly but, instead, functioned poorly all along since
early infancy.
The Uninfected infants, like the Infected ones, showed
problematic mental functioning (but of a different pattern),
but, like the Control infants, their gross motor performance
continued about average.
AUTHORS
R. Kletter - BAART-FACET, San Francisco, CA
R.J. Jeremy, C. Rumsey, P. Weintrub and M. Cowan - University
of California, San Francisco, CA
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Does Fear of AIDS Affect Behavior
of Addicts?
Richard S. Schottenfeld, Stephanie S. O’Malley and
Katurah Abdul-Salaam
BACKGROUND: How successful are outreach and prevention
ac t i v i t i e s  in changing the high r i s k  b e h a v i o r s  o f
intravenous drug users (IVDU’s)? Are addicts reducing
needle sharing or intravenous use of drugs?
Pessimism about the possibility of changing the behavior of
addicts is often expressed. Weinberg and Murray (1987), for
example, write that “[p]ast attempts to reach the drug-
abusing population through education or motivation have been
unsatisfactory ....Often alienated and self-destructive, drug
users have not been amenable to traditional approaches to
encourage behavioral change.”
Studies to date report contradictory results. Evaluation of
outreach programs in Baltimore and Sacramento support
pessimism: although knowledge about HIV transmission and
ways to prevent the spread of HIV increased, there were no
significant changes in needle sharing. Self-reported
increases in the use of steri le injection equipment,
increased use of bleach by IVDU’s, and increased use of
needle exchange programs in some countries, however,
suggests that addicts are changing their high r isk
behaviors. (DesJarlais and Friedman, 1988) In New Haven, we
were struck by reports from addicts that they were avoiding
intravenous drug use in an effort to reduce their risk for
contracting HIV infection.
METHODS: To evaluate whether opiate addicts in New Haven
have changed behaviors as a result of AIDS, we reviewed the
records of all opiate addicts seeking treatment in similar
time periods in 1986 and 1988 to determine self-reports of
route of drug administration. To determine the validity of
self -reports, we compared findings on admission physical
examinations to  se l f - repor t s for those who entered
treatment.
RESULTS: Opiate addicts evaluated in 1986 (n=60) did not
differ significantly from those evaluated in 1988 (n=82)
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with regard to demographic factors, years of opiate use, use
of cocaine, or Beck Depression scores. In 1986, 52/60 (86%)
of addicts reported current IV use, 4/60 (7%) reported past
use but none in the preceding year, and 4/60 reported never
using IV. In 1988, however, 32/82 (39%) reported no current
IV use--18/82 (22%) reported never using IV and 14/82
reported switching from IV to intranasal, inhalation or oral
use. (ChiSquare=11.368, df=2, p=.003). Current IV ‘users
had used opiates longer (mean 11.3 years) compared to those
not  currently using IV (mean 8.4 years,  t=2.20,  df=65,
p<.03). There was a trend for cocaine use to be associated
with current IV administration: 55% of current IV users also
used cocaine, compared to 37% of those not currently using
IV (Chi Square = 3.3, df=1, p=.07).
Fresh track marks were recorded in the physical examinations
of 91% of self-reported current IV users (40/44), 60% of
sel f -reported past  only IV users (3/5) ,  and 14% of  sel f -
reported never used  IV  (1 /7 ) . 25% (2 /8 )  o f  add i c t s
init ial ly reporting no IV use and 44% (4/9)  of  addicts
initially reporting past use only reported current IV use at
the time of physical examination. 9% (4/43) of addicts
initially reporting current IV use reported either part use
only (3/43) or never using IV (1/43) at the time of physical
examination.
DISCUSSION:  Se l f - r epor ted  IV  use  o f  d rugs  dec l ined
signif icantly  between 1986 and 1988 in opiate  addicts
seeking drug abuse treatment, p o s s i b l y  a s  a  r e s u l t  o f
extensive AIDS outreach efforts and the increasingly visible
impact of HIV infection in IVDU’s. By 1988, 1/6 addicts
reported having discontinued IV use and more than 1/5
reported never using IV.
In this study, self-reports of not using IV were found to be
quite unreliable, casting some doubt on the validity of the
findings. Addicts appear to bias their reports toward what
is socially acceptable or. personally desirable behavior.
Although addicts attributed their avoidance of intravenous
drug use to  concern about AIDS, changes in r o u t e  o f
administration may have resulted in part from increased
pur i ty  o f street heroin, facilitating heroin smoking or
intranasal  use- -purity of c on f i s ca ted  s t ree t  hero in  in
Connecticut averaged 50-60% in 1988, considerably higher
than in past years. The finding of s ignif icantly  less
intravenous drug use in treatment-seeking addicts in New
Raven may also not be generalizable to non-treatment seeking
addicts. 94% of addicts completing a health department
survey in 1988 reported current IV use, and 71% reported
needle-sharing. (Yale University School of Medicine)
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Demographic, Behavioral and
Clinical Features of HIV Infection
in NYC Intravenous Drug Abusers
L. S. Brown, Jr., A. Chu, T. Nemoto and B. J. Primm
INTRODUCTION
Intravenous (iv) drug abuse continues to be pivotal in the preva-
lence of the acquired immunodeficiency syndrome (AIDS) among
women, children, and ethnic/racial minorities. Despite this un-
deniable impact of iv drug abuse on HIV disease in the United
States, important gaps exist in knowledge about the sexual behav-
iors of iv drug abusers and even fewer reports are available of
the clinical features of HIV disease in iv drug abusers prior to
meeting CDC criteria for AIDS. The current study presents an ex-
amination of the prevalence of HIV infection and clinical HIV
disease in association with demographic, socioeconomic, and be-
havioral factors in a population of iv drug abusers.
PATIENTS and METHODS
From June to September 1985, we recruited 318 male and 136 fe-
male patients scheduled for physical examination in selected
methadone maintenance clinics in Brooklyn and Manhattan of New
York City. Minimal eligibility included an age of 18 years and
at least one year of opiate dependence. Ages ranged from 19 to
62 yrs. with a mean age of 35±0.35 (SEM) years; the ethnic/ra-
cial distribution was 48.9% black, 42.5% Hispanic, and 8.6%
white; and 46% of the study subjects were enrolled from Brooklyn
clinics. Drug use ranged from 1 to 38 years with a mean of
12.3±0.34 and drug treatment enrollment ranged from 0.7 to 152
months with a mean of 23±1.4 months. The study population repre-
sented 96% of the patients eligible for participation.
Trained interviewers administered a standardized questionnaire
regarding demographic and socioeconomic status, drug use pat-
terns and sexual behaviors. Medical staff performed medical
histories, physical examination, and phlebotomy.
Laboratory evaluatlon included a complete blood count, serum
electrolytes, liver function tests, hepatitis B serology by
enzyme immunoassay (Abbott) and syphilis serology by rapid
plasma reagin. We examined collected sera for HIV-l antibody
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using an ELISA technique (Genetic Systems). Repeatedly positive
specimens by ELISA were confirmed using the Western blot tech-
nique (Dupont). Sera with p24 and/or gp41 bands on Western blot
were considered positive. Sufficient information was available
to categorize 307 subjects with a modified version of the
Centers for Disease Control (CDC) staging classification for HIV
infections. The modification entailed placing persons, who were
not found to have any clinical or serological evidence of HIV in-
fection, into CDC stage 0. Using the SPSS/PC+ statistical pack-
age, univariate measures were used to analyze collected data.
RESULTS
Serological evidence for HIV infection was found in 60.6% of the
study population. Nineteen percent of 307 subjects were in
Group III or Group IV of the CDC classification system for
HIV-associated infections. While the HIV infection rate was
greater among females, ethnic/racial minorities, subjects aged
25-30 years, and those who reside in Manhattan, these trends
were not significant. Subjects who attained higher educational
levels, who resided with their spouse and/or children, who were
married, and those who admitted to receiving income from legiti-
mate employment had lower rates of infection. The HIV seroinfec-
tion rate did not differ significantly by parameters of alcohol
or tobacco use. All subjects admitted to the use of intravenous
drugs and 92% admitted to polydrug use. Frequent use of IV
drugs (p=.016), duration of drug use (p.=050), and duration of
drug treatment enrollment (p=.038) and daily methadone dose
(p=.001) were significantly associated with HIV seroinfection
status.
HIV-infected subjects had significantly lower total white blood
cell counts (p=.001), serum hematocrits (p=.006), mean corpus-
cular volumes (p=.018), absolute platelet counts (p=.018), and
serum albumin levels (p=.001). Serum globulin levels were signi-
ficantly (p=.001) higher in HIV-infected subjects. The dally
methadone dose was significantly associated (p=.005) with CDC
HIV stage, from a mean 45.5±2.3 mgs. in Group 0 subjects to
34.3±2.8 mgs. in Group IV subjects. Demographic and socioeco-
nomic variables did not significantly differentiate seropositive
subjects from seronegatlve subjects. Only behavioral factors
(p=.001) and clinical indicators (p=.003) were found to distin-
guish the HIV-infected from the non-infected and CDC HIV stage.
CONCLUSION
These findings strongly support aggressive efforts to reduce
parenteral drug use and enroll intravenous drug users into effec-
tive drug treatment.
AFFILIATIONS: Division of Research and Medical Affairs, Addic-
tion Research and Treatment Corporation, Brooklyn, NY and Harlem
Hospital, Department of Medicine, College of Physicians and
Surgeons, Columbia University, New York, NY.
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Psychiatric Symptoms in HIV Test
Consenters and Refusers
George Woody, David S. Metzger, A. Thomas McLellan
Charles P. O’Brien and Domenic DiPhilipis
Fifty five methadone maintained opiate addicts were randomly selected
to participate in a pilot study of HIV testing and high risk behavior. All
agreed to complete an interview and questionnaire regarding high risk
sexual and drug use behavior. Thirty three also agreed to be tested for
the HIV virus and only one was positive. Five of those who refused said
they had been tested within the last year and were negative.
Amounts of sexual and drug-using high risk behavior reported did not
differ among those who agreed to be tested and those who declined.
Psychiatric symptoms, however, were significantly different between the
two groups. Those who agreed to be tested had more frequent and
intense symptoms of anxiety and depression than those who declined.
This difference is best reflected in the SCL-90 profiles of the two
groups, as seen in the graph below.
This pilot study suggests that the level of seropositivity among
methadone maintained veterans at the Philadelphia VAMC is lower
than that reported from other nearby cities. It also suggests that
patients who refuse testing have similar amounts of high risk behaviors
than those who agree, but are less psychiatrically symptomatic. These
higher symptom levels in those who agree to be tested may be a
ref lect ion of  under ly ing anxiety. ,  which could be at t r ibuted to
characterological factors and (or) actual participation in high risk
behaviors.
One implication of these findings is that IVDU’s who argee to be tested
for HIV may be more susceptable to the development of psychiatric
disorders than those who decline. This could be particularly relevant if
they test positive. Another implication is that raising anxiety levels about
the potential for infection among those who decline may improve
compliance with HIV testing.
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XL-90 Subscale Scores by HIV Test Consent
Center for Studies on Addiction
University of Pennsylvania / Philadelphia VA Medical Center
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Addict Beliefs About Access to HIV
Test Results
Donald A. Calsyn, George Freeman, Jr., Andrew J. Saxon
and Stephen Whittaker
Characteristics of IVDU’s who sought out HIV antibody testing and their
beliefs about who should have access to HIV test results were examined in
186 male and 87 female IVDU’s in treatment. Sample demographics were:
a g e  ( x = 3 8 . 4 , =7.4)! white 69.9, black 23.8, other 4.8%. Those who
had sought out HIV antibody testing at an alternate site (N = 107) were
younger  (x=37.0 , =7.2) and less likely to be employed (19%)
compared to  those not  seeking the  tes t  (N=160;  x=39.4, = 7 . 4 ,
t = 2 . 6 4 ,  p < . 0 1 ; 34%,  x2  =7 .0 , p < . 0 1 ) . There were no
education, race or sex differences. Test seekers had lived in current
residence fewer months (x=19.0 =3 3.2 vs x=29.8, = 4 1 . 1 ,
t=2.28, p<.05) and had been in treatment fewer months in the past 5
y e a r s  ( x = 2 2 . 8 , =18.2, vs x=32.2, =22.8, t=3.6,
p<.001). Test seekers had more needle sharing partners in the past year
( x = 6 . 2 6 , = 1 5 . 2 8  v s  x = 2 . 9 2 , = 8 . 7 0 ,  t = 2 . 2 5 ,  p < . 0 5 ) ,
but there were no differences on sexual behavior variables. Most subjects
believed the individual tested (91.8%), his/her physician (92.1%) and
sexual partner (90.6%) should have access to test results. Many felt public
health agencies (57.9%). health workers caring for the individual (60.3%),
laboratory workers (52.1) and the individual’s counselor (46.4%) should
have access. Most felt employers (16.5%), insurance companies (21.8%)
and non-public health government agencies (21.8%) should not have access.
Subjects who had already had HIV testing were more likely to feel their
counselor (55%) and health care workers (69%) should have access as
c o m p a r e d t o t h o s e n o t t e s t e d  ( 4 1 % ,  x 2 = 5 . 4 ,  p < . 0 5 ;  5 4 % ,  x 2 = 5 . 9 ,
p<.05). Those using drugs IV in the past 30 days (N = 130) were more
likely to feel government health departments (65% vs 51%, x2=5.3,
p<.05) should have access. Of those using IV drugs in past 30 days
needle sharers (N=54) were less likely to want public health agencies
(56%) or sex partners (85%) to have access compared to non needle
s h a r e r s  ( N = 7 6 ;  7 2 % ,  x 2 = 3 . 9 ,  p < . 0 5 ;  9 9 % ,  x 2 = 8 . 9 ,  p < . 0 1 ) .
Subjects who knew someone with AIDS (N=75) were less likely to feel
insurance companies (13%) and laboratory workers (42%) should have
access as compared to those not knowing someone with AIDS (N=194,
3 4 % ,  x 2 = 4 . 6 ,  p < . 0 5 ;  5 6 % ,  x 2 = 4 . 0 ,  p < . 0 5 ) . Addicts seem
willing to share HIV test results with appropriate people but seem too
willing to give results to those who have no need or such information.
AFFILIATIONS: Veterans Affairs Medical Center and Department of
Psychiatry and Behavioral Sciences, University of Washington, Seattle
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Needle Obtainment and Cleaning
Habits of Addicts
Adrew J. Saxon, Donald A. Calsyn, Stephen Whit-taker
and George Freeman, Jr.
Extensive personal interviews conducted during 1988 examined the needle
sharing, obtainment, and cleaning habits of 273 in treatment IV drug users
in Washington state where injection equipment can be legally purchased in
a drug store. HIV antibody testing done on 169 showed only 2(1.2%) as
HIV +. The sample was 68.1% male, 69.9% white and 23.8% black with a
mean age of 38.4. Primary drugs of abuse were opiates 77.1%, cocaine
11.4%, amphetamines 1.8%, ethanol 6.3%. In the prior year 68.5% had
shared needles, but only 19.9% had shared in the past month. For those
sharing the mean number of sharing partners in the past 30 days was 1.96.
Younger age was associated with more sharing while gender and race were
unrelated to sharing. Mean number of sharing partners in past year (2.3 +
8.9 S.D.) was less for subjects in treatment longer than 6 months (N = 132)
as compared to those in treatment 6 months or less (N = 138, x partners
= 6.3 + 14.1 S.D.; t=2.81, p<.01). Subjects admitting to recent IV
cocaine use (N=92) share with more people in the past year (x=7.9 +
18.0 S.D.) than those admitting to other IV drug use (N=40, x = 1.8 +
1.8 S.D.; t =3.21, p<.002). Subjects ranked buying needles in a drug store
as the most common obtainment method. Getting needles on the street
and borrowing from a friend were ranked second and third. Those using
IV drugs in the past year who identified drug store purchase as the most
frequent obtainment method (N= 110) share less frequently (x= 14.4%
+ 24.5% S.D. of injection episodes) than those getting needles from
dealers, on the street or from friends (N =48, x=26.2% ± 37.4% S.D. of
injection episodes; t =2.32, p<.05). When reusin needles 94.6% clean
with water, 57.8% with alcohol, 35.3% with bleach (20.7% boil, and 37.8%
use other methods. The most frequent settings in which users injected
were their own (63%) or friends’ homes (17%). Only 4.3% infected in a
shooting gallery. Males sharing needles in the past year (N=57) had more
sexual artners (mdn = 2.0) than those not sharing needles (N=128, mdn
= 1.0; U=2928, p<.02). Thus, youth, lack of time in treatment, cocaine
use, and sexual promiscuity were all associated with higher rates of needle
sharing. Nevertheless, the frequency of bleach use implies a specific
concern about HIV transmission, and the current avoidance of needle
sharing by most subjects (derived in part from their willingness to seek
sterile injection equipment available in area drug stores) offers one
explanation for the low HIV seroprevalence.
AFFILIATIONS: Veterans Affairs Medical Center and Department of
Psychiatry and Behavioral Sciences, University of Washington, Seattle
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Genesis of New York City’s
Experimental Needle Exchange
Program: Getting a Denigrated
Group on the Government Agenda
Cherni L. Gillman
It is imperative to investigate what governmental agencies are doing in
response to the AIDS epidemic among intravenous drug users (IVDUs). New
York City took three years to approve a small experimental needle exchange
program. This case study demonstrates how a private advocacy organization
influenced gaining assent for this program in 1988.
Broad forces in New York City determine governmental response to an issue
as controversial as a needle exchange program for addicts at risk for AIDS.
This study identifies these forces and analyzes the policy formulation of the
needle exchange program from a sociological perspective. It shows that when
dominant political forces perpetuate a status quo and fail to respond to an
epidemic, a private advocacy organization representing a competing ideology is
‘needed to compel the government to act.
The study employs a tri-level framework of inquiry. It reviews the stark data
of the wider context of AIDS among IVDUs: the federal Centers for Disease
Control (CDC) estimate that at least 50% of New York City’s 200,000 addicts
test positive for HIV, human immunodeficiency virus, the virus that causes
AIDS.
The arrangements of power that have culminated in a deadlock are discussed:
our dominant legal and medical structural interests label illegal drug use as
either a crime or a disease. Their priority is using punishment or treatment to
fight action instead of formulating strategies to prevent AIDS. The issue has
thus been turned into a choice between combatting addiction or AIDS.
This analysis characterizes ADAPT (the Association for Drug Abuse Prevention
and Treatment) as a repressed structural interest engaged in agenda-building
to protect the health needs of intravenous drug users. New York City’s
Department of Health is seen as a challenging structural interest because its
mandate is prevention, not reforming human behavior (whether through treatment
or punishment).
The concrete strategies engaged in by ADAPT to activate governmental response
to the plight of intravenous drug addicts in the AIDS epidemic are discussed
in careful detail. These include enacting the environment by taking a pro-
active rather than a reactive stance; increasing the organization’s political
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activity; reaching for sources of support from those it serves; and incorporating
symbolic elements to broaden its appeal.
The thesis of this paper is that a public health model is fighting to gain
prominence as a competing ideology in order to challenge the status quo of
health care for IVDUs in New York City. This competing ideology is
necessarily represented by an external agent because governmental response
by elected officials, health departments and law enforcement personnel is not
easily achieved.
The research presented was conducted as a case study because the focal
event  (approval  of  the needle  exchange program) occurred within a
circumscribed area (New York City) and time (1988). The comprehensiveness
that case study offers was another reason for choosing this method. Since the
needle exchange is the city’s only new project investigating how to formulate
AIDS prevention efforts among IVDUs, it merits close examination. There are
no analogous city programs with which to compare it. Additionally, case
study has been used to investigate controversy and legislation surrounding other
public health issues (such as child abuse, flouridation and smoking in public
places) which are similar to analyzing governmental response to AIDS among
IVDUs.
AFFILIATION:
Narcotic and Drug Research, Inc.
11 Beach Street, 3rd Floor
New York, N. Y. 10025
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Dr. Cherni L. Gillman
771 West End Ave. #2A
New York, N. Y. 10025
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Responses to I.V. L-Tryptophan in
MDMA Users
L. H. Price, G. A. Rlcaurte, J. H. Krystal and G. R. Heninger
Methylenedioxymethamphetamine (MDMA or “Ecstasy”)
is a recreational drug and putative adjuct to
psychotherapy that has proven to be a selective serotonin
(5-HT) neurotoxin in laboratory animals. We assessed
the long-term effects of MDMA use on 5-HT function by
comparing the responses to the 5-HT precursor,
tryptophan (TRYP) in MDMA users and matched healthy
subjects.
METHODS: Nine MDMA users (7 male, 2 female; mean
age of 34 ± 7(SD) years) and Nine Healthy subjects (7
male, 2 female, mean age of 33 ± 8 years) participated in
testing. MDMA user total accumulative MDMA dose was
13.3 ± 13.4 g. They last used MDMA 66 ± 50 days prior to
testing. After an overnight fast, TRYP, 7 g., was infused
intravenously over 20 minutes.
Serum prolactin (PRL) and subjective mood ratings were
obtained before and 90 minutes post-infusion. Between
group data were analyzed using 2-tailed Wilcoxon
Signed-Ranks Tests and within subject data were
analyzed using 2-tailed Mann-Whitney U Tests.
RESULTS: In the control group, TRYP caused significant
increases over baseline in the peak PRL response (11.0 ±
13.1 ng/ml, p<.008) and the area under the curve (AUC)
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of the PRL response (568.8 ± 762.5 ng-min/ml, p<.02). In
the MDMA group, peak PRL change (5.9 ± 8.5 ng-ml/min,
p<.07) and the AUC PRL response (224.8 ± 491.9 ng-
min/ml, p<.09) did not differ statistically from baseline or
controls. Also, mood responses to TRYP did not differ
between groups. Peak PRL TRYP response was 46% lower
and AUC PRL response was 60% lower in MDMA users
than controls.
COMMENT; In light of recent preclinical evidence that
hypothalamic 5-HT systems may be relatively resistant
to MDMA neurotoxicity, this study provides suggestive
evidence of diminished 5-HT function in MDMA users.
AFFILIATIONS:
Yale University School of Medicine
New Haven, CT
and
Johns Hopkins University School of Medicine
Baltimore, Maryland
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Human D-Amphetamine Drug
Discrimination: Testing With D-
Amphetamine and
Hydromorphone
R. J. Lamb and J. E. Henningfield
Experimental studies have shown that a wide variety of drugs can serve as
discriminative stimuli, and researchers have speculated that these discriminative
stimulus effects are similar to the subjective effects measures used in many human
studies. This study examined whether humans with histories of stimulant and
opioid abuse would learn to discriminate the effects of d-amphetamine, and
whether hydromorphone would then occasion amphetamine-approrpiate
responding. Further, this study collected self-reports of the subjective effects of
d-amphetamine and hydromorphone in order to examine to what extent the
subjective effects of these two drugs co-vary with their discriminative effects.
METHODS
Five male subjects with histories of both stimulant and opioid abuse were trained
to discriminate the presence and absence of d-amphetamine (30 mg po). Subjects
responded under a second-order color-tracking procedure. Discrimination
sessions were held 3-hours after drug administration. On their initial training
session subjects were administered the training dose of d-amphetamine, and told
this is drug A; when you receive drug A, you can earn extra money by
responding on the green lever, when you do not get drug A, you should respond
on the red lever to earn extra money. Subjects, also, completed a battery of
subjective effects forms on a computer at 0.5, 1.0, 2.0, and 4.0 hours after drug
administration. Subject vital signs were collected at these time-points as well.
The subjective effects battery included the Single Dose Questionnaire, the MBG,
LSD, PCAG, BG, and A scales of the Addiction Research Center Inventory
(ARCI), and analog ratings of drug-liking, drug-produced good and bad effects,
and drug strength.
RESULTS
Subjects readily acquired this discrimination. Administration of the training dose
of d-amphetamine occasioned increases in self-reports of feeling the drug, reports
of the drug being most like a stimulant, the MBG and A scales of the ARCI,
reports of drug-liking, and decreases in reports of the drug being most like a
blank.
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After acquisition of the discrimination, test sessions with various doses of d-
amphetamine and hydromorphone were held. Administration of d-amphetamine
(3.75-45 mg, p.o.) produced dose-related increases in amphetamine appropriate
responding. Administration of hydromorphone (1-12 mg, po) did not occasion
d-amphetamine appropriate responding.
Administration of d-amphetamine produced dose-related increases in reports of
drug-liking, the MBG and A scales of the ARCI, reports of feeling the drug, and
decreases in reports of the drug being most like a blank.
Administration of hydromorphone produced dose-related increases in reports of
drug-liking, the MBG and A scales of the ARCI, reports of feeling the drug, and
decreases in reports of the drug being most like a blank. These effects were
similar in magnitude to those produced by d-amphetamine.
Administration of d-amphetamine produced dose-related increases in reports of
the drug being most like a stimulant, while hydromorphone produced dose-related
increases in reports of the drug being most like dope. Conversely, administration
of d-amphetamine did not produce dose-related increases in reports of the drug
being most like dope, nor did hydromorphone produce increases in reports of the
drug being most like a stimulant.
During test sessions, in 16 of 16 sessions in which responding was on the
amphetamine-appropriate lever at least one report of the drug being most like a
stimulant was made; conversely, in none of the 24 sessions that responding was
not on the amphetamine-appropriate lever was there at least one report of the drug
being most like a stimulant. In contrast, the discrimination performance did not
similarly parallel other self-report measures, such as reports of drug-liking or
responses on the MBG or A scales of the ARCI.
DISCUSSION
In this study subjects readily learned to discriminate the effects of the training
dose of amphetamine. Administration of various doses of amphetamine led to a
dose-related increase in amphetamine-appropriate responding. Increases in
amphetamine-appropriate responding were accompanied by changes in self-report
measures. Administration of various doses of hydromorphone did not occasion
amphetamine-appropriate responding, despite that the administration of
hydromorphone led to similar increases in most self-report measures as were seen
after amphetamine administration. The one measure that clearly distinguished
between hydromorphone and amphetamine were reports about which drug the
administered drug was most similar to. These drug identification results were
closely correlated with the drug discrimination results. In test session on which
responding occurred on the amphetamine-appropriate lever, subjects always made
at least one stimulant identification; In the 24 test sessions were subjects did not
respond on the amphetamine-appropriate lever there were no sessions in which a
subject made a stimulant identification.
These results indicate that subjects with history of stimulant and opioid abuse can
learn to discriminate the effects of d-amphetamine, that this discrimination can be
drug class specific, and that this discrimination behavior is highly correlated with
reports of the drug being most like a stimulant.
A F F I L I A T I O N : U n i v e r s i t y  o f  M e d i c i n e  &  D e n t i s t r y ,  C a m d e n ,  N .  J .
N a t i o n a l  I n s t i t u t e  o n  D r u g  A b u s e ,  A d d i c t i o n  R e s .  C t r . ,  B a l t i m o r e ,  M D
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Alcohol Effects on Plasma
Estradiol Levels Following LHRH
Administration to Women
Jack H. Mendelson, Nancy K. Mello, Siew Koon Teoh and
James Ellingboe
Alcohol abuse and dependence may cause severe disorders of menstrual cycle
function in women, including persistent amenorrhea, anovulation, luteal phase
dysfunction and ovarian pathology. The purpose of this study was to determine
the effects of alcohol on anterior pituitary and gonadal hormones following
LHRH stimulation in normal women. Plasma levels of estradiol (E2),
luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin and
progesterone were measured in adult women prior to and following intravenous
administration of 100 mcg luteinizing hormone releasing hormone (LHRH) and
oral intake of 0.694 gm ethanol per kilogram of body weight or placebo. These
studies were carried out during both the follicular (N=12) and luteal (N=12)
phases of the menstrual cycle. Mean peak blood ethanol levels of 113 to 122
mg/dl were detected 45 to 60 min following initiation of alcohol intake. LHRH
stimulated a significant increase in LH, FSH and prolactin during the follicular
and luteal phases of the menstrual cycle (P < 0.001), but there were no
significant differences in stimulated hormone levels between the alcohol and
placebo conditions. Plasma E2 levels did not increase significantly after LHRH
administration and placebo, but there was a marked increase in plasma E2 levels
(P < 0.0001) after concurrent administration of LHRH and alcohol. The
increase in plasma E2 after concurrent LHRH and alcohol administration
exceeded baseline plasma E2 levels by 60%. The alcohol-induced stimulation of
E2 following LHRH administration may be due to changes in steroid
biotransformation by the liver as a consequence of alcohol’s effects on
intrahepatic metabolic processes. It is also possible that alcohol has a direct
effect on ovarian steroidogenesis of E2 following administration of LHRH. We
conclude that the alcohol-induced increase in E2 may contribute to suppression
of folliculogenesis with resulting anovulation and luteal phase dysfunction.
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Substance Use and Receipt of
Treatment in Persons with Recent
Spinal Cord Injuries
Sidney H. Schnoll, Allen W. Helnemann, Matthew Doll and
Kevin J. Armstrong
This study assessed the rate of self-reported substance use, con-
sequent problems, perceived need for treatment, and receipt of
treatment by persons with long-term spinal cord injury (SCI). In-
formation was obtained from 86 persons with traumatic SCI who were
between 13 and 58 years at injury, cognitively intact, injured more
than one year, English speaking, and recruited from two SCI organ-
izations. The mean age was 39.5 years at recruitment; and 69% were
men. Participants were assessed at two time periods 1 year apart.
They reported on drug use during four periods in their lives: 1)
the time prior to their SCI (Before SCI); 2) the time after their
SCI (titer SCI); 3) the 6 months prior to the 1st assessment (1st
Assess) and 4) the period between the 1st and 2nd assessment (2nd
Assess). The drugs reported on were diazepam (DIAZ), sedative-
hypnotics including other benzodiazepines and non-barbiturate sleep-
ing pills (S-H), barbiturates (BARBS), stimulants other than cocaine
(STIMS), codeine containing analgesics (COD), propoxyphene contain-
ing analgesics (PRPXY), narcotic analgesics other than codeine and
propoxyphene (NARCS) , ethanol (ETCH) , marijuana (MJ) , and cocaine
(COKE). All of the participants reported use of substances with
abuse potential at some time in their lives: the time of greatest
use was during the immediate post-injury time period. Use was de-
fined as use on three or more occasions.
Figure 1 shows drug use patterns across all of the time periods.
In all drug categories, use increased immediately after SCI with a
reduction in use over time. Over 60% of the sample used alcohol
prior to SCI with 55% still using at the time of the last assess-
ment . Over 20% of the sample were still using marijuana at the
time of the last assessment and cocaine use returned to pre-SCI
use levels.
Figure 1
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Problems related to drug use (Figure 2) were greatest after SCI ex-
cept for alcohol and marijuana. With these two substances, problems
were greatest before SCI. In all drug groups, the number of sub-
jects reporting problems decreased over time. Of the prescription
drugs, diazepam, the most frequently prescribed drug, created the
most problems. Problems with the non-prescription drugs were higher
than for the prescription drugs with cocaine sharing the largest
number of problems in relation to the number of users.
Figure 2
Few of the subjects reporting problems reported needing help (Figure
3) . Most often help for drug use was perceived either before SCI
or after SCI. Of the subjects using cocaine after SCI, 1/3 re-
ported needing help. Of those reporting need for help, very few
actually received help: diazepam, 1% before and after SCI; seda-
tive-hypnotics, none; barbiturates, none; stimulants, none; codeine,
1% before SCI; propoxyphene, 1% after SCI; narcotics, 2% before and
after SCI, 1% at 1st assessment; alcohol, 1% after SCI; marijuana,
1% after SCI; and cocaine, 2% after SCI.
Figure 3
Participants who reported a need for treatment regarding substance
abuse did not receive treatment for a variety of reasons. Twelve
percent of the sample reported changing their mind, 8% did not re-
ceive treatment because they thought they could not change their
use, 3% reported that they could not afford treatment, 3% reported
they did not know where to get help, 3% reported that others said
that treatment was not necessary, and 28% endorsed "other" as the
reason they did not receive treatment and specified that they felt
they could change themselves.
Abuse of both prescription and nonprescription drugs was reported,
suggesting the importance of close monitoring of patients with his-
tories of substance abuse and who are prescribed sedating, tranquil-
izing, or narcotic medications. The proportion of persons reporting
substance use on 3 or more occasions varied from substance used and
the time of the assessment. Further, 70% of the sample reported
one or more problems related to substance use; 16% reported believ-
ing they needed treatment for their substance use while only 7% re-
ported receiving treatment.
A f f i l i a t i o n :  M e d i c a l  C o l l e g e  o f  V i r g i n i a / V i r g i n i a  C o m m o n w e a l t h  U n i v .
R i c h m o n d ,  V A ,  I l l i n o i s  I n s t i t u t e  o f  T e c h n o l o g y ,  C h i c a g o ,  I L . ,  a n d
N o r t h w e s t e r n  U n i v e r s i t y  M e d i c a l  S c h o o l ,  C h i c a g o ,  I L
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Effect of Dose on Nicotine’s
Withdrawal-Suppressing, Adverse
and Discriminative Stimulus Effects
in Humans
John R. Huges, Steven W. Gust, Robert M. Keenan and
James W. Fenwick
Seventy-eight smokers were randomly assigned to 0,
0.5 mg (1 mg unbuffered), 2 mg and 4 mg doses of
nicotine gum. Withdrawal, side effects and
discrimination of active gum were measured via
observer and self-report 1 week post-cessation.
Higher doses did not more effectively suppress total
self-reported or observed withdrawal
(0.5=2.0=4.0>0.0). Impatience and irritability were
more dose related than other withdrawal symptoms.
Higher doses increased total side effects in a
linear fashion (4.0>2.0>0.5>0.0) and especially
increased vomiting and stomachache. Higher doses
also did not induce more accurate discrimination of
active vs placebo gum (0.5=2.0=4.0>0.0). The
ability of low dose nicotine to relieve withdrawal
and be classified as active gum could be due to
overcoming a low threshold or to a combination of
subtle peripheral effects plus instructional effect.
Whatever the reason, our results suggest the shape
of the dose-response curve varies across nicotine's
withdrawal-suppression, adverse and discriminative
stimulus effects.
AFFILIATION
Human Behavioral Pharmacology Laboratory,
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The Effects of Smoking
Deprivation on Caloric
Consumption in Women With
Bulimia Nervosa
Cynthia M. Bulik, Ronald Dahl, Leonard H. Epstein and
Walter Kaye
INTRODUCTION
It has been clearly established that smokers weigh less than
comparable non-smokers and that cessation of smoking generally
results in weight gain. The inverse relation between smoking and body
weight  is  known to  the general  publ ic  and is  an important
motivational factor for smokers. Given preliminary survey findings of
high rates of smoking in inpatient women with bulimia nervosa (75%
in comparison to the 25-50% rate recorded in the young adult female
population by the United States Public Health Service), we chose to
further examine this relationship by studying the effects of smoking
deprivation on eating behavior in women with bulimia nervosa who
were regular smokers. We hypothesized that: 1) caloric consumption
would increase under laboratory non-smoking conditions; 2) the effect
of smoking on caloric intake would be dose dependent; and 3) urges
to binge would increase under non-smoking conditions.
METHODS
Five women between the ages of 21-30 who met DSM III-R criteria for
bulimia nervosa and who were regular smokers participated in a
within subjects design. Each session lasted from 8 am-12 pm on four
consecutive days. Subjects first had an habituation day and then
were randomly assigned to order of presentation of regular smoking
(RS), low nicotine (LN), and non-smoking (NS) conditions. Subjects
were asked to abstain from both eating and smoking from 9 pm prior
to each study day. Expired air COa measures were taken before and
after each session.
The study was conducted in a research room equipped with vending
machines from which. all food and cigarettes were dispensed and
automatically recorded on a connected computer. Uneaten portions
were subtracted from the original weight to determine amount
consumed. Caloric content was determined using the United States
Department of Agriculture Handbook 456.
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On each of the experimental days, subjects ate ad lib. On the RS day,
subjects smoked their own brand of cigarette each half hour on cue.
On the LN day they smoked Carlton cigarettes (0.2 mg nicotine) with
a 76% extraction filter (holder). On smoking days, puff duration and
interval were prescribed. On the NS day subjects drew lines each half
hour on cue. Subjects used cigarette holders on each day to control
for consistency. Events were controlled by the audio portion of a
videotape. There was no experimenter contact throughout the session.
RESULTS
All subjects complied with the non-smoking request (COa<13 ppm).
The post-session COa measures were: RS (43.6 ppm; range 36.5-49.5);
LN (20.6 ppm; range 14.0-24.5); and NS (9.06 ppm; range 5.5-15.5).
Data were analyzed using a repeated measures analysis of variance.
Average caloric intake across the three experimental conditions was:
RS (477.8 kcal ± 295.2), LN (509.1 kcal ± 206.5), and NS (832.0 kcal
± 405.8) (F=5.07, p<.04). Neuman-Keuls post-hoc significance tests
indicted that the non-smoking condition was significantly different
than both of the smoking conditions, but that the smoking conditions
did not differ from each other. Two subjects approached binge levels
of consumption (1116 and 1398 kcal) on the NS day.
Macronutrient composition of food eaten indicated that calories of fat
consumed were significantly greater in the NS condition (208.3 kcal
± 148.1) than in the RS (110.2 kcal ± 107.8) or LN (115.4 kcal ± 72.0)
conditions. Fat consumption did not differ between the LN and RS
days. Calories of proteins and carbohydrates did not differ across
conditions. There were no significant differences in self-reported urges
to binge across the three experimental days.
CONCLUSIONS
In conclusion, this study demonstrated that caloric consumption
increases under laboratory non-smoking conditions in women with
bulimia nervosa who are regular smokers, and that smoking may
serve to modulate food consumption in this population. Behavioral
economic theory suggests that in their usual environment, both
cigarettes and food are available as reinforcers to these individuals.
When constraints are placed on access to one reinforcer (cigarettes),
the value and hence rate of consumption of the alternative reinforcer
(food) increases. Additional studies using more controlled methods of
smoking self-administration as well as non-nicotine cigarettes will aid
in the further determination of the effects of dose and the relative
contribution of the behavioral and pharmacological aspects of smoking
to the observed effect on caloric intake in women with bulimia.
University of Pittsburgh School of Medicine, Department of Psychiatry
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Zolpidem and Triazolam in
Humans: Behavioral Effects and
Abuse Liability
Surette M. Evans and Roland R. Griffiths
Zolpidem, an imidazopyridine, is a novel non-benzodiazepine structurally, which
binds preferentially to central omega1 receptor subtypes. The pharmacological
profile of zolpidem is in general similar to that of benzodiazepines although
zolpidem appears to be preferentially active as a hypnotic and seems to lack some
of the undesirable effects of benzodiazepines such as residual effects the next day
and decrements in memory. At this time zolpidem is marketed in Europe as a
hypnotic. The present study was undertaken to provide information about the
behavioral effects and abuse potential of zolpidem by directly comparing zolpidem
to the currently marketed benzodiazepine hypnotic, triazolam, in subjects with
histories of sedative abuse.
In an outpatient setting the acute effects of placebo, zolpidem (15, 30 and 45 mg)
and triazolam (0.25, 0.5 and 0.75 mg) were assessed using a double-blind,
cross-over, randomized design. Subjects were 15 healthy male volunteers with
histories of sedative and/or alcohol abuse. Drug effects were assessed with
objective performance tasks, observer ratings of drug effect and subject ratings of
strength of drug effect, mood, drug liking and monetary street value.
Both triazolam and zolpidem produced dose- and time-related effects on
subjective and behavioral measures. The onset of drug effect was rapid for both
drugs; usually by 30 min to 1 hr there were detectable effects. Analysis of time to
peak drug effect for the 2 highest doses of triazolam and zolpidem showed no
difference between the two drugs.
Both triazolam and zolpidem produced dose-related decrements in performance
on a variety of psychomotor tasks including balance, circular lights, enter and
recall, digit symbol substitution test and reaction time. On the picture
recall/recognition task all doses of triazolam decreased the number of pictures
recalled immediately after presentation whereas only the highest dose of zolpidem
decreased the number of pictures recalled. On delayed recall, all doses of
triazolam and zolpidem produced significant decreases. The analysis of variance
comparing the two drugs showed that triazolam produced significantly more
impairment than zolpidem on both immediate and delayed recall.
There was a dose-related increase in the percentage of subjects identifying
triazolam as a sedative, up to a maximum of 87% at 0.75 mg triazolam. At the
two lower doses, zolpidem was identified as a sedative to the same extent as
431
triazolam. However, at the highest dose of zolpidem only 33% of subjects
identified the drug as a sedative.
Both drugs produced dose-related increases on observer-rated strength of drug
effect. There were also dose-related increases in subject ratings of strength of
drug effect and drug liking for both drugs. In contrast, zolpidem. but not
triazolam, significantly increased subject ratings of bad effects, anxious/nervous,
light-headed/dizzy and queasy/sick to stomach. In addition, there were 8
incidents of vomiting following zolpidem administration and none following
triazolam administration. Overall, the results suggest that zolpidem and triazolam
produce similar effects on objective performance measures, observer-rated
measures and subject-rated measures such as strength of drug effect and drug
liking. Unlike triazolam, however, zolpidem also produces a profile of adverse
subjective effects which may limit the abuse potential of this drug. Supported in
part by NIDA Grant DA-03889.
AFFILIATION
Department of Psychiatry and Behavioral Sciences, The Johns Hopkins
University School of Medicine, Baltimore, Maryland 21224
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Can Buspirone Substitute for
Benzodiazepines in all Anxious
Patients?
Richard I. H. Wang, Domingo Tiuseco, Byung L. Roh,
Jung-Ki Cho and Carol Kochar
In the search for antianxiety agents devoid of some of the
undesirable effects of the benzodiazepines, the non-
benzodiazepine, buspirone was investigated. Buspirone was shown
to have tranquilizer activity. It has little or no sedative
effect and it lacks anticonvulsant and muscle relaxant action. It
does not interact with other CNS depressants including alcohol.
It does interact with dopamine receptors in the brain and is
believed to have dopamine agonist as well as antagonist activity.
Buspirone produces no effect on the GABA system and does not bind
to the benzodiazepine receptor.
Because of the lack of abuse potential plus its antianxiety
activity without sedation, buspirone appeared to be an ideal
compound for 3 groups of our patients: 1) patients with
generalized anxiety disorders on the methadone maintenance
Program, 2) patients who exhibit a great deal of anxiety and
craving for alcohol following the short period of acute alcohol
detoxification, and 3) patients with severe anxiety of a chronic
nature. In the first group of patients using various methods
including psycho-supportive therapy, we found the methadone
maintenance patients frequently used benzodiazepines which was
confirmed by urine surveillance. Upon confronting the patients,
we learned that they were taking diazepam, alprazolam, or
lorazepam, which they obtained from other physicians inside and
outside of our hospital and/or illegally through friends. In
order to reverse this noncompliance to treatment plans, six of
these patients on methadone maintenance participated in our
study. All were male patients. They were given buspirone 10 mg
TID for treatment of their benzcdiazepine dependence. Urine
surveillance was done twice per week. Anxiety rating scales were
completed before starting treatment with buspirone and weekly
thereafter. It was found that on buspirone 10 mg TID, the anxiety
score remained high and unchanged. The urine continued to show
positive for benzcdiazepines. These patients unanimously demanded
to discontinue the buspirone medication.
In our second group of post-alcohol detoxification patients, it
was expected that buspirone would have tremendous value in the
treatment of continued symptoms of anxiety, nervousness and
craving for alcohol. Eight patients who continued to have this
symptomatology participated in the buspirone study. The same
urine surveillance and rating forms were done before starting
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buspirone and weekly thereafter. Psycho-supportive therapy
continued as usual. At the end of one and two weeks of treatment
with buspirone, it was found that there was no imporvement of
symptamatology. Because of this, buspirone medication was
discontinued and patients were placed on low doses of
benzodiazepines.
The third group of patients with chronic severe anxiety received
buspirone 10 mg QID for two weeks. All three patients continued
to experience severe nervousness. Cur lack of effectiveness of
buspirone in these three groups of patients was discouraging. It
indicated to us that a potentially non-dependent producing
antianxiety drug may not be available for our types of patients.
Looking into the existing literature on the clinical efficacy of
buspirone, one finds two types of therapeutic responses. One
group of workers found buspirone to be equivalent to diazepam,
chlorazepate, alprazolam or lorazepam. The other group of workers
found buspirone to be ineffective in relieving anxiety,
particularly on any patient previously taking benzodiazepines. A
possible explanation for the effectiveness of buspirone is the
fact that a large percentage of patients in the study were
female. Some important points were not taken into amount, such
as, there was a week of placebo washout before the study. This is
a condition usually unsuitable for patients with reasonable
degrees of severity in anxiety to stay on the study. There was
also sizable dropout, not only among placebo patients but also on
the active medications.
It should be pointed out that it is unusual for the physicians to
tell their patients not to expect an overnight success after
taking buspirone, and it is impractical to forewarn the newer
patients that a maximal antianxiety effect may take 2 to 3 weeks.
Only the mildly anxious patients can withstand the lengthy delay
for the onset of therapeutic action. In summary, we have studied
3 types of patients with generalized anxiety disorder requiring
anxiolytic therapy. All three groups of patients, whether they
were on methadone maintenance program, post-acute alcohol
detoxification or chronically severe anxiety patients, failed to
respond to the carefully and strenuous treatment with buspirone
10 mg TID to 10 mg QID for 2-3 weeks. Clinics are confronted with
the problem of misuse and abuse of benzodiazepines. In view of
the controversy of the existing findings on the efficacy of
buspirone, better controlled studies are needed to assess the
role of buspirone in the treatment of anxiety in a variety of
patients.
REFERENCES furnished upon request.
AFFILIATION: V.A. Med. Ctr., Med. Col. of WI., Milwaukee, WI
53295
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Human Aggressive and Non-
Aggressive Responding During
Acute Tobacco Abstinence
D. R. Cherek, R. H. Bennett, J. D. Roache and J. Grabowski
Four male tobacco smoking subjects have participated in a study
to determine if changes in human operant behavior can be
detected during brief eight hour exposure to tobacco abstinence.
Subjects remained in the experimental area from 8:00 AM to 4:30
PM five days per week. Each day subjects participated in five
sessions (25 min duration), beginning at 9:00AM, 1O:OOAM, 12:00
PM, 2:OOPM and 4:OOPM. At 8:30 AM each day: (1) an initial
carbon monoxide (CO) reading was taken, (2) an expired air
sample was taken for alcohol level determination and (3) a urine
sample was taken for drug screen analysis. Alcohol and drug free
samples were required. If the initial morning CO value was below
21 ppm, subjects were paid five dollars.
During the sessions, subjects could respond on lever A or B.
Lever A responding was maintained by a fixed-ratio (FR) 100
schedule of point-presentation (1 point = ten cents). Lever B
responding ostensibly subtracted points from a fictitious person
on an FR 10 schedule and was defined as aggressive. Aggressive
responding was engendered by subtracting points from the
subjects and maintained by initiation of 250 sec intervals free
of point subtractions. Point subtractions were attributed to the
other people participating in the experiment.
During the time (approx. 6 hrs) subjects were not in sessions,
they were exposed to four different experimental conditions.
Under baseline conditions, ad libitum smoking of their preferred
brand of cigarettes was permitted. At other times subjects were
exposed to three tobacco abstinence conditions during which
smoking was not permitted during the 8.5 hr experimental day:
(1) nicotine gum, (2) placebo gum and (3) no gum. Under nicotine
and placebo gum conditions, subjects were given two pieces of 2
mg nicotine or placebo gum to chew thirty minutes before each
session. Baseline conditions were in effect until operant
responding stabilized over 10-15 sessions. Subjects were then
exposed to one of the three tobacco abstinence conditions for an
entire day, and then returned to baseline conditions. These
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alternating conditions (baseline vs abstinence) continued until
subjects were exposed to each tobacco abstinence condition
twice.
All four subjects reported smoking thirty to fifty high nicotine
delivery cigarettes per day for ten or more years. Data
collected in the laboratory also indicated that subjects were
nicotine dependent: (1) subjects typically smoked about 20
cigarettes during the six hours of free time, (2) a blood sample
taken during participation indicated high nicotine intake with
cotinine values between 300-660 ng/ml, and (3) their answers to
the Fagestrom Questionnaire indicated a high degree of
nicotine/tobacco dependence (x=9.5).
Carbon monoxide (CO) measurements were taken at the end of each
session. These measurements indicated that subjects were smoking
throughout the day during baseline conditions, and subjects were
not smoking during abstinence conditions.
Compared to baseline ad libitum smoking conditions, all four
subjects had large increases in aggressive responding under the
no gum condition. Aggressive responding was increased somewhat
under placebo gum conditions, while under nicotine gum
conditions aggressive responding was unchanged.
Non-aggressive (responses maintained by point presentation)
remained essentially unchanged under smoking and abstinence
conditions.
Our results indicate that under laboratory conditions increases
in aggressive responding are observed when dependent tobacco
smokers are exposed to an eight hour period of tobacco
abstinence. These results are consistent with subjective reports
and clinical observations of increased irritability during
tobacco withdrawal.
This research was supported by NIDA grant DA 04044.
Substance Abuse Research Center
Department of Psychiatry and Behavioral Sciences
University of Texas Health Science Center at Houston
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Physical Dependence on and
Toxicity From Caffeine
John R. Hughes, Stephen T. Higgins, Warren K. Bickel,
William K. Hunt, and Sara Pepper
In Study 1, ten moderate coffee users underwent 4 -
6 independent, randomized, double-blind, cross-over
trials of one day of 4 cups of decaffeinated coffee
and one day of 4 cups of decaffeinated coffee + 100
mg of caffeine. This trial was immediately followed
by a test for self-administration of caffeinated vs.
decaffeinated coffees. Study 2 was a direct
replication using twelve subjects. The results were
similar across studies.
Headaches, drowsiness, and fatigue were
significantly greater on the decaffeinated coffee
days than on caffeinated coffee days and occurred
repeatedly in several subjects. Headaches,
drowsiness and fatigue were prevalent (40 - 60% of
trials) and were rated severe in a substantial
minority of trials (10% to 15%). The occurrence of
headaches, drowsiness, and fatigue on the
decaffeinated days predicted subsequent self-
administration of caffeinated coffees.
Anxiety, diuresis, dizziness, muscle twitches,
tinnitus, sweating, talkativeness and tremulousness
were greater on caffeinated coffee than on
decaffeinated coffee. These symptoms were less
reliable and prevalent and of a smaller magnitude
than the withdrawal symptoms. In addition, they did
not predict avoidance of self-administration of
caffeinated coffee.
AFFILIATION
Human Behavioral Pharmacology Laboratory,
Departments of Psychiatry and Psychology, University
of Vermont, Burlington, VT 05401
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Effects of Controlled Nicotine
Doses Upon Punished and Non-
Punished Responding in Humans
R. H. Bennett, D. R. Cherek, J. D. Roache and J. E. Rose
The study reported here investigated the effects of the
inhalation of tobacco smoke of varying nicotine content upon
punished and non-punished operant responding in humans. The
tobacco smoke was administered by the spirometry method which
controls puff volume and ensures introduction of the smoke deep
into the lungs.
Five male smokers (ages 23 - 37) participated in the study.
Subjects‘ drug and alcohol use was monitored during the course
of the study by urine analysis and daily breath alcohol
measurements.
Subjects responded on a Lindlsey manipulandum to obtain points
which accumulated on a digital counter. White and red stimulus
lights were mounted to the left of the counter. All
experimental conditions and data collection were controlled by a
micro computer located in an adjacent room.
The spirometry method of tobacco smoke administration was
utilized to administer a constant puff volume of the smoke deep
into the lungs. This is a self contained system into which air
is initially pumped into a 1 liter bag which is then clamped
off. A syringe is used to draw 60 cc of smoke from a cigarette
and injected into the system. The subject then inhales the
smoke and air through a mouthpiece once the system is opened.
The bolus of air behind the smoke forces the smoke deep into the
lungs. One 60 cc puff of smoke is administered every 30 seconds
during each administration period. Twenty puffs (10 from each
of 2 cigarettes) are delivered at each administration period.
Lever pressing was maintained by a random interval 20 sec (RI
20) schedule of point presentation (1 point = ten cents). A
punishment contingency which stipulated that points were
subtracted on a variable ratio 30 (VR30) schedule, was also in
effect. In the second half of the experiment, the punishment
contingency was removed.
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An experimental session consisted of two 20 minute components
(pre and post smoke administration) separated by a smoke
administration period. The subject's heart rate, blood
pressure, and carbon monoxide expired air level were measured
before and after each smoke administration. Subjects
participated in 4 sessions daily (M-F).
On baseline session days subjects received 0.3 mg nicotine yield
cigarettes during the smoke administrations. Experimental days
were separated by baseline days and an experimental day was
instituted only once baseline responding was stable. The three
experimental manipulations were 1.2 and 2.7 mg nicotine yield
cigarettes, and a sham procedure in which no smoke was delivered
through the apparatus. Subjects responding was punished during
the first part of the experiment and, once all three
experimental manipulations were experienced, the punishment
contingency was removed and experimental manipulations were
administered a second time.
Similar CO boosts were observed with each of the different
nicotine yield cigarettes. Mean heart rate changes (before and
after smoke administration) increased with increases in nicotine
yield of the cigarette indicating an effect of nicotine.
Mean change (before and after smoke administration) in punished
responding showed a dose-related decrease as a function of
nicotine yield. The sham procedure produced a mean increase of
23 responses while the 1.2 and 2.7 mg nicotine yield cigarettes
produced mean decreases of 30 and 48 responses respectively.
Three of the five subjects experienced the non-punished RI
schedule. Two subjects showed nicotine-induced increases and
one subject showed decreases in non-punished responding.
The CO boost and heart rate data showed that the spirometry
method of smoke administration was effective in administering
tobacco smoke in a controlled manner. The similar CO boosts
across nicotine yield cigarettes demonstrates a controlled smoke
delivery while a dose dependent increase in heart rate
demonstrates nicotine yield (dose) control. The nicotine
dose-related decrease in punished responding was similar to
previous observations with CNS stimulants. The data for the
non-punished responding was variable which may be related to
very different baseline response rates of the individual
subjects.
This research was supported by NIDA grant DA 04044.
Substance Abuse Research Center
Department of Psychiatry and Behavioral Sciences
University of Texas Health Science Center at Houston
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Effects of Delta-9-THC on
Repeated Acquisition and
Performance of Response Chains
in Humans
Warren K. Bickel, John Ft. Hughes and Stephen T. Higgins
Overall, generality of drug effects has been demonstrated
between humans and non-humans responding on the repeated
acquisition and performance of response chains. In the non-
human laboratory, AS-THC has been demonstrated to produce no
effects on monkeys and pigeons performing on the repeated
acquisition procedure. The purpose of this study was to
examine the effects of AS-THC on the repeated acquisition
procedure in humans.
METHODS
Subjects: Four healthy adult volunteers (3 females, 1 male)
between the ages of 21 and 32 served as subjects. Subjects had
prior experience with marijuana.
Procedure: The repeated acquisition and performance of
behavioral chains procedures was employed. The acquisition
component required subjects to learn a lo-response sequence
using three keys of a numeric keypad. The performance
component required subjects to emit an already learned 10-
response sequence on those same three keys. The keys had to be
depressed in a predetermined order in the presence of the
numbers 0-9, which appeared sequentially in the center of a
video screen. Correct responses resulted in the subject moving
to the next link in the chains. Incorrect responses initiated a
2-sec time-out, during which responding had no programmed
consequences. Subjects also completed Visual-Analog rating
scales of drug effects. Drug effects were assessed
immediately predrug and postdrug and 30 minutes thereafter
for 4 hours.
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Drua Administration: 9-THC was administered orally in two
opaque capsules. Doses were placebo, 10 and 20 mg. Subjects
were exposed to the doses in a randomized order. Generally
each dose was replicated three times.
RESULTS
Data from peak behavioral effect (4 hrs post-drug
administration) were analyzed. In the acquisition component,
overall percent errors generally increased under drug in three
subjects. In the performance component, overall percent errors
was generally unaffected by the drug. The selective effects
observed between acquisition and performance is reflected in a
cumulative plots of errors. The subject’s rating of “strength of
drug effect” and “good” effects were also increased by drug.
CONCLUSION
1. There were individual differences in the effects of 9-THC
on percent errors on the repeated acquisition of behavioral
chains. In three subjects, 9-THC produced increases in the
acquisition component, while no effect of dose was observed in
one other subject. This data may suggest that humans may be
more sensitive to the disrupting effects of 9-THC than
nonhumans
2. Doses of 9-THC that increased percent errors in the
acquisition component had no effect in performance; that is,
selective drug effects were obtained.
3. Drug produced changes self-report measures in all subjects.
Thus, the subject showing no increase in acquisition errors
received a behaviorally active dose.
ACKNOWLEDGEMENTS
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Methadone Maintenance: High
Rate of Other Substance Use
Disorders and Relationship to
Psychiatric Comorbidity
Robert K. Brooner, George E. Bigelow and Michael W. Regier
Opioid dependent, methadone maintained patients are known to
have high rates of non-opioid substance use. However, less is
known about diagnostic prevalence for specific classes of
psychoactive substances. The present study determined the
prevalence of DSM-IIIR diagnoses of Abuse or Dependence for a
complete range of substances, and analyzed the prevalence of
multiple substance-use diagnoses as a function of concurrent
(non-substance) psychiatric diagnoses.
Participants were 68 methadone maintained subjects enrolled
in an HIV testing and education program. All diagnoses were
made using a structured interview.
Lifetime rates of Abuse or Dependence were 55.9% for Cocaine,
53% for Sedative/Hypnotics, 47.1% for Marijuana, 47.1% for
Alcohol, 8.8% for Hallucinogens, 7.3% for other Stimulants
and 1.5% for Inhalants. Forty-eight percent of the sample was
positive for a non-substance use Lifetime psychiatric
disorder, primarily involving Antisocial Personality Disorder
(29%) and Major Depression (19%). A one-factor ANOVA revealed
significant differences in the mean number of non-opioid
substance use disorders for subjects with versus without any
non-substance use psychiatric diagnosis (p=.008). A greater
number of substance use diagnoses was found for subjects with
versus without psychiatric diagnoses (p<.05). Some of the
known problems in treating substance abusers with other
psychiatric disorders may result from these patients having a
more severe substance use clinical course.
AFFILIATION: The Johns Hopkins University School of Medicine
Baltimore, MD
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Human lmmunodeficiency Virus
and Viral Hepatitis Seroepi-
demiology in New York City
Intravenous Drug Abusers (IVDAs)
L. S. Brown, Jr., M. J. Kreek, C. Trepo, A. Chu, S. E. Banks,
M. Valdes, D. Ajuluchukwu, R. Phillips and B. j. Primm
INTRODUCTION
Both human immunodeficiency virus (HIV) and hepatitis virus in-
fections are prevalent medical disorders among intravenous (IV)
drug abusers. The offending viral agents commonly associated
with hepatitis among IV drug abusers include non-A/non-B hepati-
tis virus, hepatitis B virus (HBV), and hepatitis D virus
(HDV). Previous investigations have raised the question of the
efficacy of HBV immunity, conferred either through vaccination
or a previous history of HBV infection, in the presence of HIV
infection. Other researchers have shown that the pathogenesis
of HDV infection is linked to HBV antigenemia. Still other
questions remain as to the prevalence of concomitant HBV, HIV,
and HDV infection even in a high risk group such as IV drug
abusers. As a pilot to a larger HIV seroprevalence study, we
report the results of HIV and hepatitis serology in association
with behavioral information.
PATIENTS and METHODS
In October, 1987, 50 patients, enrolled in selected drug treat-
ment clinics in New York City volunteered to participate in a
human subject approved protocol. Twenty-eight percent of the
subjects were female and 72% were male. The ethnic/racial compo-
sition included 40% black, 50% Hispanic, and 10% non-Hispanic
white subjects. The ages ranged from 23-54 years with a mean of
34.4±1.0 (SEM) years. Duration of drug use ranged from 1-35
years with a mean of 15.8±1.2 years. Drug treatment enrollment
ranged from 1-180 months with a mean of 35.9±6.6 months.
Trained interviewers administered a standardized questionnaire
of demographic factors, drug abuse patterns and sexual behav-
iors, and medical information. Drug abuse patterns included
type of drugs, frequency, and duration of drug use. Type of sex
acts, frequency of sex, and number of sex partners were among
the sexual behaviors examined. Sera was collected and analyzed
for HIV-l antibodies using an enzyme-linked immunoassay (ELISA
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from Abbott Labs). A Western blot assay (Genetic Systems) was
used to confirm repeatedly positive ELISAs. Sera with p24
and/or gp41 bands on Western blot were considered positive. A
highly sensitive monoclonal antibody assay and a standard radio-
immunoassay, respectively, were used to detect the presence of
hepatitis B surface antigen (HBsAg) and hepatitis core antibody
(anti-HBc). Two different methods were used to assay for HDV
serological markers. For delta antigen, a commerical kit
(Noctech) was used with validation by one of us (CT). We used a
commercial kit (Abbott) and an assay developed and validated by
one of us to determine the presence of delta antibody. Using
SPSS-PC+, univariate analyses was used to examine associations
between positive HBV and HIV serology and other variables.
RESULTS
The HIV-l infection rate was 54% and 86% of the subjects had at
least one marker for HBV infection. Serological evidence of
anti-HBc, anti-HBs, anti-HBe, HBsAg, and HBeAg was found in 86%.
70%. 38%. 2%. and OX, respectively of the sample. No subject
had serological evidence of HDV infection. Of the 6, 5, and 46
subjects, respectively, who admitted to sex for money, sex for
drugs, and exclusive heterosexual behaviors, 50%. 60%, and
56.51, respectively, were HIV-l seropositive, while 83.3%. 80%,
and 84.81, respectively, had at lease one HBV serological mark-
er. For every sexual or drug abuse-related behaviors, HBV infec-
tion rates were higher than HIV-l prevalence rates. HIV-l infec-
tion was significantly associated with an older age (p=.011), a
longer duration of drug use (p=.000), and anti-HBc (p=.007) sero-
status. Serological evidence of at least one marker of HBV in-
fection was significantly associated with a higher mean age
(p=.002), a longer duration of drug use (p=.005), and a lower
rate of participation in anal intercourse (p=.003).
CONCLUSIONS
The rates of HIV and HBV infection in this population were con-
siderable in this population of patients enrolled in drug treat-
ment. Because of the small sample size, results of this study
must be interpreted with caution. Relatively long durations of
drug treatment enrollment among these subjects may explain the
low HDV infection rate. Two percent of patients with only HBV
antigenemia vere at risk for HDV. These findings are consistent
with similar mechanisms of transmission between HIV-l and HBV.
Most importantly, 14% of this population had no markers of HBV
infection and could benefit from HBV immunization. To the
extent that this finding is widespread, HBV vaccination among
drug treatment enrollees has significant public health benefits.
AFFILIATIONS: Division of Research and Medical Affairs, Addic-
tion Research and Treatment Corporation, Brooklyn, NY; Depart-
ment of Medicine. Harlem Hospital, College of Physicians and
Surgeons, Columbia University, New York, NY; Rockefellar Univer-
sity, New York, NY; and Faculte Alexis Carrell, Lyons, France.
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Stress and Emotional Distress as
Possible Co-Factors in the
Development of AIDS in a Sample
of Intravenous Drug Users
Veronica Catan
Intravenous drug users have been identified as a group at risk for AIDS. It is
important to identify co-factors which may compromise immune function and
determine host response in this group.
Stress and emotional distress were chosen as co-factors to examine for two
reasons: 1. Stressful life events occur more commonly among disadvantaged
populations (Mechanic, 1986), and 2. Stress and emotional distress have been
identified as factors in illness development.
The Sample
The sample consists of 147 intravenous drug users recruited at a methadone
maintenance program in New York City. They are part of a study on risk factors
conducted by Narcotic and Drug Research, Inc.
At entry into the study, none of the subjects had sought treatment for AIDS or
AIDS related complex.
METHODS
A face to face interview using a structured questionnaire was administered in
private. Information was gathered including medical history, drug using
behavior including injection frequency, sexual behavior, emotional distress and
mood, and frequency of occurrence of a number of stressful events. A follow-
up interview was conducted nine months later. Twenty five ml of blood were
collected from each subject at intake and at follow-up. HIV status and measures
such as total lymphocytes, T4 cells, T8 cells, B cells, IGA, IGM, IGG and
T4/T8 ratio were assessed.
Stressors which were assessed included chronic stressors such as homelessness
and hunger (missing more than 9 meals per week), and acute events, such as
losing a job, being arrested, and having a breakup of a close personal
relationship. Stress was measured for events during the year preceding the first
interview and during the nine months between time 1 and time 2. Distress was
measured by anxiety and depression symptoms over the 30 days preceding the
follow-up interview. Each distress item was scored between 0 and 5 depending
on the number of days reported. A variable was computed, noncope, to look at
equal weights of stress and distress combined.
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RESULTS
Clinical AIDS is preceded by severe depletion of CD4 cells. Therefore, decline
in CD4 cells has been used as a measure of HIV-related immunosuppression and
was used in this study. Neither stress nor distress was significantly associated
with decline in CD4 cell count for time 1 to time 2.
T-Tests comparing groups at time 2 who had less than 3 ARC symptoms (Group
1) and those who had more than 3 symptoms (Group 2) showed o significant
differences in means for stress. On distress, Group 1 had a mean of 11.4 and
Group 2 had a mean of 26.2 (p = .029). A computed variable giving stress and
distress equal weight called noncope had a mean of 26.6 for Group 1 and 46.2
for Group 2 (p = .003).
DISCUSSION
This research suggests that stressful events alone are not associated with
immunosuppression, but that stress combined with emotional distress may be
associated with illness development. There are conflicting models concerning
whether being ill is associated with distress or whether distress has some effect n
illness development. Further analysis is being done which may clarify this
issue.
AFFILIATION
Narcotic and Drug Research, Inc., 11 Beach Street, New York, NY 10013
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Intravenous Heroin Use: Its
Association with HIV Infection in
Patients in Methadone Treatment
A. Chu, L. S. Brown, S. Banks, T. Nemoto and B. J. Primm
INTRODUCTION
Intravenous (IV) drug use is closely associated with human immu-
nodeficiency virus (HIV) infection. The number of HIV infected
IV drug users continues to rise. It is well documented that the
sharing contaminated needles is an important mode of HIV trans-
mission, but little is known about the relationship of other
cofactors in HIV infection. This study examined the seropreva-
lence of HIV infection among IV drug users who were enrolled in
methadone maintenance program, and more specifically the role of
heroin use as a main factor in HIV infection.
METHODS
In 1987, 218 patients were recruited from methadone treatment
clinics in New York City. A standardized questionnaire asking
the patterns of drug use and demographics was administered by
trained interviewers and sera was collected and tested for HIV
antibody using enzyme linked immunosorbent assay (ELISA) and a
confirmatory Western Blot.
RESULTS
The HIV seropositivity rate was 60.1%. Those who were HIV sero-
positive reported significantly higher frequencies of intrave-
nous heroin use in the previous 12 months than those who were
seronegative (p=0.026). Intravenous heroin users were more
likely to be infected with HIV than non-IV users (p=0.040).
Serostatus was clearly associated with the age of first intrave-
nous drug use. The participants who started using heroin intra-
venously and were addicted at an early age were significantly
more likely to be HIV seropositive. Whites participants first
started using any drugs at a significantly younger age than
blacks or Hispanics (p=0.0466). Whites also reported injecting
heroin at a significantly younger age than blacks or Hispanics
(p=0.057). The study also indicated that needle sharing behav-
iors were significantly associated with HIV positive status.
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CONCLUSIONS
The IV heroin use -and an early age to start using heroin intra-
venously were strong predictors of HIV seropositive status. among
LVDUs. More efficient education especilly focusing on younger
age groups, is needed to stop AIDS epidemic among IVDUs.
AFFILIATIONS: Addiction Research and Treatment Corporation,
Brooklyn, NY and Harlem Hospital, College of Physicians and
Surgeons and Health Administration Division, School of Public
Health, Columbia University, New York, NY.
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Time Course of Detection of 6-
Acetylmorphine in Urine After
Heroin Administration
E. J. Cone and P. Welch
The confirmed presence of the heroin metabolite,
6-acetylmorphine (6-AM), in urine provides convincing
evidence that heroin exposure occurred in the recent
past. Presently, tests for detection of heroin use
are based on detection of morphine, although it is
recognized that sources of morphine in urine include
heroin, morphine, codeine and poppy seeds.
We determined the time course of 6-AM and morphine in
urine of 6 subjects following administration of
single doses (3 and 6 mg, intramuscular) of heroin
HCl. All subjects had a history of heroin abuse but
were drug-free at the time of the study. Individual
urine specimens were collected during the first 12-hr
period after drug; thersafter, each subject's urine
was collected as 12-hr pools. Specimens were frozen
until analyzed by GC/MS. The appearances of 6-AM and
morphine in urine were immediate. Levels of 6-AM
declined rapidly and were not detectable after 8 hr,
whereas morphine (total) was detectable for 18-24
hr. Overall, it appears that there is a very limited
time window for detection of 6-AM after heroin use.
Authors Affiliations: E.J. Cone and P. Welch,
Addiction Research Center, NIDA, Baltimore, MD
21224; J. Mitchell and B. Paul, Navy Drug Screening
Laboratory, NAS, Norfolk, VA 23511
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The Effects of 0.8 G.KG Ethanol on
Cerebral Metabolism and Mood in
Normal Volunteers
Harriet de Wit, John Metz and Malcolm Cooper
This study used positron emission tomography (PET) to evaluate the effects of a
moderate dose of ethanol (ETH; 0.8 g/kg) on cerebral glucose metabolism (GM)
in normal volunteers. The study explored the relationship between ETH-
induced changes in CM and ETH-induced changes in mood.
Eight male, light social drinkers (average 5 drinks/week, aged 21-29) received
two PET scans, during which they received either ETH (0.8g/kg) or placebo.
Subjects first consumed a beverage and then were positioned in the scanner and
injected with 6-8 mCi 18-FDG. During a 45-min period of FDG uptake, they
performed a visual monitoring task (button-pressing in response to a light). The
subjects’ moods were assessed using the Profile of Mood States (POMS) prior
to, and 20 and 40 min following beverage ingestion. Regional CM was
determined using Sokoloffs model with standard rate constants and 14 regions
of interest obtained from tomographic metabolic images.
In 7 out of 8 subjects, ETH decreased whole brain CM (means: placebo 8.88
mg/100g/min and ETH 8.40 mg/100g/min). None of the regions of interest
were affected differentially by the drug. All subjects reported liking ETH more
than placebo, and 6 out of 8 correctly identified the drug as ETH. The drug did
not impair performance on the visual monitoring task but it did significantly
increase measures of positive mood (e.g. POMS scales Vigor, Friendliness,
Elation). Regional changes in CM were not correlated with relative changes in
mood after ETH.
This dose of ETH had more consistent effects on CM and mood than a
previously-tested, lower dose of ETH (0.5 g/kg): Most subjects exhibited
decreased global CM, and all subjects reported increases in positive mood.
Perhaps because of the relative homogeneity of responses to ETH, no
relationships were found between regional CM and mood.
This research was supported by DE-AC02-86ER60438, the Alcoholic Beverage
Medical Research Foundation and DA02812.
Department of Psychiatry, Pritzker School of Medicine, University of Chicago,
Chicago, IL 60637
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A Dose Run-Up and Safety
Evaluation of Nalmefene HCL in
Human Volunteers
Paul J. Fudala, Rolley E. Johnson, Stephen J. Heishman,
Edward J. Cone and Jack E. Henningfield
Four non-dependent, male volunteers (25 to 37 years of age) with
histories of opioid abuse participated in a dose run-up/safety
assessment of oral nalmefene HCl, 25-500 mg. Subjects received
two capsules (containing nalmefene HCl or placebo) by mouth and
an intramuscular injection (containing morphine sulfate, 15 mg or
placebo) at intervals of at least 72 hours between doses.
Morphine sulfate was always administered as the first treatment
condition to ensure that subjects could discriminate opioid-like
effects. One subject discontinued his participation for
non-study related reasons after receiving nalmefene 25 mg and one
discontinued participation after receiving 150 mg due to
self-reported dysphoric effects. The highest doses tested in the
two remaining subjects were 300 and 500 mg, respectively.
Since this was a non-randomized evaluation, no statistical
analyses were performed on the data. While it appeared that
nalmefene, at the doses tested, did not produce pupillary
constriction or changes in any of the other physiologic para-
meters assessed (blood pressure, heart and respiratory rate, and
oral temperature) morphine apparently produced pupillary
constriction. Nalmefene produced elevations on LSD (dysphoria)
and PCAG (apathetic sedation) scale scores in three of the
subjects: morphine produced elevations of these scores in one
subject. Only morphine produced apparent elevations on MBG
(euphoria) scale scores (three subjects). Of the 15 times that
nalmefene was administered, it was identified by subjects as an
opiate on only 2 occasions while morphine was always identified
by subjects as an opiate. Specifically, subjects identified
nalmefene as blank (placebo), opiate, marijuana, Valium, downer,
LSD, Thorazine, PCP, and "unknown, strange."
Subject-reported side effects (from a 10-item checklist)
following nalmefene administration included "tiredness and
sleepiness," "lightheadedness," and "dizziness." Subjects also
volunteered reports (not part of the structured checklist) of
"aching legs" and "unwanted erections." One subject reported
that he felt violent and "strange" after receiving nalmefene,
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75 mg, while another reported that he "felt as if he could fly"
following 300 mg of the drug. No such descriptions followed the
administration of morphine or have been reported following the
administration of nalmefene in healthy volunteers in other
studies.
Data obtained from this evaluation will be used to assess the
physiologic and behavioral effects of nalmefene HCl in a
double-blind, crossover study, and also to determine the
appropriate dosages of nalmefene to be used in an assessment of
its opioid-blocking activity.
AFFILIATION: NIDA Addiction Research Center, Baltimore, MD.
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Comparison of the Behavioral
Effects and Abuse Liability of
Ethanol and Pentobarbital in
Recreational Sedative Abusers
John J. Guarino, John D. Roache, William T. Kirk and
Roland R. Griffiths
The similarities in the behavioral and psychomotor
performance effect profile of ethanol and other
sedative-hypnotics have long been recognized. Lacking,
however, is a clear understanding of the relative abuse
liability of ethanol to the other sedative-hypnotics. In
previous studies from this laboratory, the dose-related
behavioral, subjective and psychomotor performance impairing
effects and the abuse liability of a number of drugs have
been compared to standard drugs with known abuse liability.
The purpose of this study was to investigate the dose-related
effects of ethanol for a number of behavioral, psychomotor
and subjective measures and particularly, for measures of
abuse liability, and to compare the results with those
obtained with a prototypic barbiturate, pentobarbital, under
identical laboratory conditions.
Subjects were 8 healthy males with histories of alcohol
and/or sedative abuse. Subjects resided on an 8-bed
residential research ward throughout the study. A period of 3
to 7 days on the research ward were allowed for
acclimatization to the tasks and the environment before
dosing began. Subjects received doses of ethanol (0.5, 1 and
2 gm/kg or pentobarbital (150, 300, 600 and 750 ng/70 kg) in
a within-subject double-blind, double-dummy Latin square
design. Each day subjects received both a powdered fruit
drink mix containing placebo or pentobarbital and orange
juice with or without ethanol. On any given day placebo or
an active dose of either ethanol or pentobarbital was
administered. Each day, repeated measures were made of
ethanol blood levels (BAL), objective performance (e.g.,
DSST, circular lights), subject and observer ratings of drug
effect, and subject ratings of drug liking, mood and
subjective drug effects. Data were analyzed as either raw
scores, differences from baseline or percent of predrug
performance.
The peak effect for most measures was between 1.5 and 3.5
hours after dosing for both pentobarbital and ethanol; higher
doses required longer to attain peak effect and effects of
these higher doses persisted longer. BAL recordings were
orderly with respect dose and time and were consistent with
the observed perfomance impairment to alcohol. Pentobarbital
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and ethanol produced similar dose-related decrements in task
performance on DSST, circular lights, number recall and
memory for pictures. Both drugs produced dose-related
increased in subject and observer ratings of drug effect.
At each dose level of pentobarbital, comparisons of the peak
ratings of drug effect by subjects and staff observers were
virtually identical. In contrast, while subjects and staff
observers were in concordance as to the magnitude of the drug
effect at the two lower doses of ethanol, subjects rated the
peak drug 'effect for the highest dose of ethanol sub-
stantially lower than the peak rating of staff observers. In
previous studies from this laboratory, similar under-rating
of subjective drug effects by subjects at high doses with
benzodiazepines, but not with other sedative-hypnotics.
For ethanol and pentobarbital, there were similar dose-
related increases in subject ratings of sleepy and drunken
and the subjects' retrospective ("Next Day") assesment of
the previous day's drug effect and their estimate of the
drug's street value. In general, subjects rated drug liking
and retrospective "Next Day" liking substantially lower for
ethanol than for the corresponding 600 and 750 mg doses of
pentobarbital, even when the magnitude of the drug effect on
other measures was roughly equivalent.
Pentobarbital produced significant dose-related increases in
subject ratings on the mood dimensions of sluggish, confused,
weary, drowsy and sleepy, while ethanol only produced signi-
ficant increases in the mood dimension of confused.
Observer's ratings showed corresponding dose-related
increases in confusion for both ethahol and pentobarbital.
The results of this study document the well-recognized
similarities in the behavioral and psychomotor performance
effects profiles of ethanol, and other sedative-hypnotics,
such as pentobarbital. However, ethanol's relatively modest
same-day and next day drug liking scores, combined with the
subjects' relative under-rating of ethanol's effects,
suggests that, in addition to the many well known
similarities of -ethanol to other sedative-hypnotics, there
appear to be other important, and as yet poorly understood,
differences.
Supported by NIDA Grant DA-03889.
AFFILIATIONS: Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sci.
The Johns Hopkins University School of Med.
Baltimore, Maryland 21224
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Subjective Effects of Methaqualone
Martin lonescu-Pioggia, Michael Bird and Jonathan 0.
Cole
Methaqualone (MQ) was widely abused until 1984 when it was placed in
Schedule I. Jasinski et al. (1977) conducted the first laboratory evaluation of
MQ comparing its subjective effects (SE) to those of pentobarbital in prison Ss .
MQ produced SE similar to pentobarbital and was identified by Ss and
barbiturate. The present study employed male and female, community resident,
nonmedical substance users who were not drug-dependent to compare the SE of
2 doses of MQ (200, 400 mg) to placebo (P). Ss rated SE in groups in a
naturalistic living room-like atmosphere mimicking the setting in which drugs are
normally used. Two doses of MQ and P were administered to 4 groups of 6 Ss
(n-24, 12M & 12F) in a double-blind randomized fashion. Ss’ mean NMPI
profile showed elevations on scales 4/Pd and 9?ma. SE were assessed predrug
and hourly for 4 hours using ARCI List-l 16, and were analyzed by ANACOVA
covaried for baseline. New ARCI factors and an Abuse Potential Scale (APS)
were derived. Both doses of MQ were generally distinguishable from P (p <
.05) on the following scales: Physical & Mental Sedation; Euphoria & Motor
Stimulation; Physical Unpleasantness; AP; and, the standard Sedation-Euphoria
scales. However, 200 mg was generally indistinguishable from 400 mg.
Interestingly, both doses of MQ produced equivalent Euphoria with a dose
related increase in Sedation. Results were unchanged when ARCI items were
scored on a 6 point scale or true-false. Estimates of ‘Street Value’ discriminated
both doses from P but did not discriminate between doses, with MQ 400, 200,
and P valued at $2.43, $2.08. and $0.33. respectively. In summary, the breath
of MQ’s SE is striking. This study used a different method and S population to
confirm earlier findings by Jasinski et al. (1977) that MQ is a sedative-
euphoriant with high abuse potential.
AUTHORS
M. Ionescu-Pioggia, Ph.D. - Burroughs Wellcome Co.
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The Cocaine Expectancy
Questionnaire (CEQ): Its
Construction and Predictive Utility
Adam J. Jaffe and M. Marlyne Kilbey
The Cocaine Expectancy Questionnaire (CEQ) was developed to
explore the domain of adult cocaine related expectancies. The
questionnaire items were derived from extensive open ended
interviews with 73 adult non-cocaine users, 12 experimental users and
20 abusers, as well as a review of the relevant literature. The items
were then administered to a second, similar group, and item analysis
was conducted to determine final item inclusion. A content analysis
of the interviews and resulting questionnaire revealed that adults
seem to hold well formed expectancies about the effects of cocaine,
that include: paranoia, antisocial/aggressive behavior, grandiosity,
desire for other drugs, and improvement or decrement in; sexual
functioning, relaxation, and generalized physical functioning.
Further, analyses were conducted on a matched sample of 20 non-
cocaine users and 20 abusers. These groups were compared on two
expectancy scales, cognitive and sexual functioning, considered from
past research to be of greatest theoretical interest. Results indicate
that cocaine abusers have significantly stronger expectancies of
cognitive and sexual enhancement from cocaine use than do non-users
(P<.05). Etiological implications, and the potential predictive utility
of cocaine expectancies as measured by the CEQ are discussed.
AUTHORS:
Adam J. Jaffe, Ph.D.
Yale University
Alcohol Treatment Unit
New Haven, CT 06511
M. Marlyne Kilbey, Ph.D.
Wayne State University
Detroit, MI
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Urinary Elimination Half-Life of
Delta-1-Tetrahydrocannabinol-7-oic
Acid in Heavy Marijuana Users After
Smoking
Eva K. Johansson, Leo E. Hollister and Magnus M. Halldin
ABSTRACT
The urinary excretion of 1-tetrahydrocannabinol-7-oic acid 1-THC-7-oic acid),
the major urinary metabolite of 1-THC, and the total amount of THC metabolites
was studied in heavy marijuana users after smoking using high-performance
liquid chromatography and the EMIT-d.a.u. cannabinoid assay. An average
elimination half-life (±SD) of 3.0±2.3 days was obtained for 1-THC-7-oic acid.
The average ratio (±SD) of “EMIT readings”/ 1-THC-7-oic acid concentrations
was 1.23±1.03.
INTRODUCTION
1-Tetrahydrocannabinol 1-THC) is the major psychoactive compound in
Cannabis . It is rapidly and extensively metabolized in man and only trace
amounts are excreted in the urine (Agurell et al., 1986). 1-THC-7-oic acid, the
major urinary metabolite of Al-THC, has been determined by various analytical
methods, such as high-performance liquid chromatography (HPLC), gas
chromatography and gas chromatography/mass spectrometry (Cook, 1986). For
forensic purposes, the total amount of THC metabolites is usually semiquantitated
by enzyme multiplied immunoassays (EMIT) or radioimmunoassays (RIA)
(Cook, 1986). In this study the urinary elimination half-life of 1-THC-7-oic
acid was determined in heavy marijuana users using HPLC. In addition, the 1-
THC-7-oic acid concentrations were compared to the total amount of THC-
metabolites in the urine measured by the EMIT-d.a.u. cannabinoid assay.
METHODS
Thirteen males who were heavy Cannabis users volunteered to participate in this
study. The subjects smoked four cigarettes containing with 15 mg Al-THC each
during a two day period. In addition, the subjects were allowed to smoke
marijuana in their regular manner. However, after the smoking period the
subjects had to abstain from all Cannabis use for 28 days. Urine samples of 25
mL were collected in silanized glass tubes during the days of administration and
on the first, second and third day after administration followed by every second
day during the four week period of abstinence. The semiquantitative EMIT-d.a.u.
cannabinoid assay was used to analyze the total amount of THC-metabolites in the
urine. This system is designed to detect several metabolites of 1-THC, being
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most sensitive to 1-THC-7-oic acid. Concentrations of 1-THC-7-oic acid
equivalents” were obtained using the calibration kits (cut-off level 20 ng/mL,
medium level 75 ng/mL of 1-THC-7-oic acid) supplied by Syva Scandinavia.
The concentrations of 1-THC-7-oic acid were determined by HPLC with UV
and electrochemical detection after purification on Bond-Elut -THC columns
(ElSohly et al., 1983). The detection limit of this method is 7 ng/mL urine. The
elimination rate constant was calculated from the slope obtained by
linear regression, of the data points in the urinary concentrations of 1-THC-7-oic
acid, divided by creatinine, versus time curves. The elimination half-life was
obtained from t½ = ln
RESULTS AND DISCUSSION
The urinary excretion of 1-THC-7-oic acid in thirteen male heavy marijuana
users was estimated after smoking a cumulative dose of 1-THC during two
consecutive days. The urinary concentrations of 1-THC-7-oic acid were
followed for up to 25 days by HPLC analysis. The acid concentrations were
correlated to creatinine levels in order to adjust for variations in urine flow rate.
Fifteen minutes after smoking the levels were 14-219 ng of 1-THC-7-oic
acid/mg creatinine. At 24 h and 3 days the levels had declined to 16-158 ng and
5-75 ng 1-THC-7-oic acid/mg creatinine, respectively. The elimination half-
lives ranged from 0.8-9.8 days with a mean (±SD) of 3.0±2.3 days. The
elimination half-lives increased when the time period of analysis increased, which
is in agreement with the multicompartment model. The EMIT-d.a.u. cannabinoid
assay was used to analyze the total amount of THC metabolites excreted in the
urine. The urinary levels of 1-THC-7-oic acid were compared to the
concentrations of 1-THC-7-oic acid equivalents" (within the linear range of 20-
75 ng/mL) obtained by EMIT. An average ratio±S.D. of 1.23±1.03 for the
E M I T  r e a d i n g s 1-THC-7-oic acid concentrations was found. The poor
correlation between the EMIT readings and 1-THC-7-oic acid levels is a
consequence of the EMIT assay being sensitive to several THC-metabolites
excreted in urine.
ACKNOWLEDGEMENTS
The authors would like to thank Dr. Stig Agurell for valuable discussions.
This project was supported by NIDA grant DA-03926.
REFERENCES
S. Agurell, M. Halldin, J-E. Lindgren, A. Ohlsson, M. Widman, H. Gillespie
and L. Hollister. Pharmacokinetics and Metabolism of At-Tetrahydrocannabinol
and Other Cannabinoids with Emphasis on Man. Pharmacological Reviews
38:21-43, 1986. E. Cook. Analytical Methodology for 9-Tetrahydrocannabinol
and Its Metabolites. Alcohol, Drugs and Driving. 2:79-91, 1986. M.A. ElSohly,
H.N. ElSohly, A.B. Jones, P.A. Dimson and K.E. Wells. Analysis of the major
metabolite of 9-Tetrahydrocannabinol in Urine II. A HPLC Procedure. J. Anal,
Toxicol. 7:262-264, 1983.
Eva K. Johansson1, Leo E. Hollister2 and Magnus M. Halldin3
1 Depar tment  of  Pharmacognosy,  Box 579,  BMC, S-751 23 Uppsala ,
Sweden.2Harris County Psychiatric Center, P.O. Box 20249, Houston TX
77225-0249, USA.3Department of Pharmacology, Karolinska Institute, S-10401
Stockholm, Sweden.
458
Use Predicts Treatment Outcome,
Not Opiate Dependence or
Withdrawal
Therese A. Kosten, Mark S. Bianchi and Thomas R. Kosten
The dependence syndrome concept, proposed by Edwards
and Gross (1976) for alcohol, was extended to other
drugs and is the basis of DSM-III R criteria for drug
dependence. We showed that these behavioral and
physiological aspects of dependence were related to
biological addiction in opiate addicts: greater opiate
dependence associated with more severe naloxone
precipitated opiate withdrawal (Kosten, et al, in
press). Neither opiate dependence nor withdrawal
severity was related to frequency or length of opiate
use. Moreover, we found that cocaine dependence (DSM-
III R) predicted less severe opiate withdrawal. To
test further the validity of the dependence syndrome
concept in opiate abuse, we investigated whether the
degree of opiate dependence would predict treatment
outcome in a methadone maintenance program. We also
examined the predictive utility of the other drug use
and demographic variables.
METHOD
Fifty-two of 48 opiate addicts were re-interviewed 1
year after the start of methadone maintenance
treatment (92% follow-up rate). The subjects tended
to be male (69%), white (67%), and were 32.1 ± 1.0
years old. At intake, we assessed opiate and cocaine
dependence using the Structured Clinical Instrument
for Diagnoses (SCID) and gathered additional
information on drug use history including length and
frequency of use and number of previous treatment
attempts. Frequency of opiate use was obtained by a
self-report using a 6 point scale where 6 was the most
frequent use. Opiate withdrawal severity was rated
using the Naloxone Challenge Test. These variables,
along with demographic variables, were used to predict
success in treatment, as defined by treatment length
(weeks) and percent illicit urines.
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RESULTS
Demographic predictors. Gender did not predict
treatment length nor illicit urines. More illicit
opiate urines were seen in older addicts but, age was
not related to any other success variable. Finally,
black addicts had higher percent of illicit cocaine
urines (53%) than white addicts (15%; p<0.05).
Drug use predictors. Overall, naloxone-precipitated
opiate withdrawal was not associated with treatment
success nor was opiate dependence. Cocaine dependence
predicted a greater number of illicit cocaine, but not
opiate, urines (r=0.37, p<0.01) and tended to predict
shorter treatment length (r=-0.25, p<0.1). Neither
years of opiate use nor number of past treatments
predicted treatment success. The best predictor of
treatment success was self-report of opiate use
frequency, where greater opiate use was associated
with shorter treatment length (r= -0.46, p<0.01).
Predictive model. Stepwise regression. of all
variables emphasized the predictive value of opiate
use on treatment length (partial R2 =0.21). Since
race also added to the model (partial R2 =0.05), we
analyzed the association between intake variables and
treatment success separately by race. Treatment
length was predicted extremely well by drug use in
blacks (r=-0.66) and by both drug use (r=-0.43) and
opiate dependence (r=-0.31) in whites. The stepwise
regression model for whites also included opiate
withdrawal severity as a modest predictor of outcome
(partial R2 =0.06).
DISCUSSION
We found that opiate dependence and opiate withdrawal
severity predict treatment success modestly in white
opiate addicts only. Yet, self-reports of drug use
frequency are very good predictors of treatment
outcome, especially in black opiate addicts. Whether
the self-report reflects the true frequency of use or
is a measure of perceived drug severity is not known,
but it provides an easy-to-use and very good predictor
of treatment success.
The other factors that predict failure in methadone
maintenance treatment are: 1) greater cocaine
dependence: 2) being older; and 3) being nonwhite.
However, none of these varibles predicts treatment
outcome as well as the self-report of opiate use.
From the Dept. of Psychiatry, Yale University Medical
School. Supported by NIDA grant P50DA04060.
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Buprenorphine Treatment of
Cocaine Abuse
Thomas R. Kosten, Charles J. Morgan and Herbert D. Kleber
Intravenous cocaine abuse among opioid addicts has become a
major public health problem that may be reduced by
buprenorphine, an opioid mixed agonist antagonist. This open
study compared cocaine abuse in buprenorphine (BUP) to
methadone (METH) maintained patients using two designs: 1.
cross-over, 12 METH patients at a mean METH dose of 47 (± 8
mg PO) were switched over to BUP dose of 3.8 (±0.6) mg SL for
1 month. On METH they had cocaine in 20% of their urines over
the previous 6 months, but on BUP their cocaine positive
urines dropped tenfold to 2% (t=2.8, P 0.02). 2. In the case
control, 41 BUP (3.2 ± 1.6 mg SL) were compared to 61 METH
(43 ± 8 mg PO) and 36 naltrexone (NLX) patients for the first
month in treatment. The groups were comparable in age, sex,
race and number of urines per patient (mean = 8.4). Urines
were positive for cocaine in 24% of the METH and in 3% of the
BUP group (t=5.8, df=71, P 0.0001), but overall illicit
urines did not differ (33% METH vs. 37% BUP). The NLX
patients showed no difference from the BUP patients, but
significant difference from the METH patients in cocaine
abuse (5% Positive urines) (F=17.95; df=2,137; P 0.0001).
Thus, BUP and opioid antagonists in general may be a more
effective treatment than METH for cocaine abusing opioid
addict.
AFFILIATION:
Department of Psychiatry
Yale University School of Medicine
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Marijuana and Alcohol Effects on
Mood States in Young Women
B. W. Lex, M. L. Griffin, N. K. Mello and J. H. Mendelson
Potent ial  predictors of 8 prof i le of  Mood States (POMS)
factor scores were examined for 30 young women (mean age =
26.4 years) who smoked marijuana and drank alcohol in the
community. Prospect ive data were obtained from diary
q u e s t i o n n a i r e s  s u b m i t t e d  d a i l y  d u r i n g  3  c o n s e c u t i v e
menstrual cycles. Behavioral and social variables (heavy [>
1.5 cigarettes per day] versus light [< 1.5 cigarettes per day]
marijuana smoking, use of both marijuana and alcohol on the
same day, occurrence of unusual events, and participation in
sexual activity) were strong predictors for mood factors than
were temporal  (weekdays versus weekends) or biological
(menstrual cycle phase) variables. Heavy marijuana users
consistent ly reported higher negat ive (confusion, anger,
fatigue, and tension) and lower positive (friendliness, vigor,
and elation) mood scores. This study was supported in part
by Grants DA 02905, DA 04059, DA 00101, and DA 00064
from NIDA and Grants AA 0652 and AA 06794 from NIAAA.
Alcohol and Drug Abuse Research Center, Harvard Medical
School, McLean Hospital, Belmont, MA 02178
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Microanalysis of Ethanol-Induced
Disruption of Body Sway and
Psychomotor Performance in Women
B. W. Lex and S. E. Lukas
Repeated measures of body sway, psychomotor performance,
and blood alcohol level (BAL) were obtained from 20 women
after they received either ethanol (0.56 g/kg) or isocaloric
placebo. Simple motor tasks ( f inger tapping and hand
steadiness) were unaffected by this dose. Performance on a
computer-automated version of the Digit Symbol Substitution
Test was disrupted only during the ascending portion of the
BAL curve. Body sway (static ataxia) was affected during
both peak and descending BALs. A platform device connected
to a microcomputer measured static ataxia, and a customized
software program registered the frequency and extent of
movements during each 60 second test interval. Body sway
data fo l lowing placebo or ethanol  were plot ted in three-
dimensional space. Analysis of dynamic changes showed
m o r e  p r o n o u n c e d  d i s r u p t i o n  i n  t h e  s a g i t t a l  ( a n t e r i o r -
posterior) plane than in the lateral plane. Subjects swayed
more to the posterior and to the right. Results suggest that
the apparatus and data analysis techniques provide highly
sensitive measures of body sway following a moderate dose
of ethanol. This study was supported in part by Grant AA
06794 from NIAAA.
Alcohol and Drug Abuse Research Center, Harvard Medical
School, McLean Hospital, Belmont, MA 02178
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Behavioral Effects of Alprazolam in
Chronic Therapeutic Users
I. Lucki, L. A. Kerr, R. B. Frldman, E. Schweizer and K. Rickels
This study presents initial preliminary data of a
comparison of the behavioral effects of the benzodiazepine
alprazolam in chronic medical users and normal volunteers.
Doses of 1 or 2 mg of alprazolam or placebo vere administered
double-blind to a group of 6 chronic users and 6 normal
volunteers. The chronic users (5 females, 1 male; 39.8 ± 3.2
years) vere taking alprazolam at therapeutically-appropriate
doses on a regular daily basis for at least 1 year for the
treatment of panic disorder (Dose = 2.1 ± 0.6 mg; Duration = 3.2
± 0.6 years). The normal volunteers (N=6) were matched for sex
(5 females, 1 male), age (42.7 ± 2.8 years), and educational
level vith the group of chronic users. No volunteers or
patients had a history of treatment for a substance abuse
disorder. All subjects were tested on a battery of tests of
psychomotor performance (tapping, DSST, symbol copying, CFF
threshold), verbal recall ability, subjective effects, and drug-
liking scales.
Preliminary results from the psychomotor tests suggest
that alprazolam produced somevhat less impairment of psychomotor
performance in chronic users than in drug-naive normal
volunteers. Amnesic effects of alprazolam vere measured in both
chronic users and in normal volunteers. Normal volunteers
reported increased feelings of mental and physical sedation with
increasing doses of alprazolam. Normally high level of
tranquilieation vere not changed by alprazolam in normal
volunteers. Chronic users did not report increases in mental or
physical sedation vith alprazolam. although baseline values for
this group vere somevhat higher. Alpraeolam appeared to
increase the report of tranquilization in chronic users. Normal
volunteers accurately discriminated alprazolam from placebo.
Chronic users incorrectly reported receiving alprazolam vhen
they vere actually given placebo. Alprazolam appeared to
produce a moderate degree of drug-liking in both normal
volunteers and chronic users. Supported by DA 05186.
AFFILIATION
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Naltrexone in Federal Probationers
David S. Metzger, James Cornish, George E. Woody,
A. Thomas McLellan, Patrick Druley and Charles P. O’Brien
Introduction
The opiate antagonist naltrexone hydrochloride has been proven to be
a safe and effective medication in blocking the actions of opiates and
preventing dependence. Nalt rexone has few side ef fects and
individuals taking this medication do not become dependent upon it. Its
clinical utility however, has been limited by the general lack of
acceptability of the medication among many patient populations. This
poster presents some preliminary findings from a unique treatment
program for individuals at risk of incarceration should they relapse to
opiate addiction.
The Naltrexone Treatment Program is designed to determine the
feasibility and effectiveness of naltrexone when used with individuals at
risk of incarceration should relapse occur. It is believed that this group
represents a more highly motivated patient population than may be
available in other settings.
The Program
The program is a project is located in the Federal Probation office in
Philadelphia. Although the research is administratively autonomous
from the probation office, a close working relationship with the
probation staff is maintained. We offer probationers a convenient
opportunity for treatment which would otherwise be unavailable.
The project has been operational for the past eighteen months. The
Naltrexone Treatment Program is staffed with a full-time substance
abuse research technician. A physician is on call at all times and
provides weekly on site coverage. All subjects are provided with
medical screening and monitoring as well as weekly drug counseling.
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Design and Methods
The program is being evaluated using an open, randomized control
group design. The use of a placebo control group was determined to
be inappropriate given the ability of patients to easily identify their
medication status through opiate use following random assignment.
Participation in the research is completely voluntary. Individuals with
histories of opiate dependence or who are evidencing early signs of
relapse are self referred or referred by their probation officer. The
project staff provide a full description of procedures and potential risks
and benefits of participation.
Following orientation and informed consent, volunteers are randomly
assigned to either the medication group or the control group. Those
assigned to the medication group are first challenged with naloxone to
insure that they are free of opiates. Following a successful naloxone
test, subjects are administered their first dosage of naltrexone.
Subsequently, naltrexone patients receive medication two times each
week in order to provide adequate blockade coverage.
Those individuals assigned to -the control group are also scheduled to
visit the program two times each week for counseling and monitoring.
All subjects are asked to contact their probation officers each visit.
Drug use (self report and urinalysis) and drug craving are monitored on
a weekly basis as are physical and psychological symptoms, treatment
involvements, and social functioning.
Preliminary Results
Twenty four subjects have completed the six month study phase of the
project. Preliminary results indicate that the six month retention rate for
the probationers randomly assigned to the naltrexone group is fifty
percent. There have been few negative side effects noted by patients
taking the medication. The greatest challenge facing the project is the
current low rate of identifiable opiate abuse and the epidemic use of
cocaine. This situation not only limits the number of subjects available
for study but also highlights the project’s need to address issues of
nonopiate substance abuse. Of perhaps equal importance is the fact
that our findings demonstrate that the delivery of services within a
probation environment is a viable model for drug abuse treatment
delivery. Many probationers experience significant difficulty with drug
use and the delivery of services within the probation environment has
met with acceptance from both staff and patients.
Center for Studies on Addiction
University of Pennsylvania/Philadelphia Veterans
Administration Medical Center
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The Carrier Addition Severity Index
for Adolescents (CASI-A)
K. Meyers, J. Jaeger, D. Metzger and P. Sargiotto
The Carrier Addiction Severity Index for Adolescents
(CASI-A), modeled after the Addiction Severity Index
(ASI), is a 45-60 minute semi-structured interview which
assesses eight areas critical to comprehensive
adolescent assessment and treatment outcome evaluation:
medical, education, substance use, use of free time, peer
relationships, family relationships, legal status,
psychiatric status. During the initial stage of
development, the CASI-A was piloted on three populations:
adolescents receiving inpatient substance abuse treatment
at a psychiatric facility, adolescents receiving
education at a private school for emotionally disturbed
students, and adolescents referred to the Juvenile
Justice System of Pennsylvania. Substantial revisions in
ASI content and the scoring system were necessary to
capture the unique characteristics of the adolescent
population.
Preliminary data on the most recent version of the CASI-A
(N = 25 adolescents receiving substance abuse treatment
at a psychiatric facility) indicates a lack of agreement
between adolescent objective data and their subjective
ratings in select areas. For example, 68% of the
adolescents who disclosed positive symptomatology (e.g.,
used a drug regularly, frequently went to class under the
influence) reported "no problems" with substance abuse.
50% of the adolescents who disclosed positive
symptomatology (e.g., failing grades, truancy,
contemplating dropping out) reported "no problems" with
education. This suggests that adolescents do not always
have insight into the severity of their problems and have
difficulty making judgements regarding the importance of
treatment. Their subjective ratings should, therefore,
be viewed with caution. Objective data in concrete areas
has proven most useful in assessing of this population.
Analysis of problem onset has also proven beneficial to
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overall assessment. For example, education and
psychiatric problems began earlier than substance abuse
problems (X= 5.7 grade onset education problems vs.
X = 7.5 grade onset substance abuse problems, t = 2.69,
p = .014; X = 5.0 grade onset psychiatric problems vs.
X = 7.5 grade onset substance abuse problems, t = 2.40,
p = .035), while there was no significant difference in
problem onset of other areas in comparison to substance
abuse.
Like the ASI, the CASI-A has both clinical and research
applications. The type of infomation obtained is
purposely focused to assist clinicians in identifying
treatment needs, determining individual treatment plans
or intervention referral, and monitoring change over
time. In fact, clinicians have found the instrument
beneficial during intake interviews and adolescents have
commented positively about its content, format, and
usefulness to treatment. Use of the instrument should
allow researchers to develop treatment-matching criteria,
evaluate the success of treatment-matching procedures,
and conduct treatment outcome studies. Ultimately, use
of the instrument should assist clinicians in matching
adolescents to proper treatment, and should facilitate
greater comparability of research results.
CARRIER FOUNDATION, NEW JERSEY
UNIVERSITY OF PENNSYLVANIA, PENNSYLVANIA
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Metabolic Effects of Nicotine in
Smokers and Non-smokers
Kenneth A. Perkins, Leonard H. Espstein, Richard L. Stiller,
Joan E. Sexton and Rolf G. Jacob
INTRODUCTION
Cigarette smoking is inversely related to body weight, as smokers
weigh less than nonsmokers and gain weight after stopping smoking.
Little evidence indicates that smokers consume fewer calories or
are more physically active than nonsnokers, suggesting that the
metabolic effects of smoking (more specifically, nicotine) may be
important in explaining the differences in body weight as a
function of smoking status. We recently found that nicotine
presented in spray form, isolated from tobacco smoke, produces a
significant acute increase in metabolic rate in cigarette smokers.
The present study compared the acute metabolic effects of nicotine
between smokers and nonsnokers to help determine whether chronic
tolerance may occur to these effects. Chronic tolerance would
indicate that the metabolic effect is more prominent when smokers
initially adopt the smoking habit but plays a lesser role in
determining body weight in regular smokers. A nasal spray dosing
procedure, which produces rapid dose-dependent boosts in plasma
nicotine similar in magnitude to smoking, was employed to
standardize dosing across subjects, particularly between smokers
and nonsmokers.
METHODS
Subjects were male smokers and nonsmokers (n=l0 each) matched on
age (23.2 vs. 21.7 yrs, respectively), body weight (74.8 vs. 75.5
kg), and physical fitness (38.4 vs. 41.2 mlO2/kg/min). Smokers
smoked an average of 19.8 cigs/day for 5.1 years. Metabolic rate
was assessed continuously via computerized indirect calorimetry.
Nicotine and placebo ware presented double-blind using a measured-
dose nasal spray system developed in our lab. The nicotine dose
was 15 ug/kg, approx. 1.1 mg (typical intake of smokers from an
average cigarette) for the average-weight subject in this study.
Subjects participated in 2 sessions on separate mornings, each
after overnight abstinence from smoking, caffeine, and food.
Subjects remained at rest in a comfortable reclining armchair
throughout each session. Following 30-min baseline determination
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of resting metabolic rate (RMR), subjects were presented with
nicotine or placebo every 20 mins for 2 hrs, with metabolic rate
assessed between presentations. Order of nicotine vs. placebo
was counter-balanced between the 2 sessions, arid the experimenter
was blind to subjects' smoking status.
RESULTS
There were no effects of group or session on baseline RMR, prior
to nicotine or placebo (mean±SEM for all subjects = 1.017±.019
kcal/kg/hr . Energy expenditure of smokers and nonsmokers was
significantly increased by nicotine intake (p<.01), but there was
no difference between smokers and nonsmkers. For smokers, the
man increase above baseline due to nicotine was .069±.019 kcal/
kg/hr, or 6.8% above RMR, while nonsmokers showed an increase of
.063±.014 kcal/kg/hr, or 6.4% above RMR.
The energy expenditure of nonsmokers increased slightly following
placebo (.032 kcal/kg/hr, 3.2% above RMR). We have observed
placebo responses of the same magnitude in smokers in previous
studies and have found that they appear to be due to effects of
inhaling, similar to behavioral aspects of making. However, we
did not observe a similar increase following placebo in the
smokers of this study (.010 kcal/kg/hr, 1.0% above RMR), but
therewasno significant interaction between smoking status and
nicotine/placebo on metabolic response.
DISCUSSION
To our knowledge, this is the first study directly comparing
metabolic responses to a measured dose of nicotine between
smokers and nonsmokers. Our finding of no difference in response
to nicotine between smokers and nonsmokers suggests that chronic
tolerance does not occur to the metabolic effectsof nicotine.
Thus, there does not appear to be physiological adaptation to
the metabolic effects of nicotine with chronic nicotine intake
(i.e. smoking). In addition to lack of difference in response
to nicotine, there was no difference in baseline between
smokers and nonsmokers, similar to our previous studies. These
results further support the notion that there is no long-term
effect of smoking on metabolic processes in the absence of
recent nicotine intake. Further research should determine
whether lack of differences in RMR and response to nicotine also
occurs with older smokers with longer smoking histories and with
females, who generally experience greater differences in eight
due to smoking.
Supported by R01-04174 from the National Institute on Drug Abuse.
AFFILIATION: Western Psychiatric Institute &Clinic
University of Pittsburgh School of Medicine
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Differential Anxiety Symptoms in
Cocaine vs. Alcoholic Patients
H. Pettinati, B. Evans, C. Joseph, J. Jensen and K. Meyers
Patients presenting for substance abuse treatment
typically exhibit a variety of symptoms of
psychopathology including anxiety and depression.
However, following four weeks of treatment where
abstinence has been maintained throughout, the majority
of these symptoms will subside except when a premorbid
psychiatric disorder exists. As part of a large
assessment battery, the Clinical Anxiety Scale (CAS), the
Hopkins Symptom Checklist-9Q (SCL-90-R) and Hamilton
Depression Rating Scale (HAM-D) were administered to 50
patients within a week of presenting for inpatient
substance abuse treatment. Of the 50 patients, 25 met
DSM-III-R criteria for alcohol dependence, with no other
concomitant drug abuse or dependence, and 25 met DSM-
III-R criteria for cocaine dependence and alcohol
dependence or abuse. Reassessment of psychopathology
occurred 4 weeks later, prior to discharge, at which time
patients were also assessed for current and lifetime
Axis I psychiatric disorders and Axis II personality
disorders using the Structured Clinical Interview for
DSM-III-R (SCID).
Preliminary analyses show differences in the extent of
certain types of psychopathology between patients
dependent only on alcohol versus those dependent on
cocaine and alcohol. For example, prior to discharge (at
Week 4), more patients in the cocaine and alcohol group
compared to the alcohol only dependent group met criteria
for an Axis I (20.8% vs. 12.5%, respectively) or Axis II
(60% vs. 28%, respectively) disorder. This difference
was statistically significant for Axis II psychopathology
(Chi Square= 7.62, df = 2, p<.05).
At the time of discharge, while both groups showed a
decrease in overall psychopathology on the SCL-90-R. the
471
cocaine and alcohol dependent group showed a
significantly smaller decrease (F = 4.3, p <.05) in
psychopathology and scored significantly higher than the
alcohol only dependent group. The mean total SCL-90-R
scores were significantly higher for the patients in the
alcohol and cocaine dependent group [X SCL-90-R (Week 4)
= 60.0 vs. 34.3, respectively], although the mean total
SCL-90-R scores at Week 1 were not different between the
two groups (X SCL-90-R (Week 1) = 87.3 vs. 83.3,
respectively).
While mean total CAS scores did not differ between
patient groups at Weeks 1 or 4, an item analysis on the
CAS revealed differences in types of symptoms between the
two patient groups, both at Week 1 and 4. Those
dependent only on alcohol were rated higher (increased
anxiety) on psychic tension (p=.O3) than those patients
dependent on both cocaine and alcohol. However, the
cocaine and alcohol dependent group scored significantly
higher (increased anxiety) on motor restlessness (p=.O3).
At discharge, although a diminution in symptoms of
anxiety on the CAS had occurred in both groups, motor
restlessness continued to significantly distinguish the
two groups with significantly more restlessness being
reported by those dependent on both cocaine and alcohol
(p=.01).
Preliminary data are also presented that illustrate the
interface among severity of psychopathology, severity of
craving, and nature of the personality disorder with
regard to the probability that the patient will relapse.
AFFILIATION:
Carrier Foundation
New Jersey
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Precarious Dilemmas: Mobilizing
Blacks Against AIDS
Ernest Quimby
INTRODUCTION
AIDS has disproportionately affected blacks, nationally and in N.Y.C. Black
organizations have been relatively slow in responding to the HIV epidemic,
however, because they encounter several precarious dilemmas in their
philosophy, constituency, outreach practices, and limited resources.
RESEARCH QUESTIONS
How are black organizations responding to the disproportionate effects of the
HIV epidemic on blacks?
What are the implications of black organizational response for intervention and
prevention efforts?
METHODS
Qualitative data were gathered by ethnographic methods in 1987-88. Author
attended meetings of predominantly black groups, including conferences,
street rallies, political forums and AIDS awareness events in churches,
universities, hospitals/clinics, parks, drug treatment centers, and youth
programs, mainly in New York, Atlanta, Washington, D.C., New Jersey,
Philadelphia, and Boston. Observations were conducted of their mobilization
and outreach activities. Formal and informal interviews occurred. Additional
material was compiled from media and scientific reports, field notes,
transcripts, training and educational sessions, and
related events.
CENTRAL FINDINGS/DISCUSSION
The structure of African American neighborhoods relies on governmental aid
and external assistance which may foster
attitudes towards AIDS.
conservatism and conflicting
AIDS & HIV have become metaphors representing the problematic existence
of the African American organizations and communities: uncomfortable racial
and ethnic relations, economic insufficiency, subordination and dependency,
threats to acceptable struggles for social mobility and community development,
and stigmatization of being associated with AIDS.
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Organizational effort against AIDS by some black churches and health care
organizations has been limited to meetings, rallies, & conferences which have
self-selected audiences. limited attendance, and little sustained follow-up.
African American organizations and their constituencies tend to shift
responsibility and avoid commitments to confront HIV issues by focusing on
conspiracies by whites, and moral condemnation of addiction and sexual
promiscuity. Official or private efforts to contain HIV by needle exchanges or
methadone maintenance are sometimes viewed as oppression and tacit approval
of morally condemned behavior.
Organizational efforts by professional elites are aimed at their constituencies
rather than neighborhoods. Because of the immediate and direct danger to
their constituents, drug treatment programs have mobilized faster than
churches and health care organizations. Other than treatment programs, mosts
organizations are unclear about their role in preventing AIDS.
The dilemmas of African American organizations are reflected in several ways:
infrastructural weaknesses, minimal resources, inability to compete for
massive AIDS funding, and relatively limited fundraising capabilities. Also,
most black groups were formed for purposes other than HIV intervention and
education. AIDS is frequently either considered offensive and/or of secondary
or minor importance to such organizations.
CONCLUSIONS/IMPLICATIONS
Black institutions and subcultures have not as readily responded to AIDS as
white gays, Black organizations face major dilemmas and constrains: limited
availability and control of economic and political resources, relative decline of
Black liberation movement, ideological confusion, cleavages by class, religion
and cultural origin and epidemiologically different risks of exposure to HIV.
Public health for and in black communities is a socio-economic and political
issue. Public health policy, however, is shaped and influenced by definitions,
agendas, institutions, cultures and political activity primarily outside the black
community.
Mobilization requires that a community be pre-disposed or ‘readied’ for
mobilization. Effective HIV outreach needs to consider not only information
and attitudinal change, but community development which allows its members
to identify, confront, and adapt to HIV and other new problems.
Activation, recruitment, and innovative service delivery from the ‘bottom up’
may be more effective than traditional ‘top down’ medical approaches in
stemming the disease’s spread.
AUTHOR:
Ernest Quimby, Ph.D.
Howard University
Washington, D. C. 20079
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Effects of Triazolam (TZ) on
Matching-to-Sample (MTS)
Performance in Humans
J. D. Roache, D. R. Cherek, K. A. Cowan, R. Spiga,
R. H. Bennett and J. Grabowski
It is widely recognized that benzodiazepines impair cognitive and
psychomotor task performanc in humans. However, the nature of
these behavioral disruptions has not been precisely identified.
The present study is a preliminary investigation of a computerized
MIS task designed to permit a beavioral analysis of drug effects
on a number of variables thought to be important influences on
human behavior and performance.
The MTS task utilized checkerboard-like sample (SD) patterns
displayed an a video screen and created by randomly darkening 32
(50%) of the squares of an 8 x 8 square matrix. Concurrently
presented below the SD, two comparison stimuli were a copy of the
SD and an S-Delta created by randomly varying the position of
1,2,4,8 or 16 of the SD squares. Thus, the five S-Delta conditions
were 3.125, 6.25, 12.5, 25 or 50 percent different from the SD.
Each task performance session was a multiple component schedule
consisting of fifteen 60 sec segments separated by a 15 sec time
out. A 60 sec trial of each of the five S-Delta conditions
occured within each of 3 random blocks. Subjects responded on
left or right manipulanda buttons to match the SD pattern. Correct
responses resulted in a brief tone presentation. At the end of the
day, subjects were paid $0.01 for each point derived as the total
number of correct responses minus errors (approximately $20).
The present study examined the effects of placebo and three TZ
doses (2.25, 4.5 and 9.0 ug/kq) administered orally under
double-blind conditions at 0930 hr. Seven normal healthy male
subjects participated for 8 hrs daily, three days per week.
Subjects provided drub-free urine samples and alcohol-free breath
samples daily and were required not to eat solid food or drink
caffeinated beverages in the morning of each study day. MTS task
performance occurred before drug administration and repeatedly at
0.5, 1.5, 3.0, 4.5 and 6.0 hrs following drug administration.
Subjects received no drug on the first day and placebo for the
next 4 days to allow for baseline performance acquisition.
Subsequently, TZ doses were administered in an ascending series;
usually on consecutive sessions.
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TRIAZOLAM DOSE (ug/kg)
Placebo 2 .25 4 . 5 9 . 0
S-Delta Condition (% Different from Sample)
Stable levels of performance were generally observed within the 5
day baseline period. Response rates and accuracy were an orderly
function of the SD/S-Delta difference (i.e., discriminability).
With placebo treatment, mean response rates per 60 sec trial
ranged from approximately 15 for S-Delta=3.125% to 40 for
S-Delta=50% and mean accuracy ranged from approximately 92% to
99%, respectively. Responses in one component of the muiltiple
component schedule were not signficantly affected by the S-Delta
condition of the preceding component. Overall, these data indicate
that subjects were under reasonably good SD stimulus control.
However, compared to the easier SD/S-Delta discriminations, the
more difficult discriminations engendered slower response rates
with less complete stimulus control.
The above figure shows that at 1.5 hr post-drug, TZ produced
dose-related decreases in response rate (No. Correct). This
occurred as an increasing function of the S-Delta difference from
the sample (SD) resulting in a significant (p<.001) interaction of
dose and S-Delta condition. Only the highest TZ dose (p<.001)
disrupted accurate MS performance and this occurred across all
S-Dalta conditions. TZ tended to produce greater disruption under
the weaker stimulus control conditions of the more difficult
discriminations (i.e., S-Delta = 3.125%). These results extend,
into the analysis of performance impairment, previous work
suggesting that drug effects depend upon baseline response rates
and the degree of stimulus control of behavior.
Suppprted by NIDA Grant DA-05716
AFFILIATION: Substance Abuse Research Center, UT-MSI, Department
of Psychiatry & Behavioral Sciences, University of Texas Health
Science Center at Houston, Houston, TX 77030
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Human Multioperant Responding:
Effects of Triazolam
Ralph Spiga, Don R. Cherek, Richard A. Meisch and
John D. Roache
Although aversive stimuli occasion escape, avoidance, or
aggressive responses in humans, studies of human aggressive
behavior have limited the subject to aggressive responding. In
this study we examined the effects of triazolam on human
aggressive and escape responses occasioned by point subtractions
attributed to another person.
Four male volunteers were recruited and screened. Those
volunteers who had current medical or psychiatric problems
including a history of alcoholism or substance abuse were
excluded.
Subjects participated in six 25 minute sessions each
experimental day. The sessions occurred immediately before dose
administration, and at 1/2 hour, 1 hour, 2 hours, 4 hours, and 6
hours after administration of placebo, O.l25mg/70kg,
0.25mg/70kg, or 0.5mg/70kg of triazolam. The three doses were
first administered in an ascending dose sequence and then in a
randomly ordered dose sequence. Successive triazolam doses were
separated by 72 hours.
Subjects were seated at a console consisting of three levers
marked A, B, and C, and a numeric counter. Pulls on lever A,
the point-maintained response, were maintained by an FR1OO
schedule of point presentation. At random intervals points were
subtracted from the counter ostensibly by a second subject. Ten
(10) lever B pulls, the aggressive response, ostensibly
subtracted points from this person's earnings. By pulling lever
C, the escape response, subjects protected their counter from
point loss for a period of time. Lever B, aggressive, or lever
C, escape, responses which followed a point loss postponed point
loss for 125s.
Subjects were told that the research project concerned the
effects of triazolam on physiological and motor responses. They
were told that pulling lever A 100 times would accumulate points
exchangeable for money at the end of the day. Subjects were
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informed that periodically during-the session another "person"
with whom they were paired might subtract points from their
counter. They in turn had the option of subtracting points from
this person by pulling lever B 10 times or protecting their
counter for a period of time by pulling lever C 10 times.
For each dose day and dependent measure the rates from the
session which deviated most from placebo values were selected as
data points. In one subject triazolam produced dose-dependent
decreases in the rate of point-maintained responding. In all
other subjects the lower doses of triazolam did not change or
slightly increased the rate of point-maintained responding while
the 0.5mg/70kg dose decreased the rate of-point-maintained
responding.
Three of the four subjects responded on the aggressive response
option. Dose-dependent decreases in the rate of aggressive
responding were observed in one subject. Only at the highest
triazolam dose was the rate of aggressive responding decreased
in the other three subjects. The 0.25mg/70kg dose increased the
rate of aggressive responding of the one subject who responded
on both the aggressive and escape response option.
Two of the four subjects responded on the escape option.
Dose-dependent decreases in the rate of escape responding were
observed in one subject. Only the highest triazolam dose
(0.5mg/70kg) decreased the rate of escape responding in the
second subject.
Acute administration triazolam decreased point-maintained and
aggressive responding. This effect is similar to effects
observed following acute diazepam administration. Triazolam
also decreased escape responding. Aggressive and escape
responding decreased more than point-maintained responding, even
at doses that had little or no effect on responding maintained
by point presentation.
Our results indicate that benzodiazepines not only decrease
aggressive responding occassioned by provocation and maintained
by periods free of provocation, but also suppress escape
responding initiated and maintained under the same conditions.
Thus, benzodiazepines may disrupt the relationship between
aversive stimuli (point loss) and aggressive and escape
responding.
Acknowledgement: This research was supported by NIDA grant
03166 and NIDA Post-doctoral Fellowship 05369.
Affiliation: Substance Abuse Research Center
Department of Psychiatry & Behavioral Science
The University of Texas Mental Sciences Institute
The University of Texas Medical School
Houston, Texas 77030
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The Acute Effects of Codeine on
Human Aggressive and Non-
Aggressive Behavior
Ralph Spiga, Don R. Cherek, John D. Roache and Kathy Cowan
This study examined the effect of codeine on aggressive behavior
in a controlled laboratory setting.
Ten male volunteers were recruited by advertisement, screened,
and excluded if they had current medical illness or history of
psychiatric disorders including alcoholism or substance abuse.
Sessions were conducted Monday through Friday. Thirty minutes
prior to sessions subjects were administered placebo or one of
three codeine doses of 25mg/70kg, 50mg/70kg, and 75mg/70kg.
Doses were administered first in an ascending sequence and then
twice in a randomly ordered sequence.
Two responses were concurrently available as non-reversible
options. Responses on button A earned points exchangeable for
money on a FR 100 schedule. Responses on button B subtracted
points exchangeable for money from another subject on a FR 10
schedule. Superimposed on the schedule of monetary
reinforcement was a schedule of point loss. Points were
subtracted at random times throughout the session unless the
subject responded aggressively after a point loss. Aggressive
responses following at least one point loss initiated an
interval either of 125s or of 500s during which no points were
subtracted.
After administration of the last dose subjects completed the
Buss-Durkee Hostility Inventory. This inventory assessed
history of assaultive behavior, irritability, indirect
hostility, negativism, resentment, and verbal hostility.
Subjects were told that the research project concerned
the effects of drugs on physiological and motor responses. They
were told that Button A presses would accumulate points
exchangeable for money and that periodically during the session
another "person" might subtract points from their counter.
had the option of subtracting points from this person by
They
pressing button B.
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The frequency of monetarily reinforced, non-aggressive
responding was unaffected by acute administration of codeine.
The aggressive responding per provocation, expressed as a
percent change from the placebo session preceding the acute
administration of a codeine dose, exhibited the greatest
increase for 6 of 10 subjects at the 50mg/70kg dose of codeine
(F 2, 16 = 4.50; p< .05). Effects attributable to group or dose
repetition were not significant.
Subjects were divided into two groups using their scores on the
Buss-Durkee Hostility Inventory as the basis for assignment to a
"High hostility" or a "Low hostility" group. We found an
interaction of high or low hostility with dose (F 2, 16 = 3.88;
p.<.O5). The 25mg/70kg dose decreased, relative to placebo, the
frequency of aggressive responding per provocation of high
hostility subjects while increasing the frequency of aggressive
responding per provocation of low hostility subjects. The
frequency of aggressive responding per provocation was increased
relative to placebo for both high and low hostility subjects at
the 50mg/70kg dose. Acute administration of 75mg/70kg of
codeine did not affect the frequency of aggressive responding
per provocation of either the high or low hostility group.
The major findings of this study were that acute administration
of a 50mg/70kg dose of codeine increased the frequency of
aggressive responding per provocation; that acute administration
of codeine did not effect monetarily reinforced responding; and
that acute administration of a 25mg/70kg of codeine decreased
aggressive responding per provocation of those subjects who
reported that they tended to engage in verbally hostile or
physically assaultive behaviors in the natural environment while
increasing aggressive responses per provocation in those
subjects who reported that they were not prone to verbal
hostility or physical assaultiveness.
We conclude that acute administration of codeine increases
aggressive responding following provocation and that this may be
influenced by the subject's previous history of aggressive
responding.
Acknowledgements: This research was supported by NIDA grant
03166 and Ralph Spiga was supported by NIDA
Post-doctoral Fellowship 05369.
Affiliation: Substance Abuse Research Center
Department of Psychiatry & Behavioral Science
The University of Texas Mental Sciences Institute
The University of Texas Medical School
Houston, Texas 77030
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Anterior Pituitary, Gonadal and
Adrenal Hormones in Women with
Alcohol and Polydrug Abuse
Siew K. Teoh, Barbara W. Lex, Joshua Cochin
Jack H. Mendelson and Nancy K. Mello
Chronic alcoholism and drug abuse are often associated with derangements of
reproductive function in women such as amenorrhea, anovulation, luteal phase
dysfunction and early menopause. Endocrine profiles of the first 18 consecutive
women (age 17-58) admitted to a Massachusetts hospital for treatment of
alcohol/polydrug abuse under civil commitment (Section 35A of Chapter 123 of
the general laws of Massachusetts) were studied. Twelve women were
diagnosed as alcohol dependent/ abusers according to criteria established in the
Diagnostic and Statistical Manual of the American Psychiatric Association
(DSM-III R). Their daily alcohol consumption ranged from 42-324 grams. Six
women were diagnosed as polydrug dependent. In addition to alcohol (84-830
g/day), cocaine was the most frequently abused drug followed by tranquilizers,
sedatives, marihuana, amphetamines and opiates. All women received a
thorough physical examination and laboratory studies including blood
hemogram and chemistry. All patients were drug free and had no signs of
withdrawal at the time of sample collection. Blood samples for LH, FSH,
prolactin, E2, progesterone and cortisol were also collected.
Fifty percent of the alcoholic women had hyperprolactinemia (22.3-87.5 ng/ml)
independent of amount and duration of alcohol use and 1 had secondary
amenorrhea with a normal prolactin level and low levels of LH and E2. Two
polydrug abusers had hyperprolactinemia (25.7 and 29.6 ng/ml) and 1 had
secondary amenorrhea (normal prolactin. low LH, FSH and E2). Hormone
levels were consistent with reported menstrual cycle phase or menopausal range
in 16 patients. Cortisol levels were also within normal range for all patients. Of
the 18 patients, 7 had elevated MCV and 2 were anemic. Four patients had
elevated sGPT (67-100 U/L) and 2 had marginally elevated sGOT.
The mechanisms of alcohol and drug induced derangements of reproductive
dysfunction have yet to be determined. These data confirm and extend previous
r epo r t s  t ha t  a l coho l i sm  and  d rug  abuse  may  be  a s soc i a t ed  w i th
hyperprolactinemia in women. Hyperprolactinemia may cause amenorrhea and
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disruptions of menstrual cycle but it is not invariably associated with menstrual
cycle abnormalities. The time course and prospects for recovery during
abstinence and the extent to which the reproductive system develops tolerance to
the disruptive effects of chronic alcohol and drug abuse are unknown.
Accumulating evidence of reproductive dysfunction in female alcohol and drug
abusers indicates that treatment programs should also evaluate neuroendocrine
status.
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Comparison of Amantadine and
Desipramine Combined with
Psychotherapy for Treatment of
Cocaine Dependence
W. W. Weddington, B. S. Brown, C. A. Haertzen, J. M. Hess
A. F. Kolar and J. R. Mahaffey
This paper reports the results of a single blind, placebo
controlled, 12-week trial of amantadine and desipramine for
treatment of cocaine dependent outpatients.
METHODS
Subjects. Subjects were consecutively self-referred cocaine
addicts who applied for outpatient treatment.
literate,
Subjects were
used a minimum of one gram cocaine per week for 12
weeks prior to treatment,
treatment.
and completed 14 days of initial
Exclusion criteria were current abuse/dependence on
any substance other than nicotine, current medical illness,
pregnancy, psychosis, or mandated treatment.
randomly assigned to 1 of 3 treatments:
Subjects were
(1) 12 weeks
deslpramine 200 mg per day; (2) 4 weeks amantadine 200 mg per
day followed by 8 weeks placebo; and (3) 12 weeks placebo.
Services Delivered Subjects attended 3 times per week to
receive medication, provide observed urines for toxicology, and
received indivldual counseling 2 times per week.
Instruments. Diagnostic assessments
structured questionnaires.
were performed using
Current level of psychiatric
symptomatology was determined using the SCL-9Q and the Beck
Depression Inventory.
an analog scale.
Cravlng for cocaine was measured using
Blood levels of amantadlne and deslpramine
were measured during Weeks 3. 8, and 12.
Data Analysis Results are reported as means +/- SEMs. A
one-way analysis of variance for independent measures was used
to test differences between groups on demographics and baseline
data. A mixed design ANOVA was used to show treatment effects
over weeks and the interaction of groups and weeks.
for attrltion,
To adjust
we used the last week of observation carried
forward, or "endpoint" analysis.
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RESULTS
Sample Characteristics. There were no significant differences
between treatment groups regarding demographics, quantity of
cocaine used, craving, routes of cocaine administration, and
incidence of psychiatric diagnoses.
Outcomes. There were no significant differences between
treatment groups regarding weeks in treatment: deslpramlne, 6.8
weeks; amantadine/placebo 7.4 weeks; and placebo, 8.0 weeks
(F=.36, df=2/51, p>.05). There were dramatic reductions in
cocaine use during treatment in all groups and the lower use
persisted throughout treatment (F=26.41, df=12/612, p<.0001),
but there were no significant differences in reported cocaine
use between the three treatment groups (F=.O8, df=2/51.
p>.05). There was a trend toward statistical significance
regarding maximum number of weeks of continuous cocaine-free
urines: desipramlne, 6.2; amantadine. 3.8, and placebo, 3.6
(F=2.01, df=2/51. p=.13). There were dramatic reductions in
craving for cocaine reported by subjects in all treatment
groups compared to intake throughout treatment (F=16.20.
df=12.612, p<.OOOl), but there were no significant differences
among treatment groups (F=0.55. df=2/51, p>.O5). Similarly,
there was marked lowering of depression scores by subjects in
all groups (F=13.15, df=12/612, p<.0001) but no significant
differences among groups (F=.45, df=2/51, p<.O5).
DISCUSSION
Our study demonstrated dramatic decreases in cocaine use and
craving for subjects who stayed in treatment. While we
observed a trend for subjects receiving desipramlne to maintain
a greater number of cocaine-free weeks, we did not demonstrate
statistically significant differences among groups for outcome
measures. Possibilities for this are that plasma levels were
not sufficient; twice-a-week counseling or thrice-weekly urine
analyses were sufficiently powerful to overwhelm medication
differences; or that amantadlne or deslpramine were not
efficacious.
Mean plasma concentration of deslpramine (96.8 ng/ml) in a
subsample of our subjects was less than that recommended for
treatment of depression (125/ng/ml), thus the dosage of
deslpramlne may have been subtherapeutic.
AUTHORS:
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Combination of Naloxone with
Buprenorphine in Humans
Linda L. Weinhold, George E. Bigelow and Kenzie L. Preston
Buptenorphine is a semisynthetic opioid analgesic which has morphine-like
agonist effects in non-dependent subjects. The present study was conducted to
determine whether simultaneous administration of naloxone anenuates the
agonist effects of buprenorphine.
In a resident laboratory, seven nondependent adult male volunteers (28-47 years
old), with histories of opioid abuse, participated in within-subject evaluations of
the following 7 acute drug conditions: (1) buprenorphine 0.4 mg alone, (2)
buprenorphine 0.4 mg plus naloxone 0.4 mg, (3) buprenorphine 0.4 mg plus
naloxone 0.8 mg, (4) buptenorphine 0.8 mg alone, (5) buprenorphine 0.8 mg
plus naloxone 0.4 mg, (6) buprenorphine 0.8 mg plus naloxone 0.8 mg and (7)
placebo. Physiological and subjective measures of acute drug effects were
collected at: pre-drug, and 5, 15, 30, 45, 60, 90, 120 min post drug. Data were
analyzed by analysis of covariance (ANCOVA) with repeated measures. An
overall ANCOVA was performed on all seven drug conditions and additional
ANCOVAs were performed on data subsets to determine specific buprenorphine
dose effects and naloxone dose effects.
The data analyses indicated that: (1) Bupxenorphine produced dose-related opioid
agonist effects on both physiological and subjective indices. (2) The opioid
agonist effects of buprenorphine 0.4 mg were themselves mild, but naloxone
tended to attenuate those effects on the visual analog High scale, on opioid drug
class identification, and observer agonist ratings. (3) With buprenorphine 0.8
mg, which produced more pronounced opioid agonist effects, naloxone
significantly attenuated those agonist effects on pupil diameter, respiration rate,
and opioid drug class identification. (4) Naloxone, however, did not block all
indices of the early buprenorphine agonist effects.
We conclude that a combination product of buprenorphine and naloxone may
have lower abuse liability than buprenorphine alone.
Affiliation: Research was conducted at: BPRU. D-5-West, The Johns
Hopkins/Key Medical Center, Baltimore, MD 21224. Dr L. L. Weinhold is
currently affiliated with NIDA Addiction Research Center, Baltimore, MD.
Acknowledgements: Supported in part by USPHS grants T32 DA07209, R01
DA04089, and K05 DA00050. and by Reckitt and Colman Pharmaceutical
Division.
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Abuse Liability of
Diphenhydramine in Sedative
Abusers
Barbara Wolf, John J. Guarino, Kenzie L. Preston and
Roland R. Griffiths
Diphenhydramine (Benedryl) , an antihistamine with prominent sedative
effects, has been available for more than 30 years. This investigation represents
a preliminary assessment of the abuse liability of diphenhydramine (DPH) in 10
subjects with histories of sedative abuse; all subjects reported use of
benzodiazepines and 7 subjects had also used barbiturates and/or other
sedatives. Subjects were healthy male volunteers ranging in age from 26-44
(mean 33 years). Five subjects were studied on a residential unit (3-5 weeks)
and 5 as outpatients (16 days). The study was designed as a single-blind acute
dose run-up: initial dose 50-100mg, increments of 50-100mg, maximum
planned dose 600mg. Active doses were altered with placebo every other day.
The administered maximum dose was 600mg in five, 500mg in two, 400mg in
one, and 300mg in two subjects. Five subjects did not receive the maximum
dose; in four of them this was due to adverse drug effects such as increase in
blood pressure, palpitations, restlessness, derealization (the fifth subject did not
receive 600mg for reasons unrelated to the drug effect). Subjects were asked to
rate the strength of the drug effect on a 5-point scale from ‘not at all’ to ‘very
strong’ at hourly intervals after drug administration up to 5 hours; there was a
clear dose-related increase in the subject rated peak strength of drug effect up to
the maximum dose. DPH produced dose-dependent decrements in two
psychomotor performance tasks; balance appeared to be a more sensitive
parameter than circular lights. Although DPH was most frequently identified as
a barbiturate/other hypnotic or as a benzodiazepine, it was also identified as a
stimulant and as an antidepressant. Subjects rated their “liking” on a 5-point
scale from ‘dislike or feel neutral’ to ‘very much’; this showed a dose-related
increase in peak “liking” up to 600mg in the subgroup of subjects who tolerated
these high doses. The “next day liking”, estimated the morning after the drug
administration essentially covaried with the actual time rated “liking”.
Similarly, the estimated street value showed a dose-related increase in the
subgroup of subjects tolerating 400-600mg. High doses increased subject rated
adverse effects such as confusion, forgetfulness, restlessness, anxiety,
shakiness, dizziness, dry mouth, tingling, and muscle cramps. These data
suggest some abuse potential of DPH in individuals with histories of sedative
abuse, but adverse reactions emerging at higher doses may preclude DPH from
wide-spread abuse. The finding that DPH may have some abuse liability is
supported by clinical data,. i.e., case reports of abuse of cough-syrup by
polydrug abusers and the abuse of tripelennamine, another antihistamine, in
combination with pentazocine, the so-called “T's and Blues” (Lahmeyer and
Steingold, 1980; Showalter, 1980).
Supported in part by NIDA grant DA-03889.
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Needle-Sharing -Patterns as a
Predictor of HIV Seroprevalence
Among New York City Intravenous
Drug Users (IVDUs)
K. Yee, L. S. Brown, B. J. Primm, T. Nemoto and K. Foster
INTRODUCTION
Although intravenous drug use represents the second most fre-
quent behavior associated with human immunodeficiency virus
(HIV) transmission and all AIDS cases, it represents the primary
factor in AIDS cases among women, children, ethnic minorities
and heterosexually acquired AIDS cases.
Just as previous research studies demonstrated the direct link
between certain IV drug using behaviors and an increased risk
for HIV infection, an examination of the particular patterns in
these behaviors would further enhance our ability to plan effec-
tive intervention programs that address the specific needs of
IVDUs and their sex partners, especially among ethnic
minorities.
This study focused particularly on drug using behaviors, (such
as needle-sharing and needle-cleaning patterns, and use of shoot-
ing galleries), and their association with HIV seroprevalence
among intravenous drug users (IVDUs) in New York City.
M E T H O D O L O G Y
Two hundred eighteen newly-admitted patients were recruited from
methadone maintenance clinics in Brooklyn and Manhattan, New
York in 1987. This sample included 47% Hispanics, 45% blacks,
and 8% whites, with a mean age of 33.4 years, of which 64% were
males, and 36%. females.
Following informed consent, the patients were administered a
standardized questionnaire containing variables pertaining to
demographic and socioeconomic status, drug use patterns, and
sexual behaviors. Sera were also collected and tested for HIV
antibodies via Elisa and Western Blot assays.
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Using the SPSS/PC+ statistical software package, unlvarlate and
multivariate analyses were used to analyze HIV serostatus by
behavioral data, particularly those regarding needle-sharing and
needle-cleaning patterns, and shooting gallery visits.
RESULTS
Overall, the HIV infection rate was 60%. The patients who
reported more frequent use of shooting galleries were less
likely to clean their needles than those who used shooting
galleries less often (p=.009). Those who frequented shooting
galleries tended to share needles more often than those who did
not use frequent them (p=.004). IVDUs who shared needles with
the same person for at least one year were at lesser risk for
HIV infection (p=.0262), less likely to vist shooting galleries
(p=.001), and more likely to be women (p=.03). Also, women
were more likely than men to have a spouse who injected drugs
(p=.0004). These findings concur with other studies which
suggest that women, more often than men, are involved in
monogamous relationships, and that this lifestyle usually
extends to their drug using behavior.
CONCLUSIONS
The findings of this study suggest that the frequenting of
shooting galleries is significantly associated with known risk
behaviors such as needle-sharing and a tendency to not clean
needles. Therefore, interventions directed at reducing the use
of shooting galleries, or at least, modifying behaviors in
shooting galleries may reduce the incidences of HIV infection
related to IV drug-use. The impact of these interventions may
also extend beyond IVDUs and possibly translate into a subse-
quent decrease in HIV seroprevalence among women, children, and
ethnic minorities, along with a decline in the number of cases
of heterosexual transmission of HIV.
AFFILIATIONS: Division of Research and Medical Affairs,
Addiction Research and Treatment Corporation, Brooklyn, N.Y.;
and Harlem Hospital, Department of Medicine, College of
Physicians and Surgeons, Columbia University, New York, N.Y.
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Effects of Food Deprivation on
Subjective Responses
to d-Amphetamine and Marijuana in
Humans
James Zacny and Harriet de Wit
Two studies examined the effects of 24 hours food
deprivation on subjective responses to oral d-amphetamine
(10 mg) and smoked marijuana (1.3% THC). Both studies used
a within-subjects design in which subjects received drug and
placebo in both a fed and a fasted state. In both studies, each
of the four experimental conditions - FED/DRUG,
FED/PLACEBO, FAST/DRUG, FAST/PLACEBO - was enacted
twice according to a randomized block design.
In the amphetamine study, 12 normal volunteers received
amphetamine or placebo after fasting for 24 hours or while
being in a fed state. Three subjective effects questionnaires,
the Profile of Mood States, the Addiction Research Inventory,
and the Visual Analogue Scale, were completed prior to and 1,
3 and 6 h after the early morning capsule ingestion. Typical
elevations in such subjective effects as elation and vigor
were obtained after amphetamine ingestion in both feeding
conditions, but fasting neither potentiated nor attenuated the
drug response. Subjects at the end of the session, however,
were more likely in the FAST/DRUG condition than in the
FED/DRUG condition to label the capsule they had ingested at
the beginning of the session as a stimulant.
In the marijuana study, 8 experienced smokers inhaled six
100-cc boluses of placebo or active marijuana smoke after
they had fasted for 24 hours or 1-2 hours after they had
consumed a 2000-cal meal. Subjective effects of marijuana
were assessed before, during, and after smoking. Smoke
inhalation was monitored by measuring expired-air carbon
monoxide (CO) levels before and after smoking. CO absorption
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from both placebo and active marijuana did not differ across
feeding conditions, indicating that smoke dose was similar
across feeding conditions. Typical elevations in such
subjective effects as “high” and sedation were obtained after
smoking active marijuana, but fasting neither potentiated nor
attenuated the drug response.
Although these two studies suggest that the subjective
effects of drugs are not altered by acute food deprivation,
they do not address the issue of whether food deprivation
alters the reinforcing effects of psychoactive drugs in
humans. Studies which simultaneously assess the subjective
and reinforcing effects of drugs as a function of food
deprivation would be useful.
Affiliation: Department of Psychiatry, University of Chicago,
Chicago, IL
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Effects of Acute and Chronic
Administration of (+)SKF 10,047 on
Body Temperature in the Rat
M. Bejanian, R. N. Pechnick and R. George
INTRODUCTION
Acute administration of PCP induces a dose-dependent hypothermia in rats. In
contrast, chronic administration of PCP induces hyperthermia (Pechnick and
George, 1989). The characteristics of the expression of the hypothermic and
hyperthermic effects of PCP indicate that there could be separate underlying
mechanisms for the two effects.
PCP has been shown to interact with two distinct binding sites in the brain.
These sites have been termed the PCP and sigma receptors (Quirion. et al.,
1987). Although many of the effects of PCP are postulated to be mediated
through the PCP receptor, the functional significance of the two receptors in
mediating different effects of PCP have not been defined.
Enantiomers of N-allylnormetazocine (SKF 10,047) have been shown to have
differential selectivity for sigma versus PCP receptors (Largent. et al., 1986).
The purpose of the present study was to characterize the effects of acute and
chronic administration of (+)SKF 10,047 (SKF). which has selectivity for sigma
over PCP receptors, on body temperature in the rat.
METHODS
Male Sprague-Dawley derived rats were housed individually in a room
maintained between 21-22°C. under a 12 hour light-dark cycle (lights on 0700)
for one week before testing. On day 1 the rats were weighed and baseline rectal
temperatures were recorded. Two additional pre-injection temperatures were
recorded at 30 minute intervals. The rats were injected subcutaneousely with
normal saline or (+)SKF 10,047 (5, 10 or 20 mg/kg). Rectal temperatures
were recorded every 30 minutes for 180 minutes post-injection. A second group
of rats were tested for the effects of acute administration of 40 and 80 mg/kg
SKF on body temperature. Following the pre-injection temperature
measurements, the rats were injected with normal saline or SKF (40 or 80
mg/kg) and the temperature time-course followed as described above.
On days 2 to 10, the rats were weighed, rectal temperatures were recorded, after
which the tats were injected with saline or the same dose of SKF that they had
received on day 1 (5, 10 or 20 mg/kg). On days 7 and 10 full time-course
studies were carried out as described above for day 1.
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The data were analyzed by analysis of variance. When a significant effect of
treatment was found, multiple comparisons were made between treatment
groups using Dunnett’s r-test or Scheffe’s F-Test .
RESULTS
Acute administration of SKF at the doses of 5-40 mg/kg did not have a
significant effect on body temperature of the rats. At the dose of 80 mg/kg,
SKF produced significant hypothermia. In contrast to day 1. administration of
SKF on day 7 to chronically SKF-treated animals produced hyperthermia. The
hyperthermic effects of SKF were greater at 20 mg/kg than at 5 and 10 mg/kg.
On day 10 of chronic treatment, SKF produced a dose dependent hyperthermia.
The hyperthermic effects of SKF were enhanced on day 10 compared to day 7.
Chronic treatment of animals with SKF for 10 days had no significant effect on
baseline temperatures and weights. There was a significant effect of time (days
of chronic treatment) on body temperature and on weights.
CONCLUSIONS
Acute administration of the selective sigma receptor agonist SKF at doses of
5-40 mg/kg has no significant effect on body temperature in the rat. At the dose
of  80 mg/kg,  the  acute administration of SKF produces significant
hypothermia. In contrast, chronic administration of SKF (5-20 mg/kg) produces
significant hyperthermia. The hyperthermic response is dependent on the dose
and the duration of SKF treatment.
The hypothermic effects of SKF are seen following acute administration of a
high dose of SKF (80 mg/kg). In contrast, the hyperthermic effects of SKF are
seen following chronic administration at considerably lower doses of SKF.
These characteristics indicate that there could be separate mechanisms underlying
the two effects of SKF on body temperature.
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Effects of Buspirone in the
Benzodiazepine Dependent Rat
Norman R. Boisse, Gary M. Samoriski and Yu Xie
The anxiolytic efficacy of buspirone following chronic
benzodiazepine use in man is controversial. Benzodiazepine
withdrawal may be involved. Accordingly, acute, sub-acute and
chronic buspirone experiments were designed to evaluate
buspirone (0.1, 1 and 10 mg/kg) effects during maximal
benzodiazepine withdrawal and to induce benzodiazepine-like
withdrawal in rats. Benzodiazepine dependence was induced with
chlordiazepoxide 150 mg/kg b.i.d. x 5 weeks; controls received
water; both p.o. Three days post-chlordiazepoxide, when
withdrawal is maximal, acute buspirone/water was given p.o. and
withdrawal evaluated at 0 and 30 min. by a standard neuro-
behavioral screen. In a second chronic chlordiazepoxide/water
group, buspirone dosing began 12 hours post-chlordiazepoxide
b.i.d. x 3.5 days and withdrawal evaluated. In a third set, rats
received chlordiazepoxide 150 mg/kg, water or three buspirone
doses b.i.d. x 5 weeks and spontaneous withdrawal evaluated daily
x 14 days. Acute and sub-acute buspirone failed to consistently
affect benzodiazepine withdrawal. Consistent with clinical
reports, buspirone withdrawal also failed to produce a benzo-
diazepine-like withdrawal syndrome. Therefore, buspirone is
devoid of benzodiazepine-like direct physical dependence
potential or cross physical dependence capacity. (Supported by
Bristol-Myers grant).
Section of Pharmacology, College of Pharmacy and Allied Health
Professions, Northeastern University, Boston, MA 02115.
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Profile of Opioid Withdrawal in
Newly Hatched Chickens
Maureen E. Bronson and Sheldon S. Sparber
Interest in the consequences of exposure to opioids during development stems
from the fact that many children are born passively addicted to this class of
drugs. In the early to mid 1970s, it was not uncommon to read descriptions of
morbidity and mortality in such neonates, which in retrospect appears to have
been related more to severe abstinence than to opioid exposure per se, although
the latter may contribute to congenital or postnatal developmental risk factors as
well. Unfortunately, in animal research associated with this problem, too little
attention has been paid to possible secondary or tertiary causes, such as
hypoxia/hypercapnia in pregnant experimental subjects, brought about by
inappropriately high doses of the opioid; or treatment protocols which do not
model stable maintenance schedules for pregnant women in methadone
programs. Additional sources of potential’epiphenomena include nutritional and
other neonatal experiences. As a means of eliminating possible maternal
factors, our laboratory has used the chicken embryo and neonate to study
effects of opioids, opioid withdrawal and quasi-opioid withdrawal during
development. The further characterization of withdrawal in the embryo and
neonate of this species, and its potential utility for studying the biological bases
for the adaptive process (i.e. dependence), its expression (i.e. withdrawal), and
the potential utility of selective serotonergic antagonists for nonopioid treatment
of withdrawal in the neonate are described in this communication.
The 14-day-old embryo can be shown, under appropriate experimental
conditions, to develop acute opioid dependence and express withdrawal (e.g.
increased motility) in a manner similar to that observed in older embryos.
Moreover, significant changes in brain 5-HIAA concentrations, at a time when
dependence can be demonstrated, indicate serotonergic involvement in the
adaptive process and its expression.
A single dose of methadone can also produce dependence in the newly hatched
chicken, as evidenced by precipitation of withdrawal when naloxone is injected
1-4 hours later. When a low dose of naloxone is used, withdrawal is
characterized by head shaking and distress vocalization. Moderate doses of
naloxone produce tremor, wing extension and splayed feet, while high doses
cause loss of righting reflex, which may be accompanied by convulsive-like
movements. If a higher dose of methadone is used to initiate dependence, a
much lower dose of naloxone will produce distress vocalization, tremor and
wing extension. Opioid dependent human neonates undergoing spontaneous
495
withdrawal exhibit similar or analogous signs, e.g. high-pitched cry, tremor
and, if withdrawal is severe, convulsions (Ostrea, E.M., C.J. Chavez and M.E.
Strauss. J. Pediatrics 88:642-645, 1976; Finnegan, L.P. In: Research on the
Treatment of Narcotic Addiction, State of the Art. J.R. Cooper, F.Altman, B.S.
Brown and D. Czechowica, Eds. DHHS Publication No. ADM 83-1281,
Rockville, MD, pp. 392-443, 1983).
We were also able to demonstrate dose-dependent quasi-opioid withdrawal in
the neonatal chicken. The syndrome produced by 10 mg IBMX/kg was
exacerbated by a low dose of naloxone. but the greater behavioral syndrome
produced by 20 mg IBMX/kg was not. We have recently reported this same
phenomenon in the rat (Kleven. M.K. and S.B. Sparber. J. Pharm. Exp.
Ther. 248:273-277, 1989).
Thus, the chick embryo and/or neonate provides a good model for studying the
consequences of either opioid dependence and withdrawal or withdrawal alone
(IBMX) during early development; and it should also provide a basis for
predicting potential nonopioid treatment modalities.
In support of this notion, we have recently observed that the 5-HT2 antagonist
mianserin. which attenuates true and quasi-opioid withdrawal in mature rats
(Neal, B.S. and S.B. Sparber, J. Pharm. Exp. Ther. 236:157-165, 1986;
Kleven, M.K. and S.B. Sparber, Psychopharmacology, in press), also blocks
the long term learning impairment and altered reactivity to morphine in rats
given IBMX as infants if mianserin is coadministered with the IBMX (Neal,
B.S. and S.B. Sparber, Xth International Congress of Pharmacology, Syndey,
Australia, 1987). We now report that mianserin produces dose-dependent
attenuation of distress vocalization in l-day-old chicks undergoing acute
withdrawal from methadone plus naloxone. Significant effects were seen after
pretreatment with 1 mg mianserin/kg and vocalization was not different from
controls after 5 mg mianserin/kg. This finding, combined with the evidence of
serotonergic involvement in the adaptive process of opioid dependence in the
embryo, suggest that selective serotonin receptor antagonists may prove useful
for detoxification during early development. Supported by USPHS grant
DA01880 and T32 DA 07097.
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Synthesis of Fentanyl Analogs
F. Ivy Carroll, Karl G. Boldt, P.-T. Huang,
D. K. Sawyer and George A. Brine
There are several classes of synthetic piperidine derivatives
which show analgesic activity, the 4-anilinopiperidine structure
(1, fentanyl class) having provided the most potent compounds.
An enormous number of fentanyl analogs has been prepared, many of
which are substantially more potent than morphine. A large num-
ber of fentanyl analogs has obtained clinical utility. The fent-
anyl class of analgesics has also been an attractive target for
"designer drug" chemists. Beginning in 1981 when street samples
of "China White" were identified as -methylfentanyl (Kram
et al., 1981), an increasing number of fentanyl analogs has been
identified as "designer drugs". The efforts to curb the abuse of
fentanyl analogs have required authentic compounds as reference
standards for abuse liability studies. We have synthesized fent-
anyl (1a) and the twenty analogs summarized in the Chart by adap-
tation of reported, syntheses (Bever et al., 1974; Casey et al.,
1969; Daele et al., 1976; Fifer et al., 1984; Janczyk et al.,
1978; Janssen, 1965; Lobbezoo et al., 1980; Lobbezoo et al, 1981;
Maryanoff et al., 1982; Zee et al., 1981; Zhu et al., 1983). All
of the compounds were purified as the hydrochloride salts and
characterized by TLC, melting point, 1H NMR, IR and elemental
analysis as necessary. To our knowledge, compounds 1f-h, 2 and
6b have not been previously reported in the literature.
REFERENCES
Casy, A. F., Hassan, M. M. A., Simmnonds, A. B. and Staniforth,
D., Structure-activity Relations in Analgesics Based on
4-Anilinopiperidine, J. Pharm. Pharmac., 32, 434-440 (1969).
Janssen, P. A. J., 1-Aralkyl-4-(N-arylcarbonylamino)piperidines
and Related Compounds, U. S. Patent 3,164,OOO (1965).
Jonczyk, A., Jawdosfuk, M. and Makoaza, M., Synthesis of the
Analgesic Fentanyl on an Industrial Scale, Przem. Chem., 57,
180-182 (1978).
Kram, T. C., Cooper, D. A. and Allen, A. C., Behind the Identifi-
cation of China White, Anal. Chem., 53, 1379A-1386A (1981).
Lobbezoo, M. W., Soudfjn, W. and van Wijngaarden, I., Structure
and Receptor Interactions of Morphlnemfmetfcs. Part 1.
Hydroxy and Methoxy Derivatives of Fentanyl and Some Morphine
497
Analo ues, Eur. J. Med. Chem.-Chlm. Ther., l5, 357-361
(1980).
Lobbezoo, M. W., Soudijn, W. and van Wijngaarden, I., Oplate
Receptor Interaction of Compounds Derived from or Structur-
ally Related to Fentanyl, J. Med. Chem., 24, 777-782 (1981).
Maryanoff, B. E., Simon, E. J., Gioannini, T. and Gorissen, H.,
Potential Affinity Labels for the Oplate Receptor Based on
Fentanyl and Related Compounds, J. Med. Chem., 25, 913-919
(1982)..
van Bever, W. F. M., Niemegeers, C. J. E. and Janssen, P. A. J.,
Synthetic Analgesics. Synthesis and Pharmacology of the
Diastereoisomers of N-[3-Methyl-1-(2-phenylethyl)-4-piperi-
dyl]-N-phenylpropanamide and N-[3-Methyl-1-(1-methyl-2-
phenylethyl)-4-piperldyl]-N-phenylpropanamide, J. Med. Chem.,
17, 1047-1051 (1974).
van Daele, P. G. H., De Bruyn, M. F. L., Boey, J. M., Sanczuk,
S., Agten, J. T. M. and Janssen, P. A. J., Synthetic Anal-
gesics: N-(1-[2-Arylethyl]-4-substituted 4-Piperidinyl)
N-Alkylalkanamides, Arzneim. Forsch., 26, 1521-1531 (1976).
Zee, S.-H., Lai, C.-L., Wu, Y.-M. and chen, G.-S., Preparation of
Fentanyl from Phenethylamine and Methyl Acrylate, K'o Hsueh
Fa Chan Yueh K'an, 9, 387-397 (1981).
Zhu, Y.-C., Wu, R.-Q., Chou, D.-P. and Huang, Z.-M., Studies on
Potent Analgesics. VII. Synthesis and Analgesic Activity of
Diastereoisomers of 1-ß-Hydroxy-3-methylfentanyl (7302) and
Related Compounds, Yaoxue Xuebao, 18, 900-904 (1983).
AFFILIATION
Chemistry and Life Sciences, Research Trlangle Institute,
Research Trlangle Park, North Carolina 27709, USA.
Chart
498
Effects of D1 and D2 Dopamine
Antagonists on Heroin-Trained
Drug Discrimination
William A. Corrigall and Kathleen M. Coen
Rats were trained to discriminate heroin (0.3 mg/kg from saline
in a fixed-ratio 10 food-reinforced paradigm. The discriminative
stimulus produced by heroin was first characterized in tests with
heroin metabolites monoacetyl morphine (MAM) and morphine (M);
MAM appears to be responsible for the heroin-trained stimulus,
since equi-molar doses of heroin and MAM were similar. In con-
trast, a dose of 3 mg/kg M was the lowest dose that generalized
completely to the heroin-trained stimulus. At the training dose
of heroin, doses of the D1 antagonist SCH23390 and the D2
antagonist spiperone between 0.001 and 0.01 mg/kg did not alter
responding on the drug-trained lever or response rate. At doses
of either D1 or D2 antagonist of 0.03 mg/kg and higher, both
drug-trained responding and response rate decreased in parallel.
The antagonists were also ineffective in altering the heroin
stimulus at lower heroin doses. These results suggest that the
discriminative stimulus properties of heroin do not depend
significantly on dopaminergic function.
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The Stimulus Properties of
Cocaine:. Effects of Bay K 8644 and
Nimodipine
Kathryn A. Cunningham and Patrick M. Callahan
As a result of the epidemic abuse of cocaine in the United States and the
increased incidence of adverse effects associated with cocaine exposure,
at tempts  to  both understand i ts  mechanism(s)  of  act ion and explore
pharmaceutical compounds which may be useful in the treatment of cocaine
abusers are underway. The dihydropyridine calcium channel blockers may
be of  use in  this  regard as  nifendipine has recent ly been shown to
antagonize the cardiac toxicity and lethal effects of cocaine (Trouve and
Nahas, 1986). Nifendipine and other dihydropyridines readily penetrate the
blood brain barrier (Schoemaker et al., 1983), appear to bind to discrete
areas of the brain (Gould et al., 1985) and are reported to antagonize some
stimulant-induced behaviors (Fung and Uresky, 1980; Grebb, 1986). The
present experiment was designed to investigate whether nimodipine might
block the subjective effects of cocaine. We have also assessed whether the
calcium channel agonist BAY K 8644 mimics the interoceptive cocaine cue.
METHODS
Male Sprague-Dawley rats (N=8) were trained to discriminate cocaine (10
mg/kg)  from sal ine in  a  two-choice,  water-reinforced (FR 20)  drug
discrimination task using procedures that have been described in detail
e lsewhere (Cunningham and Appel ,  1987) .  After  acquis i t ion of  the
discriminat ion and establ ishment  of  the dose-response relat ionship,
substitution tests with BAY K 8644 administered either intraperitoneally
(IP; 15 min) or orally (PO; 30 min) in an ethanol/polyethylene glycol
solvent (provided by the supplier) and combination tests with nimodipine
(IP; 60 min; dissolved in a similar solvent) were conducted.
RESULTS
Cocaine (0.625-10 mg/kg) produced a dose-related increase in responding
on the drug-lever. In substitution tests, BAY K 8644 when administered
either intraperitoneally (0.25-1.0 mg/kg; IP) or orally (1 or 2 mg/kg; PO)
engendered predominantly sal ine-lever  responding. When  g iven  in
combination with cocaine (0.625-10 mg/kg), nimodipine (0.2 or 0.4 mg/kg)
tended to shift the dose-response curve to the right. Nimodipine (0.8
mg/kg) also appeared to reduce cocaine-lever  responding after  lower
cocaine doses (1.25 and 2.5 mg/kg). However, drug-lever responding did
not differ significantly for any combination of cocaine plus nimodipine. The
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percent cocaine-lever responding at 5.0 and 10 mg/kg was unaffected by the
highest dose of nimodipine tested (1.6 mg/kg), while lower cocaine doses in
combination with nimodipine (1.6 mg/kg) could not be tested because of
response depression. Neither vehicle nor nimodipine administered alone
elicited responding on the drug lever.
DISCUSSION
The calcium antagonist BAY K 8644 crosses the blood-brain barrier, alters
central catecholamine synthesis and release (Pileblad and Carlsson, 1987;
Woodward and Leslie, 1986) and elicits significant behavioral effects
(Bourson et al., 1989; O’Neill and Boiger, 1988). In fact, BAY K 8644 is
discriminable from sal ine and this  cue is  antagonized by nifendipine
(Gladstein et al., 1987). In the present study, the subjective state induced
by BAY K 8644 is not perceived as similar to that induced by cocaine.
Nimodipine only partially blocks the subjective effects of cocaine, but this
antagonism is not robust nor dose-related. Our finding corroborates those
of Nencini and Wooiverton (1988) who reported similar attenuating effects
of 2 mg/kg, but not higher doses (4.0 and 5.6 mg/kg), of nimodipine. As
suggested by Nencini and Woolverton (1988), the partial attenuation of
stimulant cues may be related to non-specific stimulus factors elicited by
the combination of amphetamine (or cocaine) with the calcium channel
antagonist.
While calcium is a ubiquitous ion important in many biological functions,
including neurotransmitter release, our findings with BAY K 8644 and
nimodipine suggest only a subtle influence of this mediator in the subjective
state induced by cocaine.
Supported by Miles Institute for Preclinical Pharmacology.
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lndomethacin Antagonizes the
Effects of Ethanol: Effect of Route
of Administration
G. I. Elmer and F. R. George
INTRODUCTION Ethanol is proposed to initiate some of its bio-
chemical and behavioral effects via fluidization of neuronal
membranes (Goldstein et al., 1982). Since the arachidonic acid
cascade is significantly influenced by changes in lipid fluid-
ity, the behavioral effects of ethanol have been proposed to be
due in part to an increase in arachidonic acid metabolites. In
support of this hypothesis, prostaglandin synthetase inhibitors
(PGSI) have been demonstrated to be effective antagonists of the
acute activating, hypothermic, hypnotic and lethal effects of
ethanol (George, 1989). The ability of prostaglandin synthetase
inhibitors to antagonize the effects of ethanol, however, has
been demonstrated only via the intra-peritoneal (i.p.) route of
administration. The pharmacological effects of these inhibitors
could be due in part to the inhibition of the local release of
prostaglandins caused by the irritant effects of i.p. ethanol.
Therefore, the effect of route of administration on the ability
of the potent PGSI, indomethacin, to inhibit the acute hypnotic
effects of ethanol was investigated. In addition to delineat-
ing the CNS versus peripheral effects of indomethacin, the clin-
ical utility of prostaglandin synthetase inhibition in treating
acute oral ethanol hypnosis will be determined.
METHODS The effect of administration route was investigated
as a function of indomethacin dose. Indomethacin (0-10 mg/kg)
was given to male DBA/2J mice 15 minutes post 4.0 g/kg ethanol
treatment. Route of administration was varied in the following
order: i.p. ethanol (50% v/v) and i.p. indomethacin; i.g. ethan-
ol (20% v/v) and i.p. indomethacin; i.g. ethanol (20% v/v) and
i.g. indomethacin. The duration of loss of the righting reflex
following ethanol administration was used as the measurement for
the acute hypnotic effects of ethanol. After the mice were able
to right themselves three times within 30 seconds, duplicate
10 ul retro-orbital blood samples were obtained and analyzed for
blood ethanol concentration. A minimum of 5 subjects were used
per indomethacin dose and route of administration.
RESULTS Indomethacin significantly antagonized the acute hyp-
notic effects of ethanol across all routes of administration.
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(F(indomethacin)=3.38; df=4,108; p .05). For example, indometh-
acin at 2.5 g/kg decreased ethanol-induced loss of the righting
reflex 31%, 48%, and 49% when administered under the following
conditions; (i.g. ethanol/i.g. indomethacin), (i.g. ethanol/
i.p. indomethacin) and (i.p. ethanol/i.p. indomethacin), respect-
ively. Route of administration significantly affected indometh-
acin dose-response curve, (F(route)=3.55; df=2,108; p .05).
Indomethacin was most efficacious following i.p. ethanol admin-
istration; sleeptime was decreased by greater than 60% versus
38% and 33% for the i.p./i.g. and i.g./i.g. conditions, respect-
ively. Under all conditions, indomethacin treated mice regain-
ed the righting reflex at higher blood ethanol levels than did
control mice.
DISCUSSION Inhibition of prostaglandin synthetase activity and
the subsequent production of prostaglandins antagonizes the
acute effects of ethanol across all routes of administration
tested. The demonstration that indomethacin is an effective
ethanol antagonist given i.p. or i.g. following i.g. ethanol ad-
ministration support a CNS versus peripheral site of action.
That is, variation in site of administration for ethanol and
indomethacin decreases the likelyhood that indomethacin inhibit-
ed locally released eicosanoids as the primary explanation for
its ability to antagonize the effects of ethanol. In addition,
indomethacin treated animals regained the righting reflex at
significantly higher blood ethanol levels thereby supporting
a decrease in neurosensitivity to ethanol as a result of prosta-
glandin synthesis inhibition. These results combined with the
previous demonstration of indomethacins ability to antagonize
the acute hypnotic and lethal effects of ethanol extend the
range of conditions over which indomethacin is effective in an-
tagonizing the effects of ethanol. Importantly, these results
demonstrate the application of prostaglandin synthesis inhib-
ition to clinically relevant orally administered ethanol
conditions.
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Potential Neurotoxic Effects of
Self-Administered Cocaine on
Dopamine Receptors
Nick E. Goeders, Marcia A McNulty, Ann M. Guidroz and
Steven I. Dworkin
INTRODUCTION
Until recently, cocaine was viewed by the general population to be a
relatively benign substance. Current evaluations of the neurobehavioral
effects of the drug have indicated that the term “benign” is a very
inappropriate misnomer. Cocaine is one of the most efficacious
reinforcers available, and while cocaine use has continued to increase
over the last ten years, the use of other behaviorally active drugs has
steadily declined. However, the neurotoxic effects of cocaine have
received little attention even though the effects of the drug in kindling
seizures and the neurotoxic effects of similar drugs have been
demonstrated. While the effects of cocaine on neurotransmission are
extremely complex, a variety of clinical and experimental data suggest
that the behavioral actions of the drug are mediated at least in part
through an inhibition of dopamine uptake into presynaptic nerve
endings. These experiments were therefore designed to investigate the
potential neurotoxic effects of self-administered cocaine on pre- and
postsynaptic dopaminergic receptors in the rat brain using light
microscopic quantitative autoradiography.
METHODS
Groups of three adult male Fisher 344 littermate rats were used in these
experiments. Briefly, the self-administration littermate was trained to
respond under a fixed-ratio 2 schedule of cocaine presentation (0.33
mg/200 µl infusion) during daily 6 hour sessions. The yoked-cocaine
and yoked-saline littermates received simultaneous infusions of cocaine
or saline, respectively, each time that the drug was self-administered by
the first littermate. After a 30 day exposure to the drug, the animals
were anesthetized with sodium pentobarbital and were sacrificed by
cardiac perfusion. The brains were rapidly removed, embedded in brain
paste and frozen onto microtome chucks over dry-ice. Ten micron
coronal sections were cut in a cryostat microtome, and the sections were
thaw-mounted onto subbed slides and stored at -20°C until needed.
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Postsynaptic D2 dopaminergic receptors were labeled under standard
conditions using [3H]sulpiride. [3H]Mazindol was used in the presence
and absence of desmethylimipramine to label noradrenergic (desmethyl-
imipramine-sensitive) and dopaminergic (desmethyl imipramine-
insensitive) uptake sites in adjacent tissue sections. After incubation,
the slides were dried, affixed to mounting board, placed in x-ray
cassettes with radioactive standards and apposed to [3H]Ultrofilm. After
a 4 to 6 week exposure, the films were developed using standard
procedures and the density of silver grains on [3H]Ultrofilm was
quantified using computer-assisted microdensitometry.
RESULTS
Both contingent and non-contingent cocaine administration resulted in
decreases in specific [3H]sulpiride binding in the caudate nucleus when
compared to yoked-saline control animals, although this effect was
statistically significant only in the self-administration rats (p< 0.05). There
were no statistical differences in specific binding in the nucleus
accumbens. Both contingent and non-contingent cocaine administration
resu l ted  in  s ta t i s t i ca l l y  s ign i f i can t  inc reases  (p  <  0 .05)  in
desmethylimipramine-insensitive [3H]mazindol binding in both the
caudate nucleus and nucleus accumbens when compared to the yoked-
saline control animals.
CONCLUSIONS
Both contingent and non-contingent cocaine administration resulted in
an increase in dopaminergic uptake sites in the caudate nucleus and
nucleus accumbens. On the other hand, cocaine administration resulted
in a decrease in postsynaptic D2 dopaminergic receptors in the caudate
nucleus, although this effect was statistically significant only in the self-
administration animals. These data are consistent with current
hypotheses concerning the neurochemical actions of cocaine. If cocaine
binds to presynaptic uptake sites to inhibit the reuptake of dopamine,
then an increase in these uptake sites would be expected. The
increased synaptic concentration of dopamine would then result in the
compensatory decrease in postsynaptic dopaminergic receptors
observed in these experiments. These neuroadaptations may be
reflective of potential neurotoxic effects resulting from cocaine
administration. Additional studies are in progress to further characterize
these potentially neurotoxic effects.
Contract # 271-87-8118).
(Research supported by NIDA
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Assessment of the Abuse Potential
of Methocarbamol in Primates
Belinda A. Hayes and Robert L. Balster
The abuse potential of the muscle relaxant methocarbamol was
evaluated in rhesus monkeys. In one study, the ability of i.v.
methocarbamol to serve as a reinforcer was evaluated using a
standard substitution procedure. In another study, the
barbituate-like discriminative stimulus effects of methocarba-
mol were studied in monkeys trained to discriminate pentobarbi-
tal (8.0 mg/kg) from no-drug. Methocarbamol failed to function
as a positive reinforcer when cocaine (0.033 mg/kg/injection)
or methohexital (0.1 mg/kg/injection) was the baseline drug.
when methocarbamol (3.0 and 10.0 mg/kg/injection) was substi-
tuted for the two baseline drugs, rates of self-administration
fell within saline and methocarbamol vehicle ranges. In
contrast, pentobarbital (0.25 and 0.5 mg/kg/injection) provided
evidence for reinforcing effects when substituted for methohex-
ital, although not when substituted for cocaine. Methyocarbamol
(3-75 mg/kg) failed to generalize from the training dose of
pentobarbital (8.0 mg/kg) and also failed to affect overall
rates of responding. These results indicate that methocarbamol
does not possess reinforcing effects or pentobarbital-like
discriminative effects in primates over the dose range tested.
AFFILIATION
Department of Pharmamlogy & Toxicology, Medical College of
Virginia, Virginia Ccmmonwealth university, Richmond, Virginia
23298-0613.
506
Studies on the Stereoselective
Synthesis of cis-3-Methyfentanyl
Fu-Lian Hsu, Peter W. Von Ostwalden, Harold D. Banks
and C. Parker Ferguson
Fentanyl (1) was synthesized by Janssen and his co-workers in 1964
and was one of the most potent synthetic opioids developed. In the
tail-withdrawal test in rats, it was found to have almost 200 times the
potency of morphine. Its onset time and duration of action are much
shorter than that of morphine. In 1973, Riley et al. synthesized
3-methyl fentanyl  (2)  f rom 4-ani l ino-3-methylpyr id ine. Shortly
thereafter, Janssen’s group published a more practical method of
synthesizing 2 from 3-methyl-4-piperidone, which is analogous to their
fentanyl synthesis. The Schiff base reduction with NaBH4, obtained
70% cis and 30% trans of 5 which was then separated. The cis- and
trans-5 were then successfully converted to cis- and trans-3-methyl-
fentanyl in 3 steps. In the tail-withdrawal test, the racemic cis-2 was
found to be 8 times more active than the trans-isomer, which was
equipotent to fentanyl. The cis-2 was then resolved. The ED50 of (+)-
cis-3-methylfentanyl was found to be 20 times lower than fentanyl and
was 100 times more potent than the (-)-cis-3-methylfentanyl. In view of
the high potency of the cis-isomer of substituted fentanyls, we became
interested in developing an efficient methods for their preparation.
To study the stereoselective synthesis of cis-3-methylfentanyl, we
developed two different approaches: A) bulky hydride reduction of the
Schiff base, 4; B) reductive decyanation of the -aminonitrile, 6.
To study the stereoselective reduction of the Schiff base, several bulky
hydride reducing agents were employed: Super-Hydride, Red-Al, and
L-Selectride. The known geometric isomers, cis- and trans-5, were
used as the reference for comparison. The relative ratios of the cis-
and trans-isomers formed by hydride reduction of 4, were determined
by gas chromatography of the crude reaction products. The results
showed that a distinctly greater stereoselectivity in the case of
L-Selectride which formed a -14-15 fold excess of the cis -isomer.
When the reduction of 4 with L-Selectride was scaled up, the major
cis-5 was obtained in 45% yield as oxalate salt without a tedious
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separation of the isomers and was more convenient than the literature
procedure (39%).
The reductive decyanation of a-aminonitriles with NaBH4 is well-
known. In the model study, the reduction of an analog of 6 (without
3-methyl group) with NaBH4 or other bulky hydride reducing agents,
such as Red-Al, Super-Hydride, and L-Selectride gave a clean
conversion to the decyanated product. In view of the possibility of the
stereoselective decyanation of 6, with these bulky hydride reducing
agents and the elucidation of the mechanism of decyanation in this
system, the cis- and trans-a-aminonitrile, 6 were used for this study. In
the reduction of cis- and trans-6, the distributions of cis- and trans-5
were similar which was almost identical to the direct Schiff base
reduction. As in the case of the Schiff base reduction, L-Selectride
was the most stereoselective reagent. It is reasonable to conclude,
therefore, that the mechanism of the reaction of cis- and trans-6
probably proceeds through a common Schiff base intermediate.
From these studies, it was found that L-Selectride was by far the most
stereoselective reagent of the metal hydrides used in both the Schiff
base reduction and the reductive decyanations of a-aminonitrile,
producing more than a 13-fold excess of the pharmacologically more
active cis-isomer.
6
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Energy Substrate Metabolism in
Testis of Rats Treated with Delta-9-
Tetrahydrocannabinol (THC) and
Cocaine (COC)
Syed Husain
Utilization of substrates like glucose and fructose is
an important source of energy for the normal
functioning of different tissues in the body. This is
particularly true in case of brain and testis where the
demand of these substrates is much greater.
Marihuana and its psychoactive constituent 9-THC
(THC) have been shown to inhibit different gonadal
functions. We suggested that THC causes these
reproductive insults by inhibiting the utilization of
energy producing substrates in the testis. More
recently, the abuse of cocaine (COC) has also become
widespread in the younger population of the society.
Although the primary neurochemical actions and
reinforcing properties of COC have been studied
extensively, not much information is available as to
the effects of COC on energy metabolism in the testis.
Therefore, the following studies were conducted to
compare the effects of THC and COC on the metabolism
of glucose in the rat testis.
Groups of rats were treated acutely with 10mg/kg,po,THC
or 20mg/kg,ip,COC. Control rats received 2ml/kg of
sesame oil or saline. THC treated rats were sacrificed
2hr post injection whereas COC animals were killed at
15 or 30 min following drug injection. Their testes
were rapidly removed and sectioned into small pieces.
With these tissues, radio-respirometric experiments
were conducted using 5.5mM radiolabled glucose as the
substrate. In these experiments, the rate of 14CO2
production was used as an index of glucose metabolism
in these tissues. These rates in 14CO2 production from
testes of THC and COC treated rats were compared with
respective controls to determine their significance.
Previously, our studies have indicated that in-vitro
as well as in-vivo exposure of rat testicular tissue
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to THC causes a significant decrease in the utilization
of energy rich substrates by this tissue. Others
reported a consistant correlation between the
inhibition of fructose utilization and a decrease in
the motility of sperms from human, rhesus monkey and
rabbits exposed to THC. Similarly, glucose was found
to be a necessary substrate for in-vitro capacitation
and acrosomal reaction of hamster sperms. These
observations indicate an important role for glucose and
fructose metabolism in explaining different gonadal
effects of THC in the testis.
In recent years, the street use of COC has increased
considerably. Studies have shown that behavioral and
functional modifications after COC use are related to
blockade of reuptake of both dopamine and
norepinephrine. Similarly, the increased locomotor
activity following COC is correlated with an increase
in glucose utilization in medial frontal cortex and
nucleus accumbens of the mesocorticolimbic system. As
metabolism of energy rich substrates like glucose is
also vital to the functioning of tissue like testis,
we compared the effects of THC and COC on glucose
metabolism in this tissue. In this study a 10mg/kg,
po dose of THC caused a reduction of 29% in glucose
metabolism as compared to controls (p<0.001). On the
other hand, testicular tissue of rats treated with
20mg/kg, ip COC and sacrificed either at 15 or 30 min
had no significant difference in glucose metabolism
from their respective controls. These observations
suggested that as oppose to THC, COC may have no
effects on energy metabolism in the testis. However,
recent-reports indicate that effects of COC in humans
as well as in other animals vary both with dose and
with the route of its administration. In these
investigations, intravenous (iv) administration of COC
but not the intraperitoneal (ip) route resulted in
significant increases in the rate of glucose use in
medial prefrontal cortex and nucleus accumbens. In our
study, we administered COC by the ip route. This may
have contributed to the lack of COC effects on glucose
metabolism in the testis. It is likely that following
ip administration, the time required for COC absorption
is long enough for plasma esterases to degrade the drug
to its inactive metabolites. On the other hand, iv
administration,may allow enough -active drug to reach
the target tissue before it is metabolized (supported
in part by NIDA grants DA035595 and DA05215).
AFFILIATION
Department of Pharmacology, School of Medicine,
University of North Dakota, Grand Forks, ND 58201
510
MK-801 Attenuates the
Methamphetamine Induced
Decreased in Tryptophan
Hydroxylase Activity
J. W. Gibb, Michel Johnson and G. R. Hanson
Methamphetamine (METH) decreases the activity of brain trypto-
phan hydroxylase (TPH) as well as the concentrations of
5-hydroxytryptamine and 5-hydroxindoleacetic acid. Since this
alteration of serotonergic parameters persists for long periods
of time, it is suggested that the neurochemical changes are
accompanied by neuronal degeneration. Because N-methyl-D-
asparate (NMDA)receptors have been implicated in ischemia-
induced neuronal damage (Simon et al., Science 226:850, 1984),
in this study we examined whether blockade of NMOA receptors by
an NMDA antagonist attenuates the decrease in TPH activity
induced by METH. Male Sprague-Dawley rats (180-250 g) received
METH (4 x 15 mg/kg, at 6-h intervals). Rats were sacrificed
18-20 h after the last dose, the brain was removed and the
neostriatum and frontal cortex were excised.
METH decreased neostriatal TPH activity to 26% of control. When
the non-competitive NMDA receptor antagonist, MK-801 (2.5
mg/kg), was administered 15 min prior to each METH administra-
tion, the METH-induced effects on the TPH activity was depressed
to only 66% of control. METH decreased cortical TPH activity to
25% of control; when MK-801 was combined with METH administra-
tion, TPH activity was 61% of control. When MK-801 was adminis-
tered alone, there was no effect on TPH activity.
3,4-Methylenedioxymethamphetamine (MDMA, 10 mg/kg), an amphet-
amine analog, also decreased TPH activity in the neostriatum to
34% and 30% of control in the neostriatum and frontal cortex,
respectively. In contrast to METH when MK-801 was administered
in combination with MDMA, no effect of the MK-801 was observed.
This study suggests that glutamate may play a role in the
METH-induced decline in central TPH activity; however the
mechanism by which MDMA decreases TPH activity may differ from
that by which METH causes its effects.
(Supported by USPHS grants DA 00869 and DA 04221).
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Cocaine Increases Benzodiazepine
Receptors Labeled in the Mouse
Brain In Vivo with [3H]Ro 15-1788
Marianna E. Jung, Marcia A. McNulty and Nick E. Goeders
INTRODUCTION
The non-medical use of cocaine has continued to increase during the
last decade resulting in considerable interest in the clinical and
neurobiological implications o f  th i s  behav io r . I n  humans ,
benzodiazepines are of ten employed cl in ical ly for  the medical
complications associated with acute cocaine toxicity and to manage
symptoms associated with withdrawal. Convulsions are often manifested
as a major side effect of acute cocaine intoxication, and these seizures
can be treated with intravenous diazepam, but not dilantin. In addition,
major symptoms associated with cocaine withdrawal include severe
agitation, anxiety and restlessness. Although diazepam can be used to
treat cocaine-induced anxiety, benzodiazepines are not recommended
as the treatment of first choice for cocaine withdrawal since the use of
these drugs could result in a secondary dependence. Nevertheless, we
have reported previously that cocaine administration results in significant
changes in the in vitro distribution of benzodiazepine receptors
measured in discrete regions of the rat brain. The following experiments
were therefore designed to investigate the acute effects of cocaine on
benzodiazepine receptors measured in vivo using [3H]Ro 15-1788.
METHODS
Restrained adult male ICR mice (30 to 35 grams) were injected via the
tail vein with 167 µCi/kg (5 µCi/mouse) of [3H]Ro 15-1788 (79.8 Ci/mmol;
NEN) diluted with 0.9% saline. to 33 µCi/ml. For determinations of
nonspecific binding, mice were pretreated with clonazepam (5 mg/kg, ip)
30 minutes before the intravenous injection. To determine the effects of
cocaine on benzodiazepine receptor labeling in vivo, various doses of
the drug (5, 20 or 40 mg/kg, ip) were administered 5 minutes before the
intravenous injection. This time point was chosen so that the maximum
effects of the drug would be present at the time of sacrifice (15 minutes
after the cocaine injection). Sulpiride (5 mg/kg, ip) was injected 30
minutes prior to the intravenous injection of [3H]Ro 15-1788 to determine
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whether the effects of cocaine were mediated via a dopaminergic
mechanism. The mice were sacrificed 10 minutes following the
intravenous injection, and the brains were rapidly removed and
dissected over ice. Samples of the cerebral cortex, hippocampus,
diencephalon, cerebellum, striatum and brain stem were retained,
weighed and placed in glass scintillation counting vials, and the tissue
was allowed to dissolve for 24 hr at 40°C. After the digestion of the
t issue was complete,  radioact iv i ty was determined using l iquid
scintillation spectrophotometry.
RESULTS
Cocaine pretreatment (20 mg/kg, ip) resulted in region-specific increases
in binding, with statistically significant increases observed only in the
hippocampus, diencephalon and striatum (p < 0.05). No effects on
nonspecific binding were seen in any brain region with any dose of
cocaine or following pretreatment with sulpiride. Low doses of cocaine
(5 mg/kg, ip) resulted in small but nonsignificant increases in specific
binding in all brain regions studied. Higher doses (20 mg/kg, ip)
resulted in site-specific increases, while doses just below the convulsant
range (40 mg/kg, ip) resulted in significant increases in [3H]Ro 15-1788
binding all brain regions. Sulpiride alone (5 mg/kg, ip) resulted in
significant increases in specific [3H]Ro 15-1788 binding in most brain
areas studied. However, sulpiride pretreatment did not result in further
increases in the effects of cocaine (20 mg/kg, ip) on [3H]Ro 15-1788
binding in any brain region except for brain stem.
CONCLUSIONS
Cocaine pretreatment (20 mg/kg, ip) resulted in region-specific increases
in benzodiazepine receptors labeled in vivo with [3H]Ro 15-1788.
Receptors in these same brain areas are also affected by acute and
chronic cocaine administration in vitro. These cocaine-induced site-
specific increases in binding were also dose-related. Wiih higher doses
(40 mg/kg, ip), cocaine resulted in increases in specific binding in all
brain regions studied, an effect similar to that produced by buspirone or
neuroleptic drugs. The mechanism(s) of action mediating these effects
is unclear. However, the cocaine-induced increases in benzodiazepine
receptor labeling probably did not result from a direct dopamine-related
action since the blockade of D2 dopaminergic receptors with sulpiride
did not alter the effects of cocaine on [3H]Ro 15-1788 binding in vivo
Additional experiments are in progress to explore the potential
mechanisms mediating these effects. (Research supported by USPHS
Grant DA 04293).
Departments of Pharmacology & Therapeutics and Psychiatry
Louisiana State University Medical Center
Shreveport, LA 71130
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Structural Requirements for
Nicotinic Antagonists in the CNS
Thomas J. Martin, John Suchocki, Everette L. May and
Billy R. Martin
(0.07-0.27), respectively. Endo- and exo-2-norbornamine, as
w e l l  a s t h e i r  N - m e t h y l a t e d  a n a l o g s ,  p r o d u c e d  a
non-dose-responsive antagonism of no greater than 50% at
10  min  p r io r  to  S .C .  admin is t ra t ion  o f  an  ED 8 4  dose  o f
nicotine. Ant inocicept ion was assessed by the tai l - f l ick
method 5 min following administration of nicotine or saline.
Spontaneous ac t iv i t y  was measured by  in te r rup t ions  o f
in f ra red  beams fo r  a  10  m in  sess ion  10  m in  fo l l ow ing
n ico t ine  o r  sa l ine  admin is t ra t ion . Nicot ine produced
Nicot inic antagonists h a v e  b e e n  i n s t r u m e n t a l  i n  t h e
characterization of nicotine’s pharmacology. . Initial evidence
for the existence of central nicotinic receptors was based on
the fact that nicotine: exerted numerous behavioral effects
that were antagonized by ganglionic blockers that penetrated
the blood-brain barrier. The mechanism of action of nicotinic
antagonists
periphery. These compounds have not been shown to compete
h a s  b e e n  s t u d i e d  m o s t  i n t e n s i v e l y  i n  t h e
effectively for agonist binding sites in the CNS, suggestin
that their  binding si te is dist inct from that of nicot ine. A
binding site for these compounds has yet to be elucidated,
however. One criterion for a receptor-mediated mechanism
of action is structural requirements for activity Although
the structural requirements for antagonism of nicotine has
been studied extensively in the periphery, the structural
requirements for antagonism of nicotine’s behavioral effects
has yet to be thoroughly documented.
The antagonism of nicot ine- induced ant inocicept ion and
depression of spontaneous activity was studied in mice for a
v a r i e t y  o f  m e c a m y l a m i n e  ( N ,  2 ,  3 ,  3 - t e t r a m e t h y l -
2-norbornamine) analogs. All compounds were injected S.C.
antinociception with an ED84 of 2.56 mg/kg. The AD50's (95%
C. L.)  of  pempidine,  (±)-exo-mecamylamine, ( - ) -exo-mec-
amy lamine ,  (+ ) -exo-mecamy lamine  and  (± ) -endo-2 -des -
m e t h y l m e c a m y l a m i n e  w e r e  0 . 1 3  ( 0 . 0 5 - 0 . 2 9 ) ,  0 . 0 8
(0.02-0.29),  0.09 (0.04-0.23),  0.24 (0.10-0.57) and 0.13
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doses up to 10
analogs of 2-norbornamine produced similar effects.
mg/kg. Several N-alkylpyridine-substituted
Translocation of the gem-dimethyls to the methylene b r i d e
significantly reduced the activity of mecamylamine 4.5 fold,
and the N-dimethyl analog of this compound was 9 times less
potent than mecamylamine.
Nicotine depressed spontaneous locomotor activity with an
ED84 of 1.71 mg/kg. When the abovementioned analogs were
eva lua ted  fo r  the i r  ab i l i t y  to  p revent  n ico t ine- induced
hypoactivity, a structure-activity relationship was obtained
w h i c h  w a s  s i m i l a r  t o  t h a t  d e s c r i b e d  f o r  b l o c k a d e  o f
nicotine-induced antinociception.
Therefore, mecamylamine antagonizes the behavioral effects
of nicotine with modest stereoselectivity ((+)-exo/(-)-exo=
2.7). Furthermore, the methyl groups in the N-, 2-, and
3-positions appear to be necessary for optimal antagonistic
activity. These structural requirements are distinct from
those that have been reported for nicotinic agonists in the
CNS, suggesting that the agonists and antagonists do not
share common binding sites centrally.
Supported by CTR grant #12130 and NIDA grant #DA07027.
Affiliation: Department of Pharmacology and Toxicology,
M e d i c a l  C o l l e g e  o f  V i r g i n i a - V i r g i n i a  C o m m o n w e a l t h
University, Richmond, VA 23298-0613
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Diels-Alder Reactions of -New
N-Formylmorphinan-6,8-dienes
L. Maat, T. S. Lie and J. T. M. Linders
Powerful analgetic 6 ,l4 -ethenoisomorphinans, such as etorphine,
have been prepared by Diels-Alder (DA) reaction of thebaine with
mono-substituted ethenes, followed by modification of the
substituents. Little is known of the reversal of the reaction
pathway. For the preparation of potential antagonists, having a
cycloalkylmethyl group at nitrogen, one can envisage an
alternative route, namely: N-demethylation of thebaine, N-
functionalization with the cycloalkylcarbonyl group, the DA
reaction and, finally, modification of the relevant substituents.
This route has the advantage that base-sensitive dienophiles can
be utilized. We have investigated the synthesis and DA reactions
of N-formylmorphinan-6,8-dienes as a model system.
Thebaine can be converted into N -formyl-N-northebaine by N-
demethylation with diethyl azodicarboxylate, followed by
formylation with ethyl formate. Application of this procedure to
6-demethoxythebaine gave the N-formyl analogue only in moderate
yield. The formylation was carried out in the presence of silica-
alumina catalysts, such as zeolites, or cracking catalysts. An
alternative synthesis of 6-demethoxy-N-formyl-N-northebaine was
devised to start from N-formyl-N-norcodeine, in analogy with our
synthesis of 6-demethoxythebaine from codeine (Ref. 1). Mesylation
with methanesulfonyl chloride in pyridine afforded the 6-O-mesyl
ester, which was converted into the 8ß-bromo compound by brief
treatment with lithium bromide in DMF. Elimination of HBr with the
aid of tBuOK gave the desired N-formylmorphinan-6,8-diene in good
yield. When the reaction with LiBr was continued for 5 h, an
unexpected rearrangement to (R)-(Z)-7-formyl-8,9-dihydro-2-
methoxy-7H-dibenz[d,f]azonine-1-0l was observed. This compound
could be obtained also by treatment of 6-demethoxy-N-formyl-N-
northebaine with HBr.
DA reaction of 6-demethoxy-N-formyl-N-northebaine with methyl
vinyl ketone gave the crystalline 7 -acetyl-6 ,14
ethenoisomorphinan in 80% yield. The cycloaddition to the N-methyl
analogue also gave this isomer as major product, besides the 8
adduct and a trace amount of 8ß-acetyl-6ß,14ß-ethenomorphinan, in
which the dienophile had approached the diene system from the more
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hindered o-face (Scheme). The DA reaction of nitroethene to N-
formyl-N-northebaine occurred in the usual way, giving the 7
nitro-6 ,l4 -ethenomorphinan in 90% yield with no trace of other
isomers.
However, the addition of nitroethene to the 6-demethoxy analogue
yielded a 5:3:1 mixture of 8 -nitro-6 ,14 ethenoisomorphinan, Bß-
nitro-6ß,14ß-ethenomorphinan and 7 -nitro-6 ,l4 -ethenoiso-
morphinan. The different behaviour of this dienophile, when
compared to methyl vinyl ketone, can be explained by geometrical
and steric factors. Furthermore, it is known that the nitro group
is more strongly regio-directing than the acetyl group. An
important factor which has to be taken into account as well is the
tendency of these 6-demethoxy systems to give 8-substituted
adducts. The two types of DA adducts are easily distinguished by
means of their 1H NMR spectra. For the 6 ,14 -ethenoisomorphinans,
the signals for the vinylic protons are typically found between
5.3 (H-19) and 6 5.9 (H-18), whereas these protons are found
downfield from 6 6.0 in the spectra of the isomeric 6ß, 1 4ß -
ethenomorphinans. In the N-methyl derivatives of the latter
series, the nitrogen atom has a notable effect on H-19, the signal
of which is now found downfield from that of H-18. In the
corresponding N-formyl compounds, the signals for these protons
are found in the usual order. The anisotropic properties of the
nitrogen atom are largely responsible for these and other
changes, e.g. the influence on 8ß-H (Ref. 2).
The new N-formylmorphinan-6,8-dienes give entry to differently
substituted 6 ,14 -ethenoisomorphinans and the new class of
6ß,14ß-ethenomorphinans (Scheme), which may contribute to a better
insight into the conformational and spatial requirements of the
lipophilic substituent.
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Kappa Antagonist Effects of
Buprenorphine in the Rat Drug-
Discrimination Procedure
S. Stevens Negus, Mitchell J. Picker and Linda A. Dykstra
Buprenorphine is a partial mu agonist with clinical
utility as an analgesic with low abuse potential and,
possibly, as an alternative to methadone as a
maintenance drug in the treatment of opioid dependence.
More recently, evidence has begun to accumulate that
buprenorphine binds to kappa opioid receptors as well
as to mu receptors. Most of the evidence regarding
buprenorphine's activity at kappa receptors suggests
that it has little if any intrinsic efficacy at these
receptors, and that it therefore acts as a kappa
antagonist. The present study was designed to expand
on this base of evidence by evaluating buprenorphine's
ability to antagonize the discriminative stimulus
effects of the selective kappa agonist U50,488 in a
two-lever, drug discrimination procedure.
Previous studies have indicated that "perceptual
masking" may confound the interpretation of antagonism
studies employing the drug discrimination procedure.
Perceptual masking is a term borrowed from sensory
psychophysics that describes the phenomenon in which
the presentation of one stimulus prevents the
perception of a second, concurrently presented
stimulus. In view of buprenorphine's known mu-agonist
effects, it was important to determine in the present
study whether any antagonism of U50,488 by
buprenorphine could be explained by perceptual masking.
Thus, in the present study, buprenorphine could reduce
the discriminative stimulus effects of U50,488 by
either 1)blocking kappa opioid receptors (antagonism),
or 2)producing mu-receptor mediated discriminative
stimulus effects that compete with and "mask" the
discriminative stimulus effects of U50,488 (perceptual
masking). In an effort to differentiate between these
two possibilities, the selective mu agonists fentanyl
and morphine were also evaluated for their ability to
reduce the discriminative stimulus effects of U50,488.
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Since morphine, and especially fentanyl, bind with
little or no affinity to kappa opioid receptors, any
reduction in U50,488's discriminative stimulus effects
produced by these drugs should serve as an index of the
vulnerability of the U50,488 stimulus to perceptual
masking by buprenorphine's mu agonist effects.
Finally, the non-opioid barbiturate agonist
pentobarbital was also evaluated for its ability to
reduce U50,488's discriminative stimulus effects in
order to determine if non-opioids could also mask the
U50,488 stimulus.
Rats were trained to discriminate 5.6 mg/kg U50,488
from water. During substitution tests, both U50,488
(0.3-17.0 mg/kg) and the kappa agonist bremazocine
(0.01-0.3 mg/kg) produced dose-dependent increases in
drug-appropriate responding. In contrast, the mu opioid
agonists buprenorphine (0.01-0.3 mg/kg), fentanyl
(0-03-0.3 mg/kg) and morphine (1.0-10.0 mg/kg) and the
non-opioid barbiturate agonist pentobarbital (1.0-10.0
mg/kg) produced primarily water-appropriate responding
when given alone. When given in combination with the
U50,488, buprenorphine produced a dose-dependent and
complete antagonism of the discriminative stimulus
effects of the training dose of U50,488. Furthermore,
a dose of 0.1 mg/kg buprenorphine shifted the U50,488
generalization curve approximately one half log unit to
the right. These results are consistent with the
hypothesis that buprenorphine has antagonist activity
at kappa opioid receptors. However, fentanyl, morphine
and pentobarbital also antagonized the discriminative
stimulus effects of U50,488, although to lesser extents
than buprenorphine. This suggests that at least part
of buprenorphine's kappa antagonist effects in this
procedure may result from perceptual masking rather
than from blockade of kappa opioid receptors.
S. Stevens Negus, Mitchell J. Picker and Linda A.
Dykstra; Dept. of Psychology: CB#3270; University of
North Carolina, Chapel Hill, NC; 27514
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Fluorescent Probes for Peripheral-
Type Benzodiazepine Receptor
Visualization and Localization
A. H. Newman, P. Arora, B. McRae, R. T. McCabe and
P. Skolnick
Saturable, high affinity sites for benzodiazepines have been
ident i f ied in the per ipheral  t issues, t ransformed cel ls of
neuronal origin, and in some areas of the central nervous
system, with physical and pharmacological characteristics
that are distinct from classical benzodiazepine receptors.
These peripheral-type benzodiazepine receptors (PBR) occur
in many peripheral tissues but have discrete localizations as
indicated by autoradiography. The prototype ligands for the
PBR, Ro 5-4864 and PK 11195 have been shown to bind with
high affinity to lymphocytes. The objectives of this study
were  to  p repare  a  ser ies  o f  PBR se lec t i ve  f luo rescen t
ligands, to determine whether they bind to both rat kidney
membranes and mouse spleen cells, and to use fluorescent
microscopic techniques for visualization.
A series of fluorescent PBR ligands were prepared based on
R o  5 - 4 8 6 4  a n d  P K  1 1 1 9 5 . The f luorescent moiet ies
nitrobenzoxadiazole (NBD) or dansyl chloride were used to
derivatize the parent compound with varying chain lengths
(2-6 methylene groups) between the fluorescent moiety and
the pharmacophore, to achieve maximal binding to PBR. AHN
590, An NBD-derivative of PK 11195, exhibited moderate
affinity (IC 50 90 nM) to PBR as evidenced by competition
s t u d i e s  w i t h  [3 H ] R o  5 - 4 8 6 4  b i n d i n g  i n  r a t  k i d n e y .
Prel iminary f luorescent binding studies in mouse spleen
cells show that these ligands bind and fluoresce. Inhibition
of this binding with PK 11195 will determine if this binding
is specific to PBR. Further studies in lymphocytes using
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these fluorescent PBR ligands may shed light on a possible
role for PBR in the modulation of the immune system. In
addit ion these l igands may represent an al ternat ive to
radioligands to characterize PBR as well as to study binding
kinetics.
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The Effect of Methadone In Vitro
on Natural Killer (NK) Activity
Miriam Ochshorn, Gershon Bodner, David M. Novick and
Mary Jeanne Kreek
Numerous immunologic abnormalities have been reported to occur
in heroin addicts and former addicts in treatment. In earlier
studies from this laboratory, we have shown that very high
concentrations of both the active (-) and inactive (+)
enantiomers of the opioid antagonist naloxone significantly
reduce natural killer (NK) cell activity in vitro, but that
lower concentrations, such as those used in human therapeutics
or to block opioid receptors in clinical research have no effect
on NK activity (1). In clinical studies of unselected methadone
maintained patients in treatment from one month to ten years,
without or with ongoing alcohol, cocaine or other polydrug
abuse, we have found normal NK activity in over 50% of patients,
whereas studies by our group and others have shown reduced NK
activity in essentially all active heroin addicts (2). In a
recent, controlled clinical study of very long term methadone
maintained patients, each in continuous methadone treatment for
over 11 years, none with any ongoing alcohol or drug abuse, and
all anti-HIV negative, it was found that all of the long-term
methadone maintained patients had normal NK activity. In
contrast, the active heroin addicts, who were also anti-HIV
negative, had low NK activity (3). We have asked the question of
whether methadone, a synthetic long-acting opioid agonist, may
affect NK cell cytotoxicity activity.
Eight normal subjects (4 males, 4 females; mean age 28.5y, age
range 22-41y) and eight methadone maintained subjects (length of
treatment from 18 days to 20y); (7 males, 1 female; mean age
34.3y, age range 18-51y; mean methadone dose 52.5mg, methadone
dosage range 30-85mg) were studied. All bloods were drawn
between 8:30AM-9:30AM. Methadone maintained patients were
studied prior to daily dose of methadone. Peripheral blood
mononuclear cells (PBMC) were separated by Ficoll-Paque density
gradient centrifugation. PBHC were incubated for 1 hour without
or with a wide concentration range (1x10-13 to 1x10-3M) of
(-)methadone, the active enantiomer of methadone, or with
(+)methadone, the inactive enantiomer, prior to and during NK
activity assay.
The results showed no effect of methadone in concentrations
of 1x10-13 to 1x10-5M, while very high concentrations (1x10-4 to
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1x10-3M) of either enantiomer of methadone resulted in a
significant reduction of NK activity. We conclude that:
1. High concentrations of (-)methadone and also (+)methadone
lower NK cell activity, with significant reduction in NK
activity observed at methadone concentrations of 1x10-4M and
above.
2. No significant decrease or increase in NK activity results
from addition of other contrentrations of (-)methadone or
(+)methadone (1x10-5 to 1x10-13M) .
3. Both (+) and (-)methadone at high concentrations have
similar effects on NK activity; therefore this effect does not
seem to be mediated by any classically defined opioid receptor.
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Effects of Mixed-Action Opioids on
Food-Maintained Behavior of
Morphine-Pretreated and
Morphine-Tolerant Rats
Alison Oliveto, Mitchell Picker and Linda A. Dykstra
The effects of various opioid compounds were
examined i-n rats responding under a fixed-ratio 30
schedule of food presentation. Dose-effect curves
were determined in untreated rats and in rats
pretreated with 5.6 mg/kg of morphine 5-6 hr prior
to the session. In addition, dose-effect curves
were determined in rats maintained on 30.0 mg/kg of
morphine daily. In morphine-pretreated rats, the
dose-effect curves for the mu-opioid agonists
morphine and 1-methadone were unaltered from those
determined in untreated rats, whereas those for the
opioid antagonists naloxone, naltrexone, and
diprenorphine shifted at least 0.5, 0.75, and 2 log
units to the left, respectively. The does-effect
curves for the mixed-action opioids nalorphine,
nalbuphine, butorphanol, pentazocine and bremazocine
in morphine-pretreated rats were not different from
those determined in untreated rats. In rats
chronically maintained on morphine, the dose-effect
curve for morphine shifted almost 0.5 log unit to
the right, whereas the dose-effect curve for the
kappa-opioid agonist U50,488 was unaltered from that
determined in untreated rats. The dose-effect
curves for naloxone and the mixed-action opioid
nalorphine were shifted approximately 2.5 and 1.5
log units to the left, respectively; whereas that
for the mixed-action opioid butorphanol was
flattened. The dose-effect curves for the mixed-
action opioids pentazocine, nalbuphine and
bremazocine in morphine-maintained rats were not
different from those determined in untreated rats.
These results indicate that a chronic morphine
administration procedure can be employed to
differentiate mixed-action opioids from opioid
agonists in rats. (Supported by USPHS Research
Grants DA02749 and DA05314)
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Rat Pups Exposed to Morphine
In Utero
J. E. Olley, G. K. L. Tiong, N. M. von Jenner and J. Scheer
Morphine was administered in the drinking water (Badawy et al., 1982) to
female Long Evans rats. Daily fluid consumption and growth were measured.
Physical dependence, assayed by naloxone-precipitated withdrawal (Wei et al.,
1973), was developed by rats taking 0.2 or 0.4 mg/ml morphine (n=4/group).
Further groups of rats (n=16) reached maintenance levels of 0.2, 0.4 and 0.8
mg/ml morphine 1 week prior to mating and continued drinking morphine-water
throughout pregnancy. Pups were fostered to lactating untreated females within
24 h of birth.
Morphine-exposed pups were cyanotic, hypothermic, had poorer survival rate
and weight-gain than controls. Behavioral teratology techniques (Buelke-Sam et
al., 1985) applied in the first 21 days indicated that rat pups were small for their
age, showed delayed reflex development (righting and negative geotaxis) but
earlier occurrence of physical events (eye opening and incisor eruption). Tail-
flick response to 50 °C and brain opioids appeared normal on day 24.
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The Effects of Phencyclidine on
the Pituituary-Adrenal Axis are
Centrally Mediated in the Rat
Robert N. Pechnick, Bonnie M. Chun, Robert George and
Russell E. Poland
A common characteristic of many abused drugs is that they markedly disrupt
neuroendocrine function and produce changes in plasma and tissue levels of
hormones. Phencyclidine (PCP) stimulates the pituitary-adrenal axis in the rat,
inducing the release of ACTH and corticosterone (Pechnick et al., 1989).
However, the site or sites at which PCP produces these effects is not known.
The present study examined the effects of PCP on the different units of the
pituitary-adrenal axis in the rat. In addition, PCP was injected directly into the
lateral cerebral ventricles in order to determine if the effects of PCP on the
pituitary-adrenal axis are centrally-mediated.
PCP (1.0 - 20.0 mg/kg) produced dose-dependent increases in plasma levels of
both ACTH and corticosterone when measured 60 min after s.c. administration.
H o w e v e r ,  P C P  d i d  n o t  s t i m u l a t e  t h e  r e l e a s e  o f  c o r t i c o s t e r o n e  i n
hypophysectomized rats. To assess the direct effects of PCP on the release of
corticosterone from the adrenal, adrenal cells were isolated using the method of
Sayers et al. (1971). PCP (10-9 - 10-3 M) did not affect the basal release of
corticosterone from dispersed adrenal cells in vitro; however, PCP inhibited
ACTH-induced corticosterone release from the adrenal cells. These results
demonstrate that PCP has no direct stimulatory effect on the adrenal, and the
PCP-induced corticosterone release that occurs in vivo must be secondary to the
release of ACTH from the pituitary.
In order to determine whether PCP directly stimulates the release of ACTH from
the pituitaries, whole rat pituitaries were removed and placed in a superfusion
apparatus. PCP (10-5 M) had no effect on either the basal or the CRF-induced
release of ACTH from superfused pituitaries in vitro, indicating that PCP does not
act directly at the level of the pituitary. In order to ascertain whether the the
effects of PCP on the pituitary-adrenal axis are centrally-mediated, PCP was
injected directly into the lateral cerebral ventricles via chronically implanted
cannulae. PCP (10.0 - 200.0 µg) produced dose-dependent increases in plasma
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ACTH levels when measured 30 min drug injection.
The results of these studies demonstrate that PCP has no directly stimulatory
effect on either the pituitary or the adrenal. Thus, PCP stimulates the pituitary-
adrenal axis in vivo by acting at a site within the central nervous system, leading
to the subsequent release of ACTH from the pituitary.
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Effects of Naloxone and Mr 2266
on Thermonociceptive Reactions in
Diabetic Mice
K. Ramabadran, M. Bansinath, H. Turndorf and M. M. Puig
Response to opiates is affected by glucose homeostasis. The hypoglycemic hormone insulin,
has been shown to induce hyperalgesia (Goodman and Soliman, 1989). The decreased opiate
sensitivity in diabetes is considered to be primarily due to hyperglycemia (Brase and Dewey
1988; Lux et al 1988). However, some results do not support this hypothesis (Ramabadran
et al 1989a). The hyperglycemic conditions do not alter the analgesic potencies of opiates like
methadone and propoxyphene (Brase and Dewey 1988). Additionally, opiate induced
inhibition of gut transit (Bansinath et al 1988, Ramabadran et al 1989b), thermic responses
(Bansinath et al 1989a) and mydriasis (Bansinath et al 198%) are not uniformly affected in
hyperglycemic conditions. In this study, in order to provide new insights into the specific
receptor site(s) at which hyperglycemia affects the opiate sensitivity, we assessed the
hyperalgesic response of naloxone and Mr 2266.
MATERIALS AND METHODS
Mate Swiss Webster mice (25-30 g) were used. Chronic hyperglycemia (diabetes) was induced
by streptozocin (Bansinath et al 1989a). Naloxone hydrochloride (3 mg/kg) and Mr 2266 (3
mg/kg) (gift from Dr. H. Merz, Boehringer Ingelheim, F.R.G.) were injected (s.c.) in a
volume of 10 ml/kg. A minimum of 10 animals were used per group. The details of the hot
plate (Ramabadran et al 1989a) and tail immersion test (Ramabadran et al 1989c) procedures
used were essentially similar to those published earlier. In the hot plate test, the reaction
latency in drug treated mouse was calculated as percentage of mean reaction latency of the
concomitant control group. In the tail immersion test, post-drug latencies were calculated as
percentage of the respective animal’s control latency.
RESULTS
In both tests, in normoglycemic mice, naloxone and Mr 2266 induced significant hyperalgesic
response (Table 1). In streptozocin treated mice, the hyperalgesic response of naloxone was
attenuated, while that of Mr 2266 was not affected.
TABLE 1
Drug
Hot platea Immersion testa
Normo STZ Normo STZ
Naloxone 54±4* 100±12 62±6* 106±11
Mr 2266 59±6* 61±8* 56±6 * 64±10*
a Mean (± SEM) response latency expressed as % of controls; * P < 0.05 with respect to their corresponding
controls; Normo = Normoglycemic mice; STZ = Streptaocin treated min.
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DISCUSSION
Results of the present study indicate that k receptor-mediated thermonociceptive
mechanism(s) are tonically active at spinal and supraspinal levels. Furthermore, chronic
hyperglycemia fails to affect the hyperalgesic response of k opioid antagonist Mr 2266 but
attenuates the hyperalgesic response of naloxone. Chronic hyperglycemia has been shown to
attenuate the inhibition of the gastrointestinal motility induced by the k opiate agonist, U-
50488H (Ramabadran et al 1989b). Taken together, these results suggest that the
hyperglycemia induced-changes in the pharmacodynamics of k and other opiate receptor
selective agonists and antagonists may be site specific. These results support the hypothesis
that elevated glucose levels may not be the primary mechanism for the altered opiate response
in the experimental models of diabetes (Bansinath et al 1988, 1989a,b; Ramabadran et al
1989a,b).
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Characterization,of NMDA-Coupled
and Dopoamine Reuptake Carrier
Coupled [3H]-TCP Binding Sites in
Guinea Pig Brain
A. A. Reid, J. A. Monn, A. E. Jacobson, K. C. Rice and
R. B. Rothman
INTRODUCTION
Phencyclidine (PCP) has been shown to produce psychotomimetic
effects, as well as therapeutic effects, including anticonvulsant and
neuroprotective actions. PCP has also been reported to possess a
variety of biochemical actions including noncompetitive inhibition of
the effects mediated by the glutamate excitatory amino acid receptor
specifically activated by N-methyl-D-aspartate (NMDA) and inhibition
of dopamine (DA) reuptake. Most studies have reported the presence
of a single high affinity PCP binding site coupled to the NMDA
receptor complex. However, we recently demonstrated that the PCP
analog, [3H]-TCP, labelled two high affinity binding sites in guinea pig
brain distinguished by (+)MK801. In the present study we conducted
kinetic experiments to evaluate the modulation of the MK801-sensitive
(site 1) and MK801-insensitive (site 2) binding sites by NMDA
receptor agonists and antagonists and tested the hypothesis that site
2 is associated with the DA reuptake carrier in guinea pig brain.
CHARACTERIZATION OF [3H]TCP BINDING SITES
PCP binding sites were characterized in whole guinea pig brain
including cerebellum with [3H]TCP utilizing binding surface analyses.
The data best fit a two site binding model. The best-fit parameter
estimates yielded Bmax values of 631±10 (site 1) and 829±24 (site 2)
fmol/mg protein and Kd values of 14.1±0.2 nM (TCP, site 1), 46.5±1.3
nM (TCP, site 2), 3.22±0.06 nM [(+)MK801, site 1], 5208±342 nM
[(+)MK801, site 2]. about 1 mM [BTCP (TCP analog), site 1] and 1083
±167 nM (BTCP. site 2). These analyses indicate that TCP is
essentially nonselective between the two PCP sites, while (+)MK801
is 1600 fold selective for PCP site 1 and BTCP is about 1000 fold
selective for PCP site 2.
KINETIC EXPERIMENTS
Kinetic experiments were conducted to examine the ability of NMDA
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receptor agonists and antagonists to facilitate dissociation of [3H]TCP
bound to the PCP sites. The dissociation of [3H]TCP from site 1 and
site 2 proceeded very slowly. Mg (100 µM) markedly enhanced the
dissociation of [3H]TCP from site 1. The combination of Mg and AP7
(100 µM each) resulted in a reversal of Mg’s effects at site 1, while the
combination of Mg/AP7/Glutamate (100 µM each) produced the same
increased rate of dissociation of [3H]TCP from site 1 as observed with
Mg alone. These agents were essentially ineffective at PCP site 2.
DA REUPTAKE BLOCKER STUDIES
Evaluation of the association of PCP site 2 with the DA reuptake
carrier involved BTCP and GBR12909, two potent inhibitors of DA
reuptake.Guinea pig caudate membranes were preincubated with
varying concentrations of the two drugs and then washed twice by
centrifugation prior to analysis of [3H]TCP binding sites. Neither drug
had any significant effect on PCP site 1, except 10,000 nM BTCP,
which inhibited [3H]TCP binding to this site by 20%. BTCP produced a
dose-dependent wash-resistant inhibition of [3H]TCP binding to PCP
site 2 at concentrations as low as 100 nM (20% inhibition), while
GBR12909 required higher concentrations (1000 nM, 46% inhibition).
CONCLUSIONS
The kinetic experiments demonstrated that glutamate, a NMDA
receptor agonist, Mg, a noncompetitive NMDA receptor antagonist
and AP7, a competitive NMDA receptor antagonist modulated
[3H]TCP binding to PCP site 1 but not PCP site 2, which suggests that
PCP site 1 is coupled to the NMDA receptor complex. Preincubation
of guinea pig striatal membranes with varying concentrations of the
high affinity DA reuptake inhibitors, GBR12909 and BTCP, caused a
dose-dependent, wash-resistant inhibition of [3H]TCP binding to PCP
site 2 but not PCP site 1. This tight binding phenomena suggests that
PCP site 2 is associated with the DA reuptake complex. These data
raise the possibility that PCP’s behavioral effects might be separately
mediated via the two binding sites: the psychotomimetic effects could
be mediated via the DA uptake carrier site, since an increase in the
release of DA has been associated with psychotic behavior and the
therapeutic properties could be linked to PCP’s noncompetitive
inhibition of NMDA-receptor mediated effects.
REFERENCES available upon request from author.
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Progress Toward the Synthesis of
Potential Affinity Ligands for the
Analgesic Cannabinoid Receptor
Based on CP-55,244
Scott Richardson, Miles Herkenham, Seid Mirsadeghi,
M. Ross Johnson, Larry S. Melvin and Kenner C. Rice
The major pharmacologically active constituent of the marijuana
plant (Cannabis sativa) is 9-tetrahydrocannabinol ( 9-THC, 1) and for
many centuries, marijuana preparations have been used as medicinal
agents. Ancient physicians noted many clinically useful effects of
marijuana, and among these, prescribed marijuana as an antiemetic
and analgesic. Currently, synthetic 9-THC is used as an antiemetic
for patients undergoing cancer chemotherapy.
In 1976, seminal studies by Wilson et al revealed that 9-nor-9-ß-
hydroxyhexahydrocannabinol (HHC, 2) was equipotent with
morphine as an analgesic in mice and later investigations indicated a
nonopioid mechanism of action. Recent biological studies on CP-
55,244 (3), prepared at Pfizer, have revealed this drug to be an
ext remely  po ten t  l igand  for  the  newly  d i scovered  ana lges ic
cannabinoid receptor. These results have prompted us to use CP-
55,244 as a template for the design of chemical probes to further study
the structure and function of this system. We intend to use the
ketone 4 as a common intermediate in the syntheses of analogs of CP-
55,244 with electrophilic functionality in specific regions of the parent
structure. A summary of our progress in these synthetic studies will
be described.
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Excitatory Amino Acid Antagonists
as Well as GABA Agonists Cause
Barbiturate-Like Anesthesia in Rats
J. A Richter and S. L. Gatto
We are interested in determining the mechanism of barbiturate
anesthesia. Since barbiturates are known both to mimic and en-
hance GABA actions and to inhibit glutamate actions, synapses
using either of these transmitter systems could be the neuro-
chemical site for this barbiturate effect. In order to evaluate
these potential mechanisms, we have tested other drugs known to
be GABA agonists or excitatory amino acid (EAA) antagonists on
rats in vivo to determine if they can cause anesthesia and/or.
other effects also induced by barbiturates.
Male Wistar rats were implanted unilaterally with intraventri-
cular (ivt) guide cannulae. After recovery, the freely moving
animals were injected with a dose of test drug in 10 ul vehicle
over 15 sec. CNS depression was evaluated on a 7 point scale
(0=normal to 7=coma, modified after Freer and Gallagher).
Rectal temperature and respiratory rate were also measured. The
rats were randomly assigned to treatment and the observer was
blind to the test drug/dose. Each animal was used only once.
After testing the injector placement was confirmed by dye in-
jection; data are reported only for those rats in which the in-
jection was into the lateral ventricle.
Phenobarbital (PheB) was tested at BOO, 1200 and 1600 ug ivt. As
previously described by Mycek and Brezenoff (1976) it induced a
dose-related, brief period of CNS depression up to a score of at
least 6 (loss of righting reflex and only a flinch to a tail
pinch) and a brief decrease in rectal temperature. The GABA
agonist muscimol (tested at 0.3, 1 and 3 ug) caused long-lasting
CNS depression to a score of 6 and very large, long-lasting de-
creases in temperature at the two highest doses. The N-methyl-
D-aspartate (NMDA) antagonist 2-amino-5-phosphono-valieric acid
(APV) was tested at 30, 100, 300 and 1000 ug. The three higher
doses caused CNS depression to scores of 6-7; after recovery to
a score of 1 (ataxia) the ataxia was notably long lasting with
this agent. The temperature decrease caused by APV was some-
what smaller than that caused by PheB at the same CNS depression
score. Two non-NMDA antagonists were examined: 6-D-glutamyl-
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aminomethylsulfonate (GAMS) at 240 and 480 ug and 6,7-dinitro-
quinoxaline-2,3-dione (DNQX) at 25 ug. These agents also de-
pressed the CNS to a score of at least 6; at these doses they in-
duced relatively larger decreases in temperature than APV.
Respiratory rate (measured by counting chest excursions) was de-
creased below the normal rate of about 100/min at the highest
doses of PheB and muscimol. APV did not depress respiratory
rate at the doses used. DNQX also did not depress respiratory
rate at the dose tested and the effect of GAMS was modest at the
higher dose used. All of the drugs tested caused muscle relax-
ation at the highest doses in that the animals became "limp".
No catalepsy was observed with any of these agents given ivt.
These results demonstrate that the EAA antagonists tested have a
spectrum of effects similar to the GABA agonist muscimol and to
the barbiturate phenobarbital. APV at anesthetic doses seemed
to have relatively lesser effects on temperature and respiration
than the other agents, however it also caused a longer residual
ataxia. The finding that the EAA antagonists do cause CNS de-
pression resembling that induced by phenobarbital indicates that
barbiturate anesthesia might be induced by antagonizing EAA
actions just as well as by mimicking or enhancing GABAergic in-
hibition. We have some in vivo evidence for the GABAergic
mechanism in that anesthesia induced by systemic PheB can be
antagonized by local administration of bicuculline or picrotoxin
in the posterior hypothalamus (Richter and Glick, 1987). How-
ever analogous tests of the EAA mechanism are still required.
(Supported by PHS Grant DA 00796).
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Discrimination of the
Benzodiazepine Receptor
Antagonist Ro 15-1788 Using the
Conditioned Taste Aversion
Procedure
Grace A. Rowan and Irwin Lucki
Rats were trained to discriminate the stimulus properties of the
benzod iazep ine  recep to r  an tagon is t  f l umazen i l  us ing  a
conditioned taste aversion procedure. Fluid-restricted rats were
injected with flumazenil (33 mg/kg) or saline and then given
access to a 0.25% saccharin solution for 30 minutes. When rats
(N=15) received a drug trial, saccharin consumption was followed
by an injection of LiCl (1.8 mEq/kg i.p.), while on saline trials
saccharin consumption was followed by a second saline injection.
Acquisition of the discriminated taste aversion, as measured by
the differential effects on saccharin drinking between drug and
saline trials, developed after only five pairings of the flumazenil
with the LiCl injections. Unconditioned controls (N=9), that
received an identical sequence of drug and saline trials, but never
received LiCI, did not show differences in saccharin intake. The
discrimination was also verified using two-bottle preference
measures between saccharin and water.
Flumazenil demonstrated dose-dependent generalization upon
varying the training dose. Two other benzodiatepine antagonists
of different classes, CGS-8216 and ZK 93426, also demonstrated
complete subst i tut ion for  the f lumazeni l  st imulus.  Part ia l
generalization was exhibited with the inverse agonists FG 7142
and BCCE, while PTZ failed to generalize to the flumazenil
stimulus. The benzodiazepine agonists Diazepam and Alprazolam
also failed to generalize to the flumazenil stimulus. This research
was supported by DA05367 and DA05186.
The Department of Psychiatry and Pharmacology, University of
Pennsylvania, Philadelphia, PA.
536
Cation Requirement for GTP
Regulation of [1251]b-Endorphin
Binding to Mu and Sigma Opioid
Receptors
D. E. Selley and J. M. Bidlack
An important focus of drug abuse research is the difference
between the agonist properties of exogenous drugs and those of
the endogenous transmitters which they mimick. Inhibition of
agonist-receptor binding by guanine nucleotides has been used as
an indicator of coupling between receptors and guanine
nucleotide-binding regulatory proteins. The binding of
alkaloids and modified enkephalin agonists to µ and opioid
receptors is inhibited by µM concentrations of GTP. Since the
endogenous opioid peptide, ß-endorphin (ß-EP), activates both µ
and opioid receptors, we investigated the ability of GTP to
inhibit [125I]ß-EP binding to opioid receptors in rat brain
membranes.
peptides, .[3H][D-Ala2, MePhe4, GLY-ol5]enkephalin and [3H][D-
Unlike the binding of the µ- and -selective
Penicillamine2, D-Penicillamine5]enkephalin respectively,
[125I]ß-EP binding was not altered by GTP in the absence of
no significant effect. The divalent cations, Mg2+, Ca2+, and
either of these cell lines. These results indicate that
monovalent cations are required for guanine nucleotide
regulation of ß-EP binding, and that the specificity of this
requirement differs among tissues containing different relative
numbers of µ and binding sites. The site specifically
requires sodium in order to express guanine nucleotide
regulation of [125I]ß-EP binding. Guanine nucleotide regulation
the divalent cations, Mg2+, Ca2+, and Mn2+. Similar experiments
were conducted in membrane preparations from two cell lines:
NG108-15, which contain only opioid receptors, and SK-N-SH,
which contain predominantly µ opioid receptors. As in the rat
brain membranes, [125I]ß-EP binding to SK-N-SH membranes was not
affected by GTP in the absence of cations, but was inhibited by
GTP in the presence of monovalent cations, with the order of
potency being: Na+ > Li+ > K+ . [125I]ß-EP binding to NG108-15
membranes was also not inhibited by GTP in the absence of
cations. In this cell line, however, only Na+ promoted
inhibition of [125I]ß-EP binding by GTP, with Li+ and K+ having
cations. However , in the presence of NaCl, [125I]ß-EP binding
was inhibited by GTP in a concentration-dependent manner. This
Na effect on GTP regulation of binding was mimicked by Li+ and
K+, with the order of potency being: Na+ > Li+ > K+, but not by
Mn2+ did not promote inhibition of [125I]ß-EP binding by GTP in
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of [125I]ß-EP binding to the µ site occurs in the presence of
sodium, lithium, or potassium, with sodium being the most potent
promotor of this effect.
ACKNOWLEDGEMENTS: Supported by USPHS grants DA05319 and DA03742
from the National Institute on Drug Abuse.
AFFILIATIONS: Department of Pharmacology, The University of
Rochester, School of Medicine and Dentistry, Rochester, NY
14642.
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The Effects of Capsaicin Treatment
on Self-Administration of
Amphetamine Vapor in Rats
L. G. Sharpe, L. L. Weinhold and J. H. Jaffe
Drug inhalation is an increasingly popular way to self-administer psychoactive
drugs. Smoked cocaine (crack) use has increased 4 fold between 1985 to 1988 in
the USA (DAWN), providing an incentive to develop an animal model for the self-
administration of non-volatile drugs.
We recently reported that tats self-administered nebulized sufentanil (10 to 75
ug/ml) in a concentration-dependent manner (Jaffe et al. Psychomacology 1989).
However, the less potent psychoactive drugs (i.e. morphine. amphetamine and
cocaine) have failed to maintain responding for drugs in vapor form. The present
experiments were conducted to determine whether capsaicin pre-treatment, which
depletes substance P, facilitates self-administration of amphetamine and cocaine
aerosol by rats.
Rats (Sprague-Dawley) were either treated with capsaicin (n = 13) or not treated
(n=14) before exposure to amphetamine (5, 10 mg/ml) or cocaine (2.5, 5 mg/ml)
in vapor form. Capsaicin doses were 75 and 125 mg/kg given over a 3-day
period. Drug vapor self-administration was accomplished under FR schedules
where nose-poking behavior resulted in a 2-sec aerosol presentation with
subsequent 60 sec black-out periods. Drugs were delivered by a commercial
nebulizer through a hose connected to the vapor chamber. Sessions were
conducted for 3 hr or overnight (13-15 hr).
Response rates revealed that: (1) In several rats, capsaicin treatment facilitated the
self-administration of amphetamine vapor but not of cocaine vapor; (2) Our best
strategy for training rats to self-administer cocaine in aerosol form was to allow
access to 2.5 mg/ml cocaine vapor during overnight sessions (13 to 15 hr); (3)
The reported dose differential between amphetamine and cocaine self-administered
intravenously (about 1 to 10), was not observed in rats self-administering
amphetamine and cocaine in aerosol form.
Further investigations of capsaicin treatment are required to conclude that capsaicin
treatment alters self-administration of amphetamine and cocaine in aerosol form.
Affiliation: NIDA, Addiction Research Center, Baltimore, MD 21224
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One-Trial Conditioned Rotation in
Rats
Peter B. Silverman
The association of drug effects with specific environmental
stimuli is probably importantly involved in drug abuse concerns
such as relapse. We have found that in addition to the well
characterized rotational behavior that follows the acute
administration of dopamine agonists in rodents with unilateral
nigrostriatal lesions, extraordinarily persistent conditioned
rotation can be demonstrated, often after a single drug
treatment (and thus a single pairing of drug and environment).
In the work described here, the rotational behavior of lesioned
rats was tested before, shortly after, and weeks after the
administration of direct and indirect dopamine agonists.
Sprague-Dawley rats of either sex were anesthetized with sodium
pentobarbital and positioned in a stereotaxic frame. They were
lesioned by injection of 6-hydroxydopamine aimed at one
substantia nigra. Two to 4 weeks after being lesioned, rats
were individually placed in a clear plastic hemispherical bowl
for a 3 min undrugged observation period during which 360 degree
turns in either directions were counted by an observer. They
were then injected with one of the compounds of interest, placed
in the bowls, and circling was counted and recorded in 3 min
bins. These 3 min observation periods were at intervals after
injection selected to include the peak drug effect as determined
in pilot work. In some cases the sequence of undrugged
observation followed by drug administration and observation was
repeated on consecutive days or at longer intervals. In other
instances drug was given only once. In either case, undrugged
observations were made prior to drug treatment and subsequently
weeks after the treatment. In the interval between tests,
animals were left undisturbed in their home cages. In no case
was any individual animal treated with more than one drug. The
compounds tested to date include both direct (apomorphine and
LSD) and indirect (cocaine and (+)-amphetamine) acting dopamine
agonists which acutely induce rotation contralateral and
ipsilateral to the lesioned side, respectively.
540
Administration of 0.05 mg/kg apomorphine typically induced peak
contralateral rotation of 30-40 turns/3 min at 15 min after
injection. When reintroduced to the rotation bowl weeks or
months after a single such apomorphine treatment, rats rotate
rapidly contralaterally. This conditioned rotation is often
more rapid in the brief undrugged test than the peak rate
achieved acutely after drug administration. The basic finding
of a conditioned drug effect after a single apomorphine
treatment has been replicated a number of times. Conditioned
rotation is even more rapid and prolonged after repeated small
doses of apomorphine administered daily or at longer intervals.
A single treatment with 0.2 mg/kg LSD or two treatments with 0.1
mg/kg LSD resulted in acute rotation of 25-40 turns/3 min.
Similar to the result with apormorphine, LSD-treated animals
subsequently exhibited conditioned rotation when placed,
undrugged, in the rotation bowls.
In tests with (+)-amphetamine, 2 to 5 mg/kg administered on 1 to
3 occasions, ispilateral rotation of 20 to 50 turns/3 min was
induced acutely. No ispilaterally directed conditioned rotation
was ever observed in these animals. Similarly, 10-20 mg/kg
cocaine induced acute rotation of 30-60 turns per min at 10 min
after injection, but no conditioned rotation was observed in
animals that had been drug treated 1 to 3 times.
Thus at doses which induce comparable acute rates of rotation,
direct acting dopamine agonists also resulted in a clear
conditioned effect while indirect agonists did not. While it
cannot be concluded that much more frequently repeated pairings
of indirect agonists with the rotation environment wouldn't
result in conditioned rotation, the data presented here show
relative ease of conditioning with direct agonists. This may
suggest greater potential for classical conditioning via
supersensitive than normosensitive structures, an implication of
importance in drug abuse issues as well as learning in general.
Supported in part by NIDA grant DA 04423.
Affiliation: Substance Abuse Research
Department of Psychiatry - MSI
University of Texas
Houston, Texas 77030
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Neural Connectivity in the
Descending Pain Pathway
Laura J. Sim and Shirley A. Joseph
Numerous electrophysiological and neuroanatomical studies have provided
evidence that the endogenous opiocortin system provides a substrate
mediating nocioception. Electrical stimulation or morphine microinjection
into the periaqueductal gray (PAG), dorsal raphe nucleus (DRN) or nucleus
raphe magnus (NRM) elicits analgesia (1,2,3). This stimulation produced
analgesia (SPA) is naloxone reversible and results in an increase in levels of
endogenous opioid peptides. Perikarya containing opiocortin peptides can be
demonstrated immunocytochemically in two distinct regions, the arcuate
nucleus in the hypothalamus (4) and the nucleus tractus solitarius (NTS) of
the medulla (5). From our deafferentation immunocytochemical studies (6)
we have shown that the fibers emanating from the arcuate distribute to nuclei
in the descending pain pathway whereas the medullary opiocortin neurons
which contribute little to these areas. Anterograde tracing studies were
performed in order to document the terminal fields for these opiocortin
peptides.
A 2.5% solution of phaseolus vulgaris leucoagglutinin (PHA-L) was stereo-
taxically injected into the rat arcuate nucleus. PHA-L was delivered ionto-
phoretically via a glass micropipette at 5µm alternating positive current
over 20 minutes. Five to 15 days later rats were perfused or injected with
intraventricular colchicine and perfused 24-48 hours later. Animals were
perfused intracardially with saline followed by 4% paraformaldehyde in
0.1M acetate buffer (pH 6.5) then 4% paraformaldehyde in 0.1M borate
buffer (pH 9.5). Tissue was processed for PHA-L using immunocytochem-
istry with nickel enhancement to produce a purple/black granular reaction
product. Sections were then stained immunocytochemically for appropriate
peptides and transmitters with routine chromagen visualization to yield a
brown hqmogenous reaction product.
PHA-L labeled fibers and terminals were identified throughout the brain
following arcuate injections. The injection site was visualized as a discrete
group of neurons within the arcuate that was completely filled with PHA-L
reaction product. Dual staining procedures and alternate section analysis
with opiocortin (ACTH) immunocytochemistry verified that the PHA-L was
incorporated into arcuate opiocortin containing neurons. The PAG contained
dense PHA-L immunoreactive (-ir) fibers and terminals, particularly in the
ventrolateral region. PHA-L- i r  f ibers  were a lso ident i f ied in  DRN,
p a r a b r a c h i a l  n u c l e u s ,  l o c u s  c o e r u l e u s , N R M ,  n u c l e u s  r e t i c u l a r i s
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paragigantocellularis, dorsal motor nucleus of the vagus and NTS. Dual
immunocytochemical staining demonstrated that serotonin immunoreactive
neurons in the ventrolateral PAG, DRN and NRM were present in close
proximity to opiocortin fiber terminals. PHA-L-ir fibers terminated near
catecholaminergic elements in PAG, periventricular gray (PVG) and locus
coeruleus. Neurons immunoreactive to substance P, cholecystokinin (CCK),
neurotensin, enkephalin and corticotrophin releasing factor (CRF) were
identified in opiocortin terminal fields in the PAG. In addition to the
pro ject ions demonstrated to  bra instem nucle i ,  PHA-L- i r  f ibers were
immunostained in telencephalic and diencephalic nuclei innervated by arcuate
opiocortin neurons. In the forebrain, labeled fibers and terminals were
identified in the amygdaloid complex, nucleus accumbens. lateral septal
nucleus and bed nucleus of the stria terminalis. Terminal fields were also
identified in the preoptic area, anterior hypothalamus, lateral hypothalamus,
dorsomedial hypothalamus, paraventricular nucleus, supraoptic nucleus,
PVG, zona incerta, medial thalamus (paraventricular and central medial
nuclei) and habenula.
The importance of the endogenous opioid system in a supraspinal nocioceptive
mechanism has been documented. Specific regions mediating this phenomenon
include medial thalamus, PAG. NRM and DRN. These studies demonstrate
endorphinergic/ACTH terminals in brainstem regions specifically associated
with serotonergic and catecholaminergic perikarya. This suggests that a
synaptic relationship may potentiate the influence of the endogenous opioid
peptide on the descending pain pathway by way of monoaminergic systems.
Neuroendocrine Unit, University of Rochester, Rochester, NY 14642
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Opioid Dependence After
Continuous.lntrathecal Infusion of
Mu and Delta Opioids in the Rat
Craig W. Stevens and Tony L. Yaksh
The continuous intrathecal (i.t.) infusion model in rats has been used
extensively in our lab to study the time course of tolerance to spinal
antinociceptive agents; the degree of tolerance induced by agents with
varying potency; the effects of chronic naioxone administration on i.t.
morphine; and cross-tolerance between morphine and dermorphin,
morphine and alpha -agonists, and morphine and DADLE (Stevens
and Yaksh, ‘86, ‘87; Stevens, et al. '88 Stevens and Yaksh, ‘89 a,b,c).
Importantly, this model allows the induction of tolerance and
dependence in a dose-dependent or posological fashion (Yaksh and
Stevens, ‘86). By emplo ing three log-spaced infusion doses for each
agent (termed toleragen) that are chosen so as to produce equi-
effective peak effects after 1 day of i.t. infusion, we can also compare
across toleragens.
In rodents, the degree of opioid dependence can be quantified by the
appearance of characteristic withdrawal signs (Way et al. 1969). Recent
studies have shown a spinal site of opioid withdrawal (Buccafusco and
Marshall, ‘85; Marshall and Buccafusco, ‘85). Systemic studies of the
spinal expression of opioid dependence, to date, have not been
performed. The present study measures dependence as seen after
systemic naloxone in rats made tolerant to mu and delta opioids.
The continuous i.t. infusion of morphine (2, 6, or 20 nmol/h), sufentanil
(0.06, 0.2, or 0.6 nmol/h), DAMGO (0.1, 0.3, or 1.0 nmol/h), or DADLE
(2, 6, or 20 nmol/h) in awake rats produces a dose-dependent increase
in hot plate latency one day after pump implant followed by a gradual
return to baseline values by days 3-4; i.e. tolerance. Rats given
naloxone (1 mg/kg, i.p.) after 7 days i.t. infusion show a opioid
withdrawal syndrome most noted by withdrawal body shakes (WBS).
The number of WBS was proportional to the infusion dose and although
each opioid was given in equi-effective infusion doses, the agents
varied in the degree of dependence noted. Thus, as shown in the table,
highly potent agents produce less dependence. This is likely due to the
lesser receptor occupancy of potent agents (e.g. DAMGO) to produce its
effect as compared to less potent agents (e.g. morphine). The mu and/or
delta nature of spinal withdrawal remains inconclusive, although
DADLE did produce the highest levels of WBS.
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Table 1. Opioid dependence after 7-day continuous infusion of mu or delta
opioids. Data are mean (sem) of total WBS for 30 min after naloxone
administration. Groups not joined by a common underline differ at
P<.05 (ANOVA and Newman-Keuls test).
lnfusion Dose
The present results support and extend previous studies implicating a
spinal site for opioid withdrawal. Further studies are needed with more
highly selective and potent delta agonists.
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Synthesis of Exo and Endo
Mecamylamine Analogs for
Nicotinic Antagonism in the CNS
John A. Suchocki, Thomas J. Martin, Everette L. May and
Billy R. Martin
Several a t t e m p t s  t o p r e p a r e  t h e  e n d o  i s o m e r  o f
mecamylamine by way of addition of a methyl nucleophile
to the methylamine Schiff base of camphenilone were
unsuccessful. The Schiff base intermediate, however, was
reduced with L i A l H 4  t o  g i v e ,  e n d o - 2 - d e s m e t h y l -
mecamylamine in 29% yield. Notably, treatment of the
Schiff base of camphenilone with iodomethane followed by
methyl lithium gave the rearrangement product N-methyl-
isobornylamine in 35% yield, which was independently
prepared from camphor.
The tertiary N-methyl derivative of mecamylamine was
obtained in low yields (35%) by reacting mecamylamine
with iodomethane fol lowed by t reatment with  base ,
sodium methoxide. The N-methyl derivatives of exo- and
endo-2-amino-norbornane were  p r epa red  i n  mode ra t e
yields (-60%) by the reduction of the carbamate formed
f r o m 2 - a m i n o n o r b o r n a n e and 4 -n i t r opheny l
chloroformate. Another analog of mecamylamine was
prepared from 3-methylenenorbornan-2-one by way of
hydrogenation of the exocyclic double bond followed by
reduction of the methyl amine Schiff base to give N-
methyl-3-methyl-2-norbornamine in a 28% overall yield.
This product is indicated to be the 2(exo)-3(endo) isomer
b a s e d  u p o n  s t e r i c  a r g u e m e n t s  a n d  c h r o m a t o g r a p h i c
retention factors. X-ray analysis t o  c o n f i r m the
stereochemistry of this compound is presently underway.
Similarly, optically pure exo and endo isomers of (+) and
(-) N-methyl-fenchylamine have been prepared from (+)
and (-) fenchone in an overall yield of about 55% for the
546
exo isomer. An epimeric ratio of 98:2 for exo to endo
isomers was calculated.
A series of stereoisomers possessing structural features of
both nicot ine and mecamylamine were prepared from
nicotinaldehyde and optically pure s a m p l e s  o f
fenchylamine. S t r u c t u r e s  a n d  c o n f i g u r a t i o n s  w e r e
determined by analogy, spectral data and (in one instance)
X-ray crystallography. S u p p o r t e d  b y  N I D A  g r a n t
#DA07027 and CTR grant #2130.
Department of Pharmacology and Toxicology, Virginia
Commonwealth University, Medical College of Virginia,
Richmond, Virginia, 23298-0613
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Autoradiographic Localization of
3H-Dextromethorphan Binding
Sites Differs from NMDA
F. C. Tortella, R. Davey, M. Pellicano and N. G. Bowery
INTRODUCTION
Dextromethorphan (DM), a widely used non-opioid cough
suppressant which binds to high affinity sites in brain4, also
possesses anticonvulsant,
properties1 4 5.
neuroprotective and antischemic
Since DM appears capable of antagonizing the
neurophysiological and
glutamate1 2,
neuropathological effects of
it has been suggested that this (+) opiate is
also an NMDA antagonist. Using quantitative autoradiography,
we have visualized the heterogenous localization of the DM
recognition site in rat brain and report a distribution of
binding sites for 3H-cM that differs from NMDA.
METHODS
Cryostat sections (10 µm; parasagittal) of Wistar rat brains
were placed on subbed glass slides stored at -20°C. Prior to
labelling, thawed sections were incubated for 30 min at -20°C
in 50 mM Tris-HCL buffer, pH 7.4 DM recognition sites were
labelled by incubating the sections for 20 min at 20°C in
buffer solutions containing 8 nM 3H-DM (70.8 ci/mmole). The
sections were then inserted rinsed in fresh solution at 4°C
for 2 x 30 sec and dried prior to apposition with LKB
Ultrofilm. Exposure time was 4 weeks and the autoradiograms
were quantified using a Quantmet 970 image analyzer (Cambridge
Inst., PLc). Nonspecific binding was determined by
incubation with 10 mM unlabelled DM.
RESULTS AND DISCUSSION
In concurrence with the membrane binding data obtained
previausly4, 3H-DM binding was fully displaced by 10 mM DM or
1 mM chlorpromazine, but not by 10 nM codeine, NMDA,
glutamate, APV or MK801 (not show). The highest density of
3H-DM sites was measured in the cerebellar molecular layer
(10.9±2.1 nCi/mg tissue) with a much lower level measured in
the granular cell layer. The density rank order determined
from 4 sections from each of 4 rat brains was the cerebellar
molecular layer > thalmus > caudate putamen > cerebral cortex
> hippocampus CA1 > pons > cerebellar granular layer. This
contrasts with the localization of NMDA sites, as labelled
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with 3H-glutamate or 3H-MK801, where the rank order is
hippocampus CA1 > cerebral cortex > caudate putamen > thalamus
> cerebellar granular cell layer > pons > cerebellar molecular
cell layer. In contrast, some similarity with (+)SKF10047 was
noted. comparative data are summarizd in Table 1.
Table 1. Regional densities of DM and NMDA binding sites in
rat brain.
Values are expressed as a percent of the highest density for
each ligand in the regions listed.
Region 3H-DM
3H-Glutamate 3H-MK801 3H-(+)SKF
(I) (II) (III) (IV) (V)
Cerebellum mol. 100 6 <10 21 73
layer
Thalamus 89±5 16-39 20 48 64
Caudate Putamen 79±9 51 21 29 50
Cerebral Cortex 74±7 39-78 22-74 27-54 67
Hippocampus CA1 70±7 100 100 100 100
Pons Medulla 61±5 7 3 7 42
Cerebellum gran. 48.6 24 19 21 73
layer
(I)-Present study; (II)-derived from Monaghan & Cotman, 1985,
J. Neurosci. 5: 2909; (III)-derived from Maragos et al., 1988,
J. Neurosci. 8:493; (IV)-derived from Bowery et al., 1988, Br.
J. Pharmacol. 93:944; (V)-derived from Sircar et al., 1986,
JPET 237:681.
These result confirm the presence
in rat brain4
of specific DM binding sites
and demonstrate that they are heterogenously
distributed. However, these data also indicate that the
distribution of DM sites bears no resemblance to those of
NMDA. Consequently, it would appear unlikely that DM acts
directly on the NMDA receptor complex as an NMDA antagonist.
On the other hand, the similarity between the regional
localization of DM and the sigma ligand (+)SKF10047 (which
competes with high affinity for the DM site3) supports the
suggestion that these ligands bind to similar high affinity
sites in brain.
ACKNOWLEDGEMENTS: We wish to thank ICI Pharmaceuticals,
Maaclesfield, England for their generous gifts of 3H-
dextromethorphan.
Neuropharmacology Branch, Department of Medical Neurosciences
Walter Reed Army Institute of Research, Washigton, DC 20307
and *Department of pharmacology, School of Pharmacy,
University of London London ECIN 1AX, England.
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Changes in Prodynorphin Peptide
Content Following Treatment with
Morphine or Amphetamine:
Possible Role in Mechanisms of
Action of Drug of Abuse
Keith A. Trujillo and Huda Akil
The discovery of opiate receptors and endogenous opioid peptides led to early
speculation that these systems might play an important role in tolerance,
dependence and addiction. A number of early studies were therefore aimed at
determining how opiate receptors and opioid peptides were altered in the brain in
response to treatment with drugs of abuse, particularly the opiate alkaloids.
These studies. were disappointing, however, in that no consistent changes were
seen in either opiate receptors, enkephalins, or endorphins in response to chronic
treatment with these drugs.
The prodynorphin family is the most recently discovered of the endogenous
opioid peptide systems. The prodynorphin (Prodyn) precursor codes for three
opioid peptide domains: dynorphin A (Dyn A), dynorphin B (Dyn B) and Neo
Endorphin (Neo Endo), and at least one non-opioid peptide domain. The opioid
domains in the Prodyn precursor can yield a number of peptides, including Dyn A
1-17 and Dyn A 1-8 from the Dyn A domain, leumorphin and Dyn B 1-13 from
the Dyn B domain, and a-Neo Endo and ß-Neo Endo from the Neo Endo
domain. Due to the relatively recent discovery of the Prodyn family, less is
known about its regulation in brain. In order to determine the possible role of
Prodyn systems in the mechanisms of action of drugs of abuse we have examined
the response of Prodyn systems in the brain to treatment with either morphine or
amphetamine. We focused our experiments on the striatonigral Prodyn system,
examining drug-induced alterations in peptides in both the dorsal, or
“sensorimotor” striatum (caudate-putamen), and the ventral, or “limbic” striatum
(nucleus accumbens-olfactory tubercle).
METHODS
Adult male Sprague-Dawley rats were used in all experiments. For chronic
morphine administration, rats were implanted with 75 mg morphine pellets or
placebo pellets (1 pellet on day one and 3 pellets on day four; pellets obtained
from NIDA) under light ether anesthesia, and sacrificed on day seven. For
amphetamine administration, rats received a single subcutaneous injection of
d-amphetamine sulfate or saline vehicle each day for 7 days, with sacrifice 24
hours after the final injection. Brains were rapidly dissected, the tissues extracted
in methanol/HCl, and the extracts examined with radioimmunoassays highly
selective for peptides from all three opioid domains in the Prodyn precursor: Dyn
A 1-8, Dyn A 1-17, Dyn B 1-13, and a-Neo Endo.
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RESULTS AND DISCUSSION
Chronic treatment with morphine increased Prodyn peptides from all three opioid
domains, in both the dorsal striatum and the ventral striatum. Increases in the
dorsal striatum averaged 60% above control animals, while increases in the
ventral striatum averaged only 20% above control animals. Similarly, repeated
amphetamine administration increased all Prodyn peptides assayed, in both the
dorsal and ventral striatum. As with chronic morphine treatment, increases were
greater in the dorsal striatum than in the ventral striatum, ranging from 57% above
control to 92% above control in the former and averaging 30% above control in
the latter. Although previous work suggests that the effects of repeated
amphetamine are mediated by activation of mesostriatal dopamine systems,
leading to increased biosynthesis of Prodyn peptides, it is presently unclear how
morphine acts to increase these peptides. It is possible that morphine acts by a
similar mechanism, activating mesostriatal dopamine neurons at the level of the
substantia nigra and ventral tegmental area; however it is also possible that
morphine acts quite differently. Thus, rather than increasing biosynthesis,
morphine may, through feedback inhibition of Prodyn neurons, decrease release
of peptides, leading to increases in intraneuronal stores. Studies are currently
underway to determine the mechanism of action of morphine.
The qualitatively similar actions of morphine and amphetamine on striatal Prodyn
peptides suggests that these peptides may play a role in the mechanism of action
of these drugs of abuse. Although it is presently unclear what specific role
Prodyn peptides might play, there are some intriguing possibilities. For example,
since Prodyn peptides. in general, have a high selectivity for kappa opioid
receptors, and since activation of kappa receptors is aversive, it is possible that
the increased concentrations of these peptides seen after chronic drug
administration may be involved in the aversive aspects of the withdrawal
syndrome. On the other hand, since the shorter forms of Prodyn peptides. such
as Dyn A 1-8, are potent agonists at mu and delta receptors, and since activation
of mu and delta receptors is positively reinforcing, it is possible that Prodyn
peptides may play a role in the euphorigenic properties of specific drugs. In
support, we have previously obtained evidence suggesting that an acute injection
of amphetamine may cause release of Prodyn peptides in the striatum, with much
of the contribution coming from Dyn A 1-8. Further, it has been reported that
opiate antagonists may interfere with the reinforcing actions of psychomotor
stimulants. The present results appear to be very similar to those presented by G.
Hanson and coworkers at this meeting. These investigators report increases in
Dyn A, in both the caudate and the nucleus accumbens following repeated
administration of cocaine, methamphetamine or phencyclidine. Thus it appears
that a variety of drugs of abuse have interesting interactions with striatal Prodyn
systems. These systems should be studied further to determine their specific
role(s) in the actions of drugs of abuse, particularly in regards to the long-term
consequences of drug use such as tolerance, dependence and withdrawal.
Supported by NIDA NRSA DA05336 to K.A.T.. and NIDA Grant DA02265 and
NIMH Grant MH422251 to H.A.
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Modulation of Synaptosomal Free
Intracellular Calcium in Naive and
Morphine-Tolerant Mice:
Correlation of Calcium Modulation
In Vitro and In Vivo to Tolerance
Development
Sandra P. Welch, Kirsten G. Olson, David L. Stevens and
William L. Dewey
Calcium alterations in synaptosomes following morphine pretreatment were
measured by the use of FURA-2 to determine whether alterations of free,
intracellular calcium [Ca++]i in synaptosomes occur with the acute administration
of opiates in vitro and whether homeostatic alteration of free intracellular calcium
concentrations upon chronic exposure leads to the development of tolerance. We
also examined the effects of the calcium modulator, calcitonin gene-related
peptide (CGRP) on the acute and chronic effects of morphine in vivo.
Synaptosomes were prepared from mouse brain using subcellular fractionation
techniques and were loaded according to a procedure which facilitates hydrolysis
of the cell permeant FURA-2/AM to the free FURA-2. The SPEX Cation
Measurement System was used to measure the free calcium within the
synaptosomes by use of FURA-2/AM. The free calcium concentration was
determined using 224 nM as the KD for FURA-2. Each experiment was run in
triplicate and repeated using at least 3 separate sets of synaptosomes. The
synaptosomes were depolarized by the addition of a high KCl/Kreb’s buffer such
that the final depolarizing concentration of KCl in the sample cuvette was 50 mM.
Synaptosomes from naive, placebo-pelleted, and morphine pelleted animals were
tested. These results indicate that synaptosomes from tolerant mice have
significantly higher basal levels of intracellular calcium as well as significantly
higher rises in intracellular calcium in response to a depolarizing stimulus.
Treatment
Naive
Placebo
Tolerant
Ca Concentration
223(20)
N=30
285(36)
N=16
385 (16)**
N=24
% change with
depolarization
34 (3) %
N=30
30 (4)%
N=16
52 (3)**
N=24
** p< 0.01 from placebo
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Synaptosomes from placebo and morphine-pelleted mice were tested with the
calcium agonist BAY K 8644 to test for the activation of “L type” calcium
channels in the tolerant versus the non-tolerant state. These results indicate that
synaptosomes from tolerant mice are more sensitive to the activation of calcium
channels than are synaptosomes from non-tolerant (placebo) mice, suggesting
that an increase in the number or the activation of the L type calcium channel
occurs in the development of tolerance to opiates.
CONCENTRATION % INCREASE IN BASAL CALCIUM (S.E.)
OF BAY K 8644 Placebo Tolerant
10-6M 78 (23) 200 (73)*
n=6 n=6
10-7M 25 (5) 46 (10)
n=4 n=6
*p< 0.01 from Placebo
In vivo testing CGRP was administered intrathecally (5 µl/ mouse) in saline
vehicle. The chronic administration of CGRP (i.t.) was performed twice daily
(2µg/ mouse per injection) for 7 days prior to testing with a challenge dose of
morphine (4mg/kg, s.c.) in the tail-flick test. To evaluate the effects of CGRP
on physical dependence to the opiates the animals were implanted with either a
morphine or a placebo pellet at least 3 days prior to testing. The mice were
challenged with various doses of naloxone (mg/kg, s.c.) alone or in combination
with i.t. CGRP (2µg/mouse). The number of mice jumping from an 18 inch
platform and the latency of the mice to jump was quantitated.
Chronically-administered CGRP (i.t.) attenuated the development of tolerance to
morphine in morphine-pelleted mice. Placebo-pelleted mice challenged with a 4
mg/kg dose S.C. of morphine showed a significant 52% MPE in the tail-flick test
as compared to the 2% MPE observed in morphine-tolerant mice. However, in
the morphine-pelleted mice which received chronic CGRP for 7 days prior to the
morphine challenge, the %MPE was 35% (S.E.=10), significantly different from
those mice chronically injected with i.t. saline. CGRP enhanced the activity of
low doses of naloxone on naloxone-precipitated withdrawal jumping in
morphine-dependent mice, but did not precipitate jumping itself. The ED50 for
naloxone (s.c.)-precipitated jumping was shifted from 0.1 mg/kg to 0.03 mg/kg
when the naloxone was administered concurrently with the CGRP (i.t.,
2µg/mouse). The latency of the mice to jump was reduced significantly by 50%
with CGRP pretreatment in combination with naloxone.
The results in vitro are consistent with increased numbers of or the activation of
calcium channels in opiate tolerant mice. The in vivo results indicate that
homeostatic modulators of neuronal calcium such as CGRP may play a role in the
development of tolerance and physical dependence to the opiates. Taken together
the data indicate that the regulation of calcium concentrations in neurons in opiate-
sensitive pathways plays an important role in tolerance and physical dependence.
AFFILIATION: Dept. of Pharmacology & Toxicology, Medical College of
Virginia/Virginia Commonwealth University, Richmond, VA 23298-0613
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In Vivo Binding of (+)-cis
Methylfentanyl at the Opiate
Receptor Complex and Behavioral
Correlates: Evidence for a Novel
Mechanism of Action
L. Band, V. Bykov, N. Greig, C.-H. Kim, A. Hauck-Newman,
A. E. Jacobson, K. C. Rice and R. B. Rothman
Derivatives of 3-methylfentanyl are potent
antinociceptive a'gents and produce morphine-like
catalepsy (Xu et al. 1987; Zhu et al. 1983). (+)-Cis-
methylfentanyl (MF), an analog of the selective delta
opioid acylating agent SUPERFIT, displays wash-
resistance in binding to the opiate receptor complex in
vitro (Rothman et al., in press). In the present
study, the in vivo binding and behavioral efficacy of
this compound were examined in relation to the receptor
complex.
IN VIVO BINDING AND BEHAVIORAL MEASURES
Male Sprague-Dawley rats (250-300 g) were injected
intravenously with 50 µg/kg of MF or saline. Thirty
min after MF injections, two groups of animals were
injected with (+)- or (-)-6-desoxy-6-beta-fluoro-
naltrexone (cycloFOXY), an opiate antagonist. At 120
min after the initial injection, animals were tested
behaviorally. Catalepsy was determined by measuring: 1)
the latency to remove the forelimbs from a bar
suspended 9 cm above a horizontal surface (bar test],
and 2) the latency to remove the right hindlimb from a
platform 2 cm in height. A maximum score of 120 s was
assigned for each test. Behavioral tests were followed
by decapitation and quick freezing of brains in -80°C
isopentane. Brain tissue was polytroned in Tris
buffer, pH 7.0, at 0°C, followed by centrifugation and
pouring off of the supernatant (wash); the wash
procedure was repeated and membranes were frozen.
Assays for tritiated [D-ala
2,D-leu 5]enkephalin
([3H]DADL) and (3,14-dihydroxy-4,5-alpha-epoxy-6-beta-
fluoro-17-methylmorphinan) ([3H]FOXY) binding were
conducted as previously described (Rothman et al. 1987,
1988). [D-pen2, L-pen
5] enkephalin (DPLP) revealed the
delta binding site of the receptor complex (deltacx);
[3H]FOXY labeled mu sites.
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RESULTS AND CONCLUSIONS
Both measures of catalepsy yielded identical results.
Intravenous administration of MF produced maximal
catalepsy and reduced binding at all labeled sites.
(-)-, but not (+)-, cycloFOXY, completely reversed
catalepsy and attenuated masking of all sites labeled
by [3H]DADL (p < .05), including delta,, sites
(P < .001). Mu sites were not recovered.
Effects of (+)-CIS-methylfentanyl on [3E]DADL and
[3E]FOXY binding and catalepsy
Specific Binding Specific Binding Bar Test
Condition (fmol Protein) (% of Control) (Seconds)
[3H]DADL, total
SALINE 119.60 ± 12.61 100 1.25 ± 0.25
MF 57.44 ± 2.32 48.03 ± 1.94* 120.00 ± 0
MF, (-)-cyFOXY 77.64 ± 5.60 64.92 ± 4.68*† 1.25 ± 0.25
MF, (+)-cyFOXY 60.83 ± 4.37 50.86 ± 3.65* 120.00 ± 0
[3H]DADL, deltacx
SALINE 44.24 ± 4.50 100 1.25 ± 0.25
MF 12.25 ± 0.57 27.69 ± 1.29* 120.00 ± 0
MF, (-)-cyFOXY 23.93 ± 1.99 54.10 ± 4.50*†† 1.25 ± 0 25
MF, (+)-cyFOXY 13.01 ± 1.10 29.41 ± 2.49* 120.00 ± 0
[3H]FOXY
SALINE 89.05 ± 7.08 100 1.25 ± 0.25
MF 25.00 ± 1.94 28.07 ± 2.18* 120.00 ± 0
MF, (-)-cyFOXY 35.39 ± 4.23 31.22 ± 5.83* 1.25 ± 0.25
MF, (+)-cvFOXY 24.06 ± 2.73 27.92 ± 3.07* 120.00 ± 0
Data points are mean values ± S.E.M.(n = 4); *p < . 01, as compared to saline;
†p < .05, ††p <.01, as compared to MF. Data were analyzed using t-tests for
independent samples.
These data suggest that MF acts at delta,, in producing
catalepsy and may act at delta sites outside the
receptor complex. Injection of (-)-cycloFOXY at 20 min
vs. 90 min prior to collection of brains results in
full (data not shown) rather than partial recovery of
deltacx sites. Slow release of MF from lipid tissue or
plasma platelets may underlie both the partial recovery
of sites and long duration of behavioral effects. The
complete‘ reversal of behavioral measures accompanying
partial unmasking of delta,, sites (54% of control
levels) may indicate that occupancy of a critical ratio
of these receptors is necessary to produce catalepsy.
AFFILIATIONS
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Biological Evaluation of
Compounds for Their Physical
Dependence Potential and Abuse
Liability. XIII. Drug Testing
Program of the Committee on
Problems of Drug Dependence, Inc.
Arthur E. Jacobson
TESTING PROGRAMS OF THE CPDD
The Drug Testing Program of the Committee on Problems of Drug
Dependence (CPDD) relies upon researchers in three universities and
NIH to obtain data on the physical dependence potential and abuse
liability of  analges ics , and of  st imulants and depressants. The
examined compounds  are  obta ined  f rom three  d is t inct ly  d i f ferent
groups, university researchers, pharmaceutical companies, and
national and international governmental agencies. The data which
are  needed  for  these  groups  are  d i f ferent ,  and  have  been  noted
(Jacobson 1987, May and Jacobson 1989). The Drug Testing Program
receives advise and guidance from, and in general reports to the
Animal Testing Committee (Dr. T. J. Cicero, Chairman) of the CPDD.
Animal Testing Committee
The Animal Testing Committee is composed of CPDD members with an
interest and expertise in the  Animal  Test ing area and expert
consul tants  who  have  been  appointed  to  the  group (Drs .  Steven
Holtzman. Thomas Burks, Theodore Cicero, James Woods, William
Woolverton,  Graham Patr ick ,  Gai l  Winger .  Joseph Brady,  Harold
Kalant, Kenner Rice, Jack Mendelson. William Dewey, Louis Harris,
Martin Adler, and Arthur Jacobson). Nine of these fifteen individuals
are not, presently, members of the Board of the CPDD. and four of the
nine have never been members of the CPDD. The Animal Testing
Committee met jointly on May 8-9, 1989. in Ann Arbor with the Human
Test ing  Committee  ( co -chaired  by  Drs .  Nancy  Mel lo  and Marian
Fischman), and the work of the testing groups was discussed.
Communication
Results of the work from the two testing programs, performed by
researchers at various universities and NIH, are communicated to Dr.
Cicero’s Animal Testing Committee differently. The groups concerned
with testing drugs as opioids are at the University of Michigan (UM)
(Drs. James A. Woods, Fedor Medzihradsky, Charles Smith, Gail Winger.
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and Charles France), the Medical College of Virginia (MCV) (Drs.
Mario Aceto, Edward Bowman, Louis Harris, and Everette May), and the
National Institutes of Health (NIH), NIDDK (Dr. Arthur E. Jacobson and
Mariena V. Mattson).
The reports w h i c h  I  r e c e i v e  d u r i n g  t h e  y e a r  f r o m  t h e  g r o u p s
involved with the opioid program are forwarded so that each group is
aware of the work which has been completed. Their work is related to
the Animal Testing Committee at a meeting a month prior to the
annual meeting of the Board of Directors of the CPDD. Data from these
laboratories are sent. by me, to the submitters of the compounds
without prior review by the Animal Testing Committee, but after
discussion of the MCV work at quarterly meetings between the groups
at MCV and NIH (with a representative from the National Institute on
Drug Abuse (NIDA)). or after perusal of the results from UM both at
UM and NIH. The testing is done under a coded NIH number in a
“blind” fashion by the university groups and they become aware of
the chemical structure of the drugs only after I have obtained the
submitter’s release for the data, and that occurs, generally, in March
or April. The data released for publication by the submitter were
discussed at the Animal Testing Committee meeting in May. 1989.
The work on stimulants and depressants under the auspices of the
CPDD is done similarly, under a CPDD number. The groups involved
are at the University of Chicago (Drs. William Woolverton and Michael
Nader), MCV (Drs. Graham Patrick and Louis Harris), UM (Drs Gail
Winger and James Woods), and NIH (Dr. Arthur Jacobson). The
reports from the stimulant/depressant groups are handled differently
than those from the opioid testing groups. Prior to sending the
results to the submitter of the drug, complete data on the drug are
distributed to members of the Animal Testing Committee for their
comments, and these comments are incorporated into my letter to the
submitter of the drug, with the data from the various laboratories.
The results, then, are sent with the imprimatur of the CPDD.
The Animal Testing Committee has not been made aware of most of the
structures of the stimulants and depressants examined this year since
the data on four of the seven examined compounds have not, as yet.
been released by the submitter. The (first) overall report on the
examined stimulants and depressants to the Animal Testing Committee
in May contained experimental data on all of the compounds evaluated
and both structural information and partially completed experimental
data on the compounds evaluated for the World Health Organization
(WHO). The work for the WHO was only partially completed due to time
constraints, and the current system of prioritization. These data have
not. as yet. been officially sent to the WHO, but preliminary findings
were given to Dr. L. Harris, a CPDD member and a member of the WHO
Expert Committee, for  transmitta l  and discuss ion at  the  Expert
Committee meeting in Geneva, in April, 1989.
W e  h a v e , with this testing program, completed our init ia l  nine
m o n t h s  f r o m  t h e  t i m e  t h e  p r o g r a m  w a s  p u b l i c l y  o p e n e d  ( t o
pharmaceutical companies). Compounds from universities have not,
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as yet. been accepted into the program because this program has been
completely funded by the CPDD and it is quite expensive.
The CPDD is indebted to the university researchers who cooperate
w i t h  t h e  C P D D  a n d  m a k e  t h e i r  w o r k  w i t h  t h e  o p i o i d s  a n d  t h e
stimulant/depressants available to us.
Possible Expansion of the Drug Testing Program
Initial discussions have’ been held between groups at NIH and UM and
the Chairman of the Animal Testing Committee on the feasibility and
desirability of including another class of abused drugs in the Drug
Testing Program, drugs acting at phcncyclidinc (PCP) binding sites in
the brain. PCP is one of the most widely abused drugs in several
major U.S. cities, especially Washington, D.C. Since it is relatively
inexpensive and easily available through synthesis in clandestine
laboratories, few, if any, controlled substance analogs based on PCP
have appeared for illicit use. Interest in PCP-like compounds, then, is
based on its mode of action in the brain and the potential medical
usefulness of PCP analogs. These analogs have been noted to be useful
for, among other things, the treatment of ischcmia (Iversen et al.
1988) and, possibly, epilepsy (Rogawski et al. 1989). The PCP analogs
which are sought for their medical utility are those, of course, which
lack the psychotomimetic effects of PCP. The PCP-like drugs which
are likely, eventually, to be introduced by pharmaceutical companies
for  human use  might  wel l  need test ing  for  their  PCP- l ike  abuse
liability before introduction to the public. The laboratories at UM and
at NIH, NIDDK, arc currently involved with research on PCP-like
drugs, and could be initially utilized if this testing is found to be
necessary and desirable. Other laboratories might also be interested
in  jo in ing  this  program i f  a  suf f i c ient  number  o f  PCP- l ike  drugs
become available for abuse liability testing.
Database for Opioids
Over the past 35 or so years a considerable amount of data has been
generated by the laboratories assoc iated  with  the  Drug Test ing
Program of the CPDD on opiates and opioid-like compounds. These
data have been printed, “in the various proceedings of the CPDD
meetings as ‘minutes’ through 1968, as ‘reports’ through 1974 and
finally as ‘proceedings’ in 1975 and 1976, when NRC relinquished
sponsorship. The 1977 and 1978 proceedings were published by the
CPDD, Inc. Starting in 1979, the proceedings have been published as
part of the Research Monograph Series of NIDA and are archival.
Before  1979 they  were  labe led  non-archival ”  (May and Jacobson
1989). Complete compilations are maintained at NIH, MCV and UM.
However, for  outs ide  groups and for  researchers  interested  in
obtaining information on opioids, a significant part of these data
have been unavailable. A  c o m p u t e r i z e d  l i s t  o f  t h e  e x a m i n e d
compounds, cross-indexed by NIH number, submitter, company code
number, chemical family, etc., was initiated at NIH and is maintained
and updated annually at UM, with the aid of Dr. May at MCV. This
index can be used to find the year of the publication in which the
558
original work on the compound can bc located. Unfortunately, this
docs not help those rcscarchcrs who do not have access to the
complete set of data in the various volumes noted above. Further, the
availability of the computerized index and the complete data set would
not make the task of correlating the chemical structures of opioids
with their  b io log ica l  act iv i ty ,  or  s tarching  for  compounds  with
specific biological activities, less laborious. II  is conceivable that
computerization of the biological data combined with the chemical
structures  o f  the  opio ids  which  have  been examined would  a l low
much more facile entry into the database and allow researchers to ask
questions which would otherwise be impossible to resolve.
Within the past several years Dr. J. Woods at UM has initiated the
formation of a computerized database of the biological information
which has been gathered under the auspices of the CPDD at UM, MCV,
and NIH. The data which have been computerized lacks chemical
structural information re lat ing  to the compounds which were
evaluated. Several software packages are currently commercially
available for different computer systems (Apple and IBM) which
allow the more-or - less  fac i le  entry  o f  s tereochemica l ly  correct
chemical structures. No software is available, that I am aware of, for
the Apple computer system which allows retrieval of information
based on part structures. There is at least one software package
which can be used for this purpose on IBM-type (MS-DOS or OS/2
operating system) computers. This software, from Molecular Design
Ltd. (ChemBase). is available, but it is expensive and, perhaps, not as
easily utilized as, for example. ChemDraw for the Apple Macintosh
computer. A  c o m p u t e r which facilitates multi-tasking, the
simultaneous, or nearly-s imultaneous  d isplay  and interact ion o f
several commercially available software programs of diverse types.
would be most desirable to input data, query the database and store
gained information in new data subsets. At this time we are forced to
eliminate the Apple computer system because of the lack of suitable
chemical drawing software allowing part- structure retrieval, and the
MS-DOS operating system is not easily utilized as a multi-tasking
system. The IBM OS/2 and the UNIX system were designed as multi-
tasking systems, but the software now available for either operating
system is inadequate for our purposes.
The desirability of the computerization of the database, and the
available software and computer systems were discussed with the
Animal Testing Committee in May, 1989. This Committee suggested that
attempts s h o u l d  b e  m a d e to  begin the compilation of  chemical
structures  and b io log ica l  data  us ing  the  Molecular  Design Ltd .
ChemBase software and an available MS-DOS operating system, with
an appropriate subset of data. The chemical structures would  be
introduced into a database at NIH. Implementation of the suggestion
will be attempted when funding is available for personnel, software.
et al. Other commercial software packages will, also, be examined for
their utility for these purposes.
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STATISTICS
About 55 compounds were tested at MCV in the opioid program this
year (Aceto et al. 1990). and results on 40 compounds investigated at
UM are included in the rcpon from UM (Woods et al. 1990). These 95
reports concern 68 compounds of various structural types (tables 1-9).
The compounds were obtained from university researchers,
pharmaceutical industry, and governmental groups.
S e v e n  c o m p o u n d s  w e r e  r e c e i v e d  f o r  t e s t i n g  a s  s t i m u l a n t s  o r
depressants, and these were obtained from pharmaceutical industry
or governmental groups. Results obtained on the three depressants
obtained for examination for the WHO have been briefly noted in this
report.
THE OPIOID PROGRAM
The chemical structures of the various compounds which were tested
as opioids in 1989 are listed in Tables 1-9, together with the biological
w o r k  w h i c h  w a s  d o n e  w i t h  t h e m . T h e  c o m p o u n d s  w h i c h  w e r e
examined have been placed according to their conventional chemical
classification (i.e. 4,5-epoxymorphinans in t a b l e s  1 - 3 , 6,7-
b e n z o m o r p h a n s  i n  t a b l e  4 ,  4 - p h e n y l p i p e r i d i n e s  i n  t a b l e s  5 - 6 ,
fentanyl-related compounds in table 7, and miscellaneous compounds
in tables 8-9.
Stereochemical Effects
I t  i s  convenient  to  v iew the  tested  compounds  according  to  the ir
chemical classification. G e n e r a l l y ,  m o s t  n e w l y  s y n t h e s i z e d
compounds w h i c h  h a v e  t h e  b a s i c  c h e m i c a l  s t r u c t u r e k n o w n  t o
interact with opioid receptors (and the classification scheme for the
structures in the tables denote a considerable number of the major
classes of those which have been found to do so) will have some opioid
activity. Within a particular class, of course, there are important
factors which dictate activity. One of these factors relate to the
stereochemistry o f  t h e  m o l e c u l e . T h e  e n a n t i o m e r s  o f  r a c e m i c
mixtures which have been found to have opioid activity are generally
the (-)-  (levo) enantiomers.
Racemic mixtures and enantiomers of the totally synthetic opioids
have, historically, been obtained and examined, and examples of these
can be seen in table 4. The (+)-6,7-benzomorphans have little or no
opioid activity, compared with their (-)-enantiomeric relatives. They
may be of interest, however, for other reasons. Until the last few
years there were no (+)-enantiomers available for those analgesics or
antagonists which had been prepared more-or-less directly from a
p l a n t  p r o d u c t  ( e . g . ,
e p o x y m o r p h i n a n  s e r i e s ,  w h i c h  i n c l u d e s  m o r p h i n e ,  e t o r p h i n e ,
analgesics o r  a n t a g o n i s t s  i n  t h e  4 , 5 -
codeine, naloxone, naltrexone, etc.). It was not, then, at all necessary
to state whether the morphine or codeine used in an experiment was
( - ) ,  s i n c e  n o  o t h e r  f o r m ,  n o r  t h e  r a c e m a t e ,  e x i s t e d . Recently
however, Rice (1985) reported a practical total synthesis of this class
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of opioids. and several of the more important dextro enantiomers of
the 4,5-epoxymorphinans have now become available in sufficient
quantity for  b io log ica l testing ((+)-morphine, (+)-codeine, (+)-
etorphine, etc.). Three of the compounds shown in table 3 resulted
from this practical total synthesis (NIH 10617, 10620, and 10621).
The 4.5-Eooxymorphinans
( - ) -Etorphine  i s  one  o f  the  most  potent  op io id  agonists  in  v ivo .
Although its binding to opioid receptors is not completely in accord
with its potency in vivo, it is obvious that exceptional
stereoselectivity is shown by the enantiomers of etorphine, in vivo
and in vitro. In table 3, (+)-etorphine can be seen to be ineffective in
displacing the [3H]-(-)-etorphine radioligand from opioid receptors at
concentrations >10 µM. The ca. 10,000 fold binding stereoselectivity
between the dextro and lcvo enantiomers of etorphine is remarkable.
In 1964, at UM, (-)-etorphine (NIH 8068) was found to be equivalent to
morphine, in a single dose suppression (SDS) study in monkeys, at a
dose of 0.0012 mg/kg. The (+)-etorphine (NIH 10617) was studied in
SDS at MCV this year and was found to be inactive at 8 mg/kg. The (-)-
enantiomer, in vivo, was thus more than 6666 times more potent as an
opioid than (+)-etorphine. A n  i n t e r e s t i n g  b y - p r o d u c t  o f  t h i s
stereoselectivity is that the chemical resolution or separation of these
enantiomers can be more accurately checked in vitro or in vivo than
it can be by chemical instrumentation.
The (+)-thevinone and (+)-19-propylthevinol (NIH 10620 and 10621,
in table 3) synthesized by Grayson and Rice (1990) are, like (+)-
etorphine, inactive as opioids. It is interesting to note that although
the  former  (NIH 10620)  docs  not  interact  at  op io id  receptors ,  i t
appears t o  h a v e significant opioid antagonist activity in the
electrically stimulated mouse vas deferens (VD) preparation. It is
unusual to find opioid antagonists which do not interact with CNS
opioid receptors and this work will ,  therefore, be repeated. The in
vivo data from MCV will be reported next year, but sufficient work
has been done with these compounds thus far to say that they are
both inactive as opioids in vivo (to 16 mg/kg in the SDS assay).
A  N o n - P h e n o l i c  4 , 5 - E p o x y m o r o h i n a n  a n d  N - M e t h y l  S u b s t i t u t e d
Antagonists
Although most 4,5-epoxymorphinans without a phenolic hydroxyl
group in the C-3 position on the aromatic ring are relatively inactive,
NIH 10501 was found to be as potent as, or more potent than morphine
in antinociceptive assays last year (Aceto et al. 1989). and has been
found this year (table 1) to have activity in vitro as well.
The cyclopropylmethyl substituent on nitrogen in this class of opioids
is known to confer narcotic antagonist properties to the molecule. the
comparable  N-methyl relative having agonist effects. Several
exceptions have been found previously, and again this year. NIH
10544 and 10594 (table 1). which have an N-methyl moiety, do not
substitute for morphine in the SDS assay and both of them were noted
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to have antagonist activity in the TFA assay. They were both found to
be selective mu opioid antagonists in the VD preparation. with NIH
10544 having the potency of naloxonc. However, saturation of the
double  bond in  the  c innamoylamino moiety  induces  a  qual i tat ive
change in activity, from antagonist to agonist. Thus NIH 10545, the
saturated relative of NIH 10544, was found to have selective mu
agonist activity in the VD preparation (the agonist activity was also
found in  v ivo  data  f rom MCV) ,  in  contrast  with  the  potent  and
selective mu antagonist activity of NIH 10544.
Other compounds in the C-14 substituted cinnamoylamino series (e.g.,
NIH 10443 and 10445) were discussed last year, and some of those
which had the N-cyclopropylmethyl substituent were found to be
very long acting, and potent narcotic antagonists.
A Potent 4,5-Epoxymorphinan, and Selective Delta Opioid Receptor
Antagonists
The most potent of the 4,5-epoxymorphinans which were examined
this year was NIH 10549. It was found to be more than 700 times as
potent as morphine in the PPQ assay and 290 times more potent than
morphine in the TF assay. Three compounds which were originally
reported by Portoghese et al.  (1988),
and submitted to us for testing.
were resynthesized elsewhere
These compounds, NIH 10589, 10590
and 10591, exacerbate withdrawal in the SDS assay and two of them
were potent delta selective antagonists in the opioid receptor assay
(NIH 10589 and 10590). The NIH 10591, which has an N-methyl
substituent, acted as an agonist in the VD preparation, but not in vivo.
These  compounds  show great  promise  for  the  examinat ion  o f  the
specific biological effects of delta agonists and antagonists.
6,7-Benzomorphan Narcotic Antagonists
The raccmate and enantiomers of a 6,7-benzomorphan with an N-
methylallyl substituent were examined (NIH 10595, 10608 and 10612 in
table  4 )  and the  levo  enant iomer  (NIH 10595)  was  found to  have
agonist-antagonist activity. Its duration of action in nonwithdrawn
monkeys was found to be much longer than naloxone. The racemic N-
pentyl benzomorphan (NIH 10573 in table 4) was reevaluated this
year. When it was examined in 1977 (as NIH 7785, tested from 2 to 16
mg/kg). it was found to only partially reverse abstinence in the SDS
assay. However, it was not tested for its possible antagonist activity at
that time. The compound was found, this year, to be an agonist-
antagonist at MCV. It precipitated withdrawal in non-withdrawn
monkeys. The antagonist activity of NIH 10573 was not observed in
the  ta i l  f l i ck  antagonist  assay  vs .  morphine  (TFA)  or  in  the  VD
preparation.
Extremely Potent Compounds Related to Fentanyl
Although not quite as potent as carfentanil (NIH 10570 in table 7) was
noted to be last year, NIH 10579 in table 7 was found to be more than
3000 times more potent than morphine in the PPQ assay. Many
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fentanyl-like compounds have, in the past, been submitted to us from
governmental groups. These  drugs  had  been found to  have  been
prepared illicitly and marketed illegally, and were sent to us for the
purpose of obtaining sufficient pharmacological data to enable their
scheduling. There are, also, several pharmaceutical and university
groups interested in this class of opioid. Carfentanil, for example, was
tested under CPDD auspices prior to its being marketed for use as an
animal tranquillizer.
Compounds with Non-classical Opioid Structures
Most of the miscellaneous compounds in tables 8 and 9 have little or
no opioid activity. lbogaine (NIH 10567 in table 9) was sent to us for
examination with the idea that it might have potential as a
preventative for cocaine and narcotic abuse. Extracts of the lboga
plant, from which ibogaine is obtained, have been noted to have some
rather peculiar properties (Merck Index, # 4793). These extracts are
said to have been used “by African natives while stalking game, to
enable  them to  remain mot ionless  for  as  long  as  two days  whi le
retaining mental alertness”. The compound was found, at MCV, to
have weak antinociceptive activity only in the PPQ assay, nor does it
interact with opioid receptors in rat brain homogenates or in the VD
preparation with any effectiveness. It partially substitutes for
morphine (at 2 or 8 mg/kg) in the SDS assay, but this is not
necessarily indicative of opioid-like activity. We will examine the
compound further, next year, using rat infusion assays if a sufficient
quantity of the pure compound can be obtained. It is likely that most
of the compounds shown in tables 8 and 9 were not synthesized as
centrally acting analgesics.
In order to summarize the biological work  f rom UM (Woods  et  a l .
1990). and MCV (Aceto et al. 1990). in a few tables, a considerable
number of abbreviations have been used. These are listed after table
9. Only  that  work which  was  actual ly  done  this  year  has  been
recorded in the tables. Previously reported work on compounds is
noted with the year in which the report appeared. It should be
emphasized that the year noted is the titled year (e.g..  Problems of
Drug Dcpendcnce. 1986). not the year of actual publication (which
usually, but  not  a lways ,  occurred  dur ing  the  year  fo l lowing  that
denoted in the title of the publication).
Thus, from these tables, the reader can see all of the work done this
year, or when some of the work on the compound was previously
done, across all facilities associated with the opioid program under the
auspices of the CPDD. If the reader would like further, or more
complete information on a particular compound, the original report
o f  Woods  et  a l .  (1990)  and Aceto  et  a l .  (1990)  should  be  perused
through use of the assigned NIH number, since all reports are cross-
referenced by NIH number.
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TABLE 1. 4,5-EPOXYMORPHINANSa
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND ABBREVIATIONS.
b) PREVIOUSLY REPORTED - 1983. c) PREVIOUSLY REPORTED - 1987. d) LONG
DURATION OF ACTION. e) PREVIOUSLY REPORTED - 1988. f) POTENT,
“IRREVERSIBLE” ANTAGONIST OF -RECEPTORS. g) PRECIPITATED
WITHDRAWAL. h) DURATION OF ANTAGONISM OF MORPHINE. i) SELECTIVE µ-
ANTAGONIST. j) SEVERE WITHDRAWAL NOT RELIEVED BY NALOXONE. k) K-
AGONIST IN MVD. 1) MONKEY ANALGESIA (ED50=1.7); SI=IN; DD-GENERALIZED
TO CODEINE (0.01, 0.001). m) SELECTIVE µ AGONIST.
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TABLE 2. 4.5-EPOXYMORPHINANS (CONTINUED)a
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND ABBREVIATIONS.
b) REPEATED PPQ. c) PREVIOUSLY REPORTED - 1988. d) ANTAGONIZED µ,
AGONISTS. e) EXCEPT FOR WET DOG SHAKES. f) ANTAGONIST, LESS POTENT
THAN NALTREXONE. g) SELECTIVE µ RECEPTOR ANTAGONIST.
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TABLE 3. 4,5-EPOXYMORPHINANS (CONTINUED)a
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND
ABBREVIATIONS. b) =0.214. K=20.5. c) SELECTIVE RECEPTOR
ANTAGONIST. d)  EXACERBATED WITHDRAWAL. e) =0.204. K=9.01. f) =3.37.
K=688. g) PARTIAL AGONIST WITH SIGNIFICANT ANTAGONIST ACTIVITY.
h) NON-SELECTIVE OPIOID ANTAGONIST.
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TABLE 4. 6,7-BENZOMORPHANSa
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND
ABBREVIATIONS. b) PREVIOUSLY REPORTED - 1972. c) OPIOID ANTAGONIST.
d) AD50 OF 7912 VS. ED50 OF MORPHINE=3.3. AD50 OF NALOXONE AND
YOHIMBINE VS. ED80 OF 7912=3.4 AND 0.4, RESPECTIVELY. e) PREVIOUSLY
REPORTED - 1973. f) AD50 OF 8773 VS. ED50 OF MORPHINE=1.2. AD50 OF
NALOXONE AND YOHIMBINE VS. ED80 OF 8773=0.13 AND 0.12, RESPECTIVELY.
g) CNS DEPRESSION NOT REVERSED BY NALORPHINE. h) PREVIOUSLY
REPORTED - 1983. i) PREVIOUSLY REPORTED - 1988. j) WEAK ANTAGONIST OF µ
AND K-RECEPTORS. k) REPEATED THIS YEAR. I) WEAK ANTAGONIST OF µ,
RECEPTORS. m) EXCEPT FOR WET DOG SHAKES. n) µ AGONIST, AND
ANTAGONIST. o) EXACERBATED WITHDRAWAL. p) MUCH LONGER DURATION
OF ACTION THAN NALOXONE (0.01N).
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TABLE 5. 4-PHENYLPIPERIDINESa
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND
ABBREVIATIONS. b) PREVIOUSLY REPORTED - 1988. c) ERRATIC.
NALOXONE PRODUCED 65% ANTAGONISM VS. ED60 OF NIH 8032.
d) REPORTED ALSO IN 1963. e) NS (0.003 mg/kg/day); RI-PPD: MORPHINE
PLUS NIH 8032 QUALITATIVELY SIMILAR TO MORPHINE ALONE.
QUANTITATIVE CHANGE NOTED. f) PS (20); RI-PPD: MORPHINE-LIKE.
g) AD50 OF NALOXONE VS. ED80 OF NIH 10553 = 0.06. h) NON-SELECTIVE
ANTAGONIST. i) ANTAGONIST WITH SLIGHTLY HIGHER AFFINITY FOR
µ AND K  THAN
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TABLE 6. 4-PHENYLPIPERIDINES (CONTINUED)a
a) SEE TEXT FOR EXPLANATION OF COLUMN
HEADINGS AND ABBREVIATIONS. b) NON-SELECTIVE
ANTAGONIST. c) OPIOID ANTAGONIST, LESS POTENT
THAN NALTREXONE.
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TABLE 7. FENTANYL-RELATED COMPOUNDSa
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND ABBREVIATIONS.
b) PREVIOUSLY REPORTED - 1988. c) NALOXONE AD50 VS. NIH 10551 ED80 IN TF
= 3.7. d) NALOXONE AD50 VS. NIH 10570 ED80 IN TF = 0.02. NALOXONE AD50
BEFORE NIH 10570 INTRODUCTION= 0.035. e) PREVIOUSLY REPORTED - 1987.
f) µ SELECTIVE ANTAGONIST (REPORTED INACTIVE IN 1988). PRIOR WORK (IN
VIVO, 1987) INDICATED THAT THE COMPOUND HAD ONLY AGONIST ACTIVITY.
‘ERROR IN STRUCTURE IN MCV COMPILATION IN 1988.
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TABLE 8. MISCELLANEOUSa
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND ABBREVIATIONS.
b) PREVIOUSLY REPORTED - 1979. c) PREVIOUSLY REPORTED AS ACTIVE.
d) INCREASED INCIDENCE OF CERTAIN WITHDRAWAL SIGNS. e) OPIOID
ANTAGONIST. f) MAY EXACERBATE WITHDRAWAL. g) PREVIOUSLY REPORTED
- 1987. h) OTHER - SI-HIGH; DD-CS. i) PREVIOUSLY REPORTED - 1988.
j) NALOXONE AD50 VS. ED80 OF NIH 10532 = 67% AT 40. k) SIGNIFICANT K-
RECEPTOR ACTIVITY. I) NALOXONE AD50 VS. ED80 OF NIH 10533 IN PPQ AND
TF = 0.7 AND 1.0, RESPECTIVELY. m) HIGH DOSE CAUSED DISORIENTATION,
STUPOR.
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TABLE 9. MISCELLANEOUS (CONTlNUED)a
a) SEE TEXT FOR EXPLANATION OF COLUMN HEADINGS AND
ABBREVIATIONS. b) MARKED VARIABILITY IN RESPONSE RATES
BETWEEN ANIMALS.
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ABBREVIATIONS USED IN TABLES 1 - 9.
1) MOUSE ED50 OR AD50: Antinociceptive Assays (sc injection)
Confidence limits for the ED50 and AD50 are listed in the MCV and UM
reports (Aceto et al. 1990; Woods et al. 1990)].
HP = hot plate; N = Nilsen; PPO = phenylquinone; TF = tail flick; TFA =
tail flick antagonism vs. morphine. These assays are performed at
MCV, except for the HP and N (carried out at NIDDK, NIH). I = inactive,
without  a reasonable dose-response relationship. or insufficiently
active for statistical analysis.
2) In Vitro Determinations (Data from UM)
A) RBH = binding affinity, in the presence of 150mM NaCl, to rat or
monkey cerebrum membrane preparat ions ,  in  nM (parenthes ized
number, noted in previous reports, is the +sodium/-sodium [+Na/-Na]
ratio). EC50 was determined by displacement of 0.5 nM [3H]etorphine.
The EC50 of morphine from rat preparations is, for comparison = 23.6
(1.69). NE = no effect.
The efficacy of a few drugs on specific opioid receptors has been
examined, using different radioligands (see Woods et al. 1990).
NOTE: The present EC50 data cannot be directly compared with those
from some previous reports (Jacobson 1984. and preceding years) in
which -Na values were quoted. However, the former numbers can be
recalculated for comparison with those which arc currently utilized
through the use of the +Na/-Na ratio.
B) VD = electrically stimulated mouse vas deferens EC50 values.
rounded to one significant figure. Agonist activity is stated using “E”
followed by a negative number: E = 10-x M, where x = the negative
number, thus: 1E-3 = 0.001 M (1 mM), 1E-6 = 1 uM, and 1E-9 = 1 nM
(parenthesized numbers are maximum percent inhibition at EC50).
NE = no effect on inhibition of twitch; SE = slight effect on twitch;
[bracketed letters: A = antagonized by 10-7 M naltrexone; NA = not
antagonized by naltrexone; SA = slight antagonism by naltrexone].
Compounds which suppress the twitch and are not antagonized by
naltrexone or UM 979 [NIH 8859, (-)-5,9- -dimethyl-2-(3-furylmethyl)
-2 ’ -hydroxy-6 ,7 -benzomorphan]  are  sa id  to  be  non-opio id  agonists
(e.g. clonidine can suppress the twitch, but is not antagonized by
naltrexone. It is a non-opioid agonist). (The effect of UM 979 is not
noted in this report, but see the UM report (Woods et al. 1990) for
these data). Compounds which bind with reasonable affinity in the
rat brain homogenate assay, suppress the twitch in the VD, but are
not blocked by narcotic antagonists may have narcotic antagonist
properties. This is experimentally determinable by observing their
antagonism to morphine’s suppression of the twitch in the VD
preparation (for these data see Woods et al. 1990).
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3) Monkey Colony Data (from MCV; prior to 1988 from MCV or UM.
A) SDS = single dose suppression
NS = no  suppress ion ;  CS = complete  suppress ion ;  PS = part ia l
suppression. (Parenthesized numbers = dose range studied, in mg/kg;
if CS, then dose at which CS was observed is noted in the parentheses).
Potency comparison with morphine [M] may be stated, in brackets.
B) NW or PPt-W studies in non-withdrawn monkeys
PW = precipitated Withdrawal at dose levels, in mg/kg, indicated in
parentheses &/or comparison with naloxonc [N], in brackets; NP = no
precipitation; SP = slight precipitation.
4) Other Studies (OTHER);
A) RI = rat continuous infusion (data from MCV)
a) SM = substitution for morphine
NS = no substitution for morphine; CS = complete substitution;
PS = partial substitution].
b) PPD = primary physical dcpendcncc. in rats.
B) ND = non-deoendent monkeys
M-like = morphine-like effect.
C) PPD = primary physical deoendcncc (in the rhesus monkey).
D) SA or SI = self-administration or self-inicction (data from UM)
NE = no effect; High = codeine-like; IN = intermediate between saline
and codeine; SE = slight effect.
E) DD = drug discrimination (data: from UM)
NE = no effect, CS = complete suppression.
Previous Reports
Previous work on a compound is noted by year, the year listed in the
monograph title (e.g. Problems of Drug Dependence 1986). Note that
the date of publication of the monograph generally occurs one year
after the titled year of the monograph. The data which have been
published in previous reports are shown in the tables in the
appropriate -column and the year in which the original work can be
found is cited in the footnotes to the tables (e.g.,  a 1983 previous
report would indicate that the work was cited in “Problems of Drug
Dependence 1983”. which was published in 1984. The work can be
found in the Annual Report of either Aceto et al., or Woods et al.).
N O T E : Rounded numbers arc used in the tables. For precise values,
and details of the procedures, see the MCV and UM reports in these
Proceedings (Aceto et al. 1990; Woods et al. 1990).
Abbreviations for structural formulae;
CPM = cyclopropylmethyl.
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THE STIMULANT AND DEPRESSANT PROGRAM
Of the seven compounds which were examined this year, three were received
from pharmaceutical industry at the urging of the WHO, since biological data on
these three compounds were needed for  discussion at  the Expert  Committee
meeting of  WHO in April ,  1989. These compounds, ctizolam, brotizolam, and
quazepam (CPDD 0024, 0025, and 0026, respectively) are benzodiazepine-like in
structure (figure 1) and were examined as depressants.
Brotizolam. CPDD 0025, was examined by self-injection (SI) procedures at UM and
appeared to have only a slight reinforcing effect. However, administration of
CPDD 0025 resulted in drug appropriate responding in a drug discrimination
assay, at the University of Chicago, and tolerance appeared to result from the
discriminative stimulus and rate-altering effects of the compound.
Etizolam and quazcpam were also examined in drug discrimination.
Administration of etizolam (CPDD 0024) resulted in drug appropriate responding
IO all subjects tested (up to 3 mg/kg, generalization to a pentobarbital stimulus).
Quazepam (CPDD 0026) also produced discriminative stimulus effects similar IO
those ‘of pentobarbital.
All  three of  these compounds would be predicted.
assays, to have pcntobarbital-like subjective effects in
from drug discrimination
humans.
FIGURE 1. Structures of ctizolam, brotizolam and quazepam
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Dependence Studies of New
Compounds in the Rhesus
Monkey, Rat and Mouse (1989)
M. D. Aceto, E. R. Bowman, L. S. Harris and E. L. May
The identities of the test compounds were unknown to us when they were
originally submitted except for NIH 10616 (Flumazenil). Dr. Arthur Jacobson,
Laboratory of Medicinal Chemistry, NIADDK, NIH, supplied all the compounds
except caffeine. This study was done under the auspices of the Committee on
Problems of Drug Dependence, Inc.
For the most part. the procedures described by Seevers and his colleagues (1936.
1963) and Deneau (1956) regarding the facilities and training of the monkeys
were used and a brief description follows. The monkeys were injected with 3.0
mg/kg s.c. of morphine sulfate every 6 hr for at least 90 days before being used.
This dose regimen was reported by Seevers and Deneau (1963) to produce
maximal physical dependence.
Modified procedures for the precipitated withdrawal (PPt-W) and single-dose
suppression (SDS) tests were reported by Aceto and co-workers (1977 and
1978). The PPt-W test was initiated by the injection of a test drug 2 1/2 hr after
an injection of morphine and the animals were observed for signs of withdrawal.
The SDS test was started approximately 15 hr after the last dose of morphine at
which time the animals were showing withdrawal signs. The onset and duration
of action of the test drug were noted In both tests, a vehicle control and an
appropriate positive control (naloxone hydrochloride, 0.05 mg/kg or morphine
sulfate, 3.0 mg/kg) along with 2 or 3 different treatments (doses) of a test
compound were randomly allocated to the 4 or 5 monkeys of a group. Usually,
3 or 4 groups per compound were used. All drugs were given subcutaneously (1
ml/kg) and the vehicle was water except where indicated. The observer was
“blind” with regard to the treatment given. A minimal 2-week washout and
recuperation period between tests was allowed. In the primary physical
dependence (PPD) tests, the animals of a group received the drug every 4-6 hr for
30-50 days. They were placed in abrupt withdrawal and challenged with
naloxone periodically, then observed for signs of physical dependence. All
potency estimates are rough approximations only.
The rat-infusion method was reported by Teiger (1974) and certain modifications
are indicated as follows. Semi-restrained, male, Sprague-Dawley rats were
medicated with a drug by continuous infusion through indwelling intraperitoneal
cannulas for 6 days. Rats were anesthetized after which each was fitted with a
specially prepared cannula which was passed subcutaneously from the nape of the
neck to the lateral side of the lower abdomen and then inserted into the peritoneal
cavity. The cannula was anchored at both ends with silk sutures and attached to a
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flow-through swivel mechanism which allowed the animal to move about in the
cage and eat and drink normally. The swivel was connected to a syringe which
was attached to a syringe pump. The animals received 7-10 ml of solution every
24 hr.
In the substitution for morphine (SM) test, the animals first received morphine
(50 mg/kg/24 hr on the first day, 100 mg/kg/24 hr on the second day, and 200
mg/kg/24 hr from days 3-6). Then, a test drug was substituted for 2 days. The
morphine controls received an infusion of water. The animals were observed for
changes in body weight and for behavioral-withdrawal signs for 1/2 hr at 24, 48,
72 and/or 96 hr after stopping the infusion of morphine.
In the primary physical dependence (PPD) study, the rats received test compound
for 6 days and then were placed in abrupt withdrawal and observed as above.
Occasionally, a drug was given with morphine.
Three mouse tests were used in our laboratory to provide a preliminary estimate
of the potency and profile of activity of each test compound. The tests were the
tail-flick agonist (TF) and the morphine antagonist (TF vs M) tests and the
phenylquinone (PPQ) test (Dewey et al., 1970; Dewey and Harris, 1971).
Reference-standard data for these tests are shown in Table 1. In addition, Dr.
Jacobson occasionally provided us with estimated starting doses. These doses
were based on results obtained from the mouse-hot plate (HP) (Eddy and
Leimbach. 1953; Jacobson and May, 1965; Atwell and Jacobson, 1978) and
Nilsen (N) (Perrine et al., 1972) tests from his laboratory. Reference data for
these tests are shown in Table 2.
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Table 1
Comparative Data-ED50, mg/kg S.C. (95% C.L.) of Selected Standards in 3
Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick Phenylquinone
Test Antagonist Test Test
Pentazocine 15% at 10.0 18 (12-26) 1.7 (1.0-2.5)
Cyclazocine 17% at 1.0a 0.03 (0.020-0.78) 0.01(0.005-0.03)
Nalorphine·HCl None at 10.0 2.6 (0.7-10.0) 0.6 (0.03-1.44)
Naloxone·HCl None at 10.0 0.04 (0.01-0.09) No Activity
Naltrexone·HCI None at 10.0 0.007 (.002-0.02) No Activity
Morphine Sulfate 5.8(5.7-5.9) ----- 0.23(0.20-0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but there was no further increase in
reaction time.
Table 2
Comparative Data (ED50 mg/kg) [95% C.L.] from the Hot Plate and Nilsen
Assays
Hot Plate Nilsen
s.c./p.o. s.c./p.o.
Morphine Sulfate
Codeine Phosphate
Levorphanol Tarn-ate
Meperidine·HCl
0.98 (0.83-1.1) 1.3 (1.0-1.7)
6.3 (4.7-8.3) 8.3 (6.0-11.4)
6.8 (4.5-10.2) 7.4 (4.9-11.0)
13.5 (9.7-18.7) 14.7 (9.2-23.3)
0.2 (0.1-0.3) 0.2 (0.16-0.3)
2.5 (1.7-3.7)
5.3 (4.0-7.1)
(-)-Metazocine·HBr 0.6 (0.5-0.9) 0.5 (0.3-0.7)
10.6 (8.0-14.1) 26.0 (21.0-33.0)
Dihydromorphinone·HCl 0.19 (0.15-0.25) 0.2 (0.15-0.3)
0.9 (0.7-1.2) 1.8 (1.5-2.1)
Nalorphine·HCl 9.9 (5.7-2.1) 23.0 (16.2-32.7)
Cyclazocine
Pentazocine
1.5 (1.1-2.1) 0.1(0.07-0.16)
9.3 (6.7-12.8) 6.5 (4.4-8.8)
Chlorpromazine·HCl 1.1 (0.9-1.5)
No dose response for naloxone and naltrexone.
Phenobarbital, amobarbital, oxazepam, flurazepam, meprobamate and
mescaline are inactive on the hot plate test.
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NIH 7912 (±)-N-allylnormetazocine, (±)-SKF 10,047, (±)-NANM
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. - 1.9 (0.7 - 6.0)
3) PPQ - 10.4 (5.3 - 20.3)
4) HP - Inactive to 50.0
5) N - Inactive to 50.0
A. Special Study: AD50 of NIH 7912 vs ED80 of morphine in PPQ Test = 3.3
(1.9 - 9.5)
B. Special Study: AD50 of naloxone vs ED80 of NM 7912 in PPQ Test = 3.4
(1.9 - 9.8)
C. Special Study: AD50 of yohimbine vs ED80 of NIH 7912 in PPQ Test =
0.9 (0.3 - 2.2)
NlH 8032, Haloperidol
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 14.6 (10.9 - 19.5)a
2) TF vs. M. - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.011 (0.002 -
0.048)
Rodent data reported
previously.
aVery erratic results. Naloxone
produced 65% antagonism vs
the ED60 of haloperidol.
MONKEY DATA
(SDS)
This study was initiated to provide comparative data for the evaluation of certain
N-butyrophenone-prodine compounds (NIH 10494 and NIH 10495). which
were found to have opioid/neuroleptic properties. This study was also prompted
by the observation, in a previous study. that a normally docile male rhesus
monkey, when medicated with haloperidol, became unusually aggressive towards
his handler. The doses selected in this study were not in the range where severe
neuroleptic signs were observed.
As can be seen in the fig., haloperidol did not substitute for morphine. At the
highest dose, more retching and tremors were observed than with the vehicle
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controls. In addition, some of these animals appeared slower and subdued. At
the two lower doses, more restlessness and retching were noticed than in the
controls. In this dose range, none of the animals exhibited aggressive behavior.
TIME (MIN)
RAT INFUSION
A) Substitution for morphine (R-SM) As can be seen from the data on body
weight and water consumption (figs.) and overt signs (table), haloperidol did not
substitute for morphine at a dose of 0.003 mg/kg/day. At this dose, no overt
neuroleptic signs were detected.
D A Y
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B) Special Morphine Plus Haloperidol Primary Physical Dependence Study
(SR-PPD) When morphine plus haloperidol, at 2 dose levels, and morphine were
given and then abruptly withdrawn after 6 days, the withdrawal syndromes were
qualitatively similar to each other. Quantitatively, at 24 hrs, the animals receiving
haloperidol and morphine showed more weight loss and overt withdrawal signs
than those receiving morphine only or vehicle. This was in spite of the fact that
the animals receiving the combination of drugs showed severe disturbances such
as weight loss, changes in water consumption and neuroleptic behavioral signs
during the administration of drugs.
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Table. Evaluation of overt withdrawal signs observed in the infusion studies.
Rat Infusion Studies: Haloperidol substitution for morphine and haloperidol
and morphine simultaneously.
Overt Withdrawal Signs
Vehicle Infusionb
N=4
Morphine Infusiond
Vehicle Substitution
N=3
24hr 48hr 72hr 90hr 120hr
0.0 0.6 0.3±3 1.5±1.5 0.0
9 .0±3.5 c  9 .0±2.3 c  6 .3±3 .9  2 .0±1 .2  1 .0±0 .7
Morphine Infusiond
Halopetidol Substitutione
N=3 7.7±3.2 c  11 .0±5.9 c  3 .7±2 .2  1 .3±0 .9  1 .7±1 .7
Morphine plus Haloperidol
Infusiond,f, Vehicle Substitution
(high-dose regimen)
N=3 12.7±4.3 c  8.0±13.8 c  4.3±2.4 c  2.0±1.5 1.0±0.6
Morphine plus Haloperidold,g
Infusion, Vehicle Substitution
(low-dose regimen)
N=3 16.0±4.5c 7.3±1.6 c  5.3±1.6 c  2.3±0.5 0.3±0.3
aMean number of opioid-like withdrawal signs ± S.E.M. noted in a 1/2 hr
observation period at specified intervals. Signs are hypersensitivity,
squealing, hypersensitivity, aggression, wet-dog shakes, rubbing and
chewing.
bveticle volume was 8 ml/24 hr days 1-10.
cstatistically significant differences (p = 0.05 or less) between Vehicle only and
treated group. One-tailed test (Mann-Whitney test).
dMorphine SO4 infusion - 50 mg/kg day 1, 100 mg/kg day 2, and 200 mg/kg
days 3-6.
eHaloperidol infusion 3.0 mg/kg day 1, 1.5 mg/kg day 2, 0.5 mg/kg day 3,
0.01 mg/kg days 3-6 (high dose)
fHaloperidol infusion - 0.03 mg/kg on days 7 and 8, Vehicle on days 9 and 10
gHaloperidol infusion 0.5 mg/kg day 1, 0.15 mg/kg day 2, 0.003 mg/kg days
3-6 (low dose).
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NIH 8773- (-)-N-allylnormetazocine, (-)-SKF 10,047, (-)-NANM
See NIH 7912
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. - 0.2 (0.1 -
0.6) 7.1
3) PPQ - 1.3 (0.4 - 5.0)
10.3a,b,c
4 )  H P -
5) N - Inactive to 50.0
A. Special Study:
(0.05 - 0.3)
AD50 of naloxone vs ED80 of NIH 8773 in PPQ Test = 0.13
B. Special Study: AD50 of NIH 8773 vs ED80 of morphine in PPQ Test = 1.2
(0.6 - 2.3)
C. Special Study: AD50 of yohimbine vs ED80 of NIH 8773 in PPQ Test = 0.2
(0.1 - 0.3)
NIH 8775 (+)-N-allylnormetazocine, (+)-SKF 10,047, (+)-NANM
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
See NIH 7912 1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs M. - 13.2 (6.6 -
26.2) 30.0
3) Inactive to 40.0
4) HP - Inactive to 50.0
5) N - Inactive to 20.0
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NIH 9512 Baclofen, Lioresal
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or % change)
1)
2)
3)
4)
5)
TF - 0% at 1.0, 45% at
3.0, 64% at 10.0 and 3% at
30.0
TF vs. Morphine - Inactive at
1.0, 10.0 and 30.0a
PPQ - 1.2 (0.4 - 3.1)
HP - 2.1 (1.5 - 2.7)
N - Inactive to 20.0
aPreviously reported as very
active [AD50 - 0.06 (0.02 -0.17)]
in NIDA Monograph 27, 1979.
MONKEY DATA
(PPt-W)
NIH 9512 was studied in the single-dose suppression (SDS) test in monkeys
(NIDA Monograph 27, 1979). It did not substitute for morphine. In order to
fully investigate possible antagonist properties, a precipitated withdrawal test was
conducted.
In non-withdrawn, morphine-dependent monkeys, this compound increased the
incidence of certain withdrawal signs designated fighting, avoids contact,
vocalizing and in one monkey, at the high dose, retching, vomiting and
coughing. In addition, at 2.0 mg/kg. 2 monkeys vocalized when their abdomens
were palpated and had rigid abdominal muscles. Thus, although the compound
increased the incidence of certain withdrawal signs, it did not precipitate a full
withdrawal syndrome. The vehicle was H3P04 and H20.
TIME (MIN)
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Conclusion
This compound does not show antagonist activity either in the mouse
antinociception vs morphine assay or morphine-dependent monkeys.
N I H  1 0 4 4 3  1 4 ß - (p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethyl-
normorphinone mesylate
MOUSE DATA-ED OR
AD50 (95% C.L.) (mg/kg
or % change)
1) TF- Inactive at 1.0,
10.0 and 30.0a
2) TF vs. M. - 0.12 (0.07
- 0.23)a
3) PPQ - 23% at 3.0, 34%
at 10.0, 69% at 30.0
and 54% at 10.0a
4) HP - Inactive to 20.0
aReported previously in
NIDA Monograph 81, 1987
Special Duration Study: Morphine antagonism of NIH 10443 ED200
Pretreatment Time (hr) % Antagonism
24
48
76
19
72 18
NIH 10445 14ß-( p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnormorphinone mesylate
MOUSE DATA-ED OR
AD50 (95% C.L.) (mg/kg or
% change)
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) TF vs. M. - 0.8 (0.6 -
1.0)a
3) PPQ - 7.1 (3.1 - 16.4)a
4) HP-Inaetive to 20.0a
aReported previously in
NIDA Monograph 81, 1987
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Special Duration Study: Morphine antagonism of NIH 10445 ED200
Pretreatment Time (hr) % Antagonism
24 8 0
48 57
72 3 6
96 29
120 1
NIH 10446 2,6-Diamino3- p-fluorobenzylpyridine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1)
2)
TF - 3% at 0.1, 20% at
1.0, 6% at 1.00 and 0%
at 30.0
TF vs. M. - 22% at 1.0,
0% at 10.0 and 0% at 3.0
3) PPQ - 0.96 (0.31 - 2.98)
4) HP - Inactive at 5.0 and
20.0
MONKEY DATA
(SDS)
In the dose range of 4.0 - 12.0 mg/kg, NIH 10446 did not substitute for
morphine. The drug may have exacerbated withdrawal (see fig.). One animal
receiving 4.0 mg/kg showed myoclonic jerks.
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TIME (MIN)
NIH 10447, MCV 4517
hydrochloride
2-Chloro-6-(4-N- n-propylpiperidino)thiopyridine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1 )
2)
3)
4 )
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M. - 27% at 1.0,
47% at 10.0 and 16% at
30.0
PPQ - 2.6 (0.5 - 12.7)
HP - Inactive to 20.0
MONKEY DATA
A.  (SDS)
NIH 10447 does not substitute for morphine. The drug seemed to exacerbate
withdrawal (Fig. 2); however, this may be a reflection of the fact that the vehicle
controls showed an unusually weak abrupt-withdrawal syndrome.
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TIME (MIN)
B. (PPt-W)
As shown in the figure, NIH 10447 was inactive in precipitating withdrawal in
morphine-addicted monkeys. Two animals receiving the highest dose were very
drowsy and moved abut slowly one hour after drug was given. Another, at the
highest dose was not as aggressive as usual.
TIME (MIN)
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NIH 10448, MCV 4518 2-Chloro-6-(4-N-isopropylpiperidino)thiopyridine
oxalate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg\kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 37% at 0.1, 40% at
1.0, 54% at 10.0 and 84%
at 30.0
4) HP - Inactive to 20.0
MONKEY DATA
(SDS)
This compound does not substitute for morphine (see fig.). The drug may have
exacerbated withdrawal although the effect does not seem to be dose related.
TIME (MIN)
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NIH 10495, MCV 4560 N-3-(p-Fluorobenzoyl)propyl-4-phenyl-4-pro-
pionyloxy piperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF- 0.3 (0.1 - 1.1)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 0.07 (0.02 - 0.18)
4) HP - 0.32 (0.25 - 0.42)
Rodent and monkey data
reported in NIDA Monograph
90, 1988.
RAT INFUSION
A. (SDS)
As shown in the figs. (body weight loss and water consumption), NIH 10495
partly substituted for morphine at 20.0 mg/kg. Regarding behavioral signs (see
table), the drug nearly substituted for morphine. It is possible that the drug has a
delayed onset of action since body weight loss, water consumption and
behavioral withdrawal were less on days 8 than day 7. Withdrawal signs
reemerged on days 9 and 10 after the drug was withdrawn and vehicle
substituted.
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NIH 10495 SM
Rat Infusion - Cont’d
B .  ( P P D )
NIH 10495 produced a dose-related fall in body weight and drop in H20
consumption (see figs.) and dose-related increases in withdrawal signs (see table)
when withdrawn after 6 days of continuous infusion. During the first day of
infusion, the drug produced unusual changes in the H20 consumption, the low
dose increased and the high dose decreased consumption dramatically. Whether
or not this is a spurious happening is uncertain.
In any case, a physical dependence syndrome, similar to morphine’s, develops
with this agent
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NIH 10495 PPD
NIH 10495 PPD
595
C. Special Study: Morphine + NIH 10495 R-PPD
The withdrawal syndrome resulting from the abrupt withdrawal of a solution
containing morphine and NIH 10495 was qualitatively and quantitatively similar
to that produced by the morphine controls (see figs. and table).
DAY
DAY
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Table: Primary Physical Dependence (PPD) and Substitution for Morphine
Studies (SM) with NIH 10495 in Continuously-Infused Rats
Treatment
24 48 72 96
Hr in Withdrawal
Mean Number of Withdrawal Signs a,b
1. Vehicle Controlsc 0.5 1.5 0 1.3
2. Morphine Controlsd 14.2b 20.0b 9.0 b 2.0
3. NIH 10495-PPDe 9.3 b 9.3 b 8.0 3.7
(high dose)
4. NIH 10495-PPDf 12.5 6.5 5.3 2.3
(low dose)
5. NIH 10495-SDSg 3.8 0.8 12.8b 8.0 b
(high dose)
aHypersensitivity, squeaking, aggression, wet-dog shakes, rubbing and
chewing;
bOne-tailedtest Mann-Whitney U test, p < 0.05, probability value vs. water
controls;
c8 ml/24 hr. N=4;
dDose regimen of morphine SO4, 50 mg/kg on day 1. 100 mg/kg on day 2,
200 mg/kg on days 3-6. N=5;
eDose regimen of NIH 10495.20 mg/kg/day on days 1-6; then H20 as above
during withdrawal. N=3;
fDose regimen of NIH 10495 10.0 mg/kg on days 1-6; then, H20 as above
during withdrawal. N=4;
gMorphine SO4 Infusion, days 1-6 as above then, NIH 10495 on days 7 and
8, 20 mg/kg, and H20 as above on days 9 and 10. N=5 on days 7 and 8; and
4 on days 9 and 10.
NIH 10497. MCV 4558 N-[(1R)-l-Cyclopropyl]ethylnormorphine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TP - 2.0 (0.6 - 6.6)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 0.03 (0.01 - 0.2)
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MONKEY DATA
(SDS)
NIH 10497 substituted completely for morphine. The drug acted promptly and
its duration of action was about 2 hr. (see fig.). In addition, this drug is slightly
less potent than morphine. Many drug-related side effects were seen including
body sag, jaw sag, slowing, staring, and salivation. The incidence of drowsiness
was more than that observed in morphine-treated controls.
TIME (MIN)
NIH 10532. MCV 4581 (+)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-
cyclohexyl-1]benzeneacetamide d-tartrate, ((+)-U 50,488 d-tartrate)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1)
2)
3)
4)
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M. - 0% at 1.0,
2% at 10.0 and 21% at
30.0
PPQ - 6.5 (2.0 - 20.9)a
HP - Inactive at 20.0
Reported previously in NIDA
Monograph 90, 1988.
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aSpecial Study: Naloxone vs NIH 10532 ED80 in PPQ test
Naloxone Dose mg/kg sc % Antagonism
40.0 67%
20.0 64%
10.0 29%
1.0 14%
Conclusion: Very high doses of naloxone only partially antagonize the
antinociceptive activity of NIH 10532 in the PPQ test.
NIH 10533. MCV 4582 (-)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-
cyclohexyl-1] benzeneacetamide l-tartrate, ((-)-U 50,488 l-tartrate)
See NIH 10532
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 2.5 (1.0 - 6.0)a
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 0.2 (0.08 - 0.54)b
4) HP - 8.9 (6.0 - 13.2)
Rodent data reported
previously in NIDA
Monograph 90, 1988.
a. Special Study: Naloxone vs NIH 10533 ED80 in TF test = 0.7 (0.2 - 3.2)
b. Special Study: Naloxone vs NIH 10553 ED80 in PPQ test = 1.0 (0.3 - 2.9)
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NIH 10544
mesylate
14ß-(p-Methylcinnamoylamino)-7,8-dihydromorphinone
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF- 11% at 1.0 and
10.0 and 14% at 30.0
2) TF vs. M. - 0.6 (0.2 -
1.4)
3) PPQ - 17% at 0.1,
57% at 1.0, 57% at
3.0, 63% at 10.0,
51% at 30.0 and 69%
at 60.0
4) HP - Inactive at 2.0
and 10.0
MONKEY DATA
(SDS)
As shown in the accompanying graph, NIH 10544, at doses of 4 and 12 mg/kg
neither substituted for morphine nor exacerbated withdrawal.
TlME (MIN)
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NIH 10545
mesylate
14ß-(pMethylphenylpropionylamino)-7,8-dihydromorphinone
MOUSE DATA-ED OR AD50
(95% CL.) (mg/kg or %
change)
1) TF - 0.5 (0.2 - 1.5)
2) TF vs. M - 0% at 1.0 and
10.0 and 17% at 30.0
3) PPQ - 0.09 (0.03 - 0.24)
4) HP - Inactive at 2.0 and
10.0
MONKEY DATA
(SDS)
A dose-related suppression of abstinence signs in morphine-dependent and
withdrawn monkeys was observed.
completely for morphine.
At 1.0 mg/kg. the drug substituted
Onset of action was prompt offset of action was at least
that of morphine (> 140 min). NIH 10454 is estimated to be 3 to 5 x more potent
than morphine.
TlME (MIN)
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NIH 10549 14ß-Methoxy-5-methyl-7,8-dihydromorphinone hydrobromide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 0.02 (0.007 - 0.05)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.003 (0.001 -
0.006)
NIH 10551 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-
N-phenylpropanamide hydrochloride
MOUSE DATA-ED OR
AD50 (95% C.L.) (mg/kg or
% change)
1) TF - 0.0002 (0.0001 -
0.0005)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 0.00013
(0.00006 - 0.0003)
4) HP - < 0.0002
Rodent data reported
previously in NIDA
Monograph 90, 1988.
A. Special Study: Naloxone vs NIH 10551 ED80 in PPQ test AD50 = 3.7 (1.3 -
10.7)
B. Special Study: Naloxone vs ED80 of NIH 10551 in TF = 0.06 (0.03 - 0.1)
MONKEY DATA
(SDS)
Estimated potency in SDS test was 25,000 x morphine. SDS results reported
previously in NIDA Monograph 90, 1988.
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NIH 10553 (+)-4-Hydroxy-3-methy1-4-phenyl-1-(1-phenylcyclohexyl)-
piperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 8.7 (4.1 - 18.3)a
2) TF vs. M. - Inactive at
1.0. 10.0 and 30.0a
3) PPQ - 0.7 (0.3 - 2.1)a,b
4) HP - 16% at 20.0
Vehicle-5% Tween 80 in H20
aRodent data reported previously
in NIDA Monograph 90, 1988.
bSpecial Study: Naloxone vs NIH 10553 ED80 in PPQ test. AD50 = 0.06 (0.03
- 0.12)
NIH 10554 (-)-4-Hydroxy-3-methyl-4-phenyl-1-(1-phenylcyclohexyl)-
piperline hydrochloride
See NIH 10553
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 0% at 1.0, 14% at
10.0 and 34% at 30.0a
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 2.5 (0.8 - 7.3)a
4) HP - Inactive to 20 mg/kg
aVehicle 4% Tween 80 in H20
NIH 10556 (+)-5,9 -Dimethyl-2’-hydroxy-2-propyl-6,7-benzomorphan
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 3.0,
10.0 and 30.0a
2) TF vs. M. - 0% at 1.0.
6% at 10.0 and 20% at
30.0
3) PPQ - Inactive at 1.0.
10.0 and 30.0
4) HP - Inactive to 20 mg/kg
aslight ataxia
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MONKEY DATA
(SDS)
At the highest dose (8.0 mg/kg), severe ataxia was noted in all monkeys receiving
NIH 10556. In addition, one monkey vomited; developed jaw sag and appeared
stuporous. However, as shown in the graph, this compound did not substitute
completely for morphine. Most of the suppression of withdrawal signs at 8.0
mg/kg may be attributed to dimunition of response following abdominal palpation
and to a decrease in restlessness.
TIME (MIN)
NIH 10562, NIH 7890 Naloxone hydrochloride
MONKEY DATA
(SDS)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. - 0.03 (0.01 -
0.1)
3) PPQ - 1.3 (0.2 - 6.8)
As shown in the fig., NIH 10562, at 0.05 and 0.0125 mg/kg, exacerbated
withdrawal. Onset of action was prompt and offset was greater than 150 min. It
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should be noted that antagonists are much more potent and have a longer duration
of action in withdrawn, morphine-dependent monkeys.
TIME (MIN)
NH 10564 (±)-2-(2-Carboxyethyl)-5,9 dimethyl-2’-hydroxy-6,7-
benzomorphan hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or % change)
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M. - Inactive at 0.1,
1.0, 3.0, 10.0 and 30.0
3) PPQ - 1.4 (0.3 - 6.4)a
aRepeated: 16% at 0.3, 34% at 1.0,
61% at 5.0, 50% at 10.0 and 47%
at 30.0
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NIH 10565 (+)-2-Butyl-5,9 dimethy1-2’-hydroxy-6,7-benzomorphan
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1)
2)
3)
TF- Inactive at 1.0, 10.0
and 30.0
TF vs. M. Inactive at 1.0
and 30.0
PPQ - 23% at 0.1, 29% at
0.3, 43% at 1.0, 14% at
3.0, 29% at 10.0 and 43%
at 30.0
MONKEY DATA
(SDS)
At the highest dose, two monkeys were ataxic. One of. the animals also appeared
disoriented and had head tremor. In addition; some-of the monkeys at the high
and low dose did not vocalize and had relaxed muscles when their abdomens
were palpated. As indicated in the illustration, the drug did not substitute
completely for morphine.
TlME (MIN)
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NIH 10567 Ibogaine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. Inactive at
1.0, 10.0 and 30.0
3) PPQ - 9.7 (2.8 - 34.0)
4) HP - Inactive to 20.0
Vehicle - 2% Tween 80 in H20
MONKEY DATA
(SDS)
As shown in the fig, NIH 10567 reduced the total number of withdrawal signs
but did not substitute completely for morphine. Some of the monkeys, especially
at the highest dose had relaxed abdominal muscles and did not vocalize when
palpated. Partial substitution does not necessarily imply opioid activity. Severe
tremors were noted at the highest dose.
TIME (MIN)
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NIH 10569 (-)-5,9 -Dimethyl-2’-hydroxy-2-pentyl-6,7-benzomorphan
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 1.3 (0.7 - 2.4)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 1) 0.2 (0.08 -
0.6)
MONKEY DATA
SDS
As shown in the fig., NIH 10569 substituted completely for morphine at the
highest dose. The-drugs appears to be similar to morphine with respect to onset,
duration of action and potency. However, one animal receiving the highest dose
convulsed and another vomited 2 1/2 hr after drug.
TIME (MIN)
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NIH 10570 Carfentanil citrate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or % change)
1) TF - 0.00021 (0.00008 -
0.005)a
2) TF vs. M. - Inactive at 0.0001
and 0.0003a
3) PPQ - 0.000058 (0.000029 -
0.00011)a
4) HP - <0.0004a
aReported previously
See NIDA Monograph 90, 1988.
A.
B.
Special Study: Naloxone AD50 vs ED80 of morphine on Tail-Flick test of
NIH 10570 when naloxone given after NIH 10570 was 0.02 (0.01 - 0.05)
Special Study: Naloxone AD50 vs ED80 of morphine on Tail-Flick when
naloxone given before NIH 10570 was 0.035 (0.017 - 0.074).
NIH 10571 Oxymorphazine dihydrochloride
MONKEY DATA
(SDS)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 0.09 (0.03 - 0.30)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.
3)
4)
PPQ - 0.03 (0.01 - 0.08)
HP - 3.1 (2.2 - 4.3)
Vehicle - Tween80 in H20
Except for wet-dog shakes, NIH 10571 suppressed all other withdrawal signs in
withdrawn, morphine-dependent monkeys. The drug is considered to be 5-10 x
more potent than morphine and has a similar onset and offset of action (see fig.)
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TIME (MIN)
HIH 10573, NIH 7785 (±)-5.9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzo-
morphan hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
See NIH 10569
1) TF - 0.8 (0.3 - 2.0)
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0
3) PPQ - 0.2 (0.1 - 0.7)
MONKEY DATA
A.  (SDS)
This drug produced some dose-related suppression of withdrawal signs in
withdrawn, morphine-dependent monkeys. It appeared to have some agonist
and antagonist effects depending upon whether the dependent monkeys were in
withdrawal or not. It may be a partial mu agonist.
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TIME (MIN)
B. (PPt-W)
NIH 10573 produced a dose-related but low intensity withdrawal syndrome in
non-withdrawn, morphine-dependent monkeys. At the highest dose, one
monkey convulsed. Pentobarbital quickly suppressed these convulsions. The
drug acted quickly and its duration of action was longer than that of naloxone.
the positive control.
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TIME (MIN)
NIH 10579 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetamido]-
piperidine hydrochloride
MONKEY DATA
(SDS)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 0.002 (0.0004 -
0.01)
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 0.000075
(0.000045 - 0.00013)
NIH 10579 substituted completely for morphine at both doses. Its onset of action
is rapid and duration is about 90 min. The drug is approximately 1000 x more
active than morphine (see accompanying fig.)
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TIME (MIN)
NIH 10580 1-[2-(4-Ethyl-4,5-dihydro-1H-tetrazolin-5-one-1-yl)ethyl]-3-
methyl-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or % change)
1) TF - 0.5 (0.2 - 0.9)
2) TF vs. M. - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.04 (0.02 - 0.09)
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MONKEY DATA
(SDS)
At the highest dose, NIH 10580 substituted completely for morphine. Onset and
offset of action appear to be similar to morphine (see fig.). The drug is
considered to be 1 or 2 times mote potent than morphine.
TIME (MIN)
NIH 10589 Naltrindole hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2 ) TF vs.M. - Inactive at
1.0, 10.0 and 30.0
3 ) PPQ - 0% at 1.0 and 10.0
and 28% at 30.0
MONKEY DATA
(SDS)
This compound did not substitute for morphine. It exacerbated withdrawal at
both doses (see fig.). One animal became unusually aggressive towards the
handler.
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TIME (MIN)
NIH 10590 Methyl naltrindole hydrochloride
MONKEY DATA
(SDS)
MOUSE DATA-ED OR
AD50 (95% C.L.) (mg/kg
or % change)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 23% at 1.0, 11%
at 10.0 and 20% at 30.0
4) H P -
NIH 10590 did not substitute for morphine. Instead, it exacerbated withdrawal at
the highest dose (see fig.). This compound is probably a very weak mu
antagonist.
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TIME (MIN)
NIH 10591 N-Methyl-N-nomaltrindole hydrochloride
MONKEY-DATA
(SDS)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0
3) PPQ - 46% at 1.0, 49% at
30.0 and 66% at 60.0
At the highest, dose, NIH 10591 exacerbated withdrawal in withdrawn,
morphine-dependent monkeys. This compound appears to be a very weak mu
antagonist.
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TIME (MIN)
NIH 10592 (S)-N-[(1-Carboxy-2-phenyl)ethyl]-(S)-phenylalanyl-ß-alanine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg sc or %
change)
1) TF - 16% at 1.0, 8% at
10.0 and 3% at 30.0a
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0a
3) PPQ - 27% at 0.5, 57% at
1.0, 59% at 5.0, 65% at
10.0 and 59% at 30.0a
aVehicle - few drops of 2%
NaHC03 solution, then H20.
MONKEY DATA
(SDS)
At doses up to 12.0 mg/kg, NIH 10592 neither substituted for morphine nor
exacerbated withdrawal. Drug supply exhausted. The drug was dissolved in
2% NaHC03 solution, and then, H20 was added.
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NIH 10594
mesylate
14ß(p-Chlorocinnamoylamino)-7,8-dihydromorphinone
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 12% at 1.0, 9% at
10.0 and 22% at 30.0a
2) TF vs. M. - 3.8 (1.2 -
11.7)a
3) PPQ - 1.2 (0.3 - 4.8)a
aVehicle -Lactic acid and H20
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MONKEY DATA
(SDS)
NIH 10594 did not substitute for morphine. At the highest dose, one monkey
had a seizure. Drug supply exhausted.
TIME (MIN)
NIH 10595 (-)-5.9 dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) TF vs. M. - 0.8 (0.7 -
1.0)
3) PPQ - 0.8 (0.2 - 3.1)b
aSevere ataxia, shaking, and
loss of righting reflexes at 30.0
bStraub tail, ataxia,
hyperactivity at 10.0
619
MONKEY DATA
A .  S D S
The drug did not substitute for morphine. Instead, it promptly exacerbated
withdrawal in a dose-wise fashion (see fig.).
B .  P P t - W
TIME (MIN)
NIH 10595 precipitated withdrawal. The drug acted promptly and the duration of
action was at least 2 1/2 hrs much longer than that of naloxone (60-90 min).
Potency is estimated as 1/100 that of naloxone at peak effect. In addition, at the
highest dose. jaw and body sag, ataxia and eyelid ptosis were noted. The
monkeys also seemed to be disoriented at this dose.
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TIME (MIN)
NIH 10596
hydrochloride
4-(3-Hydroxyphenyl)-1,3--dimethyl-4- n-propylpiperidine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 1% at 1.0, 30% at
3.0, 59% at 10.0 and 62%
at 30.0
2) TF vs. Morphine - 0% at
1.0 and 3.0, 32% at 10.0
and 13% at 30.0
3) PPQ - 1.4 (0.6 - 3.0)
NIH 10597
hydroxhloride
4-(3-Hydroxyphenyl)-1,3-dimethyl-4- n-propylpiperidine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1)
2)
3)
TF - 17% at 1.0, 42% at
3.0, 53% at 10.0 and 36%
at 30.0
TF vs. M. - 6.1 (2.6 -
14.2)
PPQ - 2.9 (1.1 - 7.7)
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NIH 10596 4-(3-Hydroxyphenyl)-1,3,4-trimethylpiperidine (cis aryl-methyl)
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. Morphine - 1.2
(0.4 - 3.5)
3 ) PPQ - 11% at 1.0, 22% at
10.0 and 22% at 30.0
NIH 10599 4-(3-Hydroxyphenyl)-4-n-propyl-l-methylpiperidine
hydrochloride
MOUSE DATA-ED OR AD50
1) TF - 0.5 (0.1 - 1.9)
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0
3) PPQ - 0.4 (0.2 - 0.9)
(95% C.L.) (mg/kg or %
change)
NIH 10600 4-(3-Hydroxyphenyl)-1-3dimethyl-4-(2-methyl-prop-1-
yl)piperidine (trans aryl-methyl) hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 2.3 (1.2 - 4.5)a
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0
3) PPQ - 0.2 (0.1 - 0.6)
aStraub tails
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NIH 10601 4-(3-Hydroxyphenyl)-1-3-dimethyl-4-(2-methyl-prop-1-
yl)piperidine (cis aryl-methyl) hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 17.6 (12.0 - 26.2)
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0
3) PPQ - 1.7 (0.5 - 5.8)
HIV 10602 4-(3-Hydmxyphenyl)-4-isobutyl-1-methylpiperidine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 0.8 (0.3 - 2.1)
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0a
3) PPQ- 0.3 (0.1 -0.7)
aStraub tails at 30.0 - 1 of 6
died shortly after experiment.
NIH 10603 1-Phenethyl-4-phenyl-4-propionylpiperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 6.4 (2.3 - 18.0)a
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0
3) PPQ - 6.3 (3.4 - 11.4)
4 )  H P -
aStraub tail
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NIH 10604 3,5-Dimethyl-3-(3-hydroxyphenyl-1-phenethylpiperidine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) TF vs. Morphine - Inactive
at 1.0, 10.0 and 30.0
3) PPQ - 4.7 (1.5 - 15.0)
aDecreased reaction time and
tremor and convulsions in 3
animals.
NIH 10608 (+)-5,9 -Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
See NIH 10595
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. Morphine -
Inactive at 1.0, 10.0 and
30.0a
3) PPQ - 18.6 (12.0 - 29.0)
a2 hr pretreatment - 14% at
30.0
MONKEY DATA
(SDS)
NIH 10608 neither substituted for morphine nor exacerbated withdrawal (see
fig.). The apparent attenuation of withdrawal at the low dose (2.0 mg/kg) was
due to a reduced incidence of the signs designated as lying on side, restlessness
and vocalization. Also, no vomiting was noted at the low dose.
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NIH 10612 (±)-5,9 -Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
See NIH 10595
MOUSE DATA-ED OR AD50
95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) TF vs. Morphine - 0.9
(0.3 - 2.6)b
3) PPQ - 1.8 (0.5 - 6.1)
aSevere ataxia and
vocalization, decrcase tail-
flick latencies at 10.0 and
30.0.
bataxia
MONKEY DATA
A.  (SDS)
As shown in the illustration, NIH 10612 did not substitute for morphine and may
have exacerbated withdrawal at doses of 0.3 and 0.75 mg/kg. At the highest
dose, the signs ataxia, slowing and jaw sag also were noted.
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TIME (MIN)
B. (PPt-W)
NIH 10612 precipitated withdrawal in a dose-related manner. Rapid onset and
long duration (at least 2 1/2 hr) characterized the drug. The duration of action of
naloxone was approximately 90 min. Because of the dissimilar offset of action
times for NIH 10612 and naloxone. the reference standard, the potency estimate
cannot be reliably estimated.
626
TIME (MIN)
NIH 10613 Caffeine and Sodium Benzoate (U.S.P. XIV)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - 106.9 (77.00 -
148.37)
2) TF vs. M. - Inactive at 1.0,
10.0, 30.0 and 60.0
3) PPQ - Inactive at 1.0. 10.0,
30.0 and 60.0a
aDose expressed as base
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NIH 10616 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4 H- i m i d a z o [ 1 , 5 a ] [ 1 , 4 ] -
benzodiazepine-3carboxylate ethyl ester (Ro 15-1788). (Flumazenil)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1) TF - Inactive at 0.01,
0.05, 0.1, 1.0, 10.0 and
30.0 a , b
2) TF vs. M. - Inactive at
1.0, 10.0 and 30.0b
3) PPQ - Inactive at 1.0,
10.0 and 30.0b
4 ) HP -
aVocalization, decreased
latencies in TF test in 4 of 6
mice at 1.0, VEHICLE: EtoH,
propylene glycol and H20 (1:
4: 5)
between 80 and H20
MONKEY DATA
(SDS)
NIH 10616, a benxodiazepine antagonist and inverse agonist-antagonist, neither
substituted for morphine nor exacerbated withdrawal at 2.5 and 7.5 mg/kg.
Vehicle consisted of ethanol, propylene glycol and water (1: 4: 5).
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TIME (MIN)
NIH 10617 (+)-Etorphine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg or %
change)
1 ) TF - Inactive at 0.01,
0.05, 1.0, 10.0 and
30.0a
2) TF vs. M. - 1% at 0.1,
19% at 0.3, 36% at 1.0,
0% at 3.0, 9% at 10.0
and 5% at 30.0
3) PPQ - Inactive at 1.0,
10.0 and 30.0
4) HP -
aDecreased test latencies in
tail-flick test
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MONKEY DATA
(SDS)
As shown in the accompanying fig., NIH 10617 neither substituted for morphine
nor exacerbated withdrawal at the doses tested. At the highest dose, frequent
vomiting was noted in 2 of 3 monkeys.
TlME (MIN)
630
ACKNOWLEDGEMENTS
This study was supported by a contract (#271-87-8116) from the National
Institute on Drug Abuse, Dr. Geralin Lin, Contract Officer. We also
acknowledge the expert assistance of Susan M. Tucker and Christopher C. Cull.
Special thanks to Dr. Billy R. Martin, Ramona Winckler and Laura Johnson for
their help in the preparation of this manuscript using the Macintosh Plus
computer.
REFERENCES
Aceto, M.D., Flora, R.E. and Harris, L.S. The effects of naloxone and
nalorphine during the development of morphine dependence in rhesus monkeys.
Pharmacol, 15:1-9 1977.
Aceto, M.D., Flora, R.E. and Harris, L.S. Caffeine elicited withdrawal signs in
morphine-dependent rhesus monkeys. Eur J Pharmacol, 50:203-207, 1978.
Atwell, L. and Jacobson, A.E. The search for less harmful analgesics. Lab
Animal 7:42-47, 1978.
Deneau, G.A. An analysis of factors influencing the development of physical
dependence to narcotic analgesics in the rhesus monkey with methods for
predicting physical dependence liability in man. Doctoral Dissertation, University
of Michigan, 1956.
Dewey, W.L., Harris, L.S., Howes. J.F. and Nuite, J.A. The effects of various
neurohumoral modulators on the activity of morphine and the narcotic antagonists
in the tail-flick and phenylquinone tests. J Pharmacol Exp Ther , 175: 435-552,
1970.
Dewey, W.L. and Harris, L.S. Antinociceptive activity of the narcotic
antagonists analogues and antagonistic activity of narcotic analgesics in rodents.
J Pharmacol Exp Ther, 179:652-659, 1971.
Jacobson, A.E. and May, E.L. Structures related to morphine, XXXI, 2’-
Substituted benzomorphans. J Med Chem, 8:563-566, 1965.
Perrine, T.D., Atwell, L., Tice, I.B., Jacobson, A.E. and May, E.L. Analgesic
activity as determined by the Nilsen method. J Pharm Sci, 61:86-88, 1972.
Seevers, M.H. Opiate addiction in the monkey. I. Methods of study. J
Pharmacol Exp Ther, 56:147-156, 1936.
Seevers. M.H. and Deneau. G.A. Physiological aspects of tolerance and
physical dependence. In: Root, W.S. and Hofman, F.G., eds. Physiological
Pharmacology, Vol. I. New York: Academic Press, 1963. pp. 565-570.
Tieger, D.G. Induction of physical dependence on morphine, codeine, and
meperidine in the rat by continuous infusion, J Pharmacol Exp Ther, 190:408-
415, 1974.
631
1989 Annual Report, Evaluation of
New Compounds for Opioid
Activity
James H. Woods, Fedor Medzihradsky, Charles B. Smith
Gail D. Winger and Charles P. France
The evaluation of new compounds by the programs at the University
of Michigan and the Medical College of Virginia is coordinated by
Dr. Arthur E. Jacobson, Laboratory of Medicinal Chemistry,
NIDDK, National Institutes of Health, Bethesda, MD. The drugs,
which come originally from pharmaceutical companies, universites,
government laboratories, and international organizations are
submitted to Dr. Jacobson, who performs the MOUSE ANALGESIA
tests. Values obtained in these tests for some representative
opioid drugs are given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information and
(4) a recommended starting dose. After the evaluation is
complete and the report submitted to Dr. Jacobson, the submitter
is requested to release the chemical structure to include with
the evaluation data in the ANNUAL REPORT. The submitter has up
to three years before release of the structure is required.
When the structure is released all of the data on the compound
are reported to the Committee.
DRUG DISCRIMINATION IN RHESUS MONKEYS
We currently use two groups of monkeys to test the discriminative
effects of submitted drugs. One of these groups is trained to
discriminate the administration of the kappa agonist
ethylketazocine (EKC). The other group is trained to
discriminate the mu agonist, codeine.
The procedures used with the EKC-trained monkeys have been
described by Bertalmio et al. (1982). The monkeys are 'removed
from their home cages each day and seated in primate restraining
chairs. These chairs are placed in isolation chambers equipped
with two response levers, several stimulus lights and a cup to
receive Noyes, banana-flavored pellets. These monkeys are
required to make 100 consecutive responses on the correct one of
the two levers and receive ten 300-mg food pellets. The right
lever is correct if they were given a subcutaneous injection of
0.0032 mg/kg EKC immediately prior to the start of the trial.
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The left lever is designated correct if they were given a sham
injection before the start of the trial. Each trial lasts 15-min
and consists of an initial 10-min black out period followed by a
period of as long as 5 min, during which a blue light is
illuminated in the chamber and the monkey can respond for food.
If the food pellets are earned before the 5 min period is
completed, the lights are extinguished for the remainder of this
time. Typically, a daily session consists of several 15 min
trials. During a training session, if EKC is given, it is given
on the penultimate trial of that session. Responding on the
drug-appropriate lever is reinforced during that trial and on
the subsequent, final trial of the day. These last two trials
may be preceded by from zero to four sham trials on a training
day. A training session of six sham trials is also scheduled
from time to time.
With this type of multiple, discrete-trial training, the animals
can be tested with a cumulative dosing procedure. On a test
session, the first trial is preceded by an injection of saline,
and prior to subsequent trials, increasing, cumulative doses of
the test drug are administered. One hundred consecutive
responses on either lever are reinforced throughout the test
session. The test drug is administered in increasing doses until
the monkey either responds on the drug-appropriate lever, the
response rate falls to less than half of the saline-control rate,
or six trials are given. In the latter situation, it is assumed
that the selected dose range is too low, and the test is
continued at higher doses on the next test session. Each test
session is preceded and followed by a training session. The
criterion for satisfactory performance must be met on each
training session that is followed by a test session. This
criterion is that at least 90% of the responses during each trial
of a training session must be on the injection-appropriate lever,
either sham or EKC.
The procedure for the codeine-trained monkeys is similar, but not
identical. These animals are also trained and tested in a
discrete, multiple-trial paradigm. The main difference between
the codeine procedure and the EKC procedure is that the codeine
monkeys are required to make 20 rather than 100 responses, and
they receive a single pellet for correct responses. They can
earn as many as 10 pellets during the five minute, food-
availability period of each trial, but each pellet is earned by
making 20 responses. Because in this procedure, monkeys can
switch from one lever to another following the delivery of food,
an additional criterion is added for satisfactory performance.
In addition to making 90% or more of their responses on the
correct lever, the monkeys must make fewer than 40 total
responses prior to earning the first food pellet of each trial.
Tests of the discriminative effects of submitted drugs in the
codeine-trained monkeys are also done using a cumulative dosing
procedure with dosing criteria identical to those used in the
EKC-trained monkeys.
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DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression (SDS) test determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipitate
the withdrawal syndrome in nonwithdrawn (NW) morphine-dependent
monkeys. Nondependent monkeys (Normals) are used to determine
whether the acute effects of the test drug are reversible by
nalorphine or naloxone. In a primary dependence (PDS) study,
non-dependent monkeys receive the test drug every six hours for
30 days to determine whether withdrawal signs will appear when
the animals are challenged with an antagonist or when drug
administration is discontinued.
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug to
maintain responding in monkeys trained to self-inject codeine.
Each of at least three monkeys is studied with saline as a
negative control and a number of doses of the test compound until
a maximum rate of responding was obtained or until, in the
absence of evidence of a reinforcing effect, observable changes
in behavior are produced by the compound.
The schedule of intravenous drug delivery is a fixed-ratio 30;
when a light above a lever is illuminated, the 30th response
produce a five-sec intravenous drug injection accompanied by
another light that is illuminated during drug delivery. After
each injection, a ten-min timeout condition is in effect, during
which responses have no scheduled consequence and neither light
is illuminated. Each of the two daily sessions consist of 13
injections or 130 min, whichever occurs first. Other details of
the procedure and initial findings with a variety of narcotics
are given in previous reports (e.g., Woods, 1977; 1980).
Doses of the drugs are typically described in terms of mg/kg/
injection (inj). Duplicate observations of codeine (0.32
mg/kg/inj) and of saline are obtained for each monkey. A saline
substitution is conducted before and after the series of
observations on a test drug; the control rates of codeine-
reinforced responding are obtained by a random sampling of two
sessions interpolated between the drug-substitution sessions.
These data are represented in the following graphs with
individual symbols for each of the monkeys; each symbol is the
mean of duplicate observations for a given dose in each monkey.
The closed circles indicate the averaged data for observations on
the subset of monkeys used to study each drug under each of the
experimental conditions. In all cases, the rates of responding
given are those calculated during only the fixed-ratio portion of
each session.
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DISPLACEMENT OF RADIOLABELED LIGAND BINDING
Details of the binding assay, based on the displacement of 3H-
etorphine in rat brain membranes have been described previously
(Medzihradsky et al., 1984). Briefly, aliquots of a membrane
preparation from rat cerebrum are incubated with 3H-etorphine in
the presence of 150 mM NaCl, and in the presence of different
concentrations of the drug under investigation. Specific, i.e.,
opioid-receptor-related interaction of 3H-etorphine is determined
as the difference in binding obtained in the absence and presence
of an appropriate excess of unlabeled etorphine. The potency of
the drugs in displacing the specific binding of 3H-etorphine is
determined from log-probit plots of the data. It should be noted
that since April 1982 the concentration of 3H-etorphine in the
binding assay was reduced from 3.0 nM to 0.5 nM, a concentration
approaching the KD of the radiolabeled opioid. This change was
implemented in order to let the determined EC50 approximate the
true Ki of a given drug. As a consequence of the different
concentration of the radiolabeled ligand, the EC50 determined
since April, 1982 are lower than those obtained previously. For
the purpose of reference, Table II contains EC50 values of
representative opiates determined in binding assays using 0.5 nM
and 3.0 nM 3H-etorphine.
To enhance the characterization of newly synthesized opiates, we
are now investigating their selectivity in binding to mu-,
delta-, and kappa-opioid receptors in membranes from monkey brain
cortex. Thus, we are now providing EC50 values of the tested
compounds in displacing the following radiolabeled opioid
ligands:
etorphine (nonselective, reflects opioid character),
sufentanil or Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (mu
selective),
[D-Pen2-D-Pen5]enkephalin (delta selective),
U-69,593 (kappa selective).
Using the receptor-specific assays, we have described the
selectivity of various established opiates in brain membranes of
different species (Clark et al., 1988). The selection of monkey
brain as the tissue for the selective binding assays strengthens
the correlation between this in vitro assessment and the
behavioral evaluation of the tested compounds. In the ANNUAL
REPORT, the results of the selective binding assays are listed
under "Binding in monkey brain cortex".
Within our goal to enhance the molecular characterization of
novel opiates (Medzihradsky, 1987) we have established a
functional assay for receptor-effector interaction, reflecting
receptor coupling to regulatory G protein. The method is based
on the stimulation of brain GTPase by opioid agonists, a process
blocked by antagonists (Clark and Medzihradsky, 1987). We are
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presently evaluating the quantitative responses of partial
agonist-antagonists in this assay. Considering the variable
efficacy of opioid receptor occupancy (Clark et al., 1989) the
new assay provides a functional parameter in the characterization
of novel opiates, distinguishing thereby between agonists and
antagonists.
INHIBITION OF TWITCH IN ELECTRICALLY-STIMULATED MOUSE VAS
DEFERENS PREPARATIONS.
The development of new, highly selective antagonists such as the
irreversible mu receptor antagonist beta-funaltrexamine (beta-
FNA) and the reversible delta receptor antagonist ICI-174864 have
made possible the evaluation of selectivity of opioid agonists
and antagonists by use of the mouse vas deferens preparation.
Male, albino ICR mice, weighing between 25 and 30 g, are used.
The mice are decapitated, the vasa deferentia removed, and 1.5 cm
segments are suspended in organ baths which contain 30 ml of a
modified Kreb's physiological buffer. The buffer contains the
following (mM): NaCl, 118; KCl, 4.75; CaC12. 2.54; MgS04, 1.19;
KH2P04, 1.19; glucose, 11; NaHC03, 25; pargyline HCl, 0.3,
tyrosine, 0.2; ascorbic acid, 0.1; and disodium edetate. 0.03.
The buffer is saturated with 95% 02 - 5% CO2 and kept at 37° C.
The segments are attached to strain gauge transducers and
suspended between two platinum electrodes. After a 30-min
equilibration period, the segments are stimulated once every 10
sec with pairs of pulses of 2 msec duration, 1 msec apart and at
supramaximal voltage.
The following antagonists are studied: naltrexone HCl, ICI-
174864 [N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH] and beta-FNA.
Naltrexone and ICI-174864 are added to the organ baths 15 minutes
before the determination of cumulative concentration-effect
relationships for the various agonists. Beta-FNA is added to the
organ baths after the initial equilibration period. Thirty min
later, the beta-FNA is removed from the organ baths by repeated
washings with fresh buffer. The tissues are washed three times
every 5 min for 30 min. Cumulative concentration-effect
relationships for the various agonists are then determined 10 min
after the last wash (i.e., 30 min after the beta-FNA was removed
from the organ baths). EC50's are calculated by probit analysis,
and pA2 values are determined to assess relative potencies of
antagonists. All drugs which are submitted for evaluation are
studied in the following manner: 1) the submitted drug is tested
on the vas deferens preparation in the absence and in the
presence of naltrexone. The concentration of the unknown drug is
varied from the lowest with activity to that which is maximally
effective. 2) If the submitted drug inhibits the twitch, the
ability of naltrexone to reverse the inhibition is determined.
3) The submitted drug is assessed for its ability to antagonize
the actions of morphine on the vas deferens. 4) The drug is
assessed for its ability to reverse the inhibition produced by a
maximally effective concentration of morphine. 5) Finally, if
the drug has opioid agonistic activity, studies-are conducted to
determine the receptor type upon which it acts. If it has
antagonistic activity upon the vas deferens or upon any of the
636
other preparations used in the Drug Evaluation Unit, the type of
antagonism (competitive, noncompetitive) and the receptor
selectivity is determined,
see Smith (1986).
For further details of the procedure
Drugs studied in the preparation prior to 1987
were evaluated with the protocol reported in the 1985 Annual
Report.
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TABLE I
MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated for
analgesic activity by Dr. Arthur E. Jacobson. Shown below are comparative data (ED 50mg/kg)
(95% Confidence Interval) from Hot Platea-c and Nilsend assays. umol/kg
HOT PLATE NILSEN
Compound (sc/mg/kg) (oral,mg/kg) (SC, mg/kg) (oral, mg/kg)
NIH # (SC, umol/kg) (oral, umol/kg) (SC. umol/kg),, (oral, umol/kg)
Morphine sulfate
NIH 0001, 9929
Codeine phosphate
NIH 0002
Levorphanol tartrate
NIH 4590
Meperidine.HCl
NIH 5221
(-)-Metazocine.HBr
NIH 7569
0.98 (0.83-1.1)
2.9 (2.5-3.3)
6.8 (4.5-10.2)
17.1 (11.3-25.7)
0.2 (0.1-0.3)
0.5 (0.2-0.7)
5.3 (4.0-7.1)
18.7 (14.1-25.0)
0.6 (0.5-0.9) 10.6 (8.0-14.1)
1.9 (1.4-2.8) 34.1 (25.7-45.3)
6.3 (4.7-8.3)
18.9 (14.1-24.9)
13.5 (9.7-18.7)
34.0 (24.4-47.1)
1.3 (1.0-1.7)
3.9 (3.0-5.1)
7.4 (4.9-11.0)
8.3 (6.0-11.4)
24.9 (18.0-34.1)
14.7 (9.2-23.3)
18.6 (12.3-27.7)
0.2 (0.16-0.3)
37.0 (23.2-58.7)
2.5 (1.7-3.7)
0.5 (0.4-0.7)
0.5 (0.3-0.7)
1.6 (1.0-2.3)
6.2 (4.2-9.1)
26.0 (21.0-33.0)
83.6 (67.5-106.1)
TABLE I Continued
Dihydromorphinone.HCl
NIH 0123
Nalorphine.HCl
NIH 2105
Cyclazocine
NIH 7981
Pentazocine
NIH 7958
Naltrexone.HCl
NIH 8503
Naloxone.HCl
NIH 7890
0.19 (0.15-0.25) 0.9 (0.7-1.2)
0.6 (0.5-0.8) 2.8 (2.2-3.7)
9.9 (5.7-17.1)
28.4 (16.4-49.1)
1.5 (1.1-2.1)
5.5 (4.1-7.7)
9.3 (6.7-12.8)
32.6 (23.5-44.9)
0.2 (0.15-0.3) 1.8 (1.5-2.1)
0.6 (0.5-0.9)
23.0 (16.2-32.7)
66.1 (46.6-94.0)
0.1 (0.07-0.16)
0.4 (0.3-0.6)
6.5 (4.4-8.8)
22.8 (15.4-30.9)
No dose response
No dose response
5.6 (4.7-6.5)
No antinociceptive activity in hot plate assay: Phenobarbital, amobarbital, diazepam, meprobamate,
mescaline, oxazepam, flurazepam.
Chloropromazine.HCl 1.1 (0.9-1.5)
3.2 (2.4-4.2)
a) Eddy and Leimbach (1953); b) Jacobson and May (1965); c) Atwell and Jacobson (1978); d) Perrine,
Atwell, Tice, Jacobson and May (1972).
TABLE II
EC50's of representative opioids for displacement of 3H-etorphine
from rat brain membrane, and inhibition of the twitch of the
mouse vas deferens preparation.
BINDING (+ 150 mM NaCl) MVD
Compound
DPDPE
U50,488
Fentanyl
DAGO
Etorphine
(-)Cyclazocine
Naltrexone
Bremazocine
-UM 1071R*
Sufentanil
(-)SKF 10047
Ethylketazocine
Ketazocine
Morphine
DSLET
Dextrorphan
EC50
3H-etorphine 3H-etorphine
(0.5 nM) (3.0 nM)
--- ---
--- ---
--- ---
--- ---
0.37 4.2
0.53 3.40
0.63 2.34
1.42 ---
1.55 4.71
1.60 ---
3.93 20.5
6.60 19.3
14.1 63.1
23.6 140
43.0 ---
9820 18000
EC50
(nM)
5.52
6.29
37.1
81.3
0.0068
11.9
---
---
---
4.43
---
11.6
1.18
395
1.71
1010
* lR-5R-9R-2"R-5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7-
benzomorphan hydrochloride
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year, and the individual tests which were per-
formed are shown in Table III. Also shown are dates of Annual
Reports in which results are reported of earlier tests on those
compounds conducted at Michigan.
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TABLE III
SUMMARY OF TESTS PERFORMED
CHEMICAL CLASS AND/OR
NIH GENERIC NAME SA MVD BIND DD REPORT*
7589A Benzomorphan
9994 Morphine
9995 Morphine
10168 Benzomorphan
10447 Piperidine-thiopyridine
10448 Piperidine-thiopyridine
10496 Phenylpiperazinylpyradazine
10497 Morphine
10501 Ethenoisomorphinan
10526 Phenylpiperidine
10544 Morphinone
10545 Morphinone
10567 Ibogaine
10571 Oxymorphazine
10572 Naltrexone, esterone
10573 Benzomorphan
10576 Phenylvaleramide
10579 Phenylvaleramide
10580 Tetrazolyl-piperidine
10589 Naltrindole
10590 Methylnaltrindole
10591 Oxymorphindole
10592 Phenylalanyl-alanine
10594 Morphinone
10595 Benzomorphan
10597 Phenylpiperidine
10598 Phenylpiperidine
10599 Phenylpiperidine
10600 Phenylpiperidine
10601 Phenylpiperidine
10602 Phenylpiperidine
10603 Phenylpiperidine
10605 Naloxone
10606 Naloxone
10607 Naloxone
10608 Benzomorphan
10612 Benzomorphan
10617 Etorphine
10620 Thevinone
10621 Thevinol
03/30/89
10/17/88
01/12/89
10/17/88
04/03/86
04/03/86
04/04/89
12/08/88
10/17/88
10/17/88
10/30/87
10/30/87
12/23/87
01/13/88
10/17/88
10/17/88
10/17/88
10/17/88
10/17/88
01/12/89
01/12/89
01/12/89
03/30/89
10/17/88
10/17/88
10/17/88
10/17/88
10/17/88
10/17/88
03/30/89
03/30/89
11/23/88
01/12/89
01/12/89
01/12/89
01/12/89
01/12/89
03/30/89
03/30/89
03/30/89
* Date report was submitted to CPDD Biological Coordinator.
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NIH 7589A (±)-2-n-Butyl-5,9 -dimethyl-2'-hydroxy-6,7-benzomor-
phan hydrobromide
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 of 101 nM in the presence
of 150 mM NaCl.
HO
MOUSE VAS DEFERENS PREPARATION
NIH 7589A studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
No concentration of this drug
significantly inhibited the contractions of the vas deferens and
it was evaluated as an antagonist. pA2 values against the
following agonists were:
Agonist pA2 values
Sufentanil 6.43 ± 0.23
DSLET 6.59 ± 0.63
U 5 0 , 4 8 8 6.96 ± 0.65
Slope
1.5
1.7
1.8
SUMMARY
NIH 7589A had similar affinities in the two preparations; the
significant deviations from unity for the Schild plots in the
vas deferens suggests that it might not exert its actions as a
simple, competitive antagonist.
NIH 9994 N-Methyl-N-cyclopropylmethylnormorphinium iodide
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 30% at 50
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 49.3 nM in the presence of 150 mM NaCl.
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NIH 9994 N-Methyl-N-cyclopropylnormorphinium iodide
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 3.32 x 10
-6 35.1%
After naltrexone 4.84 x 10-6 18.9%
With equimolar concentration
of naltrexone Complete reversal
SUMMARY
NIH 9994 was more potent in the binding assay than in the vas
deferens. It had opioid actions in both preparations. The
compound was studied in 1982 in the smooth muscle preparation
and only recently in the binding assay.
NIH 9995 N-Methylmorphinium iodide
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive to 100
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2740 nM in the presence of 150 mH NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 2.77 x 10-7 55.1%
After naltrexone 6.08 x 10-8 46.9%
With equimolar concentration
of naltrexone Slight reversal
Equimolar concentration
with morphine No reversal
SUMMARY
NIH 9995 had no significant opioid activity in either in vitro
preparation.
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NIH 10168 (-)-2-(cis-3-Chloroallyl)-5,9 -dimethyl-2'-hydroxy-
6,7-benzomorphan hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 20% at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2.72 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
ECSO. (Ml Maximum Response
Drug alone 2.60 x 10
-8 44.6%
After naltrexone 4.14 x 10
-8 60.3%
With equimolar concentration
of naltrexone No reversal
Equimolar concentration.
with morphine Partial reversal
SUMMARY
NIH 10168 had- opioid actions in both preparations; it would
appear to be more potent in the binding assay, and it might be a
partial agonist in the vas deferens.
NIH 10447 2-Chloro-6-(4-(N-n-propyl)piperidino)thiopyridine
hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive to 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 6000 nM (9.0% at 6000 nM) in presence of 150 mM NaCl.
644
NIH 10447 2-Chloro-6-(4-(N-n-propyl)piperidino)thiopyridine
hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
With increasing concentrations, NIH 10447 caused a gradual
inhibition of the twitch which was maximal at a concentration of
3 x 10-5 M. The maximum response was a 33.7% inhibition of the
twitch. Responses to NIH 10447 were not altered in the presence
of naltrexone (10-7 M). NIH 10447 was studied as an antagonist
at a concentration of 10
-7 M. It caused a parallel shift to the
right (a 6.4-fold shift) in the sufentanil concentration-effect
curve. In the absence of NIH 10447, the EC50 for sufentanil was
3.47 nM ± 1.42 and the maximum response was a 100% inhibition of
the twitch. In the presence of NIH 10447, the EC50 for sufen-
tanil was 22.3 nM ± 5.9 and the maximum response was a 100%
inhibition of the twitch.
SUMMARY
NIH 10447 appears to be an opioid antagonist on the mouse vas
deferens preparation, but it has no significant affinity for the
etorphine binding site.
NIH 10448 2-(Chloro-6-(4-N-isopropylpiperidino)thiopyridine
oxalate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive to 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 6,000 nM (18.6% at 6,000 nM) in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
With increasing concentrations, NIH 10448 caused a gradual
inhibition of the twitch which was maximal at a concentration of
3 x 10-5 M. The maximum response was a 42.9% inhibition of the
twitch. Responses to NIH 10448 were not altered in the presence
of naltrexone (10-7 M). NIH 10448 was studied as an antagonist
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NIH 10448 2-(Chloro-6-(4-N-isopropylpiperidino)thiopyridine
oxalate
. . . (continued)
at a concentration of 10-7 M. It caused a parallel shift to the
right (a 4.3-fold shift) in the sufentanil, concentration-effect
curve. In the absence of NIH 10448, the EC50 for sufentanil was
3.47 nM ± 1.42 and the maximum response was a 100% inhibition of
the twitch. In the presence of NIH 10448, the EC50 for sufen-
tanil was 15.0 nM ± 10.4 and the maximum response was a 100%
inhibition of the twitch.
SUMMARY
These are very unusual findings (i.e., the binding and vas
deferens information are usually concordant) and the binding
information was duplicated. The antagonist activity of NIH 10448
will have to be studied more extensively if the compound has
interesting activity in the in vivo preparations. (See also NIH
10447.)
NIH 10496 (E)-3-Chlofo-6-[4-(3-phenyl-2-propenyl)-1-piperazi-
nyl]pyridazine hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive at 20
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10496 were evaluated in five
monkeys trained to respond and receive 0.32 mg/kg/inj codeine
(Woods, 1980). Rates of responding maintained by doses of 0.01
and 0.03 mg/kg/inj NIH 10496 were nearly the same as rates
maintained by saline. Rates of responding increased as doses of
NIH 10496 increased above 0.03 mg/kg/inj, and reached a maximum
at 1.0 mg/kg/inj. Higher doses could not be tested due to the
limited water solubility of the drug. Rates of responding
maintained by 1.0 mg/kg/inj NIH 10496 were nearly the same as
rates of responding maintained by 0.32 mg/kg/injection codeine
(Figure 1).
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NIH 10496 (E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-1-piperazi-
nyl]pyridazine hydrochloride
. . . (continued)
MG/KG/INJECTION
Figure 1. The data from individual monkeys are indicated by each
animal's identification number and accompanying open symbol. The
closed, connected circles indicate the average of the data from
the monkeys in this experiment. Grand Average (closed squares)
refers to a historical mean of 20 monkeys under the 0.32
mg/kg/injection codeine condition and the saline condition. The
two topmost horizontal dashed lines indicate ± 3 SEM around the
codeine grand average. The bottom dashed horizontal line
indicates + 3 SEM of the saline grand average.
DRUG DISCRIMINATION IN RHESUS MONKEYS
NIH 10496 was studied in two rhesus monkeys discriminating
between subcutaneous injections of 1.78 mg/kg of codeine and
saline. In both monkeys studied, NIH 10496 substituted comple-
tely for the codeine discriminative stimulus (see Figure 2). For
one subject doses of NIH 10496 larger than 0.1 mg/kg substituted
for codeine and a second subject responded on the codeine lever
only after a dose of 1.0 mg/kg NIH 10496. Rates of responding
were decreased in a dose-related manner by increasing doses of
NIH 10496 with responding eliminated at a cumulative dose of 3.2
mg/kg.
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NIH 10496 (E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-1-piperazi-
nyl]pyridazine hydrochloride
. . . (continued)
Figure 2
SUMMARY
NIH 10496 has significant morphine-activity in both behavioral
assays.
NIH 10497 N-(1R-1-Cyclopropyl)ethylnormorphine hydrochloride
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 of 2.14 nM in presence of
150 mM NaCl.
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NIH 10497 N-(1R-1-Cyclopropyl)ethylnormorphine hydrochloride
... (continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 4.72 x 10
-8 73.9%
After naltrexone 4.41 x 10-7 79.6%
After ICI 174.864 5.39 x 10
-8 72.0%
After ß-FNA 4.20 x 10-8 76.5%
NIH 10497 neither altered responses to sufentanil nor reversed
sufentanil's inhibitory effects.
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10497 were evaluated in four
rhesus monkeys trained to respond and receive 0.32 mg/kg/inj
codeine (Woods, 1980). Rates maintained by NIH 10497 were
generally above rates maintained by saline, but below rates
maintained by codeine. The dose maintaining the highest rate of
responding differed among subjects. See Figure 1.
Figure 1. The data from individual monkeys are indicated in open
symbols. The average data from these monkeys are indicated by
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NIH 10497 N-(1R-1-Cyclopropyl)ethylnormorphine hydrochloride
. . . (continued)
the closed and connected circles. Grand average refers to a
historical control from 20 monkeys under codeine and saline
conditions, and is shown by closed squares. The two topmost
dashed horizontal lines indicate ± 3 SEM for the codeine grand
average. The bottommost dashed horizontal line indicates + 3 SEM
for the saline grand average.
DRUG DISCRIMINATION IN RHESUS MONKEYS
NIH 10497 was tested for discriminative stimulus effects in three
monkeys trained to discriminate EKC from sham injections. NIH
10497 did not produce consistent EKC-like discriminative stimulus
effects in any monkey, although one monkey responded completely
on the EKC-appropriate lever at a single dose and returned to the
sham-appropriate lever at the next higher dose. Response rates
were suppressed at a dose of 0.10 mg/kg (See Figure 2).
Figure 2
NIH 10497 was tested for discriminative stimulus effects in two
monkeys trained to discriminate codeine from sham injections.
One monkey generalized completely to codeine at a dose of 0.001
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NIH 10497 N-(1R-1-Cyclopropyl)ethylnormorphine hydrochloride
... (continued)
mg/kg NIH 10497 (Figure 3, closed circles). Response rates were
suppressed at a dose of 0.032 mg/kg. Following administration of
0.10 mg/kg quadazocine, this monkey did not respond on the
codeine-apppropriate lever until a dose of 0.32 mg/kg NIH 10497
(Figure 3, open circles). Response rates were normal at this
dose following administration of quadazocine, despite the fact
that they had been completely suppressed at this dose in the
absence of quadazocine. The second monkey generalized completely
to codeine at a dose of 0.01 mg/kg NIH 10497 (Figure 4).
Figure 3
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NIH 10497 N-(1R-1-Cyclopropyl)ethylnormorphine hydrochloride
. . . (continued)
Figure 4
SUMMARY
NIH 10497 was a potent opioid in each of the preparations; it had
a kappa agonist profile of activity in the mouse vas deferens.
Its behavioral activities indicated a modest reinforcing effect
and discriminative effects similar to codeine.
NIH 10501 4,5- -Epoxy- -N-trimethyl-6-,14-ethenoisomorphinan-
7 -methanol
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 of 291 nM in presence of
150 mM NaCl.
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NIH 10501 4,5- -Epoxy- -N-trimethyl-6-,14-ethenoisomorphinan-
7 -methanol
. . . (continued)
MOUSE VAS DEFERENS
Drug alone
After naltrexone
After ICI 174,864
After ß-FNA
NIH 10501 neither
PREPARATION
Inhibitory
EC50 (M) Maximum Response
4.81 x 10-7 100%
5.10 x 10-5 100%
5.92 x 10-6 100%
2.85 x 10-5 93.1%
altered responses to sufentanil nor reversed
sufentanil's inhibitory effects.
SUMMARY
NIH 10501 has delta-agonist actions in the vas deferens; its
potency in both preparations was less than that of morphine.
NIH 10526 ß-1,2-Dimethyl-4-(3-hydroxyphenyl)-4-propionyloxy-
piperidine hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive to 20
'DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2885 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 5.02 x 10-8 29.0%
NIH 10526 failed to block the actions of sufentanil. DSLET, or
U50,488 in the smooth muscle preparation.
SUMMARY
NIH 10526 had very low potency in the binding assay and very low
efficacy in the vas deferens preparation.
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NIH 10544 14ß-(p-Methylcinnamoylamino)-7,8-dihydromorphinone
mesylate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive to 10
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING.
EC50 of 0.642 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10544 studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-9 M to 3 x 10-4 M. No concentration of this drug
significantly inhibited the contractions of the vas deferens and
it was evaluated as an antagonist. pA2 values against the
following agonists were:
Agonist
Sufentanil
DSLET
U50,488
pA2 values Slooe
8.55 ± 0.06 1.2
7.77 ± 0.19 1.1
7.39 ± 0.04 1.2
SUMMARY
NIH 10544 was a potent displacer of tritiated etorphine; it
appears to be a relatively selective mu-receptor antagonist in
the mouse vas deferens.
NIH 10545 14ß-(p-Methylphenylpropionylamino)-7,8-dihydromor-
phinone mesylate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 33% at 10
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NIH 10545 14ß-(p-Methylphenylpropionylamino)-7,8-dihydromor-
phinone mesylate
. . . (continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.514 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174,864
After ß-FNA
EC50 (M) Maximum Response
6.59 x 10-9 73.6%
2.25 x 10-8 62.3%
1.13 x 10-8 75.0%
1.24 x 10-8 35.2%
NIH 10545 neither altered responses to sufentanil nor reversed
its inhibitory effects.
SUMMARY
NIH 10545 appears to be a more potent than and similar in
efficacy to morphine; in the mouse vas deferens it may exert
actions through mu and delta receptors.
NIH 10567 Ibogaine hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive to 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 6,000 nM (24% inhibition at 6,000 nM) in presence of
150 mM NaCl.
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NIH 10567 Ibogaine hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
With naltrexone
Inhibitory
EC50 (M) Maximum Response
2.28 x 10-5. 100%
2.25 x 10-5 100%
At a concentration of 10-6 M, NIH 10567 did not antagonize the
actions of sufentanil, DSLET, or U50,488.
SUMMARY
NIH 10567 failed to demonstrate significant opioid activity in
either in vitro preparation.
NIH 10571 Oxymorphazine dihydrochloride
MOUSE ANLGESIA, ED50, (mg/kg)
Hot Plate: 3.1 (2.2 - 4.3)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 45.1 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174,864
After beta-FNA
EC50 (M) Maximum Response
5.77 x 10-7 99.2%
4.82 x 10-6 100%
4.12 x 10-7 100%
1.52 x 10-6 70.7%
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NIH 10571 Oxymorphazine dihydrochloride
. . . (continued)
SUMMARY
NIH 10571 had significant opioid activity in both preparations
and the data were concordant with regard to potency estimates.
NIH 10572 Mixed azine of naltrexone and estrone
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 of 1.65 nM in presence of
150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10572 was insolubie in 30% ethanol at a concentration of 3 x
10-4 M. It could not, therefore, be studied upon this prepara-
tion.
NIH 10573 (±)-5,9 -Dimethyl-2'-hydroxy-2-n-pentyl-6,7-benzo-
morphan hydrochloride
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 of 173 nM in presence of
150 mM NaCl.
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NIH 10573 (±)-5,9 -Dimethyl-2'-hydroxy-2-n-pentyl-6,7-benzo-
morphan hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.08 x 10-6 99.5%
After naltrexone 1.02 x 10-5 93.0%
After ICI 174864 1.66 x 10-6 98.7%
After ß-FNA 4.18 x 10-6 94.0%
SUMMARY
NIH 10573 has mu-agonist actions in the vas deferens, and it
displaces etorphine.
NIH 10576 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide
hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 7.5 (5.4 - 10.3)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 436 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10576 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation, in concentrations which ran ed
from 10-9 M to 3 x 10-4 M. In concentrations of 10-8 M to 10-6 M
this drug caused a very slight inhibition of the twitch (10 to
20%) which was blocked by naltrexone, 10-7 M, but not by ICI-
174864, 10-7 M. NIH 10576 acted as an opioid antagonist. At
concentrations from 10-8 M to 10-7 M this drug caused shifts to
the right in the concentration-effect curves for sufentanil and
at concentrations of 10-6 M and 10-5 M caused a marked decrease
in the maximum response obtainable. The pA2 value for this drug
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NIH 10576 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide
hydrochloride
... (continued)
with sufentanil was 7.34 ± 1.13. The slope of the Schild plots
suggests that the interaction might
Concentrations of 10-5 M and 10-6 M NIH 10576 did not shift the
not be simply competitive.
DSLET concentration-effect curve. A higher concentration could
not be tested against DSLET because the supply of 10576 has been
depleted. The same concentrations of NIH 15076 also had no
effect upon responses to U50,488 although a 10-5 M concentration
caused a very slight shift to the right.
SUMMARY
NIH 10576 had opioid actions in both preparations. It was not
very potent in the binding assay. It had interesting actions in
the vas deferens, which suggests that it is a selective antago-
nist - if not specific - for mu-receptors.
NIH 10579 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyaceta-
mido]piperidine hydrochloride
DISPLACEMENT OF SPECIFIC 3H-
ETORPHINE BINDING
EC50 49.2 nM in presence of 150
mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.46 x 10-8 99.6%
After naltrexone 7.25 x 10-7 100%
After ICI 174864 3.61 x 10-8 100%
After ß-FNA 4.98 x 10-8 77.5%
SUMMARY
NIH 10579 had significant opioid activity in both preparations.
It was a mu-selective agonist in the vas deferens.
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NIH 10580 1-[2-(4-Ethyl-4,5-dihydro-1H-tetrazolfn-5-one-1-
yl)ethyl]3-methyl-4-[N-(2-fluorophenyl)methoxyacetamido]pi-
peridine hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 957 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174864
After ß-FNA
Inhibitory
EC50 (M) Maximum Response
4.54 x 10-7 87.0%
9.47 x 10-6 30.2%
4.86 x 10-7 83.8%
2.02 x 10-6 41.3%
SUMMARY
NIH 10580 had opioid actions in both preparations. In the vas
deferens, it had mu-agonist actions.
NIH 10589 Naltrindole hydrochloride
BINDING IN MONKEY BRAIN CORTEX
EC50's were determined for the following receptor types: mu-
9.53 nM, delta - 0.214 nM and kappa - 20.5 nM. These findings
were obtained by displacing specific equilibrium binding of: 0.5
nM 3H-sufentanil (mu-selective); 1.5 nM 3H-DPDPE (delta-selec-
tive); and 1.5 nM 3H-U69,593 (kappa-selective) in membranes from
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NIH 10589 Naltrindole hydrochloride
. . . (continued)
monkey brain cortex suspended in 50 mM Tris.HCl buffer (pH 7.5)
containing 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10589 studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-6 M.
in concentrations which ranged
No concentration of this drug
significantly inhibited the contractions of the vas deferens and
it was evaluated as an antagonist. pA2 values against the
following agonists were:
Agonist pA2 values Slope
Sufentanil 7.71 ± 0.33 1.2
DSLET 9.44 ± 0.61 1.2
At a concentration of 10-7 M, NIH 10589 both slightly shifted the
U-50,488 concentration-effect curve to the right and decreased
the maximum responses to U50,488. Lower concentrations had no
effect upon responses to U50,488.
SUMMARY
NIH 10589 in both preparations was a highly selective delta
receptor ligand with selective antagonist activity in the vas
deferens.
NIH 10590 Methyl naltrindole hydrochloride
BINDING IN MONKEY BRAIN CORTEX
EC50's were determined for the following receptor types: mu-
6.42 nM, delta - 0.204 nM and kappa - 9.01 nM. These findings
were obtained by displacing specific equilibrium binding of: 0.5
nM 3H-sufentanil mu-selective); 1.5 nM 3H-DPDPE (delta-selec-
tive); and 1.5 nM 3H-U69,593 (kappa-selective) in membranes from
monkey brain cortex suspended in 50 mM Tris.HCl buffer (pH 7.5)
containing 150 mM NaCl.
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NIH 10590 Methyl naltrindole hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
NIH 10590 studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-4 M.
in concentrations which ranged
No concentration of this drug
significantly inhibited the contractions of the vas deferens and
it was evaluated as an antagonist. pA2 values against the
following agonists were:
Agonist
Sufentanil
DSLET
U50,488
SUMMARY
pA2 values Slope
7.55 ± 0.51 1.5
8.88 ± 0.89 1.6
7.02 ± 0.52 1.2
NIH 10590 is an opioid antagonist that is relatively selective
for delta receptors. It is 21-fold more potent at delta than at
mu receptors in mouse vas deferens. It is nearly 30-fold more
potent than naltrexone at delta receptors and 1/16th as potent as
naltrexone at mu receptors. It was also quite selective in the
binding assay; having higher affinity for delta binding sites in
brain.
NIH 10591 N-Methyl-N-nornaltrindole hydrochloride (Oxymorphin-
dole)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
BINDING IN MONKEY BRAIN CORTEX
EC50's were determined for the following receptor types: mu-
1080 nM, delta - 3.37 nM and kappa - 688 nM. These findings
were obtained by displacing specific equilibrium binding of: 0.5
nM 3H-sufentanil (mu-selective); 1.5 nM 3H-DPDPE (delta-selec-
tive); and 1.5 nM 3H-U69,593 (kappa-selective) in membranes from
monkey brain cortex suspended in 50 mM Tris.HCl buffer (pH 7.5)
containing 150 mM NaCl.
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NIH 10591 N-Methyl-N-nornaltrindole hydrochloride (Oxymorphin-
dole)
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174864
Inhibitory
EC50 (M) Maximum Response
4.58 x 10-8 61.2%
5.44 x 10-7 65.8%
1.17 x 10-7 58.9%
SUMMARY
NIH 10591 exerted selective actions in both preparations. It had
higher affinity for the delta binding site than others. It had
opioid partial agonist actions in the vas deferens that were
mediated through the delta receptor and, perhaps, through the mu-
receptor as well.
NIH 10592 (S)-N-[1-Carboxy-2-phenyl)ethyl]-(S)-phenylalanyl- ß-
alanine
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of > 6,000 nM (1%
inhibition at 6,000 nM) in
the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 8.08 x 10-9 30.3%
After ICI 174864 1.82 x 10-9 42.7%
At a concentration of 10-6 M, NIH 10592 did not antagonize
sufentanil, DSLET, or U-50,488. Naltrexone and ß-FNA completely
blocked all responses to NIH 10592.
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NIH 10592 (S)-N-[1-Carboxy-2-phenyl)ethyl]-(S)-phenylalanyl-ß-
alanine
. . . (continued)
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10592 were evaluated in four
monkeys experienced in responding and receiving intravenous
infusions of 0.32 mg/kg codeine (Woods, 1980). The most notable
factor evident in the pattern of self-administration of NIH 10592
was the marked variability both within and among monkeys. For
Monkey 4Z, rates of responding were not maintained above those
maintained by saline at any dose. For Monkey 8597, rates of
responding maintained by NIH 10592 were above those maintained by
saline, and below those maintained by codeine at all doses except
the largest, but a typical inverted-U shaped dose-effect curve
was not demonstrated by this monkey. Monkey 478C showed rates of
responding close to those maintained by codeine at one dose only,
a pattern that is more typical of drugs that are self-adminis-
tered; this average rate (1.13 responses per second) is the
average of one high rate (1.92 responses per second) and one
fairly low rate (0.34 responses per second). A fourth monkey
tested at this dose showed a similar pattern. This marked
variability in response rates is very unusual. It may or may not
be important to note that the highest rate of responding was
always on the first presentation of a particular dose. The lower
rate was on the second presentation, usually two days later. See
Figure 1.
M G / K G / I N J
Figure 1. The data from individual monkeys are indicated by each
animal's identification number and the accompanying open symbols
(an average of two observations at each point). The closed
circles are averages of these individual data. The closed
squares at the COD and SAL points are historical averages of data
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NIH 10592 (S)-N-[1-Carboxy-2-phenyl)ethyl]-(S)-phenylalanyl- ß -
alanine
. . . (continued)
obtained in a group of 20 monkeys after conditions of 0.32
mg/kg/inj codeine and of saline self-administration. The topmost
dashed lines are - 3 standard errors of the mean of the codeine
grand average; the bottommost dashed line is + 3 standard errors
of the mean of the saline grand average.
DRUG DISCRIMINATION IN RHESUS MONKEYS
NIH 10592 was studied in two rhesus monkeys discriminating
between S.C. injections of 1.78 mg/kg of codeine and saline. Up
to the largest dose, because of solubility limits, that could be
studied (17.8 mg/kg), NIH 10592 had no effect on response rates
and occasioned responding only on the saline lever.
SUMMARY
NIH 10592 was inactive in the binding and drug discrimination
assays under the conditions studied. It was active in the mouse
vas deferens as a mu-agonist with low apparent efficacy. It
produced some evidence of reinforcing effect; the data were
unusually variable. This is an unusual set of findings and
should be examined in more detail when more is known about the
compound in the other assays.
NIH 10594 14ß-(p-Chlorocinnamoylamino)-7,8-dihydromorphinone
mesylate
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 0.301 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10594 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 10-4 M.
in concentrations which ranged
No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens and it was
evaluated as an antagonist. pA2 values against the following
agonists were:
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HIH 10594 14ß-(p-Chlorocinnamoylamino)-7,8-dihydromorphinone
mesylate
. . . (continued)
Agonist
Sufentanil
DSLET
u50,488
pA2 values Slope
9.83 ± 0.37 1.0
8.78 ± 0.71 1.4
8.24 ± 0.57 1.6
SUMMARY
NIH 10594 was quite potent in both preparations. Its antagonist
action in the vas deferens suggests selectivity at the mu
receptor. This will be followed up in the binding assays in
monkey brain with selective ligands.
NIH 10595 (-)-5,9 -dimethyl-2'-hydroxy-2-(2-methylpropenyl)-
6,7-benzomorphan hydrochloride
DISPLACEMENT OF SPECIFIC
ETORPHINE BINDING
EC50 of 77.6 nM in presence
150 mM NaCl.
3H-
of
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 2.73 x 10
-7 51.4%
After naltrexone 7.71 x 10-7 57.5%
After ICI-174864 6.14 x 10
-7 36.6%
NIH 10595 acted also as an opioid antagonist. pA2 values against
the following agonists were as follows:
Agonist pA2 values Slopes
Sufentanil 6.77 ± 0.39 1.1
DSLET 6.28 ± 0.28 0.8
U50,488 7.06 ± 0.40 1.1
666
NIH 10595 (-)-5,9 -dimethyl-2'-hydroxy-2-(2-methylpropenyl)-
6,7-benzomorphan hydrochloride
. . . (continued)
SUMMARY
NIH 10595 is an opioid mixed agonist-antagonist less potent than
naltrexone at mu, delta, and kappa receptors. The agonist
activity of this drug appears to be upon delta receptors.
NIH 10597. 4-(3-Hydroxyphenyl)-1,3-dimethyl-4-n-propylpiperi-
dine hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 1026 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10597 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 10-4 M.
in concentrations which ranged
No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens and it was
evaluated as an antagonist. pA2 values against the following
agonists were:
Agonist pA2 values
Sufentanil 6.14 ± 0.42
DSLET 6.47 ± 0.49
U50,488 < 5.52
Slope
1.0
1.1
SUMMARY
NIH 10597 had low potency in each preparation; the pattern of
antagonist activity in the vas deferens suggests that it is
slightly selective for the mu and delta opioid receptors.
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NIH 10598 4-(3-Hydroxyphenyl)-1,3,4-trimethylpiperidine hydro-
chloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 403 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10598 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 10-4 M.
in concentrations which ranged
No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens and it was
evaluated as an antagonist. pA2 values against the following
agonists were:
Agonist
Sufentanil
DSLET
U50,488
SUMMARY
pA2 values Slope
6.91 ± 0.46 1.1
5.92 ± 0.29 0.7
6.43 ± 0.36 1.1
NIH 10598 had a low potency in the binding assay as well as the
vas deferens. Its antagonistic characteristics in the vas
deferens suggest a slightly higher affinity for mu and kappa
receptors than delta. This suggestion will be assessed with
binding assays in monkey brain with selective ligands.
NIH 10599 4-(3-Hydroxyphenyl)-4-n-propyl-1-methylpiperidine
hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 146 nM in presence
of NaCl.
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NIH 10599 4-(3-Hydroxyphenyl)-4-n-propyl-l-methylpiperidine
hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI-174864
After ß-FNA
Inhibitory
EC50 (M) Maximum Response
5.58 x 10-7 90.9%
1.95 x 10-6 35.8%
5.53 x 10-7 92.4%
1.12 x 10-6 33.9
SUMMARY
NIH 10599 had mu-agonist actions in the vas deferens; its potency
in the binding assay agreed with that in the vas deferens.
NIH 10600 4-(3-Hydroxyphenyl)-1,3-dimethyl-4-(2-methyl-prop-1-
yl)piperidine hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 46.3 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.31 x 10-7 31.9%
Both naltrexone and ICI 174,864 completely blocked the inhibitory
actions of NIH 10600. NIH 10600 did not antagonize responses to
sufentanil, DSLET or U-50,488.
SUMMARY
This is a curious compound due to the disparity of results
between the two preparations. It has opioid activity at lower
concentrations than morphine in the binding assay, but lacks high
efficacy or antagonist activity in the vas deferens.
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NIH 10601 4-(3-Hydroxyphenyl)-1,3-dimethyl-4-(2-methyl-prop-1-
yl)piperidine hydrochloride.
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 1743 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10601 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10
-4 M.
in concentrations which ranged
No concentration of this drug
significantly inhibited the contractions of the vas deferens and
it was evaluated as en antagonist. pA2 values against the
following agonists were:
Agonist pA2 values
Sufentanil 5.63 ± 0.52
DSLET 6.23 ± 0.39
U50,488 5.66 ± 0.44
Slope
1.5
1 . 2
1.3
SUMMARY
NIH 10601 had low opioid potency in both preparations. Its
antagonist profile suggests activity at each of the opioid
receptors in the vas deferens.
NIH 10602 4-(3-Hydroxyphenyl)4-isobutyl-1-methylpiperidine
hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 76.1 nM in the
presence of NaCl.
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NIH 10602 4-(3-Hydroxyphenyl)4-isobutyl-1-methylpiperidine
hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI-174864
After ß-FNA
Inhibitory
EC50 (M) Maximum Response
2.59 x 10-7 96.0%
4.75 x 10-6 53.4%
2.12 x 10-7 93.7%
1.71 x 10-7 97.0%
SUMMARY
NIH 10602 had concordant potencies in the two preparations and
was a mu agonist in the vas deferens preparation.
NIH 10603 N-Phenylethyl-4-phenyl-4-propionylpiperidine hydro-
chloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 1399 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10603 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-4 M.
in concentrations which ranged
This drug did not inhibit the twitch
at any. concentration and was evaluated as an antagonist. pA2
values against the following agonists were:
Agonist pA2 values
Sufentanil 7.09 ± 0.58
DSLET 6.39 ± 0.34
U50,488 5.94 ± 0.31
Slope
1.6
1.0
0.9
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NIH 10603 N-Phenylethyl-4-phenyl-4-propionylpiperidine hydro-
chloride
. . . (continued)
SUMMARY
NIH 10603 is an opioid antagonist that is less potent than
naltrexone at mu, delta, and kappa receptors in the vas deferens.
The binding date are consistent with its low potency in the vas
deferens.
NIH 10605 Naloxone 3,14-diacetate
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 11.8 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10605 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-9 M to 3 x 10-5 M. This drug did not inhibit the twitch
at any concentration and was evaluated as an antagonist. pA2
values against the following agonists were:
Agonist pA2 values Slopes
Sufentanil 8.03 ± 0.16 1.23
DSLET 7.65 ± 1.16 1.41
U50,488 7.39 ± 1.01 1.21
SUMMARY
NIH 10605 is an opioid antagonist which is less potent than
naltrexone at mu, delta, and kappa receptors. Note that the
slopes of the Schild plots are considerably greater than unity.
It is also less potent than naltrexone in the binding assay.
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NIH 10606 Naloxone 3,14-dipropionate maleate
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 59.2 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10606 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5
in concentrations which ranged
M. This drug did not inhibit the twitch
at any concentration and was evaluated as an antagonist. pA2
values against the following agonists were:
Agonist pA2 values Slopes
Sufentanil 8.43 ± 0.28 0.8
DSLET 7.25 ± 0.46 1.3
NIH 10606 was a non-competitive antagonist of U-50,488. Thus, a
pA2 value could not be determined.
SUMMARY
NIH 10606 was a selective mu-receptor antagonist in the vas
deferens; slightly less potent than naltrexone. It was also less
potent in the binding assay.
NIH 10607 Naloxone ethoxycarbonylhydrazone
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 7.20 nM in the
presence of NaCl.
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NIH 10607 Naloxone ethoxycarbonylhydrazone
. . . (continued)
MOUSE VAS DEEERENS PREPARATION
'Drug alone
After naltrexone
After ICI 174864
Inhibitory
EC50 (M) Maximum Response
1.02 x 10-6 32.7%
3.47 x 10-6 26.6%
6.14 x 10-7 36.6%
NIH 10607 also acted as an opioid antagonist. pA2 values against
the following against were as follows:
Agonist
Sufentenil
DSLET
U50,488
SUMMARY
pA2 values Slopes
7.93 ± 0.30 0.9
7.38 ± 0.30 0.9
7.33 ± 0.43 1.1
NIH 10607 is a partial opioid agonist which has significant
antagonistic activity. As an antagonist, it is less potent than
naltrexone at mu, delta, and kappa receptors. It is less potent
than naltrexone in the binding assay, as well.
NIH 10608 (+)-5,9 -Dimethyl-2'-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of > 6,000 nM (23.4%
inhibition at 6,000 nM) in
the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10608 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
No concentration of this drug
inhibited the twitch of the vas deferens. In a concentration of
10-6 M, this drug failed to antagonize the inhibitory actions of
sufentanil, DSLET, or U50,488.
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NIH 10608 (+)-5,9 -Dimethyl-2'-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
. . . (continued)
SUMMARY
NIH 10608 failed to display significant opioid activity in either
in vitro preparation.
NIH 10612 (+)-5,9 -Dimethyl-2'-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of 143 nM in the
presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10612 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
This drug did not inhibit the twitch
at any concentration and was evaluated as an antagonist. pA2
values against the following agonists were:
Agonist
Sufentanil
DSLET
U50,488
pA2 values
6.82 ± 0.39
5.97 ± 0.31
6.76 ± 0.36
Slope
1.1
0.9
1.1
SUMMARY
NIH 10612 is an opioid antagonist that is less potent than
naltrexone at the mu, delta, and kappa receptors. It was also
much less potent than naltrexone in the binding assay.
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NIH 10617 (+)-Etorphine hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of > 6,000 nM (10%
inhibition at 6,000 nM) in
the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10617 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
This drug did not inhibit the twitch
at any concentration. At a concentration of 10-5 M, this drug
did not shift the concentration effect curves for sufentanil,
DSLET, and U50,488.
SUMMARY
NIH 10617 had no significant opioid activity in these prepara-
tions.
NIH 10620 (+)-Thevinone hydrochloride
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of > 6,000 nM (1%
inhibition at 6,000 nM) in
the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10620 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
This drug did not inhibit the twitch
at any concentration. NIH 10620, up to 10
-5 M, did not shift
appreciably the concentration-effect curves for sufentanil,
DSLET, or U50,488.
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NIH 10620 (+)-Thevinone hydrochloride
. . . (continued)
SUMMARY
NIH 10620 had significant opioid antagonist activity in the mouse
vas deferens without having such affinity for the central
receptor.
NIH 10621 (+)-19-Propylthevinol oxidate
DISPLACEMENT OF SPECIFIC
3H-ETORPHINE BINDING
EC50 of >6,000 nM (2.7%
inhibition at 6,000 nM) in
the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10621 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation
from 10-9 M to 3 x 10-5 M.
in concentrations which ranged
This drug did not inhibit the twitch
at any concentration. NIH 10621, up to 10-5 M, did not shift
appreciably the concentration-effect curves for sufentanil,
DSLET, or U50,488.
SUMMARY
NIH 10621 failed to display significant opioid activity in these
in vitro preparations.
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The EC50 should be 1.7nM.
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mouse analgesia, 646
self-administration in monkeys, 646-647
Chloropromazine hydrochloride
mouse analgesia, 580, 639
2-Chloro-6-(4-N-n-propylpiperidino)thiopyridine hydrochloride (NIH 10447,
MCV 4517)
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 590-591
displacement of specific 3H-etorphine binding, 644
inhibition of electrically stimulated mouse vas deferens preparations, 645
mouse analgesia, 590, 644
(+)-Chloropseudoephedrine
impurity in clandestinely synthesized methamphetamine, 46
Chronic pain
arthritic inflammation in rats as a model of, 110-115
clinical effectiveness of analgesics, 102-109
pain modulation and opiates, 92-101
Clonidine
antianalgesic effect through spinal dynorphin A (1-17), 306-307
C1orazepate
abuse liability in methadone-maintenance patients, 364-365
use by alcoholics in outpatient treatment, 376-377
684
Cocaine
amantadine and desipramine for treatment of dependence, 483-484
amplitude-modulated frequency response during intoxication in rabbits, 331
attenuation of opiate withdrawal in human and rat, 361-362
binding sites related to drug self-administration, 239-246
buprenorphine treatment of abuse, 461
carbamazepine treatment in dual opiate-cocaine addiction, 316-317
characteristics of non-referred abusing mothers, 330
cognitive skills in dependent patients during detoxification, 353-354
combination with marijuana, effect on task-elicited responses, 359-360
contaminants in illict preparations, 47-49
dependence, evaluation of treatment programs, 78-84
dependence, desipramine treatment for relapse prevention, 57-63
dependence, treatment with carbamazepine, 72
desipramine treatment of abuse in methadone-maintenance patients, 322-323
differential anxiety symptoms in cocaine vs. alcoholic patients, 471-472
effect of BAY K 8644 and nimodipine on stimulant properties, 500-501
effect of fluoxetine on self-administration, 242
effect of magnesium on self-administration in rats, 339-340
effect on catecholamine levels and cardiovascular parameters, 335-336
effect on energy metabolism in testis of rats, 509-510
effect on luteinizing hormone and prolactin in monkeys, 337-338
effects on neurotensin, dynorphin and substance P in rat brain, 348
[3H]GBR 12935 binding in rat brain areas, 341-342
human psychopharmacology of intranasal use, 357-358
increases benzodiazepine receptors labeled with [3H]Ro 15-1788, 512-513
induction and loss of acute tolerance to cardiac effects in humans, 355-356
infusions in humans: cardiovascular vs. subjective effects, 351
inpatient vs. outpatient abuse treatment, 312-313
in utero exposure and the risk of SIDS, 352
neurobehavioral teratogenicity of gestational exposure, 232-238
neurotoxic effects of self-administration on dopamine receptors, 504-505
NIDA’s medication development program, 71-72
one-trial conditioned rotation in rats, 540-541
outcomes of dependence treatment, 314-315
prevalence and self-reported consequences of use, 329
procedure for evaluation of pharmacotherapy for dependence, 324-325
self-administration in monkeys suppressed by buprenorphine, 333-334
social impact of crack dealing in the inner city, 326-327
urine screening, 214
urine screening during treatment of dependence, 320-321
urine screening for diagnosis and treatment of abuse, 318-319
use with heroin by methadone-maintenance patients, 328
WIN 35,065-2 binding, 243-244
Cocaine Expectancy Questionnaire (CEQ)
its construction and predictive utility, 456
Codeine
acute effects on human aggressive and non-aggressive behavior, 479-480
urine screening, 214
Codeine phosphate (NIH 0002)
mouse analgesia, 580, 638
Corticosterone
effect of phencyclidine centrally mediated in the rat, 526-527
Cortisol
blood levels in alcoholic women, 481-482
685
Cotinine
serum levels during smoking and nicotine polacrilex treatment, 366-367
CP 55,243
effect on CAMP in mouse brain, 282-283
CP 55,244
effect on CAMP in mouse brain, 282-283
synthesis of potential affinity ligands, 532-533
CP 55,940
effect on CAMP in mouse brain, 282-283
identification of metabolites formed by mouse liver, 287-288
CP 56,667
effect on CAMP in mouse brain, 282-283
(±)-CPP
effect on firing rate of dopamine neuron, 255-263
effect on regional glucose metabolism in rat brain, 264-269
Crack
See Cocaine
CTOP
binding affinity at µ, , and K sites in guinea pig brain, 161
CTP (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2)
role in antinociception and gastrointestinal function, 167-173
Cyclazocine (NIH 7981)
mouse analgesia, 580, 639
(-)-Cyclazocine
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
N-[(1R)-1-Cyclopropyl]ethylnormorphine hydrochloride (NIH 10497, MCV 4558)
biological evaluation of physical-dependence potential and abuse liability, 564
dependence evaluation in rhesus monkeys, 598
displacement of specific 3H-etorphine binding, 648
drug discrimination in rhesus monkeys, 650-652
inhibition of electrically stimulated mouse vas deferens preparations, 649
mouse analgesia, 597
self-administration in rhesus monkeys, 649-650
DAMGO ([D-Ala2,N-methyl-Phe4,Gly5-ol]enkephalin)
dependence after intrathecal infusion in the rat, 544-545
displacement of specific 3H-etorphine binding in tat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
role in analgesia and gastrointestinal function, 167-173
Delta receptors
selective agonist and antagonists, 300-301
selectivity of halogenated DPDPE derivatives, 291-292
2-Deoxyglucose
See Glucose metabolism
Desipramine
treatment for relapse prevention in cocaine dependence, 57-63
treatment of cocaine abuse in methadone-maintenance patients, 322-323
treatment of cocaine dependence, 483-484
Dextromethorphan
binding-site localization differs from NMDA sites, 548-549
Dextrorphan
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
686
2,6-Diamino-3-p-fluorobenzylpyridine (NIH 10446)
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 589-590
mouse analgesia, 589
Diazepam
abuse liability in methadone-maintenance patients, 364-365
mouse analgesia, 580, 639
use by alcoholics in outpatient treatment, 376-377
See also Benzodiazepine
(+)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl-1]
benzeneacetamide d-tartrate [NIH 10532, MCV 4581, (+)-U 50,488 d-tartrate)]
biological evaluation of physical-dependence potential and abuse liability, 571
mouse analgesia, 598-599
(-)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl-1]
benzeneacetamide l-tartrate [NIH 10533, MCV 4582, (-)-U 50,488 l-tartrate]
biological evaluation of physical-dependence potential and abuse liability,
568, 571
mouse analgesia, 599
role in antinociception and gastrointestinal function, 167-173
Dihydromorphinone hydrochloride (NIH 0123)
mouse analgesia, 580, 639
5,7-Dihydroxytryptamine
comparison of the behavioral and neurochemical effects, 347
(-)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-benzomorphan
hydrochloride (NIH 10595)
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 620-621
displacement of specific 3H-etorphine binding, 676
inhibition of electrically stimulated mouse vas deferens preparations, 676
mouse analgesia, 619
(+)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-benzomorphan
hydrochloride (NIH 10608)
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 624-625
displacement of specific 3H-etorphine binding, 684
inhibition of electrically stimulated mouse vas deferens preparations, 684
mouse analgesia, 624
(±)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-benzomorphan
hydrochloride (NIH 10612)
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 625-627
displacement of specific 3H-etorphine binding, 685
inhibition of electrically stimulated mouse vas deferens preparations, 685
mouse analgesia, 625
(±)-5,9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzomorphan hydrochloride (NIH
10573, NIH 7785)
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 610-612
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 668
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mouse analgesia, 610
(-)-5,9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzomorphan hydrochloride (NIH
10569)
biological evaluation of physical-dependence potential and abuse liability, 567
dependence evaluation in rhesus monkeys, 608
mouse analgesia, 608
3,5-Dimethyl-3-(3-hydroxyphenyl)-l-phenethylpiperidine hydrochloride (NIH
10604)
biological evaluation of physical-dependence potential and abuse liability, 569
mouse analgesia, 624
ß-1,2-Dimethyl-4-(3-hydroxyphenyl)-4-propionyloxypiperidine hydrochloride
(NIH 10526)
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 653
inhibition of electrically stimulated mouse vas deferens preparations, 653
mouse analgesia, 653
(+)-5,9 Dimethyl-2’-hydroxy-2-propyl-6,7-benzomorphan hydrochloride (NIH
10556)
biological evaluation of physical-dependence potential and abuse liability, 567
dependence evaluation in rhesus monkeys, 604
mouse analgesia, 603
1,2-Dimethyl-3-phenylaziridines
impurity in clandestinely synthesized methamphetamine, 46
6,7-Dinitroquinoxaline-2,3-dione (DNQX)
CNS depression in the rat, 534-535
Disulfiram
current status in treatment of alcoholism, 87-88
Diphenhydramine (Benedryl)
abuse liability in sedative abusers, 486-487
Di-(ß-phenylisopropyl)amines
impurity in clandestinely synthesized amphetamine, 45
Diprenorphine
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
Ditolylguanidine
effect on firing rate of dopamine neuron, 255-263
Dizocilpine
See MK-801
Dopamine
effect of antagonists on heroin-trained drug discrimination, 499
function in brains of offsprings exposed to cocaine in utero, 234-235
neurotoxic effects of cocaine self-administration on receptors, 504-505
one-trial conditioned rotation in rats, 540-541
DPDPE (cyclic[D-Pen2,D-Pen5]enkephalin)
delta-receptor involvement in behavioral and neural plasticity, 174-179
dependence after intrathecal infusion in the rat, 544-545
displacement of specific 3H-etorphine binding in rat brain, 640
halogenated derivatives with increased potency, 291-292
inhibition of electrically stimulated mouse vas deferens preparations, 640
role in analgesia and gastrointestinal function, 167-173
Drug abuse
NIDA’s medication development program, 64-73
Drug dependence
diagnostic agreement between DSM-III and DSM-III-R disorders, 380-381
on New York City’s streets, 382-383
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Drug testing
See Urine screening
Drug withdrawal
anxiogenic effects, 127-128
DSLET
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas defer-ens preparations, 640
DTG
See Ditolylguanidine
Dynorphin
effect of methamphetamine on rat-brain levels, 348
role in chronic pain, 111
Dynorphin (1-9)
role in antinociception and gastrointestinal function, 167-173
Dynorphin A
activity in different smooth-muscle preparations, 160
binding affinity at µ, , and K sites in guinea pig brain, 164
Dynorphin A (1-8)
binding affinity at µ, , and K sites in guinea pig brain, 164
Dynorphin A (1-17)
effect on release of substance P and somatostatin in rat spinal cord, 297
induced place preference in rats, 308-309
spinal mediation of clonidine’s antianalgesic effect, 306-307
Dynorphin B
binding affinity at µ, , and K sites in guinea pig brain, 164
ß-Endorphin
activity in different smooth muscle preparations, 160
binding affinity at µ, , and K sites in guinea pig brain, 162
cation requirement for GTP regulation of binding to µ and receptors, 537
neural connectivity in the descending pain pathway, 542-543
4,5- -Epoxy- -N-trimethyl-6-14-ethenoisomorphinan-7a-methanol (NIH 10501)
biological evaluation of physical-dependence potential and abuse liability,
561, 564
displacement of specific 3H-etorphine binding, 652
inhibition of electrically stimulated mouse vas deferens preparations, 653
Estradiol
alcohol effects on plasma levels after LHRH administration to women, 425
Estrone azide (mixed with naltrexone azide) (NIH 10572)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 667
Ethanol
antagonism by indomethacin, 502-503
behavioral and EEG studies in humans, 146-151
behavioral effects and abuse liability in recreational sedative abusers, 453-454
cognitive skills in dependent patients during detoxification, 353-354
disruption of body sway and psychomotor performance in women, 463
effect on anterior pituitary, gonadal and adrenal hormones, 481-482
effect on cerebral metabolism and mood in normal volunteers, 450
effect on mood states in young women, 462
effect on plasma estradiol levels after LHRH administration to women, 425
preference in males with and without an alcoholic relative, 374-375
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Ethchlorvynol
use by alcoholics in outpatient treatment, 376-377
6 ,14 -Ethenoisomorphinans
synthesis of, 516-517
6ß,14ß-Ethenomorphinans
synthesis of, 516-517
1-[2-(4-Ethyl-4,5-dihydro-1H-tetrazolin-5-one-1-yl)ethyl]-3-methyl-4-[N-(2-
fluorophenyl)methoxyacetamido]piperidine hydrochloride (NIH 10580)
biological evaluation of physical-dependence potential and abuse liability, 570
dependence evaluation in rhesus monkeys, 614
displacement of specific 3H-etorphine binding, 670
inhibition of electrically stimulated mouse vas deferens preparations, 670
mouse analgesia, 613
Ethylketazocine
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
(-)-Ethylketazocine
activity in different smooth muscle preparations, 160
Etorphine
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
(+)-Etorphine hydrochloride (NIH 10617)
biological evaluation of physical-dependence potential and abuse liability, 566
dependence evaluation in rhesus monkeys, 630
displacement of specific 3H-etorphine binding, 686
inhibition of electrically stimulated mouse vas deferens preparations, 686
mouse analgesia, 629
Fenfluramine
comparison of the behavioral and neurochemical effects, 347
Fentanyl
FIT
biologically active conformer and its derivatives, 302-303
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
rapid development and loss of opioid tolerance in the rat, 310-311
synthesis of analogs, 497-498
tool for studying morphine-induced upregulation of opioid receptors, 192-
198
Flumazenil (NIH 10616, Ro 15-1788, 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H -
imidazo[1,5 a][1,4]-benzodiazepine-3-carboxylate ethyl ester)
biological evaluation of physical-dependence potential and abuse liability, 572
cocaine effect on receptors labeled with [3H]Ro 15-1788, 512-513
dependence evaluation in rhesus monkeys, 628-629
discrimination of withdrawal from chlordiazepoxide, 284
discrimination using conditioned taste aversion, 536
mouse analgesia, 628
N-3-(p-Fluorobenzoyl)propyl-4-phenyl-4-propionyloxy piperidine hydrochloride
(NIH 10495, MCV 4560)
biological evaluation of physical-dependence potential and abuse liability,
562,568
dependence evaluation in rats, 593-596
mouse analgesia, 593
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8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4 H-imidazo[1,5 a][1,4]-benzodiazepine-3-
carboxylate ethyl ester (NIH 10616, Ro 15-1788, Flumazenil)
biological evaluation of physical-dependence potential and abuse liability, 572
dependence evaluation in rhesus monkeys, 628-629
mouse analgesia, 628
Fluoxetine
lack of inhibition of [3H]GBR 12935 binding in rat brain areas, 341-342
Flurazepam
mouse analgesia, 580, 639
FNA
See ß-Funaltrexamine
Follicle-stimulating hormone (FSH)
blood levels in alcoholic women, 481-482
Formalin test
use in evaluation of analgesics, 116-122
N-Formylmorphinan-6,8-dienes
Diels-Alder reactions of, 516-517
ß-Funaltrexamine
µ antagonists and K agonist properties, 199-205
tool for studying morphine-induced upregulation of opioid receptors, 192-
198
Gastrointestinal function
role of opioids in, 167-173
GBR 12909
inhibition of [3H]GBR 12935 binding in rat brain areas, 341-342
[3H]GBR 12935
binding in rat brain areas, 341-342
Glucose metabolism
effect of phencyclidine and related compounds on, 264-269
6-D-Glutamylaminomethylsulfonate (DAMS)
CNS depression in the rat, 534-535
Haloperidol (NIH 8032)
biological evaluation of physical-dependence potential and abuse liability, 568
dependence evaluation in rats, 582-585
dependence evaluation in rhesus monkeys, 581-582
effect on regional glucose metabolism in rat brain, 264-269
mouse analgesia, 581
H2BAM
See 14ß-(Bromoacetamido)-7,8-dihydromorphine
H2BAMO
See 14ß-(Bromoacetamido)-7,8-dihydromorphinone
Hepatitis
seroepidemiology in i.v. drug users in New York City, 443-444
Heroin
effect of dopamine antagonists on drug discrimination, 499
i.v. use: its association with HIV infection, 447-448
time course of detection of 6-acetylmorphine in urine, 449
urine screening, 214
use with cocaine by methadone maintenance patients, 328
HIV
addict beliefs about access to test results, 417
association with i.v. heroin use, 447-448
demographic, behavioral, and clinical features of abusers in NYC, 413-414
development decline in infants born to i.v. drug abusers, 409-410
691
genesis of NYC’s experimental needle exchange program, 419-420
HIV risk behavior in admissions to methadone maintenance, 401-402
infection in i.v. drug users in methadone treatment, 405-406
mode of transmission among seroconverted i.v. drug users, 407-408
needle obtainment and cleaning habits of addicts, 418
predicted by needle-sharing patterns in i.v. drug users, 488-489
psychiatric symptoms in test consenters and refusers, 415-416
seroepidemiology in New York City i.v. drug abusers, 443-444
Hydromorphone
evaluation in human amphetamine drug discrimination, 423-424
(+)-4-Hydroxy-3-methyl-4-phenyl-1-(1-phenylcyclohexyl)-piperidine
hydrochloride (NIH 10553)
biological evaluation of physical-dependence potential and abuse liability, 571
mouse analgesia, 603
(-)-4-Hydroxy-3-methyl-4-phenyl-1-(1-phenylcyclohexyl)-piperidine
hydrochloride (NIH 10554)
biological evaluation of physical-dependence potential and abuse liability, 568
mouse analgesia, 603
4-(3-Hydroxyphenyl)-1-3-dimethyl-4-(2-methylprop-1-yl)piperidine (trans aryl-
methyl) hydrochloride (NIH 10600)
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 679
inhibition of electrically stimulated mouse vas deferens preparations, 679
mouse analgesia, 622
4-(3-Hydroxyphenyl)-1,3-dimethyl-4-(2-methylpropl-1-yl)piperidine (cis aryl-
methyl) hydrochloride (NIH 10601)
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 680
inhibition of electrically stimulated mouse vas deferens preparations, 680
mouse analgesia, 623
4-(3-Hydroxyphenyl)-1,3-dimethyl-4- n-propylpiperidine (trans aryl-methyl)
hydrochloride (NIH 10596)
biological evaluation of physical-dependence potential and abuse liability, 568
mouse analgesia, 621
4-(3-Hydroxyphenyl)-1,3-dimethyl-4- n-propylpiperidine (cis aryl-methyl)
hydrochloride (NIH 10597)
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 677
inhibition of electrically stimulated mouse vas deferens preparations, 677
mouse analgesia, 621
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-
phenylpropanamide hydrochloride (NIH 10551)
biological evaluation of physical-dependence potential and abuse liability, 570
dependence evaluation in rhesus monkeys, 602
mouse analgesia, 602
4-(3-Hydroxyphenyl)-4-isobutyl-1-methylpiperidine hydrochloride (NIH 10602)
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 680
inhibition of electrically stimulated mouse vas deferens preparations, 681
mouse analgesia, 623
4-(3-Hydroxyphenyl)-4- n-propyl-1-methylpiperidine hydrochloride (NIH 10599)
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 678
inhibition of electrically stimulated mouse vas deferens preparations, 679
mouse analgesia, 622
692
4-(3-Hydroxyphenyl)-1,3,4-trimethylpiperidine (cis aryl-methyl) hydrochloride
(NIH 10598)
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 678
inhibition of electrically stimulated mouse vas deferens preparations, 678
mouse analgesia, 622
Ibogaine hydrochloride (NIH 10567)
biological evaluation of physical-dependence potential and abuse liability,
563, 572
dependence evaluation in rhesus monkeys, 607
displacement of specific 3H-etorphine binding, 655
inhibition of electrically stimulated mouse vas deferens preparations, 666
mouse analgesia, 607, 655
Immune system
interaction with the opioid system, 186-191
morphine dependence, 293-295
Indomethacin
antagonism of ethanol effects, 502-503
Intravenous drug abusers
addict beliefs about access to HIV test results, 417
effect of fear of AIDS on behavior of addicts, 414-412
demographic, behavioral, and clinical features of HIV infection, 413-414
development decline in infants born to HIV-infected mothers, 409-410
genesis of New York City’s experimental needle exchange program, 419-420
heroin use: its association with HIV infection, 447-448
HIV infection in users in methadone treatment, 405-406
HIV and viral hepatitis seroepidemiology in NYC, 443-444
mode of HIV transmission among seroconverted users, 407-408
needle obtainment and cleaning habits of addicts, 418
needle-sharing patterns as a predictor of HIV, 488-489
primary medical care for, 403-404
risk taking among, 378-379
stress/distress as possible co-factors in development of AIDS, 445-446
Kappa receptors
buprenorphine antagonism in the rat drug-discrimination procedure, 518-519
role in chronic pain, 111-113
Ketamine
effect on firing rate of dopamine neuron, 255-263
Ketazocine
displacement of specific 3H-etorphine binding in rat brain, 640
inhibition of electrically stimulated mouse vas deferens preparations, 640
LAAM
NIDA’s medication development program, 69-70
Leu-enkephalin
activity in different smooth muscle preparations, 160
binding affinity at µ, , and K sites in guinea pig brain, 163
delta receptor involvement in behavioral and neural plasticity, 174-179
Levorphanol tartrate (NIH 4590)
mouse analgesia, 580, 638
Lithium carbonate
current status in alcoholism treatment, 88
Lorazepam
abuse liability in methadone-maintenance patients, 364-365
use by alcoholics in outpatient treatment, 376-377
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LSD
one-trial conditioned rotation in rats, 540-541
urine screening, 2 14
Luteinizing hormone
blood levels in alcoholic women, 481-482
cocaine-stimulated release in monkeys, 337-338
Luteinizing-hormone releasing hormone (LHRH)
alcohol effects on stimulation of estradiol release in women, 425
Marijuana
behavioral and EEG studies in humans, 146-151
effect of food deprivation in humans on subjective responses to, 490-491
effect on mood states in young women, 462
evaluation of DSM-III and DSM-III-R dependence criteria, 380-381
plasma 9-THC levels as a predictor of use by women, 152-158
urinary elimination half-life of 1-THC-7-oic acid after smoking, 457-458
urine screening, 214
Mazindol
amphetamine and cocaine binding, 239-246
neurotoxic effects of cocaine self-administration on receptors, 504-505
MCV 4517 (NIH 10447)
See 2-Chloro-6-(4-N-n-propylpiperidino)thiopyridine hydrochloride
MCV 45 18 (NIH 10448)
See (2-Chloro-6-(4-N-isopropylpiperidino)thiopyridine oxalate
MCV 4558 (NIH 10497)
See N-[(1R)-1-Cyclopropyl]ethylnormorphine hydrochloride
MCV 4560 (NIH 10495)
S e e  N-3- (p-Fluorobenzoyl)propyl-4-phenyl-4-pro-pionyloxy piperidine
hydrochloride
MCV 4581 (NIH 10532)
S e e  ( + ) -trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl-1]
benzeneacetamide d-tartrate [(+)-U 50,488 d-tartrate]
MDMA
See Methylenedioxymethamphetamine
psychostimulant properties, 345-346
Mecamvlamine
structural requirements for antagonism of nicotine in the CNS, 514-515
synthesis of analogs, 546-547
Meperidine (NIH 522 1)
mouse analgesia, 580, 638
Meprobamate
mouse analgesia, 580, 639
Mescaline
mouse analgesia, 580, 639
(-)-Metazocine hydrobromide (NIH 7569)
mouse analgesia, 580, 638
Met-enkephalin
activity in different smooth muscle preparations, 160
binding affinity at µ, , and K sites in guinea pig brain, 163
[Met]enkephalyl-Arg-Arg-Val-NH2
binding affinity at µ, , and K sites in guinea pig brain, 162
[Met]enkephalyl-Arg-Ars-Val-Gly-Arg-Pro--Glu-Trp-Trp-Met-Asp-Try-Gln
binding affinity at µ, , and K sites in guinea pig brain, 162
694
[Met]enkephalyl-Arg-Phe
binding affinity at µ, , and K sites in guinea pig brain, 162
Methadone
acute physical dependence precipitated by naloxone 395-396
comparison to a neuro stimulator &vice for opiate withdrawal, 388-389
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
effect on natural killer cell activity, 522-523
hypothermia as measured by gradient layer, whole-body calorimetry, 289-
290
NIDA’s medication development program, 68-69
withdrawal in newly hatched chickens, 495-496
Methadone maintenance
abuse liability of benzodiazepines in maintenance patients, 364-365
carbamazepine treatment of cocaine dependence in opiate addicts, 316-317
comparison with buprenoxphine for treatment of opiate dependence, 384
desipramine treatment of cocaine abuse in opiate addicts, 322-323
HIV infection in intravenous drug users in methadone treatment, 405-406
HIV risk behavior, antisocial behavior, etc. in admissions, 401-402
intravenous heroin use: association with HIV infection, 447-448
schema for evaluating programs, 74-77
substance abuse disorders and relationship to psychiatric comorbidity, 442
use of cocaine and heroin during, 328
Methamphetamine
attenuation of effects on tryptophan hydroxylase by MK-801, 511
clandestine synthesis, contamination with synthetic by-products, 44-46
effects on neurotensin, dynorphin and substance P in rat brain, 348
Methqualone
use by alcoholics in outpatient treatment, 376-377
subjective effects, 455
Methocarbamol
assessment of abuse potential in primates, 506
14ß-Methoxy-5-methyl-7,8-dihydromorphinone hydrobromide (NIH 10549)
biological evaluation of physical-dependence potential and abuse liability, 564
mouse analgesia, 602
N-Methyl-D-aspartate (NMDA)
antagonists produce barbiturate-Like anesthesia in the rat, 534-535
behavioral pharmacology, 270-274
binding site localization differs from dextromethorphan sites, 548-549
clinical implications of receptors, 275-281
mechanisms of phencyclidine interaction, 247-254
14ß(p-Methylcinnamoylamino)-7,8-dihydromorphinone mesylate (NIH 10544)
biological evaluation of physical-dependence potential and abuse liability, 568
561-562, 564
dependence evaluation in rhesus monkeys, 600
displacement of specific 3H-etorphine binding, 654
inhibition of electrically stimulated mouse vas deferens preparations, 654
mouse analgesia, 600, 654
N-Methyl-N-cyclopropylmethylnormorphinium iodide (NIH 9994)
biological evaluation of physical-dependence potential and abuse liability, 564
displacement of specific 3H-etorphine binding, 642
inhibition of electrically stimulated mouse vas deferens preparations, 643
mouse analgesia, 642
695
Methylenedioxymethamphetamine (MDMA)
comparison of the behavioral and neurochemical effects, 347
psychostimulant properties, 345-346
intravenous administration of L-tryptophan to users, 421-422
cis-3-Methylfentanyl
binding at the opiate receptor complex, 554-555
studies on the stereoselective synthesis, 507-508
des-5-Methyl MK-801
affinity of analogs for the phencyclidine receptor, 51-56
N-Methylmorphinium iodide (NIH 9995)
biological evaluation of physical-dependence potential and abuse liability, 564
displacement of specific 3H-etorphine binding, 643
mouse analgesia, 643
Methylnahltindole hydrochloride (NIH 10590)
binding to monkey brain cortex, 671
biological evaluation of physical-dependence potential and abuse liability,
562, 566
depedence evaluation in rhesus monkeys, 615-616
inhibition of electrically stimulated mouse vas deferens preparations, 672
mouse analgesia, 615
selective antagonist, 300-301
N-Methyl-N-nomaltrindole hydrochloride (NIH 10591)
binding to monkey brain cortex, 672
biological evaluation of physical-dependence potential and abuse liability,
562, 566
dependence evaluation in rhesus monkeys, 616-617
inhibition of electrically stimulated mouse vas deferens preparations, 673
mouse analgesia, 616, 672
Methylphenidate
inhibition of [3H]GBR 12935 binding in rat brain areas, 341-342
N-Methyl-2-(phenylmethyl)phenethylamine
impurity in clandestinely synthesized amphetamines, 46
14ß-(p-Methylphenylpropionylamino)-7,8-dihydromorphinone mesylate (NIH
10545)
biological evaluation of physical-dependence potential and abuse liability, 564
dependence evaluation in rhesus monkeys, 601
displacement of specific 3H-etorphine binding, 654
inhibition of electrically stimulated mouse vas deferens preparations, 654
mouse analgesia, 601, 654
4-Methyl-5-phenylpyrimidine
impurity in clandestinely synthesized amphetamine, 45
(±)-trans-N-Methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzo[b]-thiophene-4
acetamide (PD 117302 hydrochloride)
evaluation in the formalin test, 116-122
Microdialysis
studies of psychostimulants, 343-344
MK-801 (Dizocilpine)
activation of dopamine cell firing, 255-263
attenuation of methamphetamine effects on tryptophan hydroxylase, 511
effect on regional glucose metabolism in rat brain, 264-269
mechanisms of phencyclidine receptor interaction, 247-254
structural requirements for binding to the phencyclidine receptor, 51-56
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Morphine sulfate (NIH 0001, 9929)
activity in different smooth muscle preparations, 160
acute opioid physical dependence in humans, 393-394
behavioral and EEG studies in humans, 146-151
binding affinity at µ, , and K sites in guinea pig brain, 162
dependence after intrathecal infusion in the rat, 544-545
dependence and the immune system, 293-295
displacement of specific 3H-etorphine binding in rat brain, 640
drug discrimination in monkeys, study of opioid dependence, 298-299
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
effect on prodynorphin peptide, 550-551
evaluation in the formalin test, 116-122
free intracellular calcium in naive and tolerant states, 552-553
hypothermia as measured by gradient layer, whole-body calorimetry, 289-
290
inhibition of electrically stimulated mouse vas defer-ens preparations, 640
mechanism of effect on pupil, 304-305
mouse analgesia, 580,638
naloxone challenge after single morphine dose in humans, 385-386
Pavlovian conditioning to morphine in opiate abusers, 390-391
rats pups exposed in utero, 525
upregulation of opioid receptors, use of site-directed affinity ligands, 192-198
urine screening, 214
Mr 2266
effects on thermonociceptive reactions in diabetic mice, 528-529
Muscimol
barbiturate-like anesthesia in the rat, 534-535
Nalbuphine hydrochloride
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
evaluation in the formalin test, 116-122
Nalmefene
safety evaluation in human volunteers, 451-452
Nalorphine hydrochloride (NIH 2105)
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
induced place preference in rats, 308-309
mouse analgesia, 580, 639
Naloxone 3,14-diacetate (NIH 10605)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 682
inhibition of electrically stimulated mouse vas deferens preparations, 682
Naloxone 3,14-dipropionate maleate (NIH 10606)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 683
inhibition of electrically stimulated mouse vas deferens preparations, 683
Naloxone ethoxycarbonylhydrazone (NIH 10607)
biological evaluation of physical-dependence potential and abuse liability, 566
displacement of specific 3H-etorphine binding, 683
inhibition of electrically stimulated mouse vas deferens preparations, 684
Naloxone hydrochloride (NIH 7890, NIH 10562)
abuse liability of buprenorphine in combination with naloxone, 485
activity in different smooth muscle preparations, 160
acute opioid physical dependence in humans, 393-394
biological evaluation of physical-dependence potential and abuse liability, 565
dependence evaluation in rhesus monkeys, 604-605
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effect on morphine-pretreated and morphine-tolerant rat behavior, 524
effect on thermonociceptive reactions in diabetic mice, 528-529
mouse analgesia, 580, 604, 639
precipitated withdrawal after single dose of methadone, 395-396
time course of challenge after single morphine dose in humans, 385-386
treatment of narcotic-induced constipation, 399-400
Naltrexone azide (mixed with estrone) (NIH 10572)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 667
Naltrexone hydrochloride (NIH 8503)
discrimination in morphine-treated monkeys, 298-299
displacement of specific 3H-etorphine binding in rat brain, 640
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
inhibition of electrically stimulated mouse vas deferens preparations, 640
mouse analgesia, 580, 639
NIDA’s medication development program, 70
treatment program for federal probationers, 465-466
Naltrindole hydrochloride (NIH 10589)
binding affinity at µ, , and K sites in guinea pig brain, 161
binding to monkey brain cortex, 670-671
biological evaluation of physical-dependence potential and abuse liability,
562, 566
dependence evaluation in rhesus monkeys, 614-615
inhibition of electrically stimulated mouse vas deferens preparations, 671
mouse analgesia, 614
selective antagonist, 300-301
Nathan B. Eddy Memorial Award
Introduction by L.S. Harris, 34-35
Lecture by L.E. Hollister, 36-43
Nembutal
abuse liability in methadone-maintenance patients, 364-365
-Neo-endorphin
binding affinity at µ, , and K sites in guinea pig brain, 164
Neuro Stimulator Device
alleviating opiate withdrawal symptoms, comparison to methadone, 388-389
Neurotensin
effect of methamphetamine on rat brain levels, 348
Nicotine
abstinence effects, 123
behavioral and EEG studies in humans, 146-151
effect of dose in suppression of withdrawal in smokers, 428
effect of dose on punished and non-punished responding in humans, 438-439
evidence for pharmacological tolerance, 349-350
metabolic effects in smokers and non-smokers, 469-470
serum levels during smoking and nicotine polacrilex treatment, 366-367
structural requirements for antagonists in the CNS, 514-515
See also Smoking
Nicotine polacrilex
experimental models for smoking cessation, 366-367
NIDA
medication development program - 1989, 64-73
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NIH 0001 (NIH 9929, Morphine sulfate)
mouse analgesia, 580,638
NIH 0002 (Codeine phosphate)
mouse analgesia, 580,638
NIH 0123 (Dihydromorphinone hydrochloride)
mouse analgesia, 580, 639
NIH 2105 (Nalorphine hydrochloride)
mouse analgesia, 580,639
NIH 4590 (Levorphanol tartrate)
mouse analgesia, 580, 638
NIH 5221 (Meperidine hydrochloride)
mouse analgesia, 580, 638
NIH 7569 [(-)-Metazocine hydrobromide]
mouse analgesia, 580, 638
NIH 7589A [(±)-2-n-Butyl-5,9 dimethyl-2’-hydroxy-6,7-benzomorphan
hydrobromide]
biological evaluation of physical-dependence potential and abuse liability, 567
dependence evaluation in rats, 582-585
dependence evaluation in rhesus monkeys, 581-582
displacement of specific 3H-etorphine binding, 642
inhibition of electrically stimulated mouse vas deferens preparations, 642
mouse analgesia, 58 1
NIH 7785 [NIH 10573, (±)-5,9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzmorphan
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 610-612
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 668
mouse analgesia, 610
NIH 7890 (NIH 10562, Naloxone hydrochloride)
biological evaluation of physical-dependence potential and abuse liability, 565
dependence evaluation in rhesus monkeys, 604-605
mouse analgesia, 580, 604, 639
NIH 7912 [(±)-N-Allylnormetazocine, (±)-SKF 10,047, (±)-NANM]
biological evaluation of physical-dependence potential and abuse liability, 567
mouse analgesia, 581
NIH 7958 (Pentazocine)
mouse analgesia, 580, 639
NIH 7981 (Cyclazocine)
mouse analgesia, 580, 639
NIH 8032 (Haloperidol)
biological evaluation of physical-dependence potential and abuse liability, 548
dependence evaluation in rats, 582-585
dependence evaluation in rhesus monkeys, 581-582
mouse analgesia, 581
NIH 8503 (Naltrexone hydrochloride)
mouse analgesia, 580, 639
NIH 8773 [(-)-N-Allylnormetazocine, (-)-SKF 10,047, (-)-NANM]
biological evaluation of physical-dependence potential and abuse liability, 567
mouse analgesia, 586
NIH 8775 [(+)-N-Allylnormetazocine, (+)-SKF 10,047, (+)-NANM
biological evaluation of physicaldependence potential and abuse liability, 567
mouse analgesia, 586
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NIH 9512 (Baclofen, Lioresal)
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 587-588
mouse analgesia, 587
NIH 9929 (NIH 0001, Morphine sulfate)
mouse analgesia, 580, 638
NIH 9994 (N-Methyl-N-cyclopropylmethylnormorphinium iodide)
biological evaluation of physical-dependence potential and abuse liability, 564
displacement of specific 3H-etorphine binding, 642
inhibition of electrically stimulated mouse vas deferens preparations, 643
mouse analgesia, 642
NIH 9995 (N-Methylmorphinium iodide)
biological evaluation of physical-dependence potential and abuse liability, 564
displacement of specific 3H-etorphine binding, 643
mouse analgesia, 643
NIH 10168 [(-)-2-( cis-3-Chloroallyl)-5,9 dimethyl-2’-hydroxy-6,7-
benzomorphan hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 567
displacement of specific 3H-etorphine binding, 644
inhibition of electrically stimulated mouse vas deferens preparations, 644
mouse analgesia, 644
NIH 10443 [14ß-(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethyl-
normorphinone mesylate]
biological evaluation of physical-dependence potential and abuse liability,
562, 564
mouse analgesia, 588
NIH 10445 [14ß-(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnormorphinone mesylate]
biological evaluation of physical-dependence potential and abuse liability,
562, 564
mouse analgesia, 588
NIH 10446 (2,6-Diamino-3- p-fluorobenzylpyridine)
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 589-590
mouse analgesia, 589
NIH 10447, MCV 4517 [2-Chloro-6-(4-N-n-propylpiperidino)thiopyridine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 590-591
displacement of specific 3H-etorphine binding, 644
inhibition of electrically stimulated mouse vas deferens preparations, 645
mouse analgesia, 590, 644
NIH 10448, MCV 4518 [2-Chloro-6-(4-N-isopropylpiperidino)thiopyridine
oxalate]
biological evaluation of physical-dependence potential and abuse liability, 571
dependence evaluation in rhesus monkeys, 592
displacement of specific 3H-etorphine binding, 645
inhibition of electrically stimulated mouse vas deferens preparations, 645-646
mouse analgesia, 592, 645
NIH 10495, MCV 4560 [N-3-(p-Fluorobenzoyl)propyl-4-phenyl-4-propionyloxy
piperidine hydrochloride]
biological evaluation of physical dependence and abuse liability, 562, 568
dependence evaluation in rats, 593-596
mouse analgesia, 593
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NIH 10496 [(E)-3-Chloro-6-[4,(3-phenyl-2-propenyl)-1-piperazinyl}pyridazine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 571
drug discrimination in rhesus monkeys, 647-648
mouse analgesia, 646
self-administration in monkeys, 646-647
NIH 10497, MCV 4558 (N-[(1R)-1-Cyclopropyl]ethylnormorphine hydrochloride:)
biological evaluation of physical-dependence potential and abuse liability, 561
dependence evaluation in rhesus monkeys, 598
drug discrimination in rhesus monkeys, 650-652
displacement of specific 3H-etorphine binding, 648
inhibition of electrically stimulated mouse vas deferens preparations, 649
mouse analgesia, 597
self-administration in rhesus monkeys, 649-650
NIH 10501 (4,5- -Epoxy- -N-trimethyl-6-14-ethenoisomorphinan-7a-methanol)
biological evaluation of physical-dependence potential and abuse liability,
561, 564
displacement of specific 3H-etorphine binding, 652
inhibition of electrically stimulated mouse vas deferens preparations, 653
NIH 10526 [ß-1,2-Dimethyl-4-(3-hydroxyphenyl)-4-propionyloxypiperidine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 653
inhibition of electrically stimulated mouse vas deferens preparations, 653
mouse analgesia, 653
NIH 10532, MCV 4581 [(+)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-
cyclohexyl-1] benzeneacetamide d-tartrate, ((+)-U 50,488 d-tartrate)]
biological evaluation of physical-dependence potential and abuse Liability, 571
mouse analgesia, 598-599
NIH 10533, MCV 4582 [(-)-trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-
cyclohexyl-1] benzeneacetamide l-tatrate, ((-)-U 50,488 l-tartrate)]
biological evaluation of physical-dependence potential and abuse liability,
568, 571
mouse analgesia, 599
NIH 10544 [14ß-(p-Methylcinnamoylamino)-7,8-dihydromorphinone mesylate]
biological evaluation of physical-dependence potential and abuse liability, 568
561-562, 564
dependence evaluation in rhesus monkeys, 600
displacement of specific 3H-etorphine binding, 654
inhibition of electrically stimulated mouse vas defer-ens preparations, 654
mouse analgesia, 600, 654
NIH 10545 [14ß-(p-Methylphenylpropionylamino)-7,8-dihydromorphinone
mesylate]
biological evaluation of physical-dependence potential and abuse liability, 564
dependence evaluation in rhesus monkeys, 601
displacement of specific 3H-etorphine binding, 654
inhibition of electrically stimulated mouse vas deferens preparations, 654
mouse analgesia, 601,654
NIH 10549 (14ß-Methoxy-5-methyl-7,8-dihydromorphinone hydrobromide)
biological evaluation of physical-dependence potential and abuse liability, 564
mouse analgesia, 602
NIH 10551 [(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyI]-N-
phenylpropanamide hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 570
701
dependence evaluation in rhesus monkeys, 602
mouse analgesia, 602
NIH 10553 [(+)-4-Hydroxy-3-metyl-4-phenyl-1-(1-phenylcyclohexyl)-piperidine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 571
mouse analgesia, 603
NIH 10554 [(-)-4-Hydroxy-3-methyl-4-phenyl-1-(1-phenylcyclohexyl)-piperidine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 568
mouse analgesia, 603
NIH 10556 [(+)-5,9 Dimethyl-2’-hydroxy-2-propyl-6,7-benzomorphan
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 567
dependence evaluation in rhesus monkeys, 604
mouse analgesia, 603
NIH 10562, NIH 7890 (Naloxone hydrochloride)
biological evaluation of physical-dependence potential and abuse liability, 565
dependence evaluation in rhesus monkeys, 604-605
mouse analgesia, 580, 604, 639
NIH 10564 [(±)-2-(2-Carboxyethyl)-5,9 dimethyl-2’-hydroxy-6,7-
benzomorphan hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 567
inhibition of electrically stimulated mouse vas defer-ens preparations,
mouse analgesia, 605
NIH 10565 [(+)-2-Butyl-5,9 dimethyl-2’-hydroxy-6,7-benzomorphan
hydrochloride]
biological evaluation of physical-dependence potential and abuse Liability, 567
dependence evaluation in rhesus monkeys, 606
mouse analgesia, 606
NIH 10567 (Ibogaine hydrochloride)
biological evaluation of physicaldependence potential and abuse liability,
563, 572
dependence evaluation in rhesus monkeys, 607
displacement of specific 3H-etorphine binding, 655
inhibition of electrically stimulated mouse vas deferens preparations, 666
mouse analgesia, 607, 655
NIH 10569 [(-)-5,9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzomorphan
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 567
dependence evaluation in rhesus monkeys, 608
mouse analgesia, 608
NIH 10570 (Carfentanil citrate)
biological evaluation of physical-dependence potential and abuse liability, 570
mouse analgesia, 609
NIH 10571 (Oxymorphazine dihydrochloride)
biological evaluation of physical-dependence potential and abuse liability, 565
dependence evaluation in rhesus monkeys, 609-610
displacement of specific 3H-etorphine binding, 666
inhibition of electrically stimulated mouse vas deferens preparations, 666
mouse analgesia, 609, 666
NIH 10572 (Mixed azine of naltrexone and estrone)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 667
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NIH 10573, NIH 7785 [(±)-5,9 Dimethyl-2’-hydroxy-2-pentyl-6,7-benzmorphan
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 610-612
displacement of specific 3H-etorphine binding, 667
inhibition of electrically stimulated mouse vas deferens preparations, 668
mouse analgesia, 610
NIH 10576 {N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide
hydrochloride}
biological evaluation of physical-dependence potential and abuse liability, 570
displacement of specific 3H-etorphine binding, 668
inhibition of electrically stimulated mouse vas defer-ens preparations, 668-669
mouse analgesia, 668
NIH 10579 {1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetanido]-
piperidine hydrochloride}
biological evaluation of physical-dependence potential and abuse liability,
562-563, 570
dependence evaluation in rhesus monkeys, 612-613
displacement of specific 3H-etorphine binding, 669
inhibition of electrically stimulated mouse vas deferens preparations, 669
mouse analgesia, 612
562, 566
10590 (Methylnaltrindole hydrochloride)
binding to monkey brain cortex, 671
biological evaluation of physical-dependence potential and abuse liability,
562, 566
dependence evaluation in rhesus monkeys, 615-616
inhibition of electrically stimulated mouse vas deferens preparations, 672
mouse analgesia, 615
10591 (N-Methyl-N-nomaltrindole hydrochloride)
binding to monkey brain cortex, 672
biological evaluation of physical-dependence potential and abuse liability,
562, 566
dependence evaluation in rhesus monkeys, 616-617
inhibition of electrically stimulated mouse vas deferens preparations, 673
mouse analgesia, 616, 672
biological evaluation of physical-dependence potential and abuse liability, 572
dependence evaluation in rhesus monkeys, 617-618
displacement of specific 3H-etorphine binding, 673
NIH
NIH
NIH 10580 {1-[2-(4-Ethyl-4,5-dihydro-1H-tetrazolin-5-one-1-yl)ethyl]-3-methyl-
4-[N-(2-fluorophenyl)methoxyacetamido]piperidine hydrochloride}
biological evaluation of physical-dependence potential and abuse liability, 570
dependence evaluation in rhesus monkeys, 614
displacement of specific 3H-etorphine binding, 670
inhibition of electrically stimulated mouse vas deferens preparations, 670
mouse analgesia, 613
10589 (Naltrindole hydrochloride)
binding to monkey brain cortex, 670-671
biological evaluation of physical-dependence potential and abuse liability,
dependence evaluation in rhesus monkeys, 614-615
inhibition of electrically stimulated mouse vas deferens preparations, 671
mouse analgesia, 614
NIH
NIH 10592 [(S)-N-[(l-Carboxy-2-phenyl)ethyl]-(S)-phenylalanyl-ß-alanine]
703
drug discrimination in rhesus monkeys, 675
inhibition of electrically stimulated mouse vas deferens preparations, 673
mouse analgesia, 617
self-administration in rhesus monkeys, 674-675
NIH 10594 [14ß-(p-Chlorocinnamoylamino)-7,8-dihydromorphinone mesylate]
biological evaluation of physical dependence and abuse liability, 561, 564
dependence evaluation in rhesus monkeys, 619
displacement of specific 3H-etorphine binding, 675
inhibition of electrically stimulated mouse vas deferens preparations, 675-676
mouse analgesia, 618
NIH 10595 [(-)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 620-621
displacement of specific 3H-etorphine binding, 676
inhibition of electrically stimulated mouse vas deferens preparations, 676
mouse analgesia, 619
NIH 10596 [4-(3-Hydroxyphenyl)-1,3-dimethyl-4- n-propylpiperidine (trans aryl-
methyl) hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 568
mouse analgesia, 621
NIH 10597 [4-(3-Hydroxyphenyl)-1,3-dimethyl-4- n-propylpiperidine (cis aryl-
methyl) hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 677
inhibition of electrically stimulated mouse vas deferens preparations, 677
mouse analgesia, 621
NIH 10598 [4-(3-Hydroxyphenyl)-1,3,4-trimethylpiperidine (cis aryl-methyl)
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 568
displacement of specific 3H-etorphine binding, 678
inhibition of electrically stimulated mouse vas deferens preparations, 678
mouse analgesia, 622
NIH 10599 [4-(3-Hydroxyphenyl)-4- n-propyl-1-methylpiperidine hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 678
inhibition of electrically stimulated mouse vas deferens preparations, 679
mouse analgesia, 622
NIH 10600 [4-(3-Hydroxyphenyl)-1-3-dimethyl-4-(2-methylpropl-1-yl)piperidine
(trans aryl-methyl) hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 679
inhibition of electrically stimulated mouse vas deferens preparations, 679
mouse analgesia, 622
NIH 10601 [4-(3-Hydroxyphenyl)-1,3-dimethyl-4-(2-methylprop-1-yl)piperidine
(cis aryl-methyl) hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 680
inhibition of electrically stimulated mouse vas deferens preparations, 680
mouse analgesia, 623
NIH 10602 [4-(3-Hydroxyphenyl)-4-isobutyl-1-methylpiperidine hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 680
704
inhibition of electrically stimulated mouse vas deferens preparations, 681
mouse analgesia, 623
NIH 10603 (1-Phenethyl-4-phenyl-4-propionylpiperidine hydrochloride)
biological evaluation of physical-dependence potential and abuse liability, 569
displacement of specific 3H-etorphine binding, 681
inhibition of electrically stimulated mouse vas deferens preparations, 681
mouse analgesia, 623
NIH 10604 [3,5-Dimethyl-3-(3-hydroxyphenyl)-1-phenethylpiperidine
hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 569
mouse analgesia, 624
NIH 10605 (Naloxone 3,14-diacetate)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 682
inhibition of electrically stimulated mouse vas deferens preparations, 682
NIH 10606 (Naloxone 3,14-dipropionate maleate)
biological evaluation of physical-dependence potential and abuse liability, 565
displacement of specific 3H-etorphine binding, 683
inhibition of electrically stimulated mouse vas deferens preparations, 683
NIH 10607 (Naloxone ethoxycarbonylhydrazone)
biological evaluation of physical-dependence potential and abuse liability, 566
displacement of specific 3H-etorphine binding, 683
inhibition of electrically stimulated mouse vas deferens preparations, 684
NIH 10608 [(+)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
562,567
dependence evaluation in rhesus monkeys, 624-625
displacement of specific 3H-etorphine binding, 684
inhibition of electrically stimulated mouse vas deferens preparations, 684
mouse analgesia, 624
NIH 10612 [(±)-5,9 Dimethyl-2’-hydroxy-2-(2-methylpropenyl)-6,7-
benzomorphan hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
562, 567
dependence evaluation in rhesus monkeys, 625-627
displacement of specific 3H-etorphine binding, 685
inhibition of electrically stimulated mouse vas deferens preparations, 685
mouse analgesia, 625
NIH 10613 (Caffeine and Sodium Benzoate, U.S.P. XIV)
biological evaluation of physic&dependence potential and abuse liability, 572
mouse analgesia, 627
NIH 10616 (8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4 H-imidazo[1,5a][1,4]-
benzodiazepine-3-carboxylate ethyl ester, Ro-15-1788, Flumazenil)
biological evaluation of physical-dependence potential and abuse liability, 572
dependence evaluation in rhesus monkeys, 628-629
mouse analgesia, 628
NIH 10617 [(+)-Etorphine hydrochloride]
biological evaluation of physical-dependence potential and abuse liability, 566
dependence evaluation in rhesus monkeys, 630
displacement of specific 3H-etorphine binding, 686
inhibition of electrically stimulated mouse vas deferens preparations, 686
mouse analgesia, 629
705
NIH 10620 [(+)-Thevinone hydrochloride]
biological evaluation of physical-dependence potential and abuse liability,
561, 566
displacement of specific 3H-etorphine binding, 686
inhibition of electrically stimulated mouse vas deferens preparations, 686
NIH 10621 [(+)-19-Propylthevinol oxalate]
biological evaluation of physical-dependence potential and abuse liability,
561, 566
displacement of specific 3H-etorphine binding, 687
inhibition of electrically stimulated mouse vas deferens preparations, 687
Nimodipine
effect on stimulant properties of cocaine, 500-501
Nisoxetine
lack of inhibition of [3H]GBR 12935 binding in rat brain areas, 341-342
NMDA
See N-Methyl-D-aspartate
Norbinaltorphimine
binding affinity at µ, , and K sites in guinea pig brain, 161
NPC 12626
effect on firing rate of dopamine neurons, 255-263
opiate
acute opioid physical dependence in humans, 393-394
attenuation of withdrawal in humans and rats by cocaine, 361-362
naloxone treatment of narcotic-induced constipation, 399-400
neuro stimulator device vs. methadone in alleviating withdrawal, 388-389
pain modulation and chronic pain, 92-101
Pavlovian conditioning to morphine in abusers, 390-391
use, not dependence or withdrawal, predicts treatment outcome, 459-460
withdrawal in newly hatched chickens, 495-496
Opioids
delta receptor involvement in behavioral and neural plasticity, 174-179
involvement in thermoregulation, 180-185
interaction with the immune system, 186-191
neural connectivity in the descending pain pathway, 542-543
role in analgesia and gastrointestinal function, 167-173
Oxazepam
abuse liability in methadone-maintenance patients, 364-365
mouse analgesia, 580, 639
Oxymorphazine dihydrochloride (NIH 10571)
biological evaluation of physical-dependence potential and abuse liability, 565
dependence evaluation in rhesus monkeys, 609-610
displacement of specific 3H-etorphine binding, 666
inhibition of electrically stimulated mouse vas deferens preparations, 666
mouse analgesia, 609, 666
Oxymorphindole
selective  antagonist, 300-301
Pain modulation
opiates and chronic pain, 92-101
3H-Paroxetine
binding of amphetamine-related compounds at serotonin transporters, 241
PD 117302 hydrochloride [(±)-trans-N-Methyl-N-[2-(1-pyrrolidinyl)-
cyclohexyl]benzo[b]-thiophene-4-acetamide]
binding affinity at µ, , and K sites in guinea pig brain, 164
706
evaluation in the formalin test, 116-122
[D-Pen2,D-Pen5]enkephalin
activity in different smooth muscle preparations, 160
binding affinity at µ, , and K sites in guinea pig brain, 163
Pentazocine (NIH 7958)
effect on morphine-pretreated and morphine-tolerant rat behavior, 524
evaluation in the formalin test, 116-122
mouse analgesia, 580, 639
Pentobarbital
behavioral and EEG studies in humans, 146-151
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GPO out of stock
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GPO out of stock
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GPO out of stock
NCADI out of stock
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NCADI out of stock
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55 PROBLEMS OF DRUG DEPENDENCE, 1984: PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
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60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
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GPO Stock #017-024-01296-3 $6.50
NCADI out of stock
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NTIS PB #89-158422/AS $39
70 OPIOID PEPTIDES: MOLECULAR PHARMACOLOGY, BIOSYNTHESIS, AND
ANALYSIS. Rao S. Rapaka, Ph.D., and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1298-O $12
NTIS PB #89-158430/AS $45
71 OPIATE RECEPTOR SUBTYPES AND BRAIN FUNCTION. Roger M. Brown,
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Carl G. Leukefeld, D.S.W., eds.
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76 PROBLEMS OF DRUG DEPENDENCE, 1986. PROCEEDINGS OF THE 48TH
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NCADI out of stock
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Elizabeth R. Rahdert, Ph.D., and John Grabowski, Ph.D., eds.
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NTIS PB #89-125488/AS $23
725
78 THE ROLE OF NEUROPLASTICITY IN THE RESPONSE TO DRUGS
David P. Friedman, Ph.D., and Doris H. Clouet, Ph.D., eds.
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NTIS PB #89-125496/AS $23
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GPO Stock #017-024-01360-9 $5.50
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GPO Stock #017-024-01379-O $12
NTIS PB #90-148933/AS $45
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DEPENDENCE, INC., Louis S. Harris, Ph.D., ed.
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97 NEUROBIOLOGY OF DRUG ABUSE: LEARNING AND MEMORY. Lynda Erinoff.
ed.
98 THE COLLECTION AND INTERPRETATION OF DATA FROM HIDDEN
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